FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Gutt, R Malhotra, S Jolly, S Moghanaki, D Cheuk, AV Fosmire, H Kelly, MD Hoffman-Hogg, L Lutz, S Anscher, MS Dawson, GA AF Gutt, R. Malhotra, S. Jolly, S. Moghanaki, D. Cheuk, A. V. Fosmire, H. Kelly, M. D. Hoffman-Hogg, L. Lutz, S. Anscher, M. S. Dawson, G. A. TI Management of Metastatic Spinal Cord Compression Among Veterans Health Administration Radiation Oncologists SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY OCT 18-21, 2015 CL San Antonio, TX SP Amer Soc Radiat Oncol C1 [Gutt, R.] Washington DC VA Med Ctr, Washington, DC USA. [Malhotra, S.; Cheuk, A. V.; Dawson, G. A.] James J Peters VA Med Ctr, Bronx, NY USA. [Jolly, S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Moghanaki, D.; Anscher, M. S.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Moghanaki, D.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Fosmire, H.] Roudebush VA Med Ctr, Indianapolis, IN USA. [Kelly, M. D.] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Hoffman-Hogg, L.] Albany Stratton VA Med Ctr, Albany, NY USA. [Lutz, S.] Blanchard Valley Reg Canc Ctr, Findlay, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 1 PY 2015 VL 93 IS 3 SU S MA 3189 BP E475 EP E476 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DI0VL UT WOS:000373215301256 ER PT J AU Hyder, J Boggs, H Chuong, MD Suntharalingam, M Burrows, W Horiba, N Zandberg, DP Tyer, TN Cohen, EP Vujaskovic, Z Mohindra, P AF Hyder, J. Boggs, H. Chuong, M. D. Suntharalingam, M. Burrows, W. Horiba, N. Zandberg, D. P. Tyer, T. N. Cohen, E. P. Vujaskovic, Z. Mohindra, P. TI Impact of Incidental Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Use on Pathologic Complete Response (pCR) to Neoadjuvant Chemoradiation (NA-CRT) in Esophageal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY OCT 18-21, 2015 CL San Antonio, TX SP Amer Soc Radiat Oncol C1 [Hyder, J.; Boggs, H.; Tyer, T. N.] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA. [Chuong, M. D.; Suntharalingam, M.; Burrows, W.; Vujaskovic, Z.; Mohindra, P.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Horiba, N.; Zandberg, D. P.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Cohen, E. P.] Med Coll Wisconsin, Dept Nephrol, Milwaukee, WI 53226 USA. [Cohen, E. P.] US Dept Vet Affairs, Milwaukee, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 1 PY 2015 VL 93 IS 3 SU S MA 2390 BP E153 EP E154 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DI0VL UT WOS:000373215300390 ER PT J AU Tsai, J Mota, NP Pietrzak, RH AF Tsai, Jack Mota, Natalie P. Pietrzak, Robert H. TI US Female Veterans Who Do and Do Not Rely on VA Health Care: Needs and Barriers to Mental Health Treatment SO PSYCHIATRIC SERVICES LA English DT Article ID WOMEN VETERANS; AFGHANISTAN VETERANS; ADMINISTRATION CARE; UNINSURED VETERANS; INSURANCE-COVERAGE; PERCEIVED STIGMA; NATIONAL-HEALTH; SAMPLE; IRAQ; PSYCHOTHERAPY AB Objectives: To determine mental health service utilization and barriers among female veterans, this study examined the prevalence of U.S. female veterans who identified the U.S. Department of Veterans Affairs (VA) as their main source of health care. Methods: This observational study used data from a nationally representative sample of 1,202 veterans who completed a Web-based survey. The analysis compared sociodemographic and clinical characteristics, mental health service use, and perceived barriers to mental health care among female veterans who do and do not use the VA as their main source of health care and male veterans who mainly use VA health care. Results: By gender, 23.4% of female veterans and 19.6% of male veterans identified the VA as their main source of health care, which was not significantly different. Compared with male VA patients, women were more likely to be single, younger, and from a racial-ethnic minority group and to screen positive for depression and posttraumatic stress disorder (PTSD), but they were less likely to have a substance use disorder. Compared with female veterans who did not mainly use VA care, female VA patients were more likely to be on a low income, not employed, from racial-ethnic minority groups, and combat veterans, and they were more likely to have a disability, to screen positive for PTSD, and to report poorer mental health-related functioning. There were no group differences in mental health service use, and the most frequently endorsed barriers to using mental health care across veteran groups were "high treatment costs" and "being seen as weak." Conclusions: These findings highlight the health care needs of female VA service users and support efforts to dispel misconceptions and stigma related to mental health care. C1 [Tsai, Jack] US Dept Vet Affairs, Dept Psychiat, Connecticut Healthcare Syst, West Haven, CT USA. [Tsai, Jack; Mota, Natalie P.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Tsai, J (reprint author), US Dept Vet Affairs, Dept Psychiat, Connecticut Healthcare Syst, West Haven, CT USA. EM jack.tsai@yale.edu NR 44 TC 3 Z9 3 U1 2 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV PY 2015 VL 66 IS 11 BP 1200 EP 1206 DI 10.1176/appi.ps.201400550 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE7WD UT WOS:000370846500014 PM 26174948 ER PT J AU Martires, J Zeidler, M AF Martires, Joanne Zeidler, Michelle TI The value of mindfulness meditation in the treatment of insomnia SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Review DE cognitive behavioral therapy for insomnia (CBT-I); insomnia; mindfulness-based stress reduction (MBSR); mindfulness-based therapy for insomnia (MBTI) ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; STRESS REDUCTION; BREAST-CANCER; ANXIETY DISORDERS; CLINICAL-TRIAL; SLEEP DISTURBANCE; OLDER-ADULTS; QUALITY; PHARMACOTHERAPY AB Purpose of review Insomnia is the most common reported sleep disorder with limited treatment options including pharmacotherapy and cognitive behavioral therapy for insomnia. Pharmacotherapy can be complicated by tolerance and significant side-effects and cognitive behavioral therapy for insomnia providers are limited in number. This article reviews mindfulness meditation as an additional therapy for insomnia. Recent findings Both mindfulness-based stress reduction (MBSR) and mindfulness-based therapy for insomnia (MBTI) have been studied in the treatment of insomnia. Randomized controlled studies of MBSR and MBTI have shown overall reduction in sleep latency and total wake time and increase in total sleep time after mindfulness therapy using both patient reported outcome and quantitative measures of sleep. Mindfulness techniques have been shown to be well accepted by patients with long-lasting effects. A three-arm randomized study with MBSR, MBTI, and self-monitoring showed similar improvement in insomnia between the MBSR and MBTI groups, with possibly longer duration of efficacy in the MBTI group. Recent data show that MBTI is also an effective and accepted treatment for insomnia in older patients. Summary Increasing evidence shows that mindfulness meditation, delivered either via MBSR or MBTI, can be successfully used for the treatment of insomnia with good patient acceptance and durable results. C1 [Martires, Joanne; Zeidler, Michelle] Greater Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Zeidler, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Syst, 11301 Wilshire Blvd,111Q, Los Angeles, CA 90073 USA. EM mzeidler@mednet.ucla.edu NR 40 TC 1 Z9 1 U1 9 U2 65 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1070-5287 EI 1531-6971 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD NOV PY 2015 VL 21 IS 6 BP 547 EP 552 DI 10.1097/MCP.0000000000000207 PG 6 WC Respiratory System SC Respiratory System GA DC5GG UT WOS:000369248900001 PM 26390335 ER PT J AU Reddy, AT Andersen, RM Gelberg, L AF Reddy, Anjani T. Andersen, Ronald M. Gelberg, Lillian TI Clinicians' Beliefs and Practices Regarding Drug Use Care of Their Community Health Center Patients SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE clinicians; drug use; intervention; screening ID BRIEF INTERVENTION; NATIONAL-SURVEY; ILLICIT DRUG; ALCOHOL-USE; TRIAL; SETTINGS; PHYSICIANS; DISORDERS AB Objectives: Integration of behavioral health including substance use problems into primary care is an essential benefit that federally qualified health centers (FQHCs) will offer as part of the Affordable Care Act. This study explores FQHC primary care clinicians' beliefs and practices regarding illicit drug use assessment and treatment. Methods: We administered a 10-minute questionnaire to 68 primary care clinicians of 5 FQHCs in Los Angeles. Results: Clinicians expressed limited confidence in their ability to address patients' illicit drug use, scoring on average 3.31 on a 5-point Likert scale. Two thirds reported that they assess for drug use routinely "at every visit'' and/or "at annual visits.'' When asked how often they counsel regarding drug use (on a 5-point Likert scale from "never'' to "always''), the median response was 4 ("usually''). Regarding their perspectives on the best practical resource for addressing drug use in their clinics, 45.6% named primary care clinicians. A minority (29.4%) of clinicians had completed a clinical rotation dealing with substance use, and 27.2% reported receiving more than 10 hours of training regarding substance use problems. Having a substance use rotation was associated with greater confidence in drug use assessment and treatment (P < 0.01). More hours of substance use training was associated with greater confidence (P = 0.01) and routinely addressing substance use in their patients (P = 0.04). Conclusions: Although two thirds of the surveyed clinicians assess for drug use routinely, and on average, report that they usually address drug use, clinicians' confidence in substance use care seems to be suboptimal, but both confidence and routinely addressing substance use are associated with increased substance use education. Improving clinicians' training and integrating drug use care in FQHCs may improve confidence in substance use care and facilitate the Affordable Care Act's mandate to integrate behavioral health into routine FQHC primary care. C1 [Reddy, Anjani T.; Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Reddy, Anjani T.; Gelberg, Lillian] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Reddy, Anjani T.; Gelberg, Lillian] Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 402,11301 Wilshire Ave, Los Angeles, CA 90037 USA. [Andersen, Ronald M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Andersen, Ronald M.] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA. RP Reddy, AT (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 402,11301 Wilshire Ave, Los Angeles, CA 90037 USA. EM areddy@mednet.ucla.edu FU National Research Service Award Fellowship; NIDA [R01DA022445] FX Dr Reddy's work was supported by her National Research Service Award Fellowship. The NIDA Grant R01DA022445 funded the larger study, Quit Using Drugs Intervention Trial, that this work was part of. NR 20 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2015 VL 9 IS 6 BP 447 EP 453 DI 10.1097/ADM.0000000000000158 PG 7 WC Substance Abuse SC Substance Abuse GA DC9CR UT WOS:000369519000005 PM 26441402 ER PT J AU Gordon, AJ Lo-Ciganic, WH Cochran, G Gellad, WF Cathers, T Kelley, D Donohue, JM AF Gordon, Adam J. Lo-Ciganic, Wei-Hsuan Cochran, Gerald Gellad, Walid F. Cathers, Terri Kelley, David Donohue, Julie M. TI Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE buprenorphine; health services; Medicaid; opioid-related disorders; opioid substitution treatment ID OFFICE-BASED TREATMENT; SUBSTANCE USE DISORDERS; DEPENDENCE; NALOXONE; PREVALENCE; METHADONE; TRENDS; PHYSICIANS; ADDICTION; DIVERSION AB Objectives: Use of buprenorphine - an effective treatment for opioid use disorders (OUDs) - has increased rapidly in recent years and is often financed by Medicaid. We investigated predictors of buprenorphine treatment, patterns of care, and quality of care in a large state Medicaid program. Methods: Data from Pennsylvania Medicaid from 2007 to 2012 provided information regarding diagnoses, demographic characteristics, enrollment, and use of inpatient and outpatient services, and prescription drugs. We identified adult enrollees using buprenorphine, and examined prevalence of OUD diagnosis and patterns of use (duration and dose) and quality of care (physician visits, receipt of behavioral health counseling, urine drug screens, and other prescription drug use). We use a mixed logistic regression model to examine enrollee characteristics associated with buprenorphine use. Results: The share of enrollees with OUD filling prescriptions for buprenorphine increased from 2985 (9.8%) to 12,691 (25.2%) from 2007 to 2012. Between 26.2 and 32.0% of enrollees using buprenorphine had no diagnosis of OUD, depending on the year. Only 60.1% of enrollees with buprenorphine use received at least one urine drug screen, 41.0% had behavioral health counseling services, and 34.7 and 38.0% had other opioid and benzodiazepine claims, respectively, concomitant with buprenorphine use. Quality of care was lower among those with no OUD diagnosis recorded. The mean daily doses of buprenorphine decreased over time. We found wide variation in likelihood of buprenorphine use among those with OUD based upon age, sex, and race. Conclusions: Increases in buprenorphine treatment in a Medicaid population were observed across time; however, increases varied by age, sex, and rate, and the quality of care received seemed to be generally poor. The quality of the provision of buprenorphine treatment occurring in Medicaid populations should be further explored. C1 [Gordon, Adam J.; Cochran, Gerald; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.; Lo-Ciganic, Wei-Hsuan; Cochran, Gerald; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15240 USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15240 USA. [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Cathers, Terri; Kelley, David] Penn Dept Human Serv, Philadelphia, PA USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Bldg 30 151-C,Room 2a133,Univ Dr C, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov OI Donohue, Julie/0000-0003-2418-6017 FU Pennsylvania Department of Human Services; University of Pittsburgh; NIH, CDC [U01-CE002496]; VA; VA HSR&D Career Development Award [09-207] FX This work was supported in part by an intergovernmental agreement between the Pennsylvania Department of Human Services and the University of Pittsburgh. Authors (A.J.G., G.C., W.F.G., J.M.D.) are currently receiving grant support from the NIH, CDC (U01-CE002496), and/or the VA. W.G. is supported by a VA HSR&D Career Development Award (09-207). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. No other substantial conflicts of interest occur from the authors for the work contained within this manuscript. NR 39 TC 4 Z9 4 U1 5 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2015 VL 9 IS 6 BP 470 EP 477 DI 10.1097/ADM.0000000000000164 PG 8 WC Substance Abuse SC Substance Abuse GA DC9CR UT WOS:000369519000009 PM 26517324 ER PT J AU Jain, S Keys, D Ljubanovic, D Edelstein, CL Jani, A AF Jain, Swati Keys, Daniel Ljubanovic, Danica Edelstein, Charles L. Jani, Alkesh TI Protection Against Cold Storage-Induced Renal Tubular Cell Apoptosis SO TRANSPLANTATION LA English DT Article ID SERINE-PROTEASE ACTIVITY; DELAYED GRAFT FUNCTION; OMI/HTRA2 PROTEASE; CEREBRAL ISCHEMIA/REPERFUSION; RISK-FACTORS; DEATH; INHIBITOR; KIDNEY; REPERFUSION; ISCHEMIA AB Background. Prolonged cold storage (CS) of donor kidneys is associated with tubular cell apoptosis and caspase-3 activation. We have previously shown that pancaspase inhibition prevents CS-associated tubular apoptosis. Because of the nonspecific nature of pancaspase inhibitors, which block all caspases including proinflammatory caspase-1, the effect of specific caspase-3 inhibition during CS is unknown. X-linked inhibitor of apoptosis (XIAP) is the most potent naturally occurring specific inhibitor of caspase-3. We hypothesized that prolonged CS would decrease XIAP, whereas upregulation of XIAP with the novel compound UCF-101 would protect against caspase-3 activation and tubular cell apoptosis. Methods. LLC-PK1 tubular cells and whole kidneys from C57BL/6 mice were subjected to prolonged CS with or without UCF-101, and examined for XIAP, caspase-3, and tubular apoptosis. Results. Tubular cells subjected to prolonged CS in vitro demonstrated significantly decreased XIAP and significantly increased apoptosis, caspase-3 protein and activity. UCF-101 treatment significantly increased XIAP, significantly decreased capsase-3 protein and activity, and protected against apoptosis. To determine the therapeutic significance, whole kidneys were subjected to prolonged CS with UCF-101. UCF-101 significantly increased XIAP in donor kidneys and protected against apoptosis. Conclusions. Prolonged CS of tubular cells in vitro and whole mouse kidneys ex vivo is associated with loss of XIAP and subsequent tubular cell apoptosis. UCF-101 protects against the loss of XIAP during prolonged CS both in vitro and ex vivo, and is associated with significantly reduced tubular cell apoptosis. UCF-101 may represent an attractive approach to improve organ preservation. C1 [Jain, Swati; Keys, Daniel; Edelstein, Charles L.; Jani, Alkesh] Univ Colorado, Dept Renal Dis & Hypertens, Denver, CO 80202 USA. [Edelstein, Charles L.; Jani, Alkesh] Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO USA. [Ljubanovic, Danica] Univ Zagreb, Hosp Dubrava, SOM, Dept Pathol, Zagreb 41000, Croatia. RP Jani, A (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, 12700 East 19th Ave,C281, Aurora, CO 80045 USA. EM Alkesh.jani@ucdenver.edu FU BLRD VA [I01 BX001737]; NIDDK NIH HHS [T32 DK007135, R03 DK096151, 1 R03 DK96151-01] NR 28 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV PY 2015 VL 99 IS 11 BP 2311 EP 2316 DI 10.1097/TP.0000000000000774 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DC2ZJ UT WOS:000369087800025 PM 26177086 ER PT J AU Zanchi, D Brody, AL Montandon, ML Kopel, R Emmert, K Preti, MG Van de Ville, D Haller, S AF Zanchi, Davide Brody, Arthur L. Montandon, Marie-Louise Kopel, Rotem Emmert, Kirsten Preti, Maria Giulia Van de Ville, Dimitri Haller, Sven TI Cigarette smoking leads to persistent and dose-dependent alterations of brain activity and connectivity in anterior insula and anterior cingulate SO ADDICTION BIOLOGY LA English DT Article DE Craving; nicotine; smoking ID SUSTAINED-RELEASE BUPROPION; SUBJECT DIFFUSION DATA; FUNCTIONAL CONNECTIVITY; NICOTINE ABSTINENCE; SPATIAL STATISTICS; VOXELWISE ANALYSIS; NEURAL ACTIVITY; SMOKERS; CESSATION; MOTION AB Although many smokers try to quit smoking, only about 20-25 percent will achieve abstinence despite 6months or more of gold-standard treatment. This low success rate suggests long-term changes in the brain related to smoking, which remain poorly understood. We compared ex-smokers to both active smokers and non-smokers using functional magnetic resonance imaging (fMRI) to explore persistent modifications in brain activity and network organization. This prospective and consecutive study includes 18 non-smokers (29.5 +/- 6.7years of age, 11 women), 14 smokers (10 cigarettes a day >2years of smoking, 29.3 +/- 6.0years of age, 10 women) and 14 ex-smokers (>1year of quitting 30.5 +/- 5.7years of age, 10 women). Participants underwent a block-design fMRI study contrasting smoking cue with control (neutral cue) videos. Data analyses included task-related general linear model, seed-based functional connectivity, voxel-based morphometry (VBM) of gray matter and tract-based spatial statistics (TBSS) of white matter. Smoking cue videos versus control videos activated the right anterior insula in ex-smokers compared with smokers, an effect correlating with cumulative nicotine intake (pack-years). Moreover, ex-smokers had a persistent decrease in functional connectivity between right anterior insula and anterior cingulate cortex (ACC) compared with control participants, but similar to active smokers. Potentially confounding alterations in gray or white matter were excluded in VBM and TBSS analyses. In summary, ex-smokers with long-term nicotine abstinence have persistent and dose-dependent brain network changes notably in the right anterior insula and its connection to the ACC. C1 [Zanchi, Davide; Montandon, Marie-Louise; Kopel, Rotem; Emmert, Kirsten; Preti, Maria Giulia; Van de Ville, Dimitri] Univ Hosp Geneva, Dept Imaging & Med Informat, Geneva, Switzerland. [Zanchi, Davide; Montandon, Marie-Louise; Kopel, Rotem; Emmert, Kirsten; Preti, Maria Giulia; Van de Ville, Dimitri] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland. [Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. [Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Kopel, Rotem; Preti, Maria Giulia; Van de Ville, Dimitri] Ecole Polytech Fed Lausanne, Inst Bioengn, CH-1015 Lausanne, Switzerland. [Haller, Sven] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland. [Haller, Sven] Uppsala Univ, Dept Surg Sci, Radiol, Uppsala, Sweden. [Haller, Sven] Univ Hosp Freiburg, Dept Neuroradiol, Freiburg, Germany. [Haller, Sven] Affidea Ctr Diagnost Radiol Carouge CDRC, Geneva, Switzerland. RP Haller, S (reprint author), Affidea Ctr Diagnost Radiol Carouge CDRC, Geneva, Switzerland. EM sven.haller@me.com OI Van De Ville, Dimitri/0000-0002-2879-3861; Haller, Sven/0000-0001-7433-0203 FU Swiss National Foundation [320030_147126/1, 320030_127079/1, SNF PP00P2-146318]; Fonds Startup du Departement de Radiologie et Informatique Medicale in Geneva, Switzerland; National Institute on Drug Abuse [R01 DA20872]; Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; Tobacco-Related Disease Research Program [23XT-0002] FX We want to thank all volunteers for their participation in the study. We also thank Prof. Dr. Christian Luscher for his constructive help during the manuscript preparation. The study was supported by Swiss National Foundation grants SNF project 320030_147126/1, SNF project 320030_127079/1 and SNF PP00P2-146318 as well as the Fonds Startup du Departement de Radiologie et Informatique Medicale in Geneva, Switzerland. Dr. Brody is supported by grants from the National Institute on Drug Abuse (R01 DA20872), the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412) and the Tobacco-Related Disease Research Program (no. 23XT-0002). NR 49 TC 4 Z9 4 U1 5 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD NOV PY 2015 VL 20 IS 6 BP 1033 EP 1041 DI 10.1111/adb.12292 PG 9 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA DC1QN UT WOS:000368991600004 PM 26303184 ER PT J AU Ho, AK Thorpe, CT Pandhi, N Palta, M Smith, MA Johnson, HM AF Ho, Aaron K. Thorpe, Carolyn T. Pandhi, Nancy Palta, Mari Smith, Maureen A. Johnson, Heather M. TI Association of anxiety and depression with hypertension control: a US multidisciplinary group practice observational study SO JOURNAL OF HYPERTENSION LA English DT Article DE anxiety; depression; diagnosis; hypertension; Kaplan-Meier estimate; retrospective studies; United States ID HEALTH-CARE UTILIZATION; MIDDLE-AGED MEN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; GENERALIZED ANXIETY; CLINICAL INERTIA; UNITED-STATES; YOUNG-ADULTS; RISK-FACTOR; DISORDERS AB Objective:The presence of a mental health disorder with hypertension is associated with higher cardiovascular disease mortality than hypertension alone. Although earlier detection of hypertension has been demonstrated in patients with anxiety and depression, the relationship of mental health disorders to hypertension control is unknown. Our objective was to evaluate rates and predictors of incident hypertension control among patients with anxiety and/or depression compared with patients without either mental health diagnosis.Methods:A 4-year retrospective analysis included 4362 patients, at least 18 years old, who received primary care in a large academic group practice from 2008 to 2011. Patients met The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criteria and had a hypertension diagnosis. Kaplan-Meier analysis estimated the probability of achieving control for patients with and without anxiety and/or depression. Cox proportional hazard models were fit to identify predictors of time to control.Results:Overall, 13% (n=573) had a baseline diagnosis of anxiety and/or depression. Those with anxiety and/or depression demonstrated more primary care and specialty visits than those without either condition. After adjustment, patients with anxiety and/or depression had faster rates of hypertension control (hazard ratio [HR] 1.22; 1.07-1.39] than patients without either diagnosis. Other associations of faster hypertension control included female gender (HR 1.32; 1.20-1.44), absence of tobacco use (HR 1.17; 1.03-1.33), Medicaid use (HR 1.27; 1.09-1.49), and a higher Adjusted Clinical Group Risk Score (HR 1.13; 1.10-1.17), a measure of healthcare utilization.Conclusion:Greater healthcare utilization among patients with anxiety and/or depression may contribute to faster hypertension control. C1 [Ho, Aaron K.; Johnson, Heather M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Pandhi, Nancy; Smith, Maureen A.; Johnson, Heather M.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Palta, Mari; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Palta, Mari] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Johnson, HM (reprint author), Div Cardiovasc Med, H4-512 CSC,MC 3248,600 Highland Ave, Madison, WI 53792 USA. EM hm2@medicine.wisc.edu FU Clinical and Translational Science Award program [NCRR - UL1RR025011]; National Center for Advancing Translational Sciences of the National Institutes of Health (N.I.H.) [UL1TR000427]; National Heart, Lung, and Blood Institute of the NIH [K23HL112907]; University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health; National Institute on Aging of the N.I.H [K08AG029527]; University of Wisconsin Health Innovation Program; University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program FX This original research was supported by the Clinical and Translational Science Award program, previously through the National Center for Research Resources (NCRR - UL1RR025011), and now by the National Center for Advancing Translational Sciences of the National Institutes of Health (N.I.H.) under award number UL1TR000427. H.M.J. is supported by the National Heart, Lung, and Blood Institute of the NIH (K23HL112907), and also by the University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health. N.P. is supported by the National Institute on Aging of the N.I.H. (K08AG029527). The content is solely the responsibility of the authors and does not necessarily represent the official views of the N.I.H.; Additional funding for this project was provided by the University of Wisconsin Health Innovation Program and the University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program. NR 41 TC 3 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD NOV PY 2015 VL 33 IS 11 BP 2215 EP 2222 DI 10.1097/HJH.0000000000000693 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DB4OE UT WOS:000368491800008 PM 26259121 ER PT J AU Tseng, CW Biancotti, JC Berg, BL Gate, D Kolar, SL Muller, S Rodriguez, MD Rezai-Zadeh, K Fan, XM Beenhouwer, DO Town, T Liu, GY AF Tseng, Ching Wen Biancotti, Juan Carlos Berg, Bethany L. Gate, David Kolar, Stacey L. Mueller, Sabrina Rodriguez, Maria D. Rezai-Zadeh, Kavon Fan, Xuemo Beenhouwer, David O. Town, Terrence Liu, George Y. TI Increased Susceptibility of Humanized NSG Mice to Panton-Valentine Leukocidin and Staphylococcus aureus Skin Infection SO PLOS PATHOGENS LA English DT Article ID SCID IL2R-GAMMA(NULL) MICE; HUMAN C5A RECEPTORS; TOXINS; INFLAMMATION; SPECIFICITY; ANTAGONISTS; INJURY; MODEL; CB AB Staphylococcus aureus is a leading cause of skin and soft-tissue infections worldwide. Mice are the most commonly used animals for modeling human staphylococcal infections. However a supra-physiologic S. aureus inoculum is required to establish gross murine skin pathology. Moreover, many staphylococcal factors, including Panton-Valentine leukocidin (PVL) elaborated by community-associated methicillin-resistant S. aureus (CA-MRSA), exhibit selective human tropism and cannot be adequately studied in mice. To overcome these deficiencies, we investigated S. aureus infection in non-obese diabetic (NOD)/severe combined immune deficiency (SCID)/IL2r gamma(null) (NSG) mice engrafted with human CD34(+) umbilical cord blood cells. These "humanized" NSG mice require one to two log lower inoculum to induce consistent skin lesions compared with control mice, and exhibit larger cutaneous lesions upon infection with PVL+ versus isogenic PVL-S. aureus. Neutrophils appear important for PVL pathology as adoptive transfer of human neutrophils alone to NSG mice was sufficient to induce dermonecrosis following challenge with PVL+ S. aureus but not PVL-S. aureus. PMX53, a human C5aR inhibitor, blocked PVL-induced cellular cytotoxicity in vitro and reduced the size difference of lesions induced by the PVL+ and PVL-S. aureus, but PMX53 also reduced recruitment of neutrophils and exacerbated the infection. Overall, our findings establish humanized mice as an important translational tool for the study of S. aureus infection and provide strong evidence that PVL is a human virulence factor. C1 [Tseng, Ching Wen; Berg, Bethany L.; Kolar, Stacey L.; Mueller, Sabrina; Rodriguez, Maria D.; Liu, George Y.] Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA. [Tseng, Ching Wen; Berg, Bethany L.; Kolar, Stacey L.; Mueller, Sabrina; Rodriguez, Maria D.; Liu, George Y.] Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA. [Tseng, Ching Wen; Berg, Bethany L.; Kolar, Stacey L.; Mueller, Sabrina; Rodriguez, Maria D.; Liu, George Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Biancotti, Juan Carlos; Gate, David; Town, Terrence] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA. [Gate, David; Rezai-Zadeh, Kavon] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA. [Fan, Xuemo] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. [Beenhouwer, David O.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Beenhouwer, David O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Tseng, CW (reprint author), Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA. EM dolorsas@gmail.com; George.Liu@cshs.org FU US National Institutes of Health [R01: AI074832]; California Institute for Regenerative Medicine [RM1-01735] FX This work was supported by a grant from a US National Institutes of Health to GYL (R01: AI074832) and a grant from the California Institute for Regenerative Medicine to TT. (RM1-01735). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 3 Z9 3 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD NOV PY 2015 VL 11 IS 11 AR e1005292 DI 10.1371/journal.ppat.1005292 PG 17 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DB2IR UT WOS:000368332000039 PM 26618545 ER PT J AU Weitlauf, JC LaCroix, AZ Bird, CE Woods, NF Washington, DL Katon, JG LaMonte, MJ Goldstein, MK Bassuk, SS Sarto, GE Stefanick, ML AF Weitlauf, Julie C. LaCroix, Andrea Z. Bird, Chloe E. Woods, Nancy F. Washington, Donna L. Katon, Jodie G. LaMonte, Michael J. Goldstein, Mary K. Bassuk, Shari S. Sarto, Gloria E. Stefanick, Marcia L. TI Prospective Analysis of Health and Mortality Risk in Veteran and Non-Veteran Participants in the Women's Health Initiative SO WOMENS HEALTH ISSUES LA English DT Article ID VIETNAM-ERA VETERANS; MILITARY SERVICE; HIP FRACTURE; US MILITARY; CANCER; PATTERNS; VALIDITY; DEATH; RATES; PLUS AB Background: The health of postmenopausal women veterans is a neglected area of study. A stronger empirical evidence base is needed, and would inform the provision of health care for the nearly 1 million U.S. women veterans currently 50 years of age or older. To this end, the present work compares salient health outcomes and risk of all-cause mortality among veteran and non-veteran participants of the Women's Health Initiative (WHI). Methods: This study features prospective analysis of long-term health outcomes and mortality risk (average follow-up, 8 years) among the 3,706 women veterans and 141,009 non-veterans who participated in the WHI Observational Study or Clinical Trials. Outcome measurements included confirmed incident cases of cardiovascular disease (CVD), cancer, diabetes, hip fractures, and all-cause mortality. Results: We identified 17,968 cases of CVD, 19,152 cases of cancer, 18,718 cases of diabetes, 2,817 cases of hip fracture, and 13,747 deaths. In Cox regression models adjusted for age, sociodemographic variables, and health risk factors, veteran status was associated with significantly increased risk of all-cause mortality (hazard ratio [HR], 1.13; 95% CI, 1.03-1.23), but not with risk of CVD (HR, 1.00; 95% CI, 0.90-1.11), cancer (HR, 1.04; 95% CI, 0.95-1.14), hip fracture (HR, 1.16; 95% CI, 0.94-1.43), or diabetes (HR, 1.00; 95% CI, 0.89-1.1). Conclusions: Women veterans' postmenopausal health, particularly risk for all-cause mortality, warrants further consideration. In particular, efforts to identify and address modifiable risk factors associated with all-cause mortality are needed. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health. C1 [Weitlauf, Julie C.] VA Palo Alto Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Div Epidemiol Family & Prevent Med, La Jolla, CA 92093 USA. [Bird, Chloe E.] RAND Corp, Santa Monica, CA USA. [Bird, Chloe E.] Pardee RAND Grad Sch, Santa Monica, CA USA. [Woods, Nancy F.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Washington, Donna L.] VA Greater Los Angeles Hlth Care Syst, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Katon, Jodie G.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Katon, Jodie G.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [LaMonte, Michael J.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Goldstein, Mary K.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA. [Goldstein, Mary K.] Stanford Univ, Dept Med, Ctr Primary Care & Outcomes Res, Sch Med, Stanford, CA 94305 USA. [Bassuk, Shari S.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Sarto, Gloria E.] Univ Wisconsin, Dept Obstet & Gynecol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Stefanick, Marcia L.] Stanford Univ, Dept Med, Sch Med, Stanford Ctr Prevent Res, Stanford, CA 94305 USA. RP Weitlauf, JC (reprint author), VA Palo Alto Hlth Care Syst 151 Y, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM wjulie1@stanford.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100 004C, HHSN271201100004C]; Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Division, Career Development Award [CD206035] FX The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100 004C, and HHSN271201100004C.; Dr. Weitlauf's contribution to this work was supported in part by the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Division, Career Development Award [CD206035 2 to J.W.]. To the extent that the funding agencies associated with this project played no role (beyond financial support) in the development or execution of the study described, all investigators (authors) are independent from the sources of study funding. NR 46 TC 11 Z9 11 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2015 VL 25 IS 6 BP 649 EP 657 DI 10.1016/j.whi.2015.08.006 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DB1DH UT WOS:000368247700010 PM 26432346 ER PT J AU Wagner, C Dichter, ME Mattocks, K AF Wagner, Clara Dichter, Melissa E. Mattocks, Kristin TI Women Veterans' Pathways to and Perspectives on Veterans Affairs Health Care SO WOMENS HEALTH ISSUES LA English DT Article ID CENTERED MEDICAL HOME; PATIENT SATISFACTION; QUALITY; PERCEPTIONS; PREDICTORS; GENDER AB Background: We examined Veterans Affairs (VA) health care experiences among contemporary women veteran patients receiving care at a VA medical center. Specifically, we examined women veteran patients' satisfaction with VA care along dimensions in line with patient-centered medical home (patient-aligned care teams [PACT] in VA) priorities, and pathways through which women initially accessed VA care. Methods: We used a mixed methods research design. First, 249 racially diverse women (ages 22-64) who were past-year users of primary care at a VA medical center completed interviewer-administered surveys in 2012 assessing ratings of satisfaction with care in the past year. We then conducted in-depth qualitative interviews of a subset of women surveyed (n = 25) to gain a deeper understanding of perspectives and experiences that shaped satisfaction with care and to explore women's initial pathways to VA care. Results: Ratings of satisfaction with VA care were generally high, with some variation by demographic characteristics. Qualitative interviews revealed perceptions of care centered on the following themes: 1) barriers to care delay needed medical care, while innovative care models facilitate access, 2) women value communication and coordination of care, and 3) personalized context of VA care, including gender sensitive care shapes women's perceptions. Pathways to VA care were characterized by initial delays, often attributable to lack of knowledge or negative perceptions of VA care. Informal social networks were instrumental in helping women to overcome barriers. Conclusions: Findings highlight convergence of women's preferences with PACT priorities of timely access to care, provider communication, and coordination of care, and suggest areas for improvement. Outreach is needed to address gaps in knowledge and negative perceptions. Initiatives to enhance women veterans' social networks may provide an information-sharing resource. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health. C1 [Wagner, Clara; Dichter, Melissa E.] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA 19104 USA. [Mattocks, Kristin] VA Cent Western Massachusetts Healthcare Syst, Leeds, MA USA. [Mattocks, Kristin] Univ Massachusetts, Sch Med, Quantitat Hlth Sci & Psychiat, Worcester, MA USA. RP Wagner, C (reprint author), Philadelphia VA Med Ctr, CHERP, 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. EM Clara.Wagner@va.gov FU VA HSR&D Career Development Award [CDA 10-202]; VA VISN 4 Center for Evaluation of Patient Aligned Care Teams [CEPACT 12-005] FX This research was supported by a VA HSR&D Career Development Award (CDA 10-202) to Melissa Dichter and the VA VISN 4 Center for Evaluation of Patient Aligned Care Teams (CEPACT 12-005; PI: Dichter). The contents of this article do not necessarily represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 33 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2015 VL 25 IS 6 BP 658 EP 665 DI 10.1016/j.whi.2015.06.009 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DB1DH UT WOS:000368247700011 PM 26341566 ER PT J AU Battaglia, TA Gunn, CM McCoy, ME Mu, HH Baranoski, AS Chiao, EY Kachnic, LA Stier, EA AF Battaglia, Tracy A. Gunn, Christine M. McCoy, Molly E. Mu, Helen H. Baranoski, Amy S. Chiao, Elizabeth Y. Kachnic, Lisa A. Stier, Elizabeth A. TI Beliefs About Anal Cancer among HIV-Infected Women: Barriers and Motivators to Participation in Research SO WOMENS HEALTH ISSUES LA English DT Article ID SQUAMOUS INTRAEPITHELIAL LESIONS; AFRICAN-AMERICAN PARTICIPATION; CHILDHOOD SEXUAL-ABUSE; HUMAN-PAPILLOMAVIRUS; CLINICAL-TRIALS; PTSD CHECKLIST; SELF-EFFICACY; HEALTH; VALIDATION; TRAUMA AB Background: Infection with the human immunodeficiency virus (HIV) remains associated with a greater risk of anal cancer, despite widespread use of combination antiretroviral therapy. Evidence concerning the acceptability of anal cancer screening gives little attention to women. Because HIV-infected women have a high prevalence of depression and history of sexual trauma, understanding acceptability among this group is critical. Purpose: We sought to assess barriers and motivators to participation in anal cancer screening research among a racial/ethnically diverse HIV-infected female population. Methods: We conducted a survey based on the Health Belief Model to identify characteristics of women willing to participate in anal cancer screening research (n = 200). Bivariate analyses examined associations between willingness to participate and sociodemographics, clinical characteristics, and health beliefs. Logistic regression modeled willingness to participate in research. Main Findings: Of the women who participated, 37% screened positive for depression, 43% reported a high trauma history, and 36% screened positive for posttraumatic stress disorder. Overall, 65% reported willingness to participate in research. Those likely to participate were older, reported intravenous drug use as their HIV risk factor, and had a history of prior high-resolution anoscopy (HRA) compared with those unwilling to participate. The most commonly reported barrier to anal Pap testing was fear of pain. In adjusted analyses, a lack of fear of pain and prior experience with HRA significantly predicted willingness to participate. Conclusions: Findings suggest that, to increase participation in anal Pap and HRA-related research for HIV-infected women, a single approach may not be adequate. Rather, we must harness patients' previous experiences and address psychosocial and financial concerns to overcome barriers to participation. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Battaglia, Tracy A.; Gunn, Christine M.; McCoy, Molly E.] Boston Univ, Sch Med, Gen Internal Med Sect, Womens Hlth Unit, Boston, MA 02118 USA. [Battaglia, Tracy A.; Gunn, Christine M.; McCoy, Molly E.; Kachnic, Lisa A.] Boston Med Ctr, Boston, MA USA. [Mu, Helen H.; Stier, Elizabeth A.] Boston Univ, Med Ctr, Dept Obstet & Gynecol, Boston, MA USA. [Baranoski, Amy S.] Drexel Univ, Coll Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA. [Chiao, Elizabeth Y.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Kachnic, Lisa A.] Boston Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02118 USA. RP Gunn, CM (reprint author), Womens Hlth Unit, 801 Massachusetts Ave,First Floor, Boston, MA 02118 USA. EM Christine.Gunn@bmc.org OI Gunn, Christine/0000-0003-3340-2834 FU National Cancer Institute [U10 CA139519-02S]; National Cancer Institute Center [NCI U01 CA116892-0551]; Boston Medical Center Minority-Based Community Clinical Oncology Program [NCI 1U-10CA129519-01A1]; AIDS Malignancy Consortium [U01 CA121947]; Houston Health Services Research and Development Center for Excellence [FP90-020] FX This work was supported by the National Cancer Institute under Grant U10 CA139519-02S; National Cancer Institute Center to Reduce Cancer Health Disparities under Grant NCI U01 CA116892-0551; Boston Medical Center Minority-Based Community Clinical Oncology Program under Grant NCI 1U-10CA129519-01A1; the AIDS Malignancy Consortium under Grant U01 CA121947; and the Houston Health Services Research and Development Center for Excellence under Grant FP90-020. NR 49 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2015 VL 25 IS 6 BP 720 EP 726 DI 10.1016/j.whi.2015.06.008 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DB1DH UT WOS:000368247700019 PM 26253825 ER PT J AU Polnaszek, B Mirr, J Roiland, R Gilmore-Bykovskyi, A Hovanes, M Kind, A AF Polnaszek, Brock Mirr, Jacquelyn Roiland, Rachel Gilmore-Bykovskyi, Andrea Hovanes, Melissa Kind, Amy TI Omission of Physical Therapy Recommendations for High-Risk Patients Transitioning From the Hospital to Subacute Care Facilities SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Communication; Delivery of health care; Patient discharge; Patient discharge summaries; Patient readmission; Patient safety; Physical therapy specialty; Physicians; Rehabilitation; Subacute care ID SKILLED NURSING FACILITY; QUALITY-OF-LIFE; OLDER-ADULTS; DISCHARGE; STROKE; OUTCOMES; COMMUNICATION; CONTINUITY; PROGRAM; HAZARDS AB Objectives: To assess the quality and explore the potential impact of the communication of physical therapy (PT) recommendations in hospital discharge summaries/orders for high-risk subacute care populations, specifically targeting recommendations for (1) maintenance of patient safety, (2) assistance required for mobility, and (3) use of assistive devices. Design: Medical record abstraction of retrospective cohort comparing discharge recommendations made by inpatient PT to orders included in written hospital discharge summaries/orders, the primary form of hospital-to-subacute care communication. Data were linked to Medicare outcomes from corresponding years for all Medicare beneficiaries in the cohort. Setting: Academic hospital. Participants: All hospitalized patients (N = 613 overall) 18 years and older with primary diagnoses of stroke or hip fracture, with an inpatient PT consultation and discharged to subacute care during the years 2006 to 2008; 366 of these were Medicare beneficiaries. Interventions: Not applicable. Main Outcome Measures: Combined rehospitalization, emergency department visit, and/or death within 30 days of discharge. Results: Omission of recommendations for maintaining patient safety occurred in 54% (316/584) of patients; for assistance required for mobility, in approximately 100% (535/537); and for use of assistive devices, in 77% (409/532). As compared with those without patient safety restriction/precaution omissions, Medicare beneficiaries with such omissions demonstrated a trend toward more negative 30-day outcomes (26% vs 18%, P = .10). Similar, albeit nonsignificant, outcome trends were observed in the other omission categories. Conclusions: PT recommendations made during a hospital stay in high-risk patients are routinely omitted from hospital discharge communications to subacute care facilities. Interventions to reliably improve this communication are needed. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Polnaszek, Brock; Mirr, Jacquelyn; Hovanes, Melissa; Kind, Amy] Univ Wisconsin, Dept Med, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA. [Mirr, Jacquelyn; Roiland, Rachel; Gilmore-Bykovskyi, Andrea; Hovanes, Melissa; Kind, Amy] William S Middleton Hosp, Geriatr Res Educ & Clin Ctr, US Dept Vet Affairs, Madison, WI USA. [Roiland, Rachel; Gilmore-Bykovskyi, Andrea; Kind, Amy] Univ Wisconsin, Sch Nursing, Madison, WI USA. [Kind, Amy] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. RP Kind, A (reprint author), William S Middleton VA Hosp GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ajk@medicine.wisc.edu RI Vila, Vanessa/B-4982-2014 FU National Institute on Aging and American Federation for Aging Research Medical Student Training in Aging Research Program; National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging, American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Madison Veteran Affairs Geriatrics Research Education and Clinical Center [2014-25]; University of Wisconsin School of Medicine and Public Health's Community-Academic Partnerships core of University of Wisconsin Institute for Clinical and Translational Research [1UL1RR025011]; University of Wisconsin School of Medicine and Public Health from Wisconsin Partnership Program; National Hartford Centers of Gerontological Nursing Excellence FX Supported by the National Institute on Aging and American Federation for Aging Research Medical Student Training in Aging Research Program; a National Institute on Aging Beeson Career Development Award (award no. K23AG034551, funded by National Institute on Aging, American Federation for Aging Research, John A. Hartford Foundation, Atlantic Philanthropies, and Start Foundation); and in part by the Madison Veteran Affairs Geriatrics Research Education and Clinical Center (manuscript no. 2014-25); the University of Wisconsin School of Medicine and Public Health's Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (grant no. 1UL1RR025011); the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; and the National Hartford Centers of Gerontological Nursing Excellence. NR 36 TC 1 Z9 1 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2015 VL 96 IS 11 BP 1966 EP U239 DI 10.1016/j.apmr.2015.07.013 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DB1YX UT WOS:000368306600004 PM 26253350 ER PT J AU Hughes, AJ Hartoonian, N Parmenter, B Haselkorn, JK Lovera, JF Bourdette, D Turner, AP AF Hughes, Abbey J. Hartoonian, Narineh Parmenter, Brett Haselkorn, Jodie K. Lovera, Jesus F. Bourdette, Dennis Turner, Aaron P. TI Cognitive Impairment and Community Integration Outcomes in Individuals Living With Multiple Sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Community integration; Multiple sclerosis; Neurobehavioral manifestations; Rehabilitation ID QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; INFORMATION-PROCESSING SPEED; BECK DEPRESSION INVENTORY; FATIGUE SEVERITY SCALE; MEMORY IMPAIRMENT; GINKGO-BILOBA; QUESTIONNAIRE; DISABILITY; VALIDITY AB Objectives: To determine the association between unique domains of cognitive impairment and community integration in individuals with multiple sclerosis (MS), and to determine the contributions of cognitive impairment to community integration beyond the influence of demographic and clinical variables. Design: Cross-sectional analysis of objective neuropsychological assessment and self-report data. Data were collected during baseline assessment of a randomized, multisite controlled trial of ginkgo biloba for cognitive impairment in MS. Hierarchical regression analyses examined the association between subjective and objective measures of cognitive impairment and 3 domains of community integration, adjusting for relevant covariates. Setting: Two Veterans Affairs medical center MS clinics. Participants: Adults (N = 121; ages 24-65y) with a confirmed MS diagnosis. Interventions: Not applicable. Main Outcome Measures: Primary outcomes were scores on the Home Integration (CIQ-H), Social Integration (CIQ-S), and Productivity (CIQ-P) domains of the Community Integration Questionnaire (CIQ). Results: Cognitive impairment was associated with lower scores on the CIQ-H and CIQ-S, but not the CIQ-P. Greater levels of subjective cognitive impairment were associated with lower scores on the CIQ-H and CIQ-S. Greater levels of objective cognitive impairment, specifically slower processing speed and poorer inhibitory control, were related to lower CIQ-S scores. Subjective and objective measures of cognitive impairment were significantly and independently associated with CIQ-S. Conclusions: Objective cognitive impairment may interfere with participation in social activities. Subjective cognitive impairment is also important to assess, because individuals who perceive themselves to be cognitively impaired may be less likely to participate in both home and social activities. Clinical interventions to enhance community integration in individuals with MS may benefit from addressing objective and subjective cognitive impairment by integrating cognitive rehabilitation approaches with self-efficacy enhancing strategies. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Hughes, Abbey J.; Hartoonian, Narineh; Haselkorn, Jodie K.; Turner, Aaron P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Hughes, Abbey J.; Haselkorn, Jodie K.; Turner, Aaron P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA. [Parmenter, Brett] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Lovera, Jesus F.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA USA. [Bourdette, Dennis] Vet Affairs Portland Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Portland, OR USA. [Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA. RP Hughes, AJ (reprint author), Univ Washington, Dept Rehabil Med, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA. EM ajhughes@uw.edu RI Hughes, Abbey/K-8861-2015 OI Hughes, Abbey/0000-0002-7612-6887 FU Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [B4368R]; National Multiple Sclerosis Society [MB 0026] FX Supported by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (grant no. B4368R), and by a mentor-based fellowship grant from the National Multiple Sclerosis Society (grant no. MB 0026). The contents of this paper do not represent the view of the Department of Veterans Affairs of the U.S. Government. NR 52 TC 2 Z9 2 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2015 VL 96 IS 11 BP 1973 EP 1979 DI 10.1016/j.apmr.2015.07.003 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DB1YX UT WOS:000368306600005 PM 26189203 ER PT J AU Sawyer, K Bell, KR Ehde, DM Temkin, N Dikmen, S Williams, RM Dillworth, T Hoffman, JM AF Sawyer, Kathryn Bell, Kathleen R. Ehde, Dawn M. Temkin, Nancy Dikmen, Sureyya Williams, Rhonda M. Dillworth, Tiara Hoffman, Jeanne M. TI Longitudinal Study of Headache Trajectories in the Year After Mild Traumatic Brain Injury: Relation to Posttraumatic Stress Disorder Symptoms SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Headache; Rehabilitation; Stress disorders; post-traumatic ID COMORBID CHRONIC PAIN; US SOLDIERS; VETERANS; PTSD; DEPRESSION; SEVERITY; MODERATE; HEALTH AB Objective: To examine headache trajectories among persons with mild traumatic brain injury (MTBI) in the year after injury and the relation of headache trajectory to posttraumatic stress disorder (PTSD) at 1 year postinjury. Design: Prospective, longitudinal study. Setting: Participants were recruited through a university medical center and participated in follow-up assessments by telephone. Participants: Prospectively enrolled individuals (N=212) within 1 week of MTBI who were hospitalized for observation or other system injuries. Participants were assessed at baseline and 3, 6, and 12 months postinjury. Interventions: Not applicable. Main Outcome Measures: Participants rated average headache pain intensity using the 0 to 10 numerical rating scale at each assessment period. The PTSD Checklist-Civilian Version was completed at 12 months postinjury. Results: Latent class growth analysis produced a 4-trajectory group model, with groups labeled resolved, worsening, improving, and chronic. Multivariate regression modeling revealed that younger age and premorbid headache correlated with membership in the worse trajectory groups (worsening and chronic; P<.001). Univariate regression revealed a significant association between PTSD and membership in the worse trajectory groups (P<.001). Conclusions: Headache is common in the year after MTBI, with younger people, persons who previously had headaches, and persons with PTSD more likely to report chronic or worsening headache. Further research is needed to examine whether PTSD symptoms exacerbate headaches or whether problematic headache symptoms exacerbate PTSD. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Sawyer, Kathryn; Ehde, Dawn M.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Dillworth, Tiara; Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Bell, Kathleen R.] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA. [Temkin, Nancy; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. RP Sawyer, K (reprint author), Univ Washington, Sch Med, Box 359612, Seattle, WA 98195 USA. EM kasawyer@uw.edu FU Department of Education, National Institute on Disability and Rehabilitation Research [H133G090022]; Department of Defense Congressionally Directed Medical Research Programs [W81XWH-12-2-0109] FX Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant no. H133G090022) and Department of Defense Congressionally Directed Medical Research Programs (grant no. W81XWH-12-2-0109). NR 32 TC 3 Z9 3 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2015 VL 96 IS 11 BP 2000 EP 2006 DI 10.1016/j.apmr.2015.07.006 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DB1YX UT WOS:000368306600009 PM 26220236 ER PT J AU Satwani, P Ahn, KW Carreras, J Abdel-Azim, H Cairo, MS Cashen, A Chen, AI Cohen, JB Costa, LJ Dandoy, C Fenske, TS Freytes, CO Ganguly, S Gale, RP Ghosh, N Hertzberg, MS Hayashi, RJ Kamble, RT Kanate, AS Keating, A Kharfan-Dabaja, MA Lazarus, HM Marks, DI Nishihori, T Olsson, RF Prestidge, TD Rolon, JM Savani, BN Vose, JM Wood, WA Inwards, DJ Bachanova, V Smith, SM Maloney, DG Sureda, A Hamadani, M AF Satwani, P. Ahn, K. W. Carreras, J. Abdel-Azim, H. Cairo, M. S. Cashen, A. Chen, A. I. Cohen, J. B. Costa, L. J. Dandoy, C. Fenske, T. S. Freytes, C. O. Ganguly, S. Gale, R. P. Ghosh, N. Hertzberg, M. S. Hayashi, R. J. Kamble, R. T. Kanate, A. S. Keating, A. Kharfan-Dabaja, M. A. Lazarus, H. M. Marks, D. I. Nishihori, T. Olsson, R. F. Prestidge, T. D. Rolon, J. M. Savani, B. N. Vose, J. M. Wood, W. A. Inwards, D. J. Bachanova, V. Smith, S. M. Maloney, D. G. Sureda, A. Hamadani, M. TI A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma SO BONE MARROW TRANSPLANTATION LA English DT Article ID STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; EVENT-FREE SURVIVAL; SALVAGE THERAPY; CONDITIONING REGIMEN; DISEASE; INTENSITY; RECURRENT; CYCLOPHOSPHAMIDE; MANAGEMENT AB Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/ refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age < 30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI): 62-70), 52% (95% CI: 48-57) and 47% (95% CI: 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score >= 90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of < 1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate-and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI: 64-80), 53% (95% CI: 47-59) and 23% (95% CI: 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT. C1 [Satwani, P.] Columbia Univ, Dept Pediat, Med Ctr, Div Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY 10027 USA. [Ahn, K. W.; Carreras, J.; Hamadani, M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ahn, K. W.] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Abdel-Azim, H.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA. [Cairo, M. S.] New York Med Coll, Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY USA. [Cashen, A.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Chen, A. I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cohen, J. B.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA. [Costa, L. J.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Dandoy, C.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Fenske, T. S.] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Freytes, C. O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ganguly, S.] Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA. [Gale, R. P.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. [Ghosh, N.] Carolinas Healthcare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. [Hertzberg, M. S.] Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia. [Hayashi, R. J.] Washington Univ, Dept Pediat, Sch Med St Louis, Div Pediat Hematol Oncol, St Louis, MO 63130 USA. [Kamble, R. T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. [Kanate, A. S.] W Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA. [Kharfan-Dabaja, M. A.; Nishihori, T.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. [Lazarus, H. M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Marks, D. I.] Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. [Olsson, R. F.] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden. [Olsson, R. F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Prestidge, T. D.] Starship Childrens Hosp, Blood & Canc Ctr, Auckland, New Zealand. [Rolon, J. M.] FUNDALEU, Bone Marrow Transplante Unit, Buenos Aires, DF, Argentina. [Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37235 USA. [Vose, J. M.] Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. [Wood, W. A.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. [Inwards, D. J.] Mayo Clin, Div Hematol, Rochester, MN USA. [Bachanova, V.] Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA. [Smith, S. M.] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. [Maloney, D. G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sureda, A.] Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain. RP Hamadani, M (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA. EM mhamadani@mcw.edu FU Public Health Service from the National Cancer Institute (NCI) [U24-CA076518]; National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLBI [5U10HL069294]; NCI; Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc.; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; Leukemia & Lymphoma Society; Medac GmbH; Medical College of Wisconsin; Merck Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience, Inc.; THERAKOS, Inc.; University of Minnesota; University of Utah; Wellpoint, Inc. FX We thank the patients and centers reporting to CIBMTR and CIBMTR Lymphoma. We also thank the following committee members for their scientific input: Baldeep Wirk, Basem M William, Harry C Schouten, Nishitha M Reddy, David Rizzieri, Mahmoud Aljurf, Reinhold Munker, Brandon Hayes-Lattin, Victor A Lewis, and Maggie M Simaytis for administrative support. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the US Government. *Corporate Members. NR 38 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD NOV PY 2015 VL 50 IS 11 BP 1416 EP 1423 DI 10.1038/bmt.2015.177 PG 8 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA DB1PU UT WOS:000368281800004 PM 26237164 ER PT J AU Carley, JA Karp, JF Gentili, A Marcum, ZA Reid, MC Rodriguez, E Rossi, MI Shega, J Thielke, S Weiner, DK AF Carley, Joseph A. Karp, Jordan F. Gentili, Angela Marcum, Zachary A. Reid, M. Carrington Rodriguez, Eric Rossi, Michelle I. Shega, Joseph Thielke, Stephen Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult: Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment SO PAIN MEDICINE LA English DT Article DE Aged; Assessment; Depression; Chronic Pain; Elderly; Low Back Pain; Primary Care ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; PRIMARY-CARE PATIENTS; STAR-ASTERISK-D; LATE-LIFE; PSYCHOSOCIAL INTERVENTIONS; MEDICATION USE; HEALTH-CARE; OUTCOMES AB Objective. To present the fourth in a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults. The series presents CLBP as a syndrome, a final common pathway for the expression of multiple contributors rather than a disease localized exclusively to the lumbosacral spine. Each article addresses one of twelve important contributors to pain and disability in older adults with CLBP. This article focuses on depression. Methods. The evaluation and treatment algorithm, a table articulating the rationale for the individual algorithm components, and stepped-care drug recommendations were developed using a modified Delphi approach. The Principal Investigator, a three-member content expert panel, and a nine-member primary care panel were involved in the iterative development of these materials. The algorithm was developed keeping in mind medications and other resources available within Veterans Health Administration (VHA) facilities. As panelists were not exclusive to the VHA, the materials can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributor's clinical practice. Results. We present an algorithm and supportive materials to help guide the care of older adults with depression, an important contributor to CLBP. The case illustrates an example of a complex clinical presentation in which depression was an important contributor to symptoms and disability in an older adult with CLBP. Conclusions. Depression is common and should be evaluated routinely in the older adult with CLBP so that appropriately targeted treatments can be planned and implemented. C1 [Carley, Joseph A.; Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Marcum, Zachary A.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Reid, M. Carrington] Weill Cornell Med Coll, Div Geriatr & Palliat Med, New York, NY USA. [Rodriguez, Eric] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Rossi, Michelle I.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [Shega, Joseph] VITAS Healthcare, Miami, FL USA. [Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. RP Karp, JF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM karpjf@upmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service; ADAPT Project: Addressing Depression and Pain Together [AG033575] FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. Dr. Karp would like to acknowledge grant AG033575 (the ADAPT Project: Addressing Depression and Pain Together), which provided support for his work on this article. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. The authors thank Dave Newman for his thoughtful review of the manuscript. NR 68 TC 5 Z9 5 U1 4 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD NOV PY 2015 VL 16 IS 11 BP 2098 EP 2108 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DB1VH UT WOS:000368296600007 PM 26539754 ER PT J AU Harvey, LD Yin, Y Attarwala, IY Begum, G Deng, J Yan, HQ Dixon, CE Sun, DD AF Harvey, Lloyd D. Yin, Yan Attarwala, Insiya Y. Begum, Gulnaz Deng, Julia Yan, Hong Q. Dixon, C. Edward Sun, Dandan TI Administration of DHA Reduces Endoplasmic Reticulum Stress-Associated Inflammation and Alters Microglial or Macrophage Activation in Traumatic Brain Injury SO ASN NEURO LA English DT Article DE cortical contusion injury; docosahexaenoic acid; microglial polarization; neuroinflammation; nuclear factor kappa-light-chain-enhancer of activated B cells; secondary injury ID MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS; FATTY-ACID; ER STRESS; RESPONSES; IMPACT; RAT; EXPRESSION; DISEASES AB We investigated the effects of the administration of docosahexaenoic acid (DHA) post-traumatic brain injury (TBI) on reducing neuroinflammation. TBI was induced by cortical contusion injury in Sprague Dawley rats. Either DHA (16mg/kg in dimethyl sulfoxide) or vehicle dimethyl sulfoxide (1ml/kg) was administered intraperitonially at 5min after TBI, followed by a daily dose for 3 to 21 days. TBI triggered activation of microglia or macrophages, detected by an increase of Iba1 positively stained microglia or macrophages in peri-lesion cortical tissues at 3, 7, and 21 days post-TBI. The inflammatory response was further characterized by expression of the proinflammatory marker CD16/32 and the anti-inflammatory marker CD206 in Iba1(+) microglia or macrophages. DHA-treated brains showed significantly fewer CD16/32(+) microglia or macrophages, but an increased CD206(+) phagocytic microglial or macrophage population. Additionally, DHA treatment revealed a shift in microglial or macrophage morphology from the activated, amoeboid-like state into the more permissive, surveillant state. Furthermore, activated Iba1(+) microglial or macrophages were associated with neurons expressing the endoplasmic reticulum (ER) stress marker CHOP at 3 days post-TBI, and the administration of DHA post-TBI concurrently reduced ER stress and the associated activation of Iba1(+) microglial or macrophages. There was a decrease in nuclear translocation of activated nuclear factor kappa-light-chain-enhancer of activated B cells protein at 3 days in DHA-treated tissue and reduced neuronal degeneration in DHA-treated brains at 3, 7, and 21 days after TBI. In summary, our study demonstrated that TBI mediated inflammatory responses are associated with increased neuronal ER stress and subsequent activation of microglia or macrophages. DHA administration reduced neuronal ER stress and subsequent association with microglial or macrophage polarization after TBI, demonstrating its therapeutic potential to ameliorate TBI-induced cellular pathology. C1 [Harvey, Lloyd D.; Attarwala, Insiya Y.; Begum, Gulnaz; Deng, Julia; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Yin, Yan] Dalian Med Univ, Hosp 2, Dept Neurol, Dalian, Peoples R China. [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA. [Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sun, DD (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA. EM sund@upmc.edu OI Harvey, Lloyd/0000-0001-5934-9934; Yin, Yan/0000-0002-5982-7462 FU University of Pittsburgh Neurology Departmental start-up funds; UPMC Endowed Chair Professorship on Brain Disorder Research; National Institutes of Health [R01NS089051]; United States Department of Veterans Aairs VA [RRD#B6761R]; Brackenridge Summer and Fall Research Fellowships; Chancellor's Undergraduate Research Fellowship; Honors College-Health Sciences Research Fellowship; James V. Kunkel, M.D. Translational Research Fellowship; Chinese Dalian Municipal Bureau Study Abroad Research Award FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by University of Pittsburgh Neurology Departmental start-up funds, a UPMC Endowed Chair Professorship on Brain Disorder Research, and the National Institutes of Health [R01NS089051] (DS) and the United States Department of Veterans Aairs VA [RR&D#B6761R] (CED). LDH was supported by the Brackenridge Summer and Fall Research Fellowships, the Chancellor's Undergraduate Research Fellowship, the Honors College-Health Sciences Research Fellowship, and the James V. Kunkel, M.D. Translational Research Fellowship. YY was supported by the Chinese Dalian Municipal Bureau Study Abroad Research Award. NR 37 TC 6 Z9 6 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1759-0914 J9 ASN NEURO JI ASN Neuro PD NOV-DEC PY 2015 VL 7 IS 6 DI 10.1177/1759091415618969 PG 15 WC Neurosciences SC Neurosciences & Neurology GA DA2EH UT WOS:000367607600003 ER PT J AU Dhar, M Wong, J Karimi, A Che, J Renier, C Matsumoto, M Triboulet, M Garon, EB Goldman, JW Rettig, MB Jeffrey, SS Kulkarni, RP Sollier, E Di Carlo, D AF Dhar, Manjima Wong, Jessica Karimi, Armin Che, James Renier, Corinne Matsumoto, Melissa Triboulet, Melanie Garon, Edward B. Goldman, Jonathan W. Rettig, Matthew B. Jeffrey, Stefanie S. Kulkarni, Rajan P. Sollier, Elodie Di Carlo, Dino TI High efficiency vortex trapping of circulating tumor cells SO BIOMICROFLUIDICS LA English DT Article ID METASTATIC BREAST-CANCER; HETEROGENEITY; SIZE; SEPARATION; CAPTURE; SYSTEM; CHIP AB Circulating tumor cells (CTCs) are important biomarkers for monitoring tumor dynamics and efficacy of cancer therapy. Several technologies have been demonstrated to isolate CTCs with high efficiency but achieve a low purity from a large background of blood cells. We have previously shown the ability to enrich CTCs with high purity from large volumes of blood through selective capture in microvortices using the Vortex Chip. The device consists of a narrow channel followed by a series of expansion regions called reservoirs. Fast flow in the narrow entry channel gives rise to inertial forces, which direct larger cells into trapping vortices in the reservoirs where they remain circulating in orbits. By studying the entry and stability of particles following entry into reservoirs, we discover that channel cross sectional area plays an important role in controlling the size of trapped particles, not just the orbital trajectories. Using these design modifications, we demonstrate a new device that is able to capture a wider size range of CTCs from clinical samples, uncovering further heterogeneity. This simple biophysical method opens doors for a range of downstream interventions, including genetic analysis, cell culture, and ultimately personalized cancer therapy. (C) 2015 AIP Publishing LLC. C1 [Dhar, Manjima; Wong, Jessica; Karimi, Armin; Che, James; Matsumoto, Melissa; Di Carlo, Dino] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. [Dhar, Manjima; Karimi, Armin; Che, James; Di Carlo, Dino] Calif NanoSyst Inst, Los Angeles, CA 90095 USA. [Renier, Corinne; Sollier, Elodie] Vortex Biosci Inc, Menlo Labs, Menlo Pk, CA 94025 USA. [Triboulet, Melanie; Jeffrey, Stefanie S.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA. [Garon, Edward B.; Goldman, Jonathan W.] Univ Calif Los Angeles, Med Ctr, Div Hematol Oncol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, Med Ctr, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA 90073 USA. [Kulkarni, Rajan P.] Univ Calif Los Angeles, Med Ctr, Div Dermatol, Los Angeles, CA 90095 USA. RP Sollier, E (reprint author), Vortex Biosci Inc, Menlo Labs, 1455 Adams Dr,Suite 2010, Menlo Pk, CA 94025 USA. EM elodie@vortexbiosciences.com; dicarlo@ucla.edu FU Vortex Biosciences, Inc.; Office of Naval Research Young Investigator Program [N000141210847] FX The authors thank Dr. Oladunni Adeyiga, clinical coordinators, nurses, and all donors for their contributions toward blood sample collection. We thank Edward Pao for the PSA staining and Clementine Lemaire for the Vimentin/N-Cadherin staining optimization. This work was funded by Vortex Biosciences, Inc., and Office of Naval Research Young Investigator Program (Grant No. N000141210847). We would like to disclose the following conflicts of interest: The University of California, Los Angeles, D. Di Carlo, E. Sollier, and C. Renier have financial interests in Vortex Biosciences. NR 33 TC 4 Z9 5 U1 4 U2 10 PU AMER INST PHYSICS PI MELVILLE PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA SN 1932-1058 J9 BIOMICROFLUIDICS JI Biomicrofluidics PD NOV PY 2015 VL 9 IS 6 AR 064116 DI 10.1063/1.4937895 PG 12 WC Biochemical Research Methods; Biophysics; Nanoscience & Nanotechnology; Physics, Fluids & Plasmas SC Biochemistry & Molecular Biology; Biophysics; Science & Technology - Other Topics; Physics GA DA5CZ UT WOS:000367821100020 PM 26697126 ER PT J AU Pigeon, WR Heffner, KL Crean, H Gallegos, AM Walsh, P Seehuus, M Cerulli, C AF Pigeon, Wilfred R. Heffner, Kathi L. Crean, Hugh Gallegos, Autumn M. Walsh, Patrick Seehuus, Martin Cerulli, Catherine TI Responding to the need for sleep among survivors of interpersonal violence: A randomized controlled trial of a cognitive-behavioral insomnia intervention followed by PTSD treatment SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Sleep; Insomnia; Posttraumatic stress disorder; Depression; Interpersonal violence; Cognitive-behavioral therapy; Community-based participatory research ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; MAJOR DEPRESSIVE DISORDER; MISSING DATA; PRIMARY-CARE; PSYCHIATRIC-DISORDERS; PHYSICAL HEALTH; SEXUAL ASSAULT; THERAPY; CLINICIAN AB Sleep disturbance is a common feature of posttraumatic stress disorder (PTSD), but is not a focus of standard PTSD treatments. Psychological trauma exposure is associated with considerable physical and mental health morbidity, possibly due to the alterations in neuroendocrine function and inflammation observed in trauma exposed individuals. Although PTSD treatments are efficacious, they are associated with high drop-out rates in clinical trials and clinical practice. Finally, individuals with PTSD stemming from exposure to interpersonal violence represent an especially under-treated population with significant sleep disturbance. Community-based participatory research was utilized to design and prepare a clinical trial that randomizes recent survivors of interpersonal violence who have PTSD, depression, and insomnia to receive either: (1) Cognitive Behavioral Therapy for Insomnia (CBTi) followed by Cognitive Processing Therapy (CPT) for trauma, or (2) attention control followed by CPT. Outcome measures include subjective and objective measures of sleep, clinician-administered PTSD and depression scales, inflammatory cytokines, and salivary cortisol. Assessments are conducted at baseline, following the sleep or control intervention, and again following CPT. The design allows for: (1) the first test of a sleep intervention in this population; (2) the comparison of sequenced CBTi and CPT to attention control followed by CPT, and (3) assessing the roles of neuroendocrine function, inflammatory processes, and objective sleep markers in mediating treatment outcomes. The study's overarching hypothesis is that treating insomnia will produce reduction in insomnia, PTSD, and depression severity, allowing patients to more fully engage in, and derive optimal benefits from, cognitive processing therapy. Published by Elsevier Inc. C1 [Pigeon, Wilfred R.; Heffner, Kathi L.; Gallegos, Autumn M.; Walsh, Patrick; Seehuus, Martin] Univ Rochester, Sleep & Neurophysiol Res Lab, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA. [Pigeon, Wilfred R.] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua VA Med Ctr, Canandaigua, NY USA. [Crean, Hugh] Univ Rochester, Sch Nursing, Med Ctr, Rochester, NY 14642 USA. [Cerulli, Catherine] Univ Rochester, Susan B Anthony Ctr, Med Ctr, Rochester, NY 14642 USA. [Cerulli, Catherine] Univ Rochester, Lab Interpersonal Violence & Victimizat, Med Ctr, Rochester, NY 14642 USA. RP Pigeon, WR (reprint author), Univ Rochester, Sleep & Neurophysiol Res Lab, Med Ctr, 300 Crittenden Blvd Box PSYCH, Rochester, NY 14642 USA. EM Wilfred_pigeon@urmc.rochester.edu OI Heffner, Kathi/0000-0003-1095-1873; Crean, Hugh/0000-0001-7292-7700 FU National Institute of Nursing Research at the National Institute of Health [R01NR013909] FX The work presented here was funded by the National Institute of Nursing Research at the National Institute of Health (R01NR013909). The trial is registered with clinical trilas.gov (NCT01743339). NR 70 TC 0 Z9 0 U1 8 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2015 VL 45 BP 252 EP 260 DI 10.1016/j.cct.2015.08.019 PN B PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DA4FJ UT WOS:000367755200017 PM 26343743 ER PT J AU Coronado, K AF Coronado, Kristine TI Comment on "Emergency Nurses' Perceptions of Discharge Processes for Patients Receiving Schedule II and III Medications for Pain Management in the Emergency Department" SO JOURNAL OF EMERGENCY NURSING LA English DT Editorial Material C1 [Coronado, Kristine] South Texas Vet Hlth Care Syst, Emergency Dept, San Antonio, TX 78229 USA. RP Coronado, K (reprint author), South Texas Vet Hlth Care Syst, Emergency Dept, San Antonio, TX 78229 USA. EM chickriss@yahoo.com NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 EI 1527-2966 J9 J EMERG NURS JI J. Emerg. Nurs. PD NOV PY 2015 VL 41 IS 6 BP 468 EP 469 DI 10.1016/j.jen.2015.08.001 PG 4 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA DA1TJ UT WOS:000367578100007 PM 26546544 ER PT J AU Stewart, MW Traylor, AC Bratzke, LC AF Stewart, Mara W. Traylor, Abigail C. Bratzke, Lisa C. TI Nutrition and Cognition in Older Adults With Heart Failure A Systematic Review SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Review ID DIETARY-FAT INTAKE; IMPAIRMENT; PERFORMANCE; RISK; DEMENTIA; DYSFUNCTION; ASSOCIATION; POPULATION; DECLINE; HEALTH AB Cognitive impairment is commonly observed in older adults with heart failure; nutrition is a possible contributing factor. The purpose of the current systematic review is to examine the relationship between nutrition and cognition in older adults with heart failure. A literature review was performed through August 2015 that examined published, peer-reviewed studies from PubMed, PsycINFO, CINAHL, and Web of Science. Four articles were selected for inclusion. Findings revealed that poorer nutritional habits were associated with poorer attention, executive functioning, and memory in older adults with heart failure. Nutritional biomarkers, including anemia, hyponatremia, hypokalemia, hyperglycemia, and hypoalbuminemia, were also associated with cognitive impairment. More research is needed to explore the relationship between nutrition and cognition in this population. Descriptive studies will inform scientists as they design and test nutritional interventions to optimize cognitive function in older adults with heart failure. C1 [Stewart, Mara W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Traylor, Abigail C.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Bratzke, Lisa C.] Univ Wisconsin, Sch Nursing, Madison, WI USA. RP Stewart, MW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Unit 2B, Madison, WI 53705 USA. EM Mara.Stewart@VA.gov OI Bratzke, Lisa/0000-0002-0321-4501 FU National Institute of Nursing Research of the National Institutes of Health (NIH) [R00NR012773] FX The authors have disclosed no potential conflicts of interest, financial or otherwise. Research reported in this article was supported by the National Institute of Nursing Research of the National Institutes of Health (NIH; award number R00NR012773 [L. C. Bratzke]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 71 TC 1 Z9 1 U1 1 U2 3 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 EI 1938-243X J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD NOV PY 2015 VL 41 IS 11 BP 50 EP 59 DI 10.3928/00989134-20151015-06 PG 10 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA DA3JO UT WOS:000367693200007 PM 26505248 ER PT J AU Fanti, P Giustarini, D Rossi, R Cunningham, SED Folli, F Khazim, K Cornell, J Matteucci, E Bansal, S AF Fanti, Paolo Giustarini, Daniela Rossi, Ranieri Cunningham, Sue E. D. Folli, Franco Khazim, Khaled Cornell, John Matteucci, Elena Bansal, Shweta TI Dietary Intake of Proteins and Calories Is Inversely Associated With The Oxidation State of Plasma Thiols in End-Stage Renal Disease Patients SO JOURNAL OF RENAL NUTRITION LA English DT Article ID GELATINASE-ASSOCIATED LIPOCALIN; CHRONIC KIDNEY-DISEASE; MAINTENANCE HEMODIALYSIS-PATIENTS; SULFUR AMINO-ACIDS; METHIONINE RESTRICTION; OXIDANT STRESS; CARDIOVASCULAR-DISEASE; SKELETAL-MUSCLE; INFLAMMATION; FAILURE AB Objectives: Oxidative stress contributes to the pathogenesis of protein-energy wasting in maintenance hemodialysis (MHD) patients, but knowledge of specific effectors and mechanisms remains fragmented. Aim of the study was to define whether and how food intake is involved in the causal relationship between oxidative stress and protein-energy wasting. Methods: Seventy-one adult MHD patients and 24 healthy subjects (control) were studied cross-sectionally with analyses of diet record and of oxidative stress, as measured by a battery of plasma thiols including the protein sulfhydryl (-SH) group (PSH) levels (a marker of total protein-SH reducing capacity), the protein thiolation index (PTI, the ratio between disulfide, i.e., oxidized and reduced -SH groups in proteins), low molecular mass (LMM) thiols, LMM disulfides, and mixed LMM-protein disulfides. In addition, interleukin-6 (IL-6), albumin, C-reactive protein, and neutrophil gelatinase-associated lipocalin (NGAL) were measured as markers of inflammation. Results: The patients showed low energy (22.0 +/- 8.4 kcal/kg/day) and adequate protein (1.0 +/- 0.4 g/kg/day) intakes, high levels of cystine (CySS; patients vs. control: 113.5 [90.9-132.8] vs. 68.2 [56.2-75.7] mu M), cysteinylated proteins (CySSP; 216.0 [182.8-254.0] vs. 163.5 [150.0-195.5] mu M), and high PTI (0.76 [0.61-0.88] vs. 0.43 [0.40-0.54]; P < .001 in all comparisons). In patients, variation of CySSP was explained by a standard regression model (R = 0.775; P = .00001) that included significant contributions of protein intake (beta = -0.361), NGAL (beta = 0.387), age (beta = 0.295), and albumin (beta = 0.457). In the same model, variation of PTI (R = 0.624; P = .01) was explained by protein intake (beta = -0.384) and age (beta = 0.326) and NGAL (beta = 0.311). However, when PSH was entered as dependent variable (R = 0.730; P = .0001), only serum albumin (beta = 0.495) and age (beta = -0.280), but not dietary intake or NGAL, contributed to the model. Conclusions: In MHD, markers of thiol oxidation including CySSP and PTI show independent association with dietary intake and NGAL, whereas PSH, a marker of thiol-reducing capacity, did not associate with these same variables. The mechanism(s) responsible for inverse association between oxidative stress and food intake in MHD remain undefined. (C) 2015 by the National Kidney Foundation, Inc. All rights reserved. C1 [Fanti, Paolo; Bansal, Shweta] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Fanti, Paolo] South Texas Vet Hlth Care Syst, Renal Sect Med Serv, San Antonio, TX USA. [Giustarini, Daniela; Rossi, Ranieri] Univ Siena, Lab Pharmacol & Toxicol, Dept Life Sci, I-53100 Siena, Italy. [Cunningham, Sue E. D.] Univ Texas Hlth Sci Ctr San Antonio, Sch Hlth Profess, San Antonio, TX 78229 USA. [Folli, Franco] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA. [Khazim, Khaled] Western Galilee Hosp, Nephrol & Hypertens Unit, Nahariyya, Israel. [Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Matteucci, Elena] Univ Pisa, Dept Med, Pisa, Italy. RP Fanti, P (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr,MSC 7882, San Antonio, TX 78229 USA. EM fanti@uthscsa.edu OI Giustarini, Daniela/0000-0003-4929-5316; folli, franco/0000-0001-9824-5222 FU CSRD VA [I01 CX000264]; NCATS NIH HHS [1UL TR001120, UL1 TR001120]; NCCIH NIH HHS [AT004490, R21 AT004490] NR 49 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD NOV PY 2015 VL 25 IS 6 BP 494 EP 503 DI 10.1053/j.jrn.2015.06.003 PG 10 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA DA0UC UT WOS:000367512000008 PM 26235932 ER PT J AU Maltz, JS Tison, GH Alley, HF Budinger, TF Owens, CD Olgin, J AF Maltz, Jonathan S. Tison, Geoffrey H. Alley, Hugh F. Budinger, Thomas F. Owens, Christopher D. Olgin, Jeffrey TI Measurement of brachial artery endothelial function using a standard blood pressure cuff SO PHYSIOLOGICAL MEASUREMENT LA English DT Article DE endothelial function; arterial function; cardiovascular disease; smooth muscle; reactive hyperemia; atherosclerosis ID FLOW-MEDIATED DILATION; SMOOTH-MUSCLE RELAXATION; CARDIOVASCULAR EVENTS; NITRIC-OXIDE; CORONARY ATHEROSCLEROSIS; DEPENDENT DILATION; VASCULAR-DISEASE; EUROPEAN-SOCIETY; PREDICTIVE-VALUE; TRANSIT TIMES AB The integrity of endothelial function in major arteries (EFMA) is a powerful independent predictor of heart attack and stroke. Existing ultrasound-based non-invasive assessment methods are technically challenging and suitable only for laboratory settings. EFMA, like blood pressure (BP), is both acutely and chronically affected by factors such as lifestyle and medication. Consequently, laboratory-based measurements cannot fully gauge the effects of medical interventions on EFMA. EFMA and BP have, arguably, comparable (but complementary) value in the assessment of cardiovascular health. Widespread deployment of EFMA assessment is thus a desirable clinical goal. To this end, we propose a device based on modifying the measurement protocol of a standard electronic sphygmomanometer. The protocol involves inflating the cuff to sub-diastolic levels to enable recording of the pulse waveform before and after vasodilatory stimulus. The mechanical unloading of the arterial wall provided by the cuff amplifies the distension that occurs with each pulse, which is measured as a pressure variation in the cuff. We show that the height of the rising edge of each pulse is proportional to the change in lumen area between diastole and systole. This allows the effect of vasodilatory stimuli on the artery to be measured with high sensitivity. We compare the proposed cuff flow-mediated dilation (cFMD) method to ultrasound flow-mediated dilation (uFMD). We find significant correlation (r = 0.55, p = 0.003, N = 27) between cFMD- and uFMD-based metrics obtained when the release of a 5 min cuff occlusion is employed to induce endothelial stimulus via reactive hyperemia. cFMD is approximately proportional to the square of uFMD, representing a typical increase in sensitivity to vasodilation of 300-600%. This study illustrates the potential for an individual to conveniently measure his/her EFMA by using a low-cost reprogrammed home sphygmomanometer. C1 [Maltz, Jonathan S.; Budinger, Thomas F.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Dept Struct Biol & Imaging, Berkeley, CA 94720 USA. [Tison, Geoffrey H.; Olgin, Jeffrey] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA. [Tison, Geoffrey H.; Olgin, Jeffrey] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Alley, Hugh F.; Owens, Christopher D.] San Francisco VA Med Ctr, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA. [Alley, Hugh F.; Owens, Christopher D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Maltz, JS (reprint author), Cyclotron Rd,Mail Stop 55R0121, Berkeley, CA 94720 USA. EM jon@eecs.berkeley.edu FU US Department of Energy [DE-AC02-05CH11231]; Berkeley Lab Innovation Grant; Office of Science, Office of Basic Energy Sciences of the US Department of Energy [DE-AC02-05CH11231]; United States Government FX Funding for this work was provided, in part, by a Berkeley Lab Innovation Grant. The support and advice of Pam Seidenman and Bill Shelander of the Innovation and Partnerships Office is greatly appreciated.; This work was supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US Department of Energy under Contract No. DE-AC02-05CH11231.; this document was prepared as an account of work sponsored by the United States Government. While this document is believed to contain correct information, neither the United States Government nor any agency thereof, nor the Regents of the University of California, nor any of their employees, makes any warranty, express or implied, or assumes any legal responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by its trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof, or the Regents of the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof or the Regents of the University of California.; This manuscript has been authored by an author at Lawrence Berkeley National Laboratory under Contract No. DE-AC02-05CH11231 with the US Department of Energy. The US Government retains, and the publisher, by accepting the article for publication, acknowledges, that the US Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for US Government purposes. NR 50 TC 0 Z9 0 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0967-3334 EI 1361-6579 J9 PHYSIOL MEAS JI Physiol. Meas. PD NOV PY 2015 VL 36 IS 11 BP 2247 EP 2268 DI 10.1088/0967-3334/36/11/2247 PG 22 WC Biophysics; Engineering, Biomedical; Physiology SC Biophysics; Engineering; Physiology GA DA5LK UT WOS:000367844400003 PM 26393958 ER PT J AU Liu, H Li, W Rose, ME Hickey, RW Chen, J Uechi, GT Balasubramani, M Day, BW Patel, KV Graham, SH AF Liu, H. Li, W. Rose, M. E. Hickey, R. W. Chen, J. Uechi, G. T. Balasubramani, M. Day, B. W. Patel, K. V. Graham, S. H. TI The point mutation UCH-L1 C152A protects primary neurons against cyclopentenone prostaglandin-induced cytotoxicity: implications for post-ischemic neuronal injury SO CELL DEATH & DISEASE LA English DT Article ID TERMINAL HYDROLASE L1; PARKINSONS-DISEASE SUSCEPTIBILITY; MUTANT LOX SITES; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ENDOGENOUS ELECTROPHILE; CELLULAR-PROTEINS; CARDIAC-ARREST; UCHL1; GENE; CELLS AB Cyclopentenone prostaglandins (CyPGs), such as 15-deoxy-Delta(12,14)-prostaglandin J(2) (15dPGJ2), are reactive prostaglandin metabolites exerting a variety of biological effects. CyPGs are produced in ischemic brain and disrupt the ubiquitin-proteasome system (UPS). Ubiquitin-C-terminal hydrolase L1 (UCH-L1) is a brain-specific deubiquitinating enzyme that has been linked to neurodegenerative diseases. Using tandem mass spectrometry (MS) analyses, we found that the C152 site of UCH-L1 is adducted by CyPGs. Mutation of C152 to alanine (C152A) inhibited CyPG modification and conserved recombinant UCH-L1 protein hydrolase activity after 15dPGJ2 treatment. A knock-in (KI) mouse expressing the UCH-L1 C152A mutation was constructed with the bacterial artificial chromosome (BAC) technique. Brain expression and distribution of UCH-L1 in the KI mouse was similar to that of wild type (WT) as determined by western blotting. Primary cortical neurons derived from KI mice were resistant to 15dPGJ2 cytotoxicity compared with neurons from WT mice as detected by the WST-1 cell viability assay and caspase-3 and poly ADP ribose polymerase (PARP) cleavage. This protective effect was accompanied with significantly less ubiquitinated protein accumulation and aggregation as well as less UCH-L1 aggregation in C152A KI primary neurons after 15dPGJ2 treatment. Additionally, 15dPGJ2-induced axonal injury was also significantly attenuated in KI neurons as compared with WT. Taken together, these studies indicate that UCH-L1 function is important in hypoxic neuronal death, and the C152 site of UCH-L1 has a significant role in neuronal survival after hypoxic/ischemic injury. C1 [Liu, H.; Li, W.; Rose, M. E.; Graham, S. H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Liu, H.; Li, W.; Rose, M. E.; Chen, J.; Patel, K. V.; Graham, S. H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Hickey, R. W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA. [Uechi, G. T.; Balasubramani, M.; Day, B. W.] Univ Pittsburgh, Genom & Prote Core Labs, Pittsburgh, PA USA. [Day, B. W.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Res Off Bldg 30,Mail Code 151,Univ Dr, Pittsburgh, PA 15240 USA. EM Steven.Graham@va.gov FU VA Merit Review program; National Institutes of Health NINDS [R01NS37549]; Cancer Center Support Grant, National Cancer Institute [P30CA047904] FX This work was supported by the VA Merit Review program (SHG) and National Institutes of Health NINDS R01NS37549 (SHG). Work performed by the Biomedical Mass Spectrometry Center was supported in part by the Cancer Center Support Grant P30CA047904, National Cancer Institute. NR 55 TC 6 Z9 6 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD NOV PY 2015 VL 6 AR e1966 DI 10.1038/cddis.2015.323 PG 11 WC Cell Biology SC Cell Biology GA CZ5PU UT WOS:000367155300005 PM 26539913 ER PT J AU Cotter, G Voors, AA Prescott, MF Felker, GM Filippatos, G Greenberg, BH Pang, PS Ponikowski, P Milo, O Hua, TA Qian, M Severin, TM Teerlink, JR Metra, M Davison, BA AF Cotter, Gad Voors, Adriaan A. Prescott, Margaret F. Felker, G. Michael Filippatos, Gerasimos Greenberg, Barry H. Pang, Peter S. Ponikowski, Piotr Milo, Olga Hua, Tsushung A. Qian, Min Severin, Thomas M. Teerlink, John R. Metra, Marco Davison, Beth A. TI Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; GDF-15; RELAX-AHF study ID BETA SUPERFAMILY MEMBER; TROPONIN-T; INJURY; TRIAL AB Background Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking. Methods and results Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. Conclusions In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo. C1 [Cotter, Gad; Milo, Olga; Davison, Beth A.] Momentum Res Inc, Durham, NC 27707 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Prescott, Margaret F.; Hua, Tsushung A.; Severin, Thomas M.] Novartis Pharmaceut, New Hanover, NJ USA. [Felker, G. Michael] Duke Clin Res Inst, Durham, NC USA. [Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece. [Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Pang, Peter S.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Qian, Min] Columbia Univ, New York, NY USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Cotter, G (reprint author), Momentum Res Inc, 3100 Tower Blvd, Durham, NC 27707 USA. EM gadcotter@momentum-research.com FU Novartis Pharmaceuticals Inc. FX This study was funded by Novartis Pharmaceuticals Inc. NR 17 TC 9 Z9 9 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2015 VL 17 IS 11 BP 1133 EP 1143 DI 10.1002/ejhf.331 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY4YP UT WOS:000366415100008 PM 26333529 ER PT J AU Scales, CD Bergman, J Carter, S Jack, G Saigal, CS Litwin, MS AF Scales, Charles D., Jr. Bergman, Jonathan Carter, Stacey Jack, Gregory Saigal, Christopher S. Litwin, Mark S. CA NIDDK Urologic Dis Amer Project TI Quality of Acute Care for Patients With Urinary Stones in the United States SO UROLOGY LA English DT Article ID KIDNEY-STONES; RADIATION-EXPOSURE; CT SCANS; RISK; UROLITHIASIS; PREVALENCE; MANAGEMENT; PATTERNS; CALCULI; TRENDS AB OBJECTIVE To describe guideline adherence for patients with suspected upper tract stones. PATIENTS AND METHODS We performed a cross-sectional analysis of visits recorded by the National Hospital Ambulatory Medical Care Survey (emergency department [ED] component) in 2007-2010 (most recent data). We assessed adherence to clinical guidelines for diagnostic laboratory testing, imaging, and pharmacologic therapy. Multivariable regression models controlled for important covariates. RESULTS An estimated 4,956,444 ED visits for patients with suspected kidney stones occurred during the study period. Guideline adherence was highest for diagnostic imaging, with 3,122,229 (63%) visits providing optimal imaging. Complete guideline-based laboratory testing occurred in only 2 of every 5 visits. Pharmacologic therapy to facilitate stone passage was prescribed during only 17% of eligible visits. In multivariable analysis of guideline adherence, we found little variation by patient, provider, or facility characteristics. CONCLUSION Guideline-recommended care was absent from a substantial proportion of acute care visits for patients with suspected kidney stones. These failures of care delivery likely increase costs and temporary disability. Targeted interventions to improve guideline adherence should be designed and evaluated to improve care for patients with symptomatic kidney stones. Published by Elsevier Inc. C1 Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA. US Dept Vet Affairs, Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Scales, CD (reprint author), Duke Clin Res Inst, Div Urol Surg, DUMC 3707, Durham, NC 27710 USA. EM Chuck.scales@duke.edu FU Robert Wood Johnson Foundation Clinical Scholars program; U.S. Department of Veterans Affairs; Urologic Diseases in America Project, through the National Institute of Diabetes and Digestive and Kidney Diseases; National Library of Medicine [HHSN276201200016C] FX Charles D. Scales and Jonathan Bergman were supported by the Robert Wood Johnson Foundation Clinical Scholars program and the U.S. Department of Veterans Affairs during conduct of this research. Christopher S. Saigal and Mark S. Litwin were supported by the Urologic Diseases in America Project, through the National Institute of Diabetes and Digestive and Kidney Diseases and the National Library of Medicine (HHSN276201200016C). NR 27 TC 1 Z9 1 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2015 VL 86 IS 5 BP 914 EP 921 DI 10.1016/j.urology.2015.07.040 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CY5RZ UT WOS:000366466400016 PM 26335495 ER PT J AU Ross, C Salmon, A Strong, R Fernandez, E Javors, M Richardson, A Tardif, S AF Ross, Corinna Salmon, Adam Strong, Randy Fernandez, Elizabeth Javors, Marty Richardson, Arlan Tardif, Suzette TI Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus) SO AGING-US LA English DT Article DE nonhuman primate; antiaging; longevity; healthspan; animal models; sirolimus ID HIGH-FAT DIET; INDUCED INSULIN-RESISTANCE; LIFE-SPAN; GLUCOSE-INTOLERANCE; TRANSPLANT RECIPIENTS; MAMMALIAN TARGET; NONHUMAN PRIMATE; MTOR INHIBITION; FOOD-INTAKE; MALE-MICE AB Rapamycin has been shown to extend lifespan in rodent models, but the effects on metabolic health and function have been widely debated in both clinical and translational trials. Prior to rapamycin being used as a treatment to extend both lifespan and healthspan in the human population, it is vital to assess the side effects of the treatment on metabolic pathways in animal model systems, including a closely related non-human primate model. In this study, we found that long-term treatment of marmoset monkeys with orally-administered encapsulated rapamycin resulted in no overall effects on body weight and only a small decrease in fat mass over the first few months of treatment. Rapamycin treated subjects showed no overall changes in daily activity counts, blood lipids, or significant changes in glucose metabolism including oral glucose tolerance. Adipose tissue displayed no differences in gene expression of metabolic markers following treatment, while liver tissue exhibited suppressed G6Pase activity with increased PCK and GPI activity. Overall, the marmosets revealed only minor metabolic consequences of chronic treatment with rapamycin and this adds to the growing body of literature that suggests that chronic and/or intermittent rapamycin treatment results in improved health span and metabolic functioning. The marmosets offer an interesting alternative animal model for future intervention testing and translational modeling. C1 [Ross, Corinna] Texas A&M Univ, Dept Arts & Sci, San Antonio, TX 78224 USA. [Ross, Corinna; Salmon, Adam; Strong, Randy; Fernandez, Elizabeth; Javors, Marty; Tardif, Suzette] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78224 USA. [Salmon, Adam; Fernandez, Elizabeth; Javors, Marty] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78224 USA. [Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. [Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK 73104 USA. [Tardif, Suzette] Southwest Natl Primate Res Ctr, Texas Biomed Res Inst, San Antonio, TX 78224 USA. RP Ross, C (reprint author), Texas A&M Univ, Dept Arts & Sci, San Antonio, TX 78224 USA. EM cnross@tamusa.tamus.edu FU Barshop Institute for Longevity and Aging Studies; Glenn Foundation; San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging; Southwest National Primate Research Center [P51-OD-13986] FX This research was financially supported by the Barshop Institute for Longevity and Aging Studies, the Glenn Foundation, the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging and the Southwest National Primate Research Center (P51-OD-13986). NR 52 TC 5 Z9 5 U1 3 U2 3 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1945-4589 J9 AGING-US JI Aging-US PD NOV PY 2015 VL 7 IS 11 BP 964 EP 973 PG 10 WC Cell Biology SC Cell Biology GA CY4HR UT WOS:000366369700011 PM 26568298 ER PT J AU Boots, EA Schultz, SA Almeida, RP Oh, JM Koscik, RL Dowling, MN Gallagher, CL Carlsson, CM Rowley, HA Bendlin, BB Asthana, S Sager, MA Hermann, BP Johnson, SC Okonkwo, OC AF Boots, Elizabeth A. Schultz, Stephanie A. Almeida, Rodrigo P. Oh, Jennifer M. Koscik, Rebecca L. Dowling, Maritza N. Gallagher, Catherine L. Carlsson, Cynthia M. Rowley, Howard A. Bendlin, Barbara B. Asthana, Sanjay Sager, Mark A. Hermann, Bruce P. Johnson, Sterling C. Okonkwo, Ozioma C. TI Occupational Complexity and Cognitive Reserve in a Middle-Aged Cohort at Risk for Alzheimer's Disease SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Alzheimer's disease; Occupation; Cognitive reserve; Hippocampus; Cognition; Imaging ID SURFACE-BASED ANALYSIS; PITTSBURGH COMPOUND-B; LIFETIME OCCUPATION; EMISSION-TOMOGRAPHY; WISCONSIN-REGISTRY; BRAIN VOLUME; EDUCATION; DECLINE; DEMENTIA; ADULTS AB Higher occupational attainment has previously been associated with increased Alzheimer's disease (AD) neuropathology when individuals are matched for cognitive function, indicating occupation could provide cognitive reserve. We examined whether occupational complexity (OCC) associates with decreased hippocampal volume and increased whole-brain atrophy given comparable cognitive function in middle-aged adults at risk for AD. Participants (n = 323) underwent structural MRI, cognitive evaluation, and work history assessment. Three complexity ratings (work with data, people, and things) were obtained, averaged across up to 3 reported jobs, weighted by years per job, and summed to create a composite OCC rating. Greater OCC was associated with decreased hippocampal volume and increased whole-brain atrophy when matched for cognitive function; results remained substantively unchanged after adjusting for several demographic, AD risk, vascular, mental health, and socioeconomic characteristics. These findings suggest that, in people at risk for AD, OCC may confer resilience to the adverse effects of neuropathology on cognition. C1 [Boots, Elizabeth A.; Schultz, Stephanie A.; Almeida, Rodrigo P.; Oh, Jennifer M.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Bendlin, Barbara B.; Asthana, Sanjay; Johnson, Sterling C.; Okonkwo, Ozioma C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Boots, Elizabeth A.; Schultz, Stephanie A.; Almeida, Rodrigo P.; Oh, Jennifer M.; Dowling, Maritza N.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Rowley, Howard A.; Bendlin, Barbara B.; Asthana, Sanjay; Sager, Mark A.; Hermann, Bruce P.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Almeida, Rodrigo P.] Univ Fed Fluminense, BR-24220 Niteroi, RJ, Brazil. [Koscik, Rebecca L.; Bendlin, Barbara B.; Asthana, Sanjay; Sager, Mark A.; Hermann, Bruce P.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53705 USA. [Dowling, Maritza N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Gallagher, Catherine L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53705 USA. [Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53792 USA. RP Okonkwo, OC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. EM ozioma@medicine.wisc.edu OI Schultz, Stephanie/0000-0001-8460-4415 FU NCATS NIH HHS [UL1 TR000427]; NCRR NIH HHS [UL1RR025011]; NIA NIH HHS [K23AG045957, P50 AG033514, P50 AG033514-S1, R01 AG021155, R01 AG027161, R01 AG037639] NR 40 TC 4 Z9 4 U1 1 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD NOV PY 2015 VL 30 IS 7 BP 634 EP 642 DI 10.1093/arclin/acv041 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA CY4GQ UT WOS:000366367000005 PM 26156334 ER PT J AU Walker, RJ Smalls, BL Egede, LE AF Walker, Rebekah J. Smalls, Brittany L. Egede, Leonard E. TI Social determinants of health in adults with type 2 diabetes-Contribution of mutable and immutable factors SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetes; Social determinants; Socioeconomic; Psychological; Built environment ID OF-THE-LITERATURE; GLYCEMIC CONTROL; SELF-CARE; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL DISTRESS; SOCIOECONOMIC POSITION; MEDICATION ADHERENCE; DEPRESSION; MANAGEMENT; METAANALYSIS AB Aims: Socioeconomic, psychosocial, and neighborhood factors influence clinical outcomes and self-care behaviors in diabetes; however, few studies simultaneously assessed the impact of multiple social determinant of health factors on glycemic control. We used an explanatory model to examine the differential contribution of social determinants and clinical factors on glycemic control. Secondarily, we examined the contribution of mutable and immutable factors to identify meaningful future interventions. Methods: Six hundred and fifteen adults with type 2 diabetes in the southeastern United States were recruited. A hierarchical model was run with HbA1c as the dependent variable and independent variables entered in blocks: demographics (block 1), socioeconomic (block 2), psychosocial (block 3), built environment (block 4), clinical (block 5), and knowledge/selfcare (block 6). Results: Significant associations for HbA1c included self-efficacy (beta = -0.10, p < 0.001), social support (beta = 0.01, p < 0.05), comorbidity (beta = -0.09, p < 0.05), insulin use (beta = 0.95, p < 0.001), medication adherence (beta = -0.11, p < 0.05), and being a former smoker (beta = 0.34, p < 0.05); accounting for 24.4% of the variance. Conclusions: Important factors that drive glycemic control are mutable, and amenable to health interventions. Greater attention should be given to interventions that increase self-efficacy and social support, reduce the burden of comorbidities, and enhance medication adherence and smoking cessation. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VAMC, Charleston VA HSR&D COIN, Hlth Equ & Rural Outreach Innovat Ctr HEROIC, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Smalls, Brittany L.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 48 TC 1 Z9 1 U1 11 U2 23 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 EI 1872-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD NOV PY 2015 VL 110 IS 2 BP 193 EP 201 DI 10.1016/j.diabres.2015.09.007 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CY3NS UT WOS:000366317100011 PM 26411692 ER PT J AU Halaney, DL Zahedivash, A Phipps, JE Wang, TY Dwelle, J Le Saux, CJ Asmis, R Milner, TE Feldman, MD AF Halaney, David L. Zahedivash, Aydin Phipps, Jennifer E. Wang, Tianyi Dwelle, Jordan Le Saux, Claude Jourdan Asmis, Reto Milner, Thomas E. Feldman, Marc D. TI Differences in forward angular light scattering distributions between M1 and M2 macrophages SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE macrophage; M1 M2; angular light scattering ID LOW-COHERENCE INTERFEROMETRY; MITOCHONDRIAL MEMBRANE FRAGMENTS; TUMOR-ASSOCIATED MACROPHAGES; IN-SITU; MONONUCLEAR PHAGOCYTES; BIOLOGICAL CELLS; RAT-LIVER; ATHEROSCLEROSIS; POLARIZATION; DIFFERENTIATION AB The ability to distinguish macrophage subtypes noninvasively could have diagnostic potential in cancer, atherosclerosis, and diabetes, where polarized M1 and M2 macrophages play critical and often opposing roles. Current methods to distinguish macrophage subtypes rely on tissue biopsy. Optical imaging techniques based on light scattering are of interest as they can be translated into biopsy-free strategies. Because mitochondria are relatively strong subcellular light scattering centers, and M2 macrophages are known to have enhanced mitochondrial biogenesis compared to M1, we hypothesized that M1 and M2 macrophages may have different angular light scattering profiles. To test this, we developed an in vitro angle-resolved forward light scattering measurement system. We found that M1 and M2 macrophage monolayers scatter relatively unequal amounts of light in the forward direction between 1.6 deg and 3.2 deg with M2 forward scattering significantly more light than M1 at increasing angles. The ratio of forward scattering can be used to identify the polarization state of macrophage populations in culture. (C) 2015 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Halaney, David L.; Phipps, Jennifer E.; Le Saux, Claude Jourdan; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. [Halaney, David L.; Dwelle, Jordan; Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Zahedivash, Aydin; Wang, Tianyi; Dwelle, Jordan; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Lab Sci, San Antonio, TX 78229 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM feldmanm@uthscsa.edu OI Halaney, David/0000-0003-4437-0516 FU Veterans Health Administration Merit Grant [I01 BX000397]; Janey and Dolph Briscoe Center for Cardiovascular Research (San Antonio, Texas); Clayton Foundation for Biomedical Research (Houston, Texas); National Institutes of Health [T32 HL007446]; American Society for Laser, Medicine, and Surgery Research Grant; American Heart Association Post-doctoral Award [13POST17080074] FX This work was supported by the Veterans Health Administration Merit Grant I01 BX000397; the Janey and Dolph Briscoe Center for Cardiovascular Research (San Antonio, Texas); the Clayton Foundation for Biomedical Research (Houston, Texas); the National Institutes of Health (T32 HL007446); an American Society for Laser, Medicine, and Surgery 2013-2014 Research Grant; and an American Heart Association Post-doctoral Award (13POST17080074). NR 59 TC 1 Z9 1 U1 1 U2 4 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD NOV PY 2015 VL 20 IS 11 AR 115002 DI 10.1117/1.JBO.20.11.115002 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA CX9IA UT WOS:000366017500026 PM 26538329 ER PT J AU Tsu, AP Burish, MJ GodLove, J Ganguly, K AF Tsu, Adelyn P. Burish, Mark J. GodLove, Jason Ganguly, Karunesh TI Cortical neuroprosthetics from a clinical perspective SO NEUROBIOLOGY OF DISEASE LA English DT Review ID BRAIN-COMPUTER INTERFACES; AMYOTROPHIC-LATERAL-SCLEROSIS; ELECTROCORTICOGRAPHIC SPECTRAL-ANALYSIS; HUMAN SENSORIMOTOR CORTEX; MOTOR CORTEX; MACHINE INTERFACES; NEURAL PROSTHETICS; COGNITIVE CONTROL; ARM MOVEMENTS; STIMULATION AB Recent pilot clinical studies have demonstrated that subjects with severe disorders of movement and communication can exert direct neural control over assistive devices using invasive Brain-Machine Interface (BMI) technology, also referred to as 'cortical neuroprosthetics'. These important proof-of-principle studies have generated great interest among those with disability and clinicians who provide general medical, neurological and/or rehabilitative care. Taking into account the perspective of providers who may be unfamiliar with the field, we first review the clinical goals and fundamentals of invasive BMI technology, and then briefly summarize the vast body of basic science research demonstrating its feasibility. We emphasize recent translational progress in the target clinical populations and discuss translational challenges and future directions. Published by Elsevier Inc. C1 [Tsu, Adelyn P.; GodLove, Jason; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA USA. [Burish, Mark J.; GodLove, Jason; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Ctr Neural Engn & Prosthet, San Francisco, CA 94143 USA. [Ganguly, Karunesh] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Ganguly, K (reprint author), 1700 Owens St, San Francisco, CA 94158 USA. EM karunesh.ganguly@ucsf.edu FU Office of Academic Affairs at the Department of Veterans Affairs; Doris Duke Charitable Foundation [2013101]; UCSF Department of Neurology; NCIRE; Burroughs Wellcome Fund [1000985] FX This work was supported by a fellowship award to Adelyn Tsu from the Office of Academic Affairs at the Department of Veterans Affairs. This work was also supported by Grant 2013101 from the Doris Duke Charitable Foundation and start-up funds from the UCSF Department of Neurology and NCIRE. Karunesh Ganguly, M.D., Ph.D., also holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund (1000985). NR 109 TC 0 Z9 0 U1 5 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD NOV PY 2015 VL 83 BP 154 EP 160 DI 10.1016/j.nbd.2015.07.015 PG 7 WC Neurosciences SC Neurosciences & Neurology GA CY2HS UT WOS:000366230000015 PM 26253606 ER PT J AU Koffarnus, RL Darin, KM Hedges, A Man, B Nelson, C Peron, E Tran, T Holder, R AF Koffarnus, Robin L. Darin, Kristin M. Hedges, Ashley Man, Bernice Nelson, Cory Peron, Emily Tran Tran Holder, Renee TI An introduction to the Global Health PRN and its members SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy Global Conference on Clinical Pharmacy CY OCT 17-21, 2015 CL San Francisco, CA SP Amer Coll Clin Pharm C1 [Koffarnus, Robin L.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dallas, TX USA. [Darin, Kristin M.] Northwestern Univ, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA. [Darin, Kristin M.] Northwestern Univ, Ctr Global Hlth, Feinberg Sch Med, Chicago, IL 60611 USA. [Hedges, Ashley] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Man, Bernice] Chicago State Univ, Coll Pharm, Chicago, IL USA. [Peron, Emily] Virginia Commonwealth Univ, Sch Pharm, Richmond, VA USA. [Tran Tran; Holder, Renee] Roseman Univ Hlth Sci, Coll Pharm, Henderson, NV USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV PY 2015 VL 35 IS 11 MA 320 BP E254 EP E254 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CX9SG UT WOS:000366045000248 ER PT J AU Lichvar, A Hedges, A Benedict, N Donihi, AC AF Lichvar, Alicia Hedges, Ashley Benedict, Neal Donihi, Amy C. TI Combination of a flipped classroom and a virtual patient case to enhance active learning in the classroom SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy Global Conference on Clinical Pharmacy CY OCT 17-21, 2015 CL San Francisco, CA SP Amer Coll Clin Pharm C1 [Lichvar, Alicia] Univ Pittsburgh, Med Ctr, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Hedges, Ashley] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Benedict, Neal; Donihi, Amy C.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. RI 向飞, 郭/A-1604-2016 NR 0 TC 0 Z9 0 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV PY 2015 VL 35 IS 11 MA 39 BP E184 EP E184 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CX9SG UT WOS:000366045000036 ER PT J AU Schell, R Abramcyzk, A Fominaya, C Friedman, R Castle, S AF Schell, Ryan Abramcyzk, Anthony Fominaya, Cory Friedman, Robert Castle, Sharon TI Outcomes associated with a multidisciplinary pain oversight committee to facilitate appropriate management of chronic opioid therapy in Veterans SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy Global Conference on Clinical Pharmacy CY OCT 17-21, 2015 CL San Francisco, CA SP Amer Coll Clin Pharm C1 [Schell, Ryan; Abramcyzk, Anthony; Fominaya, Cory; Castle, Sharon] Ralph H Johnson VA Med Ctr, Serv Pharm, Charleston, SC USA. [Friedman, Robert] Ralph H Johnson VA Med Ctr, Dept Anesthesiol, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV PY 2015 VL 35 IS 11 MA 410 BP E280 EP E281 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CX9SG UT WOS:000366045000335 ER PT J AU Schneider, A Henderson, JT Harper, CC Hsu, A Saraiya, M Sawaya, GF AF Schneider, Allison Henderson, Jillian T. Harper, Cynthia C. Hsu, Amy Saraiya, Mona Sawaya, George F. TI Obstetrician-gynecologists' beliefs about performing less cervical cancer screening: the pendulum swings SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material ID NEOPLASIA C1 [Schneider, Allison] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Henderson, Jillian T.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Harper, Cynthia C.; Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Hsu, Amy] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Sawaya, George F.] Univ Calif San Francisco, Ctr Healthcare Value, San Francisco, CA 94143 USA. RP Schneider, A (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. EM George.sawaya@ucsf.edu FU NCI NIH HHS [R01 CA169093]; NICHD NIH HHS [K01 HD054495, K01HD054495] NR 5 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2015 VL 213 IS 5 BP 744 EP 745 DI 10.1016/j.ajog.2015.07.003 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CX5SS UT WOS:000365763400046 PM 26184779 ER PT J AU Oishi, SM Marshall, N Hamilton, AB Yano, EM Lerner, B Scheuner, MT AF Oishi, Sabine M. Marshall, Nell Hamilton, Alison B. Yano, Elizabeth M. Lerner, Barbara Scheuner, Maren T. TI Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach SO GENETICS IN MEDICINE LA English DT Article DE genomic medicine; health services; implementation; organization; translation ID KEY INFORMANT TECHNIQUE; HEALTH-CARE; VETERANS; CONTINUUM; DELIVERY; PERSPECTIVE; PERFORMANCE; INTEGRATION; CHALLENGES; SERVICES AB Purpose: Adoption and implementation of evidence-based genetic and genomic medicine have been slow. We describe a methodology for identifying the influence of organizational factors on adoption and implementation of these services in health-care organizations. Methods: We illustrate a three-component, mixed-methods health services research approach, including expert panels, qualitative interviews with key informants, and quantitative surveys completed by key informants. Results: This research approach yielded a baseline assessment of existing genetic health-care models in the Veterans Health Administration and identified organizational barriers to and facilitators of adoption. In aggregate, the panel and key informant strategies created a communication network of relevant organizational stakeholders and a detailed foundation of organizational knowledge from which to design tools and models for implementation-level genetic/genomic translation. Conclusion: Expert panel and key informant strategies can be used to create a backdrop of stakeholder involvement and baseline organizational knowledge within which to plan translation research and to inform strategic planning and policies for adoption and implementation of genetic services in health-care organizations. C1 [Oishi, Sabine M.; Marshall, Nell; Hamilton, Alison B.; Yano, Elizabeth M.; Scheuner, Maren T.] Vet Affairs Greater Los Angeles Healthcare Syst, Vett Affairs Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Lerner, Barbara] Vet Affairs Boston Healthcare Syst, Vet Affairs Hlth Serv Res & Dev Ctr Healthcare Or, Boston, MA USA. [Scheuner, Maren T.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Med Genet, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Oishi, SM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Vett Affairs Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. EM sabine.oishi@va.gov FU VHA Health Services Research & Development (HSRD) Service [IBD 09-101, DNA 08-128]; National Institute of Mental Health [R25 MH080916-01A2]; VA HSRD QUERI; VA HSR&D Senior Research Career Scientist Award [05-195]; VA Greater Los Angeles HSR&D Center of Innovation [CIN 13-417]; VA HSRD Service FX The VHA Health Services Research & Development (HSR&D) Service (grants IBD 09-101 and DNA 08-128) funded the research presented in this article. At the time of the study, A.B.H. was an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work, Washington University, St Louis, Missouri, through an award from the National Institute of Mental Health (R25 MH080916-01A2) and VA HSR&D QUERI. E.M.Y.'s effort was supported by a VA HSR&D Senior Research Career Scientist Award (no. 05-195). This work was further supported by the VA Greater Los Angeles HSR&D Center of Innovation (CIN 13-417). S.M.O. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors are employed by the Department of Veterans Affairs. A.B.H., E.M.Y, B.L., and M.T.S. receive research funding from the VA HSR&D Service. The views expressed within are solely those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US government. NR 40 TC 0 Z9 0 U1 3 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2015 VL 17 IS 11 BP 919 EP 926 DI 10.1038/gim.2015.7 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA CX8TL UT WOS:000365977000012 PM 25741861 ER PT J AU Folmer, RL Theodoroff, SM AF Folmer, Robert L. Theodoroff, Sarah M. TI Assessment of Blinding in a Tinnitus Treatment Trial Reply SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Letter C1 [Folmer, Robert L.; Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Folmer, Robert L.; Theodoroff, Sarah M.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM Robert.Folmer@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD NOV PY 2015 VL 141 IS 11 BP 1031 EP 1032 DI 10.1001/jamaoto.2015.2422 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CX1PZ UT WOS:000365469400021 PM 26583514 ER PT J AU Cawthon, PM Blackwell, TL Cauley, J Kado, DM Barrett-Connor, E Lee, CG Hoffman, AR Nevitt, M Stefanick, ML Lane, NE Ensrud, KE Cummings, SR Orwoll, ES AF Cawthon, Peggy M. Blackwell, Terri L. Cauley, Jane Kado, Deborah M. Barrett-Connor, Elizabeth Lee, Christine G. Hoffman, Andrew R. Nevitt, Michael Stefanick, Marcia L. Lane, Nancy E. Ensrud, Kristine E. Cummings, Steven R. Orwoll, Eric S. TI Evaluation of the Usefulness of Consensus Definitions of Sarcopenia in Older Men: Results from the Observational Osteoporotic Fractures in Men Cohort Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE sarcopenia; falls; fractures; mortality; functional limitation ID SKELETAL-MUSCLE MASS; CLINICALLY RELEVANT WEAKNESS; LOWER-EXTREMITY FUNCTION; LOW LEAN MASS; PHYSICAL PERFORMANCE; GRIP STRENGTH; CARDIOVASCULAR HEALTH; MORTALITY RISK; GAIT SPEED; FAT MASS AB ObjectiveTo evaluate the associations between definitions of sarcopenia and clinical outcomes and the ability of the definitions to discriminate those with a high likelihood of having these outcomes from those with a low likelihood. DesignOsteoporotic Fractures in Men Study. SettingSix clinical centers. ParticipantsCommunity-dwelling men aged 65 and older (N = 5,934). MeasurementsSarcopenia definitions from the International Working Group, European Working Group on Sarcopenia in Older Persons, Foundation for the National Institutes of Health Sarcopenia Project, Baumgartner, and Newman were evaluated. Recurrent falls were defined as two or more self-reported falls in the year after baseline (n = 694, 11.9%). Incident hip fractures (n = 207, 3.5%) and deaths (n = 2,003, 34.1%) were confirmed according to central review of medical records over 9.8 years. Self-reported functional limitations were assessed at baseline and 4.6 years later. Logistic regression or proportional hazards models were used to estimate associations between sarcopenia and falls, hip fractures, and death. The discriminative ability of the sarcopenia definitions (vs reference models) for these outcomes was evaluated using area under the receiver operating characteristic curve or C-statistics. Referent models included age alone for falls, functional limitations and mortality, and age and bone mineral density for hip fractures. ResultsThe association between sarcopenia according to the various definitions and risk of falls, functional limitations, and hip fractures was variable; all definitions were associated with greater risk of death, but none of the definitions materially changed discrimination based on the AUC and C-statistic when compared with reference models (change 1% in all models). ConclusionSarcopenia definitions as currently constructed did not consistently improve prediction of clinical outcomes in relatively healthy older men. C1 [Cawthon, Peggy M.; Blackwell, Terri L.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA 94158 USA. [Cauley, Jane] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Kado, Deborah M.; Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Lee, Christine G.] Portland VA Med Ctr, Portland, OR USA. [Hoffman, Andrew R.; Stefanick, Marcia L.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Nevitt, Michael] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Lane, Nancy E.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Minneapolis Vet Affairs Hlth Syst, Minneapolis, MN USA. [Orwoll, Eric S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. RP Cawthon, PM (reprint author), Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, 550 16th St,2nd Floor,Box 0560, San Francisco, CA 94158 USA. EM pcawthon@sfcc-cpmc.net RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU National Institutes of Health; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Center for Advancing Translational Sciences; NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; VA Clinical Science Research and Development Career Development Award [5IK2CW000729-02] FX MrOS is supported by National Institutes of Health funding. The National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Advancing Translational Sciences, and NIH Roadmap for Medical Research provide support under grants U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. CGL receives support from a VA Clinical Science Research and Development Career Development Award, Project number 5IK2CW000729-02. NR 44 TC 14 Z9 14 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2015 VL 63 IS 11 BP 2247 EP 2259 DI 10.1111/jgs.13788 PG 13 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CX4NV UT WOS:000365678500002 PM 26502831 ER PT J AU Rodriguez, JC Dzierzewski, JM Fung, CH Jouldjian, S Josephson, KR Mitchell, MN Song, YS Martin, JL Alessi, CA AF Rodriguez, Juan C. Dzierzewski, Joseph M. Fung, Constance H. Jouldjian, Stella Josephson, Karen R. Mitchell, Michael N. Song, Yeonsu Martin, Jennifer L. Alessi, Cathy A. TI Association Between Pain and Functional Independence in Older Adults During and After Admission to Rehabilitation After an Acute Illness or Injury SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; aged; rehabilitation; functional independence ID QUALITY-OF-LIFE; HIP FRACTURE; POSTOPERATIVE PAIN; PERSISTENT PAIN; INPATIENT REHABILITATION; MEDICAL COMPLICATIONS; STROKE; RECOVERY; SURGERY; PEOPLE AB ObjectivesTo investigate the association between pain and functional independence in older adults during and after admission to rehabilitation after an acute illness or injury. DesignProspective, observational cohort study. SettingOne community and one Veterans Affairs rehabilitation center. ParticipantsIndividuals aged 65 and older admitted for rehabilitation after an acute illness or injury (postacute rehabilitation) (N=245; mean age 80.6, 72% male)). MeasurementsPain was assessed using the Geriatric Pain Measure (GPM, score 0-100). Functional independence was measured using the motor component of the Functional Independence Measure (mFIM, score 13-91). Both scores were obtained at admission; discharge; and 3-, 6-, and 9-month follow-up. In bivariate analyses, discharge GPM and persistent pain (lasting >3months) were evaluated as predictors of mFIM score at 9months. Applying a multilevel modeling (MLM) approach, individual deviations in GPM scores were used to predict variations in mFIM. ResultsAt admission, 210 participants (87.9%) reported pain (16.3% mild (GPM<30); 49.3% moderate (GPM: 30-69); 22.1% severe (GPM>70)); 21.3% reported persistent pain after discharge. The bivariate analyses did not find statistically significant associations between discharge GPM or persistent pain and mFIM score at 9months, but in the MLM analysis, deviations in GPM were significant predictors of deviations in mFIM score, suggesting that, when individuals experienced above-average levels of pain (GPM > their personal mean GPM), they also experienced worse functional independence (mFIM C with Modified Mini-Mental State Examination score ( p =.009); m. 11778G> A with contrast sensitivity ( p =.02); m. 7445A> G with high-frequency hearing ( p =.047); and m. 5703G> A with 400 m walking speed ( p =.007). Conclusions. These results indicate that increased mtDNA heteroplasmy at disease-causing sites is associated with neurosensory and mobility function in older persons. We propose the novel use of mtDNA heteroplasmy as a simple, noninvasive predictor of age-related neurologic, sensory, and movement impairments. C1 [Tranah, Gregory J.; Rowbotham, Michael C.; Browner, Warren S.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Katzman, Shana M.] LA Eye Ctr & Clin, Los Angeles, CA USA. [Lam, Ernest T.] BioNano Genom Inc, San Diego, CA USA. [Pawlikowska, Ludmila] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. [Pawlikowska, Ludmila; Kwok, Pui-Yan] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. [Schork, Nicholas J.] J Craig Venter Inst, San Francisco, CA USA. [Schork, Nicholas J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Manini, Todd M.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. [Kritchevsky, Stephen] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Thomas, Fridtjof] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Coleman, Anne L.; Gorin, Michael B.] Jules Stein Eye Inst, Los Angeles, CA 90024 USA. [Coleman, Anne L.; Gorin, Michael B.] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA. [Helzner, Elizabeth P.] Suny Downstate Med Ctr, Dept Epidemiol & Biostat, Brooklyn, NY 11203 USA. RP Tranah, GJ (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Mission Hall Global Hlth & Clin Sci Bldg,550 16th, San Francisco, CA 94143 USA. EM gtranah@sfcc-cpmc.net FU NIH, National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institutes of Health [R01-AG028050, R03-AG032498, R01-NR012459, Z01A6000932, R01-HL121023]; Research and Education Leadership Committee of the CPMC Foundation FX This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; National Institutes of Health grants R01-AG028050, R03-AG032498, R01-NR012459, Z01A6000932, R01-HL121023, and a grant from the Research and Education Leadership Committee of the CPMC Foundation. NR 53 TC 3 Z9 3 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD NOV PY 2015 VL 70 IS 11 BP 1418 EP 1424 DI 10.1093/gerona/glv097 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CW1QF UT WOS:000364765700016 PM 26328603 ER PT J AU Zhu, CW Cosentino, S Ornstein, K Gu, Y Scarmeas, N Andrews, H Stern, Y AF Zhu, Carolyn W. Cosentino, Stephanie Ornstein, Katherine Gu, Yian Scarmeas, Nikolaos Andrews, Howard Stern, Yaakov TI Medicare Utilization and Expenditures Around Incident Dementia in a Multiethnic Cohort SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Incident dementia; Medicare; Health care use; Health care expenditures; Longitudinal follow-up ID IDENTIFYING ALZHEIMERS-DISEASE; DIAGNOSIS; CLAIMS; CARE; TRAJECTORIES; POPULATION; ASSOCIATION; ACCURACY; SERVICES; MODELS AB Few studies have examined patterns of health care utilization and costs during the period around incident dementia. Participants were drawn from the Washington Heights-Inwood Columbia Aging Project, a multiethnic, population-based, prospective study of cognitive aging of Medicare beneficiaries in a geographically defined area of northern Manhattan. Medicare utilization and expenditure were examined in individuals with clinically diagnosed dementia from 2 years before until 2 years after the initial diagnosis. A sample of non-demented individuals who were matched on socio-demographic and clinical characteristics at study enrollment was used as controls. Multivariable regression analysis estimated effects on Medicare utilization and expenditures associated with incident dementia. During the 2 years before incident dementia, rates of inpatient admissions and outpatient visits were similar between dementia patients and non-demented controls, but use of home health and skilled nursing care and durable medical equipment were already higher in dementia patients. Results showed a small but significant excess increase associated with incident dementia in inpatient admissions but not in other areas of care. In the 2 years before incident dementia, total Medicare expenditures were already higher in dementia patients than in non-demented controls. But we found no excess increases in Medicare expenditures associated with incident dementia. Demand for medical care already is increasing and costs are higher at the time of incident dementia. There was a small but significant excess risk of inpatient admission associated with incident dementia. C1 [Zhu, Carolyn W.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Bronx, NY 10468 USA. [Zhu, Carolyn W.] James J Peters VA Med Ctr, Bronx, NY USA. [Cosentino, Stephanie; Gu, Yian; Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Gertrude H Sergievsky Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, Cognit Neurosci Div, New York, NY 10027 USA. [Cosentino, Stephanie; Gu, Yian; Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA. [Ornstein, Katherine] Icahn Sch Med Mt Sinai, Div Gen Internal Med, Samuel Bronfman Dept Med, New York, NY 10029 USA. [Andrews, Howard] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. RP Zhu, CW (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM carolyn.zhu@mssm.edu FU National Institute on Aging [AG07370, AG037212]; Department of Veterans Affairs, Veterans Health Administration FX This research was supported by grants from the National Institute on Aging (AG07370, AG037212). C.W.Z. was also supported by the Department of Veterans Affairs, Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 33 TC 3 Z9 3 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD NOV PY 2015 VL 70 IS 11 BP 1448 EP 1453 DI 10.1093/gerona/glv124 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CW1QF UT WOS:000364765700020 PM 26311543 ER PT J AU Robinson, DG Gallego, JA John, M Petrides, G Hassoun, Y Zhang, JP Lopez, L Braga, RJ Sevy, SM Addington, J Kellner, CH Tohen, M Naraine, M Bennett, N Greenberg, J Lencz, T Correll, CU Kane, JM Malhotra, AK AF Robinson, Delbert G. Gallego, Juan A. John, Majnu Petrides, Georgios Hassoun, Youssef Zhang, Jian-Ping Lopez, Leonardo Braga, Raphael J. Sevy, Serge M. Addington, Jean Kellner, Charles H. Tohen, Mauricio Naraine, Melissa Bennett, Natasha Greenberg, Jessica Lencz, Todd Correll, Christoph U. Kane, John M. Malhotra, Anil K. TI A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes SO SCHIZOPHRENIA BULLETIN LA English DT Article DE clinical trial; treatment response; negative symptoms; akathisia; metabolic side effects ID CARDIOMETABOLIC RISK; COMPARATIVE EFFICACY; ANTIPSYCHOTIC-DRUGS; RAISE-ETP; OLANZAPINE; PSYCHOSIS; TOLERABILITY; QUETIAPINE; TRIAL; SCALE AB Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15-40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5-30mg/d) or risperidone (1-6mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% vs 56.8%) nor did time to response. Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia. Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Post hoc analyses suggested advantages for aripiprazole on depressed mood. Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole. Otherwise, aripiprazole would be the preferred choice over risperidone in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications. C1 [Robinson, Delbert G.; Gallego, Juan A.; John, Majnu; Petrides, Georgios; Zhang, Jian-Ping; Lencz, Todd; Correll, Christoph U.; Kane, John M.; Malhotra, Anil K.] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; John, Majnu; Petrides, Georgios; Hassoun, Youssef; Zhang, Jian-Ping; Lopez, Leonardo; Braga, Raphael J.; Naraine, Melissa; Bennett, Natasha; Greenberg, Jessica; Lencz, Todd; Correll, Christoph U.; Kane, John M.; Malhotra, Anil K.] North Shore Long Isl Jewish Hlth Syst, Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; Petrides, Georgios; Hassoun, Youssef; Zhang, Jian-Ping; Lopez, Leonardo; Braga, Raphael J.; Lencz, Todd; Correll, Christoph U.; Kane, John M.; Malhotra, Anil K.] Hofstra North Shore LIJ Sch Med, Dept Psychiat, Hempstead, NY USA. [Robinson, Delbert G.; Petrides, Georgios; Lencz, Todd; Correll, Christoph U.; Kane, John M.; Malhotra, Anil K.] Hofstra North Shore LIJ Sch Med, Dept Mol Med, Hempstead, NY USA. [John, Majnu] Hofstra Univ, Dept Math, Hempstead, NY 11550 USA. [Sevy, Serge M.] James J Peters VA Med Ctr, Bronx, NY USA. [Addington, Jean] Univ Calgary, Hotchkiss Brain Inst, Dept Psychiat, Calgary, AB, Canada. [Kellner, Charles H.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Tohen, Mauricio] Univ New Mexico, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Albuquerque, NM 87131 USA. [Correll, Christoph U.; Kane, John M.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA. RP Robinson, DG (reprint author), Zucker Hillside Hosp, Res Dept, 75-59 263rd St, Glen Oaks, NY 11004 USA. EM drobinso@nshs.edu RI Zhang, Jianping/L-9805-2016; Lencz, Todd/J-3418-2014 OI Zhang, Jianping/0000-0001-6363-6362; Lencz, Todd/0000-0001-8586-338X FU National Institutes of Health [R01 MH060004, K23MH100264, P30MH090590, P50MH080173]; Brain & Behavior Research Foundation; Bristol-Meyers Squibb; Janssen; Otsuka; St. Jude Medical; Astra Zeneca; Proteus; Ai-Cure; Corcept Therapeutics; Amgen; Genomind, Inc.; Bristol-Myers Squibb; Janssen/JJ; Novo Nordisk A/S; Takeda FX This work was supported by the National Institutes of Health (R01 MH060004 to D.G.R., K23MH100264 to J.A.G., P30MH090590 to J.M.K. and P50MH080173 to A.K.M.) and by a NARSAD Young Investigator Grant to J.A.G. from the Brain & Behavior Research Foundation. Medication supplies were donated by Bristol-Myers Squibb and by Janssen Pharmaceuticals. D.G.R. has received grants from Bristol-Meyers Squibb, Janssen, and Otsuka. G.P. has received research support from St. Jude Medical, Astra Zeneca, Proteus, Ai-Cure, Corcept Therapeutics, and Amgen. J.-P.Z. has received grant support from Genomind, Inc. L.L. has received grant funding from Janssen. C.U.C. has received grant support from Bristol-Myers Squibb, Janssen/J&J, Novo Nordisk A/S, Otsuka, and Takeda. NR 25 TC 10 Z9 10 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2015 VL 41 IS 6 BP 1227 EP 1236 DI 10.1093/schbul/sbv125 PG 10 WC Psychiatry SC Psychiatry GA CW1TR UT WOS:000364774900008 PM 26338693 ER PT J AU Zvolensky, MJ Farris, SG Kotov, R Schechter, CB Bromet, E Gonzalez, A Vujanovic, A Pietrzakf', RH Crane, M Kaplan, J Moline, J Southwick, SM Feder, A Udasin, I Reissman, DB Luft, BJ AF Zvolensky, Michael J. Farris, Samantha G. Kotov, Roman Schechter, Clyde B. Bromet, Evelyn Gonzalez, Adam Vujanovic, Anka Pietrzakf', Robert H. Crane, Michael Kaplan, Julia Moline, Jacqueline Southwick, Steven M. Feder, Adriana Udasin, Iris Reissman, Dori B. Luft, Benjamin J. TI Posttraumatic stress symptoms and smoking among World Trade Center disaster responders: A longitudinal investigation SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID HEALTH REGISTRY ENROLLEES; RECRUITED DAILY SMOKERS; PTSD CHECKLIST PCL; NICOTINE DEPENDENCE; CIGARETTE-SMOKING; NEW-YORK; PSYCHOMETRIC PROPERTIES; TERRORIST ATTACKS; NEGATIVE AFFECT; CENTER RESCUE AB Purpose: The current longitudinal study examined posttraumatic stress disorder (PTSD) symptom severity in relation to smoking abstinence and reduction over time among responders to the World Trade Center (WTC) disaster. Method: Participants were 763 police and 1881 non-traditional (e.g., construction workers) WTC responders who reported being smokers at an initial examination obtained between July 2002 and July 2011 at the WTC Health Program (WTC-HP). WTC responders were reassessed, on average, 2.5 years later. Results: For police WTC responders, higher levels of WTC-related PTSD symptoms at the initial visit were associated with a decreased likelihood of smoking abstinence (OR = 0.98, p = .002) and with decreased smoking reduction (beta = .06, p = .012) at the follow-up visit. WTC-related PTSD symptom severity was not related to likelihood of smoking abstinence or change in number of cigarettes smoked among non-traditional responders. Post hoc analyses suggested that for police, hyperarousal PTSD symptoms were predictive of decreased abstinence likelihood at the follow-up visit (OR = 0.56, p = .006). Discussion: The present fmdings suggest that PTSD symptoms may be differentially related to smoking behavior among police and non-traditional WTC responders in a naturalistic, longitudinal investigation. Future work may benefit from exploring further which aspects of PTSD (as compared to each other and to common variance) explain smoking maintenance. (C) 2015 Elsevier Inc. All rights reserved. C1 [Zvolensky, Michael J.; Farris, Samantha G.] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Kotov, Roman; Bromet, Evelyn; Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Vujanovic, Anka] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Pietrzakf', Robert H.; Southwick, Steven M.] US Dept Vet Affairs, VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzakf', Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Crane, Michael; Kaplan, Julia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Moline, Jacqueline] North Shore LIJ Hlth Syst, Dept Populat Hlth, Great Neck, NY USA. [Feder, Adriana] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Udasin, Iris] Rutgers Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA. [Reissman, Dori B.] NIOSH, WTC Hlth Program, Washington, DC USA. [Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. RP Zvolensky, MJ (reprint author), Univ Houston, 126 Heyne Bldg,Suite 104, Houston, TX 77204 USA. EM mjzvolen@central.uh.edu NR 54 TC 0 Z9 0 U1 3 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PD NOV PY 2015 VL 63 BP 46 EP 54 DI 10.1016/j.comppsych.2015.08.006 PG 9 WC Psychiatry SC Psychiatry GA CW6YA UT WOS:000365143100007 PM 26555491 ER PT J AU Maughan, BC Bachhuber, MA Mitra, N Starrels, JL AF Maughan, Brandon C. Bachhuber, Marcus A. Mitra, Nandita Starrels, Joanna L. TI Prescription monitoring programs and emergency department visits involving opioids, 2004-2011 SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Prescription drug monitoring programs; Prescription drug abuse; Opioids; Emergency departments ID FATAL HEROIN OVERDOSE; DRUG OVERDOSE; UNITED-STATES; IMPACT; DEATHS; POLICY; RISK; ANALGESICS; PROVIDERS; CLINICIAN AB Objective: To determine the association between prescription drug monitoring program (PDMP) implementation and emergency department (ED) visits involving opioid analgesics. Methods: Rates of ED visits involving opioid analgesics per 100,000 residents were estimated from the Drug Abuse Warning Network dataset for 11 geographically diverse metropolitan areas in the United States on a quarterly basis from 2004 to 2011. Generalized estimating equations assessed whether implementation of a prescriber-accessible PDMP was associated with a difference in ED visits involving opioid analgesics. Models were adjusted for calendar quarter, metropolitan area, metropolitan area-specific linear time trends, and unemployment rate. Results: Rates of ED visits involving opioid analgesics increased in all metropolitan areas. PDMP implementation was not associated with a difference in ED visits involving opioid analgesics (mean difference of 0.8 visits [95% CI: -3.7 to 5.2] per 100,000 residents per quarter). Conclusions: During 2004-2011, PDMP implementation was not associated with a change in opioid-related morbidity, as measured by emergency department visits involving opioid analgesics. Urgent investigation is needed to determine the optimal PDMP structure and capabilities to improve opioid analgesic safety. Published by Elsevier Ireland Ltd. C1 [Maughan, Brandon C.; Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Maughan, Brandon C.; Bachhuber, Marcus A.; Mitra, Nandita] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Maughan, Brandon C.; Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. RP Maughan, BC (reprint author), Univ Penn, 1303-A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM bmaughan@gmail.com; marcus.bachhuber@gmail.com; nanditam@mail.med.upenn.edu; jostarre@montefiore.org OI Bachhuber, Marcus/0000-0002-5610-8382 FU NIH [K23DA027719]; Leonard Davis Institute of Health Economics; United States Department of Veterans Affairs; Robert Wood Johnson Foundation Clinical Scholars Program at the University of Pennsylvania FX This study was funded by NIH K23DA027719 (Dr. Starrels). Drs. Maughan and Bachhuber received additional support from the Leonard Davis Institute of Health Economics, the United States Department of Veterans Affairs, and the Robert Wood Johnson Foundation Clinical Scholars Program at the University of Pennsylvania. The funding bodies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. NR 66 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2015 VL 156 BP 282 EP 288 DI 10.1016/j.drugalcdep.2015.09.024 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CW5SN UT WOS:000365057000038 PM 26454836 ER PT J AU Nguyen, T Duan, ZG Naik, AD Kramer, JR El-Serag, HB AF Theresa Nguyen Duan, Zhigang Naik, Aanand D. Kramer, Jennifer R. El-Serag, Hashem B. TI Statin Use Reduces Risk of Esophageal Adenocarcinoma in US Veterans With Barrett's Esophagus: A Nested Case-Control Study SO GASTROENTEROLOGY LA English DT Article DE Chemoprevention; Drug; Esophageal Cancer; Pharmacoepidemiology; Statin ID PROLIFERATION; PROGRESSION; APOPTOSIS; MARKERS; GROWTH; CELLS AB BACKGROUND & AIMS: Statins have been reported to protect against esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). However, there are few data from adequately powered cohort studies of subjects with BE. METHODS: We conducted a nested case-control study of a cohort of BE patients identified from national Veteran Affairs (VA) outpatient files, diagnosed with BE from 2004 through 2009. New cases of EAC recorded after BE diagnosis were identified during a follow-up period that ended in 2011 and verified using electronic medical records. We selected patients with BE without EAC (controls) using incidence density sampling; 3 controls were matched to each case based on birth year and date of BE diagnosis. Our analysis included only male patients with at least 1 VA visit per year of follow up. We identified prescriptions for statins and non-statin lipid lowering medications filled after BE diagnosis and up to 90 days before EAC diagnosis for cases and controls (during the corresponding time period); we examined the association between statin use and EAC in conditional logistic regression models. RESULTS: We compared 311 EAC cases to 856 controls. Cases were less likely to use any statins than controls (40.2% vs 54.0%; P < .01). Significantly lower proportions of cases used statins for 6-18 months (10.0% cases vs 17.1% controls) and >18 months (19.3% vs 24.0%, respectively; P < .01). Simvastatin was the most commonly prescribed statin (accounting for 86.9% of statin use); the defined daily dose of simvastatin was lower in cases than in controls (21-40 mg/day, 9.3% vs 14.5%, respectively; and >40 mg/day, 8.4% vs 12.6%, respectively; P < .01). In multivariate analysis, statin use was inversely associated with development of EAC (adjusted odds ratio [OR], 0.65; 95% confidence interval [CI], 0.47-0.91). This protective association was strongest for patients with advanced-stage EAC: in a stratified analysis, comparison of 189 cases with stage 0-1 EAC to 520 controls produced an adjusted OR of 0.85 (95% CI, 0.54-1.33). Among patients with late-stage EAC (stages 2-4, n = 106) and 291 controls, the adjusted OR was 0.44 (95% CI, 0.25-0.79). We found no association between EAC and non-statin lipid-lowering medications. CONCLUSIONS: In a case-control study of US veterans, statin use among those with BE appeared to decrease the risk of EAC. This protective effect was strongest against advanced-stage EAC, and increased with statin dose. C1 [Theresa Nguyen; Duan, Zhigang; El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Theresa Nguyen; Naik, Aanand D.; Kramer, Jennifer R.; El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), MEDVAMC 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu FU National Institutes of Health [NCI R01 116845]; Texas Digestive Disease Center NIH [DK58338]; resources of the Michael E. DeBakey VA Medical Center Section of Health Services Research and Development Center of Innovation in Quality, Effectiveness, and Safety, Houston, Texas [CIN 13-413]; National Institute of Diabetes and Digestive and Kidney Diseases [K24-04-107] FX This work was funded in part by National Institutes of Health grant NCI R01 116845, Texas Digestive Disease Center NIH grant DK58338, and resources of the Michael E. DeBakey VA Medical Center Section of Health Services Research and Development Center of Innovation in Quality, Effectiveness, and Safety (CIN 13-413), Houston, Texas. Dr El-Serag is also supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K24-04-107. The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US Government or Baylor College of Medicine. NR 22 TC 3 Z9 3 U1 3 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD NOV PY 2015 VL 149 IS 6 BP 1392 EP 1398 DI 10.1053/j.gastro.2015.07.009 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CW6GN UT WOS:000365095800027 PM 26208896 ER PT J AU Beste, LA Leipertz, SL Green, PK Dominitz, JA Ross, D Ioannou, GN AF Beste, Lauren A. Leipertz, Steven L. Green, Pamela K. Dominitz, Jason A. Ross, David Ioannou, George N. TI Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001-2013 SO GASTROENTEROLOGY LA English DT Article DE Diabetes; Hepatitis B Virus; NASH; Obesity ID CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; ALL-CAUSE MORTALITY; UNITED-STATES; VIRUS-INFECTION; VIRAL-HEPATITIS; PREVALENCE; AFFAIRS; SURVEILLANCE; PROGRESSION AB BACKGROUND & AIMS: Cirrhosis and hepatocellular carcinoma (HCC) are predicted to increase in the United States but the accuracy of prior forecasts and the contributions from various liver disease etiologies remain unclear. We aimed to determine the burden of cirrhosis and HCC according to underlying cause from 2001 to 2013. METHODS: We developed a national retrospective cohort of Veterans Affairs (VA) patients with the diagnosis of cirrhosis (n 129,998) or HCC (n = 21,326) from 2001 to 2013. We used laboratory results, International Classification of Diseases, ninth edition (ICD-9) codes, and body mass index to identify underlying etiologies. RESULTS: In 2013, VA provided care to 5,720,614 individuals, of whom 60,553 (1.06%) had cirrhosis and 7,670 (0.13%) had HCC. Hepatitis C virus (HCV) was present in an increasing proportion of cirrhosis and HCC between 2001 and 2013, reaching 48% of cirrhosis cases and deaths and 67% of HCC cases and deaths by 2013. Cirrhosis prevalence nearly doubled from 2001 to 2013 (664 to 1058 per 100,000 enrollees), driven by HCV and nonalcoholic fatty liver disease (NAFLD). Cirrhosis incidence ranged from 159 to 193 per 100,000 patient-years. Deaths in patients with cirrhosis increased from 83 to 126 per 100,000 patient-years, largely driven by HCV. HCC incidence was 2.5-fold increased from 17 to 45 per 100,000 patient-years. HCC mortality tripled from 13 to 37 per 100,000 patient-years, driven overwhelmingly by HCV, with much smaller contributions from NAFLD and alcoholic liver disease. CONCLUSIONS: Cirrhosis prevalence and mortality and HCC incidence and mortality increased from 2001 to 2013, driven by HCV, with a smaller contribution from NAFLD. If current trends continue, cirrhosis prevalence will peak in 2021. Health care systems will need to accommodate rising numbers of patients with cirrhosis and HCC. C1 [Beste, Lauren A.; Dominitz, Jason A.] Vet Affairs Puget Sound Hlth Care Syst, Primary Care Serv, Seattle, WA 98108 USA. [Beste, Lauren A.; Leipertz, Steven L.; Green, Pamela K.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Dominitz, Jason A.; Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Ross, David] US Dept Vet Affairs, HIV HCV & Publ Hlth Pathogens Programs, Off Publ Hlth Clin Publ Hlth, Washington, DC USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98108 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111-Gastro,1660 South Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Merit Review grant, Clinical Science Research and Development, Office of Research and Development, Veterans Affairs [I01CX000320]; HIV, Hepatitis, and Public Health Pathogens Program of the Office of Public Health, Department of Veterans Affairs FX This study was supported by Merit Review grant I01CX000320, Clinical Science Research and Development, Office of Research and Development, Veterans Affairs (G.N.I.) and by the HIV, Hepatitis, and Public Health Pathogens Program of the Office of Public Health, Department of Veterans Affairs (L.A.B.). The sponsors had no role in study design or collection, analysis or interpretation of the data. NR 35 TC 22 Z9 24 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD NOV PY 2015 VL 149 IS 6 BP 1471 EP + DI 10.1053/j.gastro.2015.07.056 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CW6GN UT WOS:000365095800036 PM 26255044 ER PT J AU Fidler, R Bond, R Finlay, D Guldenring, D Gallagher, A Pelter, M Drew, B Hu, X AF Fidler, Richard Bond, Raymond Finlay, Dewar Guldenring, Daniel Gallagher, Anthony Pelter, Michele Drew, Barbara Hu, Xiao TI Human factors approach to evaluate the user interface of physiologic monitoring SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE Central station; Bedside monitoring; human factors in monitoring; Usability; User interface; User experience AB Background: As technology infiltrates more of our personal and professional lives, user expectations for intuitive design have driven many consumer products, while medical equipment continues to have high training requirements. Not much is known about the usability and user experience associated with hospital monitoring equipment. This pilot project aimed to better understand and describe the user interface interaction and user experience with physiologic monitoring technology. Design: This was a prospective, descriptive, mixed-methods quality improvement project to analyze perceptions and task analyses of physiologic monitors. Methods: Following a survey of practice patterns and perceived abilities to accomplish key tasks, 10 voluntary experienced physician and nurse subjects were asked to perform a series of tasks in 7 domains of monitor operations on GE Monitoring equipment in a single institution. For each task analysis, data were collected on time to complete the task, the number of button pushes or clicks required to accomplish the task, economy of motion, and observed errors. Results: Although 60% of the participants reported incorporating monitoring data into patient care, 80% of participants preferred to receive monitoring data at the point of care (bedside). Average perceived central station usability is 5.3 out of 10 (ten is easiest). Conclusions: High variability exists in monitoring station interaction performance among those participating in this project. Alarms were almost universally silenced without cognitive recognition of the alarm state. Education related to monitoring operations appeared largely absent in this sample. Most users perceived the interface to not be intuitive, complaining of multiple layers and steps for data retrieval. These clinicians report real-time monitoring helpful for abrupt changes in condition like arrhythmias; however, reviewing alarms is not prioritized as valuable due to frequent false alarms. Participants requested exporting monitoring data to electronic medical records. Much research is needed to develop best practices for display of real-time information, organization and filtering of meaningful data, and simplified ways to find information. Published by Elsevier Inc. C1 [Fidler, Richard; Pelter, Michele; Drew, Barbara; Hu, Xiao] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Fidler, Richard] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bond, Raymond; Finlay, Dewar; Guldenring, Daniel; Gallagher, Anthony] Univ Ulster, Ulster, Ireland. RP Fidler, R (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Anesthesiol 129, San Francisco, CA 94121 USA. EM richard.fidler@ucsf.edu OI Fidler, Richard/0000-0003-4358-7887; Bond, Raymond/0000-0002-1078-2232 NR 7 TC 0 Z9 0 U1 3 U2 15 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD NOV-DEC PY 2015 VL 48 IS 6 BP 982 EP 987 DI 10.1016/j.jelectrocard.2015.08.032 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CW3MQ UT WOS:000364896800011 PM 26375330 ER PT J AU Carr, AR Paholpak, P Daianu, M Fong, SS Mather, M Jimenez, EE Thompson, P Mendez, ME AF Carr, Andrew R. Paholpak, Pongsatorn Daianu, Madelaine Fong, Sylvia S. Mather, Michelle Jimenez, Elvira E. Thompson, Paul Mendez, Mario E. TI An investigation of care-based vs. rule-based morality in frontotemporal dementia, Alzheimer's disease, and healthy controls SO NEUROPSYCHOLOGIA LA English DT Article DE Morality; Dementia; Brain; Neuropsychology; Neuroimaging; Frontotemporal ID MILD COGNITIVE IMPAIRMENT; ACQUIRED SOCIOPATHY; BEHAVIORAL VARIANT; EXECUTIVE CONTROL; DECISION-MAKING; NEURAL BASIS; MIND; EMPATHY; NETWORKS; CORTEX AB Behavioral changes in dementia, especially behavioral variant frontotemporal dementia (bvFTD), may result in alterations in moral reasoning. Investigators have not clarified whether these alterations reflect differential impairment of care-based vs. rule-based moral behavior. This study investigated 18 bvFTD patients, 22 early onset Alzheimer's disease (eAD) patients, and 20 healthy age-matched controls on care-based and rule-based items from the Moral Behavioral Inventory and the Social Norms Questionnaire, neuropsychological measures, and magnetic resonance imaging (MRI) regions of interest. There were significant group differences with the bvFTD patients rating care-based morality transgressions less severely than the eAD group and rule-based moral behavioral transgressions more severely than controls. Across groups, higher care-based morality ratings correlated with phonemic fluency on neuropsychological tests, whereas higher rule-based morality ratings correlated with increased difficulty set-shifting and learning new rules to tasks. On neuroimaging, severe care-based reasoning correlated with cortical volume in right anterior temporal lobe, and rule-based reasoning correlated with decreased cortical volume in the right orbitofrontal cortex. Together, these findings suggest that frontotemporal disease decreases care-based morality and facilitates rule-based morality possibly from disturbed contextual abstraction and set-shifting. Future research can examine whether frontal lobe disorders and bvFTD result in a shift from empathic morality to the strong adherence to conventional rules. Published by Elsevier Ltd. C1 [Carr, Andrew R.; Paholpak, Pongsatorn; Fong, Sylvia S.; Mather, Michelle; Jimenez, Elvira E.; Mendez, Mario E.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Carr, Andrew R.; Paholpak, Pongsatorn; Mather, Michelle; Jimenez, Elvira E.; Mendez, Mario E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Jimenez, Elvira E.; Mendez, Mario E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Jimenez, Elvira E.; Mendez, Mario E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Carr, Andrew R.; Paholpak, Pongsatorn; Daianu, Madelaine; Fong, Sylvia S.; Mather, Michelle; Jimenez, Elvira E.; Thompson, Paul; Mendez, Mario E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Khaen, Thailand. [Daianu, Madelaine; Thompson, Paul] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Carr, AR (reprint author), West Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM andrew.carr@va.gov FU National Institute of Aging [5R01AG034499-05]; V.A. Geriatrics Research, Education, and Clinical Care fellowship (ARC) FX This work was supported by the National Institute of Aging (Grant number 5R01AG034499-05) and a V.A. Geriatrics Research, Education, and Clinical Care fellowship (ARC). NR 59 TC 2 Z9 2 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD NOV PY 2015 VL 78 BP 73 EP 79 DI 10.1016/j.neuropsychologia.2015.09.033 PG 7 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA CW5RH UT WOS:000365053800008 PM 26432341 ER PT J AU Doll, JA Hellkamp, A Thomas, L Ho, PM Kontos, MC Whooley, MA Boyden, TF Peterson, ED Wang, TY AF Doll, Jacob A. Hellkamp, Anne Thomas, Laine Ho, P. Michael Kontos, Michael C. Whooley, Mary A. Boyden, Thomas F. Peterson, Eric D. Wang, Tracy Y. TI Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction SO AMERICAN HEART JOURNAL LA English DT Article ID AMERICAN-HEART-ASSOCIATION; SCIENTIFIC STATEMENT; TRIAL RAMIT; PREVENTION; CARDIOLOGY; EXERCISE; DISEASE; UPDATE; ADULTS AB Background Guidelines recommend cardiac rehabilitation after acute myocardial infarction, yet little is known about the impact of cardiac rehabilitation on medication adherence and clinical outcomes among contemporary older adults. The optimal number of cardiac rehabilitation sessions is not clear. Methods We linked patients 65 years or older enrolled in the Acute Coronary Treatment Intervention Outcomes Network Registry-Get With the Guidelines (ACTION Registry-GWTG) from January 2007 to December 2010 to Medicare longitudinal claims data to obtain 1 year follow-up. Results A total of 11,862 patients participated in cardiac rehabilitation after acute myocardial infarction, attending a median number of 26 sessions. Patients attending >= 26 sessions were more likely to be male, had lesser prevalence of comorbid conditions and prior revascularization, and were more likely to present with ST-segment elevation myocardial infarction, compared with patients attending 1 to 25 sessions. Among patients with Medicare Part D prescription coverage, increasing number of cardiac rehabilitation sessions was associated with improvement in adherence to secondary prevention medications such as P2Y(12) inhibitors and beta-blockers. Each 5-session increase in participation was associated with lower mortality (adjusted hazard ratio [HR] 0.87, 95% CI 0.83-0.92) and lower overall risk of major adverse cardiac event (adjusted HR 0.69, 95% CI 0.65-0.73) and death/readmission (adjusted HR 0.79, 95% CI 0.76-0.83). Conclusions In this older patient population, number of cardiac rehabilitation sessions attended was associated with improved medication adherence and lower downstream cardiovascular risk in a dose-response relationship. This provides support for the continued use of cardiac rehabilitation for older adults and encourages efforts to maximize attendance. C1 [Doll, Jacob A.; Hellkamp, Anne; Thomas, Laine; Peterson, Eric D.; Wang, Tracy Y.] Duke Clin Res Inst, Durham, NC USA. [Doll, Jacob A.; Peterson, Eric D.; Wang, Tracy Y.] Duke Univ, Dept Med, Durham, NC 27705 USA. [Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Aurora, CO USA. [Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA. [Kontos, Michael C.] Virginia Commonwealth Univ, Richmond, VA USA. [Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Boyden, Thomas F.] Spectrum Hlth, Grand Rapids, MI USA. RP Doll, JA (reprint author), Duke Univ, 2400 Pratt St, Durham, NC 27705 USA. EM jacob.doll@duke.edu OI Hellkamp, Anne/0000-0003-0919-4502 FU Eli Lilly; Daiichi Sankyo; Gilead Science; GlaxoSmith Kline; Astra Zeneca; Boston Scientific; American College of Cardiology Foundation's National Cardiovascular Data Registry; Society of Chest Pain Centers; American College of Emergency Physicians; Society of Hospital Medicine FX Dr Kontos has received consulting honoraria from Provencio, Astellas, Ikaria, and Wellpoint. Dr Wang has received research grants to the Duke Clinical Research Institute from Eli Lilly, Daiichi Sankyo, Gilead Science, GlaxoSmith Kline, Astra Zeneca, and Boston Scientific, as well as consulting honoraria from Astra Zeneca. Other authors report no relevant conflicts.; This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry. The views expressed in this manuscript represent those of the author(s) and do not necessarily represent the official views of the National Cardiovascular Data Registry or its associated professional societies identified at www.ncdr.com.; ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Chest Pain Centers, the American College of Emergency Physicians, and the Society of Hospital Medicine. NR 25 TC 5 Z9 5 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD NOV PY 2015 VL 170 IS 5 BP 855 EP 864 DI 10.1016/j.ahj.2015.08.001 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CV7EG UT WOS:000364434600004 PM 26542492 ER PT J AU Gabayan, GZ Derose, SF Chiu, VY Yiu, SC Sarkisian, CA Jones, JP Sun, BC AF Gabayan, Gelareh Z. Derose, Stephen F. Chiu, Vicki Y. Yiu, Sau C. Sarkisian, Catherine A. Jones, Jason P. Sun, Benjamin C. TI Emergency Department Crowding and Outcomes After Emergency Department Discharge SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID MYOCARDIAL-INFARCTION; CHEST-PAIN; ASSOCIATION; PERFORMANCE; PREDICTORS; PNEUMONIA; DELAYS; DEATH; CARE AB Study objective: We assess whether a panel of emergency department (ED) crowding measures, including 2 reported by the Centers for Medicare & Medicaid Services (CMS), is associated with inpatient admission and death within 7 days of ED discharge. Methods: We conducted a retrospective cohort study of ED discharges, using data from an integrated health system for 2008 to 2010. We assessed patient transit-level (n=3) and ED system-level (n=6) measures of crowding, using multivariable logistic regression models. The outcome measures were inpatient admission or death within 7 days of ED discharge. We defined a clinically important association by assessing the relative risk ratio and 95% confidence interval (Cl) difference and also compared risks at the 99th percentile and median value of each measure. Results: The study cohort contained a total of 625,096 visits to 12 EDs. There were 16,957 (2.7%) admissions and 328 (0.05%) deaths within 7 days. Only 2 measures, both of which were patient transit measures, were associated with the outcome. Compared with a median evaluation time of 2.2 hours, the evaluation time of 10.8 hours (99th percentile) was associated with a relative risk of 3.9 (95% Cl 3.7 to 4.1) of an admission. Compared with a median ED length of stay (a CMS measure) of 2.8 hours, the 99th percentile ED length of stay of 11.6 hours was associated with a relative risk of 3.5 (95% Cl 3.3 to 3.7) of admission. No system measure of ED crowding was associated with outcomes. Conclusion: Our findings suggest that ED length of stay is a proxy for unmeasured differences in case mix and challenge the validity of the CMS metric as a safety measure for discharged patients. C1 [Gabayan, Gelareh Z.; Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Gabayan, Gelareh Z.; Sarkisian, Catherine A.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA. [Derose, Stephen F.; Chiu, Vicki Y.; Yiu, Sau C.; Jones, Jason P.] Kasier Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. EM gelareh@gabayan.com FU Agency for Healthcare Research and Quality (AHRQ) [R03 HS18994]; Kaiser Permanente of Southern California; National Institutes of Health (NIH)/National Center for Research Resources (NCRR)/National Center for Advancing Translational Sciences (NCATS) University of California, Los Angeles (UCLA) Clinical and Translational Science Institute (CTSI) [KL2TR000122] FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: This research was supported by the Agency for Healthcare Research and Quality (AHRQ) (R03 HS18994 to Dr. Sun) and Kaiser Permanente of Southern California. Dr. Gabayan receives support from the National Institutes of Health (NIH)/National Center for Research Resources (NCRR)/National Center for Advancing Translational Sciences (NCATS) University of California, Los Angeles (UCLA) Clinical and Translational Science Institute (CTSI) (grant KL2TR000122). NR 25 TC 3 Z9 3 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD NOV PY 2015 VL 66 IS 5 BP 483 EP 492 DI 10.1016/j.annemergmed.2015.04.009 PG 10 WC Emergency Medicine SC Emergency Medicine GA CV9QO UT WOS:000364621900010 PM 26003004 ER PT J AU Renaud, L Harris, LG Mani, SK Kasiganesan, H Chou, JC Baicu, CF Van Laer, A Akerman, AW Stroud, RE Jones, JA Zile, MR Menick, DR AF Renaud, Ludivine Harris, Lillianne G. Mani, Santhosh K. Kasiganesan, Harinath Chou, James C. Baicu, Catalin F. Van Laer, An Akerman, Adam W. Stroud, Robert E. Jones, Jeffrey A. Zile, Michael R. Menick, Donald R. TI HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis SO CIRCULATION-HEART FAILURE LA English DT Article DE microRNA; epigenomics; heart ventricles; histone deacetylase; hypertrophy ID PRESERVED EJECTION FRACTION; TISSUE GROWTH-FACTOR; HEART-FAILURE; GENE-EXPRESSION; CLASS-I; HISTONE; HYPERTROPHY; MICRORNAS; PROLIFERATION; DISEASE AB Background-MICRORNAS (miRNAs) and histone deacetylases (HDACs) serve a significant role in the pathogenesis of a variety of cardiovascular diseases. The transcriptional regulation of miRNAs is poorly understood in cardiac hypertrophy. We investigated whether the expression of miR-133a is epigenetically regulated by class I and IIb HDACs during hypertrophic remodeling. Methods and Results-Transverse aortic constriction (TAC) was performed in CD1 mice to induce pressure overload hypertrophy. Mice were treated with class I and IIb HDAC inhibitor (HDACi) via drinking water for 2 and 4 weeks post TAC. miRNA expression was determined by real-time polymerase chain reaction. Echocardiography was performed at baseline and post TAC end points for structural and functional assessment. Chromatin immunoprecipitation was used to identify HDACs and transcription factors associated with miR-133a promoter. miR-133a expression was downregulated by 0.7- and 0.5-fold at 2 and 4 weeks post TAC, respectively, when compared with vehicle control (P<0.05). HDAC inhibition prevented this significant decrease 2 weeks post TAC and maintained miR-133a expression near vehicle control levels, which coincided with (1) a decrease in connective tissue growth factor expression, (2) a reduction in cardiac fibrosis and left atrium diameter (marker of end-diastolic pressure), suggesting an improvement in diastolic function. Chromatin immunoprecipitation analysis revealed that HDAC1 and HDAC2 are present on the miR-133a enhancer regions. Conclusions-The results reveal that HDACs play a role in the regulation of pressure overload-induced miR-133a downregulation. This work is the first to provide insight into an epigenetic-miRNA regulatory pathway in pressure overload-induced cardiac fibrosis. C1 [Renaud, Ludivine; Harris, Lillianne G.; Mani, Santhosh K.; Kasiganesan, Harinath; Baicu, Catalin F.; Van Laer, An; Zile, Michael R.; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Akerman, Adam W.; Stroud, Robert E.; Jones, Jeffrey A.] Med Univ S Carolina, Dept Cardiothorac Surg Res, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Chou, James C.] Med Univ S Carolina, Coll Pharm, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Jones, Jeffrey A.; Zile, Michael R.; Menick, Donald R.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Menick, DR (reprint author), Gazes Cardiac Res Inst, 114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM menickd@musc.edu FU National Institutes of Health through the Heart, Lung, and Blood Institute [R01HL094545, R56HL123478, R01HL123478, UL1TR000062]; United States Department of Veterans Affairs Merit Reviews through the Biomedical Laboratory Research and Development, and Clinical Sciences Research and Development Programs [I01 BX002327, I01 BX000904, 5101 CX000415-02, 5101 BX000487-04]; [T32HL07260] FX This work was supported in part by the National Institutes of Health (R01HL094545 [Dr Menick], R56HL123478 [Dr Zile], R01HL123478 [Dr Zile], and UL1TR000062 [Dr Menick]) through the Heart, Lung, and Blood Institute, by Postdoctoral Fellowship (T32HL07260 [Dr Harris]), and by United States Department of Veterans Affairs Merit Reviews (I01 BX002327 [Dr Menick], I01 BX000904 [Dr Jones], 5101 CX000415-02 and 5101 BX000487-04 [Dr Zile]) through the Biomedical Laboratory Research and Development, and Clinical Sciences Research and Development Programs. NR 58 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2015 VL 8 IS 6 BP 1094 EP 1104 DI 10.1161/CIRCHEARTFAILURE.114.001781 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CW1SQ UT WOS:000364772000011 PM 26371176 ER PT J AU Teerlink, JR Malik, FI Kass, DA AF Teerlink, John R. Malik, Fady I. Kass, David A. TI Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity" SO CIRCULATION-HEART FAILURE LA English DT Letter ID SYSTOLIC HEART-FAILURE C1 [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. [Kass, David A.] Johns Hopkins Univ, Inst Med, Baltimore, MD USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. FU NHLBI NIH HHS [R01 HL114910] NR 6 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2015 VL 8 IS 6 BP 1141 EP 1141 DI 10.1161/CIRCHEARTFAILURE.115.002492 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CW1SQ UT WOS:000364772000017 PM 26578671 ER PT J AU Billings, CJ Penman, TM McMillan, GP Ellis, EM AF Billings, Curtis J. Penman, Tina M. McMillan, Garnett P. Ellis, Emily M. TI Electrophysiology and Perception of Speech in Noise in Older Listeners: Effects of Hearing Impairment and Age SO EAR AND HEARING LA English DT Article DE Background noise; Cortical auditory evoked potentials; Event-related potentials; N1; Perception in noise; Prediction; Psychometric function; Signals in noise; Signal-to-noise ratio ID AUDITORY-EVOKED POTENTIALS; SOUNDS VERTICAL-BAR; EVENT-RELATED POTENTIALS; BROAD-BAND NOISE; MASKING; RECOGNITION; INTENSITY; FREQUENCY; AMPLITUDE; SIGNALS AB Objectives: Speech perception in background noise is difficult for many individuals, and there is considerable performance variability across listeners. The combination of physiological and behavioral measures may help to understand sources of this variability for individuals and groups and prove useful clinically with hard-to-test populations. The purpose of this study was threefold: (1) determine the effect of signal-to-noise ratio (SNR) and signal level on cortical auditory evoked potentials (CAEPs) and sentence-level perception in older normal-hearing (ONH) and older hearing-impaired (OHI) individuals, (2) determine the effects of hearing impairment and age on CAEPs and perception, and (3) explore how well CAEPs correlate with and predict speech perception in noise. Design: Two groups of older participants (15 ONH and 15 OHI) were tested using speech-in-noise stimuli to measure CAEPs and sentence-level perception of speech. The syllable /ba/, used to evoke CAEPs, and sentences were presented in speech-spectrum background noise at four signal levels (50, 60, 70, and 80 dB SPL) and up to seven SNRs (-10, -5, 0, 5, 15, 25, and 35 dB). These data were compared between groups to reveal the hearing impairment effect and then combined with previously published data for 15 young normal-hearing individuals to determine the aging effect. Results: Robust effects of SNR were found for perception and CAEPs. Small but significant effects of signal level were found for perception, primarily at poor SNRs and high signal levels, and in some limited instances for CAEPs. Significant effects of age were seen for both CAEPs and perception, while hearing impairment effects were only found with perception measures. CAEPs correlate well with perception and can predict SNR50s to within 2 dB for ONH. However, prediction error is much larger for OHI and varies widely (from 6 to 12 dB) depending on the model that was used for prediction. Conclusions: When background noise is present, SNR dominates both perception-in-noise testing and cortical electrophysiological testing, with smaller and sometimes significant contributions from signal level. A mismatch between behavioral and electrophysiological results was found (hearing impairment effects were primarily only seen for behavioral data), illustrating the possible contributions of higher order cognitive processes on behavior. It is interesting that the hearing impairment effect size was more than five times larger than the aging effect size for CAEPs and perception. Sentence-level perception can be predicted well in normal-hearing individuals; however, additional research is needed to explore improved prediction methods for older individuals with hearing impairment. C1 [Billings, Curtis J.; Penman, Tina M.; McMillan, Garnett P.; Ellis, Emily M.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Billings, Curtis J.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM curtis.billings2@va.gov FU National Institute on Deafness and Other Communication Disorders [R03DC10914]; United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service [C4844C, C8006W] FX This work was supported by grant R03DC10914 from the National Institute on Deafness and Other Communication Disorders and career development awards (C4844C and C8006W) from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service. The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government. NR 38 TC 9 Z9 9 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD NOV-DEC PY 2015 VL 36 IS 6 BP 710 EP 722 DI 10.1097/AUD.0000000000000191 PG 13 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA CV6VW UT WOS:000364410900009 PM 26502191 ER PT J AU Petrik, ML Gutierrez, PM Berlin, JS Saunders, SM AF Petrik, Megan L. Gutierrez, Peter M. Berlin, Jon S. Saunders, Stephen M. TI Barriers and facilitators of suicide risk assessment in emergency departments: a qualitative study of provider perspectives SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Suicide; Suicide risk assessment; Emergency department; Qualitative methods; Health care providers ID SELF-INFLICTED INJURY; HEALTH-CARE; IDEATION; HARM; INSTRUMENT; PREVENTION; MANAGEMENT; MORTALITY; ATTITUDES; ACCIDENT AB Objective: To understand emergency department (ED) providers' perspectives regarding the barriers and facilitators of suicide risk assessment and to use these perspectives to inform recommendations for best practices in ED suicide risk assessment. Methods: Ninety-two ED providers from two hospital systems in a Midwestern state responded to open-ended questions via an online survey that assessed their perspectives on the barriers and facilitators to assess suicide risk as well as their preferred assessment methods. Responses were analyzed using an inductive thematic analysis approach. Results: Qualitative analysis yielded six themes that impact suicide risk assessment. Time, privacy, collaboration and consultation with other professionals and integration of a standard screening protocol in routine care exemplified environmental and systemic themes. Patient engagement/participation in assessment and providers' approach to communicating with patients and other providers also impacted the effectiveness of suicide risk assessment efforts. Conclusion: The findings inform feasible suicide risk assessment practices in EDs. Appropriately utilizing a collaborative, multidisciplinary approach to assess suicide-related concerns appears to be a promising approach to ameliorate the burden placed on ED providers and facilitate optimal patient care. Recommendations for clinical care, education, quality improvement and research are offered. Published by Elsevier Inc. C1 [Petrik, Megan L.; Gutierrez, Peter M.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO 80220 USA. [Petrik, Megan L.; Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Berlin, Jon S.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA. [Saunders, Stephen M.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA. RP Petrik, ML (reprint author), Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO 80220 USA. OI Gutierrez, Peter/0000-0001-8981-8404 FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs FX The authors thank Stephen Hargarten, M.D., M.P.H., and Ed de St. Aubin, Ph.D., for consultation throughout the study as well as Renae Delucia and Brett Adams for their assistance in qualitative analysis. A portion of the writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. NR 37 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2015 VL 37 IS 6 BP 581 EP 586 DI 10.1016/j.genhosppsych.2015.06.018 PG 6 WC Psychiatry SC Psychiatry GA CV8AK UT WOS:000364498700015 PM 26208868 ER PT J AU Klein, E Brown, T Sample, M Truitt, AR Goering, S AF Klein, Eran Brown, Tim Sample, Matthew Truitt, Anjali R. Goering, Sara TI Engineering the Brain: Ethical Issues and the Introduction of Neural Devices SO HASTINGS CENTER REPORT LA English DT Article ID MIND; STIMULATION; EMBODIMENT; DISABILITY; PAIN AB Neural engineering technologies such as implanted deep brain stimulators and brain-computer interfaces represent exciting and potentially transformative tools for improving human health and well-being. Yet their current use and future prospects raise a variety of ethical and philosophical concerns. Devices that alter brain function invite us to think deeply about a range of ethical concernsidentity, normality, authority, responsibility, privacy, and justice. If a device is stimulating my brain while I decide upon an action, am I still the author of the action? Does a device make the interiority of my experience accessible to others? Will the device change the way I think of myself and others think of me? Such fundamental questions arise even when a device is designed for only a relatively circumscribed purpose, such as restoring functioning via a smart prosthetic.We are part of a National Science Foundation-funded Engineering Research Center tasked with investigating philosophical and social implications of neural engineering research and technologies. Neural devices already in clinical use, such as deep brain stimulators for Parkinson's disease or essential tremor, have spurred healthy debate about such implications. Devices currently under developmentsuch as the BrainGate System of implanted brain sensors coupled to robotics in persons with paralysis, exoskeletons for augmented movement, transcranial do-it-yourself stimulators, closed-loop brain stimulating systems, or even brain-to-brain interfacingpromise to extend and deepen these debates. At our center, brain-computer interfaces are the principal focus of work. Even acknowledging that the clinical translation of neural devices and seamless integration by end users may still largely reside in the future, the potential these devices hold calls for careful early analysis. The launching of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative in April 2013 provides further impetus for this work. C1 [Klein, Eran; Brown, Tim; Sample, Matthew; Goering, Sara] Univ Washington, Philosophy, Seattle, WA 98195 USA. [Klein, Eran] Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA. [Klein, Eran] Portland VA Med Ctr, Portland, OR USA. [Brown, Tim; Sample, Matthew] Ctr Sensorimotor Neural Engn, Seattle, WA USA. [Truitt, Anjali R.] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA. [Goering, Sara] Ctr Sensorimotor Neural Engn, Eth Thrust, Seattle, WA USA. RP Klein, E (reprint author), Univ Washington, Philosophy, Seattle, WA 98195 USA. OI Truitt, Anjali/0000-0003-1509-0072; Sample, Matthew/0000-0001-5290-1458 FU National Science Foundation [EEC-1028725] FX This work was supported by a grant from the National Science Foundation (award # EEC-1028725). The views are those of the authors and do not necessarily reflect those of the NSF. NR 57 TC 4 Z9 4 U1 6 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0093-0334 EI 1552-146X J9 HASTINGS CENT REP JI Hastings Cent. Rep. PD NOV-DEC PY 2015 VL 45 IS 6 BP 26 EP 35 DI 10.1002/hast.515 PG 10 WC Ethics; Health Care Sciences & Services; Medical Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Health Care Sciences & Services; Medical Ethics; Biomedical Social Sciences GA CW1YD UT WOS:000364787000012 PM 26556144 ER PT J AU Swenson, ER AF Swenson, Erik R. TI The True Environmental Cost of Chlorofluorocarbon-Based Inhalers SO JAMA Internal Medicine LA English DT Letter ID BAN C1 [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eswenson@u.washington.edu NR 3 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2015 VL 175 IS 11 BP 1867 EP 1867 DI 10.1001/jamainternmed.2015.5237 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CV7BO UT WOS:000364427200044 PM 26524749 ER PT J AU Reddy, A Werner, R AF Reddy, Ashok Werner, Rachel TI US Department of Veterans Affairs Primary Care Provider Turnover and Patient Satisfaction Reply SO JAMA Internal Medicine LA English DT Letter C1 [Reddy, Ashok] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Reddy, Ashok] Univ Washington, Med Ctr Scholarship Patient Care Qual & Safety, Seattle, WA 98195 USA. [Werner, Rachel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Werner, Rachel] Philadelphia VA Med Ctr, VISN Ctr Evaluat PACT 4, Philadelphia, PA USA. RP Reddy, A (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Ste BB1240,POB 356526, Seattle, WA 98195 USA. EM reddya@uw.edu NR 2 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2015 VL 175 IS 11 BP 1870 EP 1871 DI 10.1001/jamainternmed.2015.5411 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CV7BO UT WOS:000364427200049 PM 26524754 ER PT J AU Primack, BA Soneji, S Stoolmiller, M Fine, MJ Sargent, JD AF Primack, Brian A. Soneji, Samir Stoolmiller, Michael Fine, Michael J. Sargent, James D. TI Progression to Traditional Cigarette Smoking After Electronic Cigarette Use Among US Adolescents and Young Adults SO JAMA PEDIATRICS LA English DT Article ID TOBACCO PRODUCT USE; UNITED-STATES; FOLLOW-UP; FUTURE SMOKING; CESSATION; ASSOCIATION; SMOKERS; RISK; REDUCTION; IMPACT AB IMPORTANCE Electronic cigarettes (e-cigarettes) may help smokers reduce the use of traditional combustible cigarettes. However, adolescents and young adults who have never smoked traditional cigarettes are now using e-cigarettes, and these individuals may be at risk for subsequent progression to traditional cigarette smoking. OBJECTIVE To determine whether baseline use of e-cigarettes among nonsmoking and nonsusceptible adolescents and young adults is associated with subsequent progression along an established trajectory to traditional cigarette smoking. DESIGN, SETTING, AND PARTICIPANTS In this longitudinal cohort study, a national US sample of 694 participants aged 16 to 26 years who were never cigarette smokers and were attitudinally nonsusceptible to smoking cigarettes completed baseline surveys from October 1, 2012, to May 1, 2014, regarding smoking in 2012-2013. They were reassessed 1 year later. Analysis was conducted from July 1, 2014, to March 1, 2015. Multinomial logistic regression was used to assess the independent association between baseline e-cigarette use and cigarette smoking, controlling for sex, age, race/ethnicity, maternal educational level, sensation-seeking tendency, parental cigarette smoking, and cigarette smoking among friends. Sensitivity analyses were performed, with varying approaches to missing data and recanting. EXPOSURES Use of e-cigarettes at baseline. MAIN OUTCOMES AND MEASURES Progression to cigarette smoking, defined using 3 specific states along a trajectory: nonsusceptible nonsmokers, susceptible nonsmokers, and smokers. Individuals who could not rule out smoking in the future were defined as susceptible. RESULTS Among the 694 respondents, 374 (53.9%) were female and 531 (76.5%) were non-Hispanic white. At baseline, 16 participants (2.3%) used e-cigarettes. Over the 1-year follow-up, 11 of 16 e-cigarette users and 128 of 678 of those who had not used e-cigarettes (18.9%) progressed toward cigarette smoking. In the primary fully adjusted models, baseline e-cigarette use was independently associated with progression to smoking (adjusted odds ratio [AOR], 8.3; 95% CI, 1.2-58.6) and to susceptibility among nonsmokers (AOR, 8.5; 95% CI, 1.3-57.2). Sensitivity analyses showed consistent results in the level of significance and slightly larger magnitude of AORs. CONCLUSIONS AND RELEVANCE In this national sample of US adolescents and young adults, use of e-cigarettes at baseline was associated with progression to traditional cigarette smoking. These findings support regulations to limit sales and decrease the appeal of e-cigarettes to adolescents and young adults. C1 [Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Ctr Res Media Technol & Hlth, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA. [Soneji, Samir; Sargent, James D.] Dartmouth Coll, Geisel Sch Med, Norris Cotton Canc Ctr, Hanover, NH USA. [Soneji, Samir; Sargent, James D.] Dartmouth Coll, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Stoolmiller, Michael] Univ Oregon, Coll Educ, Oregon Social Learning Ctr, Eugene, OR 97403 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Res Promot, Pittsburgh, PA USA. [Sargent, James D.] Dartmouth Coll, Geisel Sch Med, Dept Pediat, Hanover, NH USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. FU National Cancer Institute [R01-CA077026, R01-CA140150, R21-CA185767]; National Center for Advancing Translational Sciences [KL2-TR001088] FX This study was supported by grant R01-CA077026 for the survey from the National Cancer Institute (Dr Sargent), grants R01-CA140150 and R21-CA185767 from the National Cancer Institute (Dr Primack), and grant KL2-TR001088 from the National Center for Advancing Translational Sciences (Dr Soneji). NR 41 TC 69 Z9 69 U1 2 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD NOV PY 2015 VL 169 IS 11 BP 1018 EP 1023 DI 10.1001/jamapediatrics.2015.1742 PG 6 WC Pediatrics SC Pediatrics GA CV7CM UT WOS:000364430000011 PM 26348249 ER PT J AU Pecina, M Bohnert, ASB Sikora, M Avery, ET Langenecker, SA Mickey, BJ Zubieta, JK AF Pecina, Marta Bohnert, Amy S. B. Sikora, Magdalena Avery, Erich T. Langenecker, Scott A. Mickey, Brian J. Zubieta, Jon-Kar TI Association Between Placebo-Activated Neural Systems and Antidepressant Responses Neurochemistry of Placebo Effects in Major Depression SO JAMA Psychiatry LA English DT Article ID TRICYCLIC ANTIDEPRESSANT; OPIOID RECEPTORS; FUNCTIONAL NEUROANATOMY; NEUROPATHIC ALLODYNIA; PSYCHIATRIC-DISORDERS; EMOTION PERCEPTION; ANALGESIA; REWARD; PAIN; TRIALS AB IMPORTANCE High placebo responses have been observed across a wide range of pathologies, severely impacting drug development. OBJECTIVE To examine neurochemical mechanisms underlying the formation of placebo effects in patients with major depressive disorder (MDD). DESIGN, SETTING, AND PARTICIPANTS In this study involving 2 placebo lead-in phases followed by an open antidepressant administration, we performed a single-blinded 2-week crossover randomized clinical trial of 2 identical oral placebos (described as having either active or inactive fast-acting antidepressant-like effects) followed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases, another agent as clinically indicated. The volunteers (35 medication-free patients with MDD at a university health system) were studied with positron emission tomography and the mu-opioid receptor-selective radiotracer [C-11]carfentanil after each 1-week inactive and active oral placebo treatment. In addition, 1 mL of isotonic saline was administered intravenously within sight of the volunteer during positron emission tomographic scanning every 4 minutes over 20 minutes only after the 1-week active placebo treatment, with instructions that the compound may be associated with the activation of brain systems involved in mood improvement. This challenge stimulus was used to test the individual capacity to acutely activate endogenous opioid neurotransmision under expectations of antidepressant effect. MAIN OUTCOMES AND MEASURES Changes in depressive symptoms in response to active placebo and antidepressant. Baseline and activation measures of mu-opioid receptor binding. RESULTS Higher baseline mu-opioid receptor binding in the nucleus accumbens was associated with better response to antidepressant treatment (r = 0.48; P = .02). Reductions in depressive symptoms after 1 week of active placebo treatment, compared with the inactive, were associated with increased placebo-induced mu-opioid neurotransmission in a network of regions implicated in emotion, stress regulation, and the pathophysiology of MDD, namely, the subgenual anterior cingulate cortex, nucleus accumbens, midline thalamus, and amygdala (nucleus accumbens: r = 0.6; P < .001). Placebo-induced endogenous opioid release in these regions was associated with better antidepressant treatment response, predicting 43% of the variance in symptom improvement at the end of the antidepressant trial. CONCLUSIONS AND RELEVANCE These data demonstrate that placebo-induced activation of the mu-opioid system is implicated in the formation of placebo antidepressant effects in patients with MDD and also participate in antidepressant responses, conferring illness resiliency, during open administration. C1 [Pecina, Marta; Bohnert, Amy S. B.; Sikora, Magdalena; Avery, Erich T.; Mickey, Brian J.; Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bohnert, Amy S. B.] US Dept Vet Affairs, Ann Arbor, MI USA. [Langenecker, Scott A.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI USA. RP Zubieta, JK (reprint author), Univ Michigan, Sch Med, Dept Psychiat, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA. EM zubieta@umich.edu RI Mickey, Brian/J-1756-2014 OI Mickey, Brian/0000-0002-7847-7680 FU National Institutes of Health [R01 MH086858]; Phil F. Jenkins Foundation; Michigan Institute for Clinical & Health Research grant [CTSA UL1RR024986] FX This work was supported by National Institutes of Health grant R01 MH086858 (Dr Zubieta), the Phil F. Jenkins Foundation, and a Michigan Institute for Clinical & Health Research grant (CTSA UL1RR024986). NR 59 TC 10 Z9 11 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2015 VL 72 IS 11 BP 1087 EP 1094 DI 10.1001/jamapsychiatry.2015.1335 PG 8 WC Psychiatry SC Psychiatry GA CV6YG UT WOS:000364417600007 PM 26421634 ER PT J AU Melanson, EL Gavin, KM Shea, KL Wolfe, P Wierman, ME Schwartz, RS Kohrt, WM AF Melanson, Edward L. Gavin, Kathleen M. Shea, Karen L. Wolfe, Pamela Wierman, Margaret E. Schwartz, Robert S. Kohrt, Wendy M. TI Regulation of energy expenditure by estradiol in premenopausal women SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE estradiol; premenopausal women; room calorimetry; resistance exercise; gonadotropin releasing hormone ID EARLY POSTMENOPAUSAL WOMEN; BODY-FAT DISTRIBUTION; GNRH AGONIST THERAPY; REPLACEMENT THERAPY; MENSTRUAL-CYCLE; ADIPOSE-TISSUE; MENOPAUSAL TRANSITION; HORMONE-THERAPY; SKELETAL-MUSCLE; METABOLIC-RATE AB Suppressing sex hormones in women for 1 wk reduces resting energy expenditure (REE). The effects of more chronic suppression on REE and other components of total energy expenditure (TEE), and whether the reduction in REE is specifically due to loss of estradiol (E-2), are not known. We compared the effects of 5 mo of sex hormone suppression (gonadotropin releasing hormone agonist therapy, GnRH(AG)) with placebo (PL) or E-2 add-back therapy on REE and the components of TEE. Premenopausal women received GnRH(AG) (leuprolide acetate 3.75 mg/mo) and were randomized to receive transdermal therapy that was either E-2 (0.075 mg/d; n = 24; means +/- SD, aged = 37 +/- 8 yr, BMI = 27.3 +/- 6.2 kg/m(2)) or placebo (n = 21; aged = 34 +/- 9 yr, BMI = 26.8 +/- 6.2 kg/m(2)). REE was measured by using a metabolic cart, and TEE, sleep EE (SEE), exercise EE (ExEE, 2 X 30 min bench stepping), non-Ex EE (NExEE), and the thermic effect of feeding (TEF) were measured by using whole room indirect calorimetry. REE decreased in GnRH(AG) + PL [mean (95% CI), -54 (-98, -15) kcal/d], but not GnRH(AG) + E-2 [+ 6 (-33, +45) kcal/d] (difference in between-group changes, P = 0.05). TEE decreased in GnRH(AG) + PL [-128 (-214, -41) kcal/d] and GnRH(AG) + E-2 [-96 (-159, -32) kcal/d], with no significant difference in between-group changes (P = 0.55). SEE decreased similarly in both GnRH(AG) + PL [-0.07 (-0.12, -0.03) kcal/min] and GnRH(AG) + E-2 [-0.07 (-0.12, -0.02) kcal/min]. ExEE decreased in GnRH(AG) + PL [-0.46 (-0.79, -0.13) kcal/min], but not GnRH(AG) + E-2 [- 0.30 (-0.65, +0.06) kcal/min]. There were no changes in TEF or NExEE in either group. In summary, chronic pharmacologic suppression of sex hormones reduced REE and this was prevented by E-2 therapy. C1 [Melanson, Edward L.; Wierman, Margaret E.] Univ Colorado, Div Endocrinol Metab & Diabet, Sch Med, Aurora, CO 80045 USA. [Melanson, Edward L.; Gavin, Kathleen M.; Shea, Karen L.; Wolfe, Pamela; Schwartz, Robert S.; Kohrt, Wendy M.] Univ Colorado, Div Geriatr Med, Sch Med, Aurora, CO 80045 USA. [Melanson, Edward L.; Gavin, Kathleen M.; Shea, Karen L.; Wierman, Margaret E.; Schwartz, Robert S.; Kohrt, Wendy M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Melanson, EL (reprint author), Univ Colorado, MS 8106,12801 East 17th Ave,RC1 South RM 7103, Aurora, CO 80045 USA. EM ed.melanson@ucdenver.edu FU National Institutes of Health [R01 AG-018198, P30 DK-048520, UL1 TR-001082, T32 AG000279, F32 AG046957] FX This work was supported by National Institutes of Health Grants R01 AG-018198; P30 DK-048520; and UL1 TR-001082, T32 AG000279, and F32 AG046957. NR 44 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV 1 PY 2015 VL 119 IS 9 BP 975 EP 981 DI 10.1152/japplphysiol.00473.2015 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA CV7TO UT WOS:000364478200004 PM 26338457 ER PT J AU Dubroff, JG Doot, RK Falcone, M Schnoll, RA Ray, R Tyndale, RF Brody, AL Hou, C Schmitz, A Lerman, C AF Dubroff, Jacob G. Doot, Robert K. Falcone, Mary Schnoll, Robert A. Ray, Riju Tyndale, Rachel F. Brody, Arthur L. Hou, Catherine Schmitz, Alexander Lerman, Caryn TI Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE PET; nicotine; addiction; 2-F-18-FA-85380; nicotine metabolite ratio; alpha 4 beta 2*nAChR ID ACETYLCHOLINE-RECEPTORS; SMOKING-CESSATION; HUMAN-BRAIN; CIGARETTE-SMOKING; TRANSDERMAL NICOTINE; TOBACCO SMOKING; IN-VIVO; RATIO; ABSTINENCE; DEPENDENCE AB The nicotine metabolite ratio (NMR), a stable measure of hepatic nicotine metabolism via the CYP2A6 pathway and total nicotine clearance, is a predictive biomarker of response to nicotine replacement therapy, with increased quit rates in slower metabolizers. Nicotine binds directly to nicotinic acetylcholine receptors (nAChRs) to exert its psychoactive effects. This study examined the relationship between NMR and nAChR (alpha 4 beta 2* subtype) availability using PET imaging of the radiotracer 2-F-18-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-18-FA-85380, or 2-F-18-FA). Methods: Twenty-four smokers-12 slow metabolizers (NMR < 0.26) and 12 normal metabolizers (NMR >= 0.26) underwent 2-F-18-FA-PET brain imaging after overnight nicotine abstinence (18 h before scanning), using a validated bolus-plus-infusion protocol. Availability of nAChRs was compared between NMR groups in a priori volumes of interest, with total distribution volume (V-T/f(P)) being the measure of nAChR availability. Cravings to smoke were assessed before and after the scans. Results: Thalamic nAChR alpha 4 beta 2* availability was significantly reduced in slow nicotine metabolizers (P = 0.04). Slow metabolizers exhibited greater reductions in cravings after scanning than normal metabolizers; however, craving was unrelated to nAChR availability. Conclusion: The rate of nicotine metabolism is associated with thalamic nAChR availability. Additional studies could examine whether altered nAChR availability underlies the differences in treatment response between slow and normal metabolizers of nicotine. C1 [Dubroff, Jacob G.; Doot, Robert K.; Hou, Catherine; Schmitz, Alexander] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Falcone, Mary; Schnoll, Robert A.; Lerman, Caryn] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Ray, Riju] GlaxoSmithKline, Global Med Affairs, Brussels, Belgium. [Tyndale, Rachel F.] Univ Toronto, CAMH, Dept Pharmacol & Toxicol, Toronto, ON, Canada. [Tyndale, Rachel F.] Univ Toronto, Dept Psychiat, CAMH, Toronto, ON, Canada. [Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Brody, Arthur L.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. RP Dubroff, JG (reprint author), Hosp Univ Penn, Div Nucl Med & Clin Mol Imaging, Dept Radiol, 3400 Spruce St,110 Donner Bldg, Philadelphia, PA 19104 USA. EM jacob.dubroff@uphs.upenn.edu FU Pharmacogenetics Research Network (PNAT) [U01-DA20830]; Abramson Cancer Center at the University of Pennsylvania; Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania (NIH), a McCabe Pilot Award (University of Pennsylvania); Commonwealth of Pennsylvania (Pennsylvania Department of Health); National Institute on Drug Abuse [R01 DA20872]; Department of Veterans Affairs Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; Tobacco-Related Disease Research Program [23XT-0002] FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by a grant from the Pharmacogenetics Research Network (PNAT, U01-DA20830), the Abramson Cancer Center at the University of Pennsylvania, the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania (NIH), a McCabe Pilot Award (University of Pennsylvania), and the Commonwealth of Pennsylvania (the Pennsylvania Department of Health disclaims responsibility for analyses, interpretations, or conclusions). Additional support was provided by Pfizer, the National Center for Research Resources, and the National Center for Advancing Translational Sciences, National Institutes of Health (UL1TR000003). Arthur Brody is supported by grants from the National Institute on Drug Abuse (R01 DA20872), the Department of Veterans Affairs Office of Research and Development (CSR&D Merit Review Award I01 CX000412), and the Tobacco-Related Disease Research Program (23XT-0002). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. No other potential conflict of interest relevant to this article was reported. NR 48 TC 3 Z9 3 U1 3 U2 7 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD NOV PY 2015 VL 56 IS 11 BP 1724 EP 1729 DI 10.2967/jnumed.115.155002 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CV6BQ UT WOS:000364356100019 PM 26272810 ER PT J AU Stewart, KR Stewart, GL Lampman, M Wakefield, B Rosenthal, G Solimeo, SL AF Stewart, Kenda R. Stewart, Greg L. Lampman, Michelle Wakefield, Bonnie Rosenthal, Gary Solimeo, Samantha L. TI Implications of the Patient-Centered Medical Home for Nursing Practice SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID CARE STAFF PERSPECTIVES; HEALTH-CARE; PROFESSIONAL BOUNDARIES; IMPLEMENTATION; DELEGATION; TEAMWORK; VETERANS; NURSES AB OBJECTIVE: The experiences of RNs and licensed practical nurses (LPNs) implementing a patient-centered medical home (PCMH) in the Department of Veterans Affairs (VA) primary care clinics were examined to understand model implications for nursing practice and professional identity. BACKGROUND: National implementation of the PCMH model, called patient-aligned care teams (PACTs) in VA, emphasizes areas of nursing expertise, yet little is known about the effect of medical homes on the day-to-day work of nurses. METHODS: As part of a formative evaluation to identify barriers and facilitators to PACT implementation, we interviewed 18 nurses implementing PACT. RESULTS: Challenges to nurse's organizational and professional roles were experienced differently by RNs and LPNs in the following areas: (1) diversified modes of care and expanded clinical duties, (2) division of labor among PACT nurses, and (3) interprofessional status in the team. CONCLUSIONS: Healthcare managers implementing PCMH should consider its inherent cultural and practice transformations. C1 [Stewart, Kenda R.; Stewart, Greg L.; Lampman, Michelle; Wakefield, Bonnie; Rosenthal, Gary; Solimeo, Samantha L.] VISN 23 Patient Aligned Care Team Demonstrat Lab, US Dept Vet Affairs, Iowa City, IA USA. [Stewart, Greg L.; Lampman, Michelle; Wakefield, Bonnie; Rosenthal, Gary; Solimeo, Samantha L.] Ctr Comprehens Access & Delivery Res & Evaluat, US Dept Vet Affairs, Iowa City, IA USA. [Stewart, Greg L.] Iowa City VA Hlth Care Syst, Vet Rural Hlth Resource Ctr Cent Reg, US Dept Vet Affairs, Iowa City, IA 52246 USA. [Stewart, Greg L.] Univ Iowa, Tippie Coll Business, Iowa City, IA USA. [Rosenthal, Gary; Solimeo, Samantha L.] Univ Iowa Carver, Div Gen Internal Med, Coll Med, Iowa City, IA USA. RP Stewart, KR (reprint author), Iowa City VA Hlth Care Syst, 601 Hwy 6 W, Iowa City, IA 52246 USA. EM kenda.stewart@va.gov FU VISN 23 PACT Demonstration Laboratory; Office of Patient Care Services, Department of Veterans Affairs; Center for Comprehensive Access and Delivery Research and Evaluation, Department of Veterans Affairs, Iowa City VA Health Care System, Iowa City [CIN 13-412] FX This work was supported by VISN 23 PACT Demonstration Laboratory, supported by the Office of Patient Care Services, Department of Veterans Affairs. Additional support was provided by the Center for Comprehensive Access and Delivery Research and Evaluation (grant CIN 13-412), Department of Veterans Affairs, Iowa City VA Health Care System, Iowa City. NR 27 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD NOV PY 2015 VL 45 IS 11 BP 569 EP 574 DI 10.1097/NNA.0000000000000265 PG 6 WC Nursing SC Nursing GA CV5SO UT WOS:000364331600011 PM 26492149 ER PT J AU Tuite, MJ Kransdorf, MJ Beaman, FD Adler, RS Amini, B Appel, M Bernard, SA Dempsey, ME Fries, IB Greenspan, BS Khurana, B Mosher, TJ Walker, EA Ward, RJ Wessell, DE Weissman, BN AF Tuite, Michael J. Kransdorf, Mark J. Beaman, Francesca D. Adler, Ronald S. Amini, Behrang Appel, Marc Bernard, Stephanie A. Dempsey, Molly E. Fries, Ian Blair Greenspan, Bennett S. Khurana, Bharti Mosher, Timothy J. Walker, Eric A. Ward, Robert J. Wessell, Daniel E. Weissman, Barbara N. TI ACR Appropriateness Criteria Acute Trauma to the Knee SO Journal of the American College of Radiology LA English DT Article DE Appropriateness criteria; knee injury; diagnostic imaging; radiograph; CT; MRI ID LATERAL PATELLAR DISLOCATION; TIBIAL PLATEAU FRACTURES; VIRTUAL NONCALCIUM TECHNIQUE; ANTERIOR CRUCIATE LIGAMENT; CLINICAL DECISION RULES; BONE-MARROW LESIONS; MENISCAL TEARS; COMPUTED-TOMOGRAPHY; IMAGING FINDINGS; LOCKED KNEE AB More than 500,000 visits to the emergency room occur annually in the United States, for acute knee trauma. Many of these are twisting injuries in young patients who can walk and bear weight, and emergent radiographs are not required. Several clinical decision rules have been devised that can considerably reduce the number of radiographs ordered without missing a clinically significant fracture. Although a fracture is seen on only 5% of emergency department knee radiographs, 86% of knee fractures result from blunt trauma. In patients with a fall or twisting injury who have focal tenderness, effusion, or inability to bear weight, radiographs should be the first imaging study obtained. If the radiograph shows no fracture, MRI is best for evaluating for a suspected meniscus or ligament tear, or the injuries from a reduced patellar dislocation. Patients with a knee dislocation should undergo radiographs and an MRI, as well as an angiographic study such as a fluoroscopic, CT, or MR angiogram. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures, by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. C1 [Tuite, Michael J.] Univ Wisconsin Hosp, Madison, WI 53792 USA. [Kransdorf, Mark J.] Mayo Clin, Phoenix, AZ USA. [Beaman, Francesca D.] Univ Kentucky, Lexington, KY USA. [Adler, Ronald S.] NYU, Ctr Musculoskeletal Care, New York, NY USA. [Amini, Behrang] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Appel, Marc] James J Peters VA Med Ctr, Bronx, NY USA. [Appel, Marc] Amer Acad Orthopaed Surg, Rosemont, IL USA. [Bernard, Stephanie A.; Mosher, Timothy J.; Walker, Eric A.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA. [Dempsey, Molly E.] Texas Scottish Rite Hosp Crippled Children, Dallas, TX USA. [Fries, Ian Blair] Chartered, Bone Spine & Hand Surg, Brick, NJ USA. [Greenspan, Bennett S.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Khurana, Bharti; Weissman, Barbara N.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ward, Robert J.] Tufts Med Ctr, Boston, MA USA. [Wessell, Daniel E.] Mayo Clin, Jacksonville, FL 32224 USA. RP Tuite, MJ (reprint author), Univ Wisconsin Hosp, Clin Sci Ctr E3 311, Dept Radiol, 600 Highland Ave, Madison, WI 53792 USA. EM mtuite@uwhealth.org OI Walker, Eric/0000-0002-2353-5935 FU Medical Metrics; Kensey Nash Corporation; Johnson and Johnson FX Timothy J. Mosher, MD, reported being a paid consultant for Medical Metrics and for Kensey Nash Corporation, and a stockholder with Johnson and Johnson. NR 69 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2015 VL 12 IS 11 BP 1164 EP 1172 DI 10.1016/j.jacr.2015.08.014 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CV4UV UT WOS:000364262900012 PM 26541130 ER PT J AU Dichter, ME Wagner, C True, G AF Dichter, Melissa E. Wagner, Clara True, Gala TI Timing of Intimate Partner Violence in Relationship to Military Service Among Women Veterans SO MILITARY MEDICINE LA English DT Article ID HEALTH AB Women U.S. military veterans report higher rates of lifetime intimate partner violence (IPV) compared with women who have never served in the military. However, we know little about the timing of IPV exposure relative to military service. To begin to understand the relationship between military service and IPV experience, we conducted surveys with 249 women military veterans seeking care at a Veterans Affairs medical center about experiences of physical, psychological, and sexual IPV before, during, and after military service. Additionally, we examined the association between deployment and IPV experience during and after military service. Findings indicated that women experienced IPV during each time period (before/during/after military service), with significant overlap of experiencing IPV during more than one time period and one-third (34.6%) experiencing IPV during all three time periods. Compared to those who were not deployed, women who had been deployed reported increased odds of experiencing psychological, but not physical or sexual, IPV during (but not after) military service. Implications of study findings for theory, research, and practice are discussed. C1 [Dichter, Melissa E.; Wagner, Clara; True, Gala] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [True, Gala] Univ Penn, Philadelphia, PA 19104 USA. RP Dichter, ME (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 3900 Woodland Ave,Bldg 4100 Annex, Philadelphia, PA 19104 USA. FU U.S. Department of Veterans Affairs, Health Services Research and Development Service [10-202]; U.S. Department of Veterans Affairs, Center for Evaluation of Patient Aligned Care Teams [12-005] FX Dr. Dichter is a Career Development Awardee, supported by the U.S. Department of Veterans Affairs, Health Services Research and Development Service (CDA #10-202). This work was additionally supported by U.S. Department of Veterans Affairs, Center for Evaluation of Patient Aligned Care Teams ("IPV Assessment and Response with the PACT Model: Needs, Barriers, and Opportunities," CEPACT #12-005, Principal Investigator: Dichter). NR 15 TC 1 Z9 1 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2015 VL 180 IS 11 BP 1124 EP 1127 DI 10.7205/MILMED-D-14-00582 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CV9UT UT WOS:000364633400007 PM 26540701 ER PT J AU Thaler, NS Sayegh, P Arentoft, A Thames, AD Castellon, SA Hinkin, CH AF Thaler, Nicholas S. Sayegh, Philip Arentoft, Alyssa Thames, April D. Castellon, Steven A. Hinkin, Charlie H. TI Increased Neurocognitive Intra-Individual Variability Is Associated With Declines in Medication Adherence in HIV-Infected Adults SO NEUROPSYCHOLOGY LA English DT Article DE HIV; intra-individual variability; medication adherence; longitudinal ID ANTIRETROVIRAL THERAPY; RESPONSE VARIABILITY; PERFORMANCE; DISORDERS; INDIVIDUALS; DISPERSION; DISEASE; TASK; ERA AB Objective: There is cross-sectional evidence that neurocognitive intra-individual variability (IIV), or dispersion, is elevated in human immunodeficiency virus (HIV) disease and is associated with declines in activities of daily living, including medication adherence. Methods: This longitudinal study extends this literature by examining whether increased neurocognitive IIV in HIV-positive persons over time predicts declines in medication adherence above and beyond changes in mean level of performance over a 6-month observation. Results: After controlling for drug use, declines in mean performance, and changes in depressive symptoms, results confirmed that increases in IIV were associated with overall poorer antiretroviral medication adherence. HIV-positive individuals with the greatest increases in dispersion demonstrated marked reductions in adherence by the third month that exceeded what was observed in less variable individuals. Conclusions: Our results indicate that increases in dispersion are associated with poorer declines in medication adherence in HIV disease, which may have implications for the early detection and remediation of suboptimal antiretroviral adherence. C1 [Thaler, Nicholas S.; Sayegh, Philip; Arentoft, Alyssa; Thames, April D.; Castellon, Steven A.; Hinkin, Charlie H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Castellon, Steven A.; Hinkin, Charlie H.] VA Greater Los Angeles Healthcare Syst, Dept Psychol, Los Angeles, CA USA. RP Thaler, NS (reprint author), 760 Westwood Plaza C8-735, Los Angeles, CA 90024 USA. EM nthaler@mednet.ucla.edu OI Arentoft, Alyssa/0000-0002-4235-4638 FU National Institutes of Health [R01 DA13799]; National Institutes of Health Ruth L. Kirschstein National Research Service award [T32 MH19535] FX This work was supported by National Institutes of Health Grant R01 DA13799 and the National Institutes of Health Ruth L. Kirschstein National Research Service award T32 MH19535. NR 29 TC 3 Z9 3 U1 0 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD NOV PY 2015 VL 29 IS 6 BP 919 EP 925 DI 10.1037/neu0000191 PG 7 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA CV9FF UT WOS:000364592100011 PM 25730729 ER PT J AU Willson, TJ Shams, A Lospinoso, J Weitzel, E McMains, K AF Willson, Thomas J. Shams, Alexandra Lospinoso, Joshua Weitzel, Erik McMains, Kevin TI Searching for Cedar: Geographic Variation in Single Aeroallergen Shows Dose Response in Internet Search Activity SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE aeroallergen; allergen; mountain cedar; juniper; Google; Internet AB Objective To assess the effect of a single aeroallergen on Internet search activity in 3 distinct geographic regions over time. Study Design A retrospective time series analysis. Setting Tertiary academic medical center. Methods Mountain Cedar pollen counts spanning the periods from 2011 to 2014 were collected for San Antonio, Dallas-Ft Worth, and Houston metro regions (Texas). Google search data for the corresponding period and regions were also obtained for the search terms pollen and mountain cedar. Data were analyzed through time series plots and autoregressive integrated moving average. Results Seasonal maximum pollen counts were greatest in San Antonio, ranging from 5413 to 9982 grains per cubic centimeter. In San Antonio, there was a strong, positive, and statistically significant effect of mountain cedar pollen count on search activity for both pollen (P = .001) and mountain cedar (P < .001) when evaluated by autoregressive integrated moving average. Conclusions Environmental levels of a single allergenmountain cedar pollenshow a geographic and temporal relationship between Internet searches and mountain cedar pollen, based on Google Trends. These data are useful to understand patients' perceptions of the health risk presented by mountain cedar pollen. In turn, this information affords practitioners the opportunity to offer targeted patient education in a geographically unique region, as well as adjust surveillance of related pathologies. C1 [Willson, Thomas J.; Weitzel, Erik] San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78234 USA. [Willson, Thomas J.; Shams, Alexandra; Weitzel, Erik; McMains, Kevin] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Lospinoso, Joshua] Portia Stat Consulting LLC, San Antonio, TX USA. [McMains, Kevin] South Texas Vet Hlth Care Syst, ENT Sect, San Antonio, TX USA. RP Willson, TJ (reprint author), San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. EM S10twillson@gmail.com NR 8 TC 0 Z9 0 U1 2 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD NOV PY 2015 VL 153 IS 5 BP 770 EP 774 DI 10.1177/0194599815601650 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CV6MF UT WOS:000364383600011 PM 26340925 ER PT J AU McMains, KC Peel, J Weitzel, EK Der-Torossian, H Couch, M AF McMains, Kevin Christopher Peel, Jennifer Weitzel, Erik K. Der-Torossian, Hirak Couch, Marion TI Perception of Shame in Otolaryngology-Head and Neck Surgery Training SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE education; otolaryngology; faculty; teaching; environment of learning ID MEDICAL-STUDENTS; PATIENT SAFETY; EXPERIENCES; GUILT AB Objective This survey was developed to assess the prevalence and effects of the perception of shame in otolaryngology-head and neck surgery residency training in the United States. Study Design Survey. Setting US otolaryngology training programs. Subjects Faculty and trainees in US otolaryngology training programs. Methods A 14-item survey to assess the prevalence of the experience of shame and the attitudes toward use of shame in otolaryngology residency training was sent to all otolaryngology-head and neck surgery program directors for distribution among their respective faculty and resident cohorts. Results A total of 267 responses were received (women, 24.7%; men, 75.3%): 42.7% of respondents were trainees; 7.0% of trainees thought that shame was a necessary/effective tool, compared with 11.4% of faculty; 50% of respondents felt that they had been personally shamed during residency; and 69.9% of respondents had witnessed another trainee being shamed during residency training. Trainees were most commonly shamed in the operating room (78.4%). Otolaryngology faculty members did the shaming 95.1% of the time. Although shaming prompted internal reflection/self-improvement in 57.4% of trainees, it also caused loss of self-confidence in 52.5%. Trainees who had been shamed were more likely to view shame as an appropriate educational tool (P < .05). Conclusion Half of respondents have felt shamed during their residency training, and a majority has witnessed a colleague being shamed. Understanding the negative impact that shaming behaviors have on the learning environment and on the performance of the individual within it is an important first step in creating an environment maximally conducive to learning, professional development, and patient safety. C1 [McMains, Kevin Christopher; Weitzel, Erik K.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA. [Peel, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Der-Torossian, Hirak] Univ Vermont, Coll Med, Burlington, VT USA. [Couch, Marion] Indiana Univ, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN USA. RP McMains, KC (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Dr, San Antonio, TX 78229 USA. EM kevin.mcmains@va.gov NR 17 TC 2 Z9 2 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD NOV PY 2015 VL 153 IS 5 BP 786 EP 790 DI 10.1177/0194599815598288 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CV6MF UT WOS:000364383600014 PM 26243025 ER PT J AU Byrne, T Fargo, JD Montgomery, AE Roberts, CB Culhane, DP Kane, V AF Byrne, Thomas Fargo, Jamison D. Montgomery, Ann Elizabeth Roberts, Christopher B. Culhane, Dennis P. Kane, Vincent TI Screening for Homelessness in the Veterans Health Administration: Monitoring Housing Stability through Repeat Screening SO PUBLIC HEALTH REPORTS LA English DT Article ID SERVICE USE; COSTS; RISK; CARE AB Objective. This study examined veterans' responses to the Veterans Health Administration's (VHA's) universal screen for homelessness and risk of homelessness during the first 12 months of implementation. Methods. We calculated the baseline annual frequency of homelessness and risk of homelessness among all veterans who completed an initial screen during the study period. We measured changes in housing status among veterans who initially screened positive and then completed a follow-up screen, assessed factors associated with such changes, and identified distinct risk profiles of veterans who completed a follow-up screen. Results. More than 4 million veterans completed an initial screen; 1.8% (n=77,621) screened positive for homelessness or risk of homelessness. Of those who initially screened positive for either homelessness or risk of homelessness and who completed a second screen during the study period, 85.0% (n=15,060) resolved their housing instability prior to their second screen. Age, sex, race, VHA eligibility, and screening location were all associated with changes in housing stability. We identified four distinct risk profiles for veterans with ongoing housing instability. Conclusion. To address homelessness among veterans, efforts should include increased and targeted engagement of veterans experiencing persistent housing instability. C1 [Byrne, Thomas] Boston Univ, Sch Social Work, Boston, MA 02155 USA. [Byrne, Thomas; Fargo, Jamison D.; Montgomery, Ann Elizabeth; Roberts, Christopher B.; Culhane, Dennis P.; Kane, Vincent] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Fargo, Jamison D.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Byrne, T (reprint author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02155 USA. EM tbyrne@bu.edu NR 23 TC 0 Z9 0 U1 3 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2015 VL 130 IS 6 BP 684 EP 692 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV8CI UT WOS:000364503700017 PM 26556940 ER PT J AU Kim, IL Pfeifer, CG Fisher, MB Saxena, V Meloni, GR Kwon, MY Kim, M Steinberg, DR Mauck, RL Burdick, JA AF Kim, Iris L. Pfeifer, Christian G. Fisher, Matthew B. Saxena, Vishal Meloni, Gregory R. Kwon, Mi Y. Kim, Minwook Steinberg, David R. Mauck, Robert L. Burdick, Jason A. TI Fibrous Scaffolds with Varied Fiber Chemistry and Growth Factor Delivery Promote Repair in a Porcine Cartilage Defect Model SO TISSUE ENGINEERING PART A LA English DT Article ID ARTICULAR-CARTILAGE; HYALURONIC-ACID; MECHANICAL-PROPERTIES; MSC CHONDROGENESIS; SUBCHONDRAL BONE; DRUG-DELIVERY; ANIMAL-MODELS; REGENERATION; TISSUE; NANOFIBERS AB Current clinically approved methods for cartilage repair are generally based on either endogenous cell recruitment (e.g., microfracture) or chondrocyte delivery (e.g., autologous chondrocyte implantation). However, both methods culminate in repair tissue with inferior mechanical properties and the addition of biomaterials to these clinical interventions may improve their efficacy. To this end, the objective of this study was to investigate the ability of multipolymer acellular fibrous scaffolds to improve cartilage repair when combined with microfracture in a large animal (i.e., minipig) model. Composite scaffolds were formulated from a combination of hyaluronic acid (HA) fibers and poly(-caprolactone) (PCL) fibers, either with or without transforming growth factor-3 (TGF3). After 12 weeks in vivo, material choice and TGF3 delivery had a significant impact on outcomes; specifically, PCL scaffolds without TGF3 had inferior gross appearance and reduced mechanical properties, whereas HA scaffolds that released TGF3 resulted in improved histological scores and increased type 2 collagen content. Importantly, analysis of the overall dataset revealed that histology, but not gross appearance, was a better predictor of mechanical properties. This study highlights the importance of scaffold properties on in vivo cartilage repair as well as the need for numerous quantitative outcome measures to fully evaluate treatment methods. C1 [Kim, Iris L.; Kwon, Mi Y.; Mauck, Robert L.; Burdick, Jason A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Kim, Iris L.; Pfeifer, Christian G.; Fisher, Matthew B.; Saxena, Vishal; Meloni, Gregory R.; Kim, Minwook; Steinberg, David R.; Mauck, Robert L.; Burdick, Jason A.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Pfeifer, Christian G.; Fisher, Matthew B.; Saxena, Vishal; Meloni, Gregory R.; Kim, Minwook; Steinberg, David R.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Burdick, JA (reprint author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA. EM burdick2@seas.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Science Foundation; National Institutes of Health [R01 EB008722]; Department of Veterans Affairs [I01 RX000700] FX This work was supported by a graduate research fellowship from the National Science Foundation (I.L.K.) and grants from the National Institutes of Health (R01 EB008722) and the Department of Veterans Affairs (I01 RX000700). The authors also acknowledge Dr. Nicole Belkin and Dr. Andrew Milby for assistance with surgeries and Dr. Ross Marklein for assistance with principal component analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. NR 47 TC 5 Z9 5 U1 1 U2 18 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD NOV 1 PY 2015 VL 21 IS 21-22 BP 2680 EP 2690 DI 10.1089/ten.tea.2015.0150 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CV7UI UT WOS:000364480600005 PM 26401910 ER PT J AU Struzyna, LA Wolf, JA Mietus, CJ Adewole, DO Chen, HI Smith, DH Cullen, DK AF Struzyna, Laura A. Wolf, John A. Mietus, Constance J. Adewole, Dayo O. Chen, H. Isaac Smith, Douglas H. Cullen, D. Kacy TI Rebuilding Brain Circuitry with Living Micro-Tissue Engineered Neural Networks SO TISSUE ENGINEERING PART A LA English DT Article ID SPINAL-CORD-INJURY; STEM-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; GUIDANCE CHANNELS; AXON REGENERATION; NEURITE EXTENSION; FUNCTIONAL RECOVERY; CHONDROITINASE ABC; NEURONAL GROWTH AB Prominent neuropathology following trauma, stroke, and various neurodegenerative diseases includes neuronal degeneration as well as loss of long-distance axonal connections. While cell replacement and axonal pathfinding strategies are often explored independently, there is no strategy capable of simultaneously replacing lost neurons and re-establishing long-distance axonal connections in the central nervous system. Accordingly, we have created micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of long integrated axonal tracts spanning discrete neuronal populations. These living micro-TENNs reconstitute the architecture of long-distance axonal tracts, and thus may serve as an effective substrate for targeted neurosurgical reconstruction of damaged pathways in the brain. Cerebral cortical neurons or dorsal root ganglia neurons were precisely delivered into the tubular constructs, and properties of the hydrogel exterior and extracellular matrix internal column (180-500m diameter) were optimized for robust neuronal survival and to promote axonal extensions across the 2.0cm tube length. The very small diameter permits minimally invasive delivery into the brain. In this study, preformed micro-TENNs were stereotaxically injected into naive rats to bridge deep thalamic structures with the cerebral cortex to assess construct survival and integration. We found that micro-TENN neurons survived at least 1 month and maintained their long axonal architecture along the cortical-thalamic axis. Notably, we also found neurite penetration from micro-TENN neurons into the host cortex, with evidence of synapse formation. These micro-TENNs represent a new strategy to facilitate nervous system repair by recapitulating features of neural pathways to restore or modulate damaged brain circuitry. C1 [Struzyna, Laura A.; Wolf, John A.; Mietus, Constance J.; Adewole, Dayo O.; Chen, H. Isaac; Smith, Douglas H.; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA. [Struzyna, Laura A.; Wolf, John A.; Adewole, Dayo O.; Chen, H. Isaac; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Struzyna, Laura A.; Adewole, Dayo O.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), Univ Penn, Dept Neurosurg, 105E Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA. EM dkacy@mail.med.upenn.edu FU U.S. Army Medical Research and Materiel Command through the Armed Forces Institute of Regenerative Medicine [W81XWH-08-2-0034]; Congressionally Directed Medical Research Program [W81XWH-10-1-0941]; Joint Warfighter Medical Research Program [W81XWH-13207004]; Department of Veterans Affairs through a RRD Merit Review [B1097-I]; National Institutes of Health/NINDS [T32-NS043126]; Penn Medicine Neuroscience Center; Graduate Research Fellowship through the National Science Foundation [DGE-1321851] FX Financial support was provided by the U.S. Army Medical Research and Materiel Command through the Armed Forces Institute of Regenerative Medicine (#W81XWH-08-2-0034), the Congressionally Directed Medical Research Program (#W81XWH-10-1-0941), and the Joint Warfighter Medical Research Program (#W81XWH-13207004); the Department of Veterans Affairs through a RR&D Merit Review (#B1097-I); the National Institutes of Health/NINDS (T32-NS043126); Penn Medicine Neuroscience Center; and a Graduate Research Fellowship through the National Science Foundation (DGE-1321851). The authors would like to thank Andrew Jaye, Joseph Morand, and Ariana Barkley for technical assistance in these studies, and Dr. James Harris for assistance with figure preparation. NR 71 TC 3 Z9 4 U1 0 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD NOV 1 PY 2015 VL 21 IS 21-22 BP 2744 EP 2756 DI 10.1089/ten.tea.2014.0557 PG 13 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CV7UI UT WOS:000364480600011 PM 26414439 ER PT J AU Lee, T Ul Haq, N AF Lee, Timmy Ul Haq, Naveed TI New Developments in Our Understanding of Neointimal Hyperplasia SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Neointimal hyperplasia; Vascular remodeling; Arteriovenous accesses; Novel therapies; Cannulation ID CHRONIC KIDNEY-DISEASE; HEMODIALYSIS VASCULAR ACCESS; ARTERIOVENOUS-FISTULA MODEL; RANDOMIZED CONTROLLED-TRIAL; INDUCED ARTERIAL ENLARGEMENT; INHIBIT INTIMAL HYPERPLASIA; ENDOTHELIAL-CELL IMPLANTS; SHEAR-STRESS; VENOUS STENOSIS; GRAFT PATENCY AB The vascular access remains the lifeline for the hemodialysis patient. The most common etiology of vascular access dysfunction is venous stenosis at the vein-artery anastomosis in arteriovenous fistula and at the vein-graft anastomosis in arteriovenous grafts (AVG). This stenotic lesion is typically characterized on histology as aggressive venous neointimal hyperplasia in both arteriovenous fistula and AVG. In recent years, we have advanced our knowledge and understanding of neointimal hyperplasia in vascular access and begun testing several novel therapies. This article will (1) review recent developments in our understanding of the pathophysiology of neointimal hyperplasia development in AVG and fistula failure, (2) discuss atypical factors leading to neointimal hyperplasia development, (3) highlight key novel therapies that have been evaluated in clinical trials, and (4) discuss future opportunities and challenges to improve our understanding of vascular access dysfunction and translate this knowledge into novel and innovative therapies. (C) 2015 by the National Kidney Foundation, Inc. All rights reserved. C1 [Lee, Timmy] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. King Faisal Specialist Hosp & Res Ctr, Dept Med, Nephrol Sect, Riyadh, Saudi Arabia. RP Lee, T (reprint author), Univ Alabama Birmingham, Dept Med, Div Nephrol, Zeigler Res Bldg 524,1720 2nd Ave South, Birmingham, AL 35294 USA. EM txlee@uab.edu FU American Society of Nephrology Carl W. Gottschalk Research Scholar Grant; University of Alabama at Birmingham Nephrology Research Training Center Anderson Innovation Award FX The author has research funding from an American Society of Nephrology Carl W. Gottschalk Research Scholar Grant and University of Alabama at Birmingham Nephrology Research Training Center Anderson Innovation Award. NR 76 TC 1 Z9 1 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 EI 1548-5609 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD NOV PY 2015 VL 22 IS 6 BP 431 EP 437 DI 10.1053/j.ackd.2015.06.010 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CV4UQ UT WOS:000364262400005 PM 26524947 ER PT J AU Jubelt, LE Volpp, KG Gatto, DE Friedman, JY Shea, JA AF Jubelt, Lindsay E. Volpp, Kevin G. Gatto, Dana E. Friedman, Joelle Y. Shea, Judy A. TI A Qualitative Evaluation of Patient-Perceived Benefits and Barriers to Participation in a Telephone Care Management Program SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Patient-Centered Care; Patient Care Management; Care Coordination; Disease Management; Chronic Disease; Health Behavior; Prevention Research AB Purpose. To examine why high-risk individuals targeted for a telephone care management program participated at low rates. Design. Study design consisted of qualitative, semistructured interviews. Setting. The setting was a large national insurer's telephone-based care management program. The program employed registered nurses to provide individually tailored education and counseling about health and health care. Subjects. Study subjects comprised members of a national insurer who were recruited to participate in a care management program but had either dropped out of the program after a short period of initial engagement or had never participated despite recruitment efforts. Measures. Interview content was divided into four categories: knowledge of the case management program, bathers to program participation, perceptions of benefits of the program, and suggestions for program improvement. Analysis. Investigators conducted a directed content analysis. Results. The most commonly cited barriers to participation were a lack of perceived need and a sense of distrust toward the program and its staff The most commonly cited benefits were psychosocial support and goal setting. Conclusion. Care management programs may benefit from changes to how insurance plan members are selected for the program and from adjusting program content to address perceived needs among members. C1 [Jubelt, Lindsay E.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Jubelt, Lindsay E.; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Jubelt, Lindsay E.; Volpp, Kevin G.; Gatto, Dana E.; Friedman, Joelle Y.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Jubelt, Lindsay E.] NYU, Dept Populat Hlth, Sch Med, New York, NY 10016 USA. [Volpp, Kevin G.; Gatto, Dana E.; Friedman, Joelle Y.; Shea, Judy A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Jubelt, LE (reprint author), NYU, Dept Populat Hlth, Sch Med, 227 East 30th St,Floor 6, New York, NY 10016 USA. EM lindsay.jubelt@nyumc.org NR 8 TC 1 Z9 1 U1 1 U2 3 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2015 VL 30 IS 2 BP 117 EP 119 DI 10.4278/ajhp.131203-ARB-610 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV0AM UT WOS:000363909000009 PM 25615709 ER PT J AU Becker, NV Asch, DA Kullgren, JT Bellamy, SL Sen, AP Volpp, KG AF Becker, Nora V. Asch, David A. Kullgren, Jeffrey T. Bellamy, Scarlett L. Sen, Aditi P. Volpp, Kevin G. TI Stages of Change and Patient Activation Measure Scores in the Context of Incentive-Based Health Interventions SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Behavioral Economics; Health Incentives; Motivation; Stage of Change; Patient Activation; Prevention Research ID BEHAVIORS; OUTCOMES AB Purpose. To determine if two widely used behavioral change measures-Stages of Change (SoC) and Patient Activation Measure (PAM)-correlate with each other; are affected by financial incentives, or predict positive outcomes in the context of incentive-based health interventions. Design. Secondary analysis of two randomized controlled trials of incentives. for weight loss and for improved diabetes self-monitoring. Setting. Philadelphia, Pennsylvania; Newark, New Jersey. Subjects. A total of 132 obese and 75 diabetic adults enrolled in one of two trials. Measures. SoC and PAM scores; weight loss and usage rate of diabetes self-monitoring equipment. Analysis. Multiple regression; Kruskal-Wallis test. Results. We found no association between baseline SoC and PAM sews in either study (p = .30 and p = .89). Regression models showed no association between baseline PAM score and SoC and subsequent outcomes for either study (weight loss study: PAM: p = .14, SoC: p = .1; diabetes study: PAM: p = .45, SoC: p = .61). Change in PAM score and SoC among participants in the intervention groups did not differ by study arm or among participants with better outcomes. Conclusion. PAM score and SoC may not effectively predict success or monitor progress among individuals enrolled in incentive-based interventions. C1 [Becker, Nora V.; Sen, Aditi P.] Univ Penn, Wharton Sch, Dept Hlth Care Management & Econ, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Dept Med, Perelman Sch Med, Philadelphia, PA USA. [Kullgren, Jeffrey T.] Univ Michigan, Inst Healthcare Policy & Innovat, VA Ctr Clin Management Res, VA Ann Arbor Healthcare Syst,Dept Internal Med,Sc, Ann Arbor, MI 48109 USA. [Bellamy, Scarlett L.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Becker, NV (reprint author), Univ Penn, Wharton Sch, Dept Hlth Care Management & Econ, 3641 Locust Walk,Suite 402, Philadelphia, PA 19104 USA. EM norab@wharton.upenn.edu NR 7 TC 0 Z9 0 U1 3 U2 8 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2015 VL 30 IS 2 BP 133 EP 135 DI 10.4278/ajhp.141001-QUAN-489 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV0AM UT WOS:000363909000012 PM 26517587 ER PT J AU Gvilia, I Suntsova, N Kumar, S McGinty, D Szymusiak, R AF Gvilia, Irma Suntsova, Natalia Kumar, Sunil McGinty, Dennis Szymusiak, Ronald TI Suppression of preoptic sleep-regulatory neuronal activity during corticotropin-releasing factor-induced sleep disturbance SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE CRF; sleep homeostasis; stress; preoptic hypothalamus ID STRESSOR-INDUCED ALTERATIONS; REDUCES SPONTANEOUS WAKING; C-FOS; HOMEOSTATIC REGULATION; GALANINERGIC NEURONS; DISCHARGE PATTERNS; AREA NEURONS; HORMONE CRH; RAT; NUCLEUS AB Corticotropin releasing factor (CRF) is implicated in sleep and arousal regulation. Exogenous CRF causes sleep suppression that is associated with activation of at least two important arousal systems: pontine noradrenergic and hypothalamic orexin/hypocretin neurons. It is not known whether CRF also impacts sleep-promoting neuronal systems. We hypothesized that CRF-mediated changes in wake and sleep involve decreased activity of hypothalamic sleep-regulatory neurons localized in the preoptic area. To test this hypothesis, we examined the effects of intracerebroventricular administration of CRF on sleep-wake measures and c-Fos expression in GABAergic neurons in the median preoptic nucleus (MnPN) and ventrolateral preoptic area (VLPO) in different experimental conditions. Administration of CRF (0.1 nmol) during baseline rest phase led to delayed sleep onset and decreases in total amount and mean duration of non-rapid eye movement (NREM) sleep. Administration of CRF during acute sleep deprivation (SD) resulted in suppression of recovery sleep and decreased c-Fos expression in MnPN/VLPO GABAergic neurons. Compared with vehicle controls, intracerebroventricular CRF potentiated disturbances of both NREM and REM sleep in rats exposed to a species-specific psychological stressor, the dirty cage of a male conspecific. The number of MnPN/VLPO GABAergic neurons expressing c-Fos was reduced in the CRF-treated group of dirty cage-exposed rats. These findings confirm the involvement of CRF in wake-sleep cycle regulation and suggest that increased CRF signaling in the brain 1) negatively affects homeostatic responses to sleep loss, 2) exacerbates stress-induced disturbances of sleep, and 3) suppresses the activity of sleep-regulatory neurons of the MnPN and VLPO. C1 [Gvilia, Irma; Kumar, Sunil; McGinty, Dennis; Szymusiak, Ronald] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91344 USA. [Gvilia, Irma; Szymusiak, Ronald] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Suntsova, Natalia; McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, Irma] Ilia State Univ, Tbilisi, Rep of Georgia. RP Gvilia, I (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM igvilia@ucla.edu FU Department of Veterans Affairs FX This study was supported by the Department of Veterans Affairs. The authors thank Keng-Tee Chow for her excellent technical assistance. NR 45 TC 0 Z9 0 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD NOV 1 PY 2015 VL 309 IS 9 BP R1092 EP R1100 DI 10.1152/ajpregu.00176.2015 PG 9 WC Physiology SC Physiology GA CV5OI UT WOS:000364320000010 PM 26333784 ER PT J AU Heisler, JM O'Connor, JC AF Heisler, Jillian M. O'Connor, Jason C. TI Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Neuroinflammation; Recognition memory; Novel object recognition; Kynurenine; Indoleamine 2,3-dioxygenase; Kynurenine monooxygenase; Neuropsychiatric symptom; Perirhinal cortex; Mouse; Behavior ID DEPRESSIVE-LIKE BEHAVIOR; OBJECT RECOGNITION; NMDA RECEPTOR; RESIDUAL SYMPTOMS; PREFRONTAL CORTEX; LIPOPOLYSACCHARIDE; BRAIN; RATS; MICE; HIPPOCAMPUS AB Cognitive dysfunction in depression is a prevalent and debilitating symptom that is poorly treated by the currently available pharmacotherapies. Research over the past decade has provided evidence for proin-flammatory involvement in the neurobiology of depressive disorders and symptoms associated with these disorders, including aspects of memory dysfunction. Recent clinical studies implicate inflammation-related changes in kynurenine metabolism as a potential pathogenic factor in the development of a range of depressive symptoms, including deficits in cognition and memory. Additionally, preclinical work has demonstrated a number of mood-related depressive-like behaviors to be dependent on indoleamine 2,3-dioxygenase-1 (ID01), the inflammation-induced rate-limiting enzyme of the kynurenine pathway. Here, we demonstrate in a mouse model, that peripheral administration of endotoxin induced a deficit in recognition memory. Mice deficient in IDO were protected from cognitive impairment. Furthermore, endotoxin-induced inflammation increased kynurenine metabolism within the perirhinal/entorhinal cortices, brain regions which have been implicated in recognition memory. A single peripheral injection of kynurenine, the metabolic product of ID01, was sufficient to induce a deficit in recognition memory in both control and IDO null mice. Finally, kynurenine monooxygenase (KMO) deficient mice were also protected from inflammation-induced deficits on novel object recognition. These data implicate IDO-dependent neurotoxic kynurenine metabolism as a pathogenic factor for cognitive dysfunction in inflammation-induced depressive disorders and a potential novel target for the treatment of these disorders. C1 [Heisler, Jillian M.; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Heisler, Jillian M.; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, Sch Med, San Antonio, TX 78229 USA. [O'Connor, Jason C.] Audie L Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP O'Connor, JC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl,216b Med Bldg, San Antonio, TX 78229 USA. EM HeislerJ@uthscsa.edu; oconnorj@uthscsa.edu FU National Institute of Mental Health [R01-MH090127, P30-MH089868]; Norman Hackerman Advanced Research Program; National Center for Advancing Translational Sciences [UL1TR001120]; NCRR-NIH [U42-RR024244]; trans-NIH Knock-Out Mouse Project (KOMP) [5U01HG004080] FX This research was supported by Grant Nos. R01-MH090127 and P30-MH089868 from the National Institute of Mental Health, the Norman Hackerman Advanced Research Program and Award Number UL1TR001120 from the National Center for Advancing Translational Sciences. The Kmo mouse model used for this research project was obtained from the KOMP Repository www.komp.org, a NCRR-NIH supported mouse strain repository (U42-RR024244). ES cells from which this mouse was generated were created by the CSD consortium from funds provided by the trans-NIH Knock-Out Mouse Project (KOMP) (Grant # 5U01HG004080). Email product inquiries to service@komp.org. NR 44 TC 9 Z9 10 U1 1 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD NOV PY 2015 VL 50 BP 115 EP 124 DI 10.1016/j.bbi.2015.06.022 PG 10 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CV4UK UT WOS:000364261800014 PM 26130057 ER PT J AU Opp, MR George, A Ringgold, KM Hansen, KM Bullock, KM Banks, WA AF Opp, Mark R. George, Amrita Ringgold, Kristyn M. Hansen, Kim M. Bullock, Kristin M. Banks, William A. TI Sleep fragmentation and sepsis differentially impact blood-brain barrier integrity and transport of tumor necrosis factor-alpha in aging SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Sleep; Aging; Sepsis; Tumor necrosis factor-alpha; Blood-brain barrier ID TNF-ALPHA; INFLAMMATORY MARKERS; ENDOTHELIAL-CELLS; YOUNG-ADULTS; RAT-BRAIN; PERMEABILITY; MICE; LIPOPOLYSACCHARIDE; DEPRIVATION; CYTOKINES AB The factors by which aging predisposes to critical illness are varied, complex, and not well understood. Sepsis is considered a quintessential disease of old age because the incidence and mortality of severe sepsis increases in old and the oldest old individuals. Aging is associated with dramatic changes in sleep quality and quantity and sleep increasingly becomes fragmented with age. In healthy adults, sleep disruption induces inflammation. Multiple aspects of aging and of sleep dysregulation interact via neuroimmune mechanisms. Tumor necrosis factor-alpha (TNF), a cytokine involved in sleep regulation and neuroimmune processes, exerts some of its effects on the CNS by crossing the blood-brain barrier (BBB). In this study we examined the impact of sepsis, sleep fragmentation, and aging on BBB disruption and TNF transport into brain. We used the cecal ligation and puncture (CLP) model of sepsis in young and aged mice that were either undisturbed or had their sleep disrupted. There was a dichotomous effect of sepsis and sleep disruption with age: sepsis disrupted the BBB and increased TNF transport in young mice but not in aged mice, whereas sleep fragmentation disrupted the BBB and increased TNF transport in aged mice, but not in young mice. Combining sleep fragmentation and CLP did not produce a greater effect on either of these BBB parameters than did either of these manipulations alone. These results suggest that the mechanisms by which sleep fragmentation and sepsis alter BBB functions are fundamentally different from one another and that a major change in the organism's responses to those insults occurs with aging. Published by Elsevier Inc. C1 [Opp, Mark R.; George, Amrita; Ringgold, Kristyn M.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA. [Hansen, Kim M.; Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. [Hansen, Kim M.; Bullock, Kristin M.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Banks, WA (reprint author), VAPSHCS, WAB, Rm 810A,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU VA; [R01 AG041287] FX Supported by R01 AG041287 (MRO) and VA (WAB). NR 63 TC 1 Z9 1 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD NOV PY 2015 VL 50 BP 259 EP 265 DI 10.1016/j.bbi.2015.07.023 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CV4UK UT WOS:000364261800028 PM 26218294 ER PT J AU Hwang, YC Hayashi, T Fujimoto, WY Kahn, SE Leonetti, DL McNeely, MJ Boyko, EJ AF Hwang, You-Cheol Hayashi, Tomoshige Fujimoto, Wilfred Y. Kahn, Steven E. Leonetti, Donna L. McNeely, Marguerite J. Boyko, Edward J. TI Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; LIPOPROTEIN CHOLESTEROL LEVELS; APOLIPOPROTEIN-A-I; VISCERAL ADIPOSITY; INSULIN-RESISTANCE; RISK-FACTORS; GLUCOSE; MELLITUS; SUBFRACTIONS; METAANALYSIS AB OBJECTIVE Recent studies have suggested that HDL cholesterol is inversely associated with the development of type 2 diabetes. However, little is known about the association between different HDL subclasses and the risk for future type 2 diabetes. RESEARCH DESIGN AND METHODS The study enrolled 406 Japanese Americans (51% male) without diabetes, aged 34-75 years. Oral glucose tolerance tests were performed to determine type 2 diabetes status at baseline, 2.5 years, 5 years, and 10 years after enrollment. HDL2, HDL3, total HDL cholesterol, and visceral adipose tissue (VAT) area by computed tomography were measured at baseline. RESULTS In univariate analysis, total HDL and HDL2 cholesterol were inversely associated with the incidence of type 2 diabetes, but HDL3 cholesterol was not. In multivariate analysis, total HDL cholesterol (odds ratio per 1-SD increment, 0.72 [95% CI 0.52-0.995], P = 0.047) and HDL2 cholesterol (odds ratio per 1-SD increment, 0.64 [95% CI 0.44-0.93], P = 0.018) were inversely associated with the risk for type 2 diabetes independent of age, sex, BM!, waist circumference, family history of diabetes, lifestyle factors, systolic blood pressure, lipid-lowering medication use, triglyceride level, HOMA-insulin resistance, and 2-h glucose; however, HDL3 cholesterol was not associated with diabetes risk. The association between diabetes risk and total HDL and HDL2 cholesterol became insignificant after adjustment for VAT area. CONCLUSIONS Subjects with higher HDL2 cholesterol were at lower risk for incident type 2 diabetes, but this association was confounded by and not independent of VAT. Higher HDL3 cholesterol was not associated with diabetes risk. C1 [Hwang, You-Cheol; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Hwang, You-Cheol] Kyung Hee Univ, Sch Med, Hosp Gangdong, Dept Med,Div Endocrinol & Metab, Seoul, South Korea. [Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. [Fujimoto, Wilfred Y.; Kahn, Steven E.; McNeely, Marguerite J.; Boyko, Edward J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. EM eboyko@uw.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-17047, DK-35816]; National Institutes of Health Clinical Center [RR-00037]; VA Puget Sound Health Care System FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases grants DK-17047 and DK-35816 to the Diabetes Research Center Clinical Nutrition Research Unit for facilities and services, and by National Institutes of Health Clinical Center grant RR-00037 to the General Clinical Research Center at the University of Washington. The VA Puget Sound Health Care System provided support to S.E.K. and E.J.B. for their involvement in this research. NR 32 TC 2 Z9 2 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2015 VL 38 IS 11 BP 2100 EP 2105 DI 10.2337/dc15-0625 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CV5WQ UT WOS:000364342500029 PM 26384391 ER PT J AU Long, JA Watts, LT Li, W Shen, Q Muir, ER Huang, SL Boggs, RC Suri, A Duong, TQ AF Long, Justin A. Watts, Lora T. Li, Wei Shen, Qiang Muir, Eric R. Huang, Shiliang Boggs, Robert C. Suri, Abhinav Duong, Timothy Q. TI The effects of perturbed cerebral blood flow and cerebrovascular reactivity on structural MRI and behavioral readouts in mild traumatic brain injury SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE functional outcomes; hypercapnia; MRI: diffusion tensor imaging; TBI ID CONTROLLED CORTICAL IMPACT; PERFUSION; RATS; DIFFUSION; HYPERPERFUSION; HYPERCAPNIA; HYPOXIA; MICROCIRCULATION; MECHANISMS; ISOFLURANE AB This study investigated the effects of perturbed cerebral blood flow (CBF) and cerebrovascular reactivity (CR) on relaxation time constant (T-2), apparent diffusion coefficient (ADC), fractional anisotropy (FA), and behavioral scores at 1 and 3 hours, 2, 7, and 14 days after traumatic brain injury (TBI) in rats. Open-skull TBI was induced over the left primary forelimb somatosensory cortex (N=8 and 3 sham). We found the abnormal areas of CBF and CR on days 0 and 2 were larger than those of the T-2, ADC, and FA abnormalities. In the impact core, CBF was reduced on day 0, increased to 2.5 times of.normal on day 2, and returned toward normal by day 14, whereas in the tissue surrounding the impact, hypoperfusion was observed on days 0 and 2. CR in the impact core was negative, most severe on day 2 but gradually returned toward normal. T-2, ADC, and FA abnormalities in the impact core were detected on day 0, peaked on day 2, and pseudonormalized by day 14. Lesion volumes peaked on day 2 and were temporally correlated with forelimb asymmetry and foot-fault scores. This study quantified the effects of perturbed CBF and CR on structural magnetic resonance imaging and behavioral readouts. C1 [Long, Justin A.; Watts, Lora T.; Li, Wei; Shen, Qiang; Muir, Eric R.; Huang, Shiliang; Boggs, Robert C.; Suri, Abhinav; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Watts, Lora T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Watts, Lora T.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Opthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu FU NIH/NINDS [R01 NS45879]; Mike Hogg Fund via the Clinical Translational Science Awards (CTSA) [UL1TR000149, TL1TR001119, KL2TR001118]; [KL2 TR001118] FX This work was supported in part by NIH/NINDS R01 NS45879 (TQD), a TL1 (JAL) and KL2 TR001118 and Mike Hogg Fund (LTW) via the Clinical Translational Science Awards (CTSA, parent grants UL1TR000149, TL1TR001119, and KL2TR001118). NR 39 TC 6 Z9 6 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD NOV PY 2015 VL 35 IS 11 BP 1852 EP 1861 DI 10.1038/jcbfm.2015.143 PG 10 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA CV4TR UT WOS:000364259900018 PM 26104285 ER PT J AU Park, JD Kim, E Werner, RM AF Park, James D. Kim, Edward Werner, Rachel M. TI Inpatient Hospital Charge Variability of US Hospitals SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hospital charges; variability ID UNINSURED ADULTS; UNITED-STATES; COST-SHIFT; HEALTH; DETERMINANTS; DISPARITIES; SERVICES; MARKET AB The range of hospital charges for similar diagnoses show tremendous variability across U.S. hospitals. This charge variability remains unexplained. We aimed to describe hospital charge variability in the U.S. and examine its relationship to local health factors. This was a descriptive study of the 2011 Medicare Inpatient Charge data summarizing inpatient hospital charges billed to Medicare. This data was evaluated using 29 county-level measures of health status, health behavior, clinical access and quality, built environment, and socioeconomic status in a clustered, multivariate linear regression. 2871 U.S. hospitals registered with Medicare and with at least ten discharges for diagnosis-related groups (DRGs) of six common inpatient conditions. Inpatient hospital charges were assessed. No community health measures were associated with hospital charges. The one notable exception associated with higher charges was higher rates of uninsured status ($344.84 higher charges for every one-percentage point increase in prevalence (p < 0.001)). One variable was associated with lower hospital charges: the percentage of children living in poverty [$309.30 lower charges for every one-percentage point increase in prevalence (p < 0.001)]. Overall, hospital charges lacked an association with population health measures, and their variability remains largely unexplained. However, the association of higher charges with uninsured status raises concerns about hospitals' price-setting strategies, such as price discrimination and cost-shifting strategies that expose vulnerable populations to great financial risks. C1 [Park, James D.] Rutgers Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ 08903 USA. [Kim, Edward] Coll New Jersey, Dept Comp Sci, Ewing, NJ USA. [Kim, Edward] Villanova Univ, Dept Comp Sci, Villanova, PA 19085 USA. [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Park, JD (reprint author), Rutgers Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ 08903 USA. EM james.d.park@rutgers.edu FU Robert Wood Johnson Foundation Health Hospital FX Funders: This analysis was awarded second place in the Robert Wood Johnson Foundation Health Hospital Price Transparency Challenge, which had no role in the conduct of the study. NR 26 TC 1 Z9 1 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2015 VL 30 IS 11 BP 1627 EP 1632 DI 10.1007/s11606-015-3352-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CU7LT UT WOS:000363721100017 PM 25931006 ER PT J AU Duru, OK Turk, N Ettner, SL Neugebauer, R Moin, T Li, JN Kimbro, L Chan, C Luchs, RH Keckhafer, AM Kirvan, A Ho, S Mangione, CM AF Duru, O. Kenrik Turk, Norman Ettner, Susan L. Neugebauer, Romain Moin, Tannaz Li, Jinnan Kimbro, Lindsay Chan, Charles Luchs, Robert H. Keckhafer, Abigail M. Kirvan, Anya Ho, Sam Mangione, Carol M. TI Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP) SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article ID MEDICATION ADHERENCE; PROGRAMS; SAVINGS AB Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care. To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the Diabetes Health Plan/DHP) on medication adherence among eligible employees and dependents. Employer-level "intent to treat" cohort study, including data from eligible employees and their dependents with diabetes, regardless of whether they were enrolled in the DHP. Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011. Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences. The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHP participants are notified up front that they must engage in their own health care (e.g., receiving diabetes-related screening) in order to remain enrolled. Mean employee adherence to metformin, statins, and ACE/ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC). Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69 %. In the first year after DHP implementation, predicted employer-level adherence for metformin (+4.9 percentage points, p = 0.017), statins (+4.8, p = 0.019), and ACE/ARBs (+4.4, p = 0.02) was higher with DHP purchase. Non-randomized, observational study. The Diabetes Health Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12 months. C1 [Duru, O. Kenrik; Turk, Norman; Ettner, Susan L.; Li, Jinnan; Kimbro, Lindsay; Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ettner, Susan L.; Mangione, Carol M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Neugebauer, Romain] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Moin, Tannaz] VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Moin, Tannaz] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chan, Charles; Luchs, Robert H.; Keckhafer, Abigail M.; Kirvan, Anya; Ho, Sam] UnitedHealthcare, Minnetonka, MN USA. RP Duru, OK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. EM kduru@mednet.ucla.edu FU Centers for Disease Control and Prevention (Division of Diabetes Translation) [DP002722]; National Institute of Diabetes and Digestive and Kidney Diseases as part of the Natural Experiments for the Translation of Diabetes (NEXT-D) Study [DP002722]; VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship [TPM65-010]; VA Greater Los Angeles Healthcare System; UCLA Robert Wood Johnson Clinical Scholars Program; U.S. Department of Veterans Affairs [67799]; NIH/NCATS UCLA CTSI [UL1TR000124]; University of California, Los Angeles; Resource Center for Minority Aging Research; Center for Health Improvement of Minority Elderly (RCMAR/CHIME) under NIH/NIA [P30-AG021684]; NIH Career Development Award [K08-AG033360] FX This study was jointly funded by the Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases as part of the Natural Experiments for the Translation of Diabetes (NEXT-D) Study (Grant number DP002722).; Dr. Moin received support from the VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program (TPM65-010), VA Greater Los Angeles Healthcare System, from 2011 to 2014. Dr. Mangione is supported in part by the UCLA Robert Wood Johnson Clinical Scholars Program and the U.S. Department of Veterans Affairs (Grant #67799). Dr. Mangione also receives support from NIH/NCATS UCLA CTSI Grant Number UL1TR000124 and from the Barbara A. Levey, M.D., and Gerald S. Levey, M.D., Endowed Chair at the David Geffen School of Medicine at UCLA.; The efforts of Drs. Mangione, Duru, and Steers are supported in part by the University of California, Los Angeles, Resource Center for Minority Aging Research and the Center for Health Improvement of Minority Elderly (RCMAR/CHIME) under NIH/NIA Grant P30-AG021684. Dr. Duru is also supported by NIH Career Development Award K08-AG033360. NR 18 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2015 VL 30 IS 11 BP 1645 EP 1650 DI 10.1007/s11606-015-3284-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CU7LT UT WOS:000363721100020 PM 25944019 ER PT J AU Deng, J Coy, D Zhang, W Sunkara, M Morris, AJ Wang, C Chaiswing, L St Clair, D Vore, M Jungsuwadee, P AF Deng, Jun Coy, Donna Zhang, Wei Sunkara, Manjula Morris, Andrew J. Wang, Chi Chaiswing, Luksana St Clair, Daret Vore, Mary Jungsuwadee, Paiboon TI Elevated Glutathione Is Not Sufficient to Protect against Doxorubicin-Induced Nuclear Damage in Heart in Multidrug Resistance-Associated Protein 1 (Mrp1/Abcc1) Null Mice SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ACUTE CARDIAC TOXICITY; LIPID-PEROXIDATION; MRP1; CARDIOTOXICITY; CARDIOMYOPATHY; TRANSFERASE; EXPRESSION; CONJUGATE; ALDEHYDES; INJURY AB Cardiotoxicity is a major dose-limiting adverse effect of doxorubicin (DOX), mediated in part by overproduction of reactive oxygen species and oxidative stress. Abcc1 (Mrp1) mediates the efflux of reduced and oxidized glutathione (GSH, GSSG) and is also a major transporter that effluxes the GSH conjugate of 4-hydroxy-2-nonenal (HNE; GS-HNE), a toxic product of lipid peroxidation formed during oxidative stress. To assess the role of Mrp1 in protecting the heart from DOX-induced cardiac injury, wild-type (WT) and Mrp1 null (Mrp1(-/-)) C57BL/6 littermate mice were administered DOX (15 mg/kg) or saline (7.5 ml/kg) i.v., and heart ventricles were examined at 72 hours. Morphometric analysis by electron microscopy revealed extensive injuries in cytosol, mitochondria, and nuclei of DOX-treated mice in both genotypes. Significantly more severely injured nuclei were observed in Mrp1(-/-) versus WT mice (P = 0.031). GSH and the GSH/GSSG ratio were significantly increased in treatment-naive Mrp1(-/-) versus WT mice; GSH remained significantly higher in Mrp1(-/-) versus WT mice after saline and DOX treatment, with no changes in GSSG or GSH/GSSG. GS-HNE, measured by mass spectrometry, was lower in the hearts of treatment-naive Mrp1(-/-) versus WT mice (P < 0.05). DOX treatment decreased GS-HNE in WT but not Mrp1(-/-) mice, so that GS-HNE was modestly but significantly higher in Mrp1(-/-) versus WT hearts after DOX. Expression of enzymes mediating GSH synthesis and antioxidant proteins did not differ between genotypes. Thus, despite elevated GSH levels in Mrp1(-/-) hearts, DOX induced significantly more injury in the nuclei of Mrp1(-/-) versus WT hearts. C1 [Deng, Jun; Coy, Donna; Zhang, Wei; Chaiswing, Luksana; St Clair, Daret; Vore, Mary] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA. [Sunkara, Manjula; Morris, Andrew J.] Univ Kentucky, Div Cardiovasc Med, Lexington, KY 40536 USA. [Wang, Chi] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA. [Chaiswing, Luksana] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Chaiswing, Luksana] Univ Wisconsin, Sch Med, Madison, WI USA. [Jungsuwadee, Paiboon] Fairleigh Dickinson Univ, Sch Pharm, Florham Pk, NJ USA. RP Vore, M (reprint author), Univ Kentucky, Dept Toxicol & Canc Biol, 306 Hlth Sci Res Bldg, Lexington, KY 40536 USA. EM maryv@email.uky.edu; paiboon@fdu.edu FU Biostatistics and Bioinformatics Shared Resource of the University of Kentucky Markey Cancer Center [P30CA177558]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103527] FX The authors thank Dr. Terry D. Oberley, University of Wisconsin Medical School, Madison, Wisconsin, who died before publication of these studies, for his expert help; Dr. Ladislav Dory, University of North Texas, Denton, Texas, for a generous gift of rabbit anti-ECSOD pAb; and Dr. Luksana Chaiswing, who was at the University of Wisconsin Medical School during the experimental phase of this research, but moved to the University of Kentucky during the preparation of this manuscript. This research was supported by the Biostatistics and Bioinformatics Shared Resource of the University of Kentucky Markey Cancer Center [P30CA177558] and by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103527]. NR 36 TC 3 Z9 3 U1 0 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD NOV PY 2015 VL 355 IS 2 BP 272 EP + DI 10.1124/jpet.115.225490 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CV3MT UT WOS:000364164000017 PM 26354996 ER PT J AU Kuehlewein, L Dansingani, KK De Carlo, TE Bonini, MA Iafe, NA Lenis, TL Freund, KB Waheed, NK Duker, JS Sadda, SR Sarraf, D AF Kuehlewein, Laura Dansingani, Kunal K. De Carlo, Talisa E. Bonini Filho, Marco A. Iafe, Nicholas A. Lenis, Tamara L. Freund, K. Bailey Waheed, Nadia K. Duker, Jay S. Sadda, Srinivas R. Sarraf, David TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TYPE 3 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE age-related macular degeneration; angiography; optical coherence tomography angiography ID RETINAL ANGIOMATOUS PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; OCT ANGIOGRAPHY; CLINICOPATHOLOGICAL CORRELATION; MOTION CORRECTION; CLASSIFICATION; SPECTRUM; THERAPY AB Purpose: To characterize the vascular structure of Type 3 neovascularization secondary to age-related macular degeneration using optical coherence tomography angiography. Methods: Optical coherence tomography angiography cube scans (3 mm x 3 mm) were acquired in 29 eyes of 24 patients with Type 3 lesions secondary to age-related macular degeneration using the RTVue XR Avanti with AngioVue, Split-spectrum amplitude-decorrelation, and motion correction technology. Automated layer segmentation boundaries were adjusted to best visualize the neovascular complex on en face projection images. Results: A distinct neovascular complex could be identified in 10 (34%) eyes, all of which were active on optical coherence tomography imaging. In all 10 eyes, the neovascular complex appeared as a small tuft of bright, high-flow tiny vessels with curvilinear morphology located in the outer retinal layers with a feeder vessel communicating with the inner retinal circulation (i.e., deep retinal capillary plexus). The mean (SD) size of the neovascular complex measured 0.07 ( 0.07) mm(2). Conclusion: With optical coherence tomography angiography, it is possible to identify small intraretinal neovascular complexes communicating with the deep retinal capillary plexus in eyes with Type 3 neovascularization secondary to age-related macular degeneration. Qualitative and quantitative analyses of Type 3 neovascular complexes can be performed using optical coherence tomography angiography. C1 [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA. [Kuehlewein, Laura; Iafe, Nicholas A.; Lenis, Tamara L.; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Dansingani, Kunal K.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Dansingani, Kunal K.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA. [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England. [De Carlo, Talisa E.; Bonini Filho, Marco A.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA. [De Carlo, Talisa E.; Bonini Filho, Marco A.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA. [De Carlo, Talisa E.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [De Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Bonini Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil. [Iafe, Nicholas A.; Lenis, Tamara L.; Sarraf, David] Stein Eye Inst, Los Angeles, CA USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu OI Dansingani, Kunal/0000-0002-7430-8601 FU Macular Foundation, Inc, New York, NY; Carl Zeiss Meditech; Massachusetts Lions Clubs; Optovue; Allergan; Carl Zeiss Meditec; Genentech; Optos; Regeneron FX K. Bailey Freund is supported by the Macular Foundation, Inc, New York, NY. He is a consultant to Optovue, Genentech, Optos, ThromboGenics, Ohr Pharmaceutical, and Heidelberg Engineering (honorarium for each). N. K. Waheed was a consultant for Iconic therapeutics, served the speaker's bureau for Thrombogenics, and receives research support from Carl Zeiss Meditech. J. S. Duker is supported by the Massachusetts Lions Clubs. He is a consultant for and receives research support from Optovue and Carl Zeiss Meditech. S. R. Sadda is a coinventor of Doheny intellectual property related to optical coherence tomography that has been licensed by Topcon Medical Systems and is a member of the scientific advisory board for Heidelberg Engineering. He receives research support from and serves as a consultant for Allergan, Carl Zeiss Meditec, Genentech, and Optos. He also serves as a consultant for Alcon, Novartis, and Roche. D. Sarraf has research grants from Regeneron and Genentech, has served on an advisory board for Genentech, and has been loaned the Optovue machine with Split-spectrum amplitude-decorrelation capability from Optovue Inc. for research purposes. The other authors have no financial/conflicting interests to disclose. NR 23 TC 20 Z9 20 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD NOV PY 2015 VL 35 IS 11 BP 2229 EP 2235 PG 7 WC Ophthalmology SC Ophthalmology GA CV5LD UT WOS:000364311100009 PM 26502007 ER PT J AU Bonini, MA Adhi, M De Carlo, TE Ferrara, D Baumal, CR Witkin, AJ Reichel, E Kuehlewein, L Sadda, SR Sarraf, D Duker, JS Waheed, NK AF Bonini Filho, Marco A. Adhi, Mehreen De Carlo, Talisa E. Ferrara, Daniela Baumal, Caroline R. Witkin, Andre J. Reichel, Elias Kuehlewein, Laura Sadda, Srinivas R. Sarraf, David Duker, Jay S. Waheed, Nadia K. TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN RETINAL ARTERY OCCLUSION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE optical coherence tomography angiography; retinal artery occlusion ID FLUORESCEIN ANGIOGRAPHY AB Purpose:To describe the retinal microvasculature of the eyes with nonarteritic retinal artery occlusion (RAO) based on optical coherence tomography angiography. Methods:Cross-sectional, prospective, observational study performed from September 2014 through February 2015. En face projection of optical coherence tomography angiography images centered at the macula and optic disk of the eyes presenting with RAO were acquired using the RTVue XR Avanti with AngioVue software. Qualitative analysis of the morphology of the superficial and deep retinal capillary plexuses, and radial peripapillary capillaries was performed. Retinal vasculature images using optical coherence tomography angiography were correlated with fluorescein angiography images. Results:Seven patients (seven eyes) were enrolled in the study, including three eyes with central RAO and four eyes with branch RAO. Distinct differences in the distribution of zones of decreased vascular perfusion between the superficial and deep retinal capillary plexus corresponding to areas of delayed dye perfusion on fluorescein angiography were demonstrated in 6 of 7 (86.5%) eyes. Conclusion:This small series suggests that optical coherence tomography angiography imaging can accurately discern retinal capillary plexuses at different levels in the eyes with RAO and may be sensitive for more precisely characterizing the extent of macular ischemia and monitoring vascular flow changes during the course of the disease. C1 [Bonini Filho, Marco A.; Adhi, Mehreen; De Carlo, Talisa E.; Ferrara, Daniela; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elias; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA. [Bonini Filho, Marco A.; Adhi, Mehreen; De Carlo, Talisa E.; Ferrara, Daniela; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elias; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA. [Bonini Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil. [De Carlo, Talisa E.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [De Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Kuehlewein, Laura; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA. [Sarraf, David] Stein Eye Inst, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Waheed, NK (reprint author), New England Eye Ctr, Tufts Med Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA. EM nadiakwaheed@gmail.com FU Research to Prevent Blindness; Massachusetts Lions Club FX Supported in part by a Research to Prevent Blindness Unrestricted grant to the New England Eye Center/Department of Ophthalmology, Tufts University School of Medicine, and Massachusetts Lions Club. NR 12 TC 6 Z9 6 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD NOV PY 2015 VL 35 IS 11 BP 2339 EP 2346 PG 8 WC Ophthalmology SC Ophthalmology GA CV5LD UT WOS:000364311100022 PM 26457398 ER PT J AU Chen, HA Kleinberger, JW Takane, KK Salim, F Fiaschi-Taesch, N Pappas, K Parsons, R Jiang, J Zhang, Y Liu, HT Wang, P Bender, AS Frank, SJ Stewart, AF AF Chen, Hainan Kleinberger, Jeffrey W. Takane, Karen K. Salim, Fatimah Fiaschi-Taesch, Nathalie Pappas, Kyrie Parsons, Ramon Jiang, Jing Zhang, Yue Liu, Hongtao Wang, Peng Bender, Aaron S. Frank, Stuart J. Stewart, Andrew F. TI Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human beta-Cells SO DIABETES LA English DT Article ID GESTATIONAL DIABETES-MELLITUS; ISLET FUNCTION; PROLACTIN RECEPTORS; PLACENTAL LACTOGENS; INSULIN-SECRETION; GENE-EXPRESSION; CYCLIN D-1; IN-VIVO; PREGNANCY; MICE AB Pregnancy in rodents is associated with a two- to three-fold increase in beta-cell mass, which is attributable to large increases in beta-cell proliferation, complimented by increases in beta-cell size, survival, and function and mediated mainly by the lactogenic hormones prolactin (PRL) and placental lactogens. In humans, however, beta-cell mass does not increase as dramatically during pregnancy, and PRL fails to activate proliferation in human islets in vitro. To determine why, we explored the human PRL-prolactin receptor (hPRLR)-Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5)-cyclin-cdk signaling cascade in human beta-cells. Surprisingly, adult human beta-cells express little or no PRLR. As expected, restoration of the hPRLR in human beta-cells rescued JAK2-STAT5 signaling in response to PRL. However, rescuing hPRLR-STAT5 signaling nevertheless failed to confer proliferative ability on adult human beta-cells in response to PRL. Surprisingly, mouse (but not human) Stat5a overexpression led to upregulation of cyclins D1-3 and cdk4, as well as their nuclear translocation, all of which are associated with beta-cell cycle entry. Collectively, the findings show that human beta-cells fail to proliferate in response to PRL for multiple reasons, one of which is a paucity of functional PRL receptors, and that murine Stat5 overexpression is able to bypass these impediments. C1 [Chen, Hainan; Takane, Karen K.; Fiaschi-Taesch, Nathalie; Liu, Hongtao; Wang, Peng; Bender, Aaron S.; Stewart, Andrew F.] Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA. [Kleinberger, Jeffrey W.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Salim, Fatimah] Duquesne Univ, Sch Nursing, Pittsburgh, PA 15219 USA. [Pappas, Kyrie; Parsons, Ramon] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA. [Jiang, Jing; Zhang, Yue; Frank, Stuart J.] Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Birmingham, AL USA. [Frank, Stuart J.] Birmingham VA Med Ctr, Endocrinol Sect, Birmingham, AL USA. RP Chen, HA (reprint author), Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA. EM hainanchen2011@gmail.com; andrew.stewart@mssm.edu FU JDRF [1-2011-603]; National Institutes of Health [R-01 DK55023, R-01 DK58259, R-01 DK 46395, U-01 DK089538, UC4 DK104211]; James A. Haley Veterans' Hospital Merit Review FX This work was supported by JDRF grant 1-2011-603; National Institutes of Health grants R-01 DK55023, R-01 DK58259, R-01 DK 46395, U-01 DK089538, and UC4 DK104211; and a James A. Haley Veterans' Hospital Merit Review (to S.J.F.). NR 49 TC 9 Z9 9 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD NOV PY 2015 VL 64 IS 11 BP 3784 EP 3797 DI 10.2337/db15-0083 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU8ZL UT WOS:000363832500018 PM 26159175 ER PT J AU Mishra, RK Tietjens, J Regan, M Whooley, MA Schiller, NB AF Mishra, Rakesh K. Tietjens, Jeremy Regan, Mathilda Whooley, Mary A. Schiller, Nelson B. TI The Prognostic Utility of Echo-Estimated Left Ventricular End-Diastolic Pressure-Volume Relationship in Stable Coronary Artery Disease: The Heart and Soul Study SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE coronary artery disease; diastolic function; echocardiography; heart failure; left ventricular end-diastolic pressure ID PRESERVED EJECTION FRACTION; LEFT ATRIAL VOLUME; DOPPLER-ECHOCARDIOGRAPHY; CARDIOVASCULAR EVENTS; NATRIURETIC PEPTIDE; AMBULATORY PATIENTS; NT-PROBNP; FAILURE; DYSFUNCTION; STIFFNESS AB Background: While changes in the left ventricular end-diastolic pressure-volume relationship (LV-EDPVR) can be estimated using echocardiography, their prognostic utility in stable coronary artery disease (CAD) is unknown. Methods: Using echo-estimated LV end-diastolic volume index and diastolic function category, the relative position of the LV-EDPVR was defined in 901 participants with stable CAD as: (1) left-shifted, (2) right-shifted, or (3) intermediate. We then evaluated the association of LV-EDPVR position relative to the intermediate category with time to hospitalization for heart failure (HF) or cardiovascular (CV) death using Cox proportional hazards models. Results: During 7.0 +/- 3.1 years of follow-up, there were 207 admissions for HF or CV deaths. Both leftward and rightward shifts of LV-EDPVR were associated with a significantly higher risk of HF or CV death (HR 1.73, 95% CI 1.15-2.62 and HR 6.75, 95% CI 4.02-11.31, respectively). In multivariable-adjusted models, these associations were attenuated but remained significant (HR 1.66, 95% CI 1.08-2.55 for left-shifted and HR 4.19, 95% CI 2.32-7.55 for right-shifted). The association of LV-EDPVR with HF or CV death was no longer significant after inclusion of N-terminal pro-brain natriuretic peptide level as a covariate. Conclusions: In stable CAD, echo-estimated leftward and rightward shifts in the LV-EDPVR are associated with HF and CV death. The loss of these associations after adjustment for N-terminal pro-brain natriuretic peptide level suggests that echo-estimated LV-EDPVR captures changes in LV filling pressure at any given LV end-diastolic volume. C1 [Mishra, Rakesh K.; Tietjens, Jeremy; Whooley, Mary A.; Schiller, Nelson B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mishra, Rakesh K.; Regan, Mathilda; Whooley, Mary A.; Schiller, Nelson B.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Mishra, RK (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111C, San Francisco, CA 94121 USA. EM rakesh.mishra@ucsf.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD NOV PY 2015 VL 32 IS 11 BP 1639 EP 1646 DI 10.1111/echo.12955 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU7SA UT WOS:000363740600005 PM 25959601 ER PT J AU Quinn, LS Anderson, BG Conner, JD Wolden-Hanson, T AF Quinn, LeBris S. Anderson, Barbara G. Conner, Jennifer D. Wolden-Hanson, Tami TI Circulating irisin levels and muscle FNDC5 mRNA expression are independent of IL-15 levels in mice SO ENDOCRINE LA English DT Article DE Irisin; Interleukin-15; Muscle; Exercise; Cytokines; Myokines ID BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; PPAR-DELTA; EXERCISE; INTERLEUKIN-15; FAT; HUMANS; ASSOCIATION; ADIPOCYTES; RESISTANCE AB Interleukin-15 (IL-15) and irisin are exercise-induced myokines that exert favorable effects on energy expenditure and metabolism. IL-15 can induce PGC-1 alpha expression, which in turn induces expression of irisin and its precursor, FNDC5. Therefore, the present study tested the hypothesis that increases in circulating irisin levels and muscle FNDC5 mRNA expression are dependent on IL-15. Circulating irisin levels and gastrocnemius muscle FNDC5 mRNA expression were examined following acute exercise in control and IL-15-deleted (IL-15 KO) mice, following injection of IL-15 into IL-15 KO mice, and in transgenic mice with elevated circulating IL-15 levels (IL-15 Tg mice). Circulating IL-15 levels and muscle PGC-1 alpha and PPAR delta mRNA expressions were determined as positive controls. No effect of IL-15 deletion on post-exercise serum irisin levels or muscle FNDC5 mRNA expression was detected. While serum IL-15 levels and muscle PGC-1 alpha expression were elevated post-exercise in control mice, both serum irisin levels and muscle FNDC5 expression decreased shortly after exercise in both control and IL-15 KO mice. A single injection of recombinant IL-15 into IL-15 KO mice that significantly increased muscle PPAR delta and PGC-1 alpha mRNA expressions had no effect on circulating irisin release, but modestly induced muscle FNDC5 expression. Additionally, serum irisin and gastrocnemius muscle FNDC5 expression in IL-15 Tg mice were similar to those of control mice. Muscle FNDC5 mRNA expression and irisin release are not IL-15-dependent in mice. C1 [Quinn, LeBris S.; Anderson, Barbara G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Quinn, LeBris S.; Wolden-Hanson, Tami] VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98108 USA. [Quinn, LeBris S.; Anderson, Barbara G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Quinn, LeBris S.; Conner, Jennifer D.] Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM quinnL@uw.edu FU Department of Veterans Affairs [BX001026] FX Supported by Merit Review #BX001026 from the Department of Veterans Affairs (LSQ), and use of resources and facilities at VA Puget Sound Health Care System. NR 34 TC 1 Z9 1 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD NOV PY 2015 VL 50 IS 2 BP 368 EP 377 DI 10.1007/s12020-015-0607-9 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU4HP UT WOS:000363488800015 PM 25920499 ER PT J AU Attia, EF McGinnis, KA Feemster, LC Akgun, KM Butt, AA Graber, CJ Fine, MJ Goetz, MB Rodriguez-Barradas, MC Pisani, MA Tindle, HA Brown, ST Soo Hoo, GW Rimland, D Gibert, CL Huang, L Freiberg, MS Hough, CL Crothers, K AF Attia, Engi F. McGinnis, Kathleen A. Feemster, Laura C. Akguen, Kathleen M. Butt, Adeel A. Graber, Christopher J. Fine, Michael J. Goetz, Matthew B. Rodriguez-Barradas, Maria C. Pisani, Margaret A. Tindle, Hilary A. Brown, Sheldon T. Soo Hoo, Guy W. Rimland, David Gibert, Cynthia L. Huang, Laurence Freiberg, Matthew S. Hough, Catherine L. Crothers, Kristina TI Association of COPD With Risk for Pulmonary Infections Requiring Hospitalization in HIV-Infected Veterans SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE COPD; pulmonary infection; pneumonia; HIV; comorbidities ID COMMUNITY-ACQUIRED PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY ERA; BACTERIAL PNEUMONIA; DISEASE; COHORT; ADULTS; TRENDS; COMORBIDITY; MORBIDITY AB Background:Pulmonary infections remain more common in HIV-infected (HIV+) compared with uninfected individuals. The increase in chronic lung diseases among aging HIV+ individuals may contribute to this persistent risk. We sought to determine whether chronic obstructive pulmonary disease (COPD) is an independent risk factor for different pulmonary infections requiring hospitalization among HIV+ patients.Methods:We analyzed data from 41,993 HIV+ Veterans in the nationwide Veterans Aging Cohort Study Virtual Cohort from 1996 to 2009. Using International Classification of Diseases, Ninth Revision codes, we identified baseline comorbid conditions, including COPD, and incident community-acquired pneumonia (CAP), pulmonary tuberculosis (TB), and Pneumocystis jirovecii pneumonia (PCP) requiring hospitalization within 2 years after baseline. We used multivariable Poisson regression to determine incidence rate ratios (IRRs) associated with COPD for each type of pulmonary infection, adjusting for comorbidities, CD4(+) cell count, HIV viral load, smoking status, substance use, vaccinations, and calendar year at baseline.Results:Unadjusted incidence rates of CAP, TB, and PCP requiring hospitalization were significantly higher among persons with COPD compared to those without COPD (CAP: 53.9 vs. 19.4 per 1000 person-years; TB: 8.7 vs. 2.8; PCP: 15.5 vs. 9.2; P 0.001). In multivariable Poisson regression models, COPD was independently associated with increased risk of CAP, TB, and PCP (IRR: 1.94, 95% confidence interval [CI]: 1.64 to 2.30; IRR: 2.60, 95% CI: 1.70 to 3.97; and IRR: 1.48, 95% CI: 1.10 to 2.01, respectively).Conclusions:COPD is an independent risk factor for CAP, TB, and PCP requiring hospitalization among HIV+ individuals. As the HIV+ population ages, the growing burden of COPD may confer substantial risk for pulmonary infections. C1 [Attia, Engi F.; Feemster, Laura C.; Hough, Catherine L.; Crothers, Kristina] Univ Washington, Dept Med, Seattle, WA USA. [McGinnis, Kathleen A.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Feemster, Laura C.] Vet Affairs Puget Sound Healthcare Syst, Vet Affairs Hlth Serv Res & Dev, Seattle, WA USA. [Akguen, Kathleen M.] Vet Affairs Connecticut Healthcare Syst, Dept Med, West Haven, CT USA. [Akguen, Kathleen M.; Pisani, Margaret A.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Graber, Christopher J.; Goetz, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Graber, Christopher J.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Med, Pittsburgh, PA 15213 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Tindle, Hilary A.; Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Tindle, Hilary A.; Freiberg, Matthew S.] Nashville Vet Affairs Med Ctr, Nashville, TN USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Dept Med, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Gibert, Cynthia L.] Washington DC Vet Affairs Med Ctr, Dept Med, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med, Washington, DC USA. [Huang, Laurence] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Attia, EF (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care, 325 Ninth Ave,Campus Box 359762, Seattle, WA 98104 USA. EM eattia@uw.edu OI Butt, Adeel/0000-0002-1118-1826; Attia, Engi/0000-0002-5044-9602; Goetz, Matthew/0000-0003-4542-992X; Crothers, Kristina/0000-0001-9702-0371 FU National Institutes of Health [R01 HL090342, F32 HL125031-01, K23 HL111116, K24 HL087713, U24-AA020794] FX Supported by the National Institutes of Health (R01 HL090342, F32 HL125031-01, K23 HL111116, K24 HL087713, and U24-AA020794). NR 53 TC 2 Z9 3 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2015 VL 70 IS 3 BP 280 EP 288 DI 10.1097/QAI.0000000000000751 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU6ID UT WOS:000363634600010 PM 26181820 ER PT J AU Johnson, HM Bartels, CM Thorpe, CT Schumacher, JR Pandhi, N Smith, MA AF Johnson, Heather M. Bartels, Christie M. Thorpe, Carolyn T. Schumacher, Jessica R. Pandhi, Nancy Smith, Maureen A. TI Differential Diagnosis and Treatment Rates Between Systolic and Diastolic Hypertension in Young Adults: A Multidisciplinary Observational Study SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID AMERICAN-HEART-ASSOCIATION; HIGH BLOOD-PRESSURE; PRIMARY-CARE USE; UNITED-STATES; CARDIOVASCULAR-DISEASE; ADMINISTRATIVE DATA; POPULATION; EDUCATION; RISK; RECOMMENDATIONS AB Differential rates of diagnosis and treatment by hypertension (HTN) type may contribute to poor HTN control in young adults. The objective of this study was to compare rates of receiving a hypertension diagnosis and antihypertensive agent among young adults with (1) isolated systolic, (2) isolated diastolic, and (3) combined systolic/diastolic HTN. A retrospective analysis was conducted in patients aged 18 to 39 years (n=3003) with incident HTN. Kaplan-Meier survival and Cox proportional hazards analyses were performed. Only 56% with isolated systolic HTN received a diagnosis compared with 63% (systolic/diastolic); 32% with isolated systolic HTN received an initial antihypertensive compared with 52% (systolic/diastolic). Compared with patients with systolic/diastolic HTN, those with isolated systolic HTN had a 50% slower diagnosis rate (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.41-0.60) and those with isolated diastolic HTN had a 26% slower rate (HR, 0.74; CI, 0.60-0.92). Patients with isolated systolic HTN had 58% slower medication initiation (HR, 0.42; CI, 0.34-0.51) and those with isolated diastolic HTN had 31% slower rates (HR,0.69; CI, 0.55-0.86). Young adults with isolated systolic HTN have lower diagnosis and treatment rates. (C) 2015 Wiley Periodicals, Inc. C1 [Johnson, Heather M.; Bartels, Christie M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Johnson, Heather M.; Bartels, Christie M.; Schumacher, Jessica R.; Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Schumacher, Jessica R.; Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA. RP Johnson, HM (reprint author), Div Cardiovasc Med, H4-512 CSC,MC 3248,600 Highland Ave, Madison, WI 53792 USA. EM hm2@medicine.wisc.edu OI Johnson, Heather/0000-0002-4916-3519 FU Clinical and Translational Science Award program through the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [UL1TR000427]; National Heart, Lung, and Blood Institute of the NIH [K23HL112907]; University of Wisconsin (UW) Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH [K23AR062381]; National Institute on Aging of the NIH [K08AG029527]; UW Health Innovation Program; UW School of Medicine and Public Health from The Wisconsin Partnership Program FX This original research was supported by the Clinical and Translational Science Award program, previously through the National Center for Research Resources (NCRRUL1RR025011), and now by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under award number UL1TR000427. Heather Johnson is supported by the National Heart, Lung, and Blood Institute of the NIH (K23HL112907), and also by the University of Wisconsin (UW) Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health. Christie Bartels is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH (K23AR062381). Nancy Pandhi is supported by the National Institute on Aging of the NIH (K08AG029527). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders did not play any role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the article for publication. Additional funding for this project was provided by the UW Health Innovation Program and the UW School of Medicine and Public Health from The Wisconsin Partnership Program. H. Johnson, C. Bartels, and N. Pandhi have clinical appointments with the academic group practice that has a financial interest in delivering care to the general population from which study participants were drawn. For the remaining authors, none were declared. NR 41 TC 1 Z9 1 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD NOV PY 2015 VL 17 IS 11 BP 885 EP 894 DI 10.1111/jch.12596 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CU7BA UT WOS:000363688500011 PM 26073687 ER PT J AU Skelton, F Hoffman, JM Reyes, M Burns, SP AF Skelton, Felicia Hoffman, Jeanne M. Reyes, Maria Burns, Stephen P. TI Examining health-care utilization in the first year following spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Health-care utilization; Spinal cord injury; Re-hospitalization ID REHOSPITALIZATION; OUTCOMES AB Objective: To identify factors associated with health-care utilization during the first year after inpatient rehabilitation (IR) in individuals with traumatic spinal cord injury (SCI). Design: Prospective cohort. Methods: One hundred and sixty-eight patients were prospectively enrolled and followed over 1 year after discharge from an SCI Model System IR program. Telephone follow-up occurred at 3, 6, 9, and 12 months. Participants were grouped into four impairment levels (C1-4 American Spinal Injury Association (ASIA) Impairment Scale (AIS) A-C, C5-C8 AIS A-C, paraplegia AIS A-C, and all AIS D). Three domains of healthcare utilization were examined: hospital care, outpatient provider visits, and home services. Results: Health-care utilization in the first year following IR was high with 45% of subjects reporting rehospitalization. Twenty percent of patients were initially discharged to a skilled nursing facility (SNF), and an additional 10% required SNF care during this first year. Overall, those with C1-4 AIS A-C used the most services. Participants discharged home used less health care compared to those discharged elsewhere. SCI due to falls (vs. vehicular crashes) was associated with fewer in-home service visits. Age, sex, race, and education were unrelated to higher use. Conclusion: Those with greater neurological impairment or not discharged home after IR had higher health-care utilization, while age was not associated with utilization. Targeted efforts to reduce genitourinary and respiratory complications may reduce the need for hospital care in the first year after IR. C1 [Skelton, Felicia; Hoffman, Jeanne M.; Reyes, Maria] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Skelton, F (reprint author), Univ Washington, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA. EM felicia.skelton@gmail.com FU SCI model systems grant FX The study was done through a model systems center; the SCI model systems grant should be mentioned. NR 12 TC 1 Z9 1 U1 2 U2 4 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2015 VL 38 IS 6 BP 690 EP 695 DI 10.1179/2045772314Y.0069000000269 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CU8KC UT WOS:000363790300002 PM 25299152 ER PT J AU Lin, YS Boninger, ML Day, KA Koontz, AM AF Lin, Yen-Sheng Boninger, Michael L. Day, Kevin A. Koontz, Alicia M. TI Ultrasonographic measurement of the acromiohumeral distance in spinal cord injury: Reliability and effects of shoulder positioning SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Ultrasound; Reliability; Shoulder positioning; Subacromial space; Spinal cord injury; Wheelchair ID SUBACROMIAL SPACE WIDTH; GREATER TUBEROSITY DISTANCE; IMPINGEMENT SYNDROME; ROTATOR CUFF; SONOGRAPHIC EVALUATION; WHEELCHAIR PROPULSION; HUMERAL DISTANCE; PARAPLEGIA; ABNORMALITIES; ASSOCIATION AB Objective: To investigate the reliability of ultrasonographic measurement of acromiohumeral distance (AHD) and the effects of shoulder positioning on AHD among manual wheelchair users (MWUs) with spinal cord injury (SCI) and an able-bodied control group. Methods: Ten MWUs with SCI and 10 able-bodied subjects participated in this study. The ultrasonographic measurements of AHD from each subject were obtained by two raters during passive and active scapular plane arm elevation in neutral, 45 degrees, 90 degrees with and without resistance and in a weight relief raise position. The measurements were recorded again by each rater using the same procedures after a 30-minute time interval. All raters were blinded to each other's measurements. Setting: University Laboratories and Veteran Affairs Healthcare System. Results: Intra-rater (intraclass correlation coefficient, ICC > 0.83) and inter-rater (ICC > 0.78) reliability was excellent for both the MWUs with SCI and able-bodied groups across all arm positions except for the 45 degrees position in the control group for one of the raters (intra-rater: ICC < 0.40 and inter-rater: ICC < 0.60). AHD significantly reduced when the shoulder was in the 90 degrees arm elevated positions with or without resistance. Conclusion: Findings from our study demonstrated that ultrasonography is a reliable means to evaluate AHD in both able bodied and individuals with SCI, who are known to have significant shoulder pathology. This technique could be used to develop reference measures and to identify changes in AHD caused by interventions. C1 [Lin, Yen-Sheng; Boninger, Michael L.; Day, Kevin A.; Koontz, Alicia M.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Lin, Yen-Sheng; Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Boninger, Michael L.; Day, Kevin A.; Koontz, Alicia M.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave Suite 400, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU VA Rehabilitation R&D Center of Excellence, Department of Veterans Affairs [B6789C] FX VA Rehabilitation R&D Center of Excellence, Project B6789C, Department of Veterans Affairs. NR 42 TC 1 Z9 1 U1 0 U2 7 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2015 VL 38 IS 6 BP 700 EP 708 DI 10.1179/2045772314Y.0000000205 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CU8KC UT WOS:000363790300004 PM 24968117 ER PT J AU Lyons, BL Korsten, MA Spungen, AM Radulovic, M Rosman, AS Hunt, K Galea, MD Kornfeld, SD Yen, C Bauman, WA AF Lyons, Brian L. Korsten, Mark A. Spungen, Ann M. Radulovic, Miroslav Rosman, Alan S. Hunt, Kristel Galea, Marinella D. Kornfeld, Stephen D. Yen, Christina Bauman, William A. TI Comparison between pulsed irrigation enhanced evacuation and polyethylene glycol-electrolyte lavage solution for bowel preparation prior to elective colonoscopy in veterans with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Polyethylene glycol; Bowel preparations; Paraplegia; Tetraplegia; Colonoscopy; Polyp detection ID ORAL SODIUM-PHOSPHATE; COLORECTAL-CANCER; CONTROLLED-TRIAL; SAFETY; GLYCOPYRROLATE; NEOSTIGMINE; IMPACTION; REGIMENS; EFFICACY AB Background: Poor preparation for elective colonoscopy is common in persons with spinal cord injury (SCI). This unsatisfactory outcome is likely due to long-standing difficulty with evacuation and decreased colonic motility. Our objective was to determine the most effective preparation for elective colonoscopy applying a novel and traditional approach to bowel cleansing. Methods: Twenty-four subjects with SCI were consented and scheduled to receive one of the two possible arms: pulsed irrigation enhanced evacuation (PIEE) or polyethylene glycol-electrolyte lavage solution (PEG; CoLyte (R)). The quality of the preparation was scored during the colonoscopy by applying the Ottawa scoring system. Results: Patients with SCI who received PIEE tended to have lower Ottawa scores and a higher percentage of acceptable preparations than did those who received PEG; however, the results were not statistically different. Conclusion: In this preliminary study in subjects with SCI, neither PIEE nor PEG produced acceptable bowel preparation for elective colonoscopy. Future studies should confirm our findings and consider studying alternative, more efficacious approaches to bowel cleansing prior to colonoscopic procedures in patients with SCI, which should provide better outcomes. C1 [Lyons, Brian L.; Korsten, Mark A.; Spungen, Ann M.; Radulovic, Miroslav; Galea, Marinella D.; Kornfeld, Stephen D.; Yen, Christina; Bauman, William A.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Korsten, Mark A.; Radulovic, Miroslav; Rosman, Alan S.; Hunt, Kristel; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Korsten, Mark A.; Galea, Marinella D.; Kornfeld, Stephen D.; Bauman, William A.] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Korsten, Mark A.; Spungen, Ann M.; Radulovic, Miroslav; Rosman, Alan S.; Hunt, Kristel; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.; Galea, Marinella D.; Kornfeld, Stephen D.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP Lyons, BL (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM brian.lyons@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service [A6428R, B2468-C, B4162-C]; James J. Peters VA Medical Center FX This research was supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (#A6428R, #B2468-C, #B4162-C) and the James J. Peters VA Medical Center. NR 24 TC 0 Z9 0 U1 0 U2 1 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2015 VL 38 IS 6 BP 805 EP 811 DI 10.1179/2045772314Y.0000000256 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CU8KC UT WOS:000363790300014 PM 25096918 ER PT J AU Ercoli, LM Petersen, L Hunter, AM Castellon, SA Kwan, L Kahn-Mills, BA Embree, LM Cernin, PA Leuchter, AF Ganz, PA AF Ercoli, L. M. Petersen, L. Hunter, A. M. Castellon, S. A. Kwan, L. Kahn-Mills, B. A. Embree, L. M. Cernin, P. A. Leuchter, A. F. Ganz, P. A. TI Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial SO PSYCHO-ONCOLOGY LA English DT Article ID CHEMOTHERAPY; COMPLAINTS; DYSFUNCTION; UPDATE; STATE AB PurposeWe conducted a randomized clinical trial evaluating the efficacy of a cognitive rehabilitation (CR) intervention compared with a wait list (WL) control condition on cognitive complaints, neuropsychological and brain functioning in breast cancer survivors (BCS). MethodsThe small group intervention of five sessions included psychoeducation and cognitive exercises. EligibilityDisease-free BCS with cognitive complaints, diagnosed with stage I, II or III breast cancer, completed primary treatment 18 months to 5 years earlier. Neurocognitive test data and cognitive complaints on the Patient's Assessment of Own Functioning Inventory (PAOFI) were assessed at baseline (T1), immediately post-intervention (T2), and 2 months later (T3). A subgroup of participants underwent resting state quantitative electroencephalography (qEEG) at all three assessment time points. ResultsForty-eight participants [mean age (SD) 53.8 (8.2)] completed T1 assessments, and 29 participants had analyzable qEEG data. The CR group improved significantly over time compared with the WL group on PAOFI total and memory scores (both p=.01) and on Rey Auditory Verbal Learning Test (RAVLT) total (trials I-V) (p=.02) and RAVLT delayed recall (p=.007) scores. On qEEG, the CR group showed a significant decrease in delta slow wave' power (p=.02) and an increase in the frontal distribution of alpha power (p=.04) from T1 to T2. ConclusionsBCS in the CR group showed immediate and sustained improvements in self-reported cognitive complaints and memory functioning on neurocognitive testing. Results of the qEEG substudy provide some support for neurophysiological changes underlying the intervention. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Ercoli, L. M.; Hunter, A. M.; Castellon, S. A.; Embree, L. M.; Cernin, P. A.; Leuchter, A. F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Ercoli, L. M.; Hunter, A. M.; Castellon, S. A.; Kwan, L.; Leuchter, A. F.; Ganz, P. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Petersen, L.; Kahn-Mills, B. A.; Ganz, P. A.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Castellon, S. A.; Embree, L. M.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ganz, P. A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. RP Ercoli, LM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. EM lercoli@mednet.ucla.edu FU Breast Cancer Research Foundation; Jonsson Cancer Center Foundation FX Funding for this research was provided by the Breast Cancer Research Foundation and the Jonsson Cancer Center Foundation. We thank Elaiza Torralba for her assistance with the study as well as the breast cancer survivors who participated in the study. NR 37 TC 10 Z9 10 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD NOV PY 2015 VL 24 IS 11 BP 1360 EP 1367 DI 10.1002/pon.3769 PG 8 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA CU6TV UT WOS:000363667600003 PM 25759235 ER PT J AU Felsenfeld, AJ Levine, BS Rodriguez, M AF Felsenfeld, Arnold J. Levine, Barton S. Rodriguez, Mariano TI Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease SO SEMINARS IN DIALYSIS LA English DT Article ID CHRONIC-RENAL-FAILURE; GROWTH-FACTOR 23; PARATHYROID-HORMONE SECRETION; LEFT-VENTRICULAR HYPERTROPHY; SERUM PHOSPHATE LEVELS; TRADE-OFF HYPOTHESIS; INTACT PTH LEVELS; FGF-RECEPTOR 1; HEMODIALYSIS-PATIENTS; VITAMIN-D AB Calcium, phosphorus, and magnesium homeostasis is altered in chronic kidney disease (CKD). Hypocalcemia, hyperphosphatemia, and hypermagnesemia are not seen until advanced CKD because adaptations develop. Increased parathyroid hormone (PTH) secretion maintains serum calcium normal by increasing calcium efflux from bone, renal calcium reabsorption, and phosphate excretion. Similarly, renal phosphate excretion in CKD is maintained by increased secretion of fibroblast growth factor 23 (FGF23) and PTH. However, the phosphaturic effect of FGF23 is reduced by downregulation of its cofactor Klotho necessary for binding FGF23 to FGF receptors. Intestinal phosphate absorption is diminished in CKD due in part to reduced levels of 1,25 dihydroxyvitamin D. Unlike calcium and phosphorus, magnesium is not regulated by a hormone, but fractional excretion of magnesium increases as CKD progresses. As 60-70% of magnesium is reabsorbed in the thick ascending limb of Henle, activation of the calcium-sensing receptor by magnesium may facilitate magnesium excretion in CKD. Modification of the TRPM6 channel in the distal tubule may also have a role. Besides abnormal bone morphology and vascular calcification, abnormalities in mineral homeostasis are associated with increased cardiovascular risk, increased mortality and progression of CKD. C1 [Felsenfeld, Arnold J.; Levine, Barton S.] Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Felsenfeld, Arnold J.; Levine, Barton S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rodriguez, Mariano] Univ Cordoba, Hosp Univ Reina Sofia, Serv Nephrol, IMIBIC, Cordoba, Spain. RP Rodriguez, M (reprint author), Univ Hosp, Serv Nefrol, Avd Menendez Pidal S-N, Cordoba 14004, Spain. EM marianorodriguezportillo@gmail.com NR 155 TC 6 Z9 7 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD NOV-DEC PY 2015 VL 28 IS 6 BP 564 EP 577 DI 10.1111/sdi.12411 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA CU8RO UT WOS:000363811000005 PM 26303319 ER PT J AU Boyers, LN Karimkhani, C Riggs, J Dellavalle, RP AF Boyers, Lindsay N. Karimkhani, Chante Riggs, Jennifer Dellavalle, Robert P. TI US campus and university debit card policies regarding tobacco and electronic cigarettes SO TOBACCO CONTROL LA English DT Letter C1 [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Karimkhani, Chante] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Riggs, Jennifer] NYU, Langone Med Ctr, Dept Internal Med, New York, NY USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Dellavalle, RP (reprint author), Dept Veteran Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu FU Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH) FX RPD is supported by grants from the Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) and is also chair of the Colorado Skin Cancer Prevention Task Force. LNB and RPD are employed by the US Department of Veterans Affairs. The CDC, NIH, and US Department of Veterans Affairs were not involved in the creation of this manuscript and its contents do not express their opinions. NR 9 TC 1 Z9 1 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD NOV PY 2015 VL 24 IS 6 BP 623 EP 624 DI 10.1136/tobaccocontrol-2014-051957 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU4BI UT WOS:000363470600025 PM 25552519 ER PT J AU Jackevicius, CA de Leon, NK Lu, LY Chang, DS Warner, AL Mody, FV AF Jackevicius, Cynthia A. de Leon, Noelle K. Lu, Lingyun Chang, Donald S. Warner, Alberta L. Mody, Freny Vaghaiwalla TI Impact of a Multidisciplinary Heart Failure Post-hospitalization Program on Heart Failure Readmission Rates SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE heart failure; hospitalization; readmission ID RANDOMIZED-TRIAL; DISCHARGE; CARE; INTERVENTION; METAANALYSIS; ADMISSIONS; MANAGEMENT; OUTCOMES; DISEASE; CLINICS AB Background: Specialized chronic heart failure (HF) clinics have demonstrated significant reductions in readmissions. Limited evidence is available regarding HF clinics in the immediate post-discharge period. Objective: To evaluate the effect of a multidisciplinary HF clinic on 90-day readmission rates and all-cause mortality in those recently discharged from a HF hospitalization. Methods: In this retrospective cohort study, patients discharged with a primary HF diagnosis who attended the HF postdischarge clinic in 2010-2012 were compared with controls from 2009. During 6 clinic visits, patients were seen by a physician assistant, clinical pharmacist specialist, and case manager, with care overseen by a cardiologist. The program focused on optimizing therapy, identifying HF etiology/precipitating factors, medication titration, education, and medication adherence. The primary outcome was 90-day HF readmission. A multivariate Cox proportional hazards model was used to compare outcomes. Results: Among the 277 patients (144 clinic, 133 control) in the study, 7.6% of patients in the clinic and 23.3% of patients in the control group were readmitted for HF within 90 days (aHR (adjusted hazard ratio) = 0.17; 95% CI = 0.07-0.41; P < 0.001; ARR (absolute risk reduction) = 15.7%; NNT (number needed to treat) = 7). Clinic patients had lower 90-day time-to-first HF readmission or all-cause mortality (9.0% vs 28.6%; aHR = 0.28; 95% CI = 0.06-0.31; P < 0.001; ARR = 19.6%; NNT = 6). Conclusions: The multidisciplinary HF posthospitalization outpatient program was associated with a significant reduction in 90-day HF readmissions in patients who were recently discharged from a HF hospitalization. C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA. [Jackevicius, Cynthia A.; Lu, Lingyun; Chang, Donald S.; Warner, Alberta L.; Mody, Freny Vaghaiwalla] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [de Leon, Noelle K.] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA. [de Leon, Noelle K.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Lu, Lingyun] Calif Northstate Univ, Coll Pharm, Elk Grove, CA USA. [Chang, Donald S.; Warner, Alberta L.; Mody, Freny Vaghaiwalla] Univ Calif Los Angeles, Los Angeles, CA USA. RP Jackevicius, CA (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Cynthia.jackevicius@va.gov FU Reginald Villacorta, MS FX We would like to acknowledge Reginald Villacorta, MS, who was a paid statistical consultant for the study. We would also like to acknowledge the following clinic providers: Jeffrey Garcia, PA-C, Maria Greco, RN, as well as the cardiology clinic nurse practitioners, cardiology fellows, clinic nurses, and clinic clerks. NR 19 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2015 VL 49 IS 11 BP 1189 EP 1196 DI 10.1177/1060028015599637 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CU0OW UT WOS:000363217800002 PM 26259774 ER PT J AU Marcum, ZA Perera, S Thorpe, JM Switzer, GE Gray, SL Castle, NG Strotmeyer, ES Simonsick, EM Bauer, DC Shorr, RI Studenski, SA Hanlon, JT AF Marcum, Zachary A. Perera, Subashan Thorpe, Joshua M. Switzer, Galen E. Gray, Shelly L. Castle, Nicholas G. Strotmeyer, Elsa S. Simonsick, Eleanor M. Bauer, Douglas C. Shorr, Ronald I. Studenski, Stephanie A. Hanlon, Joseph T. CA Hlth ABC Study USA TI Anticholinergic Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE cholinergic antagonist; accidental falls; older adults; pharmacoepidemiology ID BODY-COMPOSITION; PEOPLE; COHORT; ASSOCIATIONS; MEDICATIONS; BURDEN; ELDERS; RISK; CARE AB Background: Although it is generally accepted that anticholinergic use may lead to a fall, results from studies assessing the association between anticholinergic use and falls are mixed. In addition, direct evidence of an association between use of anticholinergic medications and recurrent falls among community-dwelling elders is not available. Objective: To assess the association between anticholinergic use across multiple anticholinergic subclasses, including over-the-counter medications, and recurrent falls. Methods: This was a longitudinal analysis of 2948 participants, with data collected via interview at year 1 from the Health, Aging and Body Composition study and followed through year 7 (1997-2004). Self-reported use of anticholinergic medication was identified at years 1, 2, 3, 5, and 6 as defined by the list from the 2015 American Geriatrics Society Beers Criteria. Dosage and duration were also examined. The main outcome was recurrent falls (2) in an ensuing 12-month period from each medication data collection. Results: Using multivariable generalized estimating equation models, controlling for demographic, health status/behaviors, and access-to-care factors, a 34% increase in likelihood of recurrent falls in anticholinergic users (adjusted odds ratio = 1.34; 95% CI = 0.93-1.93) was observed, but the results were not statistically significant; similar results were found with higher doses and longer duration of use. Conclusion: Increased point estimates suggest an association of anticholinergic use with recurrent falls, but the associations did not reach statistical significance. Future studies are needed for more definitive evidence and to examine other measures of anticholinergic burden and associations with more intermediate adverse effects such as cognitive function. C1 [Marcum, Zachary A.; Gray, Shelly L.] Univ Washington, Seattle, WA 98102 USA. [Perera, Subashan; Thorpe, Joshua M.; Switzer, Galen E.; Castle, Nicholas G.; Strotmeyer, Elsa S.; Hanlon, Joseph T.] Univ Pittsburgh, Pittsburgh, PA USA. [Thorpe, Joshua M.; Switzer, Galen E.; Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Simonsick, Eleanor M.; Studenski, Stephanie A.] NIA, Baltimore, MD 21224 USA. [Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shorr, Ronald I.] Vet Affairs Med Ctr, Gainesville, FL 32608 USA. RP Marcum, ZA (reprint author), Univ Washington, Sch Pharm, Dept Pharm, 1959 NE Pacific St,H375G,Box 357630, Seattle, WA 98102 USA. EM zmarcum@uw.edu OI Strotmeyer, Elsa/0000-0002-4093-6036 FU National Institute on Aging (NIA) [P30AG024827, T32 AG021885, K07AG033174, R01AG028050]; National Institutes of Health, NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institute of Nursing research grant [R01NR012459] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was primarily supported by National Institute on Aging (NIA) grants and contracts (P30AG024827, T32 AG021885, K07AG033174, R01AG028050). This research was also supported in part by the Intramural Research program of the National Institutes of Health, NIA (N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106), and a National Institute of Nursing research grant (R01NR012459). NR 29 TC 2 Z9 2 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2015 VL 49 IS 11 BP 1214 EP 1221 DI 10.1177/1060028015596998 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CU0OW UT WOS:000363217800005 PM 26228936 ER PT J AU Shiota, S Singh, S Anshasi, A El-Serag, HB AF Shiota, Seiji Singh, Siddharth Anshasi, Ashraf El-Serag, Hashem B. TI Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Review DE Barrett's Esophagus; Systematic Review; Meta-analysis; Prevalence; Risk Factors ID GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; RISK-FACTORS; EROSIVE ESOPHAGITIS; GENERAL-POPULATION; CHINESE POPULATION; KOREAN POPULATION; M CRITERIA; PRAGUE C; ENDOSCOPIC ESOPHAGITIS AB BACKGROUND & AIMS: The prevalence and risk factors of Barrett's esophagus (BE) in Asian countries are unclear. Studies report a wide range of BE prevalence in Asian countries. We conducted a systematic review and meta-analysis to examine the prevalence of BE and its temporal changes and risk factors in Asian countries. METHODS: Two investigators performed independent literature searches by using PubMed and EMBASE databases, and subsequent data abstraction for studies had to meet several set inclusion and exclusion criteria. Pooled BE prevalence was calculated by using a random-effect model. Estimates of relative risk for possible risk or protective factors were also calculated. RESULTS: A total of 51 studies (N [453,147), mainly from Eastern Asia, were included. The pooled prevalence of endoscopic BE was 7.8% (95% confidence interval, 5.0-12.1; 23 studies) and of histologically confirmed BE was 1.3% (95% confidence interval, 0.7-2.2; 28 studies). Most of histologic BE (82.1%) was short-segment BE (< 3 cm). There was a trend toward an increase in prevalence of BE over time from 1991 to 2014, especially in Eastern Asian countries. Within BE cohorts, pooled prevalence of low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma was 6.9%, 3.0%, and 2.0%, respectively. Reflux symptoms, male sex, hiatus hernia, and smoking were associated with a significantly increased risk of histologic BE in patients with BE compared with patients without BE. However, half of the patients with histologic BE did not have reflux symptoms. CONCLUSIONS: BE is not uncommon in Asian countries and seems to share similar risk factors and potential for neoplastic progression to those seen in Western countries. C1 [Shiota, Seiji; Anshasi, Ashraf; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX USA. [Shiota, Seiji; Anshasi, Ashraf; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. [Singh, Siddharth] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu FU National Institutes of Health [NCI R01 116845]; Texas Digestive Disease Center [NIH DK58338]; NIDDK [K24-04-107] FX Funded in part by National Institutes of Health grant NCI R01 116845 and the Texas Digestive Disease Center NIH DK58338. Dr El-Serag is also supported by NIDDK K24-04-107. This research was supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, TX. The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. NR 90 TC 8 Z9 9 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2015 VL 13 IS 11 BP 1907 EP 1918 DI 10.1016/j.cgh.2015.07.050 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT9VW UT WOS:000363165700013 PM 26260107 ER PT J AU Cadoni, S Falt, P Gallittu, P Liggi, M Mura, D Smajstrla, V Erriu, M Leung, FW AF Cadoni, Sergio Falt, Premysl Gallittu, Paolo Liggi, Mauro Mura, Donatella Smajstrla, Vit Erriu, Matteo Leung, Felix W. TI Water Exchange Is the Least Painful Colonoscope Insertion Technique and Increases Completion of Unsedated Colonoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Medication-Free Colonoscopy; Pain; Discomfort; Bowel Preparation ID RANDOMIZED CONTROLLED-TRIAL; CARBON-DIOXIDE INSUFFLATION; ON-DEMAND SEDATION; AIR INSUFFLATION; AIDED COLONOSCOPY; PATIENT PAIN; IMMERSION AB BACKGROUND & AIMS: Unsedated colonoscopy is acceptable for diagnostic, surveillance, and screening indications worldwide. However, insertion of the colonoscope can be painful; it is not clear which technique is least painful and thereby increases the likelihood of colonoscopy completion. We performed a head-to-head comparison of air insufflation (AI), carbon dioxide (CO2) insufflation, water immersion (WI), and water exchange (WE) to determine which combination of insertion techniques produces the least amount of pain. METHODS: In a patient-blinded prospective trial, 624 subjects were assigned randomly to groups that underwent colonoscopy with AI-AI, CO2-CO2, WI-AI, WE-AI, WI-CO2, or WE-CO2 insertion and withdrawal techniques, including on-demand sedation, at the St. Barbara Hospital (Iglesias, Italy) or the Vitkovice Hospital (Ostrava, Czech Republic), from October 2013 through June 2014. The primary outcome was real-time maximum insertion pain (0 = none, 10 = worst), recorded by an unblinded nurse assistant. At discharge, a blinded observer recorded the recalled maximum insertion pain and patients' and investigators' guesses about method or gas used. RESULTS: Patients and investigators correctly guessed the method used for fewer than 44% of procedures, confirming adequate blinding. The correlation between real-time and recalled maximum insertion pain (r = 0.9; P < .0005) confirmed internal validation of the primary outcome. The WE group had the lowest scores: mean pain values were 5.2 for AI-AI (95% confidence interval [CI], 4.6-5.8), 4.9 for CO2-CO2 (95% CI, 4.3-5.4), 4.3 for WI-CO2 (95% CI, 3.8-4.9), 4.0 for WI-AI (95% CI, 3.5-4.5), 3.1 for WE-CO2 (95% CI, 2.7-3.4), and 3.1 for WE-AI (95% CI, 2.7-3.6) (P < .0005). The highest proportions of patients completing unsedated colonoscopy were in the WE groups. WE groups also had significantly better colon cleanliness, particularly in the transverse and right colon (P < .0005). One limitation of the study was that colonoscopists and assistants were not blinded to water-aided insertion methods. CONCLUSIONS: In a prospective study of colonoscopy insertion methods, CO2 insufflation did not reduce real-time maximum insertion pain. Compared with AI or CO2, WI and WE reduced insertion pain. The least painful technique was WE, which significantly increased completion of unsedated colonoscopy and bowel cleanliness without prolonging insertion time. C1 [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro; Mura, Donatella] St Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. [Falt, Premysl; Smajstrla, Vit] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic. [Erriu, Matteo] Univ Cagliari, Dept Surg Sci, I-09124 Cagliari, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. EM cadonisergio@gmail.com NR 22 TC 12 Z9 12 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2015 VL 13 IS 11 BP 1972 EP + DI 10.1016/j.cgh.2015.04.178 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT9VW UT WOS:000363165700023 PM 25956838 ER PT J AU Ho, SB Brau, N Cheung, R Liu, L Sanchez, C Sklar, M Phelps, TE Marcus, SG Wasil, MM Tisi, A Huynh, L Robinson, SK Gifford, AL Asch, SM Groesslk, EJ AF Ho, Samuel B. Braeu, Norbert Cheung, Ramsey Liu, Lin Sanchez, Courtney Sklar, Marisa Phelps, Tyler E. Marcus, Sonja G. Wasil, Michelene M. Tisi, Amelia Huynh, Lia Robinson, Shannon K. Gifford, Allen L. Asch, Steven M. Groesslk, Erik J. TI Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Care Integration; Hepatitis C; Substance Use Disorders; PTSD ID SUSTAINED VIROLOGICAL RESPONSE; ANTIVIRAL TREATMENT; COST-EFFECTIVENESS; PEGYLATED INTERFERON; UNITED-STATES; INVENTORY-II; VETERANS; MANAGEMENT; DEPRESSION; MODELS AB BACKGROUND & AIMS: Patients with hepatitis C virus (HCV) infection with psychiatric disorders and/or substance abuse face significant barriers to antiviral treatment. New strategies are needed to improve treatment rates and outcomes. We investigated whether an integrated care (IC) protocol, which includes multidisciplinary care coordination and patient case management, could increase the proportion of patients with chronic HCV infection who receive antiviral treatment (a combination of interferon-based and direct-acting antiviral agents) and achieve a sustained virologic response (SVR). METHODS: We performed a prospective randomized trial at 3 medical centers in the United States. Participants (n = 363 patients attending HCV clinics) had been screened and tested positive for depression, post-traumatic stress disorder, and/or substance use; they were assigned randomly to groups that received IC or usual care (controls) from March 2009 through February 2011. A midlevel mental health practitioner was placed at each HCV clinic to provide IC with brief mental health interventions and case management, according to formal protocol. The primary end point was SVR. RESULTS: Of the study participants, 63% were non-white, 51% were homeless in the past 5 years, 64% had psychiatric illness, 65% were substance abusers within 1 year before enrollment, 57% were at risk for post-traumatic stress disorder, 71% had active depression, 80% were infected with HCV genotype 1, and 23% had advanced fibrosis. Over a mean follow-up period of 28 months, a greater proportion of patients in the IC group began receiving antiviral therapy (31.9% vs 18.8% for controls; P = .005) and achieved a SVR (15.9% vs 7.7% of controls; odds ratio, 2.26; 95% confidence interval, 1.15-4.44; P=. 018). There were no differences in serious adverse events between groups. CONCLUSIONS: Integrated care increases the proportion of patients with HCV infection and psychiatric illness and/or substance abuse who begin antiviral therapy and achieve SVRs, without serious adverse events. C1 [Ho, Samuel B.] VA San Diego Healthcare Syst, Med Serv, Gastroenterol Sect, San Diego, CA 92161 USA. [Sanchez, Courtney; Sklar, Marisa; Wasil, Michelene M.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA 92161 USA. [Robinson, Shannon K.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA 92161 USA. [Groesslk, Erik J.] VA San Diego Healthcare Syst, Div Hlth Serv Res & Dev, Res Serv, San Diego, CA 92161 USA. [Ho, Samuel B.] Univ Calif San Diego, Dept Med, Div Gastroenterol, San Diego, CA 92103 USA. [Liu, Lin] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Biostat, San Diego, CA 92103 USA. [Robinson, Shannon K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Groesslk, Erik J.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Behav Med, San Diego, CA 92103 USA. [Braeu, Norbert] James J Peters VA Med Ctr, Infect Dis Sect, Bronx, NY USA. [Marcus, Sonja G.; Tisi, Amelia] James J Peters VA Med Ctr, Res Serv, Bronx, NY USA. [Braeu, Norbert] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA. [Braeu, Norbert] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA. [Cheung, Ramsey; Phelps, Tyler E.; Groesslk, Erik J.] VA Palo Alto Healthcare Syst, Gastroenterol Sect, Med Serv, Palo Alto, CA USA. [Huynh, Lia; Asch, Steven M.] VA Palo Alto Healthcare Syst, Res Serv, Palo Alto, CA USA. [Cheung, Ramsey] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA. [Asch, Steven M.] Stanford Univ, Dept Med, Div Gen Med Disciplines, Stanford, CA 94305 USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, Infect Dis Sect, Med Serv, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Dept Hlth Policy & Management, Boston, MA 02215 USA. [Gifford, Allen L.] Boston Univ, Dept Med, Boston, MA 02215 USA. RP Ho, SB (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM samuel.ho2@va.gov FU VA Health Services Research and Development grant [IIR-07-101-3] FX Supported by VA Health Services Research and Development grant IIR-07-101-3 (ClinicalTrials.gov # NCT00722423). NR 39 TC 8 Z9 8 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2015 VL 13 IS 11 BP 2005 EP + DI 10.1016/j.cgh.2015.02.022 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT9VW UT WOS:000363165700028 PM 25724704 ER PT J AU Marathe, CS Feinle-Bisset, C Pilichiewicz, A Lange, K Jones, KL Rayner, CK Kahn, SE Horowitz, M AF Marathe, C. S. Feinle-Bisset, C. Pilichiewicz, A. Lange, K. Jones, K. L. Rayner, C. K. Kahn, S. E. Horowitz, M. TI The duodenal glucose load impacts the oral disposition index in healthy subjects SO DIABETIC MEDICINE LA English DT Article ID FUTURE; TOLERANCE; GLYCEMIA; HORMONES AB AimIn healthy subjects, the oral disposition index (ratio of insulin response to insulin sensitivity) is predictive of the development of Type2 diabetes. Gastric emptying, which exhibits a substantial interindividual variation, is a major determinant of postprandial glycaemia in health and diabetes. We sought to determine whether the rate of intraduodenal glucose delivery affects the disposition index in people without diabetes. MethodsNineteen Caucasian males received glucose infusions via an intraduodenal catheter at either 2kcal/min (ID2) or 4kcal/min (ID4) for 120min, on two separate days with measurements of blood glucose (G) and plasma insulin (I) at frequent intervals. The insulin response was estimated by the ratio of the change in insulin to that of change in glucose at 30min (I0-30/G(0-30)) and 60min (I0-60/G(0-60)). Insulin sensitivity was estimated as 1/fasting insulin. The oral disposition index (DI) was calculated as I0-30/G(0-30)x1/fasting insulin and I0-60/G(0-60)x1/fasting insulin. ResultsThe overall glycaemic response was comparable on both days, but the insulin response was much greater at ID4 when calculated at either 30 or 60min (P<0.05). DI was also greater (P<0.05) in response to ID4 than ID2. ConclusionsThe rate of duodenal glucose delivery has a major impact on insulin release and, thereby, DI. This suggests that the rate of gastric emptying, which determines duodenal glucose delivery, is a determinant of DI. C1 [Marathe, C. S.; Feinle-Bisset, C.; Pilichiewicz, A.; Lange, K.; Jones, K. L.; Rayner, C. K.; Horowitz, M.] Univ Adelaide, Discipline Med, Royal Adelaide Hosp, Adelaide, SA 5005, Australia. [Marathe, C. S.; Feinle-Bisset, C.; Lange, K.; Jones, K. L.; Rayner, C. K.; Horowitz, M.] Univ Adelaide, Ctr Res Excellence CRE Translating Nutr Sci Good, Adelaide, SA 5005, Australia. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. RP Marathe, CS (reprint author), Univ Adelaide, Discipline Med, Royal Adelaide Hosp, Adelaide, SA 5005, Australia. EM chinmaymarathe@gmail.com OI Kahn, Steven/0000-0001-7307-9002; Jones, Karen/0000-0002-1155-5816 FU National Health and Medical Research Council of Australia (NHMRC); United States Department of Veterans Affairs; NHMRC FX The study was supported by a project grant awarded by the National Health and Medical Research Council of Australia (NHMRC) and the United States Department of Veterans Affairs. CFB was supported by an NHMRC Senior Research Fellowship, and KJ by an NHMRC Career Development Fellowship. NR 10 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-3071 EI 1464-5491 J9 DIABETIC MED JI Diabetic Med. PD NOV PY 2015 VL 32 IS 11 BP 1500 EP 1503 DI 10.1111/dme.12802 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU1EW UT WOS:000363263800014 PM 25981372 ER PT J AU Chapko, MK Dufour, DR Hatia, RI Drobeniuc, J Ward, JW Teo, CG AF Chapko, Michael K. Dufour, D. Robert Hatia, Rikita I. Drobeniuc, Jan Ward, John W. Teo, Chong-Gee TI Cost-effectiveness of strategies for testing current hepatitis C virus infection SO HEPATOLOGY LA English DT Article ID POINT-OF-CARE; UNITED-STATES; HCV; ANTIBODY; POPULATIONS; MORTALITY; SETTINGS; OUTBREAK; SEROLOGY; OUTCOMES AB Six strategies for identifying hepatitis C virus (HCV) viremia, involving testing for HCV antibody (HCVAb) followed by a nucleic acid test (NAT) for HCV RNA when the antibody test is positive, are compared. Decision analysis was used to determine mean relative cost per person tested and outcomes of HCV viremia detection. Parameters included proportions of test population with HCVAb and viremia plus specificity, sensitivity, and cost of individual tests. For testing a population with an HCVAb seroprevalence of 3.25%, all strategies when adopting quantitative NAT vary little in cost (range, $29.50-$30.70) and are highly viremia specific (0.9997). Four of the strategies using venipuncture blood for HCVAb testing (whether laboratory conducted or employing a rapid, point-of-care assay) and for NAT (whether done by reflex or using separately drawn blood) achieve the highest viremia sensitivities (range, 0.9950-0.9954). Point-of-care HCVAb testing in fingerstick blood followed by NAT in venipuncture blood yields relatively lower viremia sensitivity (0.9301). The strategy that requires returning for NAT is even less viremia sensitive (<0.9000) because of follow-up loss. Strategies adopting qualitative rather than quantitative NAT are slightly cheaper (range, $28.90-$29.99), similarly viremia specific (0.9997), but less viremia sensitive (0.9456). Viremia sensitivity and specificity remain the same regardless of the proportion of HCVAb-seropositive persons in the cohort being tested. Conclusions: Strategies involving HCVAb testing in venipuncture blood, whether laboratory conducted or using a point-of-care assay, when followed by quantitative NAT done reflexively or in separately drawn blood, are comparably economical and suitably viremia sensitive. Less cost-effective is point-of-care HCVAb testing in fingerstick blood followed by NAT in venipuncture blood. Least cost-effective is the strategy requiring the tested person to return for NAT. (Hepatology 2015;62:1396-1404) C1 [Chapko, Michael K.] Vet Affairs Paget Sound Hlth Care Syst, Seattle, WA USA. [Chapko, Michael K.] Univ Washington, Seattle, WA 98195 USA. [Dufour, D. Robert] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Hatia, Rikita I.; Drobeniuc, Jan; Ward, John W.; Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. EM michael.chapko@va.gov NR 27 TC 3 Z9 3 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2015 VL 62 IS 5 BP 1396 EP 1404 DI 10.1002/hep.27966 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU1EZ UT WOS:000363264100011 PM 26126725 ER PT J AU Matthews, PE Le, T Delmar, J Okulicz, JF AF Matthews, P. E. Le, T. Delmar, J. Okulicz, J. F. TI Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; treatment; antiretroviral therapy; HAART; AIDS; Air Force; military; continuum of care; treatment cascade ID ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE; ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; CLINICAL-OUTCOMES; INITIAL TREATMENT; EARLY RETENTION; DOUBLE-BLIND; ENGAGEMENT; PREVENTION; HEALTH AB The United States Air Force HIV programme has several features that may enhance antiretroviral therapy outcomes, including free access to healthcare and mandatory clinical visits every six months at a single centre. We evaluated viral load suppression (<50copies/ml) after 12 months of initial antiretroviral therapy, with extension to 18 and 24 months. Active duty Air Force members were categorised by year of antiretroviral therapy initiation: 2000-2005 (n=95, 36.1%) and 2006-2011 (n=168, 63.9%). The median months from HIV diagnosis to initial antiretroviral therapy were shorter in the 2000-2005 group (2.4, IQR 1.2-5.9) compared with the 2006-2011 group (12.6, IQR 2.6-29.0; p<0.001). Viral load suppression was greater in the 2006-2011 group compared with the 2000-2005 group at 12 months (93.2% versus 78.6%, p=0.002) and 18 months (91.8% versus 80.3%, p=0.03), and trended higher at 24 months (90.8% versus 82.5%; p=0.15). Factors associated with viral load suppression at 12 months in multivariate models included antiretroviral therapy initiation during 2006-2011 (OR 5.22, 95% CI 1.50-18.18) and CD4 count at antiretroviral therapy initiation (OR 2.29, 95% CI 1.19-14.43 per 100cells/mu l increase). Structured programmes that minimise traditional barriers to care combined with the use of contemporary antiretroviral therapy regimens can achieve clinic-wide viral load suppression in >90% of patients. C1 [Matthews, P. E.; Delmar, J.; Okulicz, J. F.] San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. [Le, T.] South Texas Vet Hlth Care Syst, Vet Affairs Res Ctr, AIDS & HIV I Infect & Ctr Personalized Med, San Antonio, TX USA. [Le, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Okulicz, JF (reprint author), San Antonio Mil Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM jason.f.okulicz.mil@mail.mil NR 26 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2015 VL 26 IS 13 BP 951 EP 959 DI 10.1177/0956462414563631 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU2CY UT WOS:000363331400006 PM 25505041 ER PT J AU Qin, WP Li, XD Peng, YZ Harlow, LM Ren, YS Wu, YJ Li, JL Qin, YW Sun, J Zheng, SJ Brown, T Feng, JQ Ke, HZ Bauman, WA Cardozo, CC AF Qin, Weiping Li, Xiaodong Peng, Yuanzhen Harlow, Lauren M. Ren, Yinshi Wu, Yingjie Li, Jiliang Qin, Yiwen Sun, Jie Zheng, Shijia Brown, Tom Feng, Jian Q. Ke, Hua Zhu Bauman, William A. Cardozo, Christopher C. TI Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE PRECLINICAL STUDIES; ANABOLICS; OSTEOCYTES; STROMAL; STEM CELLS; WNT; -CATENIN; LRPS ID BONE-FORMATION; MECHANICAL STIMULATION; OSTEOPOROSIS; MODEL; IMMOBILIZATION; EXPRESSION; DENSITY; MUSCLE; MASS; IDENTIFICATION AB Unloading, neural lesions, and hormonal disorders after acute motor-complete spinal cord injury (SCI) cause one of the most severe forms of bone loss, a condition that has been refractory to available interventions tested to date. Thus, these features related to acute SCI provide a unique opportunity to study complex bone problems, potential efficacious interventions, and mechanisms of action that are associated with these dramatic pathological changes. This study was designed to explore the therapeutic potential of sclerostin antibody (Scl-Ab) in a rat model of bone loss after motor-complete SCI, and to investigate mechanisms underlying bone loss and Scl-Ab action. SCI rats were administered Scl-Ab (25 mg/kg/week) or vehicle beginning 7 days after injury then weekly for 7 weeks. SCI resulted in significant decreases in bone mineral density (-25%) and trabecular bone volume (-67%) at the distal femur; Scl-Ab completely prevented these deteriorations of bone in SCI rats, concurrent with markedly increased bone formation. Scanning electron microscopy revealed that SCI reduced numbers of osteocytes and dendrites concomitant with a morphology change from a spindle to round shape; Scl-Ab corrected these abnormalities in osteocytes. In ex vivo cultures of bone marrow cells, Scl-Ab inhibited osteoclastogenesis, and promoted osteoblastogenesis accompanied by increases in mRNA levels of LRP5, osteoprotegerin (OPG), and the OPG/RANKL ratio, and a decrease in DKK1 mRNA. Our findings provide the first evidence that robust bone loss after acute motor-complete SCI can be blocked by Scl-Ab, at least in part, through the preservation of osteocyte morphology and structure and related bone remodeling. Our findings support the inhibition of sclerostin as a promising approach to mitigate the striking bone loss that ensues after acute motor-complete SCI, and perhaps other conditions associated with disuse osteoporosis as a consequence of neurological disorders. (c) 2015 American Society for Bone and Mineral Research C1 [Qin, Weiping; Peng, Yuanzhen; Harlow, Lauren M.; Qin, Yiwen; Zheng, Shijia; Bauman, William A.; Cardozo, Christopher C.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. [Qin, Weiping; Wu, Yingjie; Bauman, William A.; Cardozo, Christopher C.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Li, Xiaodong; Brown, Tom; Ke, Hua Zhu] Amgen Inc, Thousand Oaks, CA 91320 USA. [Ren, Yinshi; Feng, Jian Q.] Texas A&M Univ, Baylor Coll Dent, Dallas, TX USA. [Wu, Yingjie; Sun, Jie] Dalian Med Univ, Inst Gene Engn Anim Models Human Dis, Dalian, Peoples R China. [Li, Jiliang] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46205 USA. [Bauman, William A.; Cardozo, Christopher C.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher C.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Qin, WP (reprint author), James J Peters Veteran Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM weiping.qin@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B1313-R, B0687-R, B9212-C] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (grants B1313-R and B0687-R to WQ; B9212-C to WAB). Amgen Inc. and UCB Pharma provided Scl-Ab. NR 55 TC 7 Z9 7 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD NOV PY 2015 VL 30 IS 11 BP 1994 EP 2004 DI 10.1002/jbmr.2549 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU1MV UT WOS:000363286900006 PM 25974843 ER PT J AU Carbone, LD Hovey, KM Andrews, CA Thomas, F Sorensen, MD Crandall, CJ Watts, NB Bethel, M Johnson, KC AF Carbone, Laura D. Hovey, Kathleen M. Andrews, Christopher A. Thomas, Fridtjof Sorensen, Mathew D. Crandall, Carolyn J. Watts, Nelson B. Bethel, Monique Johnson, Karen C. TI Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE DXA; AGING; DXA; OSTEOPOROSIS; GENERAL POPULATION STUDIES; MENOPAUSE ID BONE-MINERAL DENSITY; POPULATION-BASED COHORT; KIDNEY-STONES; POSTMENOPAUSAL WOMEN; UNITED-STATES; D SUPPLEMENTATION; DIETARY CALCIUM; LUMBAR SPINE; RISK; FRACTURES AB Kidney and bladder stones (urinary tract stones) and osteoporosis are prevalent, serious conditions for postmenopausal women. Men with kidney stones are at increased risk of osteoporosis; however, the relationship of urinary tract stones to osteoporosis in postmenopausal women has not been established. The purpose of this study was to determine whether urinary tract stones are an independent risk factor for changes in bone mineral density (BMD) and incident fractures in women in the Women's Health Initiative (WHI). Data were obtained from 150,689 women in the Observational Study and Clinical Trials of the WHI with information on urinary tract stones status: 9856 of these women reported urinary tract stones at baseline and/or incident urinary tract stones during follow-up. Cox regression models were used to determine the association of urinary tract stones with incident fractures and linear mixed models were used to investigate the relationship of urinary tract stones with changes in BMD that occurred during WHI. Follow-up was over an average of 8 years. Models were adjusted for demographic and clinical factors, medication use, and dietary histories. In unadjusted models there was a significant association of urinary tract stones with incident total fractures (HR 1.10; 95% CI, 1.04 to 1.17). However, in covariate adjusted analyses, urinary tract stones were not significantly related to changes in BMD at any skeletal site or to incident fractures. In conclusion, urinary tract stones in postmenopausal women are not an independent risk factor for osteoporosis. (c) 2015 American Society for Bone and Mineral Research. C1 [Carbone, Laura D.; Bethel, Monique] Dept Vet Affairs Med Ctr, Subspecialty Serv, Augusta, GA USA. [Carbone, Laura D.; Bethel, Monique] Georgia Regents Univ, Dept Med, Rheumatol Sect, Augusta, GA 30912 USA. [Hovey, Kathleen M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA. [Andrews, Christopher A.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA. [Thomas, Fridtjof; Johnson, Karen C.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Sorensen, Mathew D.] Dept Vet Affairs Med Ctr, VA Puget Sound Hlth Care Syst, Div Urol, Seattle, WA USA. [Sorensen, Mathew D.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Crandall, Carolyn J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Watts, Nelson B.] Mercy Hlth Osteoporosis & Bone Hlth Serv, Cincinnati, OH USA. RP Carbone, LD (reprint author), Georgia Regents Univ, Dept Med, Rheumatol Sect, 1120 15th St,BI 5086, Augusta, GA 30912 USA. EM lcarbone@gru.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services. The WHI publications committee approved the final version of this manuscript. This material is the result of work supported with resources and the use of facilities at the Charlie Norwood Veterans Affairs Medical Center. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 48 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD NOV PY 2015 VL 30 IS 11 BP 2096 EP 2102 DI 10.1002/jbmr.2553 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU1MV UT WOS:000363286900016 PM 25990099 ER PT J AU Kilbane, C Ramirez-Zamora, A Ryapolova-Webb, E Qasim, S Glass, GA Starr, PA Ostrem, JL AF Kilbane, Camilla Ramirez-Zamora, Adolfo Ryapolova-Webb, Elena Qasim, Salman Glass, Graham A. Starr, Philip A. Ostrem, Jill L. TI Is one large target better than two? Response SO JOURNAL OF NEUROSURGERY LA English DT Letter ID DEEP BRAIN-STIMULATION; THALAMIC-STIMULATION; TREMOR C1 [Kilbane, Camilla] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Ryapolova-Webb, Elena; Qasim, Salman; Glass, Graham A.; Starr, Philip A.; Ostrem, Jill L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Glass, Graham A.; Starr, Philip A.; Ostrem, Jill L.] San Francisco VA Med Ctr, Parkinsons Dis Res, Educ & Clin Ctr, San Francisco, CA USA. [Ramirez-Zamora, Adolfo] Albany Med Coll, Albany, NY 12208 USA. RP Kilbane, C (reprint author), Stanford Univ, Med Ctr, Stanford, CA 94305 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 EI 1933-0693 J9 J NEUROSURG JI J. Neurosurg. PD NOV PY 2015 VL 123 IS 5 BP 1349 EP 1350 PG 2 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CU3QL UT WOS:000363439800039 PM 26870866 ER PT J AU Kass, JI Lee, SC Abberbock, S Seethala, RR Duvvuri, U AF Kass, Jason I. Lee, Steve C. Abberbock, Shira Seethala, Raja R. Duvvuri, Umamaheswar TI Adenosquamous carcinoma of the head and neck: Molecular analysis using CRTC-MAML FISH and survival comparison with paired conventional squamous cell carcinoma SO LARYNGOSCOPE LA English DT Article DE Adenosquamous; carcinoma; CRCT-MAML; FISH ID MUCOEPIDERMOID CARCINOMA; TRANSLOCATION; FUSION AB Objectives/HypothesisAdenosquamous carcinoma (ASC) is a rare variant of head-and-neck squamous cell carcinoma (HNSCC) generally thought to be uniformly aggressive with poor prognosis. However, it remains unknown how overall survival compare with conventional HNSCC. Here we report for the first time that ASC does not necessarily indicate a worse prognosis than conventional HNSCC. Study Design Case-control retrospective study. Methods Forty-two primary tumors of the head and neck, treated with curative intent, were identified. Next, 2:1 matching of HNSCC was performed using the following matching criteria: gender, site, pathologic tumor stage, and pathologic node stage. Successful matching was performed for 32 of 42 tumors. Additionally, 20 samples were sent for break-apart FISH testing to evaluate for the presence of the CRTC1-MAML2 translocation. Results There was a 1.8:1 male to female ratio, with a mean age of 62 years (range 38-84). The layrnx was the most common site (26%), followed by oropharynx (24%), oral cavity (19%), and sinonasal (17%). Kaplan-Meier analysis of adenosquamous and matched HNSCC showed similar survival curves. Median survival times for ASC and HNSCC were 4 and 6 years, respectively. A random-effects Cox model with Gamma frailty revealed no statistical difference between the two groups (P=0.25). All cases of ASC were negative for the CRTC1-MAML2 translocation. Conclusion This study directly compares primary ASC with HNSCC. No difference in overall survival was detected in contradistinction to the previously thought uniformly poor prognosis. We also highlight the importance of the CRTC1-MAML2 translocation in distinguishing ASC from mucoepidermoid carcinoma. C1 [Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15261 USA. [Kass, Jason I.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15261 USA. [Seethala, Raja R.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15261 USA. [Abberbock, Shira] Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA 15261 USA. [Lee, Steve C.] Loma Linda Med Ctr, Dept Otolaryngol, Loma Linda, CA USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, VA Pittsburgh Hlth Syst, Eye & Ear Bldg,Suite 500,200 Lothrop St, Pittsburgh, PA 15261 USA. EM duvvuriu@upmc.edu NR 10 TC 4 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD NOV PY 2015 VL 125 IS 11 BP E371 EP E376 DI 10.1002/lary.25519 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA CU2XO UT WOS:000363387200003 PM 26255977 ER PT J AU Vaid, M Singh, T Prasad, R Katiyar, SK AF Vaid, Mudit Singh, Tripti Prasad, Ram Katiyar, Santosh K. TI Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis SO MOLECULAR CARCINOGENESIS LA English DT Article DE apoptosis; silymarin; melanoma; cell proliferation; angiogenesis; tumor xenograft ID MATRIX METALLOPROTEINASES; CUTANEOUS MELANOMA; KINASE INHIBITORS; ANTICANCER DRUGS; BCL-2 FAMILY; SKIN-CANCER; DEATH; PHOTOCARCINOGENESIS; MECHANISMS; EPIDEMIOLOGY AB Cutaneous malignant melanoma is the leading cause of death from skin diseases and is often associated with activating mutations of the proto-oncogene BRAF. To develop more effective strategies for the prevention or treatment of melanoma, we have examined the inhibitory effects of silymarin, a flavanoid from Silybum marianum, on melanoma cells. Using A375 (BRAF-mutated) and Hs294t (non BRAF-mutated but highly metastatic) human melanoma cell lines, we found that in vitro treatment with silymarin resulted in a dose-dependent: (i) reduction in cell viability; (ii) enhancement of either Go/G1 (A375) or G2-M (Hs294t) phase cell cycle arrest with corresponding alterations in cyclins and cyclin-dependent kinases; and (iii) induction of apoptosis. The silymarin-induced apoptosis of human melanoma cells was associated with a reduction in the levels of anti-apoptotic proteins (Bcl-2 and Bcl-xl), an increase in the levels of pro-apoptotic protein (Bax), and activation of caspases. Further, oral administration of silymarin (500mg/kg body weight/2x a week) significantly inhibited (60%, P<0.01) the growth of BRAF-mutated A375 melanoma tumor xenografts, and this was associated with: (i) inhibition of cell proliferation; (ii) induction of apoptosis of tumor cells; (iii) alterations in cell cycle regulatory proteins; and (iv) reduced expression of tumor angiogenic biomarkers in tumor xenograft tissues. These results indicate that silymarin may have a chemotherapeutic effect on human melanoma cell growth and warrant its further evaluation. (c) 2014 Wiley Periodicals, Inc. C1 [Vaid, Mudit; Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. FU Veterans Administration Merit Review Award [1I01BX001410] FX Grant sponsor: Veterans Administration Merit Review Award; Grant number: 1I01BX001410 NR 42 TC 2 Z9 3 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD NOV PY 2015 VL 54 IS 11 BP 1328 EP 1339 DI 10.1002/mc.22208 PG 12 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA CU0PX UT WOS:000363220700009 PM 25174976 ER PT J AU Barral, S Vardarajan, BN Reyes-Dumeyer, D Faber, KM Bird, TD Tsuang, D Bennett, DA Rosenberg, R Boeve, BF Graff-Radford, NR Goate, AM Farlow, M Lantigua, R Medrano, MZ Wang, XB Kamboh, MI Barmada, MM Schaid, DJ Foroud, T Weamer, EA Ottman, R Sweet, RA Mayeux, R AF Barral, Sandra Vardarajan, Badri N. Reyes-Dumeyer, Dolly Faber, Kelley M. Bird, Thomas D. Tsuang, Debby Bennett, David A. Rosenberg, Roger Boeve, Bradley F. Graff-Radford, Neill R. Goate, Alison M. Farlow, Martin Lantigua, Rafael Medrano, Martin Z. Wang, Xinbing Kamboh, M. Ilyas Barmada, Mahmud Muhiedine Schaid, Daniel J. Foroud, TatianaM. Weamer, Elise A. Ottman, Ruth Sweet, Robert A. Mayeux, Richard CA NIA-LOAD NCRAD Family Study Grp TI Genetic variants associated with susceptibility to psychosis in late-onset Alzheimer's disease families SO NEUROBIOLOGY OF AGING LA English DT Article DE Late-onset Alzheimer's disease; Psychosis; Genome-wide linkage analysis; Association analysis; Non-Hispanic Caucasian and Caribbean; Hispanic ancestry populations ID NEUROPSYCHIATRIC INVENTORY; NATIONAL INSTITUTE; LINKAGE ANALYSIS; HALLUCINATIONS; DEMENTIA; DELUSIONS; SYMPTOMS; BEHAVIOR; HEALTH; RISK AB Psychotic symptoms are frequent in late-onset Alzheimer's disease (LOAD) patients. Although the risk for psychosis in LOAD is genetically mediated, no genes have been identified. To identify loci potentially containing genetic variants associated with risk of psychosis in LOAD, a total of 263 families from the National Institute of Aging-LOAD cohort were classified into psychotic (LOAD+P, n = 215) and nonpsychotic (LOAD-P, n = 48) families based on the presence/absence of psychosis during the course of LOAD. The LOAD+P families yielded strong evidence of linkage on chromosome 19q13 (two-point [2-pt] logarithm of odds [LOD] = 3.8, rs2285513 and multipoint LOD = 2.7, rs541169). Joint linkage and association in 19q13 region detected strong association with rs2945988 (p = 8.7 x 10(-7)). Linkage results for the LOAD-P families yielded nonsignificant 19q13 LOD scores. Several 19q13 single-nucleotide polymorphisms generalized the association of LOAD+P in a Caribbean Hispanic (CH) cohort, and the strongest signal was rs10410711 (p(meta) = 5.1 x 10(-5)). A variant located 24 kb upstream of rs10410711 and rs10421862 was strongly associated with LOAD+P (p(meta) = 1.0 x 10(-5)) in a meta-analysis of the CH cohort and an additional non-Hispanic Caucasian dataset. Identified variants rs2945988 and rs10421862 affect brain gene expression levels. Our results suggest that genetic variants in genes on 19q13, some of which are involved in brain development and neurodegeneration, may influence the susceptibility to psychosis in LOAD patients. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Barral, Sandra; Vardarajan, Badri N.; Reyes-Dumeyer, Dolly; Lantigua, Rafael; Mayeux, Richard] Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA. [Barral, Sandra; Vardarajan, Badri N.; Reyes-Dumeyer, Dolly; Lantigua, Rafael; Ottman, Ruth; Mayeux, Richard] New York Presbyterian Hosp, New York, NY 10032 USA. [Barral, Sandra; Vardarajan, Badri N.; Reyes-Dumeyer, Dolly; Ottman, Ruth; Mayeux, Richard] Columbia Univ, Med Ctr, GH Sergievsky Ctr, New York, NY 10032 USA. [Barral, Sandra; Vardarajan, Badri N.; Reyes-Dumeyer, Dolly; Ottman, Ruth; Mayeux, Richard] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA. [Faber, Kelley M.; Foroud, TatianaM.] Indiana Univ, Dept Med & Mol Genet, Indianapolis, IN 46204 USA. [Bird, Thomas D.; Tsuang, Debby] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.; Tsuang, Debby] Univ Washington, Dept Med, Seattle, WA USA. [Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Rosenberg, Roger] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA. [Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Goate, Alison M.] Icanhn Sch Med Mt Sinai, New York, NY USA. [Farlow, Martin] Indiana Univ, Dept Neurol, Ctr Alzheimers Dis & Related Disorders, Indianapolis, IN 46204 USA. [Lantigua, Rafael] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA. [Medrano, Martin Z.] Pontificia Univ Catolica Madre & Maestra, Dept Geriatr, Santiago, Dominican Rep. [Wang, Xinbing; Kamboh, M. Ilyas; Barmada, Mahmud Muhiedine] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Wang, Xinbing] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Schaid, Daniel J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Weamer, Elise A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ottman, Ruth] Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY 10032 USA. [Ottman, Ruth] New York State Psychiat Inst & Hosp, Div Epidemiol, New York, NY 10032 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. RP Mayeux, R (reprint author), Columbia Univ, Med Ctr, GH Sergievsky Ctr, New York, NY 10032 USA. EM rpm2@cumc.columbia.edu RI Tsuang, Debby/L-7234-2016; Ottman, Ruth/O-2371-2013 OI Tsuang, Debby/0000-0002-4716-1894; Ottman, Ruth/0000-0001-7074-242X; Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460 FU National Institute on Aging [R01AG041797, U24AG026395, R37AG015473, AG030653, AG0 41718, AG005133, U24AG21886, AG027224] FX Study participants were enrolled under federal grants R01AG041797, U24AG026395, R37AG015473, AG030653, AG0 41718, AG005133, U24AG21886, and AG027224 from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the US Government. We would like to acknowledge Dr Andrew P. Morris for his useful contribution, assisting with the analysis, and interpretation of the MANTRA results and Dr. Jurg Ott for his contribution to evaluate linkage heterogeneity. NR 39 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV PY 2015 VL 36 IS 11 AR 3116.e9 DI 10.1016/j.neurobiolaging.2015.08.006 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CU1LA UT WOS:000363281700024 PM 26359528 ER PT J AU Bethoux, F Rogers, HL Nolan, KJ Abrams, GM Annaswamy, T Brandstater, M Browne, B Burnfield, JM Feng, WW Freed, MJ Geis, C Greenberg, J Gudesblatt, M Ikramuddin, F Jayaraman, A Kautz, SA Lutsep, HL Madhavan, S Meilahn, J Pease, WS Rao, N Seetharama, S Sethi, P Turk, MA Wallis, RA Kufta, C AF Bethoux, Francois Rogers, Helen L. Nolan, Karen J. Abrams, Gary M. Annaswamy, Thiru Brandstater, Murray Browne, Barbara Burnfield, Judith M. Feng, Wuwei Freed, Mitchell J. Geis, Carolyn Greenberg, Jason Gudesblatt, Mark Ikramuddin, Farha Jayaraman, Arun Kautz, Steven A. Lutsep, Helmi L. Madhavan, Sangeetha Meilahn, Jill Pease, William S. Rao, Noel Seetharama, Subramani Sethi, Pramod Turk, Margaret A. Wallis, Roi Ann Kufta, Conrad TI Long-Term Follow-up to a Randomized Controlled Trial Comparing Peroneal Nerve Functional Electrical Stimulation to an Ankle Foot Orthosis for Patients With Chronic Stroke SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE functional electrical stimulation; ankle foot orthosis; stroke rehabilitation; gait speed; foot drop; quality of life ID DROPPED FOOT; WALKING PERFORMANCE; HEMIPLEGIC PATIENTS; CHRONIC HEMIPARESIS; GAIT VELOCITY; SPEED; NEUROPROSTHESIS; INDIVIDUALS; BALANCE; RELIABILITY AB Background. Evidence supports peroneal nerve functional electrical stimulation (FES) as an effective alternative to ankle foot orthoses (AFO) for treatment of foot drop poststroke, but few long-term, randomized controlled comparisons exist. Objective. Compare changes in gait quality and function between FES and AFOs in individuals with foot drop poststroke over a 12-month period. Methods. Follow-up analysis of an unblinded randomized controlled trial (ClinicalTrials.gov #NCT01087957) conducted at 30 rehabilitation centers comparing FES to AFOs over 6 months. Subjects continued to wear their randomized device for another 6 months to final 12-month assessments. Subjects used study devices for all home and community ambulation. Multiply imputed intention-to-treat analyses were utilized; primary endpoints were tested for noninferiority and secondary endpoints for superiority. Primary endpoints: 10 Meter Walk Test (10MWT) and device-related serious adverse event rate. Secondary endpoints: 6-Minute Walk Test (6MWT), GaitRite Functional Ambulation Profile, and Modified Emory Functional Ambulation Profile (mEFAP). Results. A total of 495 subjects were randomized, and 384 completed the 12-month follow-up. FES proved noninferior to AFOs for all primary endpoints. Both FES and AFO groups showed statistically and clinically significant improvement for 10MWT compared with initial measurement. No statistically significant between-group differences were found for primary or secondary endpoints. The FES group demonstrated statistically significant improvements for 6MWT and mEFAP Stair-time subscore. Conclusions. At 12 months, both FES and AFOs continue to demonstrate equivalent gains in gait speed. Results suggest that long-term FES use may lead to additional improvements in walking endurance and functional ambulation; further research is needed to confirm these findings. C1 [Bethoux, Francois] Cleveland Clin, Cleveland, OH 44106 USA. [Rogers, Helen L.; Kufta, Conrad] Innovat Neurotron, Austin, TX USA. [Nolan, Karen J.] Kessler Fdn, W Orange, NJ USA. [Nolan, Karen J.] Rutgers New Jersey Med Sch, Newark, NJ USA. [Abrams, Gary M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Annaswamy, Thiru] VA North Texas Hlth Care Syst, Dallas, TX USA. [Annaswamy, Thiru] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Brandstater, Murray] Loma Linda Univ, Med Ctr, Loma Linda, CA 92350 USA. [Browne, Barbara] Magee Mem Rehabilitat Ctr, Philadelphia, PA USA. [Burnfield, Judith M.] Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, Lincoln, NE USA. [Feng, Wuwei; Kautz, Steven A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Freed, Mitchell J.] Florida Hosp Neurosci & Orthoped Res Inst, Orlando, FL USA. [Geis, Carolyn] Halifax Hlth Ctr Neurosci, Daytona Beach, FL USA. [Greenberg, Jason] Helen Hayes Hosp, W Haverstraw, NY USA. [Gudesblatt, Mark] South Shore Neurol Associates, Patchogue, NY USA. [Ikramuddin, Farha] Univ Minnesota Fairview, Minneapolis, MN USA. [Jayaraman, Arun] Rehabil Inst Chicago, Chicago, IL 60611 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Lutsep, Helmi L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Madhavan, Sangeetha] Univ Illinois, Chicago, IL USA. [Meilahn, Jill] Marshfield Clin Res Fdn, Marshfield, WI USA. [Pease, William S.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA. [Rao, Noel] Marianjoy Rehabil Hosp, Wheaton, IL USA. [Seetharama, Subramani] Hartford Hosp, Hartford, CT 06115 USA. [Sethi, Pramod] Guilford Neurol Associates, Greensboro, NC USA. [Turk, Margaret A.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Wallis, Roi Ann] West Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Wallis, Roi Ann] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bethoux, F (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM bethouf@ccf.org OI Nolan, PhD, Karen J/0000-0002-4667-0873 FU Innovative Neurotronics, Inc. FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Innovative Neurotronics, Inc. NR 42 TC 6 Z9 6 U1 4 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD NOV-DEC PY 2015 VL 29 IS 10 BP 911 EP 922 DI 10.1177/1545968315570325 PG 12 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CU2BP UT WOS:000363326800001 PM 25653225 ER PT J AU Rolston, JD Ramos, AD Heath, S Englot, DJ Lim, DA AF Rolston, John D. Ramos, Alexander D. Heath, Susan Englot, Dario J. Lim, Daniel A. TI Thalamotomy-Like Effects From Partial Removal of a Ventral Intermediate Nucleus Deep Brain Stimulator Lead in a Patient With Essential Tremor: Case Report SO NEUROSURGERY LA English DT Article DE Deep brain stimulation; Essential tremor; Thalamotomy; Ventral intermediate nucleus; Zona incerta ID HIGH-FREQUENCY STIMULATION; THALAMIC-STIMULATION; SUBTHALAMIC NUCLEUS; ELECTRICAL-STIMULATION; PARKINSONS-DISEASE; ZONA INCERTA; FOLLOW-UP; COMPLICATIONS; SUPPRESSION; ULTRASOUND AB BACKGROUND AND IMPORTANCE:The ventral intermediate nucleus of the thalamus is a primary target of deep brain stimulation (DBS) in patients with essential tremor. Despite reliable control of contralateral tremor, there is sometimes a need for lead revision in cases of infection, hardware malfunction, or failure to relieve symptoms. Here, we present the case of a patient undergoing revision after ventral intermediate nucleus (Vim) DBS failed to control his tremor. During the electrode removal, the distal portion of the lead was found to be tightly adherent to tissue within the deep brain. Partial removal of the electrode in turn caused weakness, paresthesias, and tremor control similar to the effects produced by thalamotomy or thalamic injury.CLINICAL PRESENTATION:A 48-year-old man with essential tremor had bilateral Vim DBS leads implanted 10 years earlier but had poor control of his tremor and ultimately opted for surgical revision with lead placement in the zona incerta. During attempted removal of his right lead, the patient became somnolent with contralateral weakness and paresthesias. The procedure was aborted, and postoperative neuroimaging was immediately obtained, showing no signs of stroke or hemorrhage. The patient had almost complete control of his left arm tremor postoperatively, and his weakness soon resolved.CONCLUSION:To the best of our knowledge, this is the first reported case of cerebral injury after DBS revision and offers insights into the mechanism of high-frequency electric stimulation compared with lesions. That is, although high-frequency stimulation failed to control this patient's tremor, thalamotomy-like injury was completely effective.ABBREVIATIONS:DBS, deep brain stimulationVim, ventral intermediate nucleusZI, zona incerta C1 [Rolston, John D.; Ramos, Alexander D.; Englot, Dario J.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Heath, Susan] San Francisco VA Parkinsons Dis Res Educ & Clin C, San Francisco, CA USA. [Lim, Daniel A.] San Francisco VA Med Ctr, Surg Serv, San Francisco, CA USA. RP Lim, DA (reprint author), 35 Med Ctr Way,RMB 1037, San Francisco, CA 94143 USA. EM daniel.lim@ucsf.edu RI Englot, Dario/C-3656-2013 OI Englot, Dario/0000-0001-8373-690X FU California Institute for Regenerative Medicine [CIRM RT2-01975]; Veterans Affairs [1I01 BX000252-04]; Shurl and Kay Curci Foundation; Sontag Foundation FX Research activities of Dr Lim are supported by grants from the California Institute for Regenerative Medicine (CIRM RT2-01975), the Veterans Affairs (1I01 BX000252-04), the Shurl and Kay Curci Foundation, and the Sontag Foundation. Dr Lim is a consultant to Accurexa, Inc. S. Heath is a consultant and educator for Medtronic and has a relative who is employed by Medtronic. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. NR 44 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD NOV PY 2015 VL 77 IS 5 BP E831 EP E837 DI 10.1227/NEU.0000000000000906 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CU1NX UT WOS:000363289700001 PM 26200771 ER PT J AU Malla, SR Qin, Y Mareninova, OA Elperin, JM Lotshaw, EM Ohmuraya, M French, SW Gukovskaya, AS Gukovsky, I AF Malla, S. R. Qin, Y. Mareninova, O. A. Elperin, J. M. Lotshaw, E. M. Ohmuraya, M. French, S. W. Gukovskaya, A. S. Gukovsky, I. TI Atg5 Deficiency Worsens Cerulein Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 [Malla, S. R.; Qin, Y.; Mareninova, O. A.; Elperin, J. M.; Lotshaw, E. M.; Gukovskaya, A. S.; Gukovsky, I.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Malla, S. R.; Qin, Y.; Mareninova, O. A.; Elperin, J. M.; Lotshaw, E. M.; Gukovskaya, A. S.; Gukovsky, I.] Univ Calif Los Angeles, Los Angeles, CA USA. [Ohmuraya, M.] Kumamoto Univ, Kumamoto 860, Japan. [French, S. W.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2015 VL 44 IS 8 BP 1395 EP 1395 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU2AQ UT WOS:000363324000181 ER PT J AU Vegh, ET Lotshaw, EM Shalbueva, N Mareninova, OA Elperin, JM French, SW Hegyi, P Rakonczay, Z Gukovsky, I Gukovskaya, AS AF Vegh, E. T. Lotshaw, E. M. Shalbueva, N. Mareninova, O. A. Elperin, J. M. French, S. W. Hegyi, P. Rakonczay, Z. Gukovsky, I. Gukovskaya, A. S. TI Defective Lysosomal Hydrolase Trafficking Causes Spontaneous Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 [Vegh, E. T.; Lotshaw, E. M.; Shalbueva, N.; Mareninova, O. A.; Elperin, J. M.; Gukovsky, I.; Gukovskaya, A. S.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Vegh, E. T.; Lotshaw, E. M.; Shalbueva, N.; Mareninova, O. A.; Elperin, J. M.; Gukovsky, I.; Gukovskaya, A. S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Vegh, E. T.; Hegyi, P.; Rakonczay, Z.] Univ Szeged, Dept Med 1, Szeged, Hungary. [French, S. W.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2015 VL 44 IS 8 BP 1422 EP 1422 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU2AQ UT WOS:000363324000291 ER PT J AU Wang, RX Chu, CY Nissen, NN Lewis, MS Palanisamy, N Edderkaoui, M Annamalai, A Lewis, S Zhau, HE Pandol, SJ Chung, LWK AF Wang, R. X. Chu, C. Y. Nissen, N. N. Lewis, M. S. Palanisamy, N. Edderkaoui, M. Annamalai, A. Lewis, S. Zhau, H. E. Pandol, S. J. Chung, L. W. K. TI Novel Patient-Derived CTC-Xenograft Models for the Study of Pancreatic Cancer Biology, Metastasis and Therapy SO PANCREAS LA English DT Meeting Abstract C1 [Wang, R. X.; Chu, C. Y.; Nissen, N. N.; Edderkaoui, M.; Annamalai, A.; Lewis, S.; Zhau, H. E.; Pandol, S. J.; Chung, L. W. K.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Lewis, M. S.; Pandol, S. J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Palanisamy, N.] Henry Ford Hlth Syst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2015 VL 44 IS 8 BP 1423 EP 1423 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU2AQ UT WOS:000363324000296 ER PT J AU Clark, KB AF Clark, Kevin B. TI Insight and analysis problem solving in microbes to machines SO PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY LA English DT Review DE Cognition; Decision making; Emergent computation; Heuristics; Information processing; Intelligence; Natural computing ID ANIMAL COGNITION; AMEBOID ORGANISM; QUANTUM-THEORY; INTELLIGENCE; COMPLEX; CONSCIOUSNESS; PERFORMANCE; COMPUTATION; HEURISTICS; NETWORKS AB A key feature for obtaining solutions to difficult problems, insight is oftentimes vaguely regarded as a special discontinuous intellectual process and/or a cognitive restructuring of problem representation or goal approach. However, this nearly century-old state of art devised by the Gestalt tradition to explain the non-analytical or non-trial-and-error, goal-seeking aptitude of primate mentality tends to neglect problem-solving capabilities of lower animal phyla, Kingdoms other than Animalia, and advancing smart computational technologies built from biological, artificial, and composite media. Attempting to provide an inclusive, precise definition of insight, two major criteria of insight, discontinuous processing and problem restructuring, are here reframed using terminology and statistical mechanical properties of computational complexity classes. Discontinuous processing becomes abrupt state transitions in algorithmic/heuristic outcomes or in types of algorithms/heuristics executed by agents using classical and/or quantum computational models. And problem restructuring becomes combinatorial reorganization of resources, problem-type substitution, and/or exchange of computational models. With insight bounded by computational complexity, humans, ciliated protozoa, and complex technological networks, for example, show insight when restructuring time requirements, combinatorial complexity, and problem type to solve polynomial and nondeterministic polynomial decision problems. Similar effects are expected from other problem types, supporting the idea that insight might be an epiphenomenon of analytical problem solving and consequently a larger information processing framework. Thus, this computational complexity definition of insight improves the power, external and internal validity, and reliability of operational parameters with which to classify, investigate, and produce the phenomenon for computational agents ranging from microbes to man-made devices. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. [Clark, Kevin B.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA. [Clark, Kevin B.] Univ Illinois, Natl Ctr Supercomp Applicat, Extreme Sci & Engn Discovery Environm XSEDE, Urbana, IL 61801 USA. [Clark, Kevin B.] Univ Illinois, Beckman Inst Adv Sci & Technol, NIH Ctr Macromol Modeling & Bioinformat, Theoret & Computat Biophys Grp,BioCoRE, Urbana, IL 61801 USA. RP Clark, KB (reprint author), 4229 SE Harney St, Portland, OR 97206 USA. EM kbclarkphd@yahoo.com NR 88 TC 0 Z9 0 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0079-6107 J9 PROG BIOPHYS MOL BIO JI Prog. Biophys. Mol. Biol. PD NOV PY 2015 VL 119 IS 2 BP 183 EP 193 DI 10.1016/j.pbiomolbio.2015.08.018 PG 11 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CU2KR UT WOS:000363352900007 PM 26278642 ER PT J AU Winters, B Plymate, S Zeliadt, SB Holt, S Zhang, XT Hu, E Lin, DW Morrissey, C Wooldridge, B Gore, JL Porter, MP Wright, JL AF Winters, Brian Plymate, Stephen Zeliadt, Steven B. Holt, Sarah Zhang, Xiaotun Hu, Elaine Lin, Daniel W. Morrissey, Colm Wooldridge, Bryan Gore, John L. Porter, Michael P. Wright, Jonathan L. TI Metformin Effects on Biochemical Recurrence and Metabolic Signaling in the Prostate SO PROSTATE LA English DT Article DE prostate cancer; metformin; AMPK; insulin signaling; veterans affairs ID ACTIVATED PROTEIN-KINASE; CANCER-SPECIFIC MORTALITY; BREAST-CANCER; RADICAL PROSTATECTOMY; DIABETIC-PATIENTS; LUNG-CANCER; RISK; INSULIN; MEN; SURVIVAL AB BACKGROUND. Metformin has received considerable attention as a potential anti-cancer agent. Animal and in-vitro prostate cancer (PCa) models have demonstrated decreased tumor growth with metformin, however the precise mechanisms are unknown. We examine the effects of metformin on PCa biochemical recurrence (BCR) in a large clinical database followed by evaluating metabolic signaling changes in a cohort of men undergoing prostate needle biopsy (PNB). METHODS. Men treated for localized PCa were identified in a comprehensive clinical database between 2001 and 2010. Cox regression was performed to determine association with BCR relative to metformin use. We next identified a separate case-control cohort of men undergoing prostate needle biopsy (PNB) stratified by metformin use. Differences in mean IHC scores were compared with linear regression for phosphorylated IR, IGF-IR, AKT, and AMPK. RESULTS. One thousand seven hundred and thirty four men were evaluated for BCR with mean follow up of 41 months (range 1-121 months). "Ever" metformin use was not associated with BCR (HR 1.12, 0.77-1.65), however men reporting both pre/post-treatment metformin use had a 45% reduction in BCR (HR = 0.55 (0.31-0.96)). For the tissue-based study, 48 metformin users and 42 controls underwent PNB. Significantly greater staining in phosphorylated nuclear (p-IR, p-AKT) and cytoplasmic (p-IR, p-IGF-1R) insulin signaling proteins were seen in patients with PCa detected compared to those with negative PNB (P-values all <0.006). When stratified by metformin use, IGF-1R remained significantly elevated (P = 0.01) in men with PCa detected whereas p-AMPK (P = 0.05) was elevated only in those without PCa. CONCLUSION. Metformin use is associated with reduced BCR after treatment of localized PCa when considering pre-diagnostic and cumulative dosing. In men with cancer detected on PNB, insulin signaling markers were significantly elevated compared to negative PNB patients. The finding of IGF-1R elevation in positive PNBs versus p-AMPK elevation in negative PNBs suggests altered metabolic pathway activation precipitated by metformin use. Prostate 75: 1694-1703, 2015. (C) 2015 Wiley Periodicals, Inc. C1 [Winters, Brian; Holt, Sarah; Zhang, Xiaotun; Lin, Daniel W.; Morrissey, Colm; Wooldridge, Bryan; Gore, John L.; Porter, Michael P.; Wright, Jonathan L.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Plymate, Stephen] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Plymate, Stephen; Zeliadt, Steven B.; Hu, Elaine] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Plymate, Stephen; Zeliadt, Steven B.; Hu, Elaine] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Zeliadt, Steven B.; Lin, Daniel W.; Wright, Jonathan L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Winters, B (reprint author), Univ Washington, Sch Med, Dept Urol, 1959 NE Pacific,Box 356510, Seattle, WA 98195 USA. EM wintersb@uw.edu FU National Cancer Institute [P50CA097186]; Fred Hutchinson Cancer Research Center FX Grant sponsor: National Cancer Institute; Grant number: P50CA097186; Grant sponsor: Fred Hutchinson Cancer Research Center. NR 45 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD NOV 1 PY 2015 VL 75 IS 15 BP 1694 EP 1703 DI 10.1002/pros.23049 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA CU0PJ UT WOS:000363219200003 PM 26201966 ER PT J AU Bejjani, C Snow, AL Judge, KS Bass, DM Morgan, RO Wilson, N Walder, A Looman, WJ McCarthy, C Kunik, ME AF Bejjani, Carla Snow, A. Lynn Judge, Katherine S. Bass, David M. Morgan, Robert O. Wilson, Nancy Walder, Annette Looman, Wendy J. McCarthy, Catherine Kunik, Mark E. TI Characteristics of Depressed Caregivers of Veterans With Dementia SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE caregiver; depression; veterans; dementia; elders ID ALZHEIMER-DISEASE PATIENTS; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; SELF-EFFICACY; MENTAL-HEALTH; SYMPTOMS; CARE; PREVALENCE; STRESS; COMMUNITY AB This study examined the characteristics of caregivers and persons with dementia (PWD) to determine their association with caregiver depression. Participants included 508 PWD (veterans) and 486 caregivers from Boston, Houston, Providence, Beaumont (Texas), and Oklahoma City, identified from diagnoses from medical records and recruited from February 2007 to July 2009, for a larger study evaluating Partners in Dementia Care, a care-coordination intervention. Characteristics evaluated for PWD included activities of daily living, instrumental activities of daily living, cognitive impairment, and disruptive behavior. Caregiver characteristics evaluated included caregiver unmet needs, support-service use, and number of informal helpers. Caregiver depression was measured using the Iowa form 11-item Center for Epidemiologic Studies Depression Scale. Depressed caregivers reported significantly more unmet needs than the nondepressed caregivers. Depressed caregivers also reported a high frequency of disruptive behavior in their PWD. Caregiver perceptions of unmet needs may be an important target for intervention. C1 [Bejjani, Carla; Wilson, Nancy; Walder, Annette; Kunik, Mark E.] Michael E DeBakey VA Med Ctr 152, VA HSR&D Houston Ctr Excellence, Houston, TX 77030 USA. [Bejjani, Carla] Baylor Coll Med, Houston, TX 77030 USA. [Snow, A. Lynn] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL USA. [Snow, A. Lynn] Tuscaloosa VA Med Ctr, Res & Dev Serv, Tuscaloosa, AL USA. [Judge, Katherine S.] Cleveland State Univ, Dept Psychol, Cleveland, OH 44115 USA. [Judge, Katherine S.; Bass, David M.; McCarthy, Catherine; Kunik, Mark E.] Benjamin Rose Inst Aging, Margaret Blenkner Res Inst, Cleveland, OH USA. [Morgan, Robert O.] Univ Texas Houston, Sch Publ Hlth, Dept Management Policy & Community Hlth, Houston, TX USA. [Wilson, Nancy] Baylor Coll Med, Dept Internal Med, Sect Geriatr, Houston, TX 77030 USA. [Walder, Annette] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Kunik, Mark E.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kunik, Mark E.] Educ & Clin Ctr, VA South Cent Mental Illness Res, Houston, TX USA. RP Kunik, ME (reprint author), Michael E DeBakey VA Med Ctr 152, VA HSR&D Houston Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mkunik@bcm.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, Washington, D.C. [IIR 04-238-3]; Alzheimer's Association [IIRG-08-89058]; Robert Wood Johnson Foundation [57816]; VA HSR&D Houston Center of Excellence [HFP90-020]; Michael E. DeBakey VA Medical Center, Houston, TX FX The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Grant No. IIR 04-238-3 from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, Washington, D.C.; Grant No. IIRG-08-89058 from the Alzheimer's Association; and Grant #57816 from the Robert Wood Johnson Foundation. It was also supported in part by the resources and facilities of the VA HSR&D Houston Center of Excellence (HFP90-020), Michael E. DeBakey VA Medical Center, Houston, TX. NR 52 TC 0 Z9 0 U1 3 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD NOV PY 2015 VL 30 IS 7 BP 672 EP 678 DI 10.1177/1533317512461555 PG 7 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA CT7KZ UT WOS:000362994900003 PM 23070578 ER PT J AU Cohen, BE Edmondson, D Kronish, IM AF Cohen, Beth E. Edmondson, Donald Kronish, Ian M. TI State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Review DE anxiety disorders; blood pressure; cardiovascular disease; coronary heart disease; depression; hypertension; PTSD; stress ID CORONARY-HEART-DISEASE; RANDOMIZED-CONTROLLED-TRIAL; INDUCED MYOCARDIAL-ISCHEMIA; COMORBIDITY SURVEY REPLICATION; LONG-TERM OUTCOMES; FOLLOW-UP; SECONDARY PREVENTION; COLLABORATIVE CARE; BLOOD-PRESSURE; RISK-FACTOR AB The notion that psychological states can influence physical health is hardly new, and perhaps nowhere has the mind-body connection been better studied than in cardiovascular disease (CVD). Recently, large prospective epidemiologic studies and smaller basic science studies have firmly established a connection between CVD and several psychological conditions, including depression, chronic psychological stress, posttraumatic stress disorder (PTSD), and anxiety. In addition, numerous clinical trials have been conducted to attempt to prevent or lessen the impact of these conditions on cardiovascular health. In this article, we review studies connecting depression, stress/PTSD, and anxiety to CVD, focusing on findings from the last 5 years. For each mental health condition, we first examine the epidemiologic evidence establishing a link with CVD. We then describe studies of potential underlying mechanisms and finally discuss treatment trials and directions for future research. C1 [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Cohen, Beth E.] San Francisco VA Med Ctr, Gen Internal Med, San Francisco, CA USA. [Edmondson, Donald; Kronish, Ian M.] Columbia Univ, Dept Med, Med Ctr, Ctr Behav Cardiovasc Hlth, New York, NY USA. RP Cohen, BE (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM beth.cohen@ucsf.edu RI Edmondson, Donald/G-7486-2016 FU National Heart, Lung, and Blood Institute (NHLBI) [K23 HL 094765]; American Heart Association; NHLBI [K23 HL098359, R01 HL117832]; National Center for Advancing Translational Sciences [UL1 TR000040] FX Dr B.E.C. received support from the National Heart, Lung, and Blood Institute (NHLBI) (K23 HL 094765) and the American Heart Association. Dr I.M.K. received support from the NHLBI (K23 HL098359) and from the National Center for Advancing Translational Sciences (UL1 TR000040), and Dr D.E. received support from the NHLBI (R01 HL117832). The funding sources did not have any role in the preparation of the manuscript. NR 89 TC 18 Z9 19 U1 11 U2 59 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD NOV PY 2015 VL 28 IS 11 BP 1295 EP 1302 DI 10.1093/ajh/hpv047 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CT5HV UT WOS:000362840500001 PM 25911639 ER PT J AU Jones, BE Jones, MM Huttner, B Stoddard, G Brown, KA Stevens, VW Greene, T Sauer, B Madaras-Kelly, K Rubin, M Goetz, MB Samore, M AF Jones, Barbara E. Jones, Makoto M. Huttner, Benedikt Stoddard, Gregory Brown, Kevin Antoine Stevens, Vanessa W. Greene, Tom Sauer, Brian Madaras-Kelly, Karl Rubin, Michael Goetz, Matthew Bidwell Samore, Matthew TI Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE pneumonia; antibiotic use; HCAP; nosocomial pathogens; drug-resistant pneumonia ID CARE-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT PATHOGENS; RISK-FACTORS; HEALTH; THERAPY; INFECTIONS; OUTCOMES; ASSOCIATION; MORTALITY AB Background. In 2005, pneumonia practice guidelines recommended broad-spectrum antibiotics for patients with risk factors for nosocomial pathogens. The impact of these recommendations on the ability of providers to match treatment with nosocomial pathogens is unknown. Methods. Among hospitalizations with a principal diagnosis of pneumonia at 128 Department of Veterans Affairs medical centers from 2006 through 2010, we measured annual trends in antibiotic selection; initial blood or respiratory cultures positive for methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter species; and alignment between antibiotic coverage and culture results for MRSA and P. aeruginosa, calculating sensitivity, specificity, and diagnostic odds ratio using a 2 x 2 contingency table. Results. In 95 511 hospitalizations for pneumonia, initial use of vancomycin increased from 16% in 2006 to 31% in 2010, and piperacillin-tazobactam increased from 16% to 27%, and there was a decrease in both ceftriaxone (from 39% to 33%) and azithromycin (change from 39% to 36%) (P < .001 for all). The proportion of hospitalizations with cultures positive for MRSA decreased (from 2.5% to 2.0%; P < .001); no change was seen for P. aeruginosa (1.9% to 2.0%; P = .14) or Acinetobacter spp. (0.2% to 0.2%; P = .17). For both MRSA and P. aeruginosa, sensitivity increased (from 46% to 65% and 54% to 63%, respectively; P < .001) and specificity decreased (from 85% to 69% and 76% to 68%; P < .001), with no significant changes in diagnostic odds ratio (decreases from 4.6 to 4.1 [P = .57] and 3.7 to 3.2 [P = .95], respectively). Conclusions. Between 2006 and 2010, we found a substantial increase in the use of broad-spectrum antibiotics for pneumonia despite no increase in nosocomial pathogens. The ability of providers to accurately match antibiotic coverage to nosocomial pathogens remains low. C1 [Jones, Barbara E.] SLC VA Hlth Syst & Univ Utah, Div Pulm & Crit Care Med, Coll Pharm, Salt Lake City, UT 84132 USA. [Jones, Makoto M.; Sauer, Brian; Rubin, Michael; Samore, Matthew] SLC VA Hlth Syst & Univ Utah, Div Epidemiol, Coll Pharm, Salt Lake City, UT 84132 USA. [Jones, Makoto M.] SLC VA Hlth Syst & Univ Utah, Div Infect Dis, Coll Pharm, Salt Lake City, UT 84132 USA. [Stevens, Vanessa W.] SLC VA Hlth Syst & Univ Utah, Pharmacotherapy Outcomes Res Ctr, Coll Pharm, Salt Lake City, UT 84132 USA. [Brown, Kevin Antoine] Univ Utah, Salt Lake City VA Hlth Syst, Salt Lake City, UT USA. [Stoddard, Gregory; Greene, Tom] Univ Utah, Div Epidemiol, Salt Lake City, UT USA. [Madaras-Kelly, Karl] Boise VA Med Ctr, Pocatello, ID USA. [Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Pocatello, ID 83209 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, Div Infect Dis, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Huttner, Benedikt] Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland. [Huttner, Benedikt] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland. RP Jones, BE (reprint author), SLC VA Hlth Syst & Univ Utah, Div Pulm & Crit Care Med, 30N 1900 E 701 Wintrobe, Salt Lake City, UT 84132 USA. EM barbara.jones@hsc.utah.edu RI Huttner, Benedikt/M-5616-2014 OI Huttner, Benedikt/0000-0002-1749-9464; Goetz, Matthew/0000-0003-4542-992X; Stevens, Vanessa/0000-0001-8933-5453; Brown, Kevin Antoine/0000-0002-1483-2188 FU National Institutes of Health FX This work was supported by the National Institutes of Health (training grant to B. E. J.). NR 35 TC 8 Z9 8 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1403 EP 1410 DI 10.1093/cid/civ629 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000008 PM 26223995 ER PT J AU Labreche, MJ Graber, CJ Nguyen, HM AF Labreche, Matthew J. Graber, Christopher J. Nguyen, Hien M. TI Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE pharmacokinetics; pharmacodynamics; breakpoints; susceptibility testing ID LACTAMASE-PRODUCING ENTEROBACTERIACEAE; INFECTIOUS-DISEASES SOCIETY; MONTE-CARLO-SIMULATION; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; EXTENDED-SPECTRUM; INTERPRETIVE CRITERIA; ORAL CEPHALOSPORINS; TRACT-INFECTIONS; CRITICALLY-ILL AB Given current challenges in antimicrobial resistance and drug development, infectious diseases clinicians must rely on their own ingenuity to effectively treat infections while preserving the current antimicrobial armamentarium. An understanding of pharmacokinetics (PK), pharmacodynamics (PD), antimicrobial susceptibility testing (AST), and how these concepts relate, is essential to this task. In this review, we discuss how and why PK-PD impacts AST and the way infectious diseases are being treated, with a particular focus on vancomycin for methicillin-resistant Staphylococcus aureus, penicillin for Streptococcus pneumoniae, and an update on cephalosporins for Enterobacteriaceae. Finally, we address how new ideas to exploit PK-PD can promote innovative study design and bring about more rapid regulatory review of new antimicrobials. C1 [Labreche, Matthew J.; Nguyen, Hien M.] Kaiser Permanente Northwest, Portland, OR USA. [Graber, Christopher J.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Nguyen, HM (reprint author), 9900 SE Sunnyside Rd, Clackamas, OR 97015 USA. EM hien.m.nguyen@kp.org NR 49 TC 4 Z9 4 U1 2 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1446 EP 1452 DI 10.1093/cid/civ498 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000016 PM 26105168 ER PT J AU Garrison, LE Lucas, CE Demirjian, A Sonel, AF Hicks, LA AF Garrison, Laurel E. Lucas, Claressa E. Demirjian, Alicia Sonel, Ali F. Hicks, Lauri A. TI The Case for Routine Environmental Testing for Legionella Bacteria in Healthcare Facility Water Distribution Systems-Reconciling CDC Position and Guidance Regarding Risk Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Garrison, Laurel E.; Lucas, Claressa E.; Demirjian, Alicia; Hicks, Lauri A.] Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA. [Demirjian, Alicia] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Sonel, Ali F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sonel, Ali F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Garrison, LE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30329 USA. EM lee5@cdc.gov NR 2 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1488 EP 1488 DI 10.1093/cid/civ591 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000022 PM 26195018 ER PT J AU Deng, LQ Bensing, B Yang, WM Li, RH Ware, J Varki, A Sullam, P Zhang, H AF Deng, Lingquan Bensing, Barbara Yang, Weiming Li, Renhao Ware, Jerry Varki, Ajit Sullam, Paul Zhang, Hui TI Evaluating interactions between bacterial SRR adhesins and human platelet glycoprotein GPIba by glycoproteomics approaches SO GLYCOBIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences CY DEC 01-04, 2015 CL San Francisco, CA SP Soc Glycobiol C1 [Deng, Lingquan; Yang, Weiming; Zhang, Hui] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA. [Bensing, Barbara; Sullam, Paul] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Bensing, Barbara; Sullam, Paul] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Li, Renhao] Emory Univ, Sch Med, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA. [Ware, Jerry] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA. [Varki, Ajit] Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, San Diego, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0959-6658 EI 1460-2423 J9 GLYCOBIOLOGY JI Glycobiology PD NOV PY 2015 VL 25 IS 11 MA 61 BP 1247 EP 1247 PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CT7JR UT WOS:000362991500055 ER PT J AU Dumit, NY Abboud, S Massouh, A Magilvy, JK AF Dumit, Nuhad Y. Abboud, Sarah Massouh, Angela Magilvy, Joan K. TI Role of the Lebanese family caregivers in cardiac self-care: acollective approach SO JOURNAL OF CLINICAL NURSING LA English DT Article DE collective care; emotional role; family caregiver's role; family obligation; informational role; instrumental role; interdependent self-care; self-care perception; supportive role ID HEART-FAILURE; SOCIAL SUPPORT; MYOCARDIAL-INFARCTION; DISEASE; PATIENT; HEALTH; GUIDELINE; ADHERENCE; LIFE AB Aims and objectivesThe purpose of this study was to explore perceptions of cardiac self-care among Lebanese family caregivers of cardiac patients. The specific aims were to describe the cultural context of cardiac care-giving in Lebanon and to explore the roles of family caregivers in enhancing self-care practices in patients with cardiac diseases. BackgroundThe role of family caregivers in Lebanon, a country in the Middle East, is assumed to extend beyond care-giving to making decisions on behalf of the patient and assuming responsibility for patient care. To date, there has been no study done to empirically validate this impression. DesignThe design of the study is qualitative descriptive that used semi-structured individual interviews with family caregivers of Lebanese cardiac patients. MethodThirteen family caregivers of cardiac patients were recruited from a referral medical centre in Lebanon. The participants were designated by their patients and interviewed in a place of their choice. ResultsOne overarching and three themes emerged from data analysis describing roles of family care givers in cardiac self-care. The overarching theme was: Family caregivers of Lebanese cardiac patients were unfamiliar with the term, concept and meaning of Self-Care. The moral and emotional duty to care for the family member stemmed from obligation and responsibility towards patients (theme I). Interdependent care (theme II) between cardiac patients and their families emerged as a significant cultural role. Family members play multiple supportive roles in care-giving namely emotional, informational and instrumental role (theme III). ConclusionIn this study, family caregiver role is shown to be based in the sense of obligation and duty towards the sick family member who collectively provide different types of supportive care. Relevance to clinical practiceNurses have to give significant importance to the family caregiver role as an integral part of any culturally sensitive patient/family intervention. C1 [Dumit, Nuhad Y.; Massouh, Angela] Amer Univ Beirut, Sch Nursing, Continuing Educ, Beirut, Lebanon. [Abboud, Sarah] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Abboud, Sarah] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Magilvy, Joan K.] Univ Colorado Denver, Coll Nursing, Aurora, CO USA. RP Dumit, NY (reprint author), Amer Univ Beirut, Sch Nursing, Continuing Educ, Riad El Solh 1107 2020, Beirut, Lebanon. EM ny00@aub.edu.lb FU NINR NIH HHS [T32 NR007100] NR 36 TC 1 Z9 1 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1067 EI 1365-2702 J9 J CLIN NURS JI J. Clin. Nurs. PD NOV PY 2015 VL 24 IS 21-22 BP 3318 EP 3326 DI 10.1111/jocn.12949 PG 9 WC Nursing SC Nursing GA CT6FF UT WOS:000362907300029 PM 26249817 ER PT J AU Williams, PD Piamjariyakul, U Shanberg, R Williams, AR AF Williams, Phoebe D. Piamjariyakul, Ubolrat Shanberg, Rachel Williams, Arthur R. TI Monitoring and Alleviation of Symptom Occurrence and Severity Among Thai Children and Adolescents During Cancer Treatments SO JOURNAL OF PEDIATRIC ONCOLOGY NURSING LA English DT Article DE pediatric cancer treatments; symptom monitoring and alleviation; Therapy-Related Symptom Checklist for Children; TRSC-C; parental care; complementary care; culture ID THERAPY-RELATED SYMPTOMS; QUALITY-OF-LIFE; PEDIATRIC ONCOLOGY PATIENTS; SELF-CARE; CHRONIC ILLNESS; SIBLINGS; SCALE; INTERVENTION; PERFORMANCE; DISABILITY AB Background: Symptom monitoring and alleviation are important during pediatric cancer treatments. Aims: To examine the use of the Therapy-Related Symptom Checklist for Children (TRSC-C; Thai version) for reported occurrence, severity, and management of treatment-related symptoms within a cohort of Thai pediatric oncology patients/parents Method: Cross-sectional study; convenience sample: 100 parents of 71 male children/29 females, 63% with leukemia, 37%, other diagnoses; age-groups: <5 years, n = 33; 5 to 11 years, n = 44; 12 to 17 years, n = 25. Parents reported children's symptom occurrence/severity on the TRSC-C; and complementary care methods on the Symptom Alleviation: Self-Care Methods and their symptom alleviation methods. All tools had good psychometric properties. Results: 18 symptoms on the 30-item TRSC-C occurred in 42% to 95% of children. Mean severity of symptoms was between 1.0 (a bit) and 2.0 (quite a bit); 5-month to 11-year-old children had higher (worse) TRSC-C total scores. Complementary care was used and reported. Conclusions: Monitoring of multiple symptoms with the TRSC-C and parental symptom alleviation helped children. Clinical Implications: Thai parents/patients need and accept assistance in monitoring/managing side effects of pediatric cancer therapy. C1 [Williams, Phoebe D.; Piamjariyakul, Ubolrat] Univ Kansas, Med Ctr, Kansas City, KS 66160 USA. [Shanberg, Rachel] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA. [Williams, Arthur R.] James A Haley Vet Affairs Med Ctr, US Dept Vet Affairs, CINDRR, Tampa, FL USA. [Williams, Arthur R.] George Mason Univ, Hlth Care Res & Policy, Hlth Adm & Policy, Washington, DC USA. RP Williams, PD (reprint author), Univ Kansas, Med Ctr, Sch Nursing, 3905 Rainbow Blvd,Mail Stop 4043, Kansas City, KS 66160 USA. EM pwilliam@kumc.edu NR 53 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1043-4542 EI 1532-8457 J9 J PEDIATR ONCOL NURS JI J. Pediatr. Oncol. Nurs. PD NOV-DEC PY 2015 VL 32 IS 6 BP 417 EP 428 DI 10.1177/1043454214563754 PG 12 WC Oncology; Nursing SC Oncology; Nursing GA CT7JV UT WOS:000362991900008 PM 25616370 ER PT J AU Wu, JX Arcega, R Donahue, TR Tomlinson, JS Reber, HA Hines, J AF Wu, James X. Arcega, Ramir Donahue, Timothy R. Tomlinson, James S. Reber, Howard A. Hines, Joe TI Pancreatic Oncocytic Intraductal Papillary Mucinous Neoplasms: Three Case Reports and Review of Cases in Literature SO JOURNAL OF THE PANCREAS LA English DT Review DE Oncocytic Intraductal Papillary Mucinous Neoplasm; Intraductal Oncocytic Papillary Neoplasm ID JUICE CYTOLOGY; INVASIVE-CARCINOMA; IPMN; MANAGEMENT; SUBTYPE; MUTATIONS; GNAS AB Objectives Oncocytic intraductal papillary mucinous neoplasias represent a rare morphological subtype of intraductal papillary mucinous neoplasias, accounting for 1-8% of cases. Our aim was to characterize clinical factors associated with oncocytic intraductal papillary mucinous neoplasias, and factors that may predict invasive carcinoma. Methods Patient data for three consecutive cases of oncocytic intraductal papillary mucinous neoplasia were abstracted from electronic medical records. Literature search was performed using Pubmed and Google Scholar search engines using the keywords, "oncocytic intraductal papillary mucinous neoplasm," "oncocytic intraductal papillary mucinous neoplasia," "intraductal oncocytic papillary neoplasm," and "intraductal oncocytic papillary neoplasms." Studies that reported age, gender, invasiveness, and main versus branch duct involvement were included. Results We detailed three case reports and identified 77 previously published cases of oncocytic intraductal papillary mucinous neoplasia. The mean age at diagnosis was 61.6 years. There was a significant association of oncocytic intraductal papillary mucinous neoplasias with male gender (P= 0.03), but not with main/mixed versus branch duct involvement (P= 0.053). Invasive carcinoma was observed in 55.8% of oncocytic intraductal papillary mucinous neoplasias. In a subgroup of patients that underwent KRAS mutation testing (N= 25), 7(28%) harbored a KRAS mutation; KRAS mutation did not predict presence of invasive carcinoma (P= 1.00). Conclusions Clinical factors or KRAS mutation testing cannot currently predict the malignant potential of oncocytic intraductal papillary mucinous neoplasias. Management of oncocytic intraductal papillary mucinous neoplasias should still be based upon macroscopic criteria. C1 [Wu, James X.; Donahue, Timothy R.; Tomlinson, James S.; Reber, Howard A.; Hines, Joe] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Arcega, Ramir] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Donahue, Timothy R.; Tomlinson, James S.; Reber, Howard A.; Hines, Joe] Univ Calif Los Angeles, Ctr Pancreat Dis, Los Angeles, CA USA. [Tomlinson, James S.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Wu, JX (reprint author), Dept Surg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM JamesWu@mednet.ucla.ed NR 37 TC 0 Z9 0 U1 0 U2 0 PU E S BURIONI RICERCHE BIBLIOGRAFICHE PI GENOVA PA CORSO FIRENZE 41-2, GENOVA, 16136, ITALY SN 1590-8577 J9 J PANCREAS JI J. Pancreas PD NOV PY 2015 VL 16 IS 6 BP 626 EP 632 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY6KS UT WOS:000385225400020 ER PT J AU Clynes, MA Edwards, MH Buehring, B Dennison, EM Binkley, N Cooper, C AF Clynes, M. A. Edwards, M. H. Buehring, B. Dennison, E. M. Binkley, N. Cooper, C. TI Definitions of Sarcopenia: Associations with Previous Falls and Fracture in a Population Sample SO CALCIFIED TISSUE INTERNATIONAL LA English DT Article DE Epidemiology; Sarcopenia; Dysmobility; Falls; Fractures ID EUROPEAN WORKING GROUP; HERTFORDSHIRE COHORT; OLDER-ADULTS; GAIT SPEED; PREVALENCE; STRENGTH; WOMEN; OSTEOPOROSIS; PEOPLE; EWGSOP AB Sarcopenia is common in later life and may be associated with adverse health outcomes such as disability, falls and fracture. There is no consensus definition for its diagnosis although diagnostic algorithms have been proposed by the European Working Group for Sarcopenia in Older People (EWGSOP), the International Working Group on Sarcopenia (IWGS) and the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). More recently, Binkley and colleagues devised a score-based system for the diagnosis of "dysmobility syndrome" in an attempt to combine adverse musculoskeletal phenotypes, including sarcopenia and osteoporosis, in order to identify older individuals at particular risk. We applied these criteria to participants from the Hertfordshire Cohort Study to define their prevalence in an unselected cohort of UK community-dwelling older adults and assess their relationships with previous falls and fracture. Body composition and areal bone mineral density were measured using dual-energy X-ray absorptiometry, gait speed was determined by a 3-m walk test and grip strength was assessed with a Jamar hand-held dynamometer. Researcher-administered questionnaires were completed detailing falls and fracture history. The prevalence of sarcopenia in this cohort was 3.3, 8.3 and 2.0 % using the EWGSOP, IWGS and related definition of FNIH, respectively; 24.8 % of individuals had dysmobility syndrome. Individuals with dysmobility reported significantly higher number of falls (last year and since the age of 45 years) (p < 0.01) than those without it, but no increased fracture rate was observed in this group (p = 0.96). Those with sarcopenia as defined by the IWGS reported significantly higher falls in the last year and prevalent fractures (falls in the last year: OR 2.51; CI 1.09-5.81; p = 0.03; fractures OR 2.50; CI 1.05-5.92; p = 0.04) but these significant associations were not seen when the EWGSOP definition was applied. The IWGS definition of sarcopenia appears to be an effective means of identifying individuals at risk of prevalent adverse musculoskeletal events. C1 [Clynes, M. A.; Edwards, M. H.; Dennison, E. M.; Cooper, C.] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England. [Buehring, B.; Binkley, N.] Univ Wisconsin, Osteoporosis Res Program, Div Geriatr & Gerontol, Dept Med,Sch Med & Publ Hlth, Madison, WI 53705 USA. [Buehring, B.; Binkley, N.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Dennison, E. M.] Victoria Univ, Wellington, New Zealand. [Cooper, C.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, NIHR Musculoskeletal Biomed Res Unit, Oxford OX3 5UG, England. [Cooper, C.] Univ Southampton, NIHR Nutr Biomed Res Ctr, Southampton SO16 6YD, Hants, England. [Cooper, C.] Univ Hosp Southampton NHS Trust, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England. RP Cooper, C (reprint author), Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England. EM cc@mrc.soton.ac.uk RI Buehring, Bjoern/L-5581-2013 OI Buehring, Bjoern/0000-0003-3841-624X FU Medical Research Council of Great Britain; Arthritis Research UK; International Osteoporosis Foundation; NIHR Nutrition BRC, University of Southampton; NIHR Musculoskeletal BRU, University of Oxford; University of Southampton National Institute of Health FX The Hertfordshire Cohort Study was supported by the Medical Research Council of Great Britain; Arthritis Research UK and the International Osteoporosis Foundation. The work herein was also supported by the NIHR Nutrition BRC, University of Southampton and the NIHR Musculoskeletal BRU, University of Oxford. We thank all of the men and women who took part in the Hertfordshire Cohort Study; the HCS Research Staff and Vanessa Cox who managed the data. Michael Clynes was supported by the University of Southampton National Institute of Health. NR 29 TC 12 Z9 12 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0171-967X EI 1432-0827 J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PD NOV PY 2015 VL 97 IS 5 BP 445 EP 452 DI 10.1007/s00223-015-0044-z PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CT1SB UT WOS:000362580000003 PM 26223791 ER PT J AU Fu, Y Rope, R Fargue, S Cohen, HT Holmes, RP Cohen, DM AF Fu, Y. Rope, R. Fargue, S. Cohen, H. T. Holmes, R. P. Cohen, D. M. TI A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5UTR causing primary hyperoxaluria type II SO CLINICAL GENETICS LA English DT Article DE hyperoxaluria; mutation; translation; human ID IMPERFECTA TYPE-V; REDUCTASE GRHPR; GENE; 5'-UTR; CELLS; CODON AB Primary hyperoxaluria type II is a recessive genetic disorder caused by mutations in the GRHPR gene. Although several dozen mutations have been described, all affect coding or transcript splicing. A man suspected of having primary hyperoxaluria type II was heterozygous for a novel single-nucleotide deletion (c.694delC) in GRHPR affecting Gln(232), which introduced a pre-mature termination (p.Gln232Argfs*3). Two 5untranslated region (UTR) variants of unknown significance were also noted. We show that these two variants occur in cis, on the opposite allele, and introduce-immediately upstream of the canonical translation initiation site-a novel out-of-frame translational start site. In vitro studies using the GRHPR 5UTR fused to a luciferase reporter show that the variant start site pre-empted initiation at the canonical translational start site, and this was corroborated within the broader context of 1.3kb of the GRHPR proximal promoter. This latter mechanism may be underappreciated in general; reports of clinically significant functional variation of this type are extremely rare. C1 [Fu, Y.; Rope, R.; Cohen, D. M.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Fu, Y.; Rope, R.; Cohen, D. M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Fargue, S.; Holmes, R. P.] Univ Alabama Birmingham, Sch Med, Dept Urol, Birmingham, AL 35294 USA. [Cohen, H. T.] Boston Univ, Sch Med, Renal Sect, Boston, MA 02118 USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Mailcode CH12R,3303 SW Bond Ave, Portland, OR 97239 USA. EM cohend@ohsu.edu OI Fargue, sonia/0000-0001-7451-7481 FU National Institutes of Health; Department of Veterans Affairs FX This project was supported by the National Institutes of Health and by the Department of Veterans Affairs. NR 15 TC 1 Z9 2 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9163 EI 1399-0004 J9 CLIN GENET JI Clin. Genet. PD NOV PY 2015 VL 88 IS 5 BP 494 EP 498 DI 10.1111/cge.12541 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA CT3BW UT WOS:000362682200014 PM 25410531 ER PT J AU Semenyuk, EG Poroyko, VA Johnston, PF Jones, SE Knight, KL Gerding, DN Driks, A AF Semenyuk, Ekaterina G. Poroyko, Valeriy A. Johnston, Pehga F. Jones, Sara E. Knight, Katherine L. Gerding, Dale N. Driks, Adam TI Analysis of Bacterial Communities during Clostridium difficile Infection in the Mouse SO INFECTION AND IMMUNITY LA English DT Article ID IN-SITU HYBRIDIZATION; OLIGONUCLEOTIDE PROBES; GASTROINTESTINAL-TRACT; INTESTINAL MICROBIOTA; GUT MICROBIOTA; DIARRHEA; DISEASE; HOST; ESTABLISHMENT; COLONIZATION AB Clostridium difficile infection (CDI) is a major cause of health care-associated disease. CDI initiates with ingestion of C. difficile spores, germination in the gastrointestinal (GI) tract, and then colonization of the large intestine. The interactions between C. difficile cells and other bacteria and with host mucosa during CDI remain poorly understood. Here, we addressed the hypothesis that, in a mouse model of CDI, C. difficile resides in multicellular communities (biofilms) in association with host mucosa. To do this, we paraffin embedded and then sectioned the GI tracts of infected mice at various days postinfection (p.i.). We then used fluorescent in situ hybridization (FISH) with 16S rRNA probes targeting most bacteria as well as C. difficile specifically. The results revealed that C. difficile is present as a minority member of communities in the outer (loose) mucus layer, in the cecum and colon, starting at day 1 p.i. To generate FISH probes that identify bacteria within mucus-associated communities harboring C. difficile, we characterized bacterial populations in the infected mouse GI tract using 16S rRNA gene sequence analysis of bacterial DNA prepared from intestinal content. This analysis revealed the presence of genera of several families belonging to Bacteroidetes and Firmicutes. These data suggest that formation of multispecies communities associated with the mucus of the cecum and colon is an important early step in GI tract colonization. They raise the possibility that other bacterial species in these communities modulate the ability of C. difficile to successfully colonize and, thereby, cause disease. C1 [Semenyuk, Ekaterina G.; Johnston, Pehga F.; Jones, Sara E.; Knight, Katherine L.; Driks, Adam] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA. [Poroyko, Valeriy A.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA. [Johnston, Pehga F.; Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Driks, A (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA. EM adriks@lumc.edu FU Falk Foundation; National Institutes of Health [R21AI097934, NIH 1R21AI099713-01] FX This work was funded by grants from the Falk Foundation and the National Institutes of Health (R21AI097934) to A.D. and was partly funded by a National Institutes of Health grant (NIH 1R21AI099713-01) to V.A.P. NR 46 TC 8 Z9 8 U1 5 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2015 VL 83 IS 11 BP 4383 EP 4391 DI 10.1128/IAI.00145-15 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CT0NU UT WOS:000362494000020 PM 26324536 ER PT J AU Harris, AHS Rubinsky, AD Hoggatt, KJ AF Harris, Alex H. S. Rubinsky, Anna D. Hoggatt, Katherine J. TI Possible Alternatives to Diagnosis-Based Denominators for Addiction Treatment Quality Measures SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Quality measurement; Quality comparisons; Validity; Methodology ID PERFORMANCE; FEASIBILITY; INDICATORS; ALCOHOL AB Consumers of healthcare quality measures are often unaware of how measured performance may be driven by diagnosing practices rather than the provision of high quality care. Reliance on quality metrics that depend on documented diagnoses can therefore subvert comparisons between clinicians, facilities or systems. In this study, three versions of an alcohol use disorder (AUD) treatment quality measure were calculated: method 1 the usual denominator including all diagnosed patients; method 2-a "population-based" denominator including the entire facility census; and method 3 an epidemiologically-derived denominator comprising the expected prevalence of AUD based on case-mix characteristics and geographic region. Performance rankings under the three specifications were calculated. Changes in percentile rank of up to 30-45% were observed between methods. Therefore, much of the observed between-facility differences on diagnosis-based quality measures may reflect variation in the propensity to diagnose rather than real differences in performance. Stakeholders must decide which of the validity threats produced by these different methods is least worrisome. Published by Elsevier Inc. C1 [Harris, Alex H. S.; Rubinsky, Anna D.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat & Subst Use Disorder, Qual Enhancement Res Initiat, Palo Alto, CA USA. [Hoggatt, Katherine J.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Hoggatt, Katherine J.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat & Subst Use Disorder, Qual Enhancement Res Initiat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov FU VA Health Services Research and Development (HSRD) Service [IIR 10-370-2, RCS-14-232]; VA Substance Use Disorder Quality Enhancement Research Initiative [SUDQ-LIP-1208]; VA HSR&D QUERI Career Development Award [CDA 11-261] FX This study was funded by the VA Health Services Research and Development (HSR&D) Service (IIR 10-370-2; RCS-14-232), VA Substance Use Disorder Quality Enhancement Research Initiative (SUDQ-LIP-1208), and a VA HSR&D QUERI Career Development Award (CDA 11-261) to Dr. Hoggatt. None of the authors have any conflict of interest related to this work. The views expressed herein are not necessarily those of the Department of Veterans Affairs. NR 17 TC 3 Z9 3 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV PY 2015 VL 58 BP 62 EP 66 DI 10.1016/j.jsat2015.06.004 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CS8BZ UT WOS:000362312000008 PM 26251046 ER PT J AU Burch, AE Morasco, BJ Petry, NM AF Burch, Ashley E. Morasco, Benjamin J. Petry, Nancy M. TI Patients Undergoing Substance Abuse Treatment and Receiving Financial Assistance for a Physical Disability Respond Well to Contingency Management Treatment SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Substance abuse treatment; Contingency management; Disability ID RESISTANT METHADONE PATIENTS; VOUCHER-BASED REINFORCEMENT; ADDICTION SEVERITY INDEX; RANDOMIZED-TRIAL; COCAINE ABSTINENCE; DISORDERS; PENSION; COHORT; RISK; COMORBIDITY AB Physical illness and disability are common in individuals with substance use disorders, but little is known about the impact of physical disability status on substance use treatment outcomes. This study examined the main and interactive effects of physical disability payment status on substance use treatment. Participants (N = 1,013) were enrolled in one of six prior randomized clinical trials comparing contingency management (CM) to standard care; 79 (7.8%) participants reported receiving disability payments, CM improved all three primary substance use outcomes: treatment retention, percent negative samples and longest duration of abstinence. There was no significant main effect of physical disability payment status on treatment outcomes; however, a significant treatment condition by physical disability status interaction effect emerged in terms of retention in treatment and duration of abstinence achieved. Patients who were receiving physical disability payments responded particularly well to CM, and their time in treatment and durations of drug and alcohol abstinence increased even more markedly with CM than did that of their counterparts who were not receiving physical disability assistance. These findings suggest an objectively defined cohort of patients receiving substance use treatment who respond particularly well to CM. (C) 2015 Elsevier Inc. All rights reserved. C1 [Burch, Ashley E.; Petry, Nancy M.] Univ Connecticut, Sch Med MC 3944, Calhoun Cardiol Ctr, Farmington, CT 06030 USA. [Burch, Ashley E.; Petry, Nancy M.] Univ Connecticut, Sch Med MC 3944, Dept Med, Farmington, CT 06030 USA. [Morasco, Benjamin J.] VA Portland Hlth Care Syst, Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR 97239 USA. [Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. RP Petry, NM (reprint author), Univ Connecticut, Sch Med MC 3944, 263 Farmington Ave, Farmington, CT 06030 USA. EM aburch@uchc.edu; benjamin.morasco@va.gov; npetry@uchc.edu FU NCRR NIH HHS [M01 RR006192]; NIAAA NIH HHS [R01 AA021446, P60 AA003510]; NICHD NIH HHS [R01 HD075630]; NIDA NIH HHS [R01 DA027615, R01 DA013444, P50 DA009241, P30 DA023918, R01 DA018883] NR 43 TC 1 Z9 1 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV PY 2015 VL 58 BP 67 EP 71 DI 10.1016/j.jsat.2015.06.006 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CS8BZ UT WOS:000362312000009 PM 26184649 ER PT J AU Krupski, A Graves, MC Bumgardner, K Roy-Byrne, P AF Krupski, Antoinette Graves, Meredith C. Bumgardner, Kristin Roy-Byrne, Peter TI Comparison of Homeless and Non-Homeless Problem Drug Users Recruited from Primary Care Safety-Net Clinics SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Homeless; Medical service utilization and costs; Arrests; Mental health problems; Primary care ID RISK-FACTORS; RELIABILITY; PREDICTORS; VETERANS; VALIDITY; ADULTS AB Introduction: The present study of homeless non-treatment-seeking problem drug users was designed to complement and extend previous studies which focused exclusively on treatment-seeking homeless problem drug users. Method: Data were available for 866 primary care patients with drug problems, 30% homeless and 70% housed. Results: In the 2 years prior to baseline, homeless participants had less chronic medical co-morbidity than problem drug users who were housed yet were significantly more likely to have used emergency department services, to have used them more frequently, and at higher cost. Compared to their housed counterparts, homeless participants were also more likely to have been admitted to specialized chemical dependency treatment and/or detoxification services, to have been arrested for a felony or gross misdemeanor, and to report having psychiatric problems in the prior 30 days. Conclusions: Additional support may be necessary for homeless patients presenting in primary care to benefit from substance abuse treatment given their more severe drug use problems coupled with their co-morbid health, psychiatric, and psychosocial problems. (C) 2015 Elsevier Inc. All rights reserved. C1 [Krupski, Antoinette; Graves, Meredith C.; Bumgardner, Kristin; Roy-Byrne, Peter] Univ Washington, Dept Psychiat & Behav Sci, Harborview Med Ctr, Seattle, WA 98104 USA. [Graves, Meredith C.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Krupski, A (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Harborview Med Ctr, Box 359911,325 9th Ave, Seattle, WA 98104 USA. EM krupski@uw.edu FU National Institute on Drug Abuse of the National Institutes of Health [R01DA026014] FX Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R01DA026014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 18 TC 0 Z9 0 U1 0 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV PY 2015 VL 58 BP 84 EP 89 DI 10.1016/j.jsat.2015.06.007 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CS8BZ UT WOS:000362312000012 PM 26153073 ER PT J AU Birmingham, P Buffum, MD Blegen, MA Lyndon, A AF Birmingham, Patricia Buffum, Martha D. Blegen, Mary A. Lyndon, Audrey TI Handoffs and Patient Safety: Grasping the Story and Painting a Full Picture SO WESTERN JOURNAL OF NURSING RESEARCH LA English DT Article DE handoff; handover; shift report; continuity of care ID OF-THE-LITERATURE; NURSING HANDOVER; SHIFT HANDOVERS; SURGICAL UNITS; NURSES; CARE; INFORMATION; SETTINGS; WORK; COMMUNICATION AB Effective handoff communication is critical for patient safety. Research is needed to understand how information processes occurring intra-shift impact handoff effectiveness. The purpose of this qualitative study was to examine medical-surgical nurses' (n = 21) perspectives about processes that promote and hinder patient safety intra-shift and during handoff. Results indicated that offgoing nurses' ability to grasp the story intra-shift was essential to convey the full picture during handoff. When oncoming nurses understood the picture being conveyed at the handoff, nurses jointly painted a full picture. Arriving and leaving the handoff with this level of information promoted patient safety. However, intra-shift disruptions often impeded nurses in their processes to grasp the story thus posing risks to patient safety. Improvement efforts need to target the different processes involved in grasping the story and painting a full picture. Future research needs to examine handoff practices and outcomes on units with good and poor practice environments. C1 [Birmingham, Patricia; Buffum, Martha D.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Buffum, Martha D.; Blegen, Mary A.; Lyndon, Audrey] Univ Calif San Francisco, San Francisco, CA USA. RP Birmingham, P (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM Patricia.Birmingham@va.gov FU Alpha Eta Chapter, Sigma Theta Tau International; Department of Veterans Affairs (VA) Medical Center San Francisco; National Centre for Advancing Translational Sciences; National Institutes of Health (NIH) through UCSF-CTSI [KL2TR000143] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The primary investigator received funding for a research award from the Alpha Eta Chapter, Sigma Theta Tau International. This material is a result of work supported by resources from the Department of Veterans Affairs (VA) Medical Center San Francisco. No funding from VA was received for this project. The fourth author received support from the National Centre for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI Grant KL2TR000143. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH. NR 50 TC 1 Z9 1 U1 3 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0193-9459 EI 1552-8456 J9 WESTERN J NURS RES JI West. J. Nurs. Res. PD NOV PY 2015 VL 37 IS 11 BP 1458 EP 1478 DI 10.1177/0193945914539052 PG 21 WC Nursing SC Nursing GA CT3SR UT WOS:000362727700006 PM 24951369 ER PT J AU Hanson, JL Hariri, AR Williamson, DE AF Hanson, Jamie L. Hariri, Ahmad R. Williamson, Douglas E. TI Blunted Ventral Striatum Development in Adolescence Reflects Emotional Neglect and Predicts Depressive Symptoms SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Depression; Early life stress; Emotional neglect; fMRI; Longitudinal; Neurodevelopment ID STRESSFUL LIFE EVENTS; CHILDHOOD MALTREATMENT; MAJOR DEPRESSION; PSYCHIATRIC OUTPATIENTS; AMYGDALA REACTIVITY; SENSITIVE PERIODS; ADULT DEPRESSION; BRAIN ACTIVATION; POSITIVE AFFECT; 1ST ONSET AB BACKGROUND: Emotional neglect is associated with multiple negative outcomes, particularly increased risk for depression. Motivated by increasing evidence of reward-related ventral striatum (VS) dysfunction in depression, we investigated the role of developmental changes in VS activity on the emergence of depressive symptomatology as a function of emotional neglect. METHODS: We examined relationships between longitudinal neuroimaging of reward-related VS activity, assessments of mood, and measures of emotional neglect in 106 participants first scanned between ages 11 to 15 and then 2 years later. RESULTS: We found that greater levels of emotional neglect were associated with blunted development of reward-related VS activity between the first and second assessments (as indexed by lower residualized change scores). Additionally, we found that decreases in this reward-related VS activity were related to greater depressive symptomatology and partially mediated the association between emotional neglect and subsequent depressive symptomatology. CONCLUSIONS: Our results provide an important demonstration that blunted development of reward-related VS activity as a function of emotional neglect predicts the emergence of depressive symptoms in adolescents. Further, our results are consistent with emerging evidence for the importance of reward-related VS dysfunction in the etiology and pathophysiology of depression. These results are a first step toward developing the ability to predict, prevent, and treat stress-related psychopathology through the targeting of specific neural phenotypes. C1 [Hanson, Jamie L.; Hariri, Ahmad R.] Duke Univ, Dept Psychol & Neurosci, Neurogenet Lab, Durham, NC 27710 USA. [Williamson, Douglas E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Williamson, Douglas E.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Hanson, JL (reprint author), Duke Univ, Dept Psychol & Neurosci, 417 Chapel Dr,Duke West Campus, Durham, NC 27710 USA. EM jlh125@duke.edu FU National Institute on Alcohol Abuse and Alcoholism [R01AA016274]; Genetic and Environmental Risk endowment from the Dielmann Family (DEW); National Institute on Drug Abuse [R01DA033369, R01DA031579]; National Institute of Mental Health [MH087493]; National Institute on Drug Abuse through the Center for the Study of Adolescent Risk and Resilience [P30DA023026]; National Institute of Child Health and Human Development through the Center for Developmental Science, University of North Carolina at Chapel Hill [T32HD0737625] FX This work was supported by the National Institute on Alcohol Abuse and Alcoholism (Grant R01AA016274 to DEW), the Genetic and Environmental Risk endowment from the Dielmann Family (DEW), the National Institute on Drug Abuse (Grants R01DA033369 and R01DA031579 to ARH), the National Institute of Mental Health (Grant MH087493 to Consuelo Walss-Bass), a Postdoctoral Fellowship provided by the National Institute on Drug Abuse through the Center for the Study of Adolescent Risk and Resilience (Grant P30DA023026 to JLH), and a postdoctoral fellowship provided by the National Institute of Child Health and Human Development (Grant T32HD0737625) through the Center for Developmental Science, University of North Carolina at Chapel Hill, to JLH. NR 83 TC 20 Z9 20 U1 6 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 1 PY 2015 VL 78 IS 9 BP 598 EP 605 DI 10.1016/j.biopsych.2015.05.010 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CS7OB UT WOS:000362271800004 PM 26092778 ER PT J AU Goedecke, JH Keswell, D Weinreich, C Fan, J Hauksson, J Victor, H Utzschneider, K Levitt, NS Lambert, EV Kahn, SE Olsson, T AF Goedecke, Julia H. Keswell, Dheshnie Weinreich, Carsten Fan, Jia Hauksson, Jon Victor, Hendriena Utzschneider, Kristina Levitt, Naomi S. Lambert, Estelle V. Kahn, Steven E. Olsson, Tommy TI Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women SO DIABETOLOGIA LA English DT Article DE Black African; Ectopic fat; Ethnicity; Euglycaemic-hyperinsulinaemic clamp; Hepatic insulin sensitivity; Liver fat; Peripheral insulin sensitivity; Skeletal muscle lipid ID SKELETAL-MUSCLE; ADIPOSE-TISSUE; RESISTANCE; EXPRESSION AB Aims/hypothesis There is evidence to suggest that ectopic fat deposition in liver and skeletal muscle may differ between black and white women resulting in organ-specific differences in insulin sensitivity. Accordingly, the aim of the study was to examine ethnic differences in hepatic and peripheral insulin sensitivity, and the association with hepatic and skeletal muscle lipid content, and skeletal muscle gene expression. Methods In a cross-sectional study including 30 obese premenopausal black and white women, body composition (dual energy x-ray absorptiometry), liver fat and skeletal muscle (soleus and tibialis anterior) fat accumulation (proton-magnetic resonance spectroscopy), skeletal muscle gene expression, insulin sensitivity (two-step isotope labelled, hyperinsulinaemic-euglycaemic clamp with 10 mU m(-2) min(-1) and 40 mU m(-2) min(-1) insulin infusions), and serum adipokines were measured. Results We found that, although whole-body insulin sensitivity was not different, obese white women presented with lower hepatic insulin sensitivity than black women (% suppression of endogenous glucose production [% supp EGP], median [interquartile range (IQR)]: 17 [5-51] vs 56 [29-100] %, p = 0.002). While liver fat tended to be lower (p = 0.065) and skeletal muscle fat deposition tended to be higher (p = 0.074) in black compared with white women, associations with insulin sensitivity were only observed in black women (% supp EGP vs liver fat: r = -0.57, p < 0.05 and % supp EGP vs soleus fat: r = -0.56, p < 0.05). Conclusions/interpretation These findings may suggest that black women are more sensitive to the effects of ectopic lipid deposition than white women. C1 [Goedecke, Julia H.] South African Med Res Council, Noncommunicable Dis Res Unit, ZA-7505 Tygerberg, South Africa. [Goedecke, Julia H.; Keswell, Dheshnie; Victor, Hendriena; Levitt, Naomi S.; Lambert, Estelle V.] Univ Cape Town, Dept Human Biol, Div Exercise Sci & Sports Med, ZA-7925 Cape Town, South Africa. [Weinreich, Carsten; Levitt, Naomi S.] Univ Cape Town, Dept Med, Div Diabet & Endocrinol, ZA-7925 Cape Town, South Africa. [Fan, Jia] Univ Cape Town, Dept Human Biol, MRC UCT Med Imaging Res Unit, ZA-7925 Cape Town, South Africa. [Hauksson, Jon] Umea Univ Hosp, Ctr Med Technol & Radiat Phys, S-90185 Umea, Sweden. [Utzschneider, Kristina; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Utzschneider, Kristina; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Olsson, Tommy] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Olsson, Tommy] Univ Stellenbosch, Wallenberg Res Ctr, Stellenbosch Inst Adv Study STIAS, ZA-7600 Stellenbosch, South Africa. RP Goedecke, JH (reprint author), South African Med Res Council, Noncommunicable Dis Res Unit, POB 19070, ZA-7505 Tygerberg, South Africa. EM julia.goedecke@mrc.ac.za RI Goedecke, Julia/E-1820-2016 OI Goedecke, Julia/0000-0001-6795-4771; Fan, Jia/0000-0002-0443-5904; Kahn, Steven/0000-0001-7307-9002 FU National Research Foundation of South Africa [73707]; United States Department of Veterans Affairs; Swedish Research Council [K2011-12237-15-6]; Swedish Heart and Lung Foundation; Umea University, Sweden FX This study was funded by the National Research Foundation of South Africa (Grant no. 73707), the United States Department of Veterans Affairs, the Swedish Research Council (K2011-12237-15-6), the Swedish Heart and Lung Foundation and Umea University, Sweden. NR 11 TC 2 Z9 2 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD NOV PY 2015 VL 58 IS 11 BP 2647 EP 2652 DI 10.1007/s00125-015-3720-7 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CS3RR UT WOS:000361993000022 PM 26232099 ER PT J AU Lu, ZY Zhang, XM Li, YC Lopes-Virella, MF Huang, Y AF Lu, Zhongyang Zhang, Xiaoming Li, Yanchun Lopes-Virella, Maria F. Huang, Yan TI TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes SO IMMUNOBIOLOGY LA English DT Article DE Toll-like receptor 4; Atherosclerosis; Inflammation; Diabetes ID LOW-DENSITY-LIPOPROTEIN; TOLL-LIKE RECEPTORS; APOLIPOPROTEIN-E; INNATE IMMUNITY; RHODOPSEUDOMONAS-SPHAEROIDES; RHODOBACTER-SPHAEROIDES; INSULIN-RESISTANCE; KNOCKOUT MICE; ATHEROSCLEROSIS; INFLAMMATION AB Although a large number of studies have well documented a key role of toll-like receptor (TLR)4 in atherosclerosis, it remains undetermined if TLR4 antagonist attenuates atherogenesis in mouse model for type 2 diabetes. In this study, we induced type 2 diabetes in low-density lipoprotein receptor-deficient (LDLR-/-) mice by high-fat diet (HFD). At 8 weeks old, 20 mice were fed HFD and 20 mice fed regular chow (RC) for 24 weeks. In the last 10 weeks, half HFD-fed mice and half RC-fed mice were treated with Rhodobacter sphaeroides lipopolysaccharide (Rs-LPS), an established TLR4 antagonist. After the treatment, atherosclerotic lesions in aortas were analyzed. Results showed that the HFD significantly increased body-weight, glucose, lipids including total cholesterol, triglycerides and free fatty acids, and insulin resistance, indicating that the HFD induced type 2 diabetes in LDLR-/- mice. Results also showed that Rs-LPS had no effect on HFD-increased metabolic parameters in both nondiabetic and diabetic mice. Lipid staining of aortas and histological analysis of cross-sections of aortic roots showed that diabetes increased atherosclerotic lesions, but Rs-LPS attenuated atherogenesis in diabetic mice. Furthermore, immunohistochemical studies showed that Rs-LPS reduced infiltration of monocytes/macrophages and expression of interleukin (IL)-6 and matrix metalloproteinase-9 in atherosclerotic lesions of diabetic mice. Finally, the antagonistic effect of Rs-LPS on TLR4 was demonstrated by our in vitro studies showing that Rs-LPS inhibited IL-6 secretion from macrophages and endothelial cells stimulated by LPS or LPS plus saturated fatty acid palmitate. Taken together, our study demonstrated that TLR4 antagonist was capable of attenuating vascular inflammation and atherogenesis in mice with HFD-induced type 2 diabetes. Published by Elsevier GmbH. C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Lu, Zhongyang; Zhang, Xiaoming; Li, Yanchun; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; NIH [R01 DE016353] FX This work was supported by a Merit Review grant from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs and NIH grant R01 DE016353 (to Y.H.). NR 51 TC 11 Z9 11 U1 0 U2 21 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0171-2985 J9 IMMUNOBIOLOGY JI Immunobiology PD NOV PY 2015 VL 220 IS 11 BP 1246 EP 1254 DI 10.1016/j.imbio.2015.06.016 PG 9 WC Immunology SC Immunology GA CS5TT UT WOS:000362141900007 PM 26162692 ER PT J AU Axon, RN Turner, M Buckley, R AF Axon, R. Neal Turner, Mason Buckley, Ryan TI An Update on Inpatient Hypertension Management SO CURRENT CARDIOLOGY REPORTS LA English DT Review DE Hypertension; Hospitalization; Hypertensive emergency; Cardiovascular disease ID PRESERVED EJECTION FRACTION; DECOMPENSATED HEART-FAILURE; JOINT NATIONAL COMMITTEE; HIGH BLOOD-PRESSURE; ISCHEMIC-STROKE; UNITED-STATES; 7TH REPORT; 1ST YEAR; HOSPITALIZATION; EMERGENCIES AB Hypertension is highly prevalent affecting nearly one third of the US adult population. Though generally approached as an outpatient disorder, elevated blood pressure is observed in a majority of hospitalized patients. The spectrum of hypertensive disease ranges from patients with hypertensive emergency including markedly elevated blood pressure and associated end-organ damage to asymptomatic patients with minimally elevated pressures of unclear significance. It is important to note that current evidence-based hypertension guidelines do not specifically address inpatient hypertension. This narrative review focuses primarily on best practices for diagnosing and managing nonemergent hypertension in the inpatient setting. We describe examples of common hypertensive syndromes, provide suggestions for optimal post-acute management, and point to evidence-based or consensus guidelines where available. In addition, we describe a practical approach to managing asymptomatic elevated blood pressure observed in the inpatient setting. Finally, arranging effective care transitions to ensure optimal ongoing hypertension management is appropriate in all cases. C1 [Axon, R. Neal] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Ralph H Johnson VAMC, Charleston, SC 29401 USA. [Axon, R. Neal; Buckley, Ryan] Ralph H Johnson Vet Affairs Med Ctr, Ralph H Johnson VAMC, Charleston, SC 29401 USA. [Turner, Mason] Med Univ S Carolina, Coll Med, Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Axon, RN (reprint author), Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Ralph H Johnson VAMC, MSC 111,109 Bee St, Charleston, SC 29401 USA. EM axon@musc.edu; turnerm@musc.edu; buckleyr@musc.edu RI Vila, Vanessa/B-4982-2014 NR 65 TC 2 Z9 2 U1 2 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD NOV PY 2015 VL 17 IS 11 AR 94 DI 10.1007/s11886-015-0648-y PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR6HX UT WOS:000361447600003 PM 26362300 ER PT J AU Zhao, KW Murray, EJB Murray, SS AF Zhao, Ke-Wei Murray, Elsa J. Brochmann Murray, Samuel S. TI Fibroblastic Synoviocytes Secrete Plasma Proteins Via (2)-Macroglobulins Serving as Intracellular and Extracellular Chaperones SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE (2)-MACROGLOBULIN; (1)-ANTITRYPSIN (A1AT); BLOOD: SYNOVIUM BARRIER; BONE MORPHOGENETIC PROTEIN-2; C-REACTIVE PROTEIN; CHAPERONE; INSULIN-LIKE GROWTH FACTOR-1; INTER--TRYPSIN INHIBITOR HEAVY CHAIN H4; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR-1; HIG-82 CELLS; Spp24 ID RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; PROTEOMIC ANALYSIS; ZONE PROTEIN; KNEE-JOINT; OSTEOARTHRITIS; ALPHA-2-MACROGLOBULIN; BINDING; CELLS; ALPHA(2)-MACROGLOBULIN AB Changes in plasma protein levels in synovial fluid (SF) have been implicated in osteoarthritis and rheumatoid arthritis. It was previously thought that the presence of plasma proteins in SF reflected ultrafiltration or extravasation from the vasculature, possibly due to retraction of inflamed endothelial cells. Recent proteomic analyses have confirmed the abundant presence of plasma proteins in SF from control and arthritic patients. Systematic depletion of high-abundance plasma proteins from SF and conditioned media from synoviocytes cultured in serum, and protein analysis under denaturing/reducing conditions have limited our understanding of sources and the native structures of plasma protein complexes in SF. Using Western blotting, qPCR, and mass spectrometry, we found that Hig-82 lapine fibroblastic synovicytes cultured under serum-free conditions expressed and secreted plasma proteins, including the cytokine-binding protein secreted phosphoprotein 24kDa (Spp24) and many of the proteases and protease inhibitors found in SF. Treating synoviocytes with TGF-1 or BMP-2 for 24h upregulated the expression of plasma proteins, including Spp24, (2)-HS-glycoprotein, (1)-antitrypsin, IGF-1, and C-reactive protein. Furthermore, many of the plasma proteins of mass <151kDa were secreted as disulfide-bound complexes with members of the (2)-macroglobulin (A2M) family, which serve as intracellular and extracellular chaperones, not protease inhibitors. Using brefeldin A to block vesicular traffic and protease inhibitors to inhibit endogenous activation of naive A2M, we demonstrated that the complexes were formed in the endoplasmic reticulum lumen and that Ca(2+)cysteine protease-dependent processes are involved. J. Cell. Biochem. 116: 2563-2576, 2015. Published 2015. This article is a U.S. Government work and is in the public domain in the USA C1 [Zhao, Ke-Wei] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151, Sepulveda, CA 91343 USA. [Murray, Elsa J. Brochmann; Murray, Samuel S.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, Sepulveda, CA 91343 USA. [Murray, Elsa J. Brochmann; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Murray, Samuel S.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA 90095 USA. RP Murray, SS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, Sepulveda, CA 91343 USA. EM Samuel.Murray@va.gov FU Department of Veterans Affairs [1IPBX000511, 1IORX000383] FX Grant sponsor: Department of Veterans Affairs; Grant numbers: 1IPBX000511, 1IORX000383. NR 47 TC 3 Z9 3 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 EI 1097-4644 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD NOV PY 2015 VL 116 IS 11 BP 2563 EP 2576 DI 10.1002/jcb.25201 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CR3MJ UT WOS:000361236800015 PM 25900303 ER PT J AU Sumner, JA Kronish, IM Pietrzak, RH Shimbo, D Shaffer, JA Parsons, FE Edmondson, D AF Sumner, Jennifer A. Kronish, Ian M. Pietrzak, Robert H. shimbo, Daichi Shaffer, Jonathan A. Parsons, Faith E. Edmondson, Donald TI Dimensional structure and correlates of posttraumatic stress symptoms following suspected acute coronary syndrome SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Posttraumatic stress disorder; Acute coronary syndrome; Latent structure; Confirmatory factor analysis ID CONFIRMATORY FACTOR-ANALYSIS; HEART-DISEASE; EMERGENCY-DEPARTMENT; DISORDER SYMPTOMS; MYOCARDIAL-INFARCTION; FACTORIAL INVARIANCE; MEDICATION ADHERENCE; PRIMARY-CARE; DEPRESSION; PTSD AB Background: Posttraumatic stress disorder (PTSD) is a heterogeneous construct, and some have suggested that PTSD triggered by acute coronary syndrome (ACS) may differ from PTSD due to prototypical traumas. Methods: We conducted the first examination of the latent structure of PTSD symptoms after suspected ACS in 399 adults in the REactions to Acute Care and Hospitalization (REACH) study, an observational cohort study of patients recruited from the emergency department during evaluation for ACS. Using confirmatory factor analysis, we compared the 4-factor dysphoria, 4-factor numbing, and 5-factor dysphoric arousal models of PTSD. Results: Although all models fit well, the dysphoria model was selected as the best-fitting model. Further, there was measurement invariance of the dysphoria model by sex. PTSD dimensions evidenced differential associations with indicators of threat perception during ACS evaluation and adherence to cardiprotective medication. Limitations: One limitation of this investigation is the use of self-report measures. In addition, only one-third of the sample was diagnosed with ACS at discharge; the remaining participants received diagnoses such as chest pain without a cardiac diagnosis, another symptom/disease process (e.g, hypertensive chronic kidney disease), or another cardiac disease. Conclusions: Findings suggest that suspected ACS-related PTSD symptoms are best-represented by a 4-factor structure distinguishing between specific (e.g., re-experiencing) and non-specific (dysphoria) symptoms of PTSD that has received support in the broader PTSD literature. (C) 2015 Elsevier B.V. All rights reserved. C1 [Sumner, Jennifer A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Sumner, Jennifer A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Kronish, Ian M.; shimbo, Daichi; Shaffer, Jonathan A.; Parsons, Faith E.; Edmondson, Donald] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, New York, NY 10032 USA. [Pietrzak, Robert H.] Vet Affairs Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, Clin Neurosci Div, West Haven, CT 06516 USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. RP Sumner, JA (reprint author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St, PH 9-319, New York, NY 10032 USA. EM js4456@cumc.columbia.edu RI Edmondson, Donald/G-7486-2016 FU NHLBI NIH HHS [K23 HL098359, R01 HL117832, R01 HL123368] NR 47 TC 3 Z9 3 U1 3 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD NOV 1 PY 2015 VL 186 BP 178 EP 185 DI 10.1016/j.jad.2015.06.013 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CQ9WR UT WOS:000360966400027 PM 26241667 ER PT J AU Gonzalez, R Gonzalez, S Villa, E Ramirez, M Zavala, J Armas, R Contreras, J Dassori, A Leach, RJ Flores, D Jerez, A Raventos, H Ontiveros, A Nicolini, H Escamilla, M AF Gonzalez, Robert Gonzalez, Suzanne Villa, Erika Ramirez, Mercedes Zavala, Juan Armas, Regina Contreras, Javier Dassori, Albana Leach, Robin J. Flores, Deborah Jerez, Alvaro Raventos, Henriette Ontiveros, Alfonso Nicolini, Humberto Escamilla, Michael TI Identification of circadian gene variants in bipolar disorder in Latino populations SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Circadian; Bipolar disorder; Casein Kinase 1 Epsilon; Aryl Hydrocarbon Receptor Nuclear Translocator-Like; Latino; Family-based association test ID GLYCOGEN-SYNTHASE KINASE-3-BETA; FAMILY-BASED ASSOCIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP PHASE SYNDROME; KINASE-I-EPSILON; ERB-ALPHA-GENE; CLOCK GENES; MOOD DISORDERS; SCHIZOAFFECTIVE DISORDER; 1ST-DEGREE RELATIVES AB Background: Variations in circaclian genes can impact biological rhythms. Given the rhythm disturbances that characterize bipolar disorder (BD), genes encoding components of molecular clocks are good candidate genes for the illness. Methods: A family based association analysis of circadian gene single nucleotide polymorphisms (SNPs) and BD was conducted in Latino pedigrees. 884 individuals from 207 pedigrees (473 BP phenotype and 411 unaffected family members) were genotyped. Family based single marker association testing was performed. Ancestral haplotypes (SNPs found to be in strong LD defined using confidence intervals) were also tested for association with BD. Results: Multiple suggestive associations between circadian gene SNPs and BD were noted. These included CSNK1E (rs1534891, p_000680) ARNTL (rs3789327, =0.021172), CSNK1D (rs4510078, p=0.022801), CLOCK (rs17777927, p =0.031664). Individually, none of the SNPs were significantly associated with BD after correction for multiple testing. However, a 4-locus CSNICIE haplotype encompassing the rs1534891 SNP (Z-score=2.685, permuted p=0.0076) and a 3-locus haplotype in ARNTL (Zscore=3269, permuted p=00011) showed a significant association with BD. Limitations: Larger samples are required to confirm these findings and assess the relationship between circadian gene SNPs and BD in Latinos. Conclusions: The results suggest that ARNTL and CSI= 2 fold. Mild to moderate histological changes were observed in the kidney, including loss of brush border, vacuolization of tubular cells in the cortex, cast formation and necrosis in some proximal tubular cells. Finally, myeloperoxidase and ED-1 also increased, indicating inflammation. Conclusion Suppression of MB, inhibition of mitochondrial fission/fusion and enhancement of mitophagy occur in the kidneys of recipients of liver grafts after long cold storage, which may contribute to the occurrence of AKI and increased mortality after LT. C1 [Liu, Qinlong; Krishnasamy, Yasodha; Rehman, Hasibur; Lemasters, John J.; Schnellmann, Rick G.; Zhong, Zhi] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Liu, Qinlong] Dalian Med Univ, Affiliated Hosp 2, Dalian, Liaoning Provin, Peoples R China. [Lemasters, John J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. EM zhong@musc.edu FU National Institutes of Health [DK70844, DK073336, DK037034]; Chinese National Natural Foundation [81470878] FX This study was supported, in part, by grants DK70844, DK073336 and DK037034 from the National Institutes of Health and grant #81470878 from Chinese National Natural Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 77 TC 1 Z9 1 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 19 PY 2015 VL 10 IS 10 AR e0140906 DI 10.1371/journal.pone.0140906 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT7WW UT WOS:000363026600025 PM 26480480 ER PT J AU Chatzi, C Schnell, E Westbrook, GL AF Chatzi, Christina Schnell, Eric Westbrook, Gary L. TI Localized hypoxia within the subgranular zone determines the early survival of newborn hippocampal granule cells SO ELIFE LA English DT Article ID NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; ADULT DENTATE GYRUS; VASCULAR NICHE; STIMULATES PROLIFERATION; PROGENITOR CELLS; OXYGEN-TENSION; IN-VITRO; NEUROGENESIS AB The majority of adult hippocampal newborn cells die during early differentiation from intermediate progenitors (IPCs) to immature neurons. Neural stem cells in vivo are located in a relative hypoxic environment, and hypoxia enhances their survival, proliferation and stemness in vitro. Thus, we hypothesized that migration of IPCs away from hypoxic zones within the SGZ might result in oxidative damage, thus triggering cell death. Hypoxic niches were observed along the SGZ, composed of adult NSCs and early IPCs, and oxidative byproducts were present in adjacent late IPCs and neuroblasts. Stabilizing hypoxia inducible factor-1 alpha with dimethyloxallyl glycine increased early survival, but not proliferation or differentiation, in neurospheres in vitro and in newly born SGZ cells in vivo. Rescue experiments in Bax(fl/fl) mutants supported these results. We propose that localized hypoxia within the SGZ contributes to the neurogenic microenvironment and determines the early, activity-independent survival of adult hippocampal newborn cells. C1 [Chatzi, Christina; Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. [Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR USA. [Schnell, Eric] VA Portland Hlth Care Syst, US Dept Vet Affairs, Portland, OR USA. RP Westbrook, GL (reprint author), Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. EM westbroo@ohsu.edu FU National Institutes of Health [NS R01 080979, NS P30 061800]; Ellison Medical Foundation; AXA Research Fund; U.S. Department of Veterans Affairs [CDA-2] FX National Institutes of Health NS R01 080979 Gary L Westbrook; Ellison Medical Foundation Gary L Westbrook; National Institutes of Health NS P30 061800 Gary L Westbrook; AXA Research Fund C Chatzi; U.S. Department of Veterans Affairs CDA-2 E Schnell NR 61 TC 3 Z9 3 U1 1 U2 1 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD OCT 17 PY 2015 VL 4 AR e08722 DI 10.7554/eLife.08722 PG 18 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DJ0JI UT WOS:000373887900001 PM 26476335 ER PT J AU Tago, N Katolik, A Clark, NE Montemayor, EJ Seio, K Sekine, M Hart, PJ Damha, MJ AF Tago, Nobuhiro Katolik, Adam Clark, Nathaniel E. Montemayor, Eric J. Seio, Kohji Sekine, Mitsuo Hart, P. John Damha, Masad J. TI Design, Synthesis, and Properties of Phosphoramidate 2 ',5 '-Linked Branched RNA: Toward the Rational Design of Inhibitors of the RNA Lariat Debranching Enzyme SO JOURNAL OF ORGANIC CHEMISTRY LA English DT Article ID FRONTOTEMPORAL LOBAR DEGENERATION; TDP-43; OLIGORIBONUCLEOTIDES; SPLICEOSOME; DISEASE; ANALOGS AB Two RNA fragments linked by means of a 2',5' phosphodiester bridge (2' hydroxyl of one fragment connected to the 5' hydroxyl of the other) constitute a class of nucleic acids known as branched RNAs (bRNAs). In this report we show that bRNA analogues containing 2',5' phosphoramidate linkages (bN-RNAs) inhibit the lariat debranching enzyme, a 2',5'-phosphodiesterase that has recently been implicated in neurodegenerative diseases associated with aging. bN-RNAs were efficiently generated using automated solid-phase synthesis and suitably protected branchpoint building blocks. Two orthogonally removable groups, namely the 4-monomethoxytrityl (MMTr) group and the fluorenylmethyl-oxycarbonyl (Fmoc) groups, were evaluated as protecting groups of the 2' amino functionality. The 2'-N-Fmoc methodology was found to successfully produce bN-RNAs on solid-phase oligonucleotide synthesis. The synthesized bN-RNAs resisted hydrolysis by the lariat debranching enzyme (Dbr1) and, in addition, were shown to attenuate the Dbr1-mediated hydrolysis of native bRNA. C1 [Tago, Nobuhiro; Katolik, Adam; Damha, Masad J.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada. [Tago, Nobuhiro; Seio, Kohji; Sekine, Mitsuo] Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan. [Clark, Nathaniel E.; Montemayor, Eric J.; Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA. RP Damha, MJ (reprint author), McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada. EM masad.damha@mcgill.ca FU National Science and Engineering Research Council; Department of Veterans Affairs [1 I01 BX002580]; Robert A. Welch Foundation [AQ-1399]; National Science Foundation [DBI-0905865]; Judith and Jean Pape Adams Charitable Foundation; Barshop Institute for Longevity and Aging Studies [5 T32 AG021890]; Japan Society for the Promotion of Science (JSPS) FX This work was supported in part by grants from the National Science and Engineering Research Council (to M.J.D.), Department of Veterans Affairs (1 I01 BX002580, to P.J.H.), the Robert A. Welch Foundation (AQ-1399, to P.J.H.), the National Science Foundation (DBI-0905865, to E.J.M.) the Judith and Jean Pape Adams Charitable Foundation (to P.J.H.), the Barshop Institute for Longevity and Aging Studies (5 T32 AG021890, to E.J.M. and N.E.C.), and a Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from a Japan Society for the Promotion of Science (JSPS). NR 28 TC 3 Z9 3 U1 2 U2 14 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-3263 J9 J ORG CHEM JI J. Org. Chem. PD OCT 16 PY 2015 VL 80 IS 20 BP 10108 EP 10118 DI 10.1021/acs.joc.5b01719 PG 11 WC Chemistry, Organic SC Chemistry GA CU0QU UT WOS:000363224600032 PM 26378468 ER PT J AU Liao, W Jordaan, G Nham, P Phan, RT Pelegrini, M Sharma, S AF Liao, Wei Jordaan, Gwen Nham, Phillipp Phan, Ryan T. Pelegrini, Matteo Sharma, Sanjai TI Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens SO BMC CANCER LA English DT Article DE CLL; RNA-sequencing; Differential gene expression; Alternative splicing ID COMPARATIVE GENOMIC HYBRIDIZATION; IDENTIFIES RECURRENT MUTATIONS; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; CD38 EXPRESSION; SEQ EXPERIMENTS; BREAST CANCERS; B-CELLS; C-FOS; RECEPTOR AB Background: To determine differentially expressed and spliced RNA transcripts in chronic lymphocytic leukemia specimens a high throughput RNA-sequencing (HTS RNA-seq) analysis was performed. Methods: Ten CLL specimens and five normal peripheral blood CD19+ B cells were analyzed by HTS RNA-seq. The library preparation was performed with Illumina TrueSeq RNA kit and analyzed by Illumina HiSeq 2000 sequencing system. Results: An average of 48.5 million reads for B cells, and 50.6 million reads for CLL specimens were obtained with 10396 and 10448 assembled transcripts for normal B cells and primary CLL specimens respectively. With the Cuffdiff analysis, 2091 differentially expressed genes (DEG) between B cells and CLL specimens based on FPKM (fragments per kilobase of transcript per million reads and false discovery rate, FDR q < 0.05, fold change > 2) were identified. Expression of selected DEGs (n = 32) with up regulated and down regulated expression in CLL from RNA-seq data were also analyzed by qRT-PCR in a test cohort of CLL specimens. Even though there was a variation in fold expression of DEG genes between RNA-seq and qRT-PCR; more than 90 % of analyzed genes were validated by qRT-PCR analysis. Analysis of RNA-seq data for splicing alterations in CLL and B cells was performed by Multivariate Analysis of Transcript Splicing (MATS analysis). Skipped exon was the most frequent splicing alteration in CLL specimens with 128 significant events (P-value < 0.05, minimum inclusion level difference >0.1). Conclusion: The RNA-seq analysis of CLL specimens identifies novel DEG and alternatively spliced genes that are potential prognostic markers and therapeutic targets. High level of validation by qRT-PCR for a number of DEG genes supports the accuracy of this analysis. Global comparison of transcriptomes of B cells, IGVH non-mutated CLL (U-CLL) and mutated CLL specimens (M-CLL) with multidimensional scaling analysis was able to segregate CLL and B cell transcriptomes but the M-CLL and U-CLL transcriptomes were indistinguishable. The analysis of HTS RNA-seq data to identify alternative splicing events and other genetic abnormalities specific to CLL is an added advantage of RNA-seq that is not feasible with other genome wide analysis. C1 [Liao, Wei; Jordaan, Gwen; Sharma, Sanjai] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA 90073 USA. [Nham, Phillipp; Phan, Ryan T.] VA Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Pelegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90073 USA. [Sharma, Sanjai] Univ Calif Los Angeles, West Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA 90073 USA. EM sasharma@mednet.ucla.edu FU Flight Attendants Medical Research Institute (FAMRI); Veterans Administration Merit Research award FX SS is supported by a grant from Flight Attendants Medical Research Institute (FAMRI), and Veterans Administration Merit Research award. We thank the Broad Stem Cell Research Institute at UCLA for their help in high throughput RNA sequencing. NR 68 TC 2 Z9 2 U1 3 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD OCT 16 PY 2015 VL 15 AR 714 DI 10.1186/s12885-015-1708-9 PG 14 WC Oncology SC Oncology GA CT5QP UT WOS:000362865600002 PM 26474785 ER PT J AU Li, CS Tian, HJ Zou, M Zhao, KW Li, YW Lao, LF Brochmann, EJ Duarte, MEL Daubs, MD Zhou, YH Murray, SS Wang, JC AF Li, Chen-Shuang Tian, Haijun Zou, Min Zhao, Ke-Wei Li, Yawei Lao, Lifeng Brochmann, Elsa J. Duarte, M. Eugenia L. Daubs, Michael D. Zhou, Yan-Heng Murray, Samuel S. Wang, Jeffrey C. TI Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Bone morphogenetic proteins-2; Secreted phosphoprotein 24 kD; Pancreatic cancer ID BONE MORPHOGENETIC PROTEIN-2; PROSTATE-CANCER; TUMOR-GROWTH; A549 CELLS; TGF-BETA; IN-VIVO; EXPRESSION; LESIONS; NOGGIN; OVEREXPRESSION AB The emerging role of bone morphogenetic proteins (BMPs) in the initiation and progression of multiple cancers has drawn great attention in cancer research. In this study, we report that BMP-2 can promote the proliferation of the pancreatic tumor cell line, PANC-1. Secreted phosphoprotein 24 kD (Spp24), a BMP binding protein, did not affect the proliferation of the cells but promoted the apoptosis of the cells in vitro. In a xeneograft tumor model using PANC-1 cells, BMP-2 dramatically promoted tumor growth, while Spp24 not only abolished the effect of BMP-2, but also dramatically induced tumor shrinking when used alone. Activation of Smad1/518 participated in this process as demonstrated by immunohistochemical staining of phosphorylated Smad 1/5/8. We conclude that Spp24 can be developed into a therapeutic agent that could be employed in clinical situations where the inhibition of BMPs and related proteins is advantageous. (C) 2015 Elsevier Inc. All rights reserved. C1 [Li, Chen-Shuang; Zhou, Yan-Heng] Peking Univ Sch & Hosp Stomatol, Dept Orthodont, Beijing 100081, Peoples R China. [Tian, Haijun] Second Mil Med Univ, Dept Orthopaed Surg, Changzheng Hosp, Shanghai, Peoples R China. [Tian, Haijun; Li, Yawei; Lao, Lifeng] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA. [Tian, Haijun] Bethune Sch Med, Dept Surg, Shijiazhuang 050000, Peoples R China. [Zou, Min] Xi An Jiao Tong Univ, Sch & Hosp Stomatol, Dept Orthodont, Xian 710049, Peoples R China. [Zhao, Ke-Wei; Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Angeles Healthcare Syst, Res Serv, North Hills, CA USA. [Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Brochmann, Elsa J.; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Duarte, M. Eugenia L.] Natl Inst Traumatol & Orthopaed, Rio De Janeiro, Brazil. [Daubs, Michael D.] Univ Nevada, Sch Med, Dept Surg, Div Orthopaed Surg, Las Vegas, NV 89154 USA. [Wang, Jeffrey C.] Univ So Calif, Dept Orthopaed Surg, Los Angeles, CA USA. RP Tian, HJ (reprint author), Bethune Sch Med, Dept Surg, 450 West Zhongshan Rd, Shijiazhuang 050000, Peoples R China. EM haijuntianmd@gmail.com; yanhengzhou@vip.163.com OI LI, Chenshuang/0000-0001-6331-6983 FU National Natural Science Foundation of China [81402229]; International S&T Cooperation Program of China [2013DFB30360]; Research Service of U.S. Department of Veterans Affairs [1IPBX000511, 1IORX000383] FX This work was supported by the National Natural Science Foundation of China (Grant No. 81402229), the International S&T Cooperation Program of China (Grant No. 2013DFB30360), and by the Research Service of the U.S. Department of Veterans Affairs (Grants No. 1IPBX000511 and 1IORX000383). NR 30 TC 3 Z9 3 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD OCT 16 PY 2015 VL 466 IS 2 BP 167 EP 172 DI 10.1016/j.bbrc.2015.08.124 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CT2CY UT WOS:000362610800004 PM 26334966 ER PT J AU Wells, JM Jackson, PL Viera, L Bhatt, SP Gautney, J Handley, G King, RW Xu, X Gaggar, A Bailey, WC Dransfield, MT Blalock, JE AF Wells, J. Michael Jackson, Patricia L. Viera, Liliana Bhatt, Surya P. Gautney, Joshua Handley, Guy King, R. Wilson Xu, Xin Gaggar, Amit Bailey, William C. Dransfield, Mark T. Blalock, J. Edwin TI A Randomized, Placebo-controlled Trial of Roflumilast Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE COPD; roflumilast; neutrophil; proline-glycine-proline; prolyl endopeptidase ID PDE4 INHIBITOR ROFLUMILAST; AIRWAY INFLAMMATION; CLINICAL-TRIALS; COPD; EMPHYSEMA; THERAPY; CHEMOATTRACTANT; EXACERBATIONS; AZITHROMYCIN; PATHOGENESIS AB Rationale: Roflumilast is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD). It has antiinflammatory effects; however, it is not known whether it can affect a biologic pathway implicated in COPD pathogenesis and progression. The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD. AcPGP is produced by extracellular matrix collagen breakdown with prolyl endopeptidase and leukotriene A(4) hydrolase serving as the enzymes responsible for its production and degradation, respectively. Objectives: We hypothesized that roflumilast would decrease AcPGP, halting the feed-forward cycle of inflammation Methods: We conducted a single-center, placebo-controlled, randomized study investigating 12 weeks of roflumilast treatment added to current therapy in moderate-to-severe COPD with chronic bronchitis. Subjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and quality-of-life assessment at 0, 4, and 12 weeks. Measurements and Main Results: Twenty-seven patients were enrolled in the intention-to-treat analysis. Roflumilast treatment decreased sputum AcPGP by more than 50% (P < 0.01) and prolyl endopeptidase by 46% (P = 0.02), without significant improvement in leukotriene A(4) hydrolase activity compared with placebo. Roflumilast also reduces other inflammatory markers. There were no significant changes in lung function, quality of life, or exercise tolerance between roflumilast- and placebo-treated groups. Conclusions: Roflumilast reduces pulmonary inflammation through decreasing prolyl endopeptidase activity and AcPGP. As expected for lower AcPGP levels, markers of neutrophilic inflammation are blunted. Inhibiting this self-propagating pathway lessens the overall inflammatory burden, which may alter the natural history of COPD, including the risk of exacerbation. C1 [Wells, J. Michael; Jackson, Patricia L.; Viera, Liliana; Bhatt, Surya P.; King, R. Wilson; Xu, Xin; Gaggar, Amit; Bailey, William C.; Dransfield, Mark T.; Blalock, J. Edwin] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Wells, J. Michael; Jackson, Patricia L.; Viera, Liliana; Bhatt, Surya P.; Bailey, William C.; Dransfield, Mark T.; Blalock, J. Edwin] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Jackson, Patricia L.; Viera, Liliana; King, R. Wilson; Xu, Xin; Gaggar, Amit; Blalock, J. Edwin] Univ Alabama Birmingham, UAB Program Protease & Matrix Biol, Birmingham, AL USA. [Gautney, Joshua; Handley, Guy] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Wells, J. Michael; Gaggar, Amit; Dransfield, Mark T.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Wells, JM (reprint author), 1900 Univ Blvd,MCLM 894, Birmingham, AL 35294 USA. EM jmwells@uab.edu OI Blalock, J. Edwin/0000-0001-5303-8123 FU Forest Laboratories, Inc.; The University of Alabama at Birmingham Targeted Metabolomics and Proteomics Laboratory [S10 RR17261, P30 DK079337-07, R01 AG043076-03, 4R00 HL111322-03] FX Supported by Forest Laboratories, Inc. The University of Alabama at Birmingham Targeted Metabolomics and Proteomics Laboratory receives key support from S10 RR17261, P30 DK079337-07, R01 AG043076-03, and 4R00 HL111322-03. NR 44 TC 8 Z9 8 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 15 PY 2015 VL 192 IS 8 BP 934 EP 942 DI 10.1164/rccm.201503-0543OC PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CU2NE UT WOS:000363359400008 PM 26151090 ER PT J AU Vaughn, JE Sorror, ML Storer, BE Chauncey, TR Pulsipher, MA Maziarz, RT Maris, MB Hari, P Laport, GG Franke, GN Agura, ED Langston, AA Rezvani, AR Storb, R Sandmaier, BM Maloney, DG AF Vaughn, Jennifer E. Sorror, Mohamed L. Storer, Barry E. Chauncey, Thomas R. Pulsipher, Michael A. Maziarz, Richard T. Maris, Michael B. Hari, Parameswaran Laport, Ginna G. Franke, Georg N. Agura, Edward D. Langston, Amelia A. Rezvani, Andrew R. Storb, Rainer Sandmaier, Brenda M. Maloney, David G. TI Long-Term Sustained Disease Control in Patients With Mantle Cell Lymphoma With or Without Active Disease After Treatment With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning SO CANCER LA English DT Article DE conditioning regimen; long-term follow-up; mantle cell lymphoma; nonmyeloablative conditioning; stem cell transplantation ID NON-HODGKINS-LYMPHOMA; VERSUS-HOST-DISEASE; REDUCED-INTENSITY; MARROW TRANSPLANTATION; MOLECULAR REMISSIONS; CLINICAL-TRIAL; FOLLOW-UP; BLOOD; GRAFT; MALIGNANCY AB BACKGROUND: Previously, early results were reported for allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with 2 Gy of total body irradiation with or without fludarabine and/or rituximab in 33 patients with mantle cell lymphoma (MCL). METHODS: This study examined the outcomes of 70 patients with MCL and included extended follow-up (median, 10 years) for the 33 initial patients. Grafts were obtained from human leukocyte antigen (HLA)-matched, related donors (47%), unrelated donors (41%), and HLA antigen-mismatched donors (11%). RESULTS: The 5-year incidence of nonrelapse mortality was 28%. The relapse rate was 26%. The 5-year rates of overall survival (OS) and progression-free survival (PFS) were 55% and 46%, respectively. The 10-year rates of OS and PFS were 44% and 41%, respectively. Eighty percent of surviving patients were off immunosuppression at the last follow-up. The presence of relapsed or refractory disease at the time of HCT predicted a higher rate of relapse (hazard ratio [HR], 2.94; P =.05). Despite this, OS rates at 5 (51% vs 58%) and 10 years (43% vs 45%) were comparable between those with relapsed/refractory disease and those undergoing transplantation with partial or complete remission. A high-risk cytomegalovirus (CMV) status was the only independent predictor of worse OS (HR, 2.32; P =.02). A high-risk CMV status and a low CD3 dose predicted PFS (HR, 2.22; P =.03). CONCLUSIONS: Nonmyeloablative allogeneic HCT provides a long-term survival benefit for patients with relapsed MCL, including those with refractory disease or multiple relapses. (c) 2015 American Cancer Society. C1 [Vaughn, Jennifer E.; Sorror, Mohamed L.; Chauncey, Thomas R.; Storb, Rainer; Sandmaier, Brenda M.; Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Vaughn, Jennifer E.; Sorror, Mohamed L.; Chauncey, Thomas R.; Storb, Rainer; Sandmaier, Brenda M.; Maloney, David G.] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA. [Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Clin Stat Program, Div Clin Res, Seattle, WA 98109 USA. [Storer, Barry E.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA. [Pulsipher, Michael A.] Primary Childrens Med Ctr, Pediat Blood & Marrow Transplant Program, Salt Lake City, UT USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol Hematol Malignancies, Huntsman Canc Inst, Salt Lake City, UT USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Knight Canc Inst, Portland, OR 97201 USA. [Maris, Michael B.] Colorado Blood Canc Inst, Denver, CO USA. [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Laport, Ginna G.; Rezvani, Andrew R.] Stanford Sch Med, Div Blood & Marrow Transplantat, Dept Med, Stanford, CA USA. [Franke, Georg N.; Storb, Rainer] Univ Leipzig, Div Hematol Oncol & Hemostaseol, Dept Med, D-04109 Leipzig, Germany. [Agura, Edward D.] Baylor Univ, Sch Med, Hematopoiet Stem Cell Program, Dallas, TX USA. [Langston, Amelia A.] Emory Univ, Sch Med, Div Hematol Oncol, Atlanta, GA 30322 USA. [Langston, Amelia A.] Emory Univ, Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA 30322 USA. RP Sorror, ML (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,D1-100, Seattle, WA 98109 USA. EM msorror@fredhutch.org OI Hari, Parameswaran/0000-0002-8800-297X FU National Heart, Lung, and Blood Institute of the National Institutes of Health [CA018029, CA15704, CA078902, HL088021, 5T32HL007093-38]; American Cancer Society [RSG-13-084-01-CPHPS]; Patient-Centered Outcomes Research Institute [CE-1304-7451]; American Cancer Society FX This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (grants CA018029, CA15704, CA078902, HL088021, and 5T32HL007093-38). Mohamed L. Sorror is also supported by a Research Scholar Grant from the American Cancer Society (RSG-13-084-01-CPHPS) and by a contract from the Patient-Centered Outcomes Research Institute (CE-1304-7451). Andrew Rezvani reports a Mentored Research Scholar Grant from the American Cancer Society. NR 38 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 15 PY 2015 VL 121 IS 20 BP 3709 EP 3716 DI 10.1002/cncr.29498 PG 8 WC Oncology SC Oncology GA CU1EN UT WOS:000363262700020 PM 26207349 ER PT J AU Dawes, AJ Maggard-Gibbons, M AF Dawes, Aaron J. Maggard-Gibbons, Melinda TI Reply to The Long and Winding Road in Cancer Survivorship Care SO CANCER LA English DT Letter C1 [Dawes, Aaron J.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Surg,Robert Wood Johnson Fdn Clin Scholars P, Los Angeles, CA 90095 USA. [Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90095 USA. [Maggard-Gibbons, Melinda] Olive View Univ Calif Los Angeles, Dept Surg, Med Ctr, Los Angeles, CA USA. RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Surg,Robert Wood Johnson Fdn Clin Scholars P, Los Angeles, CA 90095 USA. OI Dawes, Aaron/0000-0003-4574-6765 FU NCI NIH HHS [U54 CA143931] NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 15 PY 2015 VL 121 IS 20 BP 3750 EP 3750 DI 10.1002/cncr.29546 PG 1 WC Oncology SC Oncology GA CU1EN UT WOS:000363262700027 PM 26138082 ER PT J AU Singh, B Owens, KM Bajpai, P Desouki, MM Srinivasasainagendra, V Tiwari, HK Singh, KK AF Singh, Bhupendra Owens, Kjerstin M. Bajpai, Prachi Desouki, Mohamed Mokhtar Srinivasasainagendra, Vinodh Tiwari, Hemant K. Singh, Keshav K. TI Mitochondrial DNA Polymerase POLG1 Disease Mutations and Germline Variants Promote Tumorigenic Properties SO PLOS ONE LA English DT Article ID COPY-NUMBER; HUMAN CANCERS; SYNONYMOUS MUTATIONS; DRIVER MUTATIONS; MTDNA DEPLETION; ALPERS-SYNDROME; BREAST-CANCER; KINASE GENE; CROSS-TALK; GAMMA AB Germline mutations in mitochondrial DNA polymerase gamma (POLG1) induce mitochondrial DNA (mtDNA) mutations, depletion, and decrease oxidative phosphorylation. Earlier, we identified somatic mutations in POLG1 and the contribution of these mutations in human cancer. However, a role for germline variations in POLG1 in human cancers is unknown. In this study, we examined a role for disease associated germline variants of POLG1, POLG1 gene expression, copy number variation and regulation in human cancers. We analyzed the mutations, expression and copy number variation in POLG1 in several cancer databases and validated the analyses in primary breast tumors and breast cancer cell lines. We discovered 5-aza-2'-deoxycytidine led epigenetic regulation of POLG1, mtDNA-encoded genes and increased mitochondrial respiration. We conducted comprehensive race based bioinformatics analyses of POLG1 gene in more than 33,000 European-Americans and 5,000 African-Americans. We identified a mitochondrial disease causing missense variation in polymerase domain of POLG1 protein at amino acid 1143 (E1143G) to be 25 times more prevalent in European-Americans (allele frequency 0.03777) when compared to African-American (allele frequency 0.00151) population. We identified T251I and P587L missense variations in exonuclease and linker region of POLG1 also to be more prevalent in European-Americans. Expression of these variants increased glucose consumption, decreased ATP production and increased matrigel invasion. Interestingly, conditional expression of these variants revealed that matrigel invasion properties conferred by these germline variants were reversible suggesting a role of epigenetic regulators. Indeed, we identified a set of miRNA whose expression was reversible after variant expression was turned off. Together, our studies demonstrate altered genetic and epigenetic regulation of POLG1 in human cancers and suggest a role for POLG1 germline variants in promoting tumorigenic properties. C1 [Singh, Bhupendra; Bajpai, Prachi; Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Owens, Kjerstin M.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA. [Desouki, Mohamed Mokhtar] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA. [Srinivasasainagendra, Vinodh; Tiwari, Hemant K.] Univ Alabama Birmingham, Dept Biostat, Sect Stat Genet, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Environm Hlth, Birmingham, AL USA. [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL USA. [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA. [Singh, Keshav K.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL USA. [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Singh, KK (reprint author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. EM kksingh@uab.edu FU Veterans Administration [1I01BX001716]; NIH [R21 5R21CA176054] FX This study was supported by grants from Veterans Administration 1I01BX001716 and NIH R21 5R21CA176054. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 15 PY 2015 VL 10 IS 10 AR e0139846 DI 10.1371/journal.pone.0139846 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CU0CX UT WOS:000363184600020 PM 26468652 ER PT J AU Martin, JT Milby, AH Ikuta, K Poudel, S Pfeifer, CG Elliott, DM Smith, HE Mauck, RL AF Martin, John T. Milby, Andrew H. Ikuta, Kensuke Poudel, Subash Pfeifer, Christian G. Elliott, Dawn M. Smith, Harvey E. Mauck, Robert L. TI A radiopaque electrospun scaffold for engineering fibrous musculoskeletal tissues: Scaffold characterization and in vivo applications SO ACTA BIOMATERIALIA LA English DT Article DE Tissue engineering; Electrospinning; Intervertebral disc; Imaging; Radiography ID INTERVERTEBRAL DISC REPLACEMENT; NANOFIBROUS SCAFFOLDS; EXTRACELLULAR-MATRIX; PARTIAL MENISCECTOMY; POLYMER SCAFFOLDS; MODEL; REPAIR; CELLS; MENISCUS; VITRO AB Tissue engineering strategies have emerged in response to the growing prevalence of chronic musculoskeletal conditions, with many of these regenerative methods currently being evaluated in translational animal models. Engineered replacements for fibrous tissues such as the meniscus, annulus fibrosus, tendons, and ligaments are subjected to challenging physiologic loads, and are difficult to track in vivo using standard techniques. The diagnosis and treatment of musculoskeletal conditions depends heavily on radiographic assessment, and a number of currently available implants utilize radiopaque markers to facilitate in vivo imaging. In this study, we developed a nanofibrous scaffold in which individual fibers included radiopaque nanoparticles. Inclusion of radiopaque particles increased the tensile modulus of the scaffold and imparted radiation attenuation within the range of cortical bone. When scaffolds were seeded with bovine mesenchymal stem cells in vitro, there was no change in cell proliferation and no evidence of promiscuous conversion to an osteogenic phenotype. Scaffolds were implanted ex vivo in a model of a meniscal tear in a bovine joint and in vivo in a model of total disc replacement in the rat coccygeal spine (tail), and were visualized via fluoroscopy and microcomputed tomography. In the disc replacement model, histological analysis at 4 weeks showed that the scaffold was biocompatible and supported the deposition of fibrous tissue in vivo. Nanofibrous scaffolds that include radiopaque nanoparticles provide a biocompatible template with sufficient radiopacity for in vivo visualization in both small and large animal models. This radiopacity may facilitate image-guided implantation and non-invasive long-term evaluation of scaffold location and performance. Statement of Significance The healing capacity of fibrous musculoskeletal tissues is limited, and injury or degeneration of these tissues compromises the standard of living of millions in the US. Tissue engineering repair strategies for the intervertebral disc, meniscus, tendon and ligament have progressed from in vitro to in vivo evaluation using a variety of animal models, and the clinical application of these technologies is imminent. The composition of most scaffold materials however does not allow for visualization by methods available to clinicians (e.g., radiography), and thus it is not possible to assess their performance in situ. In this work, we describe a radiopaque nanofibrous scaffold that can be visualized radiographically in both small and large animal models and serve as a framework for the development of an engineered fibrous tissue. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. C1 [Martin, John T.; Milby, Andrew H.; Ikuta, Kensuke; Poudel, Subash; Pfeifer, Christian G.; Smith, Harvey E.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Martin, John T.; Milby, Andrew H.; Ikuta, Kensuke; Pfeifer, Christian G.; Smith, Harvey E.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Martin, John T.; Poudel, Subash; Mauck, Robert L.] Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA. [Pfeifer, Christian G.] Univ Regensburg, Med Ctr, Dept Trauma Surg, D-93053 Regensburg, Germany. [Elliott, Dawn M.] Univ Delaware, Dept Biomed Engn, Newark, DE USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. RP Martin, JT (reprint author), Univ Penn, McKay Orthopaed Res Lab, Orthopaed Surg & Bioengn, 36th St & Hamilton Walk,424 Stemmler Hall, Philadelphia, PA 19104 USA. EM johnma@mail.med.upenn.edu; andrew.milby@uphs.upenn.edu; ken.ikuta.hto@gmail.com; spoudel@seas.upenn.edu; dr.christianpfeifer@gmail.com; delliott@udel.edu; harvey.smith@uphs.upenn.edu; lemauck@mail.med.upenn.edu FU Department of Defense [OR090090]; National Institutes of Health [R01 EB02425]; Penn Center for Musculoskeletal Disorders [P30 AR050950]; Department of Veterans' Affairs [IK2 RX001476] FX This study was supported by the Department of Defense (OR090090), the National Institutes of Health (R01 EB02425), the Penn Center for Musculoskeletal Disorders (P30 AR050950), and the Department of Veterans' Affairs (IK2 RX001476, H.E.S.). NR 35 TC 2 Z9 2 U1 9 U2 38 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1742-7061 EI 1878-7568 J9 ACTA BIOMATER JI Acta Biomater. PD OCT 15 PY 2015 VL 26 BP 97 EP 104 DI 10.1016/j.actbio.2015.08.001 PG 8 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA CT6IR UT WOS:000362917200010 PM 26248165 ER PT J AU White, PL Wingard, JR Bretagne, S Loffler, J Patterson, TF Slavin, MA Barnes, RA Pappas, PG Donnelly, JP AF White, P. Lewis Wingard, John R. Bretagne, Stephane Loeffler, Juergen Patterson, Thomas F. Slavin, Monica A. Barnes, Rosemary A. Pappas, Peter G. Donnelly, J. Peter TI Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE Aspergillus; PCR; galactomannan; beta-D-glucan; aspergillosis ID LINKED-IMMUNOSORBENT-ASSAY; INVASIVE PULMONARY ASPERGILLOSIS; BRONCHOALVEOLAR LAVAGE FLUID; REAL-TIME PCR; LATEX AGGLUTINATION-TEST; BETA-D-GLUCAN; MARROW TRANSPLANT RECIPIENTS; GALACTOMANNAN ENZYME-IMMUNOASSAY; HIGH-RISK PATIENTS; FUNGAL-INFECTIONS AB Background. Aspergillus polymerase chain reaction (PCR) was excluded from the European Organisation for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive fungal disease because of limited standardization and validation. The definitions are being revised. Methods. A systematic literature review was performed to identify analytical and clinical information available on inclusion of galactomannan enzyme immunoassay (GM-EIA) (2002) and beta-D-glucan (2008), providing a minimal threshold when considering PCR. Categorical parameters and statistical performance were compared. Results. When incorporated, GM-EIA and beta-D-glucan sensitivities and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% and 89.4%, respectively. Aspergillus PCR has similar sensitivity and specificity (76.8%-88.0% and 75.0%-94.5%, respectively) and comparable utility. Methodological recommendations and commercial PCR assays assist standardization. Although all tests have limitations, currently, PCR is the only test with independent quality control. Conclusions. We propose that there is sufficient evidence that is at least equivalent to that used to include GM-EIA and beta-D-glucan testing, and that PCR is now mature enough for inclusion in the EORTC/MSG definitions. C1 [White, P. Lewis] Univ Wales Hosp, Publ Hlth Wales, Microbiol Cardiff, Cardiff CF14 4XN, S Glam, Wales. [Wingard, John R.] Univ Florida Hlth, Gainesville, FL USA. [Bretagne, Stephane] Paris Diderot Univ, AP HP, St Louis Hosp, Paris, France. [Loeffler, Juergen] Univ Wurzburg, Wurzburg, Germany. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Slavin, Monica A.] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic 3010, Australia. [Barnes, Rosemary A.] Cardiff Univ, Infect Immun & Biochem, Cardiff CF10 3AX, S Glam, Wales. [Pappas, Peter G.] Univ Alabama Birmingham, Birmingham, AL USA. [Donnelly, J. Peter] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. RP White, PL (reprint author), Univ Wales Hosp, Publ Hlth Wales, Microbiol Cardiff, Heath Pk, Cardiff CF14 4XN, S Glam, Wales. EM lewis.white@wales.nhs.uk OI Patterson, Thomas /0000-0002-9513-7127; Bretagne, Stephane/0000-0001-6870-3800; Slavin, Monica/0000-0002-8443-314X FU Myconostica; Luminex; Renishaw Diagnostics; MSD; Gilead Sciences; Pfizer; Astellas; Merck; Schering- Plough; MSD Australia; Pfizer Australia; Scynexis; T2 Biosystems; Viamet FX P. L. W. is a founding member of the European Aspergillus PCR Initiative (EAPCRI); received project funding from Myconostica, Luminex, and Renishaw Diagnostics; was sponsored by Myconostica, MSD, and Gilead Sciences to attend international meetings; and provided consultancy for Renishaw Diagnostics Limited. J. R. W. has received speaker fees from Pfizer and has provided consultancy for Merck, Astellas, Ansun and Gilead. S. B. is a founding member of the EAPCRI, received project funding from Renishaw Diagnostics, was sponsored by Pfizer and MSD to attend international meetings, and provided consultancy for Gilead. J. L. is a founding member of the EAPCRI, received an educational grant and scientific fellowship award from Pfizer, and was sponsored by Astellas to attend international meetings. T. F. P. has received research grants from Astellas and Merck, and has been a consultant or scientific advisory board member for Astellas, Merck, Scynexis, Toyoma, and Viamet. M. A. S. has been a member of advisory boards for and received research funding from Pfizer, MSD, Schering- Plough, and Gilead Sciences; serves on the Antifungal Advisory Boards of Gilead Sciences Inc, MSD, and Pfizer; and has received funding in the form of untied grants from Gilead Sciences Inc, MSD Australia, and Pfizer Australia. R. A. B. is a founding member of the EAPCRI, received an educational grant and scientific fellowship award from Gilead Sciences and Pfizer, is a member of the advisory board and speakers' bureau for Gilead Sciences, MSD, Astellas, and Pfizer, and was sponsored by Gilead Sciences and Pfizer to attend international meetings. P. G. P. has received research support from Astellas, Merck, Gilead, Scynexis, and T2 Biosystems; and has served as an ad hoc scientific advisor for Astellas, Merck, Gilead, Scynexis, T2 Biosystems, and Viamet. J. P. D. is a founding member of the EAPCRI, is a member of the advisory board for Gilead Sciences and Pfizer, and has been on speakers' bureaus for Gilead Sciences, MSD, and Pfizer. NR 93 TC 22 Z9 23 U1 1 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2015 VL 61 IS 8 BP 1293 EP 1303 DI 10.1093/cid/civ507 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WN UT WOS:000362953800011 PM 26113653 ER PT J AU Linkin, DR Richardson, DM AF Linkin, Darren R. Richardson, Diane M. TI Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical Centers Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID OLDER-ADULTS; HOSPITALIZATIONS C1 [Linkin, Darren R.] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Philadelphia Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Philadelphia, PA USA. [Richardson, Diane M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Linkin, DR (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM linkin@mail.med.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2015 VL 61 IS 8 BP 1345 EP 1345 DI 10.1093/cid/civ549 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WN UT WOS:000362953800021 PM 26157051 ER PT J AU Winston, DJ Busuttil, RW Singh, N AF Winston, Drew J. Busuttil, Ronald W. Singh, Nina TI Antifungal Prophylaxis in Liver Transplant Recipients SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID INVASIVE FUNGAL-INFECTIONS; DOUBLE-BLIND; TRIAL; FLUCONAZOLE; PREVENTION; MICAFUNGIN C1 [Winston, Drew J.; Busuttil, Ronald W.] Univ Calif Los Angeles, Med Ctr, Dept Surg, Liver Transplant Program, Los Angeles, CA 90095 USA. [Winston, Drew J.] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90095 USA. [Singh, Nina] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA 15260 USA. RP Winston, DJ (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Med, 10833 LeConte Ave,CHS,Rm 42-121, Los Angeles, CA 90095 USA. EM dwinston@mednet.ucla.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2015 VL 61 IS 8 BP 1349 EP U162 DI 10.1093/cid/civ565 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WN UT WOS:000362953800024 PM 26261207 ER PT J AU Garg, A Mennuni, MG Theodoropoulos, K Sharma, A Kostis, J Stefanini, GG AF Garg, Aakash Mennuni, Marco G. Theodoropoulos, Kleanthis Sharma, Abhishek Kostis, John Stefanini, Giulio G. TI Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting In Left Main Coronary Artery Disease: Long-Term Follow-Up Meta-Analysis Of 6156 Patients SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE PCI outcomes C1 [Garg, Aakash] St Peters Univ Hosp Rutgers RWJMS, New Brunswick, NJ USA. [Mennuni, Marco G.; Stefanini, Giulio G.] Humanitas Res Hosp, Milan, Italy. [Theodoropoulos, Kleanthis] James J Peters VA Hosp, Icahn Sch Med Mt Sinai, Bronx, NY USA. [Sharma, Abhishek] SUNY Downstate Univ, Brooklyn, NY USA. [Kostis, John] UMDNJ, CVI, New Brunswick, NJ USA. [Kostis, John] UMDNJ, RWJMS, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-463 BP B189 EP B190 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000412 ER PT J AU Krishnan, K Dvir, D Ye, J Ge, L Tseng, E AF Krishnan, Kapil Dvir, Danny Ye, Jian (James) Ge, Liang Tseng, Elaine TI Impact of Balloon-Expandable Transcatheter Aortic Valve Size on Stent and Leaflet Stresses SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Computational Modeling; Computed tomography; Transcatheter aortic valve replacement C1 [Krishnan, Kapil; Ge, Liang] UCSF Med Ctr, San Francisco, CA USA. [Dvir, Danny] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. [Ye, Jian (James)] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Tseng, Elaine] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Tseng, Elaine] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-659 BP B270 EP B270 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000601 ER PT J AU Meelu, OA Sartori, S Theodoropoulos, K Roy, S Thapi, R Baber, U Moreno, PR Krishnan, P Dangas, G Kini, A Sharma, SK Mehran, R AF Meelu, Omar A. Sartori, Samantha Theodoropoulos, Kleanthis Roy, Swathi Thapi, Roja Baber, Usman Moreno, Pedro R. Krishnan, Prakash Dangas, George Kini, Annapoorna Sharma, Samin K. Mehran, Roxana TI Outcomes Among Patients Enrolled Versus Not Enrolled In Interventional Cardiovascular Clinical Trials: Insights From A Single-center Analysis SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Clinical outcomes; Clinical Trial C1 [Meelu, Omar A.] Mt Sinai Heart, New York, NY USA. [Sartori, Samantha; Krishnan, Prakash; Sharma, Samin K.] Mt Sinai Sch Med, New York, NY USA. [Theodoropoulos, Kleanthis] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai Bronx, Bronx, NY USA. [Roy, Swathi; Thapi, Roja; Moreno, Pedro R.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Baber, Usman] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dangas, George; Kini, Annapoorna] Mt Sinai, New York, NY USA. [Mehran, Roxana] Mt Sinai Hosp, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-446 BP B182 EP B183 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000396 ER PT J AU Meelu, OA Sartori, S Theodoropoulos, K Roy, S Thapi, R Baber, U Dangas, G Moreno, PR Krishnan, P Kini, A Sharma, SK Mehran, R AF Meelu, Omar A. Sartori, Samantha Theodoropoulos, Kleanthis Roy, Swathi Thapi, Roja Baber, Usman Dangas, George Moreno, Pedro R. Krishnan, Prakash Kini, Annapoorna Sharma, Samin K. Mehran, Roxana TI Real World Generalizability Of Patients Enrolled In Clinical Trials Versus Those Not Enrolled SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Clinical Trial C1 [Meelu, Omar A.] Mt Sinai Heart, New York, NY USA. [Sartori, Samantha; Krishnan, Prakash; Sharma, Samin K.] Mt Sinai Sch Med, New York, NY USA. [Theodoropoulos, Kleanthis] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai Bronx, Bronx, NY USA. [Roy, Swathi; Thapi, Roja; Moreno, Pedro R.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Baber, Usman; Mehran, Roxana] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dangas, George; Kini, Annapoorna] Mt Sinai, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-447 BP B183 EP B183 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000397 ER PT J AU Sharma, A Sharma, SK Garg, A Vallakati, A Marmur, JD Mukherjee, D Stone, GW AF Sharma, Abhishek Sharma, Samin K. Garg, Aakash Vallakati, Ajay Marmur, Jonathan D. Mukherjee, Debabrata Stone, Gregg W. TI Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Patients with ACS vs. non-ACS: A Systematic Review and Meta-Analysis of Randomized Controlled Trials SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Acute coronary syndromes; Double anti-platelet therapy; Drug-eluting stent C1 [Sharma, Abhishek; Marmur, Jonathan D.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Sharma, Samin K.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Garg, Aakash] Icahn Sch Med Mt Sinai, James J Peters VA Hosp, Bronx, NY USA. [Vallakati, Ajay] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA. [Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA. [Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-184 BP B68 EP B69 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000148 ER PT J AU Szerlip, M Arsalan, M Holper, EM Arnold, SV Vemulapalli, S Rumsfeld, JS Brown, D Li, ZK Mack, M AF Szerlip, Molly Arsalan, Mani Holper, Elizabeth M. Arnold, Suzanne V. Vemulapalli, Sreekanth Rumsfeld, John S. Brown, David Li, Zhuokai Mack, Michael TI Outcomes of TAVR in Nonagenarians in the US: Insights from the STS/ACC TVT Registry SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Nonagenarians; Quality of life; TAVR C1 [Szerlip, Molly; Arsalan, Mani; Brown, David] Heart Hosp Baylor Plano, Plano, TX USA. [Holper, Elizabeth M.] Cardiopulm Res Sci & Technol Inst, Dallas, TX USA. [Arnold, Suzanne V.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Vemulapalli, Sreekanth] Duke Univ, Med Ctr, Durham, NC USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Li, Zhuokai] Duke Clin Res Inst, Durham, NC USA. [Mack, Michael] Baylor Healthcare Syst, Plano, TX USA. RI Li, Zhuokai/F-4681-2017 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-618 BP B252 EP B252 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000561 ER PT J AU Theodoropoulos, K Mennuni, MG Garg, A Sharma, A Stefanini, GG AF Theodoropoulos, Kleanthis Mennuni, Marco G. Garg, Aakash Sharma, Abhishek Stefanini, Giulio G. TI Long-Term Mortality Of Percutaneous Coronary Intervention With Drug-Eluting Stents Compared To Bypass Surgery In Patients With Left Main Disease Stratified By The SYNTAX Score: Comprehensive Systematic Review And Meta-Analysis Of 3372 Patients SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 27th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) CY OCT 11-15, 2015 CL San Francisco, CA DE Left main coronary artery disease; Meta-analysis; Syntax score C1 [Theodoropoulos, Kleanthis] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai Bronx, Bronx, NY USA. [Mennuni, Marco G.; Stefanini, Giulio G.] Humanitas Res Hosp, Milan, Italy. [Garg, Aakash] James J Peters VA Hosp, Icahn Sch Med Mt Sinai, Bronx, NY USA. [Sharma, Abhishek] SUNY Downstate Univ, Brooklyn, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 13 PY 2015 VL 66 IS 15 SU S MA TCT-464 BP B190 EP B190 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CU2CF UT WOS:000363329000413 ER PT J AU Pigott, K Rick, J Xie, SRX Hurtig, H Chen-Plotkin, A Duda, JE Morley, JF Chahine, LM Dahodwala, N Akhtar, RS Siderowf, A Trojanowski, JQ Weintraub, D AF Pigott, Kara Rick, Jacqueline Xie, Sharon X. Hurtig, Howard Chen-Plotkin, Alice Duda, John E. Morley, James F. Chahine, Lama M. Dahodwala, Nabila Akhtar, Rizwan S. Siderowf, Andrew Trojanowski, John Q. Weintraub, Daniel TI Longitudinal study of normal cognition in Parkinson disease SO NEUROLOGY LA English DT Article ID 5-YEAR FOLLOW-UP; DIAGNOSTIC-CRITERIA; MOTOR SUBTYPE; LEWY BODIES; DEMENTIA; IMPAIRMENT; COHORT; PROGRESSION; DISORDER; CAMPAIGN AB Objective:To report the rates and predictors of progression from normal cognition to either mild cognitive impairment (MCI) or dementia using standardized neuropsychological methods.Methods:A prospective cohort of patients diagnosed with Parkinson disease (PD) and baseline normal cognition was assessed for cognitive decline, performance, and function for a minimum of 2 years, and up to 6. A panel of movement disorders experts classified patients as having normal cognition, MCI, or dementia, with 55/68 (80.9%) of eligible patients seen at year 6. Kaplan-Meier curves and Cox proportional hazard models were used to examine cognitive decline and its predictors.Results:We enrolled 141 patients, who averaged 68.8 years of age, 63% men, who had PD on average for 5 years. The cumulative incidence of cognitive impairment was 8.5% at year 1, increasing to 47.4% by year 6. All incident MCI cases had progressed to dementia by year 5. In a multivariate analysis, predictors of future decline were male sex (p = 0.02), higher Unified Parkinson's Disease Rating Scale motor score (p 0.001), and worse global cognitive score (p < 0.001).Conclusions:Approximately half of patients with PD with normal cognition at baseline develop cognitive impairment within 6 years and all new MCI cases progress to dementia within 5 years. Our results show that the transition from normal cognition to cognitive impairment, including dementia, occurs frequently and quickly. Certain clinical and cognitive variables may be useful in predicting progression to cognitive impairment in PD. C1 [Pigott, Kara; Rick, Jacqueline; Hurtig, Howard; Chen-Plotkin, Alice; Duda, John E.; Morley, James F.; Chahine, Lama M.; Dahodwala, Nabila; Akhtar, Rizwan S.; Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Duda, John E.; Morley, James F.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU National Institute of Neurological Disorders and Stroke [P50 NS053488] FX National Institute of Neurological Disorders and Stroke P50 NS053488. NR 34 TC 20 Z9 20 U1 5 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD OCT 13 PY 2015 VL 85 IS 15 BP 1276 EP 1282 DI 10.1212/WNL.0000000000002001 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CT7QO UT WOS:000363009800004 PM 26362285 ER PT J AU Lamming, DW Cummings, NE Rastelli, AL Gao, F Cava, E Bertozzi, B Spelta, F Pili, R Fontana, L AF Lamming, Dudley W. Cummings, Nicole E. Rastelli, Antonella L. Gao, Feng Cava, Edda Bertozzi, Beatrice Spelta, Francesco Pili, Roberto Fontana, Luigi TI Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model SO ONCOTARGET LA English DT Article DE protein restriction; mTOR; mice; cancer; aging ID INDUCED INSULIN-RESISTANCE; LIFE-SPAN; COMPLEX 2; CANCER; LONGEVITY; MICE; HEALTH; GROWTH; IGF-1; PROSTATE AB Reduced dietary protein intake and intermittent fasting (IF) are both linked to healthy longevity in rodents, and are effective in inhibiting cancer growth. The molecular mechanisms underlying the beneficial effects of chronic protein restriction (PR) and IF are unclear, but may be mediated in part by a down-regulation of the IGF/mTOR pathway. In this study we compared the effects of PR and IF on tumor growth in a xenograft mouse model of breast cancer. We also investigated the effects of PR and IF on the mechanistic Target Of Rapamycin (mTOR) pathway, inhibition of which extends lifespan in model organisms including mice. The mTOR protein kinase is found in two distinct complexes, of which mTOR complex 1 (mTORC1) is responsive to acute treatment with amino acids in cell culture and in vivo. We found that both PR and IF inhibit tumor growth and mTORC1 phosphorylation in tumor xenografts. In somatic tissues, we found that PR, but not IF, selectively inhibits the activity of the amino acid sensitive mTORC1, while the activity of the second mTOR complex, mTORC2, was relatively unaffected by PR. In contrast, IF resulted in increased S6 phosphorylation in multiple metabolic tissues. Our work represents the first finding that PR may reduce mTORC1 activity in tumors and multiple somatic tissues, and suggest that PR may represent a highly translatable option for the treatment not only of cancer, but also other age-related diseases. C1 [Lamming, Dudley W.; Cummings, Nicole E.] Univ Wisconsin, Dept Med, Madison, WI USA. [Lamming, Dudley W.; Cummings, Nicole E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Lamming, Dudley W.; Cummings, Nicole E.] Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI USA. [Rastelli, Antonella L.] Washington Univ, Div Oncol, St Louis, MO USA. [Gao, Feng] Washington Univ, Div Biostat, St Louis, MO USA. [Cava, Edda; Bertozzi, Beatrice; Spelta, Francesco; Fontana, Luigi] Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO 63130 USA. [Cava, Edda] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy. [Spelta, Francesco] Univ Verona, Dept Med, I-37100 Verona, Italy. [Pili, Roberto] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA. [Fontana, Luigi] Univ Brescia, Sch Med, Dept Clin & Expt Sci, Brescia, Italy. [Fontana, Luigi] CEINGE Biotecnol Avanzate, Naples, Italy. RP Fontana, L (reprint author), Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO 63130 USA. EM dlamming@medicine.wisc.edu; fontana.luigi@gmail.com OI Cava, Edda/0000-0002-8186-039X FU Bakewell Foundation; National Institute of Health; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; K99/R00 Pathway to Independence Award from the NIH/NIA [AG041765] FX The Fontana lab is supported by grants from the Bakewell Foundation. The Lamming lab is supported in part by a grant from the National Institute of Health and startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. D.W.L is supported in part by a K99/R00 Pathway to Independence Award from the NIH/NIA (AG041765). This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 34 TC 5 Z9 6 U1 0 U2 8 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD OCT 13 PY 2015 VL 6 IS 31 BP 31233 EP 31240 DI 10.18632/oncotarget.5180 PG 8 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CU0DD UT WOS:000363185200073 PM 26378060 ER PT J AU Singh, B Li, XR Owens, KM Vanniarajan, A Liang, P Singh, KK AF Singh, Bhupendra Li, Xiurong Owens, Kjerstin M. Vanniarajan, Ayyasamy Liang, Ping Singh, Keshav K. TI Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome SO PLOS ONE LA English DT Article ID CATALYTIC SUBUNIT; POL-ZETA; CANCER-CELLS; EMBRYONIC LETHALITY; INDUCED MUTAGENESIS; MAMMALIAN-CELLS; BREAST-CANCER; ERROR-FREE; DAMAGE; GENE AB To date, mitochondrial DNA polymerase. (POLG) is the only polymerase known to be present in mammalian mitochondria. A dogma in the mitochondria field is that there is no other polymerase present in the mitochondria of mammalian cells. Here we demonstrate localization of REV3 DNA polymerase in the mammalian mitochondria. We demonstrate localization of REV3 in the mitochondria of mammalian tissue as well as cell lines. REV3 associates with POLG and mitochondrial DNA and protects the mitochondrial genome from DNA damage. Inactivation of Rev3 leads to reduced mitochondrial membrane potential, reduced OXPHOS activity, and increased glucose consumption. Conversely, inhibition of the OXPHOS increases expression of Rev3. Rev3 expression is increased in human primary breast tumors and breast cancer cell lines. Inactivation of Rev3 decreases cell migration and invasion, and localization of Rev3 in mitochondria increases survival and the invasive potential of cancer cells. Taken together, we demonstrate that REV3 functions in mammalian mitochondria and that mitochondrial REV3 is associated with the tumorigenic potential of cells. C1 [Singh, Bhupendra] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. [Li, Xiurong; Owens, Kjerstin M.; Vanniarajan, Ayyasamy] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA. [Liang, Ping] Brock Univ, Dept Biol Sci, St Catharines, ON L2S 3A1, Canada. [Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet Pathol, Ctr Free Rad Biol, Environm Hlth,Ctr Aging, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL USA. [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Singh, KK (reprint author), Univ Alabama Birmingham, Dept Genet Pathol, Ctr Free Rad Biol, Environm Hlth,Ctr Aging, Birmingham, AL 35294 USA. EM kksingh@uab.edu FU Veterans Administration [1I01BX001716] FX This study was supported by grant from Veterans Administration (1I01BX001716) to KKS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 4 Z9 4 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 13 PY 2015 VL 10 IS 10 AR e0140409 DI 10.1371/journal.pone.0140409 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT6ZJ UT WOS:000362962300091 PM 26462070 ER PT J AU Hoon, M Sinha, R Okawa, H Suzuki, SC Hirano, AA Brecha, N Rieke, F Wong, ROL AF Hoon, Mrinalini Sinha, Raunak Okawa, Haruhisa Suzuki, Sachihiro C. Hirano, Arlene A. Brecha, Nicholas Rieke, Fred Wong, Rachel O. L. TI Neurotransmission plays contrasting roles in the maturation of inhibitory synapses on axons and dendrites of retinal bipolar cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE GABA receptor; retina; synaptic inhibition; axon-dendrite ID GABA(A) RECEPTORS; RAT RETINA; PRESYNAPTIC INHIBITION; HOMEOSTATIC PLASTICITY; MOUSE RETINA; GLYCINE; CIRCUITS; TRANSMISSION; PHARMACOLOGY; TRANSPORTER AB Neuronal output is modulated by inhibition onto both dendrites and axons. It is unknown whether inhibitory synapses at these two cellular compartments of an individual neuron are regulated coordinately or separately during in vivo development. Because neurotransmission influences synapse maturation and circuit development, we determined how loss of inhibition affects the expression of diverse types of inhibitory receptors on the axon and dendrites of mouse retinal bipolar cells. We found that axonal GABA but not glycine receptor expression depends on neurotransmission. Importantly, axonal and dendritic GABAA receptors comprise distinct subunit compositions that are regulated differentially by GABA release: Axonal GABAA receptors are down-regulated but dendritic receptors are up-regulated in the absence of inhibition. The homeostatic increase in GABAA receptors on bipolar cell dendrites is pathway-specific: Cone but not rod bipolar cell dendrites maintain an up-regulation of receptors in the transmission deficient mutants. Furthermore, the bipolar cell GABAA receptor alterations are a consequence of impaired vesicular GABA release from amacrine but not horizontal interneurons. Thus, inhibitory neurotransmission regulates in vivo postsynaptic maturation of inhibitory synapses with contrasting modes of action specific to synapse type and location. C1 [Hoon, Mrinalini; Okawa, Haruhisa; Suzuki, Sachihiro C.; Wong, Rachel O. L.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA. [Sinha, Raunak; Rieke, Fred] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Sinha, Raunak; Rieke, Fred] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Hirano, Arlene A.; Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Hirano, Arlene A.; Brecha, Nicholas] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Hoon, M (reprint author), Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA. EM mhoon@uw.edu; wongr2@uw.edu FU Knights Templar Eye Foundation; Human Frontier Science Foundation; VA Career Scientist Award; Howard Hughes Medical Institute; NIH [EY10699, EY11850, EY01730, EY15573] FX We thank J. M. Fritschy, R. Enz, H. Wassle and S. Haverkamp for their generous gifts of GABA receptor antibodies, and B. Luscher for GABA gamma 2lox mice. We also thank R. Lewis for assistance with generating Grm6-Cre mice and C. Gamlin and P. Mardoum for helpful comments on the manuscript. This work was supported by Knights Templar Eye Foundation (career starter grant to M. H.), Human Frontier Science Foundation (long-term fellowship to R. S.), VA Career Scientist Award (to N.B.), the Howard Hughes Medical Institute (F.R.), and NIH Grants EY10699 (to R.O.L.W.), EY11850 (to F.R.), Vision Core Grant EY01730 (to M. Neitz), and EY15573 (to N.B.). NR 41 TC 2 Z9 2 U1 1 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 13 PY 2015 VL 112 IS 41 BP 12840 EP 12845 DI 10.1073/pnas.1510483112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT9IQ UT WOS:000363130900068 PM 26420868 ER PT J AU Dawson, GA Glushko, I Hagan, MP AF Dawson, George Anthony Glushko, Ignat Hagan, Michael Philip TI A cross-sectional view of radiation fractionation schemes used for painful bone metastases (PBM) cases within the Veterans Health Administration Radiation Oncology Centers SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Palliative Care in Oncology Symposium CY OCT 09-10, 2015 CL Boston, MA C1 James J Peters VA Med Ctr, New York, NY USA. James J Peters VA Med Ctr, Bronx, NY USA. Virginia Commonwealth Univ, Mineral, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 10 PY 2015 VL 33 IS 29 SU S MA 177 PG 1 WC Oncology SC Oncology GA DO9LD UT WOS:000378107000172 ER PT J AU Kvale, EA Rocque, G Bevis, KS Acemgil, A Taylor, RA Demark-Wahnefried, W Kenzik, K Li, YF Meneses, K Martin, M Fouad, MN Pisu, M Partridge, EE AF Kvale, Elizabeth Ann Rocque, Gabrielle Bevis, Kerri S. Acemgil, Aras Taylor, Richard A. Demark-Wahnefried, Wendy Kenzik, Kelly Li, Yufeng Meneses, Karen Martin, Michelle Fouad, Mona N. Pisu, Maria Partridge, Edward E. TI Trends in health care utilization, cost, and aggressive care at end of life among older cancer patients in the Deep South. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Palliative Care in Oncology Symposium CY OCT 09-10, 2015 CL Boston, MA C1 Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 10 PY 2015 VL 33 IS 29 SU S MA 155 PG 1 WC Oncology SC Oncology GA DO9LD UT WOS:000378107000151 ER PT J AU Walling, AM D'Ambruoso, S Pietras, C Malin, J Hurvitz, SA Watts, F Ferrell, B Zisser, A Wenger, N AF Walling, Anne M. D'Ambruoso, Sarah Pietras, Christopher Malin, Jennifer Hurvitz, Sara A. Watts, Frances Ferrell, Bruce Zisser, Ann Wenger, Neil TI Evaluation of the efficiency of an embedded palliative nurse practitioner in an oncology clinic. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Palliative Care in Oncology Symposium CY OCT 09-10, 2015 CL Boston, MA C1 Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Healthcare Hematol Oncol Breast Oncol Program, Santa Monica, CA USA. Anthem, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 10 PY 2015 VL 33 IS 29 SU S MA 146 PG 1 WC Oncology SC Oncology GA DO9LD UT WOS:000378107000142 ER PT J AU Hunnicut, J Liu, YH Richardson, A Salmon, AB AF Hunnicut, JennaLynn Liu, Yuhong Richardson, Arlan Salmon, Adam B. TI MsrA Overexpression Targeted to the Mitochondria, but Not Cytosol, Preserves Insulin Sensitivity in Diet-Induced Obese Mice SO PLOS ONE LA English DT Article ID METHIONINE-SULFOXIDE-REDUCTASE; FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; DIABETES-MELLITUS; OXIDIZED PROTEINS; RESISTANCE; STRESS; DAMAGE; CAMKII AB There is growing evidence that oxidative stress plays an integral role in the processes by which obesity causes type 2 diabetes. We previously identified that mice lacking the protein oxidation repair enzyme methionine sulfoxide reductase A (MsrA) are particularly prone to obesity-induced insulin resistance suggesting an unrecognized role for this protein in metabolic regulation. The goals of this study were to test whether increasing the expression of MsrA in mice can protect against obesity-induced metabolic dysfunction and to elucidate the potential underlying mechanisms. Mice with increased levels of MsrA in the mitochondria (TgMito MsrA) or in the cytosol (TgCyto MsrA) were fed a high fat/high sugar diet and parameters of glucose homeostasis were monitored. Mitochondrial content, markers of mitochondrial proteostasis and mitochondrial energy utilization were assessed. TgMito MsrA, but not TgCyto MsrA, mice remain insulin sensitive after high fat feeding, though these mice are not protected from obesity. This metabolically healthy obese phenotype of TgMito MsrA mice is not associated with changes in mitochondrial number or biogenesis or with a reduction of proteostatic stress in the mitochondria. However, our data suggest that increased mitochondrial MsrA can alter metabolic homeostasis under diet-induced obesity by activating AMPK signaling, thereby defining a potential mechanism by which this genetic alteration can prevent insulin resistance without affecting obesity. Our data suggest that identification of targets that maintain and regulate the integrity of the mitochondrial proteome, particular against oxidative damage, may play essential roles in the protection against metabolic disease. C1 [Hunnicut, JennaLynn; Liu, Yuhong; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA. [Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. EM salmona@uthscsa.edu OI Salmon, Adam/0000-0002-1475-7843 FU Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System; American Federation for Aging Research; San Antonio Area Foundation; VISN17 of the Veteran's Affairs Office of Research and Development FX This research was supported in part by the Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System, and funding from the American Federation for Aging Research, the San Antonio Area Foundation, and VISN17 of the Veteran's Affairs Office of Research and Development. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 48 TC 4 Z9 4 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 8 PY 2015 VL 10 IS 10 AR e0139844 DI 10.1371/journal.pone.0139844 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT0TW UT WOS:000362511000059 PM 26448611 ER PT J AU Hancock, DB Reginsson, GW Gaddis, NC Chen, X Saccone, NL Lutz, SM Qaiser, B Sherva, R Steinberg, S Zink, F Stacey, SN Glasheen, C Chen, J Gu, F Frederiksen, BN Loukola, A Gudbjartsson, DF Bruske, I Landi, MT Bickeboller, H Madden, P Farrer, L Kaprio, J Kranzler, HR Gelernter, J Baker, TB Kraft, P Amos, CI Caporaso, NE Hokanson, JE Bierut, LJ Thorgeirsson, TE Johnson, EO Stefansson, K AF Hancock, D. B. Reginsson, G. W. Gaddis, N. C. Chen, X. Saccone, N. L. Lutz, S. M. Qaiser, B. Sherva, R. Steinberg, S. Zink, F. Stacey, S. N. Glasheen, C. Chen, J. Gu, F. Frederiksen, B. N. Loukola, A. Gudbjartsson, D. F. Brueske, I. Landi, M. T. Bickeboeller, H. Madden, P. Farrer, L. Kaprio, J. Kranzler, H. R. Gelernter, J. Baker, T. B. Kraft, P. Amos, C. I. Caporaso, N. E. Hokanson, J. E. Bierut, L. J. Thorgeirsson, T. E. Johnson, E. O. Stefansson, K. TI Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence SO TRANSLATIONAL PSYCHIATRY LA English DT Article ID LUNG-CANCER RISK; ACETYLCHOLINE-RECEPTORS; GENOTYPE IMPUTATION; SMOKING-BEHAVIOR; SUSCEPTIBILITY LOCUS; EUROPEAN-AMERICANS; CONTROLLED-TRIAL; CANDIDATE GENES; FAGERSTROM TEST; QUALITY-CONTROL AB We conducted a 1000 Genomes-imputed genome-wide association study (GWAS) meta-analysis for nicotine dependence, defined by the Fagerstrom Test for Nicotine Dependence in 17 074 ever smokers from five European-ancestry samples. We followed up novel variants in 7469 ever smokers from five independent European-ancestry samples. We identified genome-wide significant association in the alpha-4 nicotinic receptor subunit (CHRNA4) gene on chromosome 20q13: lowest P = 8.0 x 10(-9) across all the samples for rs2273500-C (frequency = 0.15; odds ratio = 1.12 and 95% confidence interval = 1.08-1.17 for severe vs mild dependence). rs2273500-C, a splice site acceptor variant resulting in an alternate CHRNA4 transcript predicted to be targeted for nonsense-mediated decay, was associated with decreased CHRNA4 expression in physiologically normal human brains (lowest P = 7.3 x 10(-4)). Importantly, rs2273500-C was associated with increased lung cancer risk (N = 28 998, odds ratio = 1.06 and 95% confidence interval = 1.00-1.12), likely through its effect on smoking, as rs2273500-C was no longer associated with lung cancer after adjustment for smoking. Using criteria for smoking behavior that encompass more than the single 'cigarettes per day' item, we identified a common CHRNA4 variant with important regulatory properties that contributes to nicotine dependence and smoking-related consequences. C1 [Hancock, D. B.; Glasheen, C.] Res Triangle Inst Int, Behav Hlth & Criminal Justice Res Div, Behav & Urban Hlth Program, Res Triangle Pk, NC 27709 USA. [Reginsson, G. W.; Steinberg, S.; Zink, F.; Stacey, S. N.; Gudbjartsson, D. F.; Thorgeirsson, T. E.; Stefansson, K.] deCODE Genet Amgen, Reykjavik, Iceland. [Gaddis, N. C.] Res Triangle Inst Int, Res Comp Div, Res Triangle Pk, NC USA. [Chen, X.; Chen, J.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat, Richmond, VA USA. [Chen, X.] Univ Nevada, Nevada Inst Personalized Med, Las Vegas, NV 89154 USA. [Chen, X.] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [Saccone, N. L.] Washington Univ, Dept Genet, St Louis, MO 63110 USA. [Lutz, S. M.] Univ Colorado, Dept Biostat & Informat, Aurora, CO USA. [Qaiser, B.; Loukola, A.; Kaprio, J.] Univ Helsinki, Dept Publ Hlth, Fac Med, Helsinki, Finland. [Sherva, R.; Farrer, L.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Gu, F.; Landi, M. T.; Caporaso, N. E.] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,United States Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Frederiksen, B. N.] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Brueske, I.] German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany. [Bickeboeller, H.] Univ Gottingen, Dept Genet Epidemiol, D-37073 Gottingen, Germany. [Madden, P.; Bierut, L. J.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Farrer, L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, L.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, L.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Farrer, L.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Kaprio, J.] Natl Inst Hlth & Welf, Helsinki, Finland. [Kaprio, J.] Univ Helsinki, Inst Mol Med, Helsinki, Finland. [Kranzler, H. R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, H. R.] Philadelphia VA Med Ctr, Educ & Clin Ctr, VISN Mental Illness Res 4, Philadelphia, PA USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. [Gelernter, J.] VA CT Healthcare Ctr, Dept Psychiat, West Haven, CT USA. [Baker, T. B.] Univ Wisconsin, Ctr Tobacco Res & Intervent, Madison, WI USA. [Kraft, P.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Kraft, P.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Amos, C. I.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA. [Amos, C. I.] Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH USA. [Amos, C. I.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Hanoven, NH USA. [Hokanson, J. E.] Univ Colorado, Dept Epidemiol, Aurora, CO USA. [Johnson, E. O.] Res Triangle Inst Int, Fellow Program, Res Triangle Pk, NC 27709 USA. [Johnson, E. O.] Res Triangle Inst Int, Behav Hlth & Criminal Justice Res Div, Res Triangle Pk, NC 27709 USA. [Stefansson, K.] Univ Iceland, Fac Med, Reykjavik, Iceland. RP Hancock, DB (reprint author), Res Triangle Inst Int, Behav Hlth & Criminal Justice Res Div, Behav & Urban Hlth Program, East Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM dhancock@rti.org OI Gaddis, Nathan/0000-0001-5205-7138; Farrer, Lindsay/0000-0001-5533-4225; Hancock, Dana/0000-0003-2240-3604; Loukola, Anu-Maria/0000-0003-0542-5967; Thorgeirsson, Thorgeir/0000-0002-5149-7040; Kaprio, Jaakko/0000-0002-3716-2455 FU National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) [R01 DA035825] FX This work was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) grant number R01 DA035825. Acknowledgments for the study samples used to conduct the GWAS meta-analysis, independent replication testing for nicotine dependence and follow-up association testing with lung cancer are included in the Supplementary Information. NR 92 TC 13 Z9 13 U1 3 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD OCT 6 PY 2015 VL 5 AR e651 DI 10.1038/tp.2015.149 PG 11 WC Psychiatry SC Psychiatry GA DA2YR UT WOS:000367663600002 PM 26440539 ER PT J AU You, R Lu, W Shan, M Berlin, JM Samuel, ELG Marcano, DC Sun, ZZ Sikkema, WKA Yuan, XY Song, LZ Hendrix, AY Tour, JM Corry, DB Kheradmand, F AF You, Ran Lu, Wen Shan, Ming Berlin, Jacob M. Samuel, Errol L. G. Marcano, Daniela C. Sun, Zhengzong Sikkema, William K. A. Yuan, Xiaoyi Song, Lizhen Hendrix, Amanda Y. Tour, James M. Corry, David B. Kheradmand, Farrah TI Nanoparticulate carbon black in cigarette smoke induces DNA cleavage and Th17-mediated emphysema SO ELIFE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ELECTRON MICROSCOPY; MASS-SPECTROMETRY; AIR-POLLUTION; CELLS; INFLAMMATION; TISSUE; COPD; CYTOTOXICITY; ACTIVATION AB Chronic inhalation of cigarette smoke is the major cause of sterile inflammation and pulmonary emphysema. The effect of carbon black (CB), a universal constituent of smoke derived from the incomplete combustion of organic material, in smokers and non-smokers is less known. In this study, we show that insoluble nanoparticulate carbon black (nCB) accumulates in human myeloid dendritic cells (mDCs) from emphysematous lung and in CD11c(+) lung antigen presenting cells (APC) of mice exposed to smoke. Likewise, nCB intranasal administration induced emphysema in mouse lungs. Delivered by smoking or intranasally, nCB persisted indefinitely in mouse lung, activated lung APCs, and promoted T helper 17 cell differentiation through double-stranded DNA break (DSB) and ASC-mediated inflammasome assembly in phagocytes. Increasing the polarity or size of CB mitigated many adverse effects. Thus, nCB causes sterile inflammation, DSB, and emphysema and explains adverse health outcomes seen in smokers while implicating the dangers of nCB exposure in non-smokers. C1 [You, Ran; Lu, Wen; Shan, Ming; Yuan, Xiaoyi; Song, Lizhen; Hendrix, Amanda Y.; Corry, David B.; Kheradmand, Farrah] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [You, Ran; Lu, Wen; Corry, David B.; Kheradmand, Farrah] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [You, Ran; Lu, Wen; Corry, David B.; Kheradmand, Farrah] Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA. [Berlin, Jacob M.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA. [Berlin, Jacob M.] City Hope Natl Med Ctr, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA. [Samuel, Errol L. G.; Marcano, Daniela C.; Sun, Zhengzong; Sikkema, William K. A.; Tour, James M.] Rice Univ, Dept Chem, Houston, TX 77005 USA. [Corry, David B.; Kheradmand, Farrah] US Dept Vet Affairs, Michael E DeBakey VA Ctr, Houston, TX USA. RP Tour, JM (reprint author), Rice Univ, Dept Chem, Houston, TX 77005 USA. EM tour@rice.edu; dcorry@bcm.edu; farrahk@bcm.edu OI Marcano, Daniela C./0000-0002-3446-8010; Samuel, Errol/0000-0003-4381-9203 FU National Institutes of Health (NIH) [HL117181]; VA Merit Award FX National Institutes of Health (NIH) HL117181 David B Corry, Farrah Kheradmand; VA Merit Award David B Corry, Farrah Kheradmand; The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. NR 53 TC 3 Z9 3 U1 3 U2 11 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD OCT 5 PY 2015 VL 4 AR e09623 DI 10.7554/eLife.09623 PG 20 WC Biology SC Life Sciences & Biomedicine - Other Topics GA CU8MV UT WOS:000363798000001 PM 26437452 ER PT J AU Charles-Smith, LE Reynolds, TL Cameron, MA Conway, M Lau, EHY Olsen, JM Pavlin, JA Shigematsu, M Streichert, LC Suda, KJ Corley, CD AF Charles-Smith, Lauren E. Reynolds, Tera L. Cameron, Mark A. Conway, Mike Lau, Eric H. Y. Olsen, Jennifer M. Pavlin, Julie A. Shigematsu, Mika Streichert, Laura C. Suda, Katie J. Corley, Courtney D. TI Using Social Media for Actionable Disease Surveillance and Outbreak Management: A Systematic Literature Review SO PLOS ONE LA English DT Article ID HEALTH INFORMATION; PEER SUPPORT; FACEBOOK; INTERVENTION; ADOLESCENTS; NETWORKING; WEB; PREVALENCE; REFERENCES; INTERNET AB Objective Research studies show that social media may be valuable tools in the disease surveillance toolkit used for improving public health professionals' ability to detect disease outbreaks faster than traditional methods and to enhance outbreak response. A social media work group, consisting of surveillance practitioners, academic researchers, and other subject matter experts convened by the International Society for Disease Surveillance, conducted a systematic primary literature review using the PRISMA framework to identify research, published through February 2013, answering either of the following questions: 1. Can social media be integrated into disease surveillance practice and outbreak management to support and improve public health? 2. Can social media be used to effectively target populations, specifically vulnerable populations, to test an intervention and interact with a community to improve health outcomes? Examples of social media included are Facebook, MySpace, microblogs (e.g., Twitter), blogs, and discussion forums. For Question 1, 33 manuscripts were identified, starting in 2009 with topics on Influenza-like Illnesses (n = 15), Infectious Diseases (n = 6), Non-infectious Diseases (n = 4), Medication and Vaccines (n = 3), and Other (n = 5). For Question 2, 32 manuscripts were identified, the first in 2000 with topics on Health Risk Behaviors (n = 10), Infectious Diseases (n = 3), Non-infectious Diseases (n = 9), and Other (n = 10). Conclusions The literature on the use of social media to support public health practice has identified many gaps and biases in current knowledge. Despite the potential for success identified in exploratory studies, there are limited studies on interventions and little use of social media in practice. However, information gleaned from the articles demonstrates the effectiveness of social media in supporting and improving public health and in identifying target populations for intervention. A primary recommendation resulting from the review is to identify opportunities that enable public health professionals to integrate social media analytics into disease surveillance and outbreak management practice. C1 [Charles-Smith, Lauren E.; Corley, Courtney D.] Pacific NW Natl Lab, Data Sci & Analyt Grp, Richland, WA 99352 USA. [Reynolds, Tera L.; Streichert, Laura C.] Int Soc Dis Surveillance, Boston, MA USA. [Cameron, Mark A.] Commonwealth Sci & Ind Res Org Digital Prod Flags, Canberra, ACT, Australia. [Conway, Mike] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. [Lau, Eric H. Y.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. [Olsen, Jennifer M.] Skoll Global Threats Fund, San Francisco, CA USA. [Pavlin, Julie A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Shigematsu, Mika] Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan. [Suda, Katie J.] US Dept Vet Affairs, Ctr Innovat Complex Chron Healthcare, Hines, IL USA. RP Corley, CD (reprint author), Pacific NW Natl Lab, Data Sci & Analyt Grp, Richland, WA 99352 USA. EM court@pnnl.gov OI Charles-Smith, Lauren/0000-0003-0727-0479; Streichert, Laura/0000-0002-9684-5838 FU Pacific Northwest National Laboratory's Laboratory Directed Research and Development Program; International Society for Disease Surveillance FX Project management support for this effort was provided by the International Society for Disease Surveillance. Participation of CDC and LECS was supported in part by Pacific Northwest National Laboratory's Laboratory Directed Research and Development Program. NR 76 TC 12 Z9 12 U1 8 U2 35 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 5 PY 2015 VL 10 IS 10 AR e0139701 DI 10.1371/journal.pone.0139701 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT0PR UT WOS:000362499200052 PM 26437454 ER PT J AU Gabbita, SP Johnson, MF Kobritz, N Eslami, P Poteshkina, A Varadarajan, S Turman, J Zemlan, F Harris-White, ME AF Gabbita, S. Prasad Johnson, Ming F. Kobritz, Naomi Eslami, Pirooz Poteshkina, Aleksandra Varadarajan, Sridhar Turman, John Zemlan, Frank Harris-White, Marni E. TI Oral TNF alpha Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model SO PLOS ONE LA English DT Article ID ALZHEIMER-LIKE PATHOLOGY; HIPPOCAMPAL-LESIONS; ADAPTIVE IMMUNITY; PRECURSOR PROTEIN; TRANSGENIC MICE; A-BETA; DISEASE; BRAIN; MICROGLIA; BEHAVIOR AB Cytokines such as TNF alpha can polarize microglia/macrophages into different neuroinflammatory types. Skewing of the phenotype towards a cytotoxic state is thought to impair phagocytosis and has been described in Alzheimer's Disease (AD). Neuroinflammation can be perpetuated by a cycle of increasing cytokine production and maintenance of a polarized activation state that contributes to AD progression. In this study, 3xTgAD mice, age 6 months, were treated orally with 3 doses of the TNF alpha modulating compound isoindolin-1,3 dithione (IDT) for 10 months. We demonstrate that IDT is a TNF alpha modulating compound both in vitro and in vivo. Following long-term IDT administration, mice were assessed for learning & memory and tissue and serum were collected for analysis. Results demonstrate that IDT is safe for long-term treatment and significantly improves learning and memory in the 3xTgAD mouse model. IDT significantly reduced paired helical filament tau and fibrillar amyloid accumulation. Flow cytometry of brain cell populations revealed that IDT increased the infiltrating neutrophil population while reducing TNF alpha expression in this population. IDT is a safe and effective TNF alpha and innate immune system modulator. Thus small molecule, orally bioavailable modulators are promising therapeutics for Alzheimer's disease. C1 [Gabbita, S. Prasad; Zemlan, Frank] P2D Biosci Inc, Cincinnati, OH USA. [Varadarajan, Sridhar; Turman, John] Univ N Carolina, Dept Chem & Biochem, Wilmington, NC 28401 USA. [Johnson, Ming F.; Kobritz, Naomi; Eslami, Pirooz; Poteshkina, Aleksandra; Harris-White, Marni E.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Harris-White, Marni E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Harris-White, ME (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM marni@ucla.edu FU United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service [1OI1BX000867]; National Institutes of Health [R43 AG044213-01]; P2D Bioscience, Inc. FX This work was supported by a Merit Award #1OI1BX000867 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service to MHW and a National Institutes of Health grant (R43 AG044213-01) to MHW and SPG. P2D Bioscience, Inc. provided support in the form of salaries for authors SPG and FZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 4 Z9 4 U1 1 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 5 PY 2015 VL 10 IS 10 AR e0137305 DI 10.1371/journal.pone.0137305 PG 28 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT0PR UT WOS:000362499200001 PM 26436670 ER PT J AU Blosnich, JR Kopacz, MS McCarten, J Bossarte, RM AF Blosnich, John R. Kopacz, Marek S. McCarten, Janet Bossarte, Robert M. TI Mental Health and Self-directed Violence Among Student Service Members/Veterans in Postsecondary Education SO JOURNAL OF AMERICAN COLLEGE HEALTH LA English DT Article DE self-injurious behavior; mental health; veterans health; attempted suicide; suicidal ideation ID POSTTRAUMATIC-STRESS-DISORDER; SUICIDAL IDEATION; COLLEGE-STUDENTS; COMBAT EXPOSURE; UNITED-STATES; MALE VETERANS; ALCOHOL-USE; POPULATION; MILITARY; HARM AB Objectives: Using a sample of student service members/veterans, the current study aimed to examine the prevalence of psychiatric diagnoses and suicide-related outcomes and the association of hazardous duty with mental health. Participants: Data are from the Fall 2011 National College Health Assessment (N = 27,774). Methods: Logistic regression was used to examine (1) the association of student service member/veteran status with mental health outcomes and (2) the association of hazardous duty with mental health outcomes among student service members/veterans (n = 706). Results: Student service members/veterans had higher odds of self-harm than students without military experience. Among student service members/veterans, hazardous duty was positively associated (odds ratio [OR] = 2.00, 95% confidence interval [CI] [1.30, 3.07]) with having a psychiatric diagnosis but negatively associated (OR = 0.41, 95% CI [0.20, 0.85]) with suicidal ideation. Conclusions: Self-harm may be a unique phenomenon among service members/veterans. Suicide prevention with this population should include information about self-harm, and future research should explore whether suicidal intent underlies self-harm. C1 [Blosnich, John R.] Univ Rochester, Dept Psychiat, Rochester, NY 14642 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kopacz, Marek S.; McCarten, Janet; Bossarte, Robert M.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Blosnich, JR (reprint author), Univ Rochester, Dept Psychiat, Rochester, NY 14642 USA. FU VISN 2 Center of Excellence for Suicide Prevention from the National Institute of Mental Health [5T32MH020061]; Department of Veterans Affairs Office of Academic Affiliations; Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System FX This work was partially supported by the VISN 2 Center of Excellence for Suicide Prevention, a postdoctoral fellowship to J.R.B. in an institutional National Research Service Award from the National Institute of Mental Health (5T32MH020061), and a postdoctoral fellowship to J.R.B. through the Department of Veterans Affairs Office of Academic Affiliations and the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. The opinions expressed in this work are the authors' and do not reflect those of the funders, institutions, the Department of Veterans Affairs, or the US Government. NR 47 TC 3 Z9 3 U1 4 U2 13 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0744-8481 EI 1940-3208 J9 J AM COLL HEALTH JI J. Am. Coll. Health PD OCT 3 PY 2015 VL 63 IS 7 SI SI BP 418 EP 426 DI 10.1080/07448481.2014.931282 PG 9 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA CR5ND UT WOS:000361388900002 PM 24918517 ER PT J AU Kopacz, MS Karras, E AF Kopacz, Marek S. Karras, Elizabeth TI Student Service Members and Veterans Who Access Pastoral Care for the Purposes of Mental Health Support SO JOURNAL OF AMERICAN COLLEGE HEALTH LA English DT Article DE counseling; mental health; pastoral care ID HELP-SEEKING; MEMBERS/VETERANS; CLERGY AB . Objectives: (1) Describe the demographic characteristics of student service members and veterans (SSM/V) who seek pastoral care for mental health support; and (2) evaluate patterns of access to mental health care providers among pastoral care users and nonusers. Participants: Respondents to the Fall 2011 National College Health Assessment who reported a history of military service and ever having sought mental health care (n = 331). Methods: Differences between groups were examined using chi-square and Student's t tests. Adjusted odds ratios were estimated using ordinal logistic regression. Results: One-third of participants used pastoral care. Users were more likely to be male and older. No significant differences were noted for race/ethnicity, sexual orientation, or exposure to hazardous duty. Users had a greater than 6-fold increase in proportional odds of accessing multiple providers. Conclusions: Many SSM/V look to pastoral care for mental health support. Colleges should consider incorporating a pastoral care component into specialized health care programs provided to SSM/V. C1 [Kopacz, Marek S.; Karras, Elizabeth] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Karras, Elizabeth] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 35 TC 3 Z9 3 U1 2 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0744-8481 EI 1940-3208 J9 J AM COLL HEALTH JI J. Am. Coll. Health PD OCT 3 PY 2015 VL 63 IS 7 SI SI BP 496 EP 501 DI 10.1080/07448481.2014.923430 PG 6 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA CR5NL UT WOS:000361389700001 PM 24848307 ER PT J AU Tierney, M Finnell, DS Naegle, MA LaBelle, C Gordon, AJ AF Tierney, Matthew Finnell, Deborah S. Naegle, Madeline A. LaBelle, Colleen Gordon, Adam J. TI Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers SO SUBSTANCE ABUSE LA English DT Editorial Material ID TREATMENT FACILITIES; PHYSICIANS; PROGRAMS; WAIVERS; THERAPY; CARE C1 [Tierney, Matthew] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94103 USA. [Tierney, Matthew] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94103 USA. [Finnell, Deborah S.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. [Naegle, Madeline A.] NYU, Coll Nursing, New York, NY USA. [LaBelle, Colleen] Boston Univ, Med Ctr, Boston, MA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Tierney, M (reprint author), Univ Calif San Francisco, 1380 Howard St,2nd Floor, San Francisco, CA 94103 USA. EM mtierney@ucsf.edu NR 34 TC 0 Z9 0 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD OCT 2 PY 2015 VL 36 IS 4 BP 389 EP 392 DI 10.1080/08897077.2015.1101733 PG 4 WC Substance Abuse SC Substance Abuse GA CX2LM UT WOS:000365528300001 PM 26587696 ER PT J AU Kim, JI Ganesan, S Luo, SX Wu, YW Park, E Huang, EJ Chen, L Ding, JB AF Kim, Jae-Ick Ganesan, Subhashree Luo, Sarah X. Wu, Yu-Wei Park, Esther Huang, Eric J. Chen, Lu Ding, Jun B. TI Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons SO SCIENCE LA English DT Article ID ALCOHOL-METABOLIZING GENES; RETINOIC ACID; SYNAPTIC PLASTICITY; PARKINSONS-DISEASE; MODULATION; STRIATUM; PUTRESCINE; SYSTEM; TRANSMISSION; POLYAMINES AB Midbrain dopamine neurons are an essential component of the basal ganglia circuitry, playing key roles in the control of fine movement and reward. Recently, it has been demonstrated that gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter, is co-released by dopamine neurons. Here, we show that GABA co-release in dopamine neurons does not use the conventional GABA-synthesizing enzymes, glutamate decarboxylases GAD65 and GAD67. Our experiments reveal an evolutionarily conserved GABA synthesis pathway mediated by aldehyde dehydrogenase 1a1 (ALDH1a1). Moreover, GABA co-release is modulated by ethanol (EtOH) at concentrations seen in blood alcohol after binge drinking, and diminished ALDH1a1 leads to enhanced alcohol consumption and preference. These findings provide insights into the functional role of GABA co-release in midbrain dopamine neurons, which may be essential for reward-based behavior and addiction. C1 [Kim, Jae-Ick; Ganesan, Subhashree; Wu, Yu-Wei; Park, Esther; Chen, Lu; Ding, Jun B.] Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA. [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA. [Ding, Jun B.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. RP Ding, JB (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA. EM dingjun@stanford.edu RI Ding, Jun/B-2513-2009 OI Ding, Jun/0000-0003-0690-1312; Huang, Eric/0000-0002-5381-3801; Wu, Yu-Wei/0000-0002-4459-087X FU National Institute of Neurological Disorders and Stroke, NIH [NS075136, NS091144]; Klingenstein Foundation; National Institute of Mental Health, NIH [MH086403, MH091193] FX The authors thank A. Du and Y. Liu for technical assistance; D. Ron for suggestions on using the two-bottle-choice behavior test; and T. Sudhof, G. Panagiotakos, W. Wei, Z. Khaliq, and members of the Ding laboratory for helpful discussions. Supported by grants from the National Institute of Neurological Disorders and Stroke, NIH, NS075136, NS091144 (J.B.D.), the Klingenstein Foundation (J.B.D.), and National Institute of Mental Health, NIH, MH086403 (L.C.) and MH091193 (L.C.). The authors declare no conflicts of interest. All primary electrophysiological and immunohistochemical data are archived on a server in the Department of Neurosurgery at Stanford University School of Medicine. NR 39 TC 25 Z9 25 U1 9 U2 33 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD OCT 2 PY 2015 VL 350 IS 6256 BP 102 EP 106 DI 10.1126/science.aac4690 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS5EA UT WOS:000362098300055 PM 26430123 ER PT J AU Alves, P Robinson, E Bashir, M Feng, R Werth, VP AF Alves, Paul Robinson, Elizabeth Bashir, Muhammad Feng, Rui Werth, Victoria P. TI Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-alpha and IFN-alpha from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Alves, Paul; Robinson, Elizabeth; Bashir, Muhammad; Werth, Victoria P.] Vet Affairs Med Ctr, Dermatol, Philadelphia, PA USA. [Alves, Paul; Robinson, Elizabeth; Werth, Victoria P.] Univ Penn, Dermatol, Philadelphia, PA 19104 USA. [Bashir, Muhammad] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Feng, Rui] Univ Penn, Biostat & Epidemiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1154 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202418 ER PT J AU Andrews, JS Wahl, ER Schmajuk, G Yelin, EH Katz, PP AF Andrews, James S. Wahl, Elizabeth R. Schmajuk, Gabriela Yelin, Edward H. Katz, Patricia P. TI Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Andrews, James S.; Katz, Patricia P.] Univ Calif San Francisco, Rheumatol, San Francisco, CA 94143 USA. [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Med Rheumatol, San Francisco, CA USA. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Yelin, Edward H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1527 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202787 ER PT J AU Bawadekar, M Gendron-Fitzpatrick, A Warner, TF Lundblad, LKA Thompson, P Shelef, MA AF Bawadekar, Mandar Gendron-Fitzpatrick, Annette Warner, Thomas F. Lundblad, Lennart K. A. Thompson, Paul Shelef, Miriam A. TI Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Bawadekar, Mandar; Shelef, Miriam A.] Univ Wisconsin, Med, Madison, WI USA. [Gendron-Fitzpatrick, Annette] Univ Wisconsin, Comparat Pathol Lab Res Anim Resources Ctr, Madison, WI USA. [Gendron-Fitzpatrick, Annette] Univ Wisconsin, Pathobiol Sci, Madison, WI USA. [Warner, Thomas F.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Lundblad, Lennart K. A.] Univ Vermont, Med, Burlington, VT USA. [Thompson, Paul] Univ Massachusetts, Worcester, MA 01605 USA. [Shelef, Miriam A.] William S Middleton Mem Vet Adm Med Ctr, Med, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1038 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202302 ER PT J AU Bays, A Nayak, R Daikh, DI Yazdany, J Schmajuk, G AF Bays, Alison Nayak, Renuka Daikh, David I. Yazdany, Jinoos Schmajuk, Gabriela TI Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Bays, Alison] Univ Washington, Rheumatol, Seattle, WA 98195 USA. [Nayak, Renuka; Yazdany, Jinoos] UCSF, Rheumatol, San Francisco, CA USA. [Daikh, David I.] UCSF, VA Med Ctr, Rheumatol, San Francisco, CA USA. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2502 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204053 ER PT J AU Bays, A Wahl, ER Daikh, DI Yazdany, J Schmajuk, G AF Bays, Alison Wahl, Elizabeth R. Daikh, David I. Yazdany, Jinoos Schmajuk, Gabriela TI Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Bays, Alison] Univ Washington, Rheumatol, Seattle, WA 98195 USA. [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Med Rheumatol, San Francisco, CA USA. [Daikh, David I.] UCSF VA Med Ctr, Rheumatol, San Francisco, CA USA. [Yazdany, Jinoos] UCSF, Rheumatol, Sf, CA USA. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2490 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204041 ER PT J AU Cesaroni, M Jordan, J Schreiter, J Chevrier, M Wang, G Calderon, C Piantone, A Gourley, I Cohen, S Fretzin, S Wozniacka, A Werth, VP Benson, J AF Cesaroni, Matteo Jordan, Jarrat Schreiter, Jessica Chevrier, Marc Wang, Grace Calderon, Cesar Piantone, Alexa Gourley, Ian Cohen, Stanley Fretzin, Scott Wozniacka, Anna Werth, Victoria P. Benson, Jacqueline TI Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Cesaroni, Matteo; Jordan, Jarrat; Schreiter, Jessica; Chevrier, Marc; Benson, Jacqueline] Janssen Res & Dev LLC, Estrela Lupus Venture, Spring House, PA USA. [Wang, Grace; Piantone, Alexa] Janssen Res & Dev, Spring House, PA USA. [Calderon, Cesar] Janssen Res & Dev, Havertown, PA USA. [Gourley, Ian] Janssen Res & Dev, Wayne, PA USA. [Cohen, Stanley] Metroplex Clin Res Ctr LLC, Dallas, TX USA. [Fretzin, Scott] Dawes Fretzin Clin Res Grp LLCC, Indianapolis, IN USA. [Wozniacka, Anna] Med Univ Lodz, Lodz, Poland. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RI Wozniacka, Anna/S-9674-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 788 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202054 ER PT J AU Curtis, JR Burton, MJ Yang, S Chen, L Mikuls, TR Singh, JA Winthrop, KL Baddley, J AF Curtis, Jeffrey R. Burton, Mary Jane Yang, Shou Chen, Lang Mikuls, Ted R. Singh, Jasvinder A. Winthrop, Kevin L. Baddley, John TI Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Curtis, Jeffrey R.; Yang, Shou; Chen, Lang] Univ Alabama Birmingham, Birmingham, AL USA. [Curtis, Jeffrey R.; Singh, Jasvinder A.; Baddley, John] Birmingham VAMC, Birmingham, AL USA. [Burton, Mary Jane] Jackson VAMC, Jackson, MS USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Baddley, John] Univ Alabama Birmingham, Med, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1603 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203010 ER PT J AU Ferrer, HRG Kutzbach, AG Iraheta, I Scher, JU Von Feldt, J Ogdie-Beatty, A AF Ferrer, Helga Raquel Garcia Kutzbach, A. Garcia Iraheta, Isa Scher, Jose U. Von Feldt, Joan Ogdie-Beatty, Alexis TI Clinical and Imaging Features of Reactive Arthritis in Guatemala City SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Ferrer, Helga Raquel Garcia] Soc Worldwide Med Exchange, North Bay Village, FL USA. [Kutzbach, A. Garcia] Francisco Marroquin Univ, Sch Med, Internal Med, Rheumatol Unit AGAR, Guatemala City, Guatemala. [Iraheta, Isa] Guatemalan Assoc Rheumat Dis AGAR, Rheumatol, Guatemala City, Guatemala. [Scher, Jose U.] NYU, Sch Med, Dept Med, Div Rheumatol, New York, NY USA. [Von Feldt, Joan] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Von Feldt, Joan] Univ Penn, Philadelphia, PA 19104 USA. [Ogdie-Beatty, Alexis] Univ Penn, Med Rheumatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 693 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201687 ER PT J AU Gaffo, AL Jacobs, DR Wang, HF Saag, KG AF Gaffo, Angelo L. Jacobs, David R., Jr. Wang, Huifen Saag, Kenneth G. TI Weight Variables and Their Association with Serum Urate Concentrations and Hyperuricemia in Young Adults SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Gaffo, Angelo L.] Birmingham VA Med Ctr, Rheumatol, Birmingham, AL USA. [Gaffo, Angelo L.] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Jacobs, David R., Jr.] Univ Minnesota, Epidemiol, Minneapolis, MN USA. [Wang, Huifen] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Epidemiol Lab, Boston, MA 02111 USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 234 PG 3 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201231 ER PT J AU George, M Kreider, M Shah, R Miller, W Merkel, PA Werth, V AF George, Michael Kreider, Maryl Shah, Rupal Miller, Wallace, Jr. Merkel, Peter A. Werth, Victoria TI Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [George, Michael] Hosp Univ Penn, Dept Rheumatol, Philadelphia, PA 19104 USA. [Kreider, Maryl; Shah, Rupal] Univ Penn, Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Miller, Wallace, Jr.] Univ Penn, Radiol, Philadelphia, PA 19104 USA. [Merkel, Peter A.] Univ Penn, Div Rheumatol, Penn Vasculitis Ctr, Philadelphia, PA 19104 USA. [Werth, Victoria] Vet Affairs Med Ctr, Dermatol, Philadelphia, PA USA. [Werth, Victoria] Univ Penn, Dermatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 304 PG 5 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201299 ER PT J AU Hoyer, BF Schmajuk, G Aringer, M Johnson, SR Daikh, DI Dorner, T AF Hoyer, Bimba F. Schmajuk, Gabriela Aringer, Martin Johnson, Sindhu R. Daikh, David I. Dorner, Thomas CA SLE Criteria Steering Comm TI Multi-Center Delphi Exercise Reveals Important Key Items in Classifying SLE SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Hoyer, Bimba F.; Dorner, Thomas] Charite, Dept Med Rheumatol & Clin Immunol, D-13353 Berlin, Germany. [Hoyer, Bimba F.] German Rheumatism Res Ctr Berlin DRFZ, Berlin, Germany. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Aringer, Martin] Tech Univ Dresden, Univ Clin Ctr, Med 3, Rheumatol, D-01062 Dresden, Germany. [Johnson, Sindhu R.] Mt Sinai Hosp, Toronto Gen Hosp, Toronto Western Hosp, Med,Toronto Scleroderma Program, Toronto, ON M5G 1X5, Canada. [Johnson, Sindhu R.] Univ Toronto, Toronto, ON, Canada. [Johnson, Sindhu R.] Univ Toronto, Toronto Western Hosp, Dept Rheumatol, Toronto, ON M5T 2S8, Canada. [Johnson, Sindhu R.] Univ Toronto, Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada. [Daikh, David I.] UCSF VA Med Ctr, Rheumatol, San Francisco, CA USA. [Dorner, Thomas] Charite, German Rheumatism Res Ctr Berlin DRFZ, D-13353 Berlin, Germany. RI Hoyer, Bimba Franziska/F-3174-2016 OI Hoyer, Bimba Franziska/0000-0002-5252-1719 NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 746 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202013 ER PT J AU Hsu, HC Yan, ZQ Yang, P Wu, Q Hamilton, J Li, J Li, H Luo, B Harrington, L Mountz, J AF Hsu, Hui-Chen Yan, Zhaoqi Yang, PingAr Wu, Qi Hamilton, Jennie Li, Jun Li, Hao Luo, Bao Harrington, Laurie Mountz, John TI Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2 SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Hsu, Hui-Chen; Wu, Qi] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Hsu, Hui-Chen; Yang, PingAr; Wu, Qi] Univ Alabama Birmingham, Dept Med Clin Immunol & Rheumatol, Birmingham, AL USA. [Yan, Zhaoqi; Harrington, Laurie] Univ Alabama Birmingham, Cell Developmntl & Integrat Biol, Birmingham, AL USA. [Hamilton, Jennie] Univ Alabama Birmingham, Birmingham, AL USA. [Li, Jun] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Li, Hao; Luo, Bao] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Mountz, John] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Birmingham, AL 35294 USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1111 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202375 ER PT J AU Khan, N Tiao, J Feng, R Bird, S Choi, J George, M Gonzalez-Rivera, T Kaufman, JL Luo, JJ Micheletti, R Payne, AS Price, R Rubin, AI Sreih, AG Thomas, P Okawa, J Werth, VP AF Khan, Neelam Tiao, Janice Feng, Rui Bird, Shawn Choi, Juliana George, Michael Gonzalez-Rivera, Tania Kaufman, Jacob L. Luo, Jin Jun Micheletti, Robert Payne, Aimee S. Price, Raymond Rubin, Adam I. Sreih, Antoine G. Thomas, Preethi Okawa, Joyce Werth, Victoria P. TI Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index Among Dermatologists, Rheumatologists, and Neurologists SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Khan, Neelam; Tiao, Janice; Choi, Juliana; Micheletti, Robert; Payne, Aimee S.; Werth, Victoria P.] Hosp Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Khan, Neelam; Tiao, Janice; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Feng, Rui] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Bird, Shawn; Kaufman, Jacob L.; Price, Raymond] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [George, Michael; Gonzalez-Rivera, Tania; Thomas, Preethi] Hosp Univ Penn, Dept Rheumatol, Philadelphia, PA 19104 USA. [Luo, Jin Jun] Temple Univ, Dept Neurol, Sch Med, Philadelphia, PA 19122 USA. [Rubin, Adam I.; Okawa, Joyce] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sreih, Antoine G.] Univ Penn, Dept Rheumatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 295 PG 3 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201290 ER PT J AU Liu, ML Sharma, M Sahu, S Werth, V AF Liu, Ming-Lin Sharma, Meena Sahu, Shwetapadma Werth, Victoria TI Neutrophil Netosis Formation during the UVB Induced-Skin Inflammation SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Liu, Ming-Lin; Sharma, Meena] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Liu, Ming-Lin; Sharma, Meena] Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Sahu, Shwetapadma; Werth, Victoria] Univ Penn, Dermatol, Philadelphia, PA 19104 USA. [Sahu, Shwetapadma] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, Victoria] Philadelphia VA Med Ctr, Dermatol, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1763 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203169 ER PT J AU Mountz, JD Li, J Hamilton, J Yang, PA Wu, Q Luo, B Ding, YN Li, H Crossman, D Malarkey, E Zhou, Y Fu, YX Hsu, HC AF Mountz, John D. Li, Jun Hamilton, Jennie Yang, PingAr Wu, Qi Luo, Bao Ding, Yanna Li, Hao Crossman, David Malarkey, Erik Zhou, Yong Fu, Yang-Xin Hsu, Hui-Chen TI The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Mountz, John D.; Yang, PingAr] Univ Alabama Birmingham, Dept Med Clin Immunol & Rheumatol, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. [Li, Jun; Zhou, Yong] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Hamilton, Jennie; Ding, Yanna] Univ Alabama Birmingham, Birmingham, AL USA. [Wu, Qi; Hsu, Hui-Chen] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Luo, Bao; Li, Hao] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Crossman, David] Univ Alabama Birmingham, Genet, Birmingham, AL USA. [Malarkey, Erik] Univ Alabama Birmingham, Cell Dev & Integrated Biol, Birmingham, AL USA. [Fu, Yang-Xin] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1755 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203162 ER PT J AU Murray, SG Tonner, C Marafino, BJ Haserodt, S Schmajuk, G Yazdany, J AF Murray, Sara G. Tonner, Chris Marafino, Ben J. Haserodt, Sarah Schmajuk, Gabriela Yazdany, Jinoos TI Automated Case Identification of Lupus from an Electronic Health Record Using Novel Informatics Approaches SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Murray, Sara G.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA. [Tonner, Chris] Univ Calif San Francisco, Rheumatol, San Francisco, CA 94143 USA. [Marafino, Ben J.; Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Haserodt, Sarah] Calif Pacific Med Ctr, Internal Med, San Francisco, CA USA. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 919 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202183 ER PT J AU Navarro-Millan, I Jain, A Belsom, R Gaffo, AL Yang, S Mikuls, TR Curtis, JR AF Navarro-Millan, Iris Jain, Archana Belsom, Rebecca Gaffo, Angelo L. Yang, Shuo Mikuls, Ted R. Curtis, Jeffrey R. TI Influence of Anxiety and Depression on the Swollen to Tender Joint Count Ratio: In Pursuit of a Phenotype of RA Patients with Somatic Complaints in a US Veteran Population SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Navarro-Millan, Iris; Jain, Archana; Belsom, Rebecca] Univ Alabama Birmingham, Rheumatol, Birmingham, AL USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Rheumatol, Birmingham, AL USA. [Yang, Shuo] Univ Alabama Birmingham, Clin Immunol Rheumatol, Birmingham, AL USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Med, Omaha, NE USA. [Curtis, Jeffrey R.] Univ Alabama Birmingham, Clin Immunol & Rheumatol, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2657 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204208 ER PT J AU Ng, B AF Ng, Bernard TI Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Ng, Bernard] Puget Sound Healthsyst, US Dept Vet Affairs, Rheumatol, Seattle, WA USA. [Ng, Bernard] Univ Washington, Div Rheumatol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 577 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201572 ER PT J AU Ramos, PS Sajuthi, S Divers, J Kaufman, KM Nayak, U Chen, WM Hunt, KJ Kamen, DL Gilkeson, GS Fernandes, JK Spruill, IJ Kimberly, RP Harley, JB Garvey, WT Sale, MM Langefeld, CD AF Ramos, Paula S. Sajuthi, Satria Divers, Jasmin Kaufman, Kenneth M. Nayak, Uma Chen, Wei-Min Hunt, Kelly J. Kamen, Diane L. Gilkeson, Gary S. Fernandes, Jyotika K. Spruill, Ida J. Kimberly, Robert P. Harley, John B. Garvey, W. Timothy Sale, Michele M. Langefeld, Carl D. TI Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Ramos, Paula S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Sajuthi, Satria; Langefeld, Carl D.] Wake Forest Sch Med, Biostat Sci, Winston Salem, NC USA. [Divers, Jasmin] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Nayak, Uma; Chen, Wei-Min] Univ Virginia, Publ Hlth Sci, Charlottesville, VA USA. [Hunt, Kelly J.] Med Univ S Carolina, Publ Hlth Sci, Charleston, SC 29425 USA. [Kamen, Diane L.; Fernandes, Jyotika K.] Med Univ S Carolina, Med, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Spruill, Ida J.] Med Univ S Carolina, Nursing, Charleston, SC 29425 USA. [Kimberly, Robert P.] Univ Alabama Birmingham, Med Clin Immun & Rheumatol, Birmingham, AL USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH 45229 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Sale, Michele M.] Univ Virginia, Dept Med, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 88 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201086 ER PT J AU Sambamurthy, N Nguyen, V Diviney, P Gan, J Bush-Joseph, C Chubinskaya, S Malfait, AM Dodge, G Scanzello, CR AF Sambamurthy, Nisha Vu Nguyen Diviney, Patrick Gan, Justin Bush-Joseph, Charles Chubinskaya, Susanna Malfait, Anne-Marie Dodge, George Scanzello, Carla R. TI CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Sambamurthy, Nisha; Vu Nguyen] Univ Penn, Med Rheumatol, Philadelphia, PA 19104 USA. [Sambamurthy, Nisha; Vu Nguyen; Dodge, George] Philadelphia VA Med Ctr, Res, Philadelphia, PA USA. [Diviney, Patrick; Dodge, George] Univ Penn, Orthoped, Philadelphia, PA 19104 USA. [Gan, Justin] Rush Univ, Med Ctr, Rheumatol, Chicago, IL 60612 USA. [Bush-Joseph, Charles] Rush Univ, Med Ctr, Orthoped, Chicago, IL 60612 USA. [Chubinskaya, Susanna] Rush Univ, Med Ctr, Biochem, Chicago, IL 60612 USA. [Malfait, Anne-Marie] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Scanzello, Carla R.] Univ Penn, Rheumatol, Philadelphia, PA 19104 USA. [Scanzello, Carla R.] Univ Penn, Rheumatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Scanzello, Carla R.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2009 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203415 ER PT J AU Schmajuk, G Hoyer, BF Aringer, M Johnson, SR Dorner, T Daikh, DI AF Schmajuk, Gabriela Hoyer, Bimba F. Aringer, Martin Johnson, Sindhu R. Dorner, Thomas Daikh, David I. CA SLE Classification Criteria Steeri TI Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Hoyer, Bimba F.] Charite, Dept Med Rheumatol & Clin Immunol, D-13353 Berlin, Germany. [Hoyer, Bimba F.] German Rheumatism Res Ctr Berlin DRFZ, Berlin, Germany. [Aringer, Martin] Tech Univ Dresden, Univ Clin Ctr, Med 3, Rheumatol, D-01062 Dresden, Germany. [Johnson, Sindhu R.] Univ Toronto, Toronto Western Hosp, Dept Rheumatol, Toronto, ON M5T 2S8, Canada. [Johnson, Sindhu R.] Univ Toronto, Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada. [Dorner, Thomas] Charite, D-13353 Berlin, Germany. [Daikh, David I.] UCSF VA Med Ctr, Rheumatol, San Francisco, CA USA. RI Hoyer, Bimba Franziska/F-3174-2016 OI Hoyer, Bimba Franziska/0000-0002-5252-1719 NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 775 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202041 ER PT J AU Singh, JA Yang, S Bridges, SL Saag, KG AF Singh, Jasvinder A. Yang, Shuo Bridges, S. Louis, Jr. Saag, Kenneth G. TI Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate: A Study Using Large Intergrated National Health Network SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Singh, Jasvinder A.] Birmingham VAMC, Birmingham, AL USA. [Yang, Shuo] Univ Alabama Birmingham, Clin Immunol Rheumatol, Birmingham, AL USA. [Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Clin Immunol & Rheumatol, Birmingham, AL USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2240 PG 4 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203646 ER PT J AU Wahl, ER Gross, A Chernitskiy, V Trupin, L Yazdany, J Katz, PP AF Wahl, Elizabeth R. Gross, Andrew Chernitskiy, Vladimir Trupin, Laura Yazdany, Jinoos Katz, Patricia P. TI A Brief Patient-Reported Measure of Physical Function Is Sensitive to Changes in a Composite Disease Activity Measure in a Diverse Rheumatoid Arthritis Clinic Setting SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Med Rheumatol, San Francisco, CA USA. [Wahl, Elizabeth R.; Gross, Andrew; Chernitskiy, Vladimir; Trupin, Laura; Katz, Patricia P.] Univ Calif San Francisco, Med Rheumatol, San Francisco, CA 94143 USA. [Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2682 PG 1 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204233 ER PT J AU Wahl, ER Gross, A Chernitskiy, V Katz, PP Yazdany, J AF Wahl, Elizabeth R. Gross, Andrew Chernitskiy, Vladimir Katz, Patricia P. Yazdany, Jinoos TI Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Med Rheumatol, San Francisco, CA USA. [Wahl, Elizabeth R.; Gross, Andrew; Chernitskiy, Vladimir; Katz, Patricia P.] Univ Calif San Francisco, Med Rheumatol, San Francisco, CA 94143 USA. [Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2615 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204166 ER PT J AU Wilfong, EM Murray, SG Schmajuk, G Yazdany, J AF Wilfong, Erin M. Murray, Sara G. Schmajuk, Gabriela Yazdany, Jinoos TI Death and Infection Rates Appear Reduced in a Modern Cohort of ICU Patients with Rheumatic Disease SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Wilfong, Erin M.] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA. [Murray, Sara G.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 1404 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860202665 ER PT J AU Moss, JA Moore, RL Selleck, CS AF Moss, Jacqueline A. Moore, Randy L. Selleck, Cynthia S. TI Veteran Competencies for Undergraduate Nursing Education SO ADVANCES IN NURSING SCIENCE LA English DT Article DE competencies; curricula; Nursing Education; Veterans; Veterans Health AB Military Veterans comprise approximately 10% of the US population. Most Veterans do not receive their health care through Veterans Affairs facilities, are seen across the health care system, and their prior military service and associated health issues often go unrecognized. In this study, a modified Delphi design was used to develop a set of 10 Veteran Care Competencies and associated knowledge, skills, and attitudes for Undergraduate Nursing Education: Military and Veteran Culture, Post Traumatic Stress Disorder, Amputation and Assistive Devices, Environmental/Chemical Exposures, Substance Use Disorder, Military Sexual Trauma, Traumatic Brain Injury, Suicide, Homelessness, and Serious Illness Especially at the End of Life. C1 [Moss, Jacqueline A.] Dept Acute Chron & Continuing Care, Birmingham, AL USA. [Moore, Randy L.] Univ Alabama Birmingham, Sch Nursing, 1720 2nd Ave S, Birmingham, AL 35294 USA. [Moore, Randy L.] Birmingham Vet Affairs Med Ctr, VA Nursing Acad Partnership, Birmingham, AL USA. [Selleck, Cynthia S.] Univ Alabama Birmingham, Sch Nursing, Clin & Global Partnerships, Birmingham, AL 35294 USA. RP Moss, JA (reprint author), Univ Alabama Birmingham, Sch Nursing, 1720 2nd Ave S, Birmingham, AL 35294 USA. EM mossja@uab.edu FU Office of Academic Affiliations through the Veterans Affairs Nursing Academy FX This publication was supported in part by the Office of Academic Affiliations through the Veterans Affairs Nursing Academy, a partnership between the Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Nursing. NR 10 TC 3 Z9 3 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0161-9268 EI 1550-5014 J9 ADV NURS SCI JI Adv. Nurs. Sci. PD OCT-DEC PY 2015 VL 38 IS 4 BP 306 EP 316 DI 10.1097/ANS.0000000000000092 PG 11 WC Nursing SC Nursing GA DD2AT UT WOS:000369725500008 PM 26517342 ER PT J AU Wool, C Kozak, LE Lindley, LC AF Wool, Charlotte Kozak, Leila E. Lindley, Lisa C. TI Work Environment Facilitators to the Availability of Complementary and Alternative Therapies in Perinatal Hospices SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE CAM; hospice care; palliative care; perinatal; work environment ID PALLIATIVE CARE; MEDICINE; PAIN; MASSAGE; CANCER; TOUCH; MOOD; LIFE AB Increasingly, patients and clinicians are considering palliative care interventions during pregnancy for the maternal-fetal dyad when a life-limiting diagnosis is confirmed. Nurses are at the forefront of providing hospice and palliative care that includes planning interventions for infants nearing the end of life. However, little is known about the work environment facilitators to the availability of complementary and alternative medicine (CAM) therapies. Using a national database of perinatal hospice and palliative care providers, we describe the types of CAM therapies available and explore the influence of the nurse work environment on the availability of CAM therapies with multivariate regression analysis. This study shows that having an education environment where clinicians are trained, along with a highly educated registered nurse support staff, and a bachelor of science in nursing-educated staff was critical to the availability of CAM therapies. The clinical implications for hospice and palliative nurses caring for infants and their families are discussed. C1 [Wool, Charlotte] York Coll Penn, Dept Nursing, 441 Country Club Rd, York, PA 17403 USA. [Kozak, Leila E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kozak, Leila E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Lindley, Lisa C.] Univ Tennessee, Coll Nursing, Knoxville, TN 37996 USA. RP Wool, C (reprint author), York Coll Penn, Dept Nursing, 441 Country Club Rd, York, PA 17403 USA. EM cwool@ycp.edu OI Lindley, Lisa C./0000-0003-2960-7896 FU National Institute of Nursing Research [K01NR014490] FX This publication was made possible by grant number K01NR014490 from the National Institute of Nursing Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Nursing Research or National Institutes of Health. NR 28 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1522-2179 EI 1539-0705 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD OCT PY 2015 VL 17 IS 5 BP 391 EP 396 DI 10.1097/NJH.0000000000000167 PG 6 WC Nursing SC Nursing GA DD1YB UT WOS:000369718000004 PM 26877713 ER PT J AU Knight, JB Schott, NJ Kentor, ML Williams, BA AF Knight, Joshua B. Schott, Nicholas J. Kentor, Michael L. Williams, Brian A. TI Neurotoxicity of common peripheral nerve block adjuvants SO CURRENT OPINION IN ANESTHESIOLOGY LA English DT Review DE buprenorphine; clonidine; dexamethasone; local anesthetics; midazolam ID BRACHIAL-PLEXUS BLOCK; ACTIVATED CATION CURRENT; POSTOPERATIVE ANALGESIA; BUPRENORPHINE; BUPIVACAINE; MIDAZOLAM; DEXMEDETOMIDINE; CLONIDINE; ROPIVACAINE; DEXAMETHASONE AB Purpose of review This review outlines the analgesic role of perineural adjuvants for local anesthetic nerve block injections, and evaluates current knowledge regarding whether adjuvants modulate the neurocytologic properties of local anesthetics. Recent findings Perineural adjuvant medications such as dexmedetomidine, clonidine, buprenorphine, dexamethasone, and midazolam play unique analgesic roles. The dosing of these medications to prevent neurotoxicity is characterized in various cellular and in-vivo models. Much of this mitigation may be via reducing the dose of local anesthetic used while achieving equal or superior analgesia. Dose-concentration animal models have shown no evidence of deleterious effects. Clinical observations regarding blocks with combined bupivacaine-clonidine-buprenorphine-dexamethasone have shown beneficial effects on block duration and rebound pain without long-term evidence of neurotoxicity. In-vitro and in-vivo studies of perineural clonidine and dexmedetomidine show attenuation of perineural inflammatory responses generated by local anesthetics. Summary Dexmedetomidine added as a peripheral nerve blockade adjuvant improves block duration without neurotoxic properties. The combined adjuvants clonidine, buprenorphine, and dexamethasone do not appear to alter local anesthetic neurotoxicity. Midazolam significantly increases local anesthetic neurotoxicity in vitro, but when combined with clonidine-buprenorphine-dexamethasone (sans local anesthetic) produces no in-vitro or in-vivo neurotoxicity. Further larger-species animal testing and human trials will be required to reinforce the clinical applicability of these findings. C1 [Knight, Joshua B.; Schott, Nicholas J.; Kentor, Michael L.] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Williams, Brian A.] Univ Pittsburgh, Sch Med, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15213 USA. RP Knight, JB (reprint author), Educ Off, Dept Anesthesiol, Liliane S Kaufmann Bldg,3471 Fifth Ave,Suite 910, Pittsburgh, PA 15213 USA. EM knightjb@upmc.edu FU Department of Anesthesiology, University of Pittsburgh Medical Center; VA Pittsburgh Health System, Pittsburgh, Pennsylvania, USA FX This work was supported by the Department of Anesthesiology, University of Pittsburgh Medical Center (J.B.K., N.J.S., and M.L.K.), and by the VA Pittsburgh Health System (B.A.W.), Pittsburgh, Pennsylvania, USA. NR 28 TC 4 Z9 5 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0952-7907 EI 1473-6500 J9 CURR OPIN ANESTHESIO JI Curr. Opin. Anesthesiol. PD OCT PY 2015 VL 28 IS 5 BP 598 EP 604 DI 10.1097/ACO.0000000000000222 PG 7 WC Anesthesiology SC Anesthesiology GA DC9CY UT WOS:000369519900018 PM 26207854 ER PT J AU Fuller, SC Donald, PJ AF Fuller, Scott C. Donald, Paul J. TI Evaluating risk factors and predicting complications in head and neck reconstructive surgery SO CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY LA English DT Review DE complications; microvascular; reconstruction; risk factors ID FREE-FLAP RECONSTRUCTION; CLEAN-CONTAMINATED HEAD; FREE-TISSUE TRANSFER; C-REACTIVE PROTEIN; MICROVASCULAR HEAD; PERIOPERATIVE COMPLICATIONS; CANCER SURGERY; DEFECTS; HYPERCOAGULABILITY; THERAPY AB Purpose of reviewComplications in head and neck reconstructive surgery can have devastating effects. There is a tremendous body of literature examining risk factors that may predict complications in this patient population, thereby minimizing or avoiding adverse outcomes.Recent findingsRotational thromboelastometry may provide a mechanism to predict coagulopathy in patients undergoing microvascular reconstruction. Surveillance of serum C-reactive protein levels may provide an additional tool for early intervention in wound complications Controversy persists in the literature regarding specific risk factors and associated perioperative complications.SummaryPerioperative medical and surgical complications are commonplace in the management of complex oncologic disease and attendant defect reconstructions. Potential risk factors have been examined exhaustively in the literature without a consensus being established. C1 [Fuller, Scott C.] US Dept Vet Affairs, Northern Calif Healthcare Syst, Div Otolaryngol, 10535 Hosp Way, Mather, CA 95655 USA. [Fuller, Scott C.; Donald, Paul J.] Univ Calif, Davis Med Ctr, Dept Otolaryngol, Sacramento, CA USA. RP Fuller, SC (reprint author), US Dept Vet Affairs, Northern Calif Healthcare Syst, Div Otolaryngol, 10535 Hosp Way, Mather, CA 95655 USA. EM scott.fuller@va.gov NR 40 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1068-9508 EI 1531-6998 J9 CURR OPIN OTOLARYNGO JI Curr. Opin. Otolaryngol. Head Neck Surg. PD OCT PY 2015 VL 23 IS 5 BP 415 EP 419 DI 10.1097/MOO.0000000000000192 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA DC7RB UT WOS:000369416800009 PM 26339973 ER PT J AU Plenter, R Jain, S Ruller, CM Nydam, TL Jani, AH AF Plenter, Robert Jain, Swati Ruller, Chelsea M. Nydam, Trevor L. Jani, Alkesh H. TI Murine Kidney Transplant Technique SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Medicine; Issue 104; renal; transplant; mouse; immunology; rejection; surgery ID MICE; ANASTOMOSES; THROMBOSIS; VESSELS; INTACT AB The first mouse kidney transplant technique was published in 1973(1) by the Russell laboratory. Although it took some years for other labs to become proficient in and utilize this technique, it is now widely used by many laboratories around the world. A significant refinement to the original technique using the donor aorta to form the arterial anastomosis instead of the renal artery was developed and reported in 1993 by Kalina and Mottram (2) with a further advancement coming from the same laboratory in 1999 (3). While one can become proficient in this model, a search of the literature reveals that many labs still experience a high proportion of graft loss due to arterial thrombosis. We describe here a technique that was devised in our laboratory that vastly reduces the arterial thrombus reported by others (4,5). This is achieved by forming a heel-and-toe cuff of the donor infra-renal aorta that facilitates a larger anastomosis and straighter blood flow into the kidney. C1 [Plenter, Robert] Univ Colorado, Colorado Ctr Transplantat Care Res & Educ, Denver, CO 80202 USA. [Plenter, Robert] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Jain, Swati; Jani, Alkesh H.] Univ Colorado, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80202 USA. [Jain, Swati; Jani, Alkesh H.] Univ Colorado, Denver, CO 80202 USA. [Ruller, Chelsea M.; Nydam, Trevor L.] Univ Colorado, Sch Med, Dept Surg, Denver, CO USA. [Jani, Alkesh H.] Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO USA. RP Plenter, R (reprint author), Univ Colorado, Colorado Ctr Transplantat Care Res & Educ, Denver, CO 80202 USA. EM robert.plenter@ucdenver.edu FU [1R03DK096151] FX This work was supported in part by 1R03DK096151. NR 14 TC 1 Z9 1 U1 0 U2 0 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD OCT PY 2015 IS 104 AR e52848 DI 10.3791/52848 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DB5SB UT WOS:000368572800011 PM 26555373 ER PT J AU Payne, SN Maher, ME Tran, NH Van De Hey, DR Foley, TM Yueh, AE Leystra, AA Pasch, CA Jeffrey, JJ Clipson, L Matkowskyj, KA Deming, DA AF Payne, S. N. Maher, M. E. Tran, N. H. Van De Hey, D. R. Foley, T. M. Yueh, A. E. Leystra, A. A. Pasch, C. A. Jeffrey, J. J. Clipson, L. Matkowskyj, K. A. Deming, D. A. TI PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors SO ONCOGENESIS LA English DT Article ID PAPILLARY MUCINOUS NEOPLASM/CARCINOMA; CELL LUNG-CANCER; DUCTAL ADENOCARCINOMA; CLINICAL-TRIALS; PATHWAY INHIBITORS; BREAST-CANCER; MICE; KRAS; GEMCITABINE; COOPERATE AB Aberrations in the phosphoinositide 3-kinase (PI3K) signaling pathway have a key role in the pathogenesis of numerous cancers by altering cell growth, metabolism, proliferation and apoptosis. Interest in targeting the PI3K signaling cascade continues, as new agents are being clinically evaluated. PIK3CA mutations result in a constitutively active PI3K and are present in a subset of pancreatic cancers. Here we examine mutant PIK3CA-mediated pancreatic tumorigenesis and the response of PIK3CA mutant pancreatic cancers to dual PI3K/mammalian target of rapamycin (mTOR) inhibition. Two murine models were generated expressing a constitutively active PI3K within the pancreas. An increase in acinar-to-ductal metaplasia and pancreatic intraepithelial neoplasms (PanINs) was identified. In one model these lesions were detected as early as 10 days of age. Invasive pancreatic ductal adenocarcinoma developed in these mice as early as 20 days of age. These cancers were highly sensitive to treatment with dual PI3K/mTOR inhibition. In the second model, PanINs and invasive cancer develop with a greater latency owing to a lesser degree of PI3K pathway activation in this murine model. In addition to PI3K pathway activation, increased ERK1/2 signaling is common in human pancreatic cancers. Phosphorylation of ERK1/2 was also investigated in these models. Phosphorylation of ERK1/2 is demonstrated in the pre-neoplastic lesions and invasive cancers. This activation of ERK1/2 is diminished with dual PI3K/mTOR inhibition. In summary, PIK3CA mutations can initiate pancreatic tumorigenesis and these cancers are particularly sensitive to dual PI3K/mTOR inhibition. Future studies of PI3K pathway inhibitors for patients with PIK3CA mutant pancreatic cancers are warranted. C1 [Payne, S. N.; Pasch, C. A.; Jeffrey, J. J.; Matkowskyj, K. A.; Deming, D. A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Maher, M. E.; Tran, N. H.; Van De Hey, D. R.; Foley, T. M.; Yueh, A. E.; Deming, D. A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI USA. [Leystra, A. A.; Clipson, L.] Univ Wisconsin, Dept Oncol, Madison, WI USA. [Matkowskyj, K. A.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Matkowskyj, K. A.; Deming, D. A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Deming, DA (reprint author), Univ Wisconsin, Med, 600 Highland Ave,K6-544, Madison, WI 53792 USA. EM ddeming@medicine.wisc.edu FU National Institutes of Health [P30 CA014520]; UW Carbone Cancer Center; UW Department of Medicine; UW School of Medicine and Public Health; UW Graduate School through the Wisconsin Alumni Research Foundation FX This project was supported by the National Institutes of Health P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); and start-up funds (DAD) from the UW Carbone Cancer Center, UW Department of Medicine, UW School of Medicine and Public Health, and the UW Graduate School through the Wisconsin Alumni Research Foundation. NR 45 TC 4 Z9 5 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-9024 J9 ONCOGENESIS JI Oncogenesis PD OCT PY 2015 VL 4 AR e169 DI 10.1038/oncsis.2015.28 PG 10 WC Oncology SC Oncology GA DB7FE UT WOS:000368679300002 PM 26436951 ER PT J AU Lozano, BE Gros, DF Killeen, T Jaconis, M Beylotte, FM Boyd, S Back, SE AF Lozano, Brian E. Gros, Daniel F. Killeen, Therese Jaconis, Maryanne Beylotte, Francis M., III Boyd, Stephen Back, Sudie E. TI To Reduce or Abstain? Substance Use Goals in the Treatment of Veterans With Substance Use Disorders and Comorbid PTSD SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ABSTINENCE; THERAPY; PREDICTORS; DEPENDENCE; DRINKING AB Background: Posttraumatic stress disorder (PTSD) and substance use disorders (SUD) frequently co-occur. Previous research demonstrates the utility of goals in attaining improved SUD outcomes, however, no previous studies have examined goal choices in the context of integrated treatment for comorbid PTSD and SUD. Objectives: The present study investigated correlates of treatment entry goals to either reduce or abstain from substance use. Methods: Participants (N = 60) were treatment-seeking veterans with current PTSD and SUD. Participants completed self-report and clinician-rated measures of substance use, PTSD, and affective symptoms as part of a larger randomized controlled trial. Results: Half (30/60) of participants endorsed a treatment entry goal to reduce substance use (reducers). Compared to participants who endorsed a treatment entry goal of abstinence (abstainers), reducers were significantly younger, more likely to be employed, more likely to have served in recent military conflicts (Operations Enduring/Iraqi Freedom), and endorsed significantly fewer symptoms of alcohol dependence. Conclusions and Scientific Significance: The findings demonstrate clinically relevant differences based on treatment entry goals, suggesting that individuals are often able to choose conceivably appropriate treatment goals based, most notably, on the severity of their SUD. Collaboratively engaging patients in establishing treatment goals that are consistent with their beliefs and desires in conjunction with empirical findings is particularly relevant in the context of treatment for SUD and PTSD where many patients are ambivalent about treatment and attrition is common. C1 [Lozano, Brian E.; Gros, Daniel F.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Lozano, Brian E.; Gros, Daniel F.; Killeen, Therese; Jaconis, Maryanne; Beylotte, Francis M., III; Boyd, Stephen; Back, Sudie E.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Lozano, BE (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM Brian.Lozano@va.gov FU NIDA [DA021228]; NIAAA [T32 AA007474]; Veterans Affairs Clinical Sciences Research and Development [CX000845] FX The authors would like to acknowledge support from NIDA grant number DA021228 (Back, S. E.), NIAAA T32 AA007474 (Woodward, J.), Veterans Affairs Clinical Sciences Research and Development CX000845 (Gros, D. F.). NR 25 TC 2 Z9 2 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD OCT PY 2015 VL 24 IS 7 BP 578 EP 581 DI 10.1111/ajad.12263 PG 4 WC Substance Abuse SC Substance Abuse GA DB4SD UT WOS:000368502500001 PM 26300219 ER PT J AU Jacobs, P Ang, A Hillhouse, MP Saxon, AJ Nielsen, S Wakim, PG Mai, BE Mooney, LJ Potter, JS Blaine, JD AF Jacobs, Petra Ang, Alfonso Hillhouse, Maureen P. Saxon, Andrew J. Nielsen, Suzanne Wakim, Paul G. Mai, Barbara E. Mooney, Larissa J. Potter, Jennifer S. Blaine, Jack D. TI Treatment Outcomes in Opioid Dependent Patients With Different Buprenorphine/Naloxone Induction Dosing Patterns and Trajectories SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID MAINTENANCE TREATMENT; METHADONE; RETENTION; TRIAL; EXPERIENCE; PREDICTORS; HEALTH AB Background and Objectives: Induction is a crucial period of opioid addiction treatment. This study aimed to identify buprenorphine/naloxone (BUP) induction patterns and examine their association with outcomes (opioid use, retention, and related adverse events [AEs]). Methods: The secondary analysis of a study of opioid-dependent adults seeking treatment in eight treatment settings included 740 participants inducted on BUP with flexible dosing. Results: Latent class analysis models detected six distinctive induction trajectories: bup1-started and remained on low; bup2started low, shifted slowly to moderate; bup3-started low, shifted quickly to moderate; bup4-started high, shifted to low; bup5-started and remained on moderate; bup6-started moderate, shifted to high dose (Fig. 1). Baseline characteristics, including Clinical Opioid Withdrawal Scale (COWS), were important predictors of retention. When controlled for the baseline characteristics, bup6 participants were three times less likely to drop out the first 7 days than bup1 participants (adjusted hazard ratio (aHR) = .28, p = .03). Opioid use and AEs were similar across trajectories. Participants on >= 16 mg BUP compared to those on < 16 mg at Day 28 were less likely to drop out (aHR = .013, p = .001) and less likely to have AEs during the first 28 days (aOR = .57, p = .03). Discussion and Conclusions: BUP induction dosing was guided by an objective measure of opioid withdrawal. Participants with higher baseline COWS whose BUP doses were raised more quickly were less likely to drop out in the first 7 days than those whose doses were raised slower. Scientific Significance: This study supports the use of an objective measure of opioid withdrawal (COWS) during BUP induction to improve retention early in treatment. C1 [Jacobs, Petra; Blaine, Jack D.] EMMES Corp, Rockville, MD USA. [Ang, Alfonso; Hillhouse, Maureen P.; Mooney, Larissa J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Saxon, Andrew J.] VA Puget Sound Hlth Care, Seattle, WA USA. [Nielsen, Suzanne] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Wakim, Paul G.] NIDA, Ctr Clin Trials Network, Rockville, MD USA. [Mai, Barbara E.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Potter, Jennifer S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Jacobs, P (reprint author), EMMES Corp, Rockville, MD USA. EM petraejacobs@gmail.com OI Nielsen, Suzanne/0000-0001-5341-1055 FU National Institute on Drug Abuse; Clinical Trials Network: Pacific Northwest Node, NIH/NIDA [5 U10 DA013714-08]; NHMRC [1013803] FX The original START study was funded by the National Institute on Drug Abuse, where the buprenorphine/naloxone for START was provided by Reckitt Benckiser Pharmaceuticals. The authors of this secondary analysis collaborated on the implementation of START and received the dataset. Dr. Saxon has grant support from the Clinical Trials Network: Pacific Northwest Node. 5 U10 DA013714-08, NIH/NIDA, served on the Pharmaceutical, Scientific Advisory Board, Alkermes, Inc. and has been a presenter for Reckitt-Benckiser, Inc. He has no publishing constraints. Dr. Nielsen is supported by a NHMRC Research Fellowship (#1013803), has been an investigator on united educational grants from Reckitt-Benckiser, completely unrelated to this work, no publishing constraints. Dr. Blaine has been a treatment advocate for Reckitt Benckiser Pharmaceuticals, Inc., with no publishing constraints. The authors alone are responsible for the content and writing of this paper. NR 23 TC 2 Z9 2 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD OCT PY 2015 VL 24 IS 7 BP 667 EP 675 DI 10.1111/ajad.12288 PG 9 WC Substance Abuse SC Substance Abuse GA DB4SD UT WOS:000368502500014 PM 26400835 ER PT J AU Ioannou, GN Berry, K AF Ioannou, George N. Berry, Kristin TI Comparison of Liver Transplant-related Survival Benefit in Patients With vs Without Hepatocellular Carcinoma in the United States. SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.; Berry, Kristin] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 49 BP 232A EP 233A PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375400050 ER PT J AU El-Serag, HB Richardson, P Kanwal, F AF El-Serag, Hashem B. Richardson, Peter Kanwal, Fasiha TI Incidence and Predictors of hepatocellular Carcinoma following Sustained Virological Response: A national Cohort Study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Richardson, Peter; Kanwal, Fasiha] Emory Univ, Med Gastroenterol & Hepatol, Houston, TX USA. [El-Serag, Hashem B.] Houston VA Med Ctr, Houston, TX USA. [El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 90 BP 253A EP 254A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375400091 ER PT J AU Beste, LA Leipertz, S Green, P Dominitz, JA Ross, D Ioannou, GN AF Beste, Lauren A. Leipertz, Steven Green, Pamela Dominitz, Jason A. Ross, David Ioannou, George N. TI Trends in the burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans from 2001-2013 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Dominitz, Jason A.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Beste, Lauren A.; Leipertz, Steven; Green, Pamela; Dominitz, Jason A.; Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Ross, David] Dept Vet Affairs, Off Publ Hlth, Washington, DC USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 128 BP 274A EP 274A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401013 ER PT J AU Sulkowski, MS Brau, N Lawitz, E Shiffman, ML Towner, WJ Ruane, PJ Doehle, B Wang, J McNally, J Osinusi, A Brainard, DM McHutchison, JG Reau, N Patel, K AF Sulkowski, Mark S. Brau, Norbert Lawitz, Eric Shiffman, Mitchell L. Towner, William J. Ruane, Peter J. Doehle, Brian Wang, Jing McNally, John Osinusi, Anu Brainard, Diana M. McHutchison, John G. Reau, Nancy Patel, Keyur TI A Randomized Controlled Trial of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV Infected Patients: The Phase 3 ASTRAL-2 Study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA. [Brau, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Brau, Norbert] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lawitz, Eric] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA. [Shiffman, Mitchell L.] Liver Inst Virginia, Richmond, VA USA. [Towner, William J.] Kaiser Permanente, Los Angeles, CA USA. [Ruane, Peter J.] Ruane Med, Los Angeles, CA USA. [Doehle, Brian; Wang, Jing; McNally, John; Osinusi, Anu; Brainard, Diana M.; McHutchison, John G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Reau, Nancy] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Patel, Keyur] Duke Univ, Sch Med, Durham, NC USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 205 BP 313A EP 313A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401090 ER PT J AU Minguez, B Aytaman, A Ventura-Cots, M Badshah, MB Citti, CC Platt, HL Chen, TY Kikuchi, L Marcus, S Yin, M Aberg, J Dieterich, D Schwartz, ME Brau, N AF Minguez, Beatriz Aytaman, Ayse Ventura-Cots, Meritxell Badshah, Maaz B. Citti, Caitlin C. Platt, Heather L. Chen, Ting-Yi Kikuchi, Luciana Marcus, Sonja Yin, Michael Aberg, Judith Dieterich, Douglas Schwartz, Myron E. Braeu, Norbert TI Trends of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients over Time, 1995-2013 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Minguez, Beatriz; Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Liver Unit, Barcelona, Spain. [Aytaman, Ayse] VA New York Harbor HCS, Brooklyn, NY USA. [Aytaman, Ayse] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Badshah, Maaz B.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Citti, Caitlin C.; Aberg, Judith; Dieterich, Douglas; Braeu, Norbert] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Platt, Heather L.; Yin, Michael] Columbia Univ, Med Ctr, Div Infect Dis, New York, NY USA. [Chen, Ting-Yi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, SP, Brazil. [Marcus, Sonja; Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Schwartz, Myron E.] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 380 BP 402A EP 403A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401264 ER PT J AU Kikuchi, L Citti, CC Chen, TY Platt, HL Kaplan, DE Ventura-Cots, M Jain, MK Vispo, E Daruich, J Nunez, M Barreiro, P Minguez, B Aytaman, A Rimland, D Brau, N AF Kikuchi, Luciana Citti, Caitlin C. Chen, Ting-Yi Platt, Heather L. Kaplan, David E. Ventura-Cots, Meritxell Jain, Mamta K. Vispo, Eugenia Daruich, Jorge Nunez, Marina Barreiro, Pablo Minguez, Beatriz Aytaman, Ayse Rimland, David Braeu, Norbert TI Sorafenib Therapy in HIV-infected Patients with Hepatocellular Carcinoma (HCC) SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Kikuchi, Luciana] Univ Sao Paulo, Gastroenterol, Sao Paulo, Brazil. [Citti, Caitlin C.; Braeu, Norbert] Icahn Sch Med Mt Sinai, Infectious Dis & Liver Dis, New York, NY 10029 USA. [Citti, Caitlin C.; Platt, Heather L.; Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Chen, Ting-Yi; Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA. [Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Barcelona, Spain. [Vispo, Eugenia; Barreiro, Pablo] Hosp Carlos III, Madrid, Spain. [Daruich, Jorge] Univ Buenos Aires, Buenos Aires, DF, Argentina. [Nunez, Marina] Wake Forest Univ, Winston Salem, NC 27109 USA. [Aytaman, Ayse] VA New York Harbor HCS, Brooklyn, NY USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 438 BP 430A EP 430A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401321 ER PT J AU Badshah, MB Ventura-Cots, M Citti, CC Kikuchi, L Marcus, S Minguez, B Chen, TY Hernandez, MD Aberg, J Schwartz, ME Dieterich, D Brau, N AF Badshah, Maaz B. Ventura-Cots, Meritxell Citti, Caitlin C. Kikuchi, Luciana Marcus, Sonja Minguez, Beatriz Chen, Ting-Yi Hernandez, Maria D. Aberg, Judith Schwartz, Myron E. Dieterich, Douglas Braeu, Norbert TI Improved Survival of Hepatocellular Carcinoma (HCC) in HIV/Hepatitis B Virus (HBV)-Coinfected Patients Who Are Diagnosed Through HCC Screening SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Badshah, Maaz B.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Ventura-Cots, Meritxell] Hosp Univ Vall Hebron, Barcelona, Spain. [Citti, Caitlin C.; Aberg, Judith; Dieterich, Douglas; Braeu, Norbert] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, SP, Brazil. [Marcus, Sonja; Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain. [Chen, Ting-Yi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Hernandez, Maria D.] Univ Miami, Sch Med, Miami, FL USA. [Schwartz, Myron E.] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 457 BP 439A EP 440A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401340 ER PT J AU Kriss, M Edwards, M Golden-Mason, L Larson, C Diener, K Rosen, HR AF Kriss, Michael Edwards, Michael Golden-Mason, Lucy Larson, Colin Diener, Katrina Rosen, Hugo R. TI High-throughput sequencing to define the miRNA cargo of LSEC-derived, anti-viral exosomes SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Kriss, Michael; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Div Gastroenterol & Hepatol, Aurora, CO USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. [Edwards, Michael] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Larson, Colin; Diener, Katrina] Univ Colorado, Genom & Microarray Core, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 503 BP 461A EP 462A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401386 ER PT J AU Egert, EM Johnson, RD Watts, MM Booty, J Damjanov, N Mohr, R Griffiths, J Lee, M Shaikh, HA Hawley, RC Ghosh, MS Mungiole, NS Kaplan, DE AF Egert, E. M. Johnson, Rena D. Watts, Micah M. Booty, Jordan Damjanov, Nevena Mohr, Rosemary Griffiths, Jenifer Lee, Major Shaikh, Haroon A. Hawley, Richard C. Ghosh, Martha S. Mungiole, Nicole S. Kaplan, David E. TI A Regional Multidisciplinary Liver Tumor Board improves Access to Hepatocellular Carcinoma Treatment for Patients Geographically Distant from Tertiary Medical Center SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Egert, E. M.] Coatesville VA Med Ctr, Cochranville, PA USA. [Johnson, Rena D.] Wilmington VA Med Ctr, Wilmington, DE USA. [Watts, Micah M.; Booty, Jordan; Damjanov, Nevena; Mohr, Rosemary; Lee, Major; Mungiole, Nicole S.; Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Griffiths, Jenifer; Shaikh, Haroon A.; Hawley, Richard C.] Lebanon VA Med Ctr, Lebanon, PA USA. [Ghosh, Martha S.] Wilkes Barre VA Med Ctr, Wilkes Barre, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 521 BP 469A EP 469A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401404 ER PT J AU Hunt, CM Beste, LA Ioannou, GN Lowy, E Provenzale, DT Kelley, MJ Suzuki, A Moylan, CA Oloruntoba, OO Tillmann, HL Lim, JK Ross, D AF Hunt, Christine M. Beste, Lauren A. Ioannou, George N. Lowy, Elliott Provenzale, Dawn T. Kelley, Michael J. Suzuki, Ayako Moylan, Cynthia A. Oloruntoba, Omobonike O. Tillmann, Hans L. Lim, Joseph K. Ross, David TI Hepatitis B Testing Prior to Administration of Rituximab, Ofatumumab and Obinutuzumab in the National Veterans Affairs Health Healthcare System, 2002-2014 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Hunt, Christine M.; Provenzale, Dawn T.; Kelley, Michael J.; Moylan, Cynthia A.; Oloruntoba, Omobonike O.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA. [Hunt, Christine M.; Provenzale, Dawn T.; Kelley, Michael J.; Moylan, Cynthia A.; Oloruntoba, Omobonike O.] Durham VA Med Ctr, Dept Med, Durham, NC USA. [Ross, David] USDA, Off Publ Hlth, Washington, DC 20250 USA. [Beste, Lauren A.; Ioannou, George N.; Lowy, Elliott] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Ioannou, George N.; Lowy, Elliott] Univ Washington, Seattle, WA 98195 USA. [Suzuki, Ayako] Univ Arkansas Med Sci, Dept Med, Div Hepatol, Little Rock, AR 72205 USA. [Lim, Joseph K.] Yale Univ, Sch Med, Dept Med, Div Hepatol, New Haven, CT 06510 USA. [Tillmann, Hans L.] Eastern Carolina Univ, Dept Med, Greenville, NC USA. [Suzuki, Ayako] Cent Arkansas Vet Heathcare Syst, Dept Med, Div Hepatol, Little Rock, AR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 540 BP 478A EP 479A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401423 ER PT J AU Yarnykh, VL Tartaglione, E Ioannou, GN AF Yarnykh, Vasily L. Tartaglione, Erica Ioannou, George N. TI Fast macromolecular proton fraction (MPF) mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Yarnykh, Vasily L.] Univ Washington, Radiol, Seattle, WA 98195 USA. [Yarnykh, Vasily L.] Tomsk State Univ, Biol & Biophys Res Inst, Tomsk, Russia. [Tartaglione, Erica; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Med, Seattle, WA 98195 USA. RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 803 BP 609A EP 609A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402127 ER PT J AU Ioannou, GN Subramanian, S Chait, A Yeh, MM Haigh, WG Savard, C AF Ioannou, George N. Subramanian, Savitha Chait, Alan Yeh, Matthew M. Haigh, W. G. Savard, Christopher TI Cholesterol crystallization within hepatocyte lipid droplets and its role in NASH SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Ioannou, George N.; Subramanian, Savitha; Chait, Alan; Yeh, Matthew M.; Savard, Christopher] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George N.; Haigh, W. G.; Savard, Christopher] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 923 BP 664A EP 664A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402247 ER PT J AU Basu, P Shah, NJ John, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj J. John, Nimy Aloysius, M. Brown, Robert TI Sofosbuvir and Ledipasvir in attainment of SVR12 in sickle cell disease (SCD) sub-population with chronic hepatitis C (CHC). a single center prospective open label clinical pilot study - SLASH C Trial SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Basu, Patrick; John, Nimy; Aloysius, M.] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Brown, Robert] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1037 BP 715A EP 716A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402360 ER PT J AU Ho, SB Monto, A Peyton, A Kaplan, DE Byrne, S Moon, S Zhu, YN Seyedkazemi, S Rossaro, L Brainard, DM Guyer, W Shaikh, OS Fuchs, M Morgan, TR AF Ho, Samuel B. Monto, Alexander Peyton, Adam Kaplan, David E. Byrne, Sean Moon, Scott Zhu, Yanni Seyedkazemi, Star Rossaro, Lorenzo Brainard, Diana M. Guyer, William Shaikh, Obaid S. Fuchs, Michael Morgan, Timothy R. TI Twelve Weeks of Sofosbuvir plus Ribavirin is Effective for Treatment of Genotype 2 HCV in Difficult to Treat US Veterans with Cirrhosis - Results of the VALOR-HCV Study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Ho, Samuel B.] VA San Diego Healthcare Syst, Gastroenterol, San Diego, CA USA. [Monto, Alexander] UCSF SFVAMC, Gastroenterol, San Francisco, CA USA. [Peyton, Adam] Miami VA Healthcare Syst, Gastroenterol, Miami, FL USA. [Kaplan, David E.] Philadelphia VA Med Ctr, Gastroenterol, Philadelphia, PA USA. [Byrne, Sean; Moon, Scott; Zhu, Yanni; Seyedkazemi, Star; Rossaro, Lorenzo; Brainard, Diana M.; Guyer, William] Gilead Sci, Foster City, CA USA. [Shaikh, Obaid S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fuchs, Michael] Richmond VA Med Ctr, Richmond, VA USA. [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Gastroenterol, Long Beach, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1041 BP 718A EP 718A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402364 ER PT J AU Basu, P Shah, NJ John, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj J. John, Nimy Aloysius, M. Brown, Robert TI Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Basu, Patrick; John, Nimy; Aloysius, M.] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Brown, Robert] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 2 Z9 2 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1074 BP 736A EP 736A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402396 ER PT J AU Basu, P Shah, NJ John, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj J. John, Nimy Aloysius, M. Brown, Robert TI Sofosbuvir, Ledipasvir in IBD treated patients with advanced biologics including Ribavirin eradicating Chronic Hepatitis C: SOLATAIRE C Trial. A multi-center clinical prospective pilot study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Basu, Patrick; John, Nimy; Aloysius, M.] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Brown, Robert] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1075 BP 737A EP 737A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375402397 ER PT J AU Su, F Yu, L Berry, K Liou, IW Landis, CS Reyes, J Rayhill, SC Ioannou, GN AF Su, Feng Yu, Lei Berry, Kristin Liou, Iris W. Landis, Charles S. Reyes, Jorge Rayhill, Stephen C. Ioannou, George N. TI Aging of liver transplant registrants and recipients: trends and impact on waiting list and post-transplantation outcomes SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Su, Feng; Yu, Lei; Liou, Iris W.; Landis, Charles S.; Reyes, Jorge; Rayhill, Stephen C.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1211 BP 808A EP 809A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375403005 ER PT J AU Mannem, A Rogal, SS Sharma, V Francis, F Cacciarelli, TV Shaikh, OS AF Mannem, Arun Rogal, Shari S. Sharma, Vivek Francis, Fadi Cacciarelli, Thomas V. Shaikh, Obaid S. TI Oral Interferon-free Antiviral Regimens in Liver Transplant Recipients with Hepatitis C: a Real Life Experience SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Mannem, Arun; Shaikh, Obaid S.] Univ Pittsburgh, Sch Med, Med Gastroenterol, Pittsburgh, PA USA. [Mannem, Arun; Rogal, Shari S.; Sharma, Vivek; Francis, Fadi; Cacciarelli, Thomas V.; Shaikh, Obaid S.] Vet Affairs Pittsburgh Healthcare Syst, Med Gastroenterol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1753 BP 1063A EP 1064A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375403545 ER PT J AU Gjuka, D Song, XL Yoo, W Yoo, SY Wang, J Fallon, MB Ioannou, GN Harrison, SA Beretta, L AF Gjuka, Donjeta Song, Xiaoling Yoo, Wonbeak Yoo, Suk Young Wang, Jing Fallon, Michael B. Ioannou, George N. Harrison, Stephen A. Beretta, Laura TI Non-invasive Diagnosis of Non-alcoholic Steatohepatitis (NASH) using a Panel of Fatty Acids SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Gjuka, Donjeta; Yoo, Wonbeak; Beretta, Laura] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol, Houston, TX 77030 USA. [Song, Xiaoling] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Yoo, Suk Young; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Bioinformat & Computat Biol, Houston, TX 77030 USA. [Fallon, Michael B.] Univ Texas MD Anderson Canc Ctr, Div Gastroenterol, Houston, TX 77030 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Harrison, Stephen A.] Brooke Army Med Ctr, Dept Med, Houston, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 2151 BP 1255A EP 1256A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404393 ER PT J AU Batki, SL AF Batki, Steven L. TI What Is the Right Pharmacotherapy for Alcohol Use Disorder in Patients With Schizophrenia? SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material DE Antipsychotics; Comorbidity; Schizophrenia; Substance-Related Disorders ID SUBSTANCE USE DISORDER; NALTREXONE; DEPENDENCE C1 [Batki, Steven L.] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94121 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Batki, SL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu FU NIH/NIAAA [RO1 AA013655]; Department of Defense [W81XWH-12-2-0137, W81XWH-11-2-0245] FX This work was supported in part by NIH/NIAAA Grant RO1 AA013655 and Department of Defense Grants W81XWH-12-2-0137 and W81XWH-11-2-0245 and with the support of the resources of the San Francisco Veterans Affairs Medical Center. NR 10 TC 0 Z9 0 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2015 VL 76 IS 10 BP E1336 EP E1337 DI 10.4088/JCP.14com09611 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DB2OC UT WOS:000368347900018 PM 26528663 ER PT J AU Kennedy, GT Okusanya, OT Keating, JJ Heitjan, DF Deshpande, C Litzky, LA Albelda, SM Drebin, JA Nie, SM Low, PS Singhal, S AF Kennedy, Gregory T. Okusanya, Olugbenga T. Keating, Jane J. Heitjan, Daniel F. Deshpande, Charuhas Litzky, Leslie A. Albelda, Steven M. Drebin, Jeffrey A. Nie, Shuming Low, Philip S. Singhal, Sunil TI The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas SO ANNALS OF SURGERY LA English DT Article DE intraoperative diagnosis; optical biopsy; surgical oncology ID EXPRESSION; SURGERY AB Background:With increasing use of chest computed tomography scans, indeterminate pulmonary nodules are frequently detected as an incidental finding and present a diagnostic challenge. Tissue biopsy followed by histological review and immunohistochemistry is the gold standard to obtain a diagnosis and the most common malignant finding is a primary lung adenocarcinoma. Our objective was to determine whether an intraoperative optical biopsy (molecular imaging) may provide an alternative approach for determining if a pulmonary nodule is a primary lung adenocarcinoma.Methods:Before surgery, 30 patients with an indeterminate pulmonary nodule were intravenously administered a folate receptor-targeted fluorescent contrast agent specific for primary lung adenocarcinomas. During surgery, the nodule was removed and the presence of fluorescence (optical biopsy) was assessed in the operating room to determine if the nodule was a primary pulmonary adenocarcinoma. Standard-of-care frozen section and immunohistochemical staining on permanent sections were then performed as the gold standard to validate the results of the optical biopsy.Results:Optical biopsies identified 19 of 19 (100%) primary pulmonary adenocarcinomas. There were no false positive or false negative diagnoses. An optical biopsy required 2.4 minutes compared to 26.5 minutes for frozen section (P<0.001) and it proved more accurate than frozen section in diagnosing lung adenocarcinomas.Conclusions:An optical biopsy has excellent positive predictive value for intraoperative diagnosis of primary lung adenocarcinomas. With refinement, this technology may prove to be an important supplement to standard pathology for examining close surgical margins, identifying lymph node involvement, and determining whether suspicious nodules are malignant. C1 [Kennedy, Gregory T.; Okusanya, Olugbenga T.; Keating, Jane J.; Drebin, Jeffrey A.; Singhal, Sunil] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Kennedy, Gregory T.; Okusanya, Olugbenga T.; Keating, Jane J.; Drebin, Jeffrey A.; Singhal, Sunil] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Heitjan, Daniel F.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Deshpande, Charuhas; Litzky, Leslie A.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Albelda, Steven M.; Singhal, Sunil] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Nie, Shuming] Emory Univ, Dept Biomed Engn, Atlanta, GA 30322 USA. [Nie, Shuming] Emory Univ, Dept Chem, Atlanta, GA 30322 USA. [Low, Philip S.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. RP Singhal, S (reprint author), Hosp Univ Penn, Div Thorac Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM Sunil.Singhal@uphs.upenn.edu OI Low, Philip/0000-0001-9042-5528 FU Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I011CX001189]; National Institutes of Health [P30 CA016520] FX This work was supported by Award Number I011CX001189 (SS, CD) from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development. This work was also supported by the National Institutes of Health P30 CA016520 (DFH). NR 13 TC 5 Z9 5 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD OCT PY 2015 VL 262 IS 4 BP 602 EP 609 DI 10.1097/SLA.0000000000001452 PG 8 WC Surgery SC Surgery GA DA7QT UT WOS:000367999800006 PM 26366539 ER PT J AU Dawes, AJ Sacks, GD Cryer, HG Gruen, JP Preston, C Gorospe, D Cohen, M McArthur, DL Russell, MM Maggard-Gibbons, M Ko, CY AF Dawes, Aaron J. Sacks, Greg D. Cryer, H. Gill Gruen, J. Peter Preston, Christy Gorospe, Deidre Cohen, Marilyn McArthur, David L. Russell, Marcia M. Maggard-Gibbons, Melinda Ko, Clifford Y. CA Los Angeles Cty Trauma Consortium TI Compliance With Evidence-Based Guidelines and Interhospital Variation in Mortality for Patients With Severe Traumatic Brain Injury SO JAMA SURGERY LA English DT Article ID BLOOD-STREAM INFECTIONS; CARE QUALITY MEASURES; INTRACRANIAL-PRESSURE; UNITED-STATES; RELIABILITY ADJUSTMENT; INPATIENT MORTALITY; SURGICAL OUTCOMES; HEAD-INJURY; ASSOCIATION; IMPROVEMENT AB IMPORTANCE Compliance with evidence-based guidelines in traumatic brain injury (TBI) has been proposed as a marker of hospital quality. However, the association between hospital-level compliance rates and risk-adjusted clinical outcomes for patients with TBI remains poorly understood. OBJECTIVE To examine whether hospital-level compliance with the Brain Trauma Foundation guidelines for intracranial pressure monitoring and craniotomy is associated with risk-adjusted mortality rates for patients with severe TBI. DESIGN, SETTING, AND PARTICIPANTS All adult patients (N = 734) who presented to a regional consortium of 14 hospitals from January 1, 2009, through December 31, 2010, with severe TBI (ie, blunt head trauma, Glasgow Coma Scale score of < 9, and abnormal intracranial findings from computed tomography of the head). Data analysis took place from December 2013 through January 2015. We used hierarchical mixed-effects models to assess the association between hospital-level compliance with Brain Trauma Foundation guidelines and mortality rates after adjusting for patient-level demographics, severity of trauma (eg, mechanism of injury and Injury Severity Score), and TBI-specific variables (eg, cranial nerve reflexes and findings from computed tomography of the head). MAIN OUTCOMES AND MEASURES Hospital-level risk-adjusted inpatient mortality rate and hospital-level compliance with Brain Trauma Foundation guidelines for intracranial pressure monitoring and craniotomy. RESULTS Unadjusted mortality rates varied by site from 20.0% to 50.0% (median, 42.6; interquartile range, 35.5-46.2); risk-adjusted rates varied from 24.3% to 56.7% (median, 41.1; interquartile range, 36.4-47.8). Overall, only 338 of 734 patients (46.1%) with an appropriate indication underwent placement of an intracranial pressure monitor and only 134 of 335 (45.6%) underwent craniotomy. Hospital-level compliance ranged from 9.6% to 65.2% for intracranial pressure monitoring and 6.7% to 76.2% for craniotomy. Despite widespread variation in compliance across hospitals, we found no association between hospital-level compliance rates and risk-adjusted patient outcomes (Spearman. = 0.030 [P = .92] for ICP monitoring and Spearman. = -0.066 [P = .83] for craniotomy). CONCLUSIONS AND RELEVANCE Hospital-level compliance with evidence-based guidelines has minimal association with risk-adjusted outcomes in patients with severe TBI. Our results suggest that caution should be taken before using compliance with these measures as independent quality metrics. Given the complexity of TBI care, outcomes-based metrics, including functional recovery, may be more accurate than current process measures at determining hospital quality. C1 [Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Cohen, Marilyn; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Dawes, Aaron J.; Sacks, Greg D.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. [Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Gruen, J. Peter] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA. [Preston, Christy; Gorospe, Deidre] Cty Los Angeles Dept Hlth Serv, Emergency Med Serv Agcy, Los Angeles, CA USA. [McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA. RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Surg, 757 Westwood Plaza,Room B7-11, Los Angeles, CA 90095 USA. EM adawes@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 FU Veterans Affairs Robert Wood Johnson Clinical Scholars Program; Veterans Affairs Office of Academic Affiliations FX This study was supported by the Veterans Affairs Robert Wood Johnson Clinical Scholars Program (Drs Dawes and Sacks) and the Veterans Affairs Office of Academic Affiliations (Dr Dawes). NR 46 TC 8 Z9 8 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD OCT PY 2015 VL 150 IS 10 BP 965 EP 972 DI 10.1001/jamasurg.2015.1678 PG 8 WC Surgery SC Surgery GA DA1WB UT WOS:000367585200010 PM 26200744 ER PT J AU Godbole, R Zider, A Betancourt, J Saggar, R Kamangar, N AF Godbole, Rohit Zider, Alexander Betancourt, Jaime Saggar, Rajan Kamangar, Nader TI Achieving Early Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy: A Case Series SO CHEST LA English DT Meeting Abstract C1 [Godbole, Rohit; Zider, Alexander; Betancourt, Jaime; Saggar, Rajan; Kamangar, Nader] VA Greater Los Angeles Healthcare Syst GLA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2015 VL 148 IS 4 SU S MA 1003A DI 10.1378/chest.2276141 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CZ5SU UT WOS:000367163100453 ER PT J AU Hoo, GS Barack, B Vazirani, S Li, ZP Wu, C AF Hoo, Guy Soo Barack, Bruce Vazirani, Sondra Li, Zhaoping Wu, Carol TI The Increasing Use of D-Dimer Testing in Suspected Pulmonary Embolism SO CHEST LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2015 VL 148 IS 4 SU S MA 918A DI 10.1378/chest.2281445 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CZ5SU UT WOS:000367163100368 ER PT J AU Graham, ZA Gallagher, PM Cardozo, CP AF Graham, Zachary A. Gallagher, Philip M. Cardozo, Christopher P. TI Focal adhesion kinase and its role in skeletal muscle SO JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY LA English DT Review DE Focal adhesion kinase; Hypertrophy; Muscle development; Exercise ID SERUM RESPONSE FACTOR; PROTEIN-SYNTHESIS; TYROSINE PHOSPHORYLATION; ALPHA-7-BETA-1 INTEGRIN; QUANTITATIVE CHANGES; RESISTANCE EXERCISE; MYOBLAST FUSION; GENE-EXPRESSION; FACTOR PLAYS; FIBER-TYPE AB Skeletal muscle has a remarkable ability to respond to different physical stresses. Loading muscle through exercise, either anaerobic or aerobic, can lead to increases in muscle size and function while, conversely, the absence of muscle loading stimulates rapid decreases in size and function. A principal mediator of this load-induced change is focal adhesion kinase (FAK), a downstream non-receptor tyrosine kinase that translates the cytoskeletal stress and strain signals transmitted across the cytoplasmic membrane by integrins to activate multiple anti-apoptotic and cell growth pathways. Changes in FAK expression and phosphorylation have been found to correlate to specific developmental states in myoblast differentiation, muscle fiber formation and muscle size in response to loading and unloading. With the capability to regulate costamere formation, hypertrophy and glucose metabolism, FAK is a molecule with diverse functions that are important in regulating muscle cell health. C1 [Graham, Zachary A.; Cardozo, Christopher P.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Gallagher, Philip M.] Univ Kansas, Appl Physiol Lab, Lawrence, KS 66045 USA. [Graham, Zachary A.; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM christopher.cardozo@mssm.edu RI Gallagher, Philip/R-9937-2016 OI Gallagher, Philip/0000-0003-4563-4536 FU Veterans Affairs Rehabilitation Research and Development Service [B9212C]; James J. Peters VA Medical Center FX This work was supported by a Veterans Affairs Rehabilitation Research and Development Service grant (B9212C) and the James J. Peters VA Medical Center, where Dr. Cardozo is a member of the Medical-Surgical Service and Dr. Graham is a member of the Research Service. NR 95 TC 3 Z9 4 U1 0 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0142-4319 EI 1573-2657 J9 J MUSCLE RES CELL M JI J. Muscle Res. Cell Motil. PD OCT PY 2015 VL 36 IS 4-5 BP 305 EP 315 DI 10.1007/s10974-015-9415-3 PG 11 WC Cell Biology SC Cell Biology GA CX1HA UT WOS:000365446000003 PM 26142360 ER PT J AU Guo, FJ Garvey, WT AF Guo, Fangjian Garvey, W. Timothy TI Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; TREATMENT PANEL-III; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK; INSULIN-RESISTANCE; AFRICAN-AMERICANS; CLINICAL ENDOCRINOLOGISTS; POSITION STATEMENT; METABOLIC SYNDROME; PHYSICAL-ACTIVITY AB Context: Metabolic syndrome traits are important risk factors for diabetes; however, each trait has different predictive power for future diabetes. Additionally, the impact of insulin resistance on metabolic profile can differ by gender and racial group, suggesting that gender-race specific prediction algorithms for diabetes may be warranted. Objective: To develop a quantitative scoring system based on weighting of risk components in the cardiometabolic disease staging (CMDS) system for the prediction of future diabetes. Design, Setting, and Participants: We derived the CMDS score in 2857 participants with valid follow-up information on incident diabetes from the Coronary Artery Risk Development in Young Adults study and validated it in 6425 older participants from the Atherosclerosis Risk in Communities study. We assigned a simple integer value for each CMDS risk factor component. Main Outcome Measures: Incident diabetes. Results: Fasting glucose, 2-hour glucose, waist circumference, and blood pressure components contributed similarly for the prediction of future diabetes (CMDS scores, 23, 21, 26, and 20, respectively). The area under the receiver operating characteristic curve was 0.7158 for the CMDS scoring system, whereas it was 0.7053 for the Framingham diabetes score. The CMDS components performed differently for prediction of future diabetes in Black and White men and women. The components with the highest predictive power for diabetes were waist circumference in Black men, 2-hour glucose in Black women, and fasting glucose in both White men and White women. Conclusions: The weighted CMDS score has high model discrimination power for diabetes and can be used clinically to identify patients for weight loss therapy based on differential risk for future diabetes. C1 [Guo, Fangjian] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA. [Guo, Fangjian] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35233 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Guo, FJ (reprint author), Univ Texas Med Branch, Dept Obstet & Gynecol, 301 Univ Blvd, Galveston, TX 77555 USA. EM faguo@utmb.edu; garveyt@uab.edu OI Guo, Fangjian/0000-0003-3729-2724 FU Department of Veterans Affairs; University of Alabama at Birmingham Diabetes Research Center [P60-DK079626]; Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the NIH [T32HD055163]; National Institutes of Health (NIH) [DK-038765, DK-083562] FX This study was partly supported by the Merit Review program of the Department of Veterans Affairs, the National Institutes of Health (NIH) (Grants DK-038765 and DK-083562), and the University of Alabama at Birmingham Diabetes Research Center (Grant P60-DK079626). F.G. is currently supported by an institutional training grant (National Research Service Award T32HD055163) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NICHD or the NIH. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. NR 36 TC 2 Z9 3 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2015 VL 100 IS 10 BP 3871 EP 3877 DI 10.1210/jc.2015-2691 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CW3WI UT WOS:000364922600058 PM 26241327 ER PT J AU Miles, SR Smith, TL Maieritsch, KP Ahearn, EP AF Miles, Shannon R. Smith, Tracey L. Maieritsch, Kelly P. Ahearn, Eileen P. TI Fear of Losing Emotional Control Is Associated With Cognitive Processing Therapy Outcomes in US Veterans of Afghanistan and Iraq SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PTSD; SCALE; CARE AB Evidence-based treatments for posttraumatic stress disorder (PTSD) can reduce symptoms and improve veterans' psychological health. Unfortunately, many veterans leave treatment before receiving maximum benefit. Fear of emotions is related to severity of PTSD, and changes in fear of emotions are correlated with changes in PTSD symptoms. This study built upon the literature linking greater fear of emotions to PTSD severity by examining whether pretreatment fear of emotions, measured by the Affect Control Scale, was associated with completion of cognitive processing therapy (CPT) and severity of posttreatment PTSD in a sample of 89 U.S. veterans who had served in Afghanistan and Iraq. About 60% of veterans completed 10 or more therapy sessions. A logistic regression on 51 of the 89 subjects that more fear of anxiety at pretreatment was associated with decreased likelihood of completing treatment, OR = 0.93, 95% CI [0.87, 1.00]. Of those veterans who completed treatment, higher fear of anger at pretreatment was negatively related to severity of PTSD posttreatment (beta = -.29, p = .037), in a model with the other predictors. Assessing veterans for fear of anxiety and anger before CPT and teaching emotion regulation skills to those in need may reduce treatment dropout. C1 [Miles, Shannon R.] Michael E DeBakey Vet Affairs VA Med Ctr, Mental Hlth Care Line, Houston, TX USA. [Miles, Shannon R.; Smith, Tracey L.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Miles, Shannon R.] South Cent Mental Illness Res Educ & Clin Ctr MIR, Houston, TX USA. [Maieritsch, Kelly P.] Edward Hines Jr VA Hosp, Mental Hlth Serv Line, Hines, IL USA. [Ahearn, Eileen P.] Univ Wisconsin Hosp & Clin, Dept Psychiat, Madison, WI 53792 USA. [Smith, Tracey L.; Ahearn, Eileen P.] William S Middleton Mem Vet Adm Med Ctr, Mental Hlth Serv Line, Madison, WI USA. RP Miles, SR (reprint author), Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM shannon.reynolds@utulsa.edu RI Smith, Tracey/J-2030-2014 OI Smith, Tracey/0000-0001-5338-9142 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Houston VA HSR&D Center for Innovations in Quality, Effectiveness Safety [IQUEST: CIN13-413]; South Central Mental Illness Research, Education, and Clinical Center (MIRECC); U.S. Army Medical Research Acquisition Activity (USAMRAA) [W81XWH-08-2-0130] FX This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Houston VA HSR&D Center for Innovations in Quality, Effectiveness & Safety (IQUEST: CIN13-413), South Central Mental Illness Research, Education, and Clinical Center (MIRECC), and U.S. Army Medical Research Acquisition Activity (USAMRAA; W81XWH-08-2-0130; ClinicalTrials.gov Identifier: NCT00941629). The funding sources had no role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the paper for publication. The views expressed in this article are those of the authors and do not necessarily reflect the views, position, or policy of the Department of Veterans Affairs, IQUEST, the South Central MIRECC, the U.S. Department of Defense. NR 15 TC 3 Z9 3 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD OCT PY 2015 VL 28 IS 5 BP 475 EP 479 DI 10.1002/jts.22036 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX0KL UT WOS:000365385200014 PM 26397721 ER PT J AU Price, M Kuhn, E Hoffman, JE Ruzek, J Acierno, R AF Price, Matthew Kuhn, Eric Hoffman, Julia E. Ruzek, Josef Acierno, Ron TI Comparison of the PTSD Checklist (PCL) Administered via a Mobile Device Relative to a Paper Form SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PSYCHOMETRIC-PROPERTIES; COMPUTER; EQUIVALENCE; TECHNOLOGY; TELEHEALTH; VETERANS AB Mobile devices are increasingly used to administer self-report measures of mental health symptoms. There are significant differences, however, in the way that information is presented on mobile devices compared to the traditional paper forms that were used to administer such measures. Such differences may systematically alter responses. The present study evaluated if and how responses differed for a self-report measure, the PTSD Checklist (PCL), administered via mobile device relative to paper and pencil. Participants were 153 trauma-exposed individuals who completed counterbalanced administrations of the PCL on a mobile device and on paper. PCL total scores (d = 0.07) and item responses did not meaningfully or significantly differ across administrations. Power was sufficient to detect a difference in total score between administrations determined by prior work of 3.46 with a d = 0.23. The magnitude of differences between administration formats was unrelated to prior use of mobile devices or participant age. These findings suggest that responses to self-report measures administered via mobile device are equivalent to those obtained via paper and they can be used with experienced as well as naive users of mobile devices. C1 [Price, Matthew] Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA. [Kuhn, Eric; Hoffman, Julia E.; Ruzek, Josef] Dept Vet Affairs Palo Alto Hlth Care Syst, Disseminat & Training Div, Natl Ctr PTSD, Palo Alto, CA USA. [Hoffman, Julia E.] Dept Vet Affairs Palo Alto Healthcare Syst, Ctr Healthcare Evaluat, Palo Alto, CA USA. [Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD OCT PY 2015 VL 28 IS 5 BP 480 EP 483 DI 10.1002/jts.22037 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CX0KL UT WOS:000365385200015 PM 26375277 ER PT J AU Nielson, JL Paquette, J Liu, AW Guandique, CF Tovar, CA Inoue, T Irvine, KA Gensel, JC Kloke, J Petrossian, TC Lum, PY Carlsson, GE Manley, GT Young, W Beattie, MS Bresnahan, JC Ferguson, AR AF Nielson, Jessica L. Paquette, Jesse Liu, Aiwen W. Guandique, Cristian F. Tovar, C. Amy Inoue, Tomoo Irvine, Karen-Amanda Gensel, John C. Kloke, Jennifer Petrossian, Tanya C. Lum, Pek Y. Carlsson, Gunnar E. Manley, Geoffrey T. Young, Wise Beattie, Michael S. Bresnahan, Jacqueline C. Ferguson, Adam R. TI Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury SO NATURE COMMUNICATIONS LA English DT Article ID KNOWLEDGE-BASED APPROACH; CELL-DEATH; BIG DATA; RATING-SCALE; RATS; MECHANISMS; CONSEQUENCES; DEGENERATION; NEUROSCIENCE; TRANSLATION AB Data-driven discovery in complex neurological disorders has potential to extract meaningful syndromic knowledge from large, heterogeneous data sets to enhance potential for precision medicine. Here we describe the application of topological data analysis (TDA) for data-driven discovery in preclinical traumatic brain injury (TBI) and spinal cord injury (SCI) data sets mined from the Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI) repository. Through direct visualization of inter-related histopathological, functional and health outcomes, TDA detected novel patterns across the syndromic network, uncovering interactions between SCI and co-occurring TBI, as well as detrimental drug effects in unpublished multicentre preclinical drug trial data in SCI. TDA also revealed that perioperative hypertension predicted long-term recovery better than any tested drug after thoracic SCI in rats. TDA-based data-driven discovery has great potential application for decision-support for basic research and clinical problems such as outcome assessment, neurocritical care, treatment planning and rapid, precision-diagnosis. C1 [Nielson, Jessica L.; Liu, Aiwen W.; Guandique, Cristian F.; Manley, Geoffrey T.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, San Francisco, CA 94143 USA. [Paquette, Jesse] Tagb Io, San Francisco, CA 94131 USA. [Tovar, C. Amy] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA. [Inoue, Tomoo] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9800856, Japan. [Irvine, Karen-Amanda] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA 94110 USA. [Gensel, John C.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Dept Physiol, Lexington, KY 40536 USA. [Kloke, Jennifer; Carlsson, Gunnar E.] Ayasdi Inc, Menlo Pk, CA 94025 USA. [Petrossian, Tanya C.] GenePeeks Inc, New York, NY 10001 USA. [Lum, Pek Y.] Capella Biosci, Palo Alto, CA 94301 USA. [Carlsson, Gunnar E.] Stanford Univ, Dept Math, Stanford, CA 94305 USA. [Young, Wise] Rutgers State Univ, Dept Cell Biol & Neurosci, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ 08854 USA. [Ferguson, Adam R.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurosurg, San Francisco, CA 94110 USA. RP Ferguson, AR (reprint author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA. EM adam.ferguson@ucsf.edu OI Nielson, Jessica/0000-0002-3677-3959 FU Craig H. Neilsen Foundation [224308]; National Institutes of Health (NIH) [NS067092, NS069537, NS038079, NS031193, AG032518, NS079030, NS032000]; NYSCoRE [CO19772]; Department of Defense (DoD) [W81XWH-10-1-0910, W81XWH-13-1-0297]; Wings for Life Foundation [WFLUS008/12, WFLUS006/14] FX This work was funded by the Craig H. Neilsen Foundation Grant 224308, the National Institutes of Health (NIH) NS067092 (A.R.F.), NS069537 (A.R.F), NS038079 (J.C.B. and M.S.B.), NS031193 and AG032518 (M.S.B. and J.C.B.), NS079030 (J.L.N.), NS032000 (W.Y.; M.S.B. site PI, multicentre study); NYSCoRE CO19772 (M.S.B. and J.C.B.), the Department of Defense (DoD) grants W81XWH-10-1-0910 (M.S.B.) and W81XWH-13-1-0297 (M.S.B.), and Wings for Life Foundation grants WFLUS008/12 and WFLUS006/14 (A.R.F.). We thank J.R. Huie and J. Haefeli for useful comments, and A. Lin and S. Visuthikraisee for technical support. NR 55 TC 9 Z9 9 U1 5 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD OCT PY 2015 VL 6 AR 8581 DI 10.1038/ncomms9581 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CW4AD UT WOS:000364932600028 PM 26466022 ER PT J AU Teng, E Taylor, K Bilousova, T Weiland, D Pham, T Zuo, XH Yang, FS Chen, PP Glabe, CG Takacs, A Hoffman, DR Frautschy, SA Cole, GM AF Teng, Edmond Taylor, Karen Bilousova, Tina Weiland, David Thaidan Pham Zuo, Xiaohong Yang, Fusheng Chen, Ping-Ping Glabe, Charles G. Takacs, Alison Hoffman, Dennis R. Frautschy, Sally A. Cole, Gregory M. TI Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A beta pathology and modulates A beta oligomerization SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Docosahexaenoic acid; beta-amyloid; Aggregation; Oligomers; Fibrillar; Prefibrillar; Hippocampus; Transgenic; Alzheimer's disease ID MILD COGNITIVE IMPAIRMENT; POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; AMYLOID-BETA; DOCOSAHEXAENOIC ACID; MOUSE MODEL; DOUBLE-BLIND; IN-VITRO; SYNAPTIC PLASTICITY AB Increased dietary consumption of docosahexaenoic acid (DHA) is associated with decreased risk for Alzheimer's disease (AD). These effects have been postulated to arise from DHA's pleiotropic effects on AD pathophysiology, including its effects on beta-amyloid (A beta) production, aggregation, and toxicity. While in vitro studies suggest that DHA may inhibit and reverse the formation of toxic A beta oligomers, it remains uncertain whether these mechanisms operate in vivo at the physiological concentrations of DHA attainable through dietary supplementation. We sought to clarify the effects of dietary DHA supplementation on A beta indices in a transgenic APP/PS1 rat model of AD. Animals maintained on a DHA-supplemented diet exhibited reductions in hippocampal A beta plaque density and modest improvements on behavioral testing relative to those maintained on a DHA-depleted diet. However, DHA supplementation also increased overall soluble A beta oligomer levels in the hippocampus. Further quantification of specific conformational populations of A beta oligomers indicated that DHA supplementation increased fibrillar (i.e. putatively less toxic) A beta oligomers and decreased prefibrillar (i.e. putatively more toxic) A beta oligomers. These results provide in vivo evidence suggesting that DHA can modulate A beta aggregation by stabilizing soluble fibrillar A beta oligomers and thus reduce the formation of both A beta plaques and prefibrillar AS oligomers. However, since fibrillar A beta oligomers still retain inherent neurotoxicity, DHA may need to be combined with other interventions that can additionally reduce fibrillar A beta oligomer levels for more effective prevention of AD in clinical settings. Published by Elsevier Inc. C1 [Teng, Edmond; Taylor, Karen; Bilousova, Tina; Weiland, David; Thaidan Pham; Zuo, Xiaohong; Yang, Fusheng; Chen, Ping-Ping; Frautschy, Sally A.; Cole, Gregory M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. [Teng, Edmond; Weiland, David; Zuo, Xiaohong; Yang, Fusheng; Chen, Ping-Ping; Frautschy, Sally A.; Cole, Gregory M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Zuo, Xiaohong] Capital Med Univ, Xuanwu Hosp, Beijing Inst Geriatr, Dept Neurobiol & Neurol, Beijing, Peoples R China. [Glabe, Charles G.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA. [Glabe, Charles G.] King Abdulaziz Univ, King Fahd Med Res Ctr, Dept Biochem, Jeddah 21413, Saudi Arabia. [Glabe, Charles G.] King Abdulaziz Univ, King Fahd Med Res Ctr, Expt Biochem Unit, Jeddah 21413, Saudi Arabia. [Takacs, Alison; Hoffman, Dennis R.] Retina Fdn Southwest, Dallas, TX USA. [Hoffman, Dennis R.] UT Southwestern Med Ctr, Dept Ophthalmol, Dallas, TX USA. RP Teng, E (reprint author), West Los Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu RI Zuo, Xiaohong/H-6254-2016 FU National Institute on Aging [K08 AG34628, RC1 AG035878]; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation FX This work was supported by the National Institute on Aging (K08 AG34628 [to ET; jointly sponsored by NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor] and RC1 AG035878 [to GMC]). We would like to thank Eric Y. Haden for cross-linked A beta oligomers, Christopher C. Giza for behavioral testing space, and Ta-Lee Teng for technical assistance. NR 70 TC 4 Z9 4 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD OCT PY 2015 VL 82 BP 552 EP 560 DI 10.1016/j.nbd.2015.09.002 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CW4RO UT WOS:000364980000052 PM 26369878 ER PT J AU Zile, MR Abraham, WT Weaver, FA Butter, C Ducharme, A Halbach, M Klug, D Lovett, EG Muller-Ehmsen, J Schafer, JE Senni, M Swarup, V Wachter, R Little, WC AF Zile, Michael R. Abraham, William T. Weaver, Fred A. Butter, Christian Ducharme, Anique Halbach, Marcel Klug, Didier Lovett, Eric G. Mueller-Ehmsen, Jochen Schafer, Jill E. Senni, Michele Swarup, Vijay Wachter, Rolf Little, William C. TI Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Baroreflex; Heart failure; Resynchronization; Autonomic nervous system; Randomized controlled trial ID PROGNOSTIC IMPLICATIONS; ARTERIAL BAROREFLEX; FAILING HEART; HF TRIAL; INHIBITION; METOPROLOL; SYSTEM AB AimsIncreased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex activation therapy, BAT) results in centrally mediated reduction of sympathetic and increase in parasympathetic activity. Because patients treated with cardiac resynchronization therapy (CRT) may have less sympathetic/parasympathetic imbalance, we hypothesized that there would be differences in the response to BAT in patients with CRT vs. those without CRT. Methods and resultsNew York Heart Association (NYHA) Class III patients with an ejection fraction (EF) 35% were randomized (1 : 1) to ongoing guideline-directed medical and device therapy (GDMT, control) or ongoing GDMT plus BAT. Safety endpoint was system-/procedure-related major adverse neurological and cardiovascular events (MANCE). Efficacy endpoints were Minnesota Living with Heart Failure Quality of Life (QoL), 6-min hall walk distance (6MHWD), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and HF hospitalization rate. In this sample, 146 patients were randomized (70 control; 76 BAT) and were 140 activated (45 with CRT and 95 without CRT). MANCE-free rate at 6 months was 100% in CRT and 96% in no-CRT group. At 6 months, in the no-CRT group, QoL score, 6MHWD, LVEF, NT-proBNP and HF hospitalizations were significantly improved in BAT patients compared with controls. Changes in efficacy endpoints in the CRT group favoured BAT; however, the improvements were less than in the no-CRT group and were not statistically different from control. ConclusionsBAT is safe and significantly improved QoL, exercise capacity, NTpro-BNP, EF, and rate of HF hospitalizations in GDMT-treated NYHA Class III HF patients. These effects were most pronounced in patients not treated with CRT. C1 [Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. [Abraham, William T.] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA. [Weaver, Fred A.] Univ So Calif, Keck Sch Med, Div Vasc Surg & Endovasc Therapy, Los Angeles, CA 90033 USA. [Butter, Christian] Immanuel Heart Ctr Bernau, Med Sch Brandenburg, Dept Cardiol, Bernau, Germany. [Ducharme, Anique] Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada. [Halbach, Marcel] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany. [Klug, Didier] Univ Hosp, Dept Cardiol A, Lille, France. [Lovett, Eric G.] CVRx Inc, Dept Res, Minneapolis, MN USA. [Mueller-Ehmsen, Jochen] Asklepios Klin Altona, Dept Med, Hamburg, Germany. [Schafer, Jill E.] NAMSA Inc, Dept Stat, Minneapolis, MN USA. [Senni, Michele] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy. [Swarup, Vijay] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA. [Wachter, Rolf] Univ Med Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany. [Wachter, Rolf] German Cardiovasc Res Ctr DZHK, Gottingen, Germany. [Little, William C.] Univ Mississippi, Div Cardiovasc, Med Ctr, Jackson, MS 39216 USA. RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, 114 Doughty St,Thurmond Gazes 323, Charleston, SC 29425 USA. EM zilem@musc.edu OI Wachter, Rolf/0000-0003-2231-2200 FU CVRx, Inc., Minneapolis, MN, USA FX This study was funded by CVRx, Inc., Minneapolis, MN, USA. NR 26 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD OCT PY 2015 VL 17 IS 10 BP 1066 EP 1074 DI 10.1002/ejhf.299 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CV9ZZ UT WOS:000364649800015 PM 26011593 ER PT J AU Henry, SG Czarnecki, D Kahn, VC Chou, WYS Fagerlin, A Ubel, PA Rovner, DR Alexander, SC Knight, SJ Holmes-Rovner, M AF Henry, Stephen G. Czarnecki, Danielle Kahn, Valerie C. Chou, Wen-Ying Sylvia Fagerlin, Angela Ubel, Peter A. Rovner, David R. Alexander, Stewart C. Knight, Sara J. Holmes-Rovner, Margaret TI Patient-physician communication about early stage prostate cancer: analysis of overall visit structure SO HEALTH EXPECTATIONS LA English DT Article DE discourse analysis; patient-centred communication; prostate cancer; qualitative research; structure; transitions; veterans ID MEDICAL ENCOUNTERS; DECISION-MAKING; BAD-NEWS; TRANSITIONS; PARTICIPATION; DISCOURSE; SKILLS; MEN AB Background We know little about patient-physician communication during visits to discuss diagnosis and treatment of prostate cancer. Objective To examine the overall visit structure and how patients and physicians transition between communication activities during visits in which patients received new prostate cancer diagnoses. Participants Forty veterans and 18 urologists at one VA medical centre. Methods We coded 40 transcripts to identify major communication activities during visits and used empiric discourse analysis to analyse transitions between activities. Results We identified five communication activities that occurred in the following typical sequence: 'diagnosis delivery', 'risk classification', 'options talk', 'decision talk' and 'next steps'. The first two activities were typically brief and involved minimal patient participation. Options talk was typically the longest activity; physicians explicitly announced the beginning of options talk and framed it as their professional responsibility. Some patients were unsure of the purpose of visit and/or who should make treatment decisions. Conclusion Visits to deliver the diagnosis of early stage prostate cancer follow a regular sequence of communication activities. Physicians focus on discussing treatment options and devote comparatively little time and attention to discussing the new cancer diagnosis. Towards the goal of promoting patient-centred communication, physicians should consider eliciting patient reactions after diagnosis delivery and explaining the decision-making process before describing treatment options. C1 [Henry, Stephen G.] Univ Calif Davis, Div Gen Med Geriatr & Bioeth, Sacramento, CA 95817 USA. [Czarnecki, Danielle] Univ Michigan, Dept Sociol, Ann Arbor, MI 48109 USA. [Kahn, Valerie C.; Fagerlin, Angela] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA. [Chou, Wen-Ying Sylvia] NCI, Behav Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Fagerlin, Angela] Ann Arbor VA HSR&D Ctr Clin Management Res, Ann Arbor, MI USA. [Fagerlin, Angela] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Fagerlin, Angela] Univ Michigan, Dept Psychol, Ann Arbor, MI USA. [Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. [Rovner, David R.] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA. [Alexander, Stewart C.] Duke Univ, Dept Med, Durham, NC USA. [Alexander, Stewart C.] Durham VA Med Ctr, Durham, NC USA. [Knight, Sara J.] Vet Hlth Adm, Off Res & Dev, VA Hlth Serv Res & Dev, Washington, DC USA. [Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Holmes-Rovner, Margaret] Michigan State Univ, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA. RP Henry, SG (reprint author), Univ Calif Davis, Div Gen Med Geriatr & Bioeth, 4150 5 St Suite 2400, Sacramento, CA 95817 USA. EM sghenry@ucdavis.edu FU Blue Cross Blue Shield of Michigan Foundation (Detroit, MI) [1722.II]; University of Michigan Robert Wood Johnson Foundation Health and Society Scholars program; IIR Merit Award from the U.S. Department of Veterans Affairs (Washington, DC) [IIR 05-283] FX This study was supported in part by grants from the Blue Cross Blue Shield of Michigan Foundation (1722.II; Detroit, MI) and the University of Michigan Robert Wood Johnson Foundation Health and Society Scholars program (Ann Arbor, MI) to Dr. Henry. The parent study was funded by an IIR Merit Award from the U.S. Department of Veterans Affairs (IIR 05-283, Washington, DC) to Dr. Fagerlin. NR 36 TC 2 Z9 2 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-6513 EI 1369-7625 J9 HEALTH EXPECT JI Health Expect. PD OCT PY 2015 VL 18 IS 5 BP 1757 EP 1768 DI 10.1111/hex.12168 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CW5OU UT WOS:000365046700093 PM 24372758 ER PT J AU Lau, KM Parikh, M Harvey, DJ Huang, CJ Farias, ST AF Lau, Karen M. Parikh, Mili Harvey, Danielle J. Huang, Chun-Jung Farias, Sarah Tomaszewski TI Early Cognitively Based Functional Limitations Predict Loss of Independence in Instrumental Activities of Daily Living in Older Adults SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Alzheimer's disease; Dementia; Everyday function; Instrumental activities of daily living; Cognition; Disability ID DATA SET UDS; ALZHEIMERS-DISEASE; DISABLEMENT PROCESS; NEUROPSYCHOLOGICAL TESTS; EVERYDAY COGNITION; ECOLOGICAL VALIDITY; CAREGIVER BURDEN; MILD DEMENTIA; IMPAIRMENT; DISABILITY AB Older adults with early forms of neurodegenerative disease are at risk for functional disability, which is often defined by the loss of independence in instrumental activities of daily living (IADLs). The current study investigated the influence of mild changes in everyday functional abilities (referred to as functional limitations) on risk for development of incident functional disability. A total of 407 participants, who were considered cognitively normal or diagnosed with mild cognitive impairment (MCI) at baseline, were followed longitudinally over an average 4.1 years (range=0.8-9.2 years). Informant-based ratings from the Everyday Cognition (ECog; Farias et al., 2008) and the Instrumental Activities of Daily Living (Lawton & Brody, 1969) scales assessed the degree of functional limitations and incident IADL disability, respectively. Cox proportional hazards models revealed that more severe functional limitations (as measured by the Total ECog score) at baseline were associated with approximately a four-fold increased risk of developing IADL disability a few years later. Among the ECog domains, functional limitations in Everyday Planning, Everyday Memory, and Everyday Visuospatial domains were associated with the greatest risk of incident functional disability. These results remained robust even after controlling for participants' neuropsychological functioning on tests of executive functions and episodic memory. Current findings indicate that early functional limitations have prognostic value in identifying older adults at risk for developing functional disability. Findings highlight the importance of developing interventions to support everyday abilities related to memory, executive function, and visuospatial skills in an effort to delay loss of independence in IADLs. C1 [Lau, Karen M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lau, Karen M.; Farias, Sarah Tomaszewski] Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA. [Parikh, Mili] Vet Affairs Northern Calif Hlth Care Syst, Mather, CA USA. [Harvey, Danielle J.; Huang, Chun-Jung] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Div Biostat, Sacramento, CA 95817 USA. RP Farias, ST (reprint author), Univ Calif Davis, Sch Med, Dept Neurol, 4860 Y St,Suite 3700, Sacramento, CA 95817 USA. EM sarah.farias@ucdmc.ucdavis.edu FU National Institute on Aging [AG031252, AG10129] FX This study was supported by the following grants from the National Institute on Aging (grant numbers: AG031252 and AG10129). The authors have no conflicts of interest to report. No competing financial interests exist. NR 78 TC 1 Z9 1 U1 4 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD OCT PY 2015 VL 21 IS 9 SI SI BP 688 EP 698 DI 10.1017/S1355617715000818 PG 11 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA CW4JT UT WOS:000364958300004 PM 26391766 ER PT J AU Chang, HB Gao, X Nepomuceno, R Hu, SS Sun, DD AF Chang, He Benny Gao, Xin Nepomuceno, Rachel Hu, Shaoshan Sun, Dandan TI Na+/H+ exchanger in the regulation of platelet activation and paradoxical effects of cariporide SO EXPERIMENTAL NEUROLOGY LA English DT Article; Proceedings Paper CT 3rd Pangu Stroke Conference CY OCT 10-12, 2014 CL Beijing, PEOPLES R CHINA DE Cariporide; EXPEDITION trial; HOE 642; Ischemia reperfusion; NHE1; Platelet aggregation ID SODIUM-HYDROGEN EXCHANGE; LOW-DENSITY-LIPOPROTEIN; NHE-1 INHIBITOR CARIPORIDE; TRANSIENT ISCHEMIC ATTACK; PORCINE BLOOD-PLATELETS; MYOCARDIAL-INFARCTION; CLINICAL-IMPLICATIONS; CEREBRAL-ISCHEMIA; PROTEIN-KINASE; MINOR STROKE AB Platelets are anucleated cell fragments derived from mature megalcaryocytes and function in hemostasis when the endothelium is injured. Hemostasis involving platelets can be divided into four phases: adhesion, activation, secretion, and aggregation. Platelet activation requires a rise in intracellular Ca2+ concentrations and results in both a morphological change and the secretion of platelet granule contents. Na+/H+ exchanger isoform I (NHE1) regulates the intracellular pH (pH(i)) and the volume of platelets. In addition, NHE1 plays a large role in platelet activation. Thrombus generation involves NHE1 activation and an increase in [Ca2+](i), which results from NHE1-mediated Na+ overload and the reversal of the Na+/Ca2+ exchanger. Cariporide (HOE-642), a potent NHE1 inhibitor, has inhibitory effects on the degranulation of human platelets, the formation of plateletleukocyte-aggregates, and the activation of the GPIIb/IIIa receptor (PAC-1). However, despite the demonstrated protection against myocardial infarction as mediated by cariporide in patients undergoing coronary artery bypass graft surgery, the EXPEDITION clinical trial revealed that cariporide treatment increased mortality due to thromboembolic stroke. These findings suggest that a better understanding of NHE1 and its effect on platelet function and procoagulant factor regulation is warranted in order to develop therapies using NHE inhibitors. (C) 2015 Elsevier Inc. All rights reserved. C1 [Chang, He Benny; Gao, Xin; Nepomuceno, Rachel; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Gao, Xin; Hu, Shaoshan] Harbin Med Univ, Affiliated Hosp 2, Dept Neurol Surg, Harbin 150086, Peoples R China. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. RP Sun, DD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-598 South Biomed Sci Tower BST, Pittsburgh, PA 15213 USA. EM sund@upmc.edu OI Nepomuceno, Rachel/0000-0003-2358-7820 FU NIH [R01 NS048216]; Chinese Academy of Sciences Program [2014 YS14C11]; Technology Cooperation of Province FX This work was supported in part by NIH grant R01 NS048216 (DS) and Technology Cooperation of Province and Chinese Academy of Sciences Program 2014 YS14C11 (SH). NR 66 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2015 VL 272 SI SI BP 11 EP 16 DI 10.1016/j.expneurol.2014.12.023 PG 6 WC Neurosciences SC Neurosciences & Neurology GA CV6AS UT WOS:000364353700003 PM 25595121 ER PT J AU Shi, H Hu, XM Leak, RK Shi, YJ An, CR Suenaga, J Chen, J Gao, YQ AF Shi, Hong Hu, Xiaoming Leak, Rehana K. Shi, Yejie An, Chengrui Suenaga, Jun Chen, Jun Gao, Yanqin TI Demyelination as a rational therapeutic target for ischemic or traumatic brain injury SO EXPERIMENTAL NEUROLOGY LA English DT Article; Proceedings Paper CT 3rd Pangu Stroke Conference CY OCT 10-12, 2014 CL Beijing, PEOPLES R CHINA DE Demyelination; Oligodendrocyte; Remyelination; Cerebral ischemia; Traumatic brain injury ID OLIGODENDROCYTE PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; RECEPTOR/IL-6 FUSION PROTEIN; SPINAL-CORD-INJURY; MITOCHONDRIAL DYSFUNCTION; MULTIPLE-SCLEROSIS AB Previous research on stroke and traumatic brain injury (TBI) heavily emphasized pathological alterations in neuronal cells within gray matter. However, recent studies have highlighted the equal importance of white matter integrity in long-term recovery from these conditions. Demyelination is a major component of white matter injury and is characterized by loss of the myelin sheath and oligodendrocyte cell death. Demyelination contributes significantly to long-term sensorimotor and cognitive deficits because the adult brain only has limited capacity for oligodendrocyte regeneration and axonal remyelination. In the current review, we will provide an overview of the major causes of demyelination and oligodendrocyte cell death following acute brain injuries, and discuss the crosstalk between myelin, axons, microglia, and astrocytes during the process of demyelination. Recent discoveries of molecules that regulate the processes of remyelination may provide novel therapeutic targets to restore white matter integrity and improve long-term neurological recovery in stroke or TBI patients. (C) 2015 Elsevier Inc. All rights reserved. C1 [Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Inst Brain Sci, Shanghai 200032, Peoples R China. [Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China. [Shi, Hong] Tongji Univ, Shanghai Pulm Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China. [Hu, Xiaoming; Shi, Yejie; Suenaga, Jun; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Hu, Xiaoming; Shi, Yejie; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, 3500 Terrace St, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; yqgao@shmu.edu.cn RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201 FU Natural Science Foundation of Shanghai [14ZR1434600]; Natural Science Foundation of China [81171149, 81371306, 81228008]; Shanghai Committee of Science and Technology Research Program [14431907002]; American Heart Association Scientist Development [13SDG14570025]; Doctoral Training Fund from the Chinese Ministry of Education [20120071110042]; NIH/NINDS [NS36736, NS43802, NS45048, NS089534]; Department of Veterans Affairs Research Career Scientist Award and RR D Merit Review [1l01IX000420] FX This work was supported by the Natural Science Foundation of Shanghai grant 14ZR1434600 (to H.S.), the Natural Science Foundation of China grants 81171149 and 81371306 (to Y.G.), and 81228008 (to J.C.), the Shanghai Committee of Science and Technology Research Program 14431907002 (to Y.G.), the American Heart Association Scientist Development grant 13SDG14570025 (to X.H.), Doctoral Training Fund from the Chinese Ministry of Education 20120071110042 (to J.C.), NIH/NINDS grants NS36736, NS43802, NS45048 and NS089534 (to J.C.), and the Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review 1l01IX000420 (to J.C.). NR 177 TC 4 Z9 4 U1 2 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2015 VL 272 SI SI BP 17 EP 25 DI 10.1016/j.expneurol.2015.03.017 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CV6AS UT WOS:000364353700004 PM 25819104 ER PT J AU Suenaga, J Hu, XM Pu, HJ Shi, YJ Hassan, SH Xu, MY Leak, RK Stetler, RA Gao, YQ Chen, J AF Suenaga, Jun Hu, Xiaoming Pu, Hongjian Shi, Yejie Hassan, Sulaiman Habib Xu, Mingyue Leak, Rehana K. Stetler, R. Anne Gao, Yanqin Chen, Jun TI White matter injury and microglia/macrophage polarization are strongly linked with age-related long-term deficits in neurological function after stroke SO EXPERIMENTAL NEUROLOGY LA English DT Article; Proceedings Paper CT 3rd Pangu Stroke Conference CY OCT 10-12, 2014 CL Beijing, PEOPLES R CHINA DE Aging; Microglia; Distal middle cerebral artery occlusion (dMCAO); Cerebral blood perfusion ID MIDDLE CEREBRAL-ARTERY; ISCHEMIC BRAIN-INJURY; PERIPHERAL IMMUNE-SYSTEM; INFLAMMATORY MEDIATORS; OCCLUSION; MICE; RATS; HYPOPERFUSION; ACTIVATION; CONTRIBUTE AB Most of the successes in experimental models of stroke have not translated well to the clinic. One potential reason for this failure is that stroke mainly afflicts the elderly and the majority of experimental stroke studies rely on data gathered from young adult animals. Therefore, in the present study we established a reliable, reproducible model of stroke with low mortality in aged (18 month) male mice and contrasted their pathophysiological Changes with those in young (2 month) animals. To this end, mice were subjected to permanent tandem occlusion of the left distal middle cerebral artery (dMCAO) with ipsilateral common carotid artery occlusion (CCAO). Cerebral blood flow (CBF) was evaluated repeatedly during and after stroke. Reduction of CBF was more dramatic and sustained in aged mice. Aged mice exhibited more severe long-term sensorimotor deficits, as manifested by deterioration of performance in the Rotarod and hanging wire tests up to and after stroke. Aged mice also exhibited significantly worse long-term cognitive deficits after stroke, as measured by the Morris water maze test Consistent with these behavioral observations, brain infarct size and neuronal tissue loss after dMCAO were significantly larger in aged mice at 2 d and 14 d, respectively. The young versus aged difference in neuronal tissue loss, however, did not persist until 35 d after dMCAO. In contrast to the transient difference in neuronal tissue loss, we found significant and long lasting deterioration of white matter in aged animals, as revealed by the loss of myelin basic protein (MBP) staining in the striatum at 35 d after dMCAO. We further examined the expression of M1 (CD16/CD32) and M2 (CD206) markers in Iba-1(+) microglia by double immunofluorescent staining. In both young and aged mice, the expression of M2 markers peaked around 7 d after stroke whereas the expression of M1 markers peaked around 14 d after stroke, suggesting a progressive M2-to-M1 phenotype shift in both groups. However, aged mice exhibited significantly reduced M2 polarization compared to young adults. Remarkably, we discovered a strong positive correlation between favorable neurological outcomes after dMCAO and MBP levels or the number of M2 microglia/macrophages. In conclusion, our studies suggest that the distal MCAO stroke model consistently results in ischemic brain injury with long-term behavioral deficits, and is therefore suitable for the evaluation of long-term stroke outcomes. Furthermore, aged mice exhibit deterioration of functional outcomes after stroke and this deterioration is linked to white matter damage and reductions in M2 microglia/macrophage polarization. (C) 2015 Elsevier Inc. All rights reserved. C1 [Suenaga, Jun; Hu, Xiaoming; Pu, Hongjian; Shi, Yejie; Hassan, Sulaiman Habib; Stetler, R. Anne; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA. [Hu, Xiaoming; Pu, Hongjian; Xu, Mingyue; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Hu, Xiaoming; Pu, Hongjian; Xu, Mingyue; Gao, Yanqin; Chen, Jun] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Hu, Xiaoming; Shi, Yejie; Stetler, R. Anne; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201 FU U.S. National Institutes of Health [NS36736, NS43802, NS45048, NS089534]; U.S. Department of Veterans Affairs Research Career Scientist Award and RRD Merit Review [I01RX000420]; Rotary Foundation Global Scholarship [GG1412044]; American Heart Association Scientist Development [13SDG14570025]; Postdoctoral Fellowship Award [15POST22260011]; Chinese Natural Science Foundation [81020108021, 81171149, 81371306, J1210041, 81228008] FX This work was supported by U.S. National Institutes of Health grants NS36736, NS43802, NS45048 and NS089534 (to JC), U.S. Department of Veterans Affairs Research Career Scientist Award and RR&D Merit Review I01RX000420 (to JC), Rotary Foundation Global Scholarship grant GG1412044 (to JS), American Heart Association Scientist Development grant 13SDG14570025 (to XH), Postdoctoral Fellowship Award 15POST22260011 (to YS), and Chinese Natural Science Foundation grants 81020108021, 81171149, 81371306 and J1210041 (to YG), and 81228008 (to JC). NR 48 TC 18 Z9 18 U1 1 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2015 VL 272 SI SI BP 109 EP 119 DI 10.1016/j.expneurol.2015.03.021 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CV6AS UT WOS:000364353700013 PM 25836044 ER PT J AU Zhang, WT Wang, HL Zhang, H Leak, RK Shi, YJ Hu, XM Gao, YQ Chen, J AF Zhang, Wenting Wang, Hailian Zhang, Hui Leak, Rehana K. Shi, Yejie Hu, Xiaoming Gao, Yanqin Chen, Jun TI Dietary supplementation with omega-3 polyunsaturated fatty acids robustly promotes neurovascular restorative dynamics and improves neurological functions after stroke SO EXPERIMENTAL NEUROLOGY LA English DT Article; Proceedings Paper CT 3rd Pangu Stroke Conference CY OCT 10-12, 2014 CL Beijing, PEOPLES R CHINA DE Docosahexaenoic acid; Eicosapentaenoic acid; Revascularization; Angiogenesis; Neurogenesis; Oligodendrogenesis; Angiopoietin 1; Oligodendrocyte precursor cell ID ISCHEMIC BRAIN-INJURY; FACTOR-INDUCED ANGIOGENESIS; VASCULAR NEURAL-NETWORK; NEUROBLAST MIGRATION; ENDOGENOUS NEUROGENESIS; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; FISH CONSUMPTION; STEM-CELLS; STRATEGIES AB Stroke is a devastating neurological disease with no satisfactory therapies to preserve long-term neurological function, perhaps due to the sole emphasis on neuronal survival in most preclinical studies. Recent studies have revealed the importance of protecting multiple cell types in the injured brain, such as oligodendrocytes and components of the neurovascular unit, before long-lasting recovery of function can be achieved. For example, revascularization in the ischemic penumbra is critical to provide various neurotrophic factors that enhance the survival and activity of neurons and other progenitor cells, such as oligodendrocyte precursor cells. In the present study, we hypothesized that chronic dietary supplementation with fish oil promotes post-stroke angiogenesis, neurogenesis, and oligodendrogenesis, thereby leading to long-term functional improvements. Mice received dietary supplementation with n-3 PUFA-enriched fish oil for three months before and up to one month after stroke. As expected, dietary n-3 PUFAs significantly increased levels of n-3 PUFAs in the brain and improved long-term behavioral outcomes after cerebral ischemia. n-3 PUFAs also robustly improved revascularization and angiogenesis and boosted the survival of NeuN/BrdU labeled newborn neurons up to 35 days after stroke injury. Furthermore, these pro-neurogenic effects were accompanied by robust oligodendrogenesis. Thus, this is the first study to demonstrate that chronic dietary intake of n-3 PUFAs is an effective prophylactic measure not only to protect against ischemic injury for the long term but also to actively promote neurovascular restorative dynamics and brain repair. (C) 2015 Elsevier Inc. All rights reserved. C1 [Zhang, Wenting; Wang, Hailian; Zhang, Hui; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Wenting; Wang, Hailian; Zhang, Hui; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Zhang, Wenting; Wang, Hailian; Zhang, Hui; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Fudan Univ, Huashan Hosp, Dept Anesthesiol, Shanghai 200032, Peoples R China. [Zhang, Wenting; Wang, Hailian; Zhang, Hui; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200032, Peoples R China. [Zhang, Wenting; Shi, Yejie; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Shi, Yejie; Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Zhang, WT (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM wtzhang@fudan.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU U.S. National Institutes of Health [NS36736, NS43802, NS45048]; U.S. Department of Veterans Affairs Research Career Scientist Award and RR D Merit Review [RX-000420-01]; Chinese Natural Science Foundation [81020108021, 81171149, 81371306, 81228008, 81301123]; Shanghai Committee of Science and Technology Support Program [14431907002]; Ministry of Education of China PhD-training [20120071110042]; China Postdoctoral Science Foundation [20110490665]; Shanghai Postdoctoral Sustentation Fund [11R21410500]; National Natural Science Foundation [81100978, 81471332] FX W.Z. and H.W. contributed equally to this research. This project was supported by the U.S. National Institutes of Health grants NS36736, NS43802 and NS45048 (to J.C.), the U.S. Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review RX-000420-01 (to J.C.), the Chinese Natural Science Foundation grants 81020108021, 81171149, 81371306 (to Y.G.), 81228008 (to J.C.), 81301123 (to H.W.), the Shanghai Committee of Science and Technology Support Program 14431907002 (to Y.G.), and the Ministry of Education of China PhD-training grant 20120071110042 (to J.C.). W.Z. was supported by the China Postdoctoral Science Foundation grants (No. 20110490665), the Shanghai Postdoctoral Sustentation Fund (No. 11R21410500), and the National Natural Science Foundation grants (No. 81100978 and No. 81471332). We thank Shiduo Lu for performing animal surgery and Hui Gao for excellent administrative support. NR 56 TC 4 Z9 4 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD OCT PY 2015 VL 272 SI SI BP 170 EP 180 DI 10.1016/j.expneurol.2015.03.005 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CV6AS UT WOS:000364353700020 PM 25771800 ER PT J AU Banks, WA AF Banks, William A. TI Peptides and the blood-brain barrier SO PEPTIDES LA English DT Article DE Peptides; Blood-brain barrier; AJ Kastin; Delta sleep-inducing peptide; Regulatory proteins; Cytokines ID CARRIER-MEDIATED TRANSPORT; DSIP PEPTIDES; AMINO-ACIDS; RAT-BRAIN; SATURABLE SYSTEM; PERMEABILITY; TYR-MIF-1; PENETRATION; CROSSES; ALPHA AB The demonstration that peptides and regulatory proteins can cross the blood-brain barrier (BBB) is one of the major contributions of Dr. Abba J. Kastin. He was the first to propose that peptides could cross the BBB, the first to show that an endogenous peptide did so, and the first to describe a saturable transport system at the BBB for peptides. His work shows that in crossing the BBB, peptides and regulatory proteins act as informational molecules, informing the brain of peripheral events. Brain-to-blood passage helps to control levels of peptides with the brain and can deliver information in the brain-to-blood direction. He showed that the transporters for peptides and proteins are not static, but respond to developmental and physiological changes and are affected by disease states. As such, the BBB is adaptive to the needs of the CNS, but when that adaption goes awry, the BBB can be a cause of disease. The mechanisms by which peptides and proteins cross the BBB offer opportunities for drug delivery of these substances or their analogs to the brain in the treatment of diseases of the central nervous system. Published by Elsevier Inc. C1 [Banks, William A.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA. [Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. RP Banks, WA (reprint author), Rm810A Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU Veterans Affairs FX Supported by Veterans Affairs. NR 50 TC 6 Z9 6 U1 2 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 EI 1873-5169 J9 PEPTIDES JI Peptides PD OCT PY 2015 VL 72 BP 16 EP 19 DI 10.1016/j.peptides.2015.03.010 PG 4 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA CW0SO UT WOS:000364699900003 PM 25805003 ER PT J AU Taylor, AB Pica-Mattoccia, L Polcaro, CM Donati, E Cao, XH Basso, A Guidi, A Rugel, AR Holloway, SP Anderson, TJC Hart, PJ Cioli, D LoVerde, PT AF Taylor, Alexander B. Pica-Mattoccia, Livia Polcaro, Chiara M. Donati, Enrica Cao, Xiaohang Basso, Annalisa Guidi, Alessandra Rugel, Anastasia R. Holloway, Stephen P. Anderson, Timothy J. C. Hart, P. John Cioli, Donato LoVerde, Philip T. TI Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine SO PLoS Neglected Tropical Diseases LA English DT Article ID IN-VITRO METABOLISM; LIQUID-CHROMATOGRAPHY; SCHISTOSOMA-MANSONI; RESOLUTION AB Background For over two decades, a racemic mixture of oxamniquine (OXA) was administered to patients infected by Schistosoma mansoni, but whether one or both enantiomers exert antischistosomal activity was unknown. Recently, a similar to 30 kDa S. mansoni sulfotransferase (SmSULT) was identified as the target of OXA action. Methodology/Principal Findings Here, we separate the OXA enantiomers using chromatographic methods and assign their optical activities as dextrorotary [(+)-OXA] or levorotary [(-)-OXA]. Crystal structures of the parasite enzyme in complex with optically pure (+)-OXA and (-)-OXA) reveal their absolute configurations as S- and R-, respectively. When tested in vitro, S-OXA demonstrated the bulk of schistosomicidal activity, while R-OXA had antischistosomal effects when present at relatively high concentrations. Crystal structures R-OXA center dot SmSULT and S-OXA center dot SmSULT complexes reveal similarities in the modes of OXA binding, but only the S-OXA enantiomer is observed in the structure of the enzyme exposed to racemic OXA. Conclusions/Significance Together the data suggest the higher schistosomicidal activity of S-OXA is correlated with its ability to outcompete R-OXA binding the sulfotransferase active site. These findings have important implications for the design, syntheses, and dosing of new OXA-based antischistosomal compounds. C1 [Taylor, Alexander B.; Cao, Xiaohang; Rugel, Anastasia R.; Holloway, Stephen P.; Hart, P. John; LoVerde, Philip T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Pica-Mattoccia, Livia; Basso, Annalisa; Guidi, Alessandra; Cioli, Donato] CNR, Inst Cell Biol & Neurobiol, Rome, Italy. [Polcaro, Chiara M.; Donati, Enrica] CNR, Inst Chem Methodol, Rome, Italy. [Basso, Annalisa] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Anderson, Timothy J. C.] Texas Biomed Res Inst, San Antonio, TX USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Taylor, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjh@biochem.uthscsa.edu; dcioli@ibc.cnr.it; loverde@uthscsa.edu FU NIH [1R01AI115691]; WHO [HQNTD1206356]; UTHSCSA Presidents Collaborative Research Fund; Robert A. Welch Foundation [AQ-1399]; National Institute of General Medical Sciences from the National Institutes of Health [P41 GM103403]; NIH-ORIP HEI grant [S10 RR029205]; Argonne National Laboratory [DE-AC02-06CH11357]; National Center for Advancing Translational Sciences, National Institutes of Health [TL1 TR001119] FX This research was supported by NIH grant 1R01AI115691 (PTL and PJH), WHO grant HQNTD1206356 (PTL), the UTHSCSA Presidents Collaborative Research Fund (PTL and PJH), and the Robert A. Welch Foundation (AQ-1399, PJH) Support for the X-ray Crystallography Core Laboratory by the UTHSCSA Office of the Vice President for Research is gratefully acknowledged. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. ARR was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant TL1 TR001119. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2015 VL 9 IS 10 AR e0004132 DI 10.1371/journal.pntd.0004132 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CV7NC UT WOS:000364459600037 PM 26485649 ER PT J AU Sibila, O Suarez-Cuartin, G Rodrigo-Troyano, A Fardon, TC Finch, S Mateus, EF Garcia-Bellmunt, L Castillo, D Vidal, S Sanchez-Reus, F Restrepo, MI Chalmers, JD AF Sibila, Oriol Suarez-Cuartin, Guillermo Rodrigo-Troyano, Ana Fardon, Thomas C. Finch, Simon Mateus, Eder Freddy Garcia-Bellmunt, Laia Castillo, Diego Vidal, Silvia Sanchez-Reus, Ferran Restrepo, Marcos I. Chalmers, James D. TI Secreted mucins and airway bacterial colonization in non-CF bronchiectasis SO RESPIROLOGY LA English DT Article DE bronchiectasis; bronchial colonization; lung defense mechanism; mucin ID CYSTIC FIBROSIS BRONCHIECTASIS; CELLS IN-VITRO; EPITHELIAL-CELLS; MUC5B MUCINS; LONG-TERM; DISEASE; MUCUS; INFLAMMATION; MECHANISMS; SPUTUM AB Background and objective: Secreted mucins play a key role in antibacterial defence in the airway, but have not previously been characterized in non-cystic fibrosis (CF) bronchiectasis patients. We aim to investigate the relationship between secreted mucins levels and the presence of bacterial colonization due to potentially pathogenic microorganisms (PPM) in the airways of stable bronchiectasis patients. Methods: Clinically stable bronchiectasis patients were studied prospectively at two centres. Patients with other pulmonary conditions were excluded. Spontaneous sputum was subject to bacterial culture, and secreted mucins (MUC2, MUC5AC and MUC5B) were measured in sputum supernatants by ELISA. Results: A total of 50 patients were included. PPM were identified from sputum samples in 30 (60%), with Pseudomonas aeruginosa (n = 10) and Haemophilus influenzae (n = 10) as the most common PPM. There were no baseline differences among airway colonized and non-colonized patients. Patients with airways colonized by PPM presented higher levels of airway MUC2. No differences in MUC5AC levels were found among groups, whereas MUC5B levels were undetectable. Patients with P. aeruginosa colonization expressed the highest levels of MUC2. High levels of MUC2 and MUC5AC are also correlated with disease severity using the Bronchiectasis Severity Index. Conclusions: Airway MUC2 levels were higher in bronchiectasis patients colonized with PPM compared with those without airway colonization, especially in patients with P. aeruginosa. These findings suggest that airway-secreted mucins levels may play a role in the pathogenesis of airway infection in non-CF bronchiectasis. C1 [Sibila, Oriol; Suarez-Cuartin, Guillermo; Rodrigo-Troyano, Ana; Garcia-Bellmunt, Laia; Castillo, Diego] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Resp Dept, E-08193 Barcelona, Spain. [Sibila, Oriol; Suarez-Cuartin, Guillermo; Rodrigo-Troyano, Ana; Mateus, Eder Freddy; Garcia-Bellmunt, Laia; Castillo, Diego; Vidal, Silvia; Sanchez-Reus, Ferran] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau IIB St Pau, E-08193 Barcelona, Spain. [Mateus, Eder Freddy; Vidal, Silvia] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Expt Immunol Lab, E-08193 Barcelona, Spain. [Sanchez-Reus, Ferran] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Microbiol, E-08193 Barcelona, Spain. [Fardon, Thomas C.; Finch, Simon; Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Crit Care Dept, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Med, San Antonio, TX 78229 USA. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Resp Dept, St Antoni M Claret St 167, Barcelona 08025, Spain. EM osibila@santpau.cat OI Castillo, Diego/0000-0002-4862-3595 FU Sociedad Espanola de Neumologia (SEPAR); Fundacio Catalana de Pneumologia (FUCAP); Tenovus Scotland; National Heart, Lung, and Blood Institute [K23HL096054] FX The project described was supported by Sociedad Espanola de Neumologia (SEPAR), Fundacio Catalana de Pneumologia (FUCAP) and Tenovus Scotland. Dr Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. NR 33 TC 4 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD OCT PY 2015 VL 20 IS 7 BP 1082 EP 1088 DI 10.1111/resp.12595 PG 7 WC Respiratory System SC Respiratory System GA CV9GD UT WOS:000364594700012 PM 26172851 ER PT J AU Roussos, P Katsel, P Fam, P Tan, WL Purohit, DP Haroutunian, V AF Roussos, Panos Katsel, Pavel Fam, Peter Tan, Weilun Purohit, Dushyant P. Haroutunian, Vahram TI The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia SO ALZHEIMERS & DEMENTIA LA English DT Article DE Microglia; TYROBP; Mutation; Inflammation; Gene expression; Protein ID CUTTING EDGE; DISEASE; RESPONSES; MICROGLIA; SCHIZOPHRENIA; VARIANTS; IMMUNITY; REGISTRY; NODES; DAP12 AB Introduction: The objective of this study was to elucidate the relationship between the triggering receptor expressed on myeloid cells 2 (TREM2) risk variant, neuropathological lesions, alterations in gene and protein expression, and the severity of neuroinflammation. Methods: The genetic association study of the R47 H TREM2 variant with Alzheimer's disease (AD), neuropathology, and changes in TREM2 and TYRO protein tyrosine kinase-binding protein (TYROBP) gene and protein expression, and neuroinflammatory markers. Results: The TREM2 variant is associated with: (i) AD (odds ratio: 4.76; P = .014); (ii) increased density of amyloid plaques and neurofibrillary tangles in multiple brain regions; (iii) increased TREM2 (P = .041) and TYROBP (P = .006) gene expression; (iv) decreased TREM2 protein levels (P = .016); and (v) upregulation of proinflammatory cytokines (regulated on activation, normal T cell expressed and secreted [RANTES] and interferon [IFN] gamma) (P = .003) and nominal downregulation of protective markers (alpha 2-macroglobulin, interleukin 4 or IL-4, and ApoA1) (P = .018). Discussion: These findings link the TREM2 missense mutation with specific molecular abnormalities and increases in neuropathological lesions in the human brain. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Roussos, Panos; Katsel, Pavel; Tan, Weilun; Purohit, Dushyant P.; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY 10029 USA. [Roussos, Panos; Haroutunian, Vahram] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Fam, Peter; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Purohit, Dushyant P.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. RP Haroutunian, V (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM vahram.haroutunian@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU National Institutes of Health [P01-AG02219, P50-AG05138, MH066392]; Veteran Administration MIRECC; Leir Foundation; Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai FX This work was supported by National Institutes of Health (P01-AG02219, P50-AG05138, MH066392 to VH), Veteran Administration MIRECC, Leir Foundation. This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD OCT PY 2015 VL 11 IS 10 BP 1163 EP 1170 DI 10.1016/j.jalz.2014.10.013 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CV0UD UT WOS:000363968000005 PM 25499537 ER PT J AU Ahmed, S Lewis, M Matuk, R Pisegna, J AF Ahmed, Shahzad Lewis, Micheal Matuk, Robin Pisegna, Joseph TI Heterotopic Salivary Gland Tissue in the Rectum of a Patient With Eosinophilic Colitis and Redundant Colon SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Ahmed, Shahzad] Cedars Sinai Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90048 USA. [Lewis, Micheal; Pisegna, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Matuk, Robin] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 456 BP S196 EP S196 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715901006 ER PT J AU Al-Jiboury, H Wilgus, J Benhammou, J Patel, A Jacob, N Ohning, G Otomo-Corgel, J Pisegna, JR AF Al-Jiboury, Hala Wilgus, Jeremy Benhammou, Jihane Patel, Arpan Jacob, Noam Ohning, Gordon Otomo-Corgel, Joan Pisegna, Joseph R. TI The Gastric Refluxate in Patients With Gastroesophageal Reflux Disease (GERD) Has a Protective Effect on Periodontal Microbiota SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Al-Jiboury, Hala] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Wilgus, Jeremy; Jacob, Noam; Otomo-Corgel, Joan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Benhammou, Jihane] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Patel, Arpan; Ohning, Gordon] Univ Calif Los Angeles, Los Angeles, CA USA. [Pisegna, Joseph R.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth System, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1723 BP S731 EP S731 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715903336 ER PT J AU Basu, PP Shah, NJ John, N Aloysius, M Brown, R AF Basu, P. Patrick Shah, Niraj James John, Nimy Aloysius, Mark Brown, Robert, Jr. TI Sofosbuvir and Ledipasvir in IBD Patients Treated With Advanced Biologics Including Ribavirin Eradicating Chronic Hepatitis C: Solataire C Trial: A Multicenter Clinical Prospective Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Shah, Niraj James] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Yonkers, NY USA. [John, Nimy; Aloysius, Mark] Kings Cty Hosp Med Ctr, Forest Hills, NY USA. [Brown, Robert, Jr.] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2204 BP S916 EP S916 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904362 ER PT J AU Basu, PP Shah, NJ John, N Aloysius, M Brown, R AF Basu, P. Patrick Shah, Niraj James John, Nimy Aloysius, Mark Brown, Robert, Jr. TI Sofosbuvir and Ledipasvir in Attainment of SVR12 in Sickle Cell Disease (SCD) Sub-population With Chronic Hepatitis C (CHC): A Single-Center, Prospective, Open-Label Clinical Pilot Stud: SLASH C Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Shah, Niraj James] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Yonkers, NY USA. [John, Nimy; Aloysius, Mark] Kings Cty Hosp Med Ctr, Forest Hills, NY USA. [Brown, Robert, Jr.] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2198 BP S914 EP S914 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904356 ER PT J AU Basu, PP Shah, NJ John, N Aloysius, M Brown, R AF Basu, P. Patrick Shah, Niraj James John, Nimy Aloysius, Mark Brown, Robert, Jr. TI Sofosbuvir and Ledipasvir Versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. SLAM C Study, Interim Data SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA. [Shah, Niraj James] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Yonkers, NY USA. [John, Nimy; Aloysius, Mark] Kings Cty Hosp Med Ctr, Forest Hills, NY USA. [Brown, Robert, Jr.] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2192 BP S912 EP S912 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904350 ER PT J AU Benhammou, J Vu, J Parsons, W Luong, L Oh, S Lewis, M Beaven, S Germano, P Pisegna, JR AF Benhammou, Jihane Vu, John Parsons, Will Luong, Leon Oh, Suwan Lewis, Michael Beaven, Simon Germano, Patrizia Pisegna, Joseph R. TI Improvement in Hepatic Steatosis, Visceral Adiposity, and Appetite by High Dietary Protein Supplementation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Benhammou, Jihane] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vu, John; Parsons, Will; Luong, Leon; Oh, Suwan; Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Beaven, Simon] Univ Calif Los Angeles, Los Angeles, CA USA. [Germano, Patrizia] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Pisegna, Joseph R.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2155 BP S897 EP S898 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904313 ER PT J AU Benhammou, J Al-Jiboury, H Jacob, N Ghassemi, K Sedarat, A Pisegna, J AF Benhammou, Jihane Al-Jiboury, Hala Jacob, Noam Ghassemi, Kevin Sedarat, Alireza Pisegna, Joseph TI EUS-Guided Fine Needle Aspiration (FNA) More Accurately Identifies Small Pancreatic Neuroendocrine Tumors (PNETs) Than CT-Guided FNA SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Benhammou, Jihane] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Al-Jiboury, Hala; Ghassemi, Kevin; Sedarat, Alireza] Univ Calif Los Angeles, Los Angeles, CA USA. [Jacob, Noam; Pisegna, Joseph] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 65 BP S27 EP S27 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715900066 ER PT J AU Francis, F Kulich, SM Hashash, LG AF Francis, Fadi Kulich, Scott M. Hashash, Laws G. TI Diarrhea, Ascites, and Eosinophilia SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Francis, Fadi] Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kulich, Scott M.; Hashash, Laws G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1106 BP S481 EP S482 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715902205 ER PT J AU Garapati, K Camero, A Echavarria, J Malakouti, M Kundrotas, L AF Garapati, Karthik Camero, Alfredo Echavarria, Juan Malakouti, Mazyar Kundrotas, Leon TI Adherence to Surveillance Colonoscopy: An Investigation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Garapati, Karthik; Camero, Alfredo; Echavarria, Juan; Malakouti, Mazyar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kundrotas, Leon] Audie L Murphy Vet Affairs Hosp, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2286 BP S948 EP S948 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904445 ER PT J AU Goyal, D Kim, S Dutson, E Chen, YJ Pisegna, J Watson, RR AF Goyal, Deepinder Kim, Stephen Dutson, Erik Chen, Yijun Pisegna, Joseph Watson, Rabindra R. TI Endoscopic Trans-Oral Outlet Reduction in Combination with Gastroplasty (TORe-G) Is a Novel Technique That Is Highly Efficacious and Safe for Weight Loss in Patients With Failed Roux-en-Y Gastric Bypass (RYGB) SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Goyal, Deepinder] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Dutson, Erik; Chen, Yijun] Univ Calif Los Angeles, Los Angeles, CA USA. [Pisegna, Joseph] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Watson, Rabindra R.] Univ Calif Los Angeles, Intervent Endoscopy Serv, Los Angeles, CA USA. [Watson, Rabindra R.] Ctr Obes & Metab Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1521 BP S656 EP S657 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715903134 ER PT J AU Hashash, JG Bista, R Staton, KD Hartman, DJ Regueiro, M Binion, DG Francis, F Alnabhan, S Baidoo, L Swoger, J Brand, R Liu, Y AF Hashash, Jana G. Bista, Rajan Staton, Kevin D. Hartman, Douglas J. Regueiro, Miguel Binion, David G. Francis, Fadi Alnabhan, Samer Baidoo, Leonard Swoger, Jason Brand, Randall Liu, Yang TI Identifying Colonic Dysplasia and Cancer From Rectal Nuclear Nano-morphology Markers in Ulcerative Colitis Patients SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Hashash, Jana G.; Bista, Rajan; Alnabhan, Samer; Baidoo, Leonard; Brand, Randall; Liu, Yang] Univ Pittsburgh, Pittsburgh, PA USA. [Staton, Kevin D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hartman, Douglas J.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Regueiro, Miguel; Swoger, Jason] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Binion, David G.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Francis, Fadi] Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1895 BP S804 EP S805 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904054 ER PT J AU Jacob, N Benhammou, J Al-Jiboury, H Patel, A Sedarat, A Lewis, M Pisegna, JR AF Jacob, Noam Benhammou, Jihane Al-Jiboury, Hala Patel, Arpan Sedarat, Alireza Lewis, Michael Pisegna, Joseph R. TI Duodenal Neuroendocrine Tumors (DNETs): A Case Series and Establishment of a Registry for Proposed Classification SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Jacob, Noam; Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Benhammou, Jihane] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Al-Jiboury, Hala; Patel, Arpan; Sedarat, Alireza] Univ Calif Los Angeles, Los Angeles, CA USA. [Pisegna, Joseph R.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2425 BP S1007 EP S1008 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715905055 ER PT J AU Kalra, A Hunt, K Gross, J Kwon, W Somrov, S Gal, C Kirtich, S Aytaman, A AF Kalra, Amita Hunt, Kristel Gross, Jonathan Kwon, William Somrov, Serge Gal, Christopher Kirtich, Sabina Aytaman, Ayse TI Creation of a VISN Wide Multi-Disciplinary, Multi-Facility Team and Tumor Board: Its Impact on Timeliness and Quality of Hepatocellular Carcinoma Care SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Kalra, Amita; Gal, Christopher] SUNY Downstate, Brooklyn, NY USA. [Hunt, Kristel] James J Peters VA Med Ctr, Bronx, NY USA. [Gross, Jonathan] VA New York Harbor Hlth Care Syst, Brooklyn, NY USA. [Kwon, William] Brooklyn VA Harbor Healthcare Syst, Brooklyn, NY USA. [Somrov, Serge; Aytaman, Ayse] Brooklyn VA Harbor Healthcare Syst, Brooklyn, NY USA. [Kirtich, Sabina] Brooklyn VA, Brooklyn, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 2075 BP S872 EP S872 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904234 ER PT J AU Leung, FW Amato, A Cadoni, S Falt, P Friedland, S Hsieh, YH Leung, J Liggi, M Sul, J Yen, A AF Leung, Felix W. Amato, Arnaldo Cadoni, Sergio Falt, Premsyl Friedland, Shai Hsieh, Yu-Hsi Leung, Joseph Liggi, Mauro Sul, James Yen, Andrew TI Novel Developments in Water-Aided Techniques for Education and Research (WATER) in Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Leung, Felix W.] VA Greater Los Angeles Hth Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. [Amato, Arnaldo] Valduce Hosp, Como, Italy. [Cadoni, Sergio; Liggi, Mauro] S Barbara Hosp, Iglesias, CI, Italy. [Falt, Premsyl] Vitkovice Hosp, Zaluzanskeho, Czech Republic. [Friedland, Shai] Palo Alto VA Med Ctr, Palo Alto, CA USA. [Hsieh, Yu-Hsi] Tzu Chi Gen Hosp, Chiayi, Taiwan. [Leung, Joseph; Yen, Andrew] Sacramento VA Med Ctr, Mather, CA USA. [Sul, James] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1265 BP S556 EP S557 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715902364 ER PT J AU Snyder, D Kathpalia, P Sontag, S AF Snyder, Diana Kathpalia, Priya Sontag, Stephen TI Surveillance Colonoscopy to Detect Colorectal Cancer in Patients With Inflammatory Bowel Disease: Is It Too Frequent? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Snyder, Diana] Loyola Univ, Med Ctr, River Grove, IL USA. [Kathpalia, Priya] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Sontag, Stephen] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1977 BP S837 EP S837 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715904136 ER PT J AU Yen, AW Leung, JW Leung, FW AF Yen, Andrew W. Leung, Joseph W. Leung, Felix W. TI Underwater Resection of Colorectal Neoplasia: Taking the Plunge Into a New Technique SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 80th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 16-21, 2015 CL Honolulu, HI SP Amer Coll Gastroenterol C1 [Yen, Andrew W.; Leung, Joseph W.] Sacramento VA Med Ctr, Mather, CA USA. [Yen, Andrew W.; Leung, Joseph W.] Univ Calif Davis, Sch Med, Mather, CA USA. [Leung, Felix W.] VA Greater Los Angeles Hlth Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] UCLA, David Geffen Sch Med, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 SU 1 MA 1593 BP S686 EP S686 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KO UT WOS:000363715903206 ER PT J AU Baan, M Kibbe, CR Bushkofsky, JR Harris, TW Sherman, DS Davis, DB AF Baan, Mieke Kibbe, Carly R. Bushkofsky, Justin R. Harris, Ted W. Sherman, Dawn S. Davis, Dawn Belt TI Transgenic expression of the human growth hormone minigene promotes pancreatic beta-cell proliferation SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE human growth hormone; transgene expression; FoxM1; beta-cell; proliferation ID TRANSCRIPTION FACTOR; PARATHYROID-HORMONE; DIABETES SUSCEPTIBILITY; GLUCOSE-HOMEOSTASIS; ISLET MASS; TGF-ALPHA; MICE; PROTEIN; LIVER; OVEREXPRESSION AB Transgenic mouse models are designed to study the role of specific proteins. To increase transgene expression the human growth hormone (hGH) minigene, including introns, has been included in many transgenic constructs. Until recently, it was thought that the hGH gene was not spliced, transcribed, and translated to produce functional hGH protein. We generated a transgenic mouse with the transcription factor Forkhead box M1 (FoxM1) followed by the hGH minigene, under control of the mouse insulin promoter (MIP) to target expression specifically in the pancreatic beta-cell. Expression of FoxM1 in isolated pancreatic islets in vitro stimulates beta-cell proliferation. We aimed to investigate the effect of FoxM1 on beta-cell mass in a mouse model for diabetes mellitus. However, we found inadvertent coexpression of hGH protein from a spliced, bicistronic mRNA. MIP-FoxM1-hGH mice had lower blood glucose and higher pancreatic insulin content, due to increased beta-cell proliferation. hGH signals through the murine prolactin receptor, and expression of its downstream targets tryptophan hydroxylase-1 (Tph1), tryptophan hydroxylase-2 (Tph2), and cytokine-inducible SH2 containing protein (Cish) was increased. Conversely, transcriptional targets of FoxM1 were not upregulated. Our data suggest that the phenotype of MIP-FoxM1-hGH mice is due primarily to hGH activity and that the FoxM1 protein remains largely inactive. Over the past decades, multiple transgenic mouse strains were generated that make use of the hGH minigene to increase transgene expression. Our work suggests that each will need to be carefully screened for inadvertent hGH production and critically evaluated for the use of proper controls. C1 [Baan, Mieke; Kibbe, Carly R.; Bushkofsky, Justin R.; Harris, Ted W.; Sherman, Dawn S.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Davis, DB (reprint author), 4147 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM dbd@medicine.wisc.edu FU National Institutes of Health [T32 RR023916, T32 OD010423, T32AG000213]; NIDDK [DK083442]; University of Wisconsin Department of Medicine FX This work was supported by the National Institutes of Health training grants T32 RR023916 (MB), T32 OD010423 (MB), and T32AG000213 (CK). DBD was supported by NIDDK DK083442 and the University of Wisconsin Department of Medicine. This work was performed with facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States government. NR 39 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD OCT 1 PY 2015 VL 309 IS 7 BP R788 EP R794 DI 10.1152/ajpregu.00244.2015 PG 7 WC Physiology SC Physiology GA CV2QT UT WOS:000364102200009 PM 26202070 ER PT J AU Macqueen, IT Shannon, EM Dawes, AJ Ostrzega, N Russell, MM Maggard-Gibbons, M AF Macqueen, Ian T. Shannon, Evan M. Dawes, Aaron J. Ostrzega, Nora Russell, Marcia M. Maggard-Gibbons, Melinda TI The Role of Surgery in the Clinical Management of Primary Gastrointestinal Non-Hodgkin's Lymphoma SO AMERICAN SURGEON LA English DT Article ID PRIMARY GASTRIC LYMPHOMA; PRIMARY COLONIC LYMPHOMA; CONSERVATIVE MANAGEMENT; GERMAN MULTICENTER; SURVIVAL; OUTCOMES; DISEASE; TRACT AB Primary gastrointestinal non-Hodgkin's lymphoma (PGINHL) is a heterogeneous family of tumors, with treatment modalities including chemotherapy, surgery, and radiotherapy. Because the role of surgery in PGINHL remains disputed, this study aims to assess the impact of operative resection on survival. We used a pathology database to identify all cases of PGINHL diagnosed at a single academic-affiliated medical center from 1988 to 2013. Demographic and clinical data were abstracted from the medical record. We summarized the clinical courses of patients with PGINHL and then performed a survival analysis to compare overall and disease-free survival, stratified by demographic and clinical variables. We identified 33 patients diagnosed with PGINHL during the study period. Of 29 who subsequently received treatment at the institution, 15 initially underwent chemotherapy, 10 underwent surgical resection, and 4 underwent surgery for other reasons such as diagnosis without resection or management of disease complications. Three patients suffered surgical complications and two of these patients died. We found no difference in overall survival between patients receiving surgical resection and patients managed initially with chemotherapy. This case series supports a continued role for surgical resection in the management of patients with PGINHL, though anticipated benefits should be weighed against the risk of complications. C1 [Macqueen, Ian T.; Russell, Marcia M.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Macqueen, Ian T.; Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda] VA Greater Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Shannon, Evan M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dawes, Aaron J.] VA Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA. [Ostrzega, Nora] Olive View UCLA, Dept Pathol, Med Ctr, Sylmar, CA USA. [Maggard-Gibbons, Melinda] Olive View UCLA, Dept Surg, Med Ctr, Sylmar, CA USA. RP Macqueen, IT (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ronald Reagan UCLA,Med Ctr, 757 Westwood Plaza,B711, Los Angeles, CA 90095 USA. EM imacqueen@mednet.ucla.edu FU Department of Veterans Affairs; VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program FX MacQueen was supported by the Department of Veterans Affairs. Dawes was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program. NR 24 TC 1 Z9 2 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD OCT PY 2015 VL 81 IS 10 BP 988 EP 994 PG 7 WC Surgery SC Surgery GA CV0LE UT WOS:000363941400016 PM 26463295 ER PT J AU Dawes, AJ Reardon, S Chen, VL Kaiser, W Russell, MM Ko, CY Lin, AY AF Dawes, Aaron J. Reardon, Sarah Chen, Victor L. Kaiser, William Russell, Marcia M. Ko, Clifford Y. Lin, Anne Y. TI Wireless Technology to Track Surgical Patients after Discharge: A Pilot Study SO AMERICAN SURGEON LA English DT Article ID COLORECTAL SURGERY; RISK-FACTORS; READMISSION; IMPROVEMENT; INTERNET; RATES AB Failure to detect changes in patients' postoperative health status increases the risk of adverse outcomes, including complications and readmission. We sought to design and implement a real-time surveillance system for postoperative colorectal surgery patients using wireless health technology. Participants were assigned a preprogrammed tablet computer during their inpatient hospitalization, and asked to complete a daily survey regarding their postoperative health status until their first clinic visit. Surveys were transmitted wirelessly to a secure database for review. As a pilot study, we report on our first 20 consecutively enrolled patients, monitored for 265 patient days. Overall compliance was 63 per cent (data available for 166 of the 265 days), but varied by patient from 26 to 100 per cent. We were able to reliably collect basic data on postoperative health status as well as patient-reported outcomes not previously captured by standard assessment techniques. Qualitative data suggest that the experience strengthened patients' relationship with their surgeon and aided in their recovery. Postoperative remote monitoring is feasible, and provides more detailed and complete information to the clinical team. Wireless health technology represents an opportunity to close the information gap between discharge and first clinic visit, and, eventually, to improve patient-provider communication, increase patient satisfaction, and prevent unnecessary readmissions. C1 [Dawes, Aaron J.; Reardon, Sarah; Russell, Marcia M.; Ko, Clifford Y.; Lin, Anne Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Russell, Marcia M.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dawes, Aaron J.] Univ Calif Los Angeles, VA Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. [Chen, Victor L.; Kaiser, William] Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90095 USA. [Chen, Victor L.; Kaiser, William] Univ Calif Los Angeles, Wireless Hlth Inst, Los Angeles, CA 90095 USA. RP Dawes, AJ (reprint author), Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza,B711, Los Angeles, CA 90095 USA. EM adawes@mednet.ucla.edu FU VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program FX AJD was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program. NR 22 TC 0 Z9 0 U1 1 U2 2 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD OCT PY 2015 VL 81 IS 10 BP 1061 EP 1066 PG 6 WC Surgery SC Surgery GA CV0LE UT WOS:000363941400030 PM 26463309 ER PT J AU MacQueen, IT Dawes, AJ Hadnott, T Strength, K Moran, GJ Holschneider, C Russell, MM Maggard-Gibbons, M AF MacQueen, Ian T. Dawes, Aaron J. Hadnott, Tracy Strength, Kristen Moran, Gregory J. Holschneider, Christine Russell, Marcia M. Maggard-Gibbons, Melinda TI Use of a Hospital-Wide Screening Program for Early Detection of Sepsis in General Surgery Patients SO AMERICAN SURGEON LA English DT Article ID SEPTIC SHOCK; RANDOMIZED-TRIAL; CARE AB Sepsis remains a significant source of mortality among hospitalized patients. This study examines the usage of a vital sign-based screening protocol in identifying postoperative patients at risk for sepsis at an academic-affiliated medical center. We identified all general surgery inpatients undergoing abdominopelvic surgery from January to June 2014, and compared those with positive screening tests to a sample of screen-negative controls. Multivariate logistic regression was used to identify predictors of positive screening tests and progression to severe sepsis. In total, 478 patients underwent abdominopelvic operations, 59 had positive screening tests, 33 qualified for sepsis, and six progressed to severe sepsis. Predictors of a positive screening test were presence of cancer [odds ratio (OR) 30.7, 95% confidence interval (CI) 2.2-420], emergency operation (OR 6.5, 95% CI 1.7-24), longer operative time (OR 2.2/h, 95% CI 1.2-4.1), and presence of postoperative infection (OR 6.4, 95% CI 1.5-27). The screening protocol had sensitivity 100 per cent and specificity 88 per cent for severe sepsis. We identified no predictors of severe sepsis. In conclusion, vital sign-based screening provides value by drawing early attention to patients with potential to develop sepsis, but escalation of care for these patients should be based on clinical judgment. C1 [MacQueen, Ian T.; Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [MacQueen, Ian T.; Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Dawes, Aaron J.] VA Robert Wood Johnson Fdn Clin Scholars Program, Los Angeles, CA USA. [Hadnott, Tracy; Holschneider, Christine] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Strength, Kristen] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moran, Gregory J.] Olive View UCLA Med Ctr, Dept Emergency Med, Sylmar, CA 91342 USA. [Moran, Gregory J.] Olive View UCLA Med Ctr, Dept Infect Dis, Sylmar, CA 91342 USA. [Holschneider, Christine] Olive View UCLA Med Ctr, Dept Obstet & Gynecol, Sylmar, CA 91342 USA. [Maggard-Gibbons, Melinda] Olive View UCLA Med Ctr, Dept Surg, Sylmar, CA 91342 USA. RP MacQueen, IT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Surg, 757 Westwood Plaza,B711, Los Angeles, CA 90095 USA. EM imacqueen@mednet.ucla.edu FU Department of Veterans Affairs; VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program FX ITM was supported by the Department of Veterans Affairs. AJD was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program. Judy McGee and Karla Nungaray were instrumental in the collection of our data. NR 9 TC 1 Z9 1 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD OCT PY 2015 VL 81 IS 10 BP 1074 EP 1079 PG 6 WC Surgery SC Surgery GA CV0LE UT WOS:000363941400032 PM 26463311 ER PT J AU Hoffman, RM Shi, Y Freedland, SJ Keating, NL Walter, LC AF Hoffman, Richard M. Shi, Ying Freedland, Stephen J. Keating, Nancy L. Walter, Louise C. TI Treatment patterns for older veterans with localized prostate cancer SO CANCER EPIDEMIOLOGY LA English DT Article DE Prostatic neoplasms; Prostatectomy; Radiotherapy; Watchful waiting; Aged; Physician's practice patterns ID RADICAL PROSTATECTOMY; ANDROGEN DEPRIVATION; MEN; RISK; MANAGEMENT; ANTIGEN; SURVIVAL; OUTCOMES; THERAPY; UPDATE AB Objective: Concerns about over-treatment have led to practice guidelines discouraging active treatment of prostate cancer (PCa) in men with limited life expectancies and/or low-risk tumors. We evaluated treatment patterns for older veterans with localized PCa, particularly those with low-risk features. Methods: We used VA Cancer Registry data to identify men aged 65+ diagnosed with clinically localized PCa between January 1st, 2003 and December 31st, 2008. We obtained baseline data on demographics, tumor characteristics, comorbidities, and initial treatment within 6 months of diagnosis: radical prostatectomy, radiotherapy, primary androgen-deprivation therapy (PADT), or no active treatment. National VA surveys provided facility data, including academic affiliation, availability of oncologic specialists, and distance to radiotherapy facilities. Multinomial regression analyses determined associations between patient and facility characteristics and cancer treatment for men with localized (stage < III) and low-risk PCa (stage <= IIa, PSA < 10 ng/mL, Gleason <= 6). Results: 17,206 veterans had localized PCa, 32% age 75+, 12% had comorbidity scores >= 3, and 33% had low-risk tumors. Overall, 39% received radiotherapy, 6% surgery, 20% PADT, and 35% no active treatment. For those with low-risk cancers, older men (RR = 0.36, 95% CI 0.30-0.43) and sicker men (RR = 0.75, 95% CI 0.62-0.90) were less likely to receive surgery or radiotherapy versus no active treatment. Over time, more of these men received no active treatment (from 41% to 57%, P < 0.001) while fewer received PADT (from 11% to 4%, P < 0.001). Conclusion: VA treatment patterns followed evidence-based guidelines against treating older and sicker men with surgery or radiotherapy, for decreasing use of PADT, and for increasingly withholding active treatment, particularly for men with low-risk PCa. Published by Elsevier Ltd. C1 [Hoffman, Richard M.] Univ Iowa, Carver Coll Med, Dept Med, Iowa City, IA 52242 USA. [Shi, Ying; Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Shi, Ying; Walter, Louise C.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA. [Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. RP Hoffman, RM (reprint author), Univ Iowa, Carver Coll Med, Dept Med, Iowa City, IA 52242 USA. EM richard-m-hoffman@uoiwa.edu; Ying.Shi2@va.gov; stephen.freedland@cshs.org; keating@hcp.med.harvard.edu; louise.walter@ucsf.edu FU National Cancer Institute at the National Institutes of Health [R01CA134425]; National Institute on Aging at the National Institutes of Health [K24AG041180]; New Mexico Veterans Affairs Health Care System; Prostate Cancer Foundation FX Grant R01CA134425 from the National Cancer Institute at the National Institutes of Health (LCW, SJF, RMH), grant K24AG041180 from the National Institute on Aging at the National Institutes of Health (LCW), the New Mexico Veterans Affairs Health Care System (RMH), and the Prostate Cancer Foundation (NLK). NR 35 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD OCT PY 2015 VL 39 IS 5 BP 769 EP 777 DI 10.1016/j.canep.2015.07.005 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CV0PQ UT WOS:000363953300015 PM 26228494 ER PT J AU Edwards, MH Buehring, B AF Edwards, Mark H. Buehring, Bjoern TI Novel Approaches to the Diagnosis of Sarcopenia SO JOURNAL OF CLINICAL DENSITOMETRY LA English DT Article DE Dysmobility; epidemiology; gait speed; grip strength; physical performance; sarcopenia ID LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE; SKELETAL-MUSCLE; OLDER-ADULTS; STRENGTH; MASS; ASSOCIATIONS; DEFINITION; MORTALITY AB Sarcopenia is common in older people and is associated with disability, reduced mobility, hospitalization, and various comorbidities. Although it has been recognized for over a quarter of a century, we do not currently have a universally adopted definition. This limits our ability to compare results from different studies and impedes the development of novel therapies. Although sarcopenia was initially defined purely based on low muscle mass, the importance of measures of muscle function has been realized and these have been included in recent operational definitions. These continue to evolve with some including an assessment of adiposity and others adding further components of musculoskeletal health in a score-based approach. This review describes the importance of reaching a widely accepted method to define sarcopenia in both research and clinical practice. It details the ways in which the definition has changed since its initial inception and explores how it may continue to evolve in the future. The different methods by which components of sarcopenia can be measured are described, and the various advantages and disadvantages of these techniques are evaluated. Clearly, there are several other similar syndromes in older people, such as frailty and cachexia; their relationships and overlap with sarcopenia are also explored. C1 [Edwards, Mark H.] Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton SO16 6YD, Hants, England. [Buehring, Bjoern] Univ Wisconsin, Osteoporosis Res Program, Div Geriatr & Gerontol, Dept Med,Sch Med & Publ Hlth, Madison, WI USA. [Buehring, Bjoern] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. RP Edwards, MH (reprint author), Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Tremona Rd, Southampton SO16 6YD, Hants, England. EM me@mrc.soton.ac.uk RI Buehring, Bjoern/L-5581-2013 OI Buehring, Bjoern/0000-0003-3841-624X NR 25 TC 4 Z9 4 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1094-6950 EI 1559-0747 J9 J CLIN DENSITOM JI J. Clin. Densitom. PD OCT-DEC PY 2015 VL 18 IS 4 BP 472 EP 477 DI 10.1016/j.jocd.2015.04.010 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CV4TS UT WOS:000364260000010 PM 26059568 ER PT J AU Fitzmorris, PS Morris, JL Fettig, DM AF Fitzmorris, Paul Stephen Morris, Jason L. Fettig, David Michael TI An Unusual Presentation of Hepatocellular Carcinoma SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material C1 [Fitzmorris, Paul Stephen; Morris, Jason L.; Fettig, David Michael] Univ Alabama Birmingham, Birmingham, AL 35233 USA. [Morris, Jason L.; Fettig, David Michael] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Fitzmorris, PS (reprint author), Univ Alabama Birmingham, Birmingham, AL 35233 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 IS 10 BP 1395 EP 1395 DI 10.1038/ajg.2015.23 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KP UT WOS:000363716200003 PM 26465899 ER PT J AU Nawaz, H Koutroumpakis, E Easler, J Slivka, A Whitcomb, DC Singh, VP Yadav, D Papachristou, GI AF Nawaz, Haq Koutroumpakis, Efstratios Easler, Jeffrey Slivka, Adam Whitcomb, David C. Singh, Vijay P. Yadav, Dhiraj Papachristou, Georgios I. TI Elevated Serum Triglycerides are Independently Associated With Persistent Organ Failure in Acute Pancreatitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID FREE FATTY-ACIDS; HYPERLIPIDEMIC PANCREATITIS; HYPERTRIGLYCERIDEMIC PANCREATITIS; NECROTIZING PANCREATITIS; RESPIRATORY-FAILURE; CURRENT KNOWLEDGE; RISK-FACTOR; CLASSIFICATION; MANAGEMENT; NECROSIS AB OBJECTIVES: Hypertriglyceridemia (HTG) represents a major health problem with prevalence exceeding 30% in the U.S. The present study aims to assess the effect of elevated serum triglyceride (TG) levels on the severity of acute pancreatitis (AP). METHODS: Prospectively enrolled AP patients were categorized into normal, mild, moderate, and severe/very severe categories based on their TG levels and compared in respect to demographics, comorbidities, and clinical outcomes. Multivariate analysis determined whether elevated TG levels were independently associated with persistent organ failure. RESULTS: Two hundred and one out of 400 AP patients had serum TGs measured within 72 h of presentation, of which 115 had normal TG levels and 86 HTG (20 mild, 41 moderate, and 25 severe/very severe). Patients with HTG were of younger age (44 vs. 52 years), predominantly male (65% vs. 45%), obese (57% vs. 34%), diabetic (38% vs. 17%), and developed more frequently persistent organ failure (40% vs. 17%) compared with those with normal TGs (P<0.02). The rate of persistent organ failure increased proportionally with HTG severity grades (17% when normal TGs, 30% in mild, 39% in moderate, and 48% in severe/very severe HTG, P-trend<0.001). On multivariate analysis controlling for age, gender, body mass index, diabetes, and alcohol etiology, moderate HTG (odds ratio (OR), 2.6; P=0.04) and severe/very severe HTG (OR, 4.9; P=0.009) were independently associated with persistent organ failure. CONCLUSIONS: Elevated serum TGs in AP patients are independently and proportionally correlated with persistent organ failure regardless of etiology. TG-mediated lipotoxicity may be an attractive target to design novel interventions for severe AP. C1 [Nawaz, Haq; Koutroumpakis, Efstratios; Easler, Jeffrey; Slivka, Adam; Whitcomb, David C.; Yadav, Dhiraj; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Singh, Vijay P.] Mayo Clin, Dept Med, Div Gastroenterol, Scottsdale, AZ USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Dept Med, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. EM papachri@pitt.edu FU Veterans Affairs Merit Review Award [IQ1CX000272-Q1A2] FX The study was supported by a Veterans Affairs Merit Review Award (IQ1CX000272-Q1A2: PI: G.I.P). NR 41 TC 11 Z9 12 U1 4 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2015 VL 110 IS 10 BP 1497 EP 1503 DI 10.1038/ajg.2015.261 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU7KP UT WOS:000363716200018 PM 26323188 ER PT J AU Anyanwu, CO Fiorentino, DF Chung, L Dzuong, C Wang, Y Okawa, J Carr, K Propert, KJ Werth, VP AF Anyanwu, C. O. Fiorentino, D. F. Chung, L. Dzuong, C. Wang, Y. Okawa, J. Carr, K. Propert, K. J. Werth, V. P. TI Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID QUALITY-OF-LIFE; OUTCOME MEASURES; LUPUS-ERYTHEMATOSUS; RELIABILITY; INSTRUMENT; VALIDITY AB Background The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) was developed for use in clinical trials and longitudinal patient assessment. Objectives To characterize disease severity using the CDASI and assess the responsiveness of this instrument to clinically meaningful changes in disease activity. Methods Patients with cutaneous dermatomyositis at the University of Pennsylvania (UPenn, n = 93) and Stanford University (Stanford, n = 106) were prospectively evaluated using the CDASI, physician global assessment (PGA) Likert scales and a visual analogue scale (VAS). Data was analysed using logistic regression models and receiver operating characteristic curves to select cut-offs. Results Baseline CDASI activity scores for the patients evaluated at UPenn ranged from 0 to 47 (median 17), and baseline PGA VAS scores ranged from 0 to 9.6 (median 1.1). At UPenn a CDASI activity score of 19 differentiated mild from moderate and severe disease. At Stanford baseline CDASI scores ranged from 0 to 48 (median 21), baseline PGA VAS scores ranged from 0 to 9.7 (median 4.2) and CDASI activity scores of 14 or less characterized mild disease. When a 2-cm change in the PGA VAS was regarded as a clinically significant improvement, a 4-point (UPenn) or 5-point (Stanford) change in CDASI reflected a minimal clinically significant response. Conclusions The CDASI is a valid and responsive measure that can be used to characterize cutaneous dermatomyositis severity and detect improvement in disease activity. Variations in cut-offs may be due to differences in disease severity between the two populations or inter-rater variations in the use of the external gold measures. C1 [Anyanwu, C. O.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Anyanwu, C. O.; Okawa, J.; Carr, K.; Werth, V. P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Fiorentino, D. F.; Chung, L.; Dzuong, C.] Stanford Univ, Div Immunol & Rheumatol, Dept Dermatol & Med, Sch Med, Stanford, CA 94305 USA. [Wang, Y.; Propert, K. J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health [NIH K24-AR 02207, UL1000003] FX This project is supported by the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by the National Institutes of Health [NIH K24-AR 02207 (V.P.W.); UL1000003 (K.J.P.)]. NR 15 TC 6 Z9 6 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD OCT PY 2015 VL 173 IS 4 BP 969 EP 974 DI 10.1111/bjd.13915 PG 6 WC Dermatology SC Dermatology GA CU9WG UT WOS:000363896800020 PM 25994337 ER PT J AU Akrivos, J Ravona-Springer, R Schmeidler, J LeRoith, D Heymann, A Preiss, R Hoffman, H Koifman, K Silverman, JM Beeri, MS AF Akrivos, Jimmy Ravona-Springer, Ramit Schmeidler, James LeRoith, Derek Heymann, Anthony Preiss, Rachel Hoffman, Hadas Koifman, Keren Silverman, Jeremy M. Beeri, Michal Schnaider TI Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE HbA1c; C-reactive protein; cognitive function; type 2 diabetes; older people ID C-REACTIVE PROTEIN; ACUTE GLUCOSE FLUCTUATIONS; METABOLIC SYNDROME; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; FOLLOW-UP; DECLINE; RISK; PERFORMANCE; INDIVIDUALS AB Objective: Glycated hemoglobin (HbA1c) and C-reactive protein (CRP) have been associated with cognitive impairment independently. However, it is unclear if their combination exacerbates poor cognitive function. We assessed whether long-term glycemic level and glycemic variability modulate the association of systemic inflammation with cognitive function, in a sample of cognitively normal older people with type 2 diabetes. Methods: A retrospective cohort study of 777 randomly selected participants from similar to 11,000 patients in the Maccabi Healthcare Services Diabetes Registry, as part of the Israel Diabetes and Cognitive Decline study. Subjects averaged 18 (+/-9.4) HbA1c measures in the Maccabi Healthcare Services Registry, which were used to calculate long-term glycemic level (HbA1c-mean) and glycemic variability (HbA1c-standard deviation (SD)). Linear regression models assessed the interactions of CRP, a marker of systemic inflammation, with HbA1c-mean and HbA1c-SD on subjects' performance in tests of Memory, Executive Functions, Attention, and Semantic Categorization. Results: Quadratic interactions of CRP with HbA1c-SD approached significance for executive functions and overall cognition. However, after Bonferroni adjustment, none of the interactions of CRP with HbA1c were statistically significant. In partial correlations according to HbA1c-SD tertiles, CRP was weakly correlated in the middle tertile with decreased performance in the domains of semantic categorization (r= -0.166, p=0.011), executive functions (r=-0.136, p=0.038), and overall cognition (r= -0.157, p=0.016). Conclusions: Glycated hemoglobin does not substantially modulate the association of CRP with cognition in a sample of cognitively normal, community dwelling older people with relatively well-managed type 2 diabetes. Copyright (C) 2015 John Wiley & Sons, Ltd. C1 [Akrivos, Jimmy; Schmeidler, James; Silverman, Jeremy M.; Beeri, Michal Schnaider] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Akrivos, Jimmy; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Ravona-Springer, Ramit; Koifman, Keren; Beeri, Michal Schnaider] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Ramat Gan, Israel. [LeRoith, Derek] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [LeRoith, Derek] Rambam Med Ctr, Haifa, Israel. [Heymann, Anthony; Preiss, Rachel; Hoffman, Hadas] Maccabi Healthcare Serv, Tel Aviv, Israel. [Beeri, Michal Schnaider] IDC Herzliya, Herzliyya, Israel. RP Akrivos, J (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM Jimmy.Akrivos@mssm.edu FU NIA [R01 AG034087]; Leroy Schecter Foundation; Helen Bader Foundation; Irma T. Hirschl Scholar award; American Federation for Aging Research (AFAR); Alzheimer's Association [NIRG-11-205083] FX This study was supported by NIA grant R01 AG034087 to Dr. Beeri, the Leroy Schecter Foundation, the Helen Bader Foundation, and the Irma T. Hirschl Scholar award to Dr. Beeri, the American Federation for Aging Research (AFAR) Young Investigator award, and the Alzheimer's Association grant NIRG-11-205083 to Dr. Ravona-Springer. NR 30 TC 3 Z9 4 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD OCT PY 2015 VL 30 IS 10 BP 1093 EP 1100 DI 10.1002/gps.4267 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CU7OB UT WOS:000363729700012 PM 25703191 ER PT J AU Roden-Reynolds, DC Walker, MH Wasserman, CR Dean, JC AF Roden-Reynolds, Devin C. Walker, Megan H. Wasserman, Camille R. Dean, Jesse C. TI Hip proprioceptive feedback influences the control of mediolateral stability during human walking SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE biomechanics; locomotion; sensory feedback; vibration ID LEG MUSCLE VIBRATION; CENTER-OF-MASS; LATERAL BALANCE; FOOT PLACEMENT; FRONTAL PLANE; DYNAMIC STABILITY; TENDON VIBRATION; TREADMILL WALKING; HUMAN STANCE; STEP WIDTH AB Active control of the mediolateral location of the feet is an important component of a stable bipedal walking pattern, although the roles of sensory feedback in this process are unclear. In the present experiments, we tested whether hip abductor proprioception influenced the control of mediolateral gait motion. Participants performed a series of quiet standing and treadmill walking trials. In some trials, 80-Hz vibration was applied intermittently over the right gluteus medius (GM) to evoke artificial proprioceptive feedback. During walking, the GM was vibrated during either right leg stance (to elicit a perception that the pelvis was closer mediolaterally to the stance foot) or swing (to elicit a perception that the swing leg was more adducted). Vibration during quiet standing evoked leftward sway in most participants (13 of 16), as expected from its predicted perceptual effects. Across the 13 participants sensitive to vibration, stance phase vibration caused the contralateral leg to be placed significantly closer to the midline (by similar to 2 mm) at the end of the ongoing step. In contrast, swing phase vibration caused the vibrated leg to be placed significantly farther mediolaterally from the midline (by similar to 2 mm), whereas the pelvis was held closer to the stance foot (by similar to 1 mm). The estimated mediolateral margin of stability was thus decreased by stance phase vibration but increased by swing phase vibration. Although the observed effects of vibration were small, they were consistent with humans monitoring hip proprioceptive feedback while walking to maintain stable mediolateral gait motion. C1 [Roden-Reynolds, Devin C.; Walker, Megan H.; Wasserman, Camille R.; Dean, Jesse C.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. [Dean, Jesse C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Dean, JC (reprint author), Med Univ S Carolina, 77 President St MSC700, Charleston, SC 29425 USA. EM deaje@musc.edu OI Dean, Jesse/0000-0003-2034-4217 FU Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service [1IK2RX000750-01A1] FX This study was partially supported by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service, through Grant No. 1IK2RX000750-01A1. NR 58 TC 3 Z9 3 U1 7 U2 12 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD OCT 1 PY 2015 VL 114 IS 4 BP 2220 EP 2229 DI 10.1152/jn.00551.2015 PG 10 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA CU5CC UT WOS:000363548300015 PM 26289467 ER PT J AU Cragan, JD Young, BA Correa, A AF Cragan, Janet D. Young, Bessie A. Correa, Adolfo TI Renin-Angiotensin System Blocker Fetopathy SO JOURNAL OF PEDIATRICS LA English DT Editorial Material ID EARLY-PREGNANCY; MALFORMATIONS; INHIBITION; EXPOSURE C1 [Cragan, Janet D.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Young, Bessie A.] Univ Washington, Dept Med, Div Nephrol, Vet Affairs Puget Sound,Kidney Res Inst, Seattle, WA 98195 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. RP Correa, A (reprint author), Univ Mississippi, Med Ctr, Dept Med, 2500 North State St, Jackson, MS 39216 USA. EM acorrea@umc.edu FU Intramural CDC HHS [CC999999]; NCCIH NIH HHS [U01 AT006239, 1U01AT006239-01]; NHLBI NIH HHS [HHSN268201300049C, HHSN268201300046C]; NIDDK NIH HHS [R01 DK102134, 1R01DK102134-01]; NIMHD NIH HHS [P60MD002249-01, P60 MD002249]; PHS HHS [HHSN268201300047C, HHSN268201300049C, HHSN268201300046C] NR 18 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2015 VL 167 IS 4 BP 792 EP 794 DI 10.1016/j.jpeds.2015.07.024 PG 3 WC Pediatrics SC Pediatrics GA CU5BE UT WOS:000363545800004 PM 26254838 ER PT J AU Naples, JG Marcum, ZA Perera, S Gray, SL Newman, AB Simonsick, EM Yaffe, K Shorr, RI Hanlon, JT AF Naples, Jennifer G. Marcum, Zachary A. Perera, Subashan Gray, Shelly L. Newman, Anne B. Simonsick, Eleanor M. Yaffe, Kristine Shorr, Ronald I. Hanlon, Joseph T. CA Hlth Aging Body Composition Study TI Concordance Between Anticholinergic Burden Scales SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cholinergic antagonists; aged; drug use ID OLDER-PEOPLE; DRUG BURDEN; BODY-COMPOSITION; ASSOCIATIONS; HEALTH; INDEX; MEDICATIONS; DECLINE; ELDERS AB ObjectivesTo evaluate concordance of five commonly used anticholinergic scales. DesignCross-sectional secondary analysis. SettingPittsburgh, Pennsylvania, and Memphis, Tennessee. ParticipantsCommunity-dwelling adults aged 70 to 79 with baseline medication data from the Health, Aging, and Body Composition Study (N = 3,055). MeasurementsAny anticholinergic use, weighted scores, and total standardized daily dosage were calculated using five anticholinergic measures (Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), Drug Burden Index anticholinergic component (DBI-ACh), and Summated Anticholinergic Medications Scale (SAMS)). Concordance was evaluated using kappa statistics and Spearman rank correlations. ResultsAny anticholinergic use in rank order was 51% for the ACB, 43% for the ADS, 29% for the DBI-ACh, 23% for the ARS, and 16% for the SAMS. Kappa statistics for all pairwise use comparisons ranged from 0.33 to 0.68. Similarly, concordance as measured using weighted kappa statistics ranged from 0.54 to 0.70 for the three scales not incorporating dosage (ADS, ARS, ACB). Spearman rank correlation between the DBI-ACh and SAMS was 0.50. ConclusionOnly low to moderate concordance was found between the five anticholinergic scales. Future research is needed to examine how these differences in measurement affect their predictive validity with respect to clinically relevant outcomes, such as cognitive impairment. C1 [Naples, Jennifer G.; Perera, Subashan; Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Marcum, Zachary A.; Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Perera, Subashan] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Shorr, Ronald I.] Malcolm Randall Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. RP Naples, JG (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufmann Med Bldg Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA. EM jgn13@pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU Intramural NIH HHS; NIA NIH HHS [R01 AG037451, K07 AG033174, K07-AG033174, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, P30 AG024827, P30-AG024827, R01-AG037451, T32 AG021885, T32-AG021885]; NINR NIH HHS [NR012459, R01 NR012459] NR 22 TC 7 Z9 7 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2015 VL 63 IS 10 BP 2120 EP 2124 DI 10.1111/jgs.13647 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CU8PQ UT WOS:000363805800021 PM 26480974 ER PT J AU Beckett, MK Elliott, MN Haviland, AM Burkhart, Q Gaillot, S Montfort, D Saliba, D AF Beckett, Megan K. Elliott, Marc N. Haviland, Amelia M. Burkhart, Q. Gaillot, Sarah Montfort, Daisy Saliba, Debra TI Living Alone and Patient Care Experiences: The Role of Gender in a National Sample of Medicare Beneficiaries SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Living arrangements; Patient experience; Gender; Medicare ID CAHPS(R) HOSPITAL SURVEY; PSYCHOMETRIC PROPERTIES; CONSUMER ASSESSMENT; TRANSITIONAL CARE; ELDERLY PERSONS; MARITAL-STATUS; HEART-FAILURE; MANAGED CARE; HEALTH PLANS; OLDER-ADULTS AB Seniors who live alone are a large, growing population with poorer health outcomes. We examine the little-studied health care experiences and immunizations of older adults who live alone. We use regression-based case-mix adjustment to compare immunizations and health care experiences of 325,649 adults aged 65 and older who lived alone to those who did not, overall and by gender and health status, using nationally representative data from the Medicare Consumer Assessment of Healthcare Providers and Systems (MCAHPS) surveys. Outcomes were five global care ratings (health plan, drug plan, doctor, specialists, all care), six composite care measures (getting needed care, getting care quickly, doctor communication, customer service, getting needed drugs, getting information from drug plan), and two immunization measures (influenza, pneumonia). About 30.3% of respondents lived alone. Women, older beneficiaries, and low income (Medicaid eligible) beneficiaries reported living alone at substantially higher rates than their counterparts. Care experiences for 8 of the 13 measures were significantly worse for those who lived alone than for others. The association differed significantly in magnitude by gender for 10 measures, with larger average differences for men. The largest disadvantages for those living alone were for immunization measures (eg, influenza -6 percentage points, for men living alone vs other men). The disadvantages of living alone were not consistently greater for those in worse health. Living alone is associated with worse care experiences and immunization, especially for men. Health plans should target quality improvement and outreach efforts to beneficiaries who live alone, especially men. C1 [Beckett, Megan K.; Elliott, Marc N.; Haviland, Amelia M.; Burkhart, Q.; Montfort, Daisy; Saliba, Debra] RAND Corp, Santa Monica, CA 90401 USA. [Haviland, Amelia M.] Carnegie Mellon Univ, H John Heinz III Coll Publ Policy & Management, Pittsburgh, PA 15213 USA. [Gaillot, Sarah] Ctr Medicare & Medicaid Serv, Div Consumer Assessment & Plan Performance, Baltimore, MD USA. [Saliba, Debra] Ctr Geriatr Res Educ & Clin, US Dept Vet Affairs, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Dept Med, Borun Ctr, Los Angeles, CA 90024 USA. RP Elliott, MN (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM elliott@rand.org FU Centers for Medicare and Medicare Services [HHSM-500-2005-00028I] FX This work was supported by the Centers for Medicare and Medicare Services (contract HHSM-500-2005-00028I awarded to RAND). NR 34 TC 1 Z9 1 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2015 VL 70 IS 10 BP 1242 EP 1247 DI 10.1093/gerona/glv037 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CU4FD UT WOS:000363481600009 PM 25869525 ER PT J AU van Steenoven, I Aarsland, D Weintraub, D AF van Steenoven, Inger Aarsland, Dag Weintraub, Daniel TI Reply to letter to the editor "Independent application of MoCA/MMSE conversion' by Armstrong et al. SO MOVEMENT DISORDERS LA English DT Letter C1 [van Steenoven, Inger] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1081 HV Amsterdam, Netherlands. [van Steenoven, Inger] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, NL-1081 HV Amsterdam, Netherlands. [Aarsland, Dag] Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP van Steenoven, I (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands. EM i.vansteenoven@vumc.nl OI Aarsland, Dag/0000-0001-6314-216X NR 2 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD OCT PY 2015 VL 30 IS 12 BP 1711 EP 1711 DI 10.1002/mds.26367 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA CU2GU UT WOS:000363342800022 PM 26228296 ER PT J AU Schneider, BG Mera, R Piazuelo, MB Bravo, JC Zabaleta, J Delgado, AG Bravo, LE Wilson, KT El-Rifai, W Peek, RM Correa, P AF Schneider, Barbara G. Mera, Robertino Piazuelo, M. Blanca Bravo, Juan C. Zabaleta, Jovanny Delgado, Alberto G. Bravo, Luis E. Wilson, Keith T. El-Rifai, Wael Peek, Richard M., Jr. Correa, Pelayo TI DNA Methylation Predicts Progression of Human Gastric Lesions SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID HELICOBACTER-PYLORI INFECTION; E-CADHERIN GENE; CANCER-RISK; HYPERMETHYLATION; AGE; CLASSIFICATION; CELLS; ERADICATION; BIOPSIES; COHORT AB Background: Development of the intestinal subtype of gastric adenocarcinoma is marked by a progression of histopathologic lesions. Residents of the Andean regions of Colombia are at high risk for gastric cancer. Methods: A cohort of 976 Colombian subjects was followed over 16 years examining effects of Helicobacter pylori eradication and treatment with antioxidants on progression of lesions. We performed methylation analysis of DNA from baseline antral biopsies from 104 subjects for whom follow-up data were available for at least 12 years. Methylation was quantitated for AMPH, CDKN2A, CDH1, EN1, EMX1, NKX6-1, PCDH10, RPRM, RSPO2, SORCS3, ZIC1, and ZNF610 genes, using Pyrosequencing. Results: Levels of DNA methylation were associated with baseline diagnosis for AMPH, EMX1, RPRM, RSPO2, SORCS3, and ZNF610. After adjusting for baseline diagnosis and H. pylori infection, methylation levels of AMPH, PCDH10, RSPO2, and ZNF610 had progression coefficients that increased and P values that decreased over 6, 12, and 16 years. Methylation for SORCS3 was associated with progression at all 3 time points but without the continual strengthening of the effect. Scores for mononuclear leukocytes, polymorphonuclear leukocytes, or intraepithelial lymphocytes were unrelated to progression. Conclusions: Methylation levels of AMPH, PCDH10, RSPO2, SORCS3, and ZNF610 predict progression of gastric lesions independent of the effect of duration of H. pylori infection, baseline diagnosis, gender of the patient, or scores for mononuclear leukocytes, polymorphonuclear leukocytes, or intraepithelial lymphocytes. Impact: DNA methylation levels in AMPH, PCDH10, RSPO2, SORCS3, and ZNF610 may contribute to identification of persons with gastric lesions likely to progress. (C) 2015 AACR. C1 [Schneider, Barbara G.; Mera, Robertino; Piazuelo, M. Blanca; Delgado, Alberto G.; Wilson, Keith T.; Peek, Richard M., Jr.; Correa, Pelayo] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA. [Bravo, Juan C.] Fdn Valle Lili, Cali, Colombia. [Zabaleta, Jovanny] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA USA. [Zabaleta, Jovanny] Stanley Scott Canc Ctr, New Orleans, LA USA. [Bravo, Luis E.] Univ Valle, Sch Med, Dept Pathol, Cali, Colombia. [Wilson, Keith T.; El-Rifai, Wael] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA. [Wilson, Keith T.; El-Rifai, Wael] US Dept Vet Affairs, Off Med Res, Nashville, TN USA. [El-Rifai, Wael] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA. RP Schneider, BG (reprint author), Vanderbilt Univ, Med Ctr, 2215 Garland Ave,Room 1030C MRB 4, Nashville, TN 37232 USA. EM barbara.schneider@vanderbilt.edu OI Schneider, Barbara/0000-0003-4421-1355 FU National Center for Research Resources [UL1 RR024975-01]; National Center for Advancing Translational Sciences [2 UL2 TR000445-06]; Department of Veterans Affairs [I01 BX001453]; [P01 CA28842]; [R01 CA77955]; [R01 CA177372]; [P01 CA116087]; [P30 DK058404]; [R01 DK053620]; [R01 CA190612]; [R01 DK58587] FX This study was supported by the National Center for Research Resources, grant UL1 RR024975-01, which is now at the National Center for Advancing Translational Sciences, Grant 2 UL2 TR000445-06 (by a pilot grant to B.G. Schneider); grants P01 CA28842 (to P. Correa, K.T. Wilson, and L.E. Bravo), R01 CA77955 (to R.M. Peek Jr.), R01 CA177372 (to W. El-Rifai), P01 CA116087 (to R.M. Peek Jr.), P30 DK058404 (to R.M. Peek Jr.), R01 DK053620 (to K.T. Wilson), R01 CA190612 (to K.T. Wilson), R01 DK58587 (to R.M. Peek Jr.); and grant I01 BX001453 (to K.T. Wilson) from the Department of Veterans Affairs. NR 50 TC 4 Z9 5 U1 2 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2015 VL 24 IS 10 BP 1607 EP 1613 DI 10.1158/1055-9965.EPI-15-0388 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CU3CR UT WOS:000363401800020 PM 26269563 ER PT J AU Hadac, JN Leystra, AA Olson, TJP Maher, ME Payne, SN Yueh, AE Schwartz, AR Albrecht, DM Clipson, L Pasch, CA Matkowskyj, KA Halberg, RB Deming, DA AF Hadac, Jamie N. Leystra, Alyssa A. Olson, Terrah J. Paul Maher, Molly E. Payne, Susan N. Yueh, Alexander E. Schwartz, Alexander R. Albrecht, Dawn M. Clipson, Linda Pasch, Cheri A. Matkowskyj, Kristina A. Halberg, Richard B. Deming, Dustin A. TI Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence SO CANCER PREVENTION RESEARCH LA English DT Article ID MULTIPLE INTESTINAL NEOPLASIA; ONCOGENIC K-RAS; COLORECTAL-CANCER; GENE-THERAPY; MOUSE; MICE; MODEL; TUMORIGENESIS; POLYPOSIS; DELIVERY AB Human colorectal cancers often possess multiple mutations, including three to six driver mutations per tumor. The timing of when these mutations occur during tumor development and progression continues to be debated. More advanced lesions carry a greater number of driver mutations, indicating that colon tumors might progress from adenomas to carcinomas through the stepwise accumulation of mutations following tumor initiation. However, mutations that have been implicated in tumor progression have been identified in normal-appearing epithelial cells of the colon, leaving the possibility that these mutations might be present before the initiation of tumorigenesis. We utilized mouse models of colon cancer to investigate whether tumorigenesis still occurs through the adenoma-to-carcinoma sequence when multiple mutations are present at the time of tumor initiation. To create a model in which tumors could concomitantly possess mutations in Apc, Kras, and Pik3ca, we developed a novel minimally invasive technique to administer an adenovirus expressing Cre recombinase to a focal region of the colon. Here, we demonstrate that the presence of these additional driver mutations at the time of tumor initiation results in increased tumor multiplicity and an increased rate of progression to invasive adenocarcinomas. These cancers can even metastasize to retroperitoneal lymph nodes or the liver. However, despite having as many as three concomitant driver mutations at the time of initiation, these tumors still proceed through the adenoma-to-carcinoma sequence. (C) 2015 AACR. C1 [Hadac, Jamie N.; Leystra, Alyssa A.; Clipson, Linda] Univ Wisconsin, Dept Oncol, Madison, WI 53792 USA. [Olson, Terrah J. Paul] Univ Wisconsin, Dept Surg, Div Gen Surg, Madison, WI 53792 USA. [Maher, Molly E.; Yueh, Alexander E.; Deming, Dustin A.] Univ Wisconsin, Div Hematol & Oncol, Madison, WI 53792 USA. [Payne, Susan N.; Pasch, Cheri A.; Matkowskyj, Kristina A.; Halberg, Richard B.; Deming, Dustin A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53792 USA. [Schwartz, Alexander R.; Albrecht, Dawn M.; Halberg, Richard B.] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Madison, WI 53792 USA. [Matkowskyj, Kristina A.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Matkowskyj, Kristina A.; Deming, Dustin A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Deming, DA (reprint author), Univ Wisconsin, 600 Highland Ave,K6-544, Madison, WI 53792 USA. EM ddeming@medicine.wisc.edu FU Funk Out Cancer; Conquer Cancer Foundation of the American Society of Clinical Oncology; NIH [T32 CA09017, T32 CA009135, R21 CA170876, R01 CA123438]; AACR Career Development Award for Colorectal Cancer Research [12-20-01-HALB]; UW Division of Gastroenterology and Hepatology; UW Department of Medicine; UW School of Medicine and Public Health; UW Carbone Cancer Center; UW Graduate School through the Wisconsin Alumni Research Foundation; University of Wisconsin Carbone Cancer Center [P30 CA014520]; UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group FX This work was partially funded by Funk Out Cancer, a memorial event dedicated to Kate Gates Falaschi. This work was also supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award (to D.A. Deming); T32 CA09017 (to T.J. Paul Olson), T32 CA009135 (to J.N. Hadac. and A. A. Leystra), R21 CA170876 (to R.B. Halberg) and R01 CA123438 (to R.B. Halberg) from the NIH; 2012 AACR Career Development Award for Colorectal Cancer Research, Grant Number 12-20-01-HALB (to R.B. Halberg); start-up funds (to R.B. Halberg) from the UW Division of Gastroenterology and Hepatology, the UW Department of Medicine, and the UW School of Medicine and Public Health; and start-up funds (to D.A. Deming) from the UW Carbone Cancer Center, UW Department of Medicine, UW School of Medicine and Public Health, and the UW Graduate School through the Wisconsin Alumni Research Foundation; P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group (to R.B. Halberg and D.A. Deming); and Funk Out Cancer (to D.A. Deming). NR 50 TC 4 Z9 4 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD OCT PY 2015 VL 8 IS 10 BP 952 EP 961 DI 10.1158/1940-6207.CAPR-15-0003 PG 10 WC Oncology SC Oncology GA CU3BS UT WOS:000363399200009 PM 26276752 ER PT J AU Karakasheva, TA Waldron, TJ Eruslanov, E Kim, SB Lee, JS O'Brien, S Hicks, PD Basu, D Singhal, S Malavasi, F Rustgi, AK AF Karakasheva, Tatiana A. Waldron, Todd J. Eruslanov, Evgeniy Kim, Sang-Bae Lee, Ju-Seog O'Brien, Shaun Hicks, Philip D. Basu, Devraj Singhal, Sunil Malavasi, Fabio Rustgi, Anil K. TI CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer SO CANCER RESEARCH LA English DT Article ID CYCLIC ADP-RIBOSE; NITRIC-OXIDE; IMMUNE SUPPRESSION; MOUSE MODEL; CD38; INFLAMMATION; GENE; MICROENVIRONMENT; TRANSCRIPTION; LYMPHOCYTES AB Myeloid-derived suppressor cells (MDSC) are an immunosuppressive population of immature myeloid cells found in advanced-stage cancer patients and mouse tumor models. Production of inducible nitric oxide synthase (iNOS) and arginase, as well as other suppressive mechanisms, allows MDSCs to suppress T-cell-mediated tumor clearance and foster tumor progression. Using an unbiased global gene expression approach in conditional p120-catenin knockout mice (L2-cre; p120ctn(f/f)), a model of oral-esophageal cancer, we have identified CD38 as playing a vital role in MDSC biology, previously unknown. CD38 belongs to the ADP-ribosyl cyclase family and possesses both ectoenzyme and receptor functions. It has been described to function in lymphoid and early myeloid cell differentiation, cell activation, and neutrophil chemotaxis. We find that CD38 expression in MDSCs is evident in other mouse tumor models of esophageal carcinogenesis, and CD38(high) MDSCs are more immature than MDSCs lacking CD38 expression, suggesting a potential role for CD38 in the maturation halt found in MDSC populations. CD38(high) MDSCs also possess a greater capacity to suppress activated T cells, and promote tumor growth to a greater degree than CD38(low) MDSCs, likely as a result of increased iNOS production. In addition, we have identified novel tumor-derived factors, specifically IL6, IGFBP3, and CXCL16, which induce CD38 expression by MDSCs ex vivo. Finally, we have detected an expansion of CD38(+) MDSCs in peripheral blood of advanced-stage cancer patients and validated targeting CD38 in vivo as a novel approach to cancer therapy. (C) 2015 AACR. C1 [Karakasheva, Tatiana A.; Waldron, Todd J.; Hicks, Philip D.; Rustgi, Anil K.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Karakasheva, Tatiana A.; Waldron, Todd J.; Hicks, Philip D.; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Eruslanov, Evgeniy; O'Brien, Shaun; Singhal, Sunil] Hosp Univ Penn, Sch Med, Dept Surg, Thorac Surg Res Lab, Philadelphia, PA 19104 USA. [Kim, Sang-Bae; Lee, Ju-Seog] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Basu, Devraj] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Basu, Devraj; Singhal, Sunil] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. [Malavasi, Fabio] Univ Turin, Dept Med Sci, Sch Med, Lab Immunogenet, Turin, Italy. [Rustgi, Anil K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA. RP Rustgi, AK (reprint author), Univ Penn, 951 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA. EM anil2@mail.med.upenn.edu OI MALAVASI, Fabio/0000-0002-1844-174X FU NIH/NCI [P01-CA098101, U01-CA14305603]; NIH/NIDDK [T32-DK007066]; NIH [F32-CA162719, R01-CA163256-01]; NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases [P30-DK050306]; American Cancer Society [RP-10-033-01-CCE]; NIH NIH/NIDCR [K08-DE022842]; Italian Ministry of Education, University and Research (Progetto PRIN); Italian Ministry of Education, University and Research (FIRB); Fondazione Ricerca in Medicina Sperimentale (FIRMS) FX This work was supported by the NIH/NCI grant P01-CA098101 (A.K. Rustgi, T.J. Waldron, T.A. Karakasheva), NIH/NCI grant U01-CA14305603 (A.K. Rustgi), NIH/NIDDK (T32-DK007066 to T. Waldron), NIH (F32-CA162719 to T. Waldron), NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), American Cancer Society (RP-10-033-01-CCE), NIH NIH/NIDCR (K08-DE022842 to D. Basu), NIH (Transformative R01-CA163256-01 to S. Singhal), Italian Ministry of Education, University and Research (Progetto PRIN and FIRB to F. Malavasi), and by the Fondazione Ricerca in Medicina Sperimentale (FIRMS; F. Malavasi). NR 49 TC 12 Z9 12 U1 2 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2015 VL 75 IS 19 BP 4074 EP 4085 DI 10.1158/0008-5472.CAN-14-3639 PG 12 WC Oncology SC Oncology GA CU2ES UT WOS:000363336800011 PM 26294209 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Contrast-associated Acute Kidney Injury SO CRITICAL CARE CLINICS LA English DT Article DE Contrast; Acute kidney injury; Nephrotoxin; Prevention; latrogenic ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; GLOMERULAR-FILTRATION-RATE; RADIOCONTRAST-INDUCED NEPHROPATHY; GELATINASE-ASSOCIATED LIPOCALIN; LONG-TERM MORTALITY; HIGH-RISK PATIENTS; SODIUM-BICARBONATE; CARDIAC ANGIOGRAPHY AB Contrast-associated acute kidney injury (CAAKI) is a common iatrogenic condition. The principal risk factors for CAAKI are underlying renal impairment, diabetes in the setting of kidney disease, and intravascular volume depletion, effective or absolute. CAAKI is associated with serious adverse short-term and long-term outcomes, including mortality and more rapidly progressive chronic kidney disease, although the causal nature of these associations remains unproved. Patients with chronic kidney disease and other risk factors for CAAKI who present with acute coronary syndrome should undergo indicated angiographic procedures. C1 [Weisbord, Steven D.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E120 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 75 TC 1 Z9 1 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0704 EI 1557-8232 J9 CRIT CARE CLIN JI Crit. Care Clin. PD OCT PY 2015 VL 31 IS 4 BP 725 EP + DI 10.1016/j.ccc.2015.06.008 PG 12 WC Critical Care Medicine SC General & Internal Medicine GA CU3OK UT WOS:000363434500009 PM 26410140 ER PT J AU Trombetta-eSilva, J Rosset, EA Hepfer, RG Wright, GJ Baicu, C Yao, H Bradshaw, AD AF Trombetta-eSilva, Jessica Rosset, Emilie A. Hepfer, R. Glenn Wright, Gregory J. Baicu, Catalin Yao, Hai Bradshaw, Amy D. TI Decreased Mechanical Strength and Collagen Content in SPARC-Null Periodontal Ligament Is Reversed by Inhibition of Transglutaminase Activity SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE BONE MATRIX; NONCOLLAGENOUS PROTEINS; DENTAL BIOLOGY; EXTRACELLULAR MATRIX; CROSS-LINKS ID SMOOTH-MUSCLE-CELLS; CROSS-LINKING; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR-MATRIX; DEFICIENT MICE; FACTOR XIIIA; I COLLAGEN; FIBRONECTIN; OSTEONECTIN; SEROTONIN AB The periodontal ligament (PDL) is a critical tissue that provides a physical link between the mineralized outer layer of the tooth and the alveolar bone. The PDL is composed primarily of nonmineralized fibrillar collagens. Expression of secreted protein acidic and rich in cysteine (SPARC/osteonectin), a collagen-binding matricellular protein, has been shown to be essential for collagen homeostasis in PDL. In the absence of SPARC, PDL collagen fibers are smaller and less dense than fibers that constitute WT PDL. The aim of this study was to identify cellular mechanisms by which SPARC affected collagen fiber assembly and morphology in PDL. Cross-linking of fibrillar collagens is one parameter that is known to affect insoluble collagen incorporation and fiber morphology. Herein, the reduction in collagen fiber size and quantity in the absence of SPARC expression was shown to result in a PDL with reduced molar extraction force in comparison to that of WT mice (C57Bl/6J). Furthermore, an increase in transglutaminase activity was found in SPARC-null PDL by biochemical analyses that was supported by immunohistochemical results. Specifically, collagen I was identified as a substrate for transglutaminase in PDL and transglutaminase activity on collagen I was found to be greater in SPARC-null tissues in comparison to WT. Strikingly, inhibition of transglutaminase activity in SPARC-null PDL resulted in increases in both collagen fiber thickness and in collagen content, whereas transglutaminase inhibitors injected into WT mice resulted in increases in collagen fiber thickness only. Furthermore, PDL treated with transglutaminase inhibitors exhibited increases in molar extraction force in WT and in SPARC-null mice. Thus, SPARC is proposed to act as a critical regulator of transglutaminase activity on collagen I with implications for mechanical strength of tissues. (C) 2015 American Society for Bone and Mineral Research. C1 [Trombetta-eSilva, Jessica; Rosset, Emilie A.; Yao, Hai; Bradshaw, Amy D.] Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Hepfer, R. Glenn; Wright, Gregory J.; Yao, Hai] Clemson Univ, Dept Bioengn, Clemson, SC USA. [Baicu, Catalin; Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, 114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM bradshad@musc.edu FU NIH [F30DE023009-01, F31DE023482, R01DE021134]; Veteran's Administration [1I01BX001385-01A1] FX This work was supported by NIH F30DE023009-01 (J.T-eS.), NIH predoctoral fellowship award F31DE023482 (GJW), Veteran's Administration Merit Award 1I01BX001385-01A1 (ADB), and NIH R01DE021134 (HY). NR 38 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2015 VL 30 IS 10 BP 1914 EP 1924 DI 10.1002/jbmr.2522 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU1MR UT WOS:000363286500020 PM 25827352 ER PT J AU Batth, IS Yun, HY Kumar, AP AF Batth, Izhar Singh Yun, Huiyoung Kumar, Addankl P. TI Recepteur d'Origine Nantais (RON), More Than a Kinase: Role in Castrate-Resistant Prostate Cancer SO MOLECULAR CARCINOGENESIS LA English DT Article DE prostate cancer; castrate resistance; receptor tyrosine kinase; RON ID MACROPHAGE-STIMULATING PROTEIN; ANDROGEN RECEPTOR; TYROSINE KINASE; CELL-LINE; DIFFERENTIAL EXPRESSION; MESENCHYMAL TRANSITION; INHIBITOR BMS-777607; ALTERED EXPRESSION; TUMOR-GROWTH; LUNG-CANCER AB Prostate cancer (PCA) is the second leading cause of cancer-related deaths in men in the United States. It is natural for a hormone-driven malignancy such as prostate cancer that androgen deprivation therapy (ADT) would be the preferred treatment for clinical disease management. However, after initial treatment response a vast majority of patients develop metastatic castrate-resistant prostate cancer (CRPC), which is fatal. While great headway has been made to understand the possible mechanisms that drive castrate-resistant disease, a bonafide cure remains elusive. Reactivation of androgen receptor (AR) signaling partly contributes to the emergence of CRPC. Here we briefly examine some of the known mechanisms of AR reactivation including intratumoral synthesis of androgens, modulation of AR coregulators, and AR variants with constitutive activity as well as activation of receptor tyrosine kinases. We primarily focus on the emerging dual function of the receptor tyrosine kinase (recepteur d'origine nantais; RON) as a traditional tyrosine kinase and transcription factor. We further discuss activation of RON as an alternate mechanism in the development of CRPC and available therapeutic approaches for clinical management of CRPC by combined inhibition of RON and AR. (C) 2015 Wiley Periodicals, Inc. C1 [Batth, Izhar Singh; Kumar, Addankl P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Yun, Huiyoung; Kumar, Addankl P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Kumar, Addankl P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Kumar, Addankl P.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Kumar, Addankl P.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kumar, AP (reprint author), Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 110 TC 2 Z9 2 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD OCT PY 2015 VL 54 IS 10 BP 937 EP 946 DI 10.1002/mc.22354 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA CU0PW UT WOS:000363220600001 PM 26152593 ER PT J AU Hambright, HG Batth, IS Xie, JP Ghosh, R Kumar, AP AF Hambright, Heather G. Batth, Izhar Singh Xie, Jianping Ghosh, Rita Kumar, Addanki Pratap TI Palmatine Inhibits Growth and Invasion in Prostate Cancer Cell: Potential Role for rpS6/NF kappa B/FLIP SO MOLECULAR CARCINOGENESIS LA English DT Article DE palmatine; prostate cancer; rpS6 ID AMURENSE BARK EXTRACT; TRANSGENIC ADENOCARCINOMA; NEXRUTINE; INVOLVEMENT; EXPRESSION; BERBERINE; NETWORK; PROTEIN; MODEL; AXIS AB Novel agents are desperately needed for improving the quality of life and 5-year survival to more than 30% for metastatic castrate-resistant prostate cancer. Previously we showed that Nexrutine, Phellodendron amurense bark extract, inhibits prostate tumor growth in vitro and in vivo. Subsequently using biochemical fractionation we identified butanol fraction contributes to the observed biological activities. We report here that palmatine, which is present in the butanol fraction, selectively inhibits growth of prostate cancer cells without significant effect on non-tumorigenic prostate epithelial cells. By screening receptor tyrosine kinases in a protein kinase array, we identified ribosomal protein S6, a downstream target of p70S6K and the Akt/ mTOR signaling cascade as a potential target. We further show that palmatine treatment is associated with decreased activation of NF and its downstream target gene FLIP. These events led to inhibition of invasion. Similar results were obtained using parent extract Nexrutine (Nx) suggesting that palmatine either in the purified form or as one of the components in Nx is a potent cytotoxic agent with tumor invasion inhibitory properties. Synergistic inhibition of rpS6/NF kappa B/FLIP axis with palmatine may have therapeutic potential for the treatment of prostate cancer and possibly other malignancies with their constitutive activation. These data support a biological link between rpS6/NF kappa B/FLIP in mediating palmatine-induced inhibitory effects and warrants additional preclinical studies to test its therapeutic efficacy. (C) 2014 Wiley Periodicals, Inc. C1 [Hambright, Heather G.; Batth, Izhar Singh; Xie, Jianping; Ghosh, Rita; Kumar, Addanki Pratap] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Ghosh, Rita; Kumar, Addanki Pratap] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pharmacol, San Antonio, TX 78229 USA. [Ghosh, Rita; Kumar, Addanki Pratap] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA. [Kumar, Addanki Pratap] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kumar, AP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. FU Veterans Affairs-Merit Award [I01 BX 000766-01]; National Cancer Institute [1RO1 CA 135451, R21 CA 137578, RO1 CA 149516]; Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio through National Cancer Institute [2P30 CA 054174-17] FX Grant sponsor: Veterans Affairs-Merit Award; Grant number: I01 BX 000766-01; Grant sponsor: National Cancer Institute; Grant numbers: 1RO1 CA 135451; R21 CA 137578; RO1 CA 149516; Grant sponsor: Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio through National Cancer Institute; Grant number: 2P30 CA 054174-17 NR 27 TC 7 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD OCT PY 2015 VL 54 IS 10 BP 1227 EP 1234 DI 10.1002/mc.22192 PG 8 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA CU0PW UT WOS:000363220600026 PM 25043857 ER PT J AU Kothari, S Foster, CS Pistilli, M Liesegang, TL Daniel, E Sen, HN Suhler, EB Thorne, JE Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Lawrence, SD Kempen, JH AF Kothari, Srishti Foster, C. Stephen Pistilli, Maxwell Liesegang, Teresa L. Daniel, Ebenezer Sen, H. Nida Suhler, Eric B. Thorne, Jennifer E. Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Lawrence, Scott D. Kempen, John H. CA Systemic Immunosuppressive Therapy TI The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis SO OPHTHALMOLOGY LA English DT Article ID SECONDARY GLAUCOMA; REGRESSION-ANALYSIS; STANDARDIZATION; PATHOGENESIS; DISEASE; DEXAMETHASONE; NOMENCLATURE; CHILDHOOD; CHILDREN; STEROIDS AB Purpose: To characterize the risk and risk factors for intraocular pressure (IOP) elevation in pediatric noninfectious uveitis. Design: Multicenter retrospective cohort study. Participants: Nine hundred sixteen children (1593 eyes) younger than 18 years at presentation with noninfectious uveitis followed up between January 1978 and December 2007 at 5 academic uveitis centers in the United States. Methods: Medical records review by trained, certified experts. Main Outcome Measures: Prevalence and incidence of IOP of 21 mmHg or more and 30 mmHg or more and incidence of a rise in IOP by 10 mmHg or more. To avoid underascertainment, outcomes were counted as present when IOP-lowering therapies were in use. Results: Initially, 251 (15.8%) and 46 eyes (2.9%) had IOP >= 21 mmHg and >= 30 mmHg, respectively. Factors significantly associated with presenting IOP elevation included age of 6 to 12 years (versus other pediatric ages), prior cataract surgery, pars plana vitrectomy, duration of uveitis >= 6 months, contralateral IOP elevation, presenting visual acuity worse than 20/40, and topical corticosteroid use (in a dose-response relationship). The median follow-up was 1.25 years (interquartile range, 0.4-3.66). The estimated incidence of any observed IOP elevation to >= 21 mmHg, to >= 30 mmHg, and increase in IOP by >= 10 mmHg was 33.4%, 14.8%, and 24.4%, respectively, within 2 years. Factors associated with IOP elevation included pars plana vitrectomy, contralateral IOP elevation (adjusted hazard ratio [aHR], up to 9.54; P < 0.001), and the use of topical (aHR, up to 8.77 that followed a dose-response relationship; P < 0.001), periocular (aHR, up to 7.96; P < 0.001), and intraocular (aHR, up to 19.7; P < 0.001) corticosteroids. Conclusions: Intraocular pressure elevation affects a large minority of children with noninfectious uveitis. Statistically significant risk factors include IOP elevation or use of IOP-lowering treatment in the contralateral eye and local corticosteroid use that demonstrated a dose-and route of administration-dependent relationship. In contrast, use of immunosuppressive drug therapy did not increase such risk. Pediatric eyes with noninfectious uveitis should be followed up closely for IOP elevation, especially when strong risk factors such as the use of local corticosteroids and contralateral IOP elevation are present. (C) 2015 by the American Academy of Ophthalmology. C1 [Kothari, Srishti; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Waltham, MA USA. [Kothari, Srishti; Foster, C. Stephen] Ocular Immunol & Uveitis Fdn, Waltham, MA USA. [Kothari, Srishti; Pistilli, Maxwell; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Pistilli, Maxwell; Kempen, John H.] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA. [Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Safety Harbor, FL USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. [Lawrence, Scott D.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA. [Kempen, John H.] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kempen, JH (reprint author), Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu FU National Eye Institute; National Eye Institute, National Institutes of Health, Bethesda, Maryland [EY014943]; Research to Prevent Blindness, Inc., New York, New York; Paul and Evanina Mackall Foundation; Lois Pope Life Foundation (New York, NY); Research to Prevent Blindness James S. Adams Special Scholar Award; Research to Prevent Blindness Harrington Special Scholar Award; Research to Prevent Blindness Senior Scientific Investigator Award; Department of Veterans' Affairs, Washington, DC FX Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: EY014943 [J.H.K.]); Research to Prevent Blindness, Inc., New York, New York; the Paul and Evanina Mackall Foundation; the Lois Pope Life Foundation (New York, NY); J.H.K. was a Research to Prevent Blindness James S. Adams Special Scholar Award recipient; J.E.T. was a Research to Prevent Blindness Harrington Special Scholar Award recipient; and D.A.J. and J.T.R. were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study; G.A.L.-C. previously was supported by and R.B.N. and H.N.S. continue to be supported by intramural funds from the National Eye Institute; E.B.S. receives support from the Department of Veterans' Affairs, Washington, DC. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript. NR 44 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2015 VL 122 IS 10 BP 1987 EP 2001 DI 10.1016/j.ophtha.2015.06.041 PG 15 WC Ophthalmology SC Ophthalmology GA CU4IP UT WOS:000363491500015 PM 26233626 ER PT J AU Paulson, EC Veenstra, CM Vachani, A Ciunci, CA Epstein, AJ AF Paulson, E. Carter Veenstra, Christine M. Vachani, Anil Ciunci, Christine A. Epstein, Andrew J. TI Trends in Surveillance for Resected Colorectal Cancer, 2001-2009 SO CANCER LA English DT Article DE colon cancer; epidemiology; guideline adherence; rectal cancer; surveillance ID FOLLOW-UP; PRACTICE GUIDELINE; AMERICAN-SOCIETY; COLON-CANCER; SURVIVORS; POPULATION; PROTOCOL; RECEIPT; CARE AB BACKGROUND: Little is known about recent trends in surveillance among the more than 1 million US colorectal cancer (CRC) survivors. Moreover, for stage I disease, which accounts for more than 30% of survivors, the guidelines are limited, and the use of surveillance has not been well studied. Guidelines were changed in 2005 to include recommendations for computed tomography (CT) surveillance in select patients, but the impact of these changes has not been explored. METHODS: A retrospective analysis of patients who were identified in the Survival, Epidemiology, and End Results-Medicare database and underwent resection of stage I to III CRC between 2001 and 2009 was performed. The receipt of guideline-determined sufficient surveillance, including office visits, colonoscopy, carcinoembryonic antigen (CEA) testing, and CT imaging, in the 3 years after resection was evaluated. RESULTS: The study included 23,990 colon cancer patients and 5665 rectal cancer patients. Rates of office visits and colonoscopy were high and stable over the study period. Rates of CEA surveillance increased over the study period but remained low, even for stage III disease. Rates of CT imaging increased gradually during the study period, but the 2005 guideline change had no effect. Stage II patients, including high-risk patients, received surveillance at significantly lower rates than stage III patients despite similar recommendations. Conversely, up to 30% of stage I patients received nonrecommended CEA testing and CT imaging. CONCLUSIONS: There continues to be substantial underuse of surveillance for CRC survivors and particularly for stage II patients, who constitute almost 40% of survivors. The 2005 guideline change had a negligible impact on CT surveillance. Conversely, although guidelines are limited, many stage I patients are receiving intensive surveillance. (C) 2015 American Cancer Society. C1 [Paulson, E. Carter; Vachani, Anil; Ciunci, Christine A.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Paulson, E. Carter; Epstein, Andrew J.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Paulson, E. Carter; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Veenstra, Christine M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Veenstra, Christine M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Paulson, EC (reprint author), Philadelphia VA Med Ctr, Surg Business Off, 3900 Woodland Ave,5th Floor, Philadelphia, PA 19104 USA. EM paulsone@uphs.upenn.edu FU National Cancer Institute (Cancer Center Support) [P30 CA016520]; Abramson Cancer Center Population Science Pilot Project FX This study was supported by the National Cancer Institute (Cancer Center Support Grant P30 CA016520) and the Abramson Cancer Center Population Science Pilot Project. NR 18 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2015 VL 121 IS 19 BP 3525 EP 3533 DI 10.1002/cncr.29469 PG 9 WC Oncology SC Oncology GA CT4MY UT WOS:000362782000026 PM 26079928 ER PT J AU Radulovic, M Schilero, GJ Yen, C Bauman, WA Wecht, JM Ivan, A La Fountaine, MF Korsten, MA AF Radulovic, M. Schilero, G. J. Yen, C. Bauman, W. A. Wecht, J. M. Ivan, A. La Fountaine, M. F. Korsten, M. A. TI Greatly increased prevalence of esophageal dysmotility observed in persons with spinal cord injury SO DISEASES OF THE ESOPHAGUS LA English DT Article DE esophageal motility; gastroesophageal reflux disease; high-resolution manometry; spinal cord injury ID GASTROESOPHAGEAL-REFLUX DISEASE; MOTILITY DISORDERS; ACID EXPOSURE; ABNORMALITIES; SPHINCTER; PRESSURE; CRITERIA; HUMANS AB The effects of spinal cord injury (SCI) on esophageal motility are largely unknown. Furthermore, due to the complete or partial loss of sensory innervation to the upper gastrointestinal tract, a symptom-based diagnosis of esophageal dysmotility is problematic in the SCI population. To determine the prevalence and characterize the type of motility disorders observed in persons with chronic SCI compared with that of able-bodied (AB) controls based on esophageal pressure topography isometrics acquired by high-resolution manometry and categorized by application of the Chicago Classification. High-resolution manometry of the esophagus was performed in 39 individuals: 14 AB, 12 with paraplegia (level of injury between T4-T12) and 13 with tetraplegia (level of injury between C5-C7). A catheter containing multiple pressure sensors arranged at 360 degrees was introduced into the esophagi of subjects at a distance that allowed visualization of both the upper esophageal sphincters (UES) and lower esophageal sphincters (LES). After a period to acquire pressures at baseline, subjects were asked to perform 10 wet swallows with 5-mL boluses of isotonic saline while esophageal pressure and impedance were being recorded. No significant differences were noted for gender, age, or body mass index between AB and SCI groups. Twenty-one of 25 (84%) subjects with SCI had at least one motility abnormality: 12% with Type II achalasia, 4% with Type III achalasia, 20% with esophagogastric junction outflow obstruction, 4% with the hypercontractile esophagus, and 48% with peristaltic abnormalities (weak peristalsis with small or large defects or frequent failed peristalsis). In contrast, only 7% (1 out of 14) of the AB subjects had any type of esophageal motility disorder. Despite the lack of subjective complaints and clinical awareness, esophageal dysmotility appears to be a highly prevalent condition in persons with SCI. The use of new and improved techniques, as well as a more stringent classification system, permitted the identification of the presence of nonspecific motility disorders in almost all SCI subjects, including four individuals who were previously undiagnosed with achalasia. Future work in persons with SCI is required to clarify the clinical impact of this observation and to study potential associations between esophageal dysmotility, gastroesophageal reflux disease, and pulmonary function. An increased awareness of esophageal dysfunction in the SCI population may lead to the development of new clinical guidelines for the diagnosis, prevention, and treatment of these largely unrecognized disorders. C1 [Radulovic, M.; Schilero, G. J.; Yen, C.; Bauman, W. A.; Wecht, J. M.; Ivan, A.; La Fountaine, M. F.; Korsten, M. A.] Natl Ctr Excellence Med Consequences Spinal Cord, Rehabil Res & Dev Serv, Bronx, NY USA. [Radulovic, M.; Schilero, G. J.; Bauman, W. A.; Korsten, M. A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Radulovic, M.; Schilero, G. J.; Bauman, W. A.; Korsten, M. A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Schilero, G. J.; Bauman, W. A.; Wecht, J. M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [La Fountaine, M. F.] Seton Hall Univ, Sch Hlth & Med Sci, Essex Cty, NJ USA. RP Radulovic, M (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Room 7A-13K 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM miroslav.radulovic@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service [B9212-C]; James J. Peters VA Medical Center FX This research was supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (Grants #B9212-C) and the James J. Peters VA Medical Center. NR 23 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1120-8694 EI 1442-2050 J9 DIS ESOPHAGUS JI Dis. Esophagus PD OCT PY 2015 VL 28 IS 7 BP 699 EP 704 DI 10.1111/dote.12272 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5ZU UT WOS:000362890600014 PM 25224683 ER PT J AU Krishnan, K Ge, L Haraldsson, H Hope, MD Saloner, DA Guccione, JM Tseng, EE AF Krishnan, Kapil Ge, Liang Haraldsson, Henrik Hope, Michael D. Saloner, David A. Guccione, Julius M. Tseng, Elaine E. TI Ascending thoracic aortic aneurysm wall stress analysis using patient-specific finite element modeling of in vivo magnetic resonance imaging SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Ascending thoracic aortic aneurysm; Wall stress; Finite element analysis ID INTERNATIONAL REGISTRY; INTIMAL TEARS; DISSECTION; VALVE; PATHOGENESIS; FLOW; ROOT AB OBJECTIVES: Rupture/dissection of ascending thoracic aortic aneurysms (aTAAs) carries high mortality and occurs in many patients who did not meet size criteria for elective surgery. Elevated wall stress may better predict adverse events, but cannot be directly measured in vivo, rather determined from finite element (FE) simulations. Current computational models make assumptions that limit accuracy, most commonly using in vivo imaging geometry to represent zero-pressure state. Accurate patient-specific wall stress requires models with zero-pressure three-dimensional geometry, material properties, wall thickness and residual stress. We hypothesized that wall stress calculated from in vivo imaging geometry at systemic pressure underestimates that using zero-pressure geometry. We developed a novel method to derive zero-pressure geometry from in vivo imaging at systemic pressure. The purpose of this study was to develop the first patient-specific aTAA models using magnetic resonance imaging (MRI) to assess material properties and zero-pressure geometry. Wall stress results from FE models using systemic pressure were compared with those from models using zero-pressure correction. METHODS: Patients with aTAAs <5 cm underwent ECG-gated computed tomography angiography (CTA) and displacement encoding with stimulated echo (DENSE)-MRI. CTA lumen geometry was used to create surface contour meshes of aTAA geometry. DENSE-MRI measured cyclic aortic wall strain from which wall material property was derived. Zero-and systemic pressure geometries were created. Simulations were loaded to systemic pressure using the ABAQUS FE software. Wall stress analyses were compared between zero-pressure-corrected and systemic pressure geometry FE models. RESULTS: Peak first principal wall stress (primarily aligned in the circumferential direction) at systolic pressure for the zero-pressure correction models was 430.62 +/- 69.69 kPa, whereas that without zero-pressure correction was 312.55 +/- 39.65 kPa (P = 0.004). Peak second principal wall stress (primarily aligned in the longitudinal direction) at systolic pressure for the zero-pressure correction models was 200.77 +/- 43.13 kPa, whereas that without zero-stress correction was 156.25 +/- 25.55 kPa (P = 0.02). CONCLUSIONS: Previous FE aTAA models from in vivo CT and MRI have not accounted for zero-pressure geometry or patient-specific material property. We demonstrated that zero-pressure correction significantly impacts wall stress results. Future computational models that use wall stress to predict aTAA adverse events must take into account zero-pressure geometry and patient material property for accurate wall stress determination. C1 [Krishnan, Kapil; Ge, Liang; Guccione, Julius M.; Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Dept Surg, San Francisco, CA 94143 USA. [Krishnan, Kapil; Ge, Liang; Haraldsson, Henrik; Hope, Michael D.; Saloner, David A.; Guccione, Julius M.; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Haraldsson, Henrik; Hope, Michael D.; Saloner, David A.] Univ Calif San Francisco, Med Ctr, Dept Radiol, San Francisco, CA 94143 USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org FU University of California [246590] FX This work was supported by the University of California, proof-of-concept grant 246590. NR 26 TC 5 Z9 6 U1 3 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD OCT PY 2015 VL 21 IS 4 BP 471 EP 480 DI 10.1093/icvts/ivv186 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CT8HU UT WOS:000363056800016 PM 26180089 ER PT J AU Peskind, ER Kraemer, B Zhang, J AF Peskind, Elaine R. Kraemer, Brian Zhang, Jing TI Biofluid Biomarkers of Mild Traumatic Brain Injury Whither Plasma Tau SO JAMA NEUROLOGY LA English DT Editorial Material ID CSF PHOSPHORYLATED TAU; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; BLOOD; DIAGNOSIS C1 [Peskind, Elaine R.] Vet Affairs NW Network Mental Illness Res Educ &, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. [Kraemer, Brian] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Kraemer, Brian] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Sch Med, Seattle, WA 98195 USA. [Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98195 USA. RP Peskind, ER (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S ColumbianWay,S-116MIRECC, Seattle, WA 98108 USA. EM elaine.peskind@va.gov FU BLRD VA [I01 BX002619] NR 15 TC 1 Z9 1 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD OCT PY 2015 VL 72 IS 10 BP 1103 EP 1105 DI 10.1001/jamaneurol.2015.1789 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA CT6ZQ UT WOS:000362963000002 PM 26237033 ER PT J AU Hayden, EY Yamin, G Beroukhim, S Chen, B Kibalchenko, M Jiang, L Ho, L Wang, J Pasinetti, GM Teplow, DB AF Hayden, Eric Y. Yamin, Ghiam Beroukhim, Shiela Chen, Benson Kibalchenko, Mikhail Jiang, Lin Ho, Lap Wang, Jun Pasinetti, Giulio M. Teplow, David B. TI Inhibiting amyloid -protein assembly: Size-activity relationships among grape seed-derived polyphenols SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; amyloid -protein (A); grape seeds; inhibitors; oligomers; polyphenols ID SMALL MOLECULE DOCKING; BETA-PROTEIN; ALZHEIMERS-DISEASE; WINE CONSUMPTION; CROSS-LINKING; EADOCK DSS; DEMENTIA; EXTRACT; FIBRILLOGENESIS; OLIGOMERIZATION AB Epidemiological evidence that red wine consumption negatively correlates with risk of Alzheimer's disease has led to experimental studies demonstrating that grape seed extracts inhibit the aggregation and oligomerization of A invitro and ameliorate neuropathology and behavioral deficits in a mouse model of Alzheimer's disease. The active agent in the extracts is a mixed population of polyphenolic compounds. To evaluate the relative potency of each of these compounds, HPLC was used to fractionate the mixture into monomers, dimers, and oligomers. Each fraction was analyzed for its effect on A conformational dynamics (circular dichroism), oligomerization (zero-length photochemical cross-linking), aggregation kinetics (Thioflavin T fluorescence), and morphology (electron microscopy). The relative activities of each fraction were determined on the basis of molar concentration (mol/L) or mass concentration (g/L). When molar concentration, the number concentration of each polyphenolic compound, was considered, the oligomer fraction was the most potent inhibitor of A oligomerization and aggregation. However, when mass concentration, the number concentration of phenolic groups, was considered, monomers were the most potent inhibitors. To understand these ostensibly contradictory results, a model of polyphenol:A complexation was developed. This model, which was found to be consistent with published X-ray crystallographic studies, offers an explanation for the effects of functional group polyvalency on inhibitor activity. Our data emphasize the importance of an in-depth understanding of the mechanism(s) underlying concentration dependence' in inhibitor systems involving polyfunctional agents. C1 [Hayden, Eric Y.; Yamin, Ghiam; Beroukhim, Shiela; Chen, Benson; Kibalchenko, Mikhail; Jiang, Lin; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Yamin, Ghiam] Univ Calif Los Angeles, Neurosci Interdept Ph Program, Med Sci Training Program, Los Angeles, CA 90095 USA. [Ho, Lap; Wang, Jun; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ho, Lap; Wang, Jun; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. [Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, MBI, Los Angeles, CA 90095 USA. [Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, BRI, Los Angeles, CA 90095 USA. RP Teplow, DB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 635 Charles E Young Dr S,Room 445, Los Angeles, CA 90095 USA. EM dteplow@mednet.ucla.edu FU UCLA Chemistry-Biology Interface (CBI) Training Program; UCLA Training Program in Neural Repair; Jim Easton Consortium for Alzheimer's Drug Discovery, and Biomarkers at UCLA; NIH [AG027818, NS038328, AG041295]; NCCIH Center [1PO1AT004511-031] FX We thank Dr. Zhefeng Gou for helpful discussions. This work was supported by grants from the UCLA Chemistry-Biology Interface (CBI) Training Program, UCLA Training Program in Neural Repair, Jim Easton Consortium for Alzheimer's Drug Discovery, and Biomarkers at UCLA, and NIH grants AG027818, NS038328, and AG041295. This study was supported in part through support from the NCCIH Center Grant 1PO1AT004511-031 to GMP. Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Drs. Pasinetti, Wang, and Ho are named inventors on a patent filed through the Icahn School of Medicine at Mount Sinai for the use of grape seed extract for the treatment of Alzheimer's disease and other neurodegenerative disorders. Drs Pasinetti, Wang, and Ho are entitled to receive royalties from this invention. NR 44 TC 2 Z9 2 U1 7 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD OCT PY 2015 VL 135 IS 2 BP 416 EP 430 DI 10.1111/jnc.13270 PG 15 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CT5DP UT WOS:000362828200019 PM 26228682 ER PT J AU Roiland, RA Lin, F Phelan, C Chapman, BP AF Roiland, R. A. Lin, F. Phelan, C. Chapman, B. P. TI Stress regulation as a link between executive function and pre-frailty in older adults SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE Pre-frailty; executive function; stress regulation ID HEART-RATE-VARIABILITY; POOR COGNITIVE PERFORMANCE; SLEEP QUALITY; WOMENS HEALTH; INFLAMMATION; AGE; ATTENTION; INDEXES; SAMPLE; ASSOCIATION AB Both pre-frailty and frailty are linked with impaired executive function (EF) but the mechanism underlying this relationship is not known. Williams and colleagues' model posits EF affects health outcomes via stress regulation. This model was utlized to test indicators of stress regulation as mediators of the relationship between EF and pre-frailty in older adults. Cross-sectional. Academic general clinical research centers. 690 community-dwelling older adults a parts per thousand yen 50 years of age. Pre-frailty was measured using a modified form of the Fried Frailty measure. EF was assessed via telephone-based neurocognitive assessments. Indicators of stress regulation included: stress exposure (measured by perceived stress), reactivity and recovery (measured by heart rate) and restoration (measured by serum interleukin-6 and sleep quality). 396 individuals were classified as non-frail, 277 as pre-frail, and 17 as frail. Pre-frail and non-frail individuals were included in data analyses. Compared to non-frail individuals, pre-frail were older and exhibited poorer EF, higher levels of stress exposure and poorer stress restoration. Poorer EF was associated with greater stress exposure, less stress reactivity, longer stress recovery and poorer stress restoration. The total effect of the relationship between EF and pre-frailty was significant with significant indirect effects supporting stress exposure and restoration as mediators of the relationship. Stress exposure and restoration appear to mediate the relationship between EF and pre-frailty. Longitudinal studies are needed to clarify the direction of causality and determine whether stress regulation processes are appropriate targets for interventions aiming to prevent declines in EF and the development of pre-frailty. C1 [Roiland, R. A.; Phelan, C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr 11 G, Madison, WI 53705 USA. [Lin, F.] Univ Rochester, Sch Nursing, Rochester, NY 14627 USA. [Chapman, B. P.] Univ Rochester, Dept Psychiat, Rochester, NY 14627 USA. RP Roiland, RA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr 11 G, Madison, WI 53705 USA. EM rachel.roiland@va.gov FU U.S. Department of Veterans Affairs, Biomedical Laboratory Research & Development Program [IK2 CX000535] FX This manuscript was partially prepared during postdoctoral training (RR) at the William S. Middleton Veterans Affairs Hospital in Madison, WI; GRECC manuscript 003. This work was also supported by Career Development Award #IK2 CX000535 (CP) from the U.S. Department of Veterans Affairs, Biomedical Laboratory Research & Development Program. The views and content expressed in this article are soley the responsibility of the authors and do not necessarily reflect the position, policy, or official views of the Department of Veterans Affairs, U.S. government, or the National Institutes of Health. NR 54 TC 1 Z9 1 U1 2 U2 5 PU SPRINGER FRANCE PI PARIS PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE SN 1279-7707 EI 1760-4788 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD OCT PY 2015 VL 19 IS 8 BP 828 EP 838 DI 10.1007/s12603-015-0476-1 PG 11 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA CT3CL UT WOS:000362683900005 PM 26412287 ER PT J AU Clemens, P Reay, D Bastacky, S Wack, K Stolz, D Robbins, R AF Clemens, P. Reay, D. Bastacky, S. Wack, K. Stolz, D. Robbins, R. TI D-amino acid substitution of peptide-mediated NF-kappa B suppression in mdx mice preserves therapeutic benefit in skeletal muscle, but causes kidney toxicity SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 20th International Congress of the World-Muscle-Society CY SEP 30-OCT 04, 2015 CL Brighton, ENGLAND SP World Muscle Soc C1 [Clemens, P.; Reay, D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bastacky, S.; Wack, K.; Stolz, D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Robbins, R.] Scripps Florida, Jupiter, FL USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2015 VL 25 SU 2 MA G.P.364 BP S294 EP S295 DI 10.1016/j.nmd.2015.06.388 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CT6LV UT WOS:000362925400384 ER PT J AU Hawkins, EJ Malte, CA Grossbard, JR Saxon, AJ AF Hawkins, Eric J. Malte, Carol A. Grossbard, Joel R. Saxon, Andrew J. TI Prevalence and Trends of Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs Patients with Post-traumatic Stress Disorder, 2003-2011 SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Trends in Benzodiazepine Use; Post-Traumatic Stress Disorder; Trends in Opioid Use; High-Risk Conditions ID PATIENTS PRESCRIBED OPIOIDS; CHRONIC PAIN PATIENTS; MENTAL-HEALTH; RISK-FACTORS; OVERDOSE DEATHS; PRESCRIPTION; THERAPY; ALCOHOL; DISCONTINUATION; METAANALYSIS AB BackgroundPatients with post-traumatic stress disorder (PTSD) have complex and multiple symptoms, including anxiety, insomnia, and co-occurring pain, often treated with opioids and benzodiazepines. While concurrent use of these medications poses safety concerns, little is known about the trends of long-term concurrent use and the prevalence of high-risk conditions among those who are prescribed them. Study objectives were to examine the trends in annual prevalence of long-term concurrent opioid and benzodiazepine use among patients with PTSD and prevalence of high-risk conditions in concurrent users of these medications. DesignRetrospective review of pharmacy records of the Veteran Affairs Northwest Integrated Network (VISN20). SubjectsPatients (n=66,210) with PTSD receiving care during 2003-2011. MethodsConcurrent use was defined as overlapping opioid and benzodiazepine prescriptions for 90 consecutive days. Gender-specific logistic regressions estimated long-term concurrent use of these medications and tested for linear trends over 9-years. ResultsThe trend in age-adjusted long-term concurrent opioid and benzodiazepine use over 9-years increased 52.7%, from 3.6% (95% confidence interval, 3.3-3.9%) to 5.5% (5.3-5.8%), in men and 79.5%, from 3.9% (3.0-5.0%) to 7.0% (6.2-7.9%), in women. In 2011, 17.1% of long-term concurrent users were prescribed morphine-equivalent daily doses of opioids 100 mg and 49.4% had a documented high-risk condition. ConclusionDespite known risks associated with prescribing opioids and benzodiazepines concurrently, the adjusted prevalence of long-term concurrent use rose significantly among men and women with PTSD in VISN20 over a 9-year period. Common use of these medications among patients with high-risk conditions suggests comprehensive strategies are needed to identify and monitor patients at increased risk for adverse outcomes. C1 [Hawkins, Eric J.; Malte, Carol A.; Saxon, Andrew J.] Hlth Serv Res & Dev HSR&D Seattle Ctr Innovat Vet, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.; Grossbard, Joel R.; Saxon, Andrew J.] Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Hawkins, Eric J.; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Eric.Hawkins@va.gov NR 61 TC 4 Z9 4 U1 5 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD OCT PY 2015 VL 16 IS 10 BP 1943 EP 1954 DI 10.1111/pme.12787 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CT5YS UT WOS:000362887800011 PM 26332513 ER PT J AU Harden, P Ahmed, S Ang, K Wiedemer, N AF Harden, Paul Ahmed, Sara Ang, Katie Wiedemer, Nancy TI Clinical Implications of Tapering Chronic Opioids in a Veteran Population SO PAIN MEDICINE LA English DT Article DE Tapering; Opioids; Veteran; Chronic ID CHRONIC NONCANCER PAIN; LOW-BACK-PAIN; TRANSDERMAL FENTANYL; THERAPY; OVERDOSE; HEALTH; METAANALYSIS; ASSOCIATION; DEATHS; SAFETY AB ObjectiveTo determine if patients receiving chronic opioid therapy can be tapered to lower opioid doses without a subsequent increase in pain. DesignRetrospective and prospective chart review at a VA Medical Center. MethodsPatients were included in the review if they were prescribed opioids chronically for at least 90 consecutive days and if a plan to taper opioid doses was agreed upon. Patients 89 years of age and older, patients with cancer, and patients exhibiting aberrant behavior were excluded. The primary endpoint was to determine the percent reduction of morphine equivalents (ME) over a 12-month period. Secondary endpoints included percent reduction of ME at 3 and 6 months, change in pain perception at 3, 6, and 12 months, and change in the number of adjuvant medications prescribed at 3, 6, and 12 months. Data were analyzed utilizing descriptive statistics. ResultsA total of 50 patient charts were included in the study. The average percent reduction of opioid doses was 46% over a 12-month period. Seventy percent of patients either experienced no change in pain or had less pain when comparing baseline to 12 months. An equal percentage of patients either had no change in the number of adjuvant medications prescribed or had more adjuvant medications prescribed when comparing baseline to 12 months. ConclusionsPatients in the population studied can be successfully tapered to lower opioid doses and may not necessarily experience more pain. C1 [Harden, Paul; Ahmed, Sara; Ang, Katie; Wiedemer, Nancy] Philadelphia VA Med Ctr, Dept Pharm, Philadelphia, PA USA. RP Harden, P (reprint author), 3900 Woodland Ave,Pharm Serv 119, Philadelphia, PA 19104 USA. EM paul.harden@va.gov NR 24 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD OCT PY 2015 VL 16 IS 10 BP 1975 EP 1981 DI 10.1111/pme.12812 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CT5YS UT WOS:000362887800014 PM 26119793 ER PT J AU Chen, HL Ding, D Wang, J Zhao, QH Meng, HJ Li, HL Gao, YT Shu, XO Tanner, CM Hong, Z Yang, G AF Chen, Honglei Ding, Ding Wang, Jian Zhao, Qianhua Meng, Haijiao Li, Honglan Gao, Yu-Tang Shu, Xiao-Ou Tanner, Caroline M. Hong, Zhen Yang, Gong TI Parkinson's disease research in a prospective cohort in China SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease/Parkinsonism; Risk factors in epidemiology; Cohort studies ID ORGANOCHLORINE PESTICIDES; DIETARY PATTERNS; RISK; PREVALENCE; SMOKING; HEALTH; SERUM; EPIDEMIOLOGY; ASSOCIATION; POPULATION AB Introduction: China has the largest population of Parkinson's disease (PD) patients; however few etiological studies of PD have been conducted in China. Methods: The Shanghai Women's Health Study recruited 74,941 women in urban Shanghai, aged 40 to 70, from 1996 to 2000. Self-reported PD cases were invited for a neurological examination and diagnoses were made by a movement disorder specialist. Results: This cohort had very few smokers (2.7%), alcohol drinkers (2.3%), and post-menopausal hormone users (4.3%); however, tea drinking (29.9%) and exposure to tobacco smoke from husbands (61.8%) were common. A total of 301 participants reported PD diagnosis during the follow-up. The diagnosis was confirmed in 76 (57%) of the 133 clinically examined patients. An additional 19 (53%) PD cases were identified out of 36 participants who self-confirmed the diagnosis and provided a history on PD symptoms and treatments. As expected, increasing age was strongly associated with PD risk. Further, PD risk appears to be inversely associated with exposures to second-hand tobacco smoke from husbands and tea drinking, and positively with education, although none of these reached statistical significance. The age-adjusted odds ratio (OR) was 0.7 (95% confidence interval; 0.4-1.1) for participants whose husbands were current smokers at baseline and 0.8 (0.5-1.3) for ever tea-drinkers. Compared with primary education or lower, the age-adjusted OR was 1.3 (0.7-2.4) for middle school and 1.6 (1.0-2.7) for high school or above. Conclusion: PD research in this unique cohort is feasible and, with extended follow-up, will allow for prospective PD etiological research in China. Published by Elsevier Ltd. C1 [Chen, Honglei] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. [Ding, Ding; Wang, Jian; Zhao, Qianhua; Meng, Haijiao; Hong, Zhen] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200433, Peoples R China. [Shu, Xiao-Ou; Yang, Gong] Vanderbilt Univ, Nashville, TN 37235 USA. [Li, Honglan; Gao, Yu-Tang] Shanghai Canc Inst, Shanghai, Peoples R China. [Tanner, Caroline M.] Univ Calif San Francisco, Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Chen, HL (reprint author), NIEHS, Epidemiol Branch, 111 TW Alexander Dr POB 12233,Mail Drop A3-05, Res Triangle Pk, NC 27709 USA. EM chenh2@niehs.nih.gov OI Chen, Honglei/0000-0003-3446-7779 FU Intramural Research Program of NIH; National Institute of Environmental Health Sciences [Z01-ES-101986]; NIH [R37CA070867, UM1CA182910] FX The study was supported by the Intramural Research Program of NIH, the National Institute of Environmental Health Sciences (Z01-ES-101986) and in part by NIH Grant R37CA070867 and UM1CA182910. NR 30 TC 3 Z9 3 U1 2 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD OCT PY 2015 VL 21 IS 10 BP 1200 EP 1204 DI 10.1016/j.parkreldis.2015.08.020 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA CT5OB UT WOS:000362858600011 PM 26318964 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, D Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP Moyer, V Flores, G AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alexander H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. Moyer, Virginia Flores, Glen CA US Preventive Serv Task Force TI Screening for Iron Deficiency Anemia in Young Children: USPSTF Recommendation Statement SO PEDIATRICS LA English DT Article ID INFANTS; AGE AB DESCRIPTION: Update of the US Preventive Services Task Force (USPSTF) 2006 recommendation on screening for iron deficiency anemia. METHODS: The USPSTF reviewed the evidence on the association between change in iron status as a result of intervention and improvement in child health outcomes, as well as screening for and treatment of iron deficiency anemia with oral iron formulations, in children ages 6 to 24 months. POPULATION: This recommendation applies to children ages 6 to 24 months living in the United States who are asymptomatic for iron deficiency anemia. It does not apply to children younger than age 6 months or older than 24 months, children who are severely malnourished, children who were born prematurely or with low birth weight, or children who have symptoms of iron deficiency anemia. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in children ages 6 to 24 months. (I statement) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alexander H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alexander H.] Virginia Commonwealth Univ, Richmond, VA USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), 540 Gaither Rd, Rockville, MD 20850 USA. EM coordinator@uspstf.net NR 18 TC 5 Z9 5 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2015 VL 136 IS 4 BP 746 EP 752 DI 10.1542/peds.2015-2567 PG 7 WC Pediatrics SC Pediatrics GA CT6TC UT WOS:000362944300061 PM 26347426 ER PT J AU Ozburn, AR Janowsky, AJ Crabbe, JC AF Ozburn, Angela R. Janowsky, Aaron J. Crabbe, John C. TI Commonalities and Distinctions Among Mechanisms of Addiction to Alcohol and Other Drugs SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Review DE Alcohol; Cocaine; Drugs of Abuse; Animal Models; Addiction ID CONTEXT-INDUCED REINSTATEMENT; NUCLEUS-ACCUMBENS SHELL; COCAINE-SEEKING BEHAVIOR; AMINE-ASSOCIATED RECEPTOR-1; CUE-INDUCED REINSTATEMENT; MEDIAL PREFRONTAL CORTEX; VENTRAL TEGMENTAL AREA; INTERMITTENT ETHANOL EXPOSURE; DOPAMINE D-1-FAMILY RECEPTORS; SELF-ADMINISTRATION MODEL AB BackgroundAlcohol abuse is comorbid with abuse of many other drugs, some with similar pharmacology and others quite different. This leads to the hypothesis of an underlying, unitary dysfunctional neurobiological basis for substance abuse risk and consequences. MethodsIn this review, we discuss commonalities and distinctions of addiction to alcohol and other drugs. We focus on recent advances in preclinical studies using rodent models of drug self-administration. ResultsWhile there are specific behavioral and molecular manifestations common to alcohol, psychostimulant, opioid, and nicotine dependence, attempts to propose a unifying theory of the addictions inevitably face details where distinctions are found among classes of drugs. ConclusionsFor alcohol, versus other drugs of abuse, we discuss and compare advances in: (i) neurocircuitry important for the different stages of drug dependence; (ii) transcriptomics and genetical genomics; and (iii) enduring effects, noting in particular the contributions of behavioral genetics and animal models. C1 [Ozburn, Angela R.; Janowsky, Aaron J.; Crabbe, John C.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Ozburn, Angela R.; Janowsky, Aaron J.; Crabbe, John C.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Sch Med, Portland, OR 97201 USA. [Ozburn, Angela R.; Crabbe, John C.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA. [Janowsky, Aaron J.] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA. [Janowsky, Aaron J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. RP Ozburn, AR (reprint author), 3181 SW Sam Jackson Pk Rd L470, Portland, OR 97239 USA. EM ozburn@ohsu.edu FU BLRD VA [I01 BX000313, I01 BX002758, IK2 BX002488]; NIAAA NIH HHS [AA10760, AA020245, AA13519, P50 AA010760, P60 AA010760, R24 AA020245, U01 AA013519]; NIDA NIH HHS [P50 DA018165] NR 176 TC 3 Z9 3 U1 4 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2015 VL 39 IS 10 BP 1863 EP 1877 DI 10.1111/acer.12810 PG 15 WC Substance Abuse SC Substance Abuse GA CS9OI UT WOS:000362420100002 PM 26431116 ER PT J AU Cummings, DE AF Cummings, David E. TI Taste and the regulation of food intake: it's not just about flavor SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Editorial Material ID LIPIDS C1 [Cummings, David E.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA. RP Cummings, DE (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [DK084324, DK103842, DK089528] NR 10 TC 6 Z9 6 U1 0 U2 5 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2015 VL 102 IS 4 BP 717 EP 718 DI 10.3945/ajcn.115.120667 PG 2 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CS7CO UT WOS:000362241900001 PM 26354541 ER PT J AU Taber, DJ Pilch, NA Trofe-Clark, J Kaiser, TE AF Taber, D. J. Pilch, N. A. Trofe-Clark, J. Kaiser, T. E. TI A National Survey Assessing the Current Workforce of Transplant Pharmacists Across Accredited US Solid Organ Transplant Programs SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID UNITED-STATES; PATIENT-CARE; RECIPIENTS; ADHERENCE; SERVICES; TEAM; FAILURE; CENTERS AB Integration of pharmacists into multidisciplinary transplant patient care has advanced in recent years, with limited data available to evaluate the current status of the profession. This was a national survey developed as an AST Pharmacy COP initiative. Responses were solicited from pharmacists practicing at U.S. transplant programs based on UNOS listing; 176 participants from 113 centers (41%) responded, with 79% practicing <= 10 years. There is a median of 1.4 pharmacist full-time equivalents (FTEs) (range 0.1-7.1) for every 100 transplants. The predominant activities performed by pharmacists during the transplant phase include medication review (95%), lab review (92%), allergy review (88%), medication therapy management (92%), bedside rounds (87%), medication education (79%), documentation (71%), and coordinating discharge medications (58%). Similar activities were reported during the other phases, but participation was less common. The involvement of dedicated transplant pharmacists within multidisciplinary care has become standard at a large number of centers, although expansion is still needed to ensure core pharmaceutical care components are provided to all transplant recipients across all centers. These results inform on the typical responsibilities of pharmacists practicing within the field of transplantation and illustrate that the level of pharmacist involvement significantly varies across transplant centers and the phases of transplantation. C1 [Taber, D. J.] Ralph H Johnson VA Med Ctr, Dept Pharm, Charleston, SC 29401 USA. [Taber, D. J.] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA. [Pilch, N. A.] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. [Trofe-Clark, J.] Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA. [Trofe-Clark, J.] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Kaiser, T. E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. RP Taber, DJ (reprint author), Ralph H Johnson VA Med Ctr, Dept Pharm, Charleston, SC 29401 USA. EM taberd@musc.edu FU South Carolina Clinical and Translational (SCTR) Institute [NIH/NCATS UL1TR000062] FX Survey development, dissemination and reporting were supported by the South Carolina Clinical and Translational (SCTR) Institute through grant no. NIH/NCATS UL1TR000062. The authors wish to thank the following people for their efforts with the design, analysis and interpretation of this endeavor: Additional Workforce Committee Members: Clark Benedetti, Drew Silverman, Eric Tichy, Jeong Park, Karen Hardinger, Mark Baillie, Spencer Martin, and Travis Dick. Survey Development and Review: Mark Baillie, Jeong Park, and Travis Dick. Survey Piloting: Karen Hardinger, Winston Ally, and Jeong Park. Manuscript Review: Samir Patel, Eric Tichy, Barrett Crowther, Rita Alloway, Lisa McDevitt, and Christin Rogers. NR 22 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2015 VL 15 IS 10 BP 2683 EP 2690 DI 10.1111/ajt.13323 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA CT2WJ UT WOS:000362665400020 PM 25988533 ER PT J AU Rogus-Pulia, N Churness, K Hind, J Gangnon, R Banaszynski, K Robbins, J AF Rogus-Pulia, Nicole Churness, Kim Hind, Jacqueline Gangnon, Ronald Banaszynski, Kelsey Robbins, JoAnne TI Comparison of Maximal Lingual Pressure Generation During Isometric Gross and Fine Sensorimotor Tasks in Healthy Adults SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Deglutition disorders; Pressure; Rehabilitation; Tongue ID TONGUE STRENGTH; OROPHARYNGEAL DYSPHAGIA; OLDER-ADULTS; EXERCISE; MUSCLE; AGE; INDIVIDUALS; SARCOPENIA; EVOLUTION; ENDURANCE AB Objectives: To (1) compare 2 distinct isometric lingual press tasks, fine sensorimotor versus gross sensorimotor, at multiple sensor locations in relation to age and sex; and (2) provide a normative data set using a lingual-strengthening device. Design: Cohort study. Setting: University. Participants: Healthy men and women (N=71; age range, 21-82y) recruited from the community. Interventions: Participants were stratified by age and sex and divided into 3 age groups. Participants completed, in random order, 2 isometric tasks: (1) fine sensorimotor: tongue press maximally and discreetly against each of 5 sensors; and (2) gross sensorimotor: tongue press maximally against all 5 sensors simultaneously. Main Outcome Measures: Primary outcome was maximum isometric pressure in hectopascals (hPa). Secondary outcomes were time to reach peak pressure (s) and pressure gradient (hPa/s). Results: Maximum pressures were significantly lower in those of older age for both fine and gross sensorimotor lingual tasks (P<.01), with the front and back sensors showing the greatest decline (35% and 45%, respectively). Pressure differences between tasks (P=. 0 12) resulted in the fine sensorimotor task generating higher pressures at the front sensor for all age groups. However, the gross sensorimotor task generated faster maximum pressures at all sensor locations for all age groups. For both sensorimotor tasks, subjects of older age as a whole generated less steep pressure gradients (P<.001). Conclusions: Age-related decline in tongue strength is greater at the anterior and posterior tongue. Results indicate a simpler gross sensorimotor task may be more beneficial for targeting timing as a biomechanical parameter during therapy, and the fine sensorimotor task may be more beneficial for targeting strength. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Rogus-Pulia, Nicole; Churness, Kim; Hind, Jacqueline; Banaszynski, Kelsey; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Rogus-Pulia, Nicole; Churness, Kim; Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol & Hepatol, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Banaszynski, Kelsey] Univ Wisconsin, Dept Nutr, Madison, WI USA. RP Rogus-Pulia, N (reprint author), 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA. EM npulia@wisc.edu FU United States Department of Agriculture [NRI2007-2234] FX Supported by the United States Department of Agriculture (grant no. NRI2007-2234). The views and content expressed in this article are solely the responsibility of the authors and do not necessarily reflect the position, policy, or official views of the Department of Veteran Affairs or the U.S. Government. NR 43 TC 0 Z9 0 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2015 VL 96 IS 10 BP 1785 EP 1794 DI 10.1016/j.apmr.2015.04.024 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CT2GX UT WOS:000362621100006 PM 25986206 ER PT J AU Bogner, HR McClintock, HFD Hennessy, S Kurichi, JE Streim, JE Xie, DW Pezzin, LE Kwong, PL Stineman, MG AF Bogner, Hillary R. McClintock, Heather F. de Vries Hennessy, Sean Kurichi, Jibby E. Streim, Joel. E. Xie, Dawei Pezzin, Liliana E. Kwong, Pui L. Stineman, Margaret G. TI Patient Satisfaction and Perceived Quality of Care Among Older Adults According to Activity Limitation Stages SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Aged; Disabled persons; Medicare; Patient satisfaction; Rehabilitation ID CURRENT BENEFICIARY SURVEY; HEALTH-CARE; MEDICARE BENEFICIARIES; ELDERLY-PEOPLE; DISABILITIES; COMMUNITY; LIFE; HEARING; DEAF AB Objective: To examine whether patient satisfaction and perceived quality of medical care are related to stages of activity limitations among older adults. Design: Cross-sectional study. Setting: Medicare Current Beneficiary Survey (MCBS) for calendar years 2001 to 2011. Participants: A population-based sample (N=42,584) of persons aged >= 65 years living in the community. Interventions: Not applicable. Main Outcome Measures: MCBS questions were categorized under 5 patient satisfaction and perceived quality dimensions: care coordination and quality, access barriers, technical skills of primary care physicians, interpersonal skills of primary care physicians, and quality of information provided by primary care physicians. Persons were classified into a stage of activity limitation (0-IV) derived from self-reported difficulty levels performing activities of daily living (ADL) and instrumental ADL. Results: Compared with older beneficiaries with no limitations at ADL stage 0, the adjusted odds ratios (ORs) for stage I (mild) to stage III (severe) for satisfaction with care coordination and quality ranged from .85 (95% confidence interval [CI], .80-.92) to .79 (95% CI, .70-.89). Compared with ADL stage 0, satisfaction with access barriers ranged from OR=.81 (95% CI, .76.87) at stage I to a minimum of OR=.67 (95% CI, .59-.76) at stage Similarly, compared with older beneficiaries at ADL stage 0, perceived quality of the technical skills of their primary care physician ranged from OR=.87 (95% CI, .82-.94) at stage I to a minimum of OR=.81 (95% CI, .72-.91) at stage III. Conclusions: Medicare beneficiaries at higher stages of activity limitation, although not necessarily the highest stage of activity limitation, reported less satisfaction with medical care. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Bogner, Hillary R.; McClintock, Heather F. de Vries] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Bogner, Hillary R.; McClintock, Heather F. de Vries; Hennessy, Sean; Kurichi, Jibby E.; Xie, Dawei; Kwong, Pui L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hennessy, Sean] Univ Penn, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA. [Streim, Joel. E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Streim, Joel. E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Pezzin, Liliana E.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. RP Bogner, HR (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Family Med & Community Hlth, Perelman Sch Med, 928 Blockley Hall, Philadelphia, PA 19104 USA. EM hillary.bogner@uphs.upenn.edu FU Patient-Centered Outcomes Research Institute Project Program award [AD-12-11-4567]; National Institutes of Health [R01AG040105, R01HD074756]; American Heart Association [13GRNT17000021]; National Institute of Mental Health [R21 MH094940, R34 MH085880] FX Supported through a Patient-Centered Outcomes Research Institute Project Program award (no. AD-12-11-4567), by the National Institutes of Health (grant nos. R01AG040105, R01HD074756), the American Heart Association (award no. 13GRNT17000021), and the National Institute of Mental Health (grant nos. R21 MH094940, R34 MH085880). NR 35 TC 3 Z9 3 U1 3 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2015 VL 96 IS 10 BP 1810 EP 1819 DI 10.1016/j.apmr.2015.06.005 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CT2GX UT WOS:000362621100009 PM 26119464 ER PT J AU Ishida, JH Marafino, BJ McCulloch, CE Dalrymple, LS Dudley, RA Grimes, BA Johanseng, KL AF Ishida, Julie H. Marafino, Ben J. McCulloch, Charles E. Dalrymple, Lorien S. Dudley, R. Adams Grimes, Barbara A. Johanseng, Kirsten L. TI Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PRACTICE GUIDELINES; DIALYSIS PATIENTS; THERAPY; MANAGEMENT; ANEMIA; BOLUS; RISK AB Background and objectives Anemia guidelines for CKD recommend withholding intravenous iron in the setting of active infection, although no data specifically support this recommendation. This study aimed to examine the association between intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Design, setting, participants, & measurements This was a retrospective observational cohort study using data from the US Renal Data System of 22,820 adult Medicare beneficiaries on in-center hemodialysis who had received intravenous iron in the 14 days preceding their first hospitalization for bacterial infection in 2010. In multivariable analyses, the association between receipt of intravenous iron at any point from the day of hospital admission to discharge and all-cause 30-day mortality, mortality in 2010, length of hospital stay, and readmission for infection or death within 30 days of discharge was evaluated. Results There were 2463 patients (10.8%) who received intravenous iron at any point from the day of admission to discharge. Receipt of intravenous iron was not associated with age, dialysis vintage, or comorbidities. There were 2618 deaths within 30 days of admission and 6921 deaths in 2010 (median follow-up 173 days; 25th and 75th percentiles, 78-271 days). The median length of stay was 7 days (25th and 75th percentiles, 5-12 days). Receipt of intravenous iron was not associated with higher 30-day mortality (odds ratio, 0.86; 95% confidence interval [95% CI], 0.74 to 1.00), higher mortality in 2010 (hazard ratio, 0.92; 95% CI, 0.85 to 1.00), longer mean length of stay (10.1 days [95% CI, 9.7 to 10.5] versus 10.5 days [95% CI, 10.3 to 10.7]; P=0.05), or readmission for infection or death within 30 days of discharge (odds ratio, 1.08; 95% CI, 0.96 to 1.22) compared with no. receipt of intravenous iron. Conclusions This analysis does not support withholding intravenous iron upon admission for bacterial infection in hemodialysis patients, although clinical trials are required to make definitive recommendations. C1 [Ishida, Julie H.; Johanseng, Kirsten L.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, Div Nephrol, San Francisco, CA 94143 USA. [Dudley, R. Adams] Univ Calif San Francisco, Dept Med, Philip R Lee Inst Hlth Policy Studies, Div Pulm & Crit Care, San Francisco, CA USA. [McCulloch, Charles E.; Dudley, R. Adams; Grimes, Barbara A.; Johanseng, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Marafino, Ben J.; Dudley, R. Adams] Univ Calif San Francisco, Ctr Healthcare Value, San Francisco, CA 94143 USA. [Ishida, Julie H.; Johanseng, Kirsten L.] San Francisco VA Med Ctr, Div Nephrol, Dept Med, San Francisco, CA 94121 USA. [Dalrymple, Lorien S.] Univ Calif Davis, Dept Med, Div Nephrol, Davis, CA 95616 USA. RP Ishida, JH (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,111J, San Francisco, CA 94121 USA. EM julie.ishida@ucsf.edu FU American Society of Nephrology; National Institute of Diabetes and Digestive and Kidney Diseases [K24-DK085153, K23-DK093584, N01-DK7005]; University of California, San Francisco Clinical and Translational Science Institute [UL1-TR000004] FX This publication was made possible by grants from the American Society of Nephrology (to J.H.I.), the National Institute of Diabetes and Digestive and Kidney Diseases (K24-DK085153 to K.L.J., K23-DK093584 to L.S.D., and N01-DK7005 to K.L.J. and B.A.G.), and the University of California, San Francisco Clinical and Translational Science Institute (UL1-TR000004 to C.E.M. and B.A.G.). NR 22 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD OCT PY 2015 VL 10 IS 10 BP 1799 EP 1805 DI 10.2215/CJN.01090115 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CT2JK UT WOS:000362627600015 PM 26416943 ER PT J AU Elder, WB Morrow, SL Brooks, GR AF Elder, William B. Morrow, Susan L. Brooks, Gary R. TI Sexual Self-Schemas of Gay Men: A Qualitative Investigation SO COUNSELING PSYCHOLOGIST LA English DT Article DE gender; LGBT; multiculturalism; qualitative; race; ethnicity ID GENDER-ROLE CONFLICT; HETEROSEXUAL MEN; RELATIONSHIP SATISFACTION; PSYCHOLOGICAL DISTRESS; COUNSELING PSYCHOLOGY; RACIAL IDENTITY; MASCULINE SELF; BISEXUAL MEN; BODY-IMAGE; PORNOGRAPHY AB Self-schemas derive from past experience, influence current experiences, and facilitate the processing of sexual information. Using this concept, this study addressed the following question: How do gay men understand their own sexual self-schemas? Perspectives of 20 gay men were drawn together using a grounded theory methodology and member checking. A seven-category model emerged depicting the behaviors and values participants described as the gay male sexual schema (e.g., Avoidance of Emotional Expression; Pornography and Sexual Orientation Identity; Physically Attractive Men; Managing Sex and Social Perception; Competition for Men; Sex, Emotion, and Intimacy; and Commitment and Work in Relationships). In addition, all participants discussed a process of sexual self-schema transition over time. The resulting model may be used in counseling and in social justice and advocacy to produce adaptive changes for gay male clients. C1 [Elder, William B.] South Texas Vet Hlth Care Syst, San Antonio, TX 78240 USA. [Morrow, Susan L.] Univ Utah, Counseling Psychol Program, Salt Lake City, UT USA. [Brooks, Gary R.] Baylor Univ, Doctoral Psychol Program, Waco, TX 76798 USA. RP Elder, WB (reprint author), South Texas Vet Hlth Care Syst, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM William.Elder2@va.gov NR 101 TC 0 Z9 0 U1 5 U2 16 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0011-0000 EI 1552-3861 J9 COUNS PSYCHOL JI Couns. Psychol. PD OCT PY 2015 VL 43 IS 7 BP 942 EP 969 DI 10.1177/0011000015606222 PG 28 WC Psychology, Applied SC Psychology GA CT0JS UT WOS:000362481900001 ER PT J AU Elder, WB Morrow, SL Brooks, GR AF Elder, William B. Morrow, Susan L. Brooks, Gary R. TI Sexual Self-Schemas of Bisexual Men: A Qualitative Investigation SO COUNSELING PSYCHOLOGIST LA English DT Article DE multiculturalism; gender; LGBT; race; ethnicity; qualitative ID AFRICAN-AMERICAN MEN; PERSONAL CONSTRUCT THEORY; GENDER-ROLE-CONFLICT; GAY MEN; COUNSELING PSYCHOLOGY; IDENTITY DEVELOPMENT; HOMOSEXUAL IDENTITY; BODY-IMAGE; AROUSAL PATTERNS; MALE-ADOLESCENTS AB This qualitative study investigated the sexual self-schemas and masculinity ideologies of 20 bisexual men. Sexual self-schema was defined as a cognitive generalization about sexual aspects of the self, as derived from past experience and sociocultural context, which guides current experiences and facilitates the processing of sexual information. In-depth interviews, a focus group, documentary evidence, and grounded theory analysis were used. Categories were coded and analyzed, revealing two models. The first, the sexual self-schema of bisexual men, is an eight-category model of the bisexual male sexual self-schema describing men's relationships with other men and with women, as well as attitudes about themselves. The second model, the process of emerging awareness of bisexual attraction, outlines how sexual and romantic relationship experiences lead to bisexual sexual orientation identity. The two theoretical models depict how bisexual men understand their own sexual self-schemas. Implications for counseling psychology research and practice are addressed. C1 [Elder, William B.] South Texas Vet Hlth Care Syst, San Antonio, TX 78240 USA. [Morrow, Susan L.] Univ Utah, Counseling Psychol Program, Salt Lake City, UT USA. [Brooks, Gary R.] Baylor Univ, Doctoral Psychol Program, Waco, TX 76798 USA. RP Elder, WB (reprint author), South Texas Vet Hlth Care Syst, Psychol Serv, 5788 Eckhert Rd,116A PCT, San Antonio, TX 78240 USA. EM William.Elder2@va.gov NR 150 TC 0 Z9 0 U1 6 U2 21 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0011-0000 EI 1552-3861 J9 COUNS PSYCHOL JI Couns. Psychol. PD OCT PY 2015 VL 43 IS 7 BP 970 EP 1007 DI 10.1177/0011000015608242 PG 38 WC Psychology, Applied SC Psychology GA CT0JS UT WOS:000362481900002 ER PT J AU Back, SE Gros, DF Price, M LaRowe, S Flanagan, J Brady, KT Davis, C Jaconis, M McCauley, JL AF Back, Sudie E. Gros, Daniel F. Price, Matthew LaRowe, Steve Flanagan, Julianne Brady, Kathleen T. Davis, Charles Jaconis, Maryanne McCauley, Jenna L. TI Laboratory-induced stress and craving among individuals with prescription opioid dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Stress; Trier; Cues; Prescription opioids; Opiates ID ALCOHOL CUE REACTIVITY; DRUG-ABUSE; PSYCHOSOCIAL STRESS; CONTROLLED-TRIAL; COLD PRESSOR; CHRONIC PAIN; RELAPSE; ADDICTION; SEEKING; MECHANISMS AB Background: Stress and conditioned drug cues have been implicated in the initiation, maintenance and relapse to substances of abuse. Although stress and drug cues are often encountered together, little research exists on whether stress potentiates the response to drug cues. Method: Participants (N = 75) were 39 community recruited individuals with current prescription opioid (PO) dependence and 36 healthy controls. Participants stayed overnight in the hospital for one night and then completed laboratory testing the following morning. During laboratory testing, participants were randomly assigned to a stress task (Trier Social Stress Task; TSST) or a no-stress condition. Following the stress manipulation, all participants completed a PO cue paradigm. Immediately before and after the stress and cue tasks, the following were assessed: subjective (stress, craving, anger, sadness, happiness), physiological (heart rate, blood pressure, galvanic skin response), and neuroendocrine responses (cortisol and dehydroepiandrosterone). Results: Internal validity of the stress task was demonstrated, as evidenced by significantly higher subjective stress, as well as cortisol, heart rate and blood pressure in the TSST compared to the no-stress group. Individuals with PO dependence evidenced significantly greater reactivity to the stress task than controls. Craving increased significantly in response to the drug cue task among PO participants. No stress x cue interaction was observed. Conclusions: In this study, heightened stress reactivity was observed among individuals with PO dependence. Exposure to acute stress, however, did not potentiate craving in response to conditioned drug cues. Published by Elsevier Ireland Ltd. C1 [Back, Sudie E.; Gros, Daniel F.; LaRowe, Steve; Flanagan, Julianne; Brady, Kathleen T.; Davis, Charles; Jaconis, Maryanne; McCauley, Jenna L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Back, Sudie E.; Gros, Daniel F.; LaRowe, Steve; Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. RP Back, SE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,POB 250861, Charleston, SC 29425 USA. EM backs@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU National Institute on Drug Abuse (NIDA) [K23 DA021228, DA036566, K24 DA00435]; Department of Veteran Affairs Clinical Sciences Research and Development [CX000845]; NIAAA [AA007474] FX This work was supported by grants from the National Institute on Drug Abuse (NIDA) to S. E. Back (K23 DA021228), J.L. McCauley (DA036566) and K. T. Brady (K24 DA00435), and a grant from the Department of Veteran Affairs Clinical Sciences Research and Development to D. F. Gros (CX000845). The authors would also like to acknowledge support from NIAAA T32 grant number AA007474 (Woodward, J.). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIDA, the Department of Veterans Affairs, or the United States government. We would like to thank the following individuals for their assistance with study design and data collection: Dr. Ronald See, Dr. Elizabeth Cox, Ms. Mary Ashley Mercer, Ms. Katie Lawson, and Ms. Emily Hartwell. NR 70 TC 1 Z9 1 U1 7 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2015 VL 155 BP 60 EP 67 DI 10.1016/j.drugalcdep.2015.08.019 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CS8AB UT WOS:000362307000009 PM 26342626 ER PT J AU Abreo, AP Chertow, GM Dalrymple, LS Kaysen, GA Johansen, KL AF Abreo, Adrian P. Chertow, Glenn M. Dalrymple, Lorien S. Kaysen, George A. Johansen, Kirsten L. TI Association of bioimpedance spectroscopy-based volume estimation with postdialysis hypotension in patients receiving hemodialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Bioimpedance spectroscopy; end-stage renal disease; hemodialysis; volume status ID DRY-WEIGHT; BLOOD-PRESSURE; WHOLE-BODY; MULTIFREQUENCY BIOIMPEDANCE; DIALYSIS PATIENTS; FLUID VOLUME; DYSFUNCTION; REDUCTION; MORTALITY; TRIAL AB Clinical examination to determine the dry weight of patients on hemodialysis (HD) has been problematic, with studies showing discordance between physician assessment and objective measures of volume status.We studied the association between predialysis bioimpedance spectroscopy (BIS)-based estimates of fluid overload and postdialysis hypotension in 635 patients in the United States Renal Data System ACTIVE/ADIPOSE (A Cohort study To Investigate the Value of Exercise/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD) study receiving HD in 2009-2011. We recorded predialysis and postdialysis weight and blood pressures over 3 consecutive HD sessions and performed BIS before a single session. Using a previously reported method of estimating normohydration weight, we estimated postdialysis fluid overload (FOpost) in liters. We used logistic regression with extracellular water/total body water (ECW/TBW) or estimated FOpost as the primary predictor and 1 or more postdialysis systolic blood pressures less than 110mmHg as the dependent variable. Models were adjusted for age, sex, race, ultrafiltration rate per kilogram of body weight, end-stage renal disease vintage, diabetes mellitus, heart failure, and albumin. Higher ECW/TBW was associated with lower odds of postdialysis hypotension (odds ratio [OR] 0.35, 95% confidence interval [CI] 0.15-0.84 per 0.1, P=0.02). Every liter of FOpost was associated with lower adjusted odds of postdialysis hypotension (OR 0.86, 95% CI 0.79-0.95, P=0.003). Prospective studies are needed to determine whether this application of BIS could improve current clinical efforts to minimize episodes of postdialysis hypotension without leading to volume overload. C1 [Abreo, Adrian P.] Univ Cincinnati, Coll Med, Div Nephrol, Cincinnati, OH 45267 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Abreo, AP (reprint author), Univ Cincinnati, Coll Med, MSB, 231 Albert Sabin Way,G261, Cincinnati, OH 45267 USA. EM adrian.abreo@uc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [N01-DK-7-0005, N01-DK-7-5004]; [K24DK085153]; [K23DK093584] FX This work was supported through contracts N01-DK-7-0005 and N01-DK-7-5004 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a K24DK085153 grant, and a K23DK093584 (LSD) grant. NR 27 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1492-7535 EI 1542-4758 J9 HEMODIAL INT JI Hemodial. Int. PD OCT PY 2015 VL 19 IS 4 BP 536 EP 542 DI 10.1111/hdi.12305 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CT1TN UT WOS:000362584500024 PM 25881673 ER PT J AU Noto, MJ Boyd, KL Burns, WJ Varga, MG Peek, RM Skaar, EP AF Noto, Michael J. Boyd, Kelli L. Burns, William J. Varga, Matthew G. Peek, Richard M., Jr. Skaar, Eric P. TI Toll-Like Receptor 9 Contributes to Defense against Acinetobacter baumannii Infection SO INFECTION AND IMMUNITY LA English DT Article ID NEGATIVE BACTERIAL PNEUMONIA; HOST-RESISTANCE; PULMONARY INFECTION; DISEASES-SOCIETY; DENDRITIC CELLS; INNATE IMMUNITY; BAD BUGS; TLR9; CARBAPENEM; DNA AB Acinetobacter baumannii is a common nosocomial pathogen capable of causing severe diseases associated with significant morbidity and mortality in impaired hosts. Pattern recognition receptors, such as the Toll-like receptors (TLRs), play a key role in pathogen detection and function to alert the immune system to infection. Here, we examine the role for TLR9 signaling in response to A. baumannii infection. In a murine model of A. baumannii pneumonia, TLR9(-/)-mice exhibit significantly increased bacterial burdens in the lungs, increased extrapulmonary bacterial dissemination, and more severe lung pathology compared with those in wild-type mice. Following systemic A. baumannii infection, TLR9(-/)-mice have significantly increased bacterial burdens in the lungs, as well as decreased proinflammatory cytokine and chemokine production. These results demonstrate that TLR9-mediated pathogen detection is important for host defense against the opportunistic pathogen Acinetobacter baumannii. C1 [Noto, Michael J.; Burns, William J.; Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. [Noto, Michael J.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN 37212 USA. [Boyd, Kelli L.; Burns, William J.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Varga, Matthew G.; Peek, Richard M., Jr.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu OI Varga, Matthew/0000-0002-2075-3224 FU Department of Veterans Affairs merit award [INFB-024-13F]; National Institutes of Health [R01DK58587, R01CA77955, P01CA116087, 2T32HL087738-06] FX This research was supported by Department of Veterans Affairs merit award INFB-024-13F to E.P.S., National Institutes of Health grants R01DK58587, R01CA77955, and P01CA116087 to R.M.P., and National Institutes of Health grant 2T32HL087738-06 to M.J.N. E.P.S. is a Burroughs Wellcome Fellow in the Pathogenesis of Infectious Diseases. NR 48 TC 5 Z9 5 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD OCT PY 2015 VL 83 IS 10 BP 4134 EP 4141 DI 10.1128/IAI.00410-15 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CT0NJ UT WOS:000362492600034 PM 26238713 ER PT J AU Doll, JA Hellkamp, A Ho, PM Kontos, MC Whooley, MA Peterson, ED Wang, TY AF Doll, Jacob A. Hellkamp, Anne Ho, P. Michael Kontos, Michael C. Whooley, Mary A. Peterson, Eric D. Wang, Tracy Y. TI Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction SO JAMA INTERNAL MEDICINE LA English DT Letter ID AMERICAN-HEART-ASSOCIATION; SCIENTIFIC STATEMENT; PREVENTION; CARDIOLOGY C1 [Doll, Jacob A.; Hellkamp, Anne; Peterson, Eric D.; Wang, Tracy Y.] Duke Clin Res Inst, Durham, NC USA. [Doll, Jacob A.; Hellkamp, Anne; Peterson, Eric D.; Wang, Tracy Y.] Duke Univ, Dept Med, Div Cardiol, Durham, NC USA. [Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Sch Med, Dept Med, Div Cardiol, Aurora, CO USA. [Kontos, Michael C.] Virginia Commonwealth Univ, Dept Med, Div Cardiol, Richmond, VA 23284 USA. [Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. RP Doll, JA (reprint author), 2400 Pratt St, Durham, NC 27705 USA. EM jacob.doll@duke.edu FU AHRQ HHS [U19HS021092] NR 7 TC 9 Z9 9 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2015 VL 175 IS 10 BP 1700 EP 1702 DI 10.1001/jamainternmed.2015.3819 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CT1WY UT WOS:000362594600022 PM 26237309 ER PT J AU Khan, RF Feder, S Goldstein, NE Chaudhry, SI AF Khan, Rabeea F. Feder, Shelli Goldstein, Nathan E. Chaudhry, Sarwat I. TI Symptom Burden Among Patients Who Were Hospitalized for Heart Failure SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Khan, Rabeea F.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Feder, Shelli] Yale Univ, Sch Nursing, New Haven, CT 06520 USA. [Goldstein, Nathan E.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Goldstein, Nathan E.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Chaudhry, Sarwat I.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA. RP Chaudhry, SI (reprint author), Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, Harkness Off Bldg,367 Cedar St,Room 416, New Haven, CT 06520 USA. NR 5 TC 3 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2015 VL 175 IS 10 BP 1713 EP 1715 DI 10.1001/jamainternmed.2015.3871 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CT1WY UT WOS:000362594600029 PM 26280896 ER PT J AU Falvey, JR Burke, RE Stevens-Lapsley, JE AF Falvey, Jason R. Burke, Robert E. Stevens-Lapsley, Jennifer E. TI Physical Function and Hospital Readmissions SO JAMA INTERNAL MEDICINE LA English DT Letter ID DISCHARGE; ELDERS C1 [Falvey, Jason R.; Stevens-Lapsley, Jennifer E.] Univ Colorado, Dept Phys Med & Rehabil, Phys Therapy Program, Aurora, CO 80045 USA. [Burke, Robert E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Burke, Robert E.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. RP Falvey, JR (reprint author), Univ Colorado, Dept Phys Med & Rehabil, Phys Therapy Program, 13121 E 17th Ave,Anschutz Med Campus, Aurora, CO 80045 USA. EM Jason.Falvey@ucdenver.edu FU NCATS NIH HHS [UL1 TR001082] NR 9 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2015 VL 175 IS 10 BP 1722 EP 1723 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CT1WY UT WOS:000362594600039 PM 26436745 ER PT J AU Kutner, JS Ritchie, CS Abernethy, AP AF Kutner, Jean S. Ritchie, Christine S. Abernethy, Amy P. TI Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Kutner, Jean S.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Ritchie, Christine S.] Jewish Home San Francisco, Ctr Res Aging, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Abernethy, Amy P.] Duke Univ, Sch Med, Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC USA. RP Abernethy, AP (reprint author), Duke Univ, Med Ctr, POB 3436, Durham, NC 27710 USA. EM amy.abernethy@duke.edu FU NINR NIH HHS [UC4-NR012584, U24 NR014637, U24-NR014637] NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2015 VL 175 IS 10 BP 1725 EP 1726 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CT1WY UT WOS:000362594600044 PM 26436751 ER PT J AU Radulovic, M Anand, P Korsten, MA Gong, B AF Radulovic, Miroslav Anand, Preeti Korsten, Mark A. Gong, Bing TI Targeting Ion Channels: An Important Therapeutic Implication in Gastrointestinal Dysmotility in Patients With Spinal Cord Injury SO JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Review DE Dysmotility; Gastrointestinal; Interstitial cells of Cajal; Ion channels; Myocytes, smooth muscle ID SENSITIVE K+ CHANNELS; COLONIC SMOOTH-MUSCLE; PROTEIN-KINASE-C; INTERSTITIAL-CELLS; POTASSIUM CHANNELS; SMALL-INTESTINE; INHIBITORY NEUROTRANSMISSION; PACEMAKER ACTIVITY; MURINE COLON; GUINEA-PIG AB Gastrointestinal (GI) dysmotility is a severe, and common complication in patients with spinal cord injury (SCI). Current therapeutic methods using acetylcholine analogs or laxative agents have unwanted side effects, besides often fail to have desired effect. Various ion channels such as ATP-sensitive potassium (K-ATP) channel, calcium ions (Ca2+)-activated potassium ions (K+) channels, voltage-sensitive Ca2+ channels and chloride ion (Cl-) channels are abundantly expressed in GI tissues, and play an important role in regulating GI motility. The release of neurotransmitters from the enteric nerve terminal, innervating GI interstitial cells of Cajal (ICC), and smooth muscle cells (SMC), causes inactivation of K+ and Cl- channels, increasing Ca2+ influx into cytoplasm, resulting in membrane depolarization and smooth muscle contraction. Thus, agents directly regulating ion channels activity either in ICC or in SMC may affect GI peristalsis and would be potential therapeutic target for the treatment of GI dysmotility with SCI. C1 [Radulovic, Miroslav; Korsten, Mark A.; Gong, Bing] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Anand, Preeti; Gong, Bing] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Radulovic, Miroslav; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences SCI, Bronx, NY USA. RP Gong, B (reprint author), Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Placc, New York, NY 10029 USA. EM bing.gong@va.gov FU US Department of Veterans Affairs; Alzheimer's Association [IIRG-12-242345] FX This paper is supported by a grant from US Department of Veterans Affairs to Miroslav Radulovic and Mark A Korsten, and by a grant from Alzheimer's Association (IIRG-12-242345) to Bing Gong. NR 61 TC 0 Z9 1 U1 1 U2 1 PU KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY PI GANGNAM-GU PA RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU, SEOUL 135-839, SOUTH KOREA SN 2093-0879 EI 2093-0887 J9 J NEUROGASTROENTEROL JI J. Neurogastroenterol. Motil. PD OCT PY 2015 VL 21 IS 4 BP 494 EP 502 DI 10.5056/jnm15061 PG 9 WC Gastroenterology & Hepatology; Clinical Neurology SC Gastroenterology & Hepatology; Neurosciences & Neurology GA CT3GT UT WOS:000362695900006 PM 26424038 ER PT J AU Christensen, R Singh, JA Wells, GA Tugwell, PS AF Christensen, Robin Singh, Jasvinder A. Wells, George A. Tugwell, Peter S. TI Do "Evidence-Based Recommendations" Need to Reveal the Evidence? Minimal Criteria Supporting an "Evidence Claim" SO JOURNAL OF RHEUMATOLOGY LA English DT Editorial Material ID SYSTEMATIC REVIEWS; QUALITY; GUIDELINES; GRADE; STRENGTH C1 [Christensen, Robin] Bispebjerg & Frederiksberg Hosp, Parker Inst, Musculoskeletal Stat Unit, Dept Rheumatol, Copenhagen, Denmark. [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham VA Med Ctr, Dept Med,Sch Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Wells, George A.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada. [Tugwell, Peter S.] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada. RP Christensen, R (reprint author), Copenhagen Univ Hosp Frederiksberg, Musculoskeletal Stat Unit, Parker Inst, Nordre Fasanvej 57, DK-2000 Copenhagen F, Denmark. EM robin.christensen@regionh.dk OI Tugwell, Peter/0000-0001-5062-0556 NR 20 TC 2 Z9 2 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1737 EP 1739 DI 10.3899/jrheum.150846 PG 3 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900003 PM 26429204 ER PT J AU Maxwell, LJ Wells, GA Simon, LS Conaghan, PG Grosskleg, S Scrivens, K Beaton, DE Bingham, CO Busse, JW Christensen, R Goel, N Juni, P Kaiser, U Lyddiatt, A Mease, PJ Ostelo, RW Phillips, K Sapunar, D Singh, JA Strand, V Taylor, AM Terwee, CB Tugwell, P AF Maxwell, Lara J. Wells, George A. Simon, Lee S. Conaghan, Philip G. Grosskleg, Shawna Scrivens, Kerry Beaton, Dorcas E. Bingham, Clifton O., III Busse, Jason W. Christensen, Robin Goel, Niti Jueni, Peter Kaiser, Ulrike Lyddiatt, Anne Mease, Philip J. Ostelo, Raymond W. Phillips, Kristine Sapunar, Damir Singh, Jasvinder A. Strand, Vibeke Taylor, Ann M. Terwee, Caroline B. Tugwell, Peter TI Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE PAIN MEASUREMENT; CHRONIC PAIN; OUTCOMES RESEARCH; SYSTEMATIC REVIEW ID UPDATED METHOD GUIDELINES; CLINICAL-TRIALS; IMMPACT RECOMMENDATIONS; SYSTEMATIC REVIEWS; METHODOLOGICAL QUALITY; COSMIN CHECKLIST; FINDINGS TABLES; SETS AB Objective. To assess the current state of reporting of pain outcomes in Cochrane reviews on chronic musculoskeletal painful conditions and to elicit opinions of patients, healthcare practitioners, and methodologists on presenting pain outcomes to patients, clinicians, and policymakers. Methods. We identified all reviews in the Cochrane Library of chronic musculoskeletal pain conditions from Cochrane review groups (Back, Musculoskeletal, and Pain, Palliative, and Supportive Care) that contained a summary of findings (SoF) table. We extracted data on reported pain domains and instruments and conducted a survey and interviews on considerations for SoF tables (e.g., pain domains, presentation of results). Results. Fifty-seven SoF tables in 133 Cochrane reviews were eligible. SoF tables reported pain in 56/57, with all presenting results for pain intensity (20 different outcome instruments), pain interference in 8 SoF tables (5 different outcome instruments), and pain frequency in 1 multiple domain instrument. Other domains like pain quality or pain affect were not reported. From the survey and interviews [response rate 80% (36/45)], we derived 4 themes for a future research agenda: pain domains, considerations for assessing truth, discrimination, and feasibility; clinically important thresholds for responder analyses and presenting results; and establishing hierarchies of outcome instruments. Conclusion. There is a lack of standardization in the domains of pain selected and the manner that pain outcomes are reported in SoF tables, hampering efforts to synthesize evidence. Future research should focus on the themes identified, building partnerships to achieve consensus and develop guidance on best practices for reporting pain outcomes. C1 [Maxwell, Lara J.] Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa, ON, Canada. Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada. Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. SDG LLC, Cambridge, MA USA. Univ Leeds, Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. Univ Ottawa, Ottawa, ON, Canada. Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. Inst Work & Hlth, Toronto, ON, Canada. Johns Hopkins Univ, Dept Med, Div Rheumatol, Baltimore, MD USA. McMaster Univ, Dept Clin Epidemiol & Biostat, Dept Anesthesia, Hamilton, ON, Canada. McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada. Bispebjerg & Frederiksberg Hosp, Musculoskeletal Stat Unit, Dept Rheumatol, Parker Inst, Copenhagen, Denmark. Duke Univ, Sch Med, Dept Med, Quintiles Inc,Div Rheumatol, Durham, NC 27706 USA. Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland. Univ Hosp Carl Gustav Carus, Dresden, Germany. Univ Washington, Seattle, WA 98195 USA. Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands. Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Univ Split, Sch Med, Lab Pain Res, Split, Croatia. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA. Cardiff Univ, Inst Infect & Immun, Cardiff CF10 3AX, S Glam, Wales. Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Epidemiol & Biostat, Amsterdam, Netherlands. Vrije Univ Amsterdam, Med Ctr Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. Univ Ottawa, Fac Med, Dept Med, Ottawa Hosp Res Inst, Ottawa, ON, Canada. Univ Ottawa, Clin Epidemiol Program, Ottawa, ON, Canada. Univ Ottawa, Fac Med, Inst Populat Hlth, Ottawa, ON, Canada. RP Maxwell, LJ (reprint author), Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa, ON, Canada. EM lmaxwell@uottawa.ca RI Sapunar, Damir/E-7247-2010 OI Sapunar, Damir/0000-0002-8352-4402; Busse, Jason/0000-0002-0178-8712; Tugwell, Peter/0000-0001-5062-0556 FU German Ministry of Education and Research [BMBF 01GY1326]; Oak Foundation; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; US National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891, P30-AR053503]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; Patient-Centered Outcomes Research Institute (PCORI) Pilot Project Program Award [1IP2-PI000737-01]; PCORI Methodology Award [SC14-1402-10818]; Takeda; Savient; Regeneron; Allergan; Astra Zeneca; Biotronik; Biosensors International; Eli Lilly; The Medicines Company; Biosensors; St. Jude Medical; Canadian Institutes of Health Research (CIHR) FX U. Kaiser received a grant from the German Ministry of Education and Research (BMBF 01GY1326); R. Christensen, grants from the Oak Foundation to the Musculoskeletal Statistics Unit at the Parker Institute; J.A. Singh, grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, US National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI); C.O. Bingham, in part by grants and awards NIAMS P30-AR053503, a Patient-Centered Outcomes Research Institute (PCORI) Pilot Project Program Award (1IP2-PI000737-01), and a PCORI Methodology Award (SC14-1402-10818); J.A. Singh, research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron and Allergan; member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee, and Veterans Affairs Rheumatology Field Advisory Committee; D.E. Beaton, C.O. Bingham, P. Conaghan, L.S. Simon, J.A. Singh, V. Strand, P. Tugwell, and G.A. Wells are members of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 pharmaceutical and clinical research companies, but they do not receive financial remuneration for their activities; P. Juni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly, and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, and The Medicines Company; PT has received honoraria for quality of life consultancy with BMS, chairs data safety monitoring boards for Chelsea and UCB, has mandated for the FDA, co-chairs an industry board of 6 companies (Abbott, BMS, Merck, Roche, Schering Plough, UCB) for a biologics registry of the Ontario Rheumatology Association [Ontario Biologics Research Initiative (arms-length registry that independently collects information)], received a grant from the Canadian Institutes of Health Research (CIHR) matched by funding from these pharmaceutical companies); and receives an honorarium from the CIHR grant. Statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of NIAMS, the National Institutes of Health, or the Patient-Centered Outcomes Research Institute, its Board of Governors, or Methodology Committee. NR 25 TC 0 Z9 0 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1934 EP 1942 DI 10.3899/jrheum.141423 PG 9 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900033 PM 26373562 ER PT J AU Beaton, DE Terwee, CB Singh, JA Hawker, GA Patrick, DL Burke, LB Toupin-April, K Tugwell, PS AF Beaton, Dorcas E. Terwee, Caroline B. Singh, Jasvinder A. Hawker, Gillian A. Patrick, Donald L. Burke, Laurie B. Toupin-April, Karine Tugwell, Peter S. TI A Call for Evidence-based Decision Making When Selecting Outcome Measurement Instruments for Summary of Findings Tables in Systematic Reviews: Results from an OMERACT Working Group SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE EVIDENCE BASED; OUTCOME MEASUREMENT; REPRODUCIBILITY OF RESULTS; HEALTH STATUS INDICATORS; SYSTEMATIC REVIEWS ID PATIENT-CENTERED OUTCOMES; METHODOLOGICAL QUALITY; CLINICAL-TRIALS; INTERNATIONAL DELPHI; COSMIN CHECKLIST; FILTER 2.0; OSTEOARTHRITIS; KNEE; PAIN; RESPONSIVENESS AB Objective. Systematic reviews often struggle with how to combine information when more than 1 instrument is used across studies being synthesized. Different techniques have been suggested based on frequency of use in the literature, or on consensus. We explore an approach blending 2 initiatives: OMERACT (Outcome Measurement in Rheumatology) and COSMIN (Consensus On Selection of Measurement Instruments), and investigate the effects of an evidence-based measurement approach on selection of outcomes. Methods. Readings were circulated to attendees registered for a preconference workshop on pain measurement. Three instruments were considered and exercises conducted to engage people in the content and measurement performance of these tools. Consensus was sought that an evidence-based approach could be created for selection of instruments for summary of findings (SoF) tables. Results. The blending of COSMIN and OMERACT approaches led to an evidence-based approach that depended both on a clear definition of target concept and a review of measurement performance of the instrument. Participants emphasized that conceptual clarity and practical considerations should come before measurement property results. Conclusion. Evidence-based approaches can be adopted for selection of instruments for SoF tables. A research agenda was formulated. C1 St Michaels Hosp, Li Ka Shing Knowledge Inst, Musculoskeletal Hlth & Outcomes Res, Toronto, ON M5B 1W8, Canada. [Beaton, Dorcas E.] Inst Work & Hlth, Toronto, ON, Canada. [Beaton, Dorcas E.; Hawker, Gillian A.] Univ Toronto, Toronto, ON, Canada. [Terwee, Caroline B.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands. [Terwee, Caroline B.] EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Hawker, Gillian A.] Womens Coll Hosp, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Patrick, Donald L.] Univ Washington, Seattle Qual Life Grp, Ctr Disabil Policy & Res, Seattle, WA 98195 USA. US FDA, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Toupin-April, Karine] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada. Ottawa Hosp, Res Inst, Fac Med, Dept Med, Ottawa, ON, Canada. Univ Ottawa, Clin Epidemiol Program, Ottawa, ON, Canada. Univ Ottawa, Fac Med, Inst Populat Hlth, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Beaton, DE (reprint author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM beatond@smh.ca OI Tugwell, Peter/0000-0001-5062-0556 FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; US National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; Patient Centered Outcomes Research Institute [CE-1304-6631]; Takeda; Savient; Regeneron; Allergan FX Supported through the OMERACT premeeting conference on pain measurement. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, US National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging U01 AG018947, National Cancer Institute U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, and Allergan. JAS is a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS, DEB, and PT are members of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. NR 45 TC 1 Z9 1 U1 2 U2 5 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1954 EP 1961 DI 10.3899/jrheum.141446 PG 8 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900036 PM 26373567 ER PT J AU Busse, JW Bartlett, SJ Dougados, M Johnston, BC Guyatt, GH Kirwan, JR Kwoh, K Maxwell, LJ Moore, A Singh, JA Stevens, R Strand, V Suarez-Almazor, ME Tugwell, P Wells, GA AF Busse, Jason W. Bartlett, Susan J. Dougados, Maxime Johnston, Bradley C. Guyatt, Gordon H. Kirwan, John R. Kwoh, Kent Maxwell, Lara J. Moore, Andrew Singh, Jasvinder A. Stevens, Randall Strand, Vibeke Suarez-Almazor, Maria E. Tugwell, Peter Wells, George A. TI Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE OMERACT; OUTCOMES; PAIN; CLINICAL TRIALS; VISUAL ANALOG SCALE; SYSTEMATIC REVIEWS ID CHRONIC NEUROPATHIC PAIN; MOTOR CORTEX RTMS; QUALITY-OF-LIFE; IMMPACT RECOMMENDATIONS; OUTCOME MEASURES; RANDOMIZED-TRIAL; EFFECT SIZE; METAANALYSIS; DIFFERENCE; RELIEF AB Objective. Pain is a patient-important outcome, but current reporting in randomized controlled trials and systematic reviews is often suboptimal, impeding clinical interpretation and decision making. Methods. A working group at the 2014 Outcome Measures in Rheumatology (OMERACT 12) was convened to provide guidance for reporting treatment effects regarding pain for individual studies and systematic reviews. Results. For individual trials, authors should report, in addition to mean change, the proportion of patients achieving 1 or more thresholds of improvement from baseline pain (e.g., >=. 20%, >= 30%, >= 50%), achievement of a desirable pain state (e.g., no worse than mild pain), and/or a combination of change and state. Effects on pain should be accompanied by other patient-important outcomes to facilitate interpretation. When pooling data for metaanalysis, authors should consider converting all continuous measures for pain to a 100 mm visual analog scale (VAS) for pain and use the established, minimally important difference (MID) of 10 mm, and the conventionally used, appreciably important differences of 20 mm, 30 mm, and 50 mm, to facilitate interpretation. Effects <= 0.5 units suggest a small or very small effect. To further increase interpretability, the pooled estimate on the VAS should also be transformed to a binary outcome and expressed as a relative risk and risk difference. This transformation can be achieved by calculating the probability of experiencing a treatment effect greater than the MID and the thresholds for appreciably important differences in pain reduction in the control and intervention groups. Conclusion. Presentation of relative effects regarding pain will facilitate interpretation of treatment effects. C1 [Busse, Jason W.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada. [Busse, Jason W.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada. [Busse, Jason W.; Johnston, Bradley C.; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Bartlett, Susan J.] McMaster Univ, Dept Med, Hamilton, ON, Canada. [Bartlett, Susan J.] Royal Victoria Hosp, Div Rheumatol, Montreal, PQ H3A 1A1, Canada. [Bartlett, Susan J.] Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada. [Dougados, Maxime] Paris Descartes Univ, Cochin Hosp, APHP,PRES Sorbonne Paris Cite, Rheumatol Dept,INSERM,U1153,Clin Epidemiol & Bios, Paris, France. [Johnston, Bradley C.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada. [Johnston, Bradley C.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Johnston, Bradley C.] Univ Toronto, Hosp Sick Children, Dept Anesthesia & Pain Med, Toronto, ON M5G 1X8, Canada. [Kirwan, John R.] Univ Bristol, Acad Rheumatol Unit, Bristol Royal Infirm, Bristol, Avon, England. [Kwoh, Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, Kent] Vet Affairs VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Maxwell, Lara J.] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. [Moore, Andrew] Univ Oxford, Nuffield Div Anaesthet, Pain Res, Oxford, England. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Stevens, Randall] Celgene Corp, Inflammat & Immunol Clin Res, Summit, NJ USA. [Stevens, Randall] Rutgers State Univ, Dept Med, Div Rheumatol, New Brunswick, NJ 08903 USA. [Strand, Vibeke] Stanford Univ, Div Immunol Rheumatol, Palo Alto, CA 94304 USA. [Suarez-Almazor, Maria E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Tugwell, Peter] Univ Ottawa, Fac Med, Dept Med, Inst Populat Hlth, Ottawa, ON, Canada. [Tugwell, Peter] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Tugwell, Peter; Wells, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Busse, JW (reprint author), McMaster Univ, Michael G DeGroote Sch Med, Dept Anesthesia, Hamilton, ON, Canada. EM bussejw@mcmaster.ca RI DOUGADOS, MAXIME/P-5287-2016 OI Busse, Jason/0000-0002-0178-8712; Bartlett, Susan/0000-0001-9755-2490; Tugwell, Peter/0000-0001-5062-0556 FU US Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; Patient-Centered Outcomes Research Institute [CE-1304-6631]; NIAMS [K24AR053593] FX JAS is supported by grants from the US Agency for Health Quality and Research Center for Education and Research on Therapeutics U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging U01 AG018947, National Cancer Institute U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA, and research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute. MSA is the recipient of a K24 award from NIAMS (K24AR053593) NR 49 TC 9 Z9 9 U1 1 U2 2 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1962 EP 1970 DI 10.3899/jrheum.141440 PG 9 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900037 PM 25979719 ER PT J AU Christensen, R Maxwell, LJ Juni, P Tovey, D Williamson, PR Boers, M Goel, N Buchbinder, R March, L Terwee, CB Singh, JA Tugwell, P AF Christensen, Robin Maxwell, Lara J. Jueni, Peter Tovey, David Williamson, Paula R. Boers, Maarten Goel, Niti Buchbinder, Rachelle March, Lyn Terwee, Caroline B. Singh, Jasvinder A. Tugwell, Peter TI Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE OMERACT; METAANALYSIS; OSTEOARTHRITIS; PAIN; PATIENT OUTCOME ASSESSMENT; COCHRANE COLLABORATION ID CLINICAL-TRIALS; SYSTEMATIC REVIEWS; RECOMMENDATIONS; HIP; GUIDELINES; MANAGEMENT; PROTOCOLS; COSMIN AB Objective. Although protocol registration for systematic reviews is still not mandatory, reviewers should be strongly encouraged to register the protocol to identify the methodological approach, including all outcomes of interest. This will minimize the likelihood of biased decisions in reviews, such as selective outcome reporting. A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. Methods. Multiple outcome measurement instruments exist to measure the same outcome. Metaanalysis of knee osteoarthritis (OA) trials, and the assessment of pain as an outcome, was used as an exemplar to assess how Outcome Measures in Rheumatology (OMERACT), the Cochrane Collaboration, and other international initiatives might contribute in this area. The meeting began with formal presentations of background topics, empirical evidence from the literature, and a brief introduction to 2 existing hierarchical lists of pain outcome measurement instruments recommended for metaanalyses of knee OA trials. Results. After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses. Tools that could be used to steer development of such a prioritized list are the COSMIN checklist (COnsensus-based Standards for the selection of health status Measurement Instruments) and the OMERACT Filter 2.0. Conclusion. We list meta-epidemiological research agenda items that address the frequency of reported outcomes in trials, as well as methodologies to assess the best measurement properties (i.e., truth, discrimination, and feasibility). C1 Copenhagen Univ Hosp, Musculoskeletal Stat Unit, Parker Inst, Dept Rheumatol, Bispebjerg, Denmark. Copenhagen Univ Hosp, Musculoskeletal Stat Unit, Parker Inst, Dept Rheumatol, Frederiksberg, Denmark. Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. Univ Ottawa, Dept Med, Ottawa, ON, Canada. Univ Bern, Inst Social & Prevent Med, Dept Clin Res, Bern, Switzerland. Univ Bern, Clin Trials Unit Bern, Dept Clin Res, Bern, Switzerland. Cochrane Collaborat, London, England. Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England. Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands. Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands. Quintiles Inc, Durham, NC USA. Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA. Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia. Cabrini Hlth, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia. Univ Sydney, Northern Clin Sch, Inst Bone & Joint Res, Dept Rheumatol, Sydney, NSW 2006, Australia. Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Epidemiol & Biostat, Amsterdam, Netherlands. Vrije Univ Amsterdam, Med Ctr Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. Birmingham Vet Affairs VA Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. RP Christensen, R (reprint author), Copenhagen Univ Hosp Frederiksberg, Musculoskeletal Stat Unit, Parker Inst, Nordre Fasanvej 57, DK-2000 Copenhagen F, Denmark. EM robin.christensen@regionh.dk OI Tugwell, Peter/0000-0001-5062-0556 FU Oak Foundation; Australian National Health and Research Council Practitioner Fellowship; Medical Research Council; European Commission; US Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19 HS021110,]; US National Institute of Arthritis and Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; US National Institute on Aging [U01 AG018947]; US National Cancer Institute [U10 CA149950]; Patient-Centered Outcomes Research Institute [CE-1304-6631] FX RC is supported by unrestricted grants from The Oak Foundation; RB is supported in part by an Australian National Health and Research Council Practitioner Fellowship; PRW is supported by grants for the COMET Initiative from the Medical Research Council and the European Commission; JAS is supported by grants from the US Agency for Health Quality and Research Center for Education and Research on Therapeutics U19 HS021110, US National Institute of Arthritis and Musculoskeletal and Skin Diseases P50 AR060772 and U34 AR062891, US National Institute on Aging U01 AG018947, US National Cancer Institute U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA, and research contract CE-1304-6631 from theA Patient-Centered Outcomes Research Institute. NR 34 TC 1 Z9 1 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1971 EP 1975 DI 10.3899/jrheum.141384 PG 5 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900038 PM 25934823 ER PT J AU Sloan, VS Grosskleg, S Pohl, C Wells, GA Singh, JA AF Sloan, Victor S. Grosskleg, Shawna Pohl, Christoph Wells, George A. Singh, Jasvinder A. TI The OMERACT First-time Participant ("Newbie") Program: Initial Assessment and Lessons Learned SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE OMERACT; FILTER; OUTCOME MEASURES; TRAINING SESSION; PARTICIPANT EXPERIENCE ID OUTCOME MEASUREMENT SETS; NOMINAL GROUP TECHNIQUE; CLINICAL-TRIALS; FILTER 2.0; RHEUMATOLOGY AB Objective. To describe the experience of a first-time participant ("newbie") training program at the Outcome Measures in Rheumatology 12 meeting in 2014. Methods. We conducted newbie sessions at OMERACT 12, including a 2-hour introductory session on Day 1, followed by 1-h evening followup sessions on days 1-4 of OMERACT 12. Pre- and postmeeting surveys assessed participants' level of comfort with the principles of the OMERACT Filters 1.0 (truth, discrimination, feasibility), and Filter 2.0 (the essential tools for OMERACT methodology), the different types of OMERACT sessions, and whether participants felt welcome. Results. In all, 25 new attendees participated in the introductory session and 10-16 attended followup sessions. Fewer participants reported being somewhat or extremely uncomfortable with the meeting, comparing Day 1 (preintroductory session) to days 1-4 (post): (1) with different OMERACT sessions: 56% (pre) versus 6%, 0%, 8%, and 6% (post days 1-4, respectively); and (2) with principles of the OMERACT filter, 64% (pre) versus 7%, 0%, 8%, and 0% (post), respectively. Most reported feeling welcome (100%) and that they were able to contribute substantively to breakout sessions (87%) on Day 1 evening; results were sustained on days 2-4. Conclusion. First-time participant training sessions increased the comfort level of the participants with the OMERACT meeting structure and filter, and increased the ability of the new attendees to feel they could contribute to the OMERACT process. C1 [Sloan, Victor S.] Rutgers Robert Wood Johnson Med Sch, Med, New Brunswick, NJ USA. [Sloan, Victor S.] UCB Biosci Inc, Raleigh, NC USA. [Grosskleg, Shawna] Univ Ottawa, OMERACT, Ottawa, ON, Canada. [Pohl, Christoph] Charite, Dept Internal Med Rheumatol Clin Immunol Osteol P, Schlosspark Klin, Teaching Hosp, D-13353 Berlin, Germany. [Wells, George A.] Ottawa Heart Inst, Biostat, Ottawa, ON, Canada. [Wells, George A.] Univ Ottawa, Ottawa, ON, Canada. [Singh, Jasvinder A.] Univ Alabama Birmingham, Med & Epidemiol, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com NR 8 TC 0 Z9 0 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2015 VL 42 IS 10 BP 1976 EP 1981 DI 10.3899/jrheum.141200 PG 6 WC Rheumatology SC Rheumatology GA CS7AC UT WOS:000362234900039 PM 26034159 ER PT J AU Solomon, AJ Klein, EP Corboy, JR Bernat, JL AF Solomon, Andrew J. Klein, Eran P. Corboy, John R. Bernat, James L. TI Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Multiple sclerosis; clinical trials; conflict of interest; professional conduct and ethics; industry-sponsored clinical trials ID POTENTIAL RESEARCH PARTICIPANTS; FINANCIAL INTERESTS; VIEWS; DISCLOSURE; GUIDELINES; ATTITUDES AB Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials. C1 [Solomon, Andrew J.] Univ Vermont, Coll Med, Burlington, VT 05401 USA. [Klein, Eran P.] Oregon Hlth & Sci Univ, Portland, OR USA. [Klein, Eran P.] Portland VA Med Ctr, Portland, VA USA. [Klein, Eran P.] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA. [Corboy, John R.] Univ Colorado, Sch Med, Boulder, CO 80309 USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bernat, James L.] Dartmouth Hitchcock Med Ctr, Dept Neurol, Lebanon, NH USA. RP Solomon, AJ (reprint author), Univ Vermont, Coll Med, 1 South Prospect St,Arnold 2, Burlington, VT 05401 USA. EM andrew.solomon@uvm.edu FU National Multiple Sclerosis Society; Biogen Idec; Novartis; Sun Pharma; Celgene Therapeutics; National Institutes of Health; Juvenile Diabetes Research Foundation; Diogenix; Birth of Bioethics FX Andrew J Solomon received a research grant from the National Multiple Sclerosis Society and was a primary investigator in a multicenter clinical trial for a medication sponsored by Biogen Idec.; John R Corboy reports that within the last year he was a primary investigator in a multicenter clinical trial for a medication sponsored by Novartis, Sun Pharma, Celgene Therapeutics, the National Multiple Sclerosis Society, and the National Institutes of Health. He has received research grants from the Juvenile Diabetes Research Foundation, the National Multiple Sclerosis Society, and Diogenix. He has served as a consultant for Novartis, Celgene Therapeutics, Teva Neurosciences, and Biogen Idec. He has received honoraria for speaking engagements from Pro CE, Rocky Mountain MS Center, via Genzyme, and for Grand Rounds at multiple academic institutions. He has been compensated for medical-legal work, as an Editor for Neurology: Clinical Practice, and is an uncompensated board member, NMSS Colorado-Wyoming Chapter.; Eran P Klein has received honoraria for speaking at academic conferences and receives royalty payments for The Birth of Bioethics (Georgetown University Press, 2003). NR 26 TC 1 Z9 1 U1 2 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD OCT PY 2015 VL 21 IS 12 BP 1593 EP 1599 DI 10.1177/1352458515569101 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CT1AK UT WOS:000362529200013 PM 25716879 ER PT J AU Jovanovich, A Chonchol, M AF Jovanovich, Anna Chonchol, Michel TI Reductions in FGF-23 levels associated with improved outcomes SO NATURE REVIEWS NEPHROLOGY LA English DT News Item ID DISEASE AB Elevated levels of fibrobast growth factor 23 (FGF-23) are associated with cardiovascular and all-cause mortality in patients with kidney disease. A secondary analysis of the EVOLVE trial reports that cinacalcet-induced reductions in FGF-23 were associated with a reduced risk of cardiovascular events in patients with secondary hyperparathyroidism on dialysis. C1 [Jovanovich, Anna] Denver VA Med Ctr, Med Serv, Renal Sect, Denver, CO 80220 USA. [Chonchol, Michel] Univ Colorado Denver, Anschutz Med Ctr, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. RP Chonchol, M (reprint author), Univ Colorado Denver, Anschutz Med Ctr, Div Renal Dis & Hypertens, 13199 East Montview Blvd,Suite 495, Aurora, CO 80045 USA. EM michel.chonchol@ucdenver.edu NR 10 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 EI 1759-507X J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD OCT PY 2015 VL 11 IS 10 BP 572 EP 573 DI 10.1038/nrneph.2015.125 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA CT3GN UT WOS:000362695300003 PM 26215510 ER PT J AU Zhao, W Wang, J Bi, WN Ferruzzi, M Yemul, S Freire, D Mazzola, P Ho, L Dubner, L Pasinetti, GM AF Zhao, Wei Wang, Jun Bi, Weina Ferruzzi, Mario Yemul, Shrishailam Freire, Daniel Mazzola, Paolo Ho, Lap Dubner, Lauren Pasinetti, Giulio Maria TI Novel application of brain-targeting polyphenol compounds in sleep deprivation-induced cognitive dysfunction SO NEUROCHEMISTRY INTERNATIONAL LA English DT Article DE Sleep deprivation; Polyphenols; Cognitive dysfunction; Resilience; Memory consolidation ID GREEN TEA CATECHINS; ALZHEIMERS-DISEASE; MOUSE MODEL; SYNAPTIC PLASTICITY; S6 KINASE; MEMORY; METABOLISM; HIPPOCAMPUS; DISORDERS; PATHWAY AB Sleep deprivation produces deficits in hippocampal synaptic plasticity and hippocampal-dependent memory storage. Recent evidence suggests that sleep deprivation disrupts memory consolidation through multiple mechanisms, including the down-regulation of the cAMP-response element-binding protein (CREB) and of mammalian target of rapamycin (mTOR) signaling. In this study, we tested the effects of a Bioactive Dietary Polyphenol Preparation (BDPP), comprised of grape seed polyphenol extract, Concord grape juice, and resveratrol, on the attenuation of sleep deprivation-induced cognitive impairment. We found that BDPP significantly improves sleep deprivation-induced contextual memory deficits, possibly through the activation of CREB and mTOR signaling pathways. We also identified brain-available polyphenol metabolites from BDPP, among which quercetin-3-O-glucuronide activates CREB signaling and malvidin-3-O-glucoside activates mTOR signaling. In combination, quercetin and malvidin-glucoside significantly attenuated sleep deprivation-induced cognitive impairment in -a mouse model of acute sleep deprivation. Our data suggests the feasibility of using select brain-targeting polyphenol compounds derived from BDPP as potential therapeutic agents in promoting resilience against sleep deprivation-induced cognitive dysfunction. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Zhao, Wei; Wang, Jun; Bi, Weina; Yemul, Shrishailam; Freire, Daniel; Mazzola, Paolo; Ho, Lap; Dubner, Lauren; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Geriatr, New York, NY 10029 USA. [Zhao, Wei; Wang, Jun; Bi, Weina; Ho, Lap; Pasinetti, Giulio Maria] James J Peter VA Med Ctr, Geriatr Res Educ Clin Ctr, Bronx, NY USA. [Ferruzzi, Mario] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Mazzola, Paolo] Univ Milano Bicocca, Dept Hlth Sci, Monza, Italy. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Mazzola, Paolo/0000-0002-0484-1136 FU Icahn School of Medicine at Mount Sinai; National Center for Complementary and Integrative Health (NCCIH) [P50 AT008661-01]; Office of Dietary Supplements (ODS) FX This study was supported by discretionary funding from the Icahn School of Medicine at Mount Sinai to Dr. Giulio Pasinetti. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. This publication was supported by Grant Number P50 AT008661-01, titled "Dietary Botanicals in the Preservation of Cognitive and Psychological Resilience," from the National Center for Complementary and Integrative Health (NCCIH) and the Office of Dietary Supplements (ODS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCIH, ODS, or the National Institutes of Health. NR 47 TC 2 Z9 2 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0197-0186 EI 1872-9754 J9 NEUROCHEM INT JI Neurochem. Int. PD OCT PY 2015 VL 89 BP 191 EP 197 DI 10.1016/j.neuint.2015.07.023 PG 7 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CT2CO UT WOS:000362609800020 PM 26235983 ER PT J AU Kasckow, J Gao, SS Hanusa, B Rotondi, A Chinman, M Zickmund, S Gurklis, J Fox, L Cornelius, J Richmond, I Haas, GL AF Kasckow, John Gao, Shasha Hanusa, Barbara Rotondi, Armando Chinman, Matthew Zickmund, Susan Gurklis, John Fox, Lauren Cornelius, Jack Richmond, Ira Haas, Gretchen L. TI Telehealth Monitoring of Patients with Schizophrenia and Suicidal Ideation SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID DEPRESSION RATING-SCALE; VETERANS; RISK; SYMPTOMS; MORTALITY; DISORDER; OUTCOMES; MINI AB A telehealth system was developed to monitor risk following hospitalization for suicidal ideation. We hypothesized that 3months of telehealth monitoring will result in a greater reduction in suicidal ideation. Veterans with schizophrenia admitted with recent suicidal ideation and/or a suicidal attempt were recruited into a discharge program of VA Usual Care with daily Health Buddy (c) monitoring (HB) or Usual Care (UC) alone. Fifteen of 25 were randomized to HB and 10 received UC. Daily adherence in the use of the HB system during months 1-3 was, respectively, 86.9%, 86.3%, and 84.1%. There were significant improvements in Beck Scale for Suicide Ideation scores in HB participants. There were no changes in depressive symptoms. Telehealth monitoring for this population of patients appears to be feasible. C1 [Kasckow, John] VA Pittsburgh MIRECC, CHERP & Behav Hlth, Pittsburgh, PA USA. [Kasckow, John; Cornelius, Jack; Haas, Gretchen L.] UPMC Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Gao, Shasha; Zickmund, Susan] VA Pittsburgh CHERP, Pittsburgh, PA USA. [Hanusa, Barbara; Rotondi, Armando; Chinman, Matthew; Fox, Lauren; Cornelius, Jack] VA Pittsburgh MIRECC, Pittsburgh, PA USA. [Rotondi, Armando] UPMC Crit Care, Pittsburgh, PA USA. [Chinman, Matthew] CHERP, Pittsburgh, PA USA. [Zickmund, Susan] UPMC Dept Med, Pittsburgh, PA USA. [Gurklis, John] VA Pittsburgh Behav Hlth, Pittsburgh, PA USA. [Richmond, Ira] VA Pittsburgh Patient Care Serv, Pittsburgh, PA USA. [Haas, Gretchen L.] VA Pittsburgh MIRECC & Behav Hlth, Pittsburgh, PA USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, Behav Hlth 116A, Univ Dr C, Pittsburgh, PA 15240 USA. EM kasckowjw@upmc.edu FU VISN 4 MIRECC; HSRD PPO [10-249-2] FX Funded by the VISN 4 MIRECC and HSRD PPO 10-249-2 (JWK). The views do not represent the views of the U.S. Department of veterans Affairs or that of the U.S. government. NR 33 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD OCT PY 2015 VL 45 IS 5 BP 600 EP 611 DI 10.1111/sltb.12154 PG 12 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CT3FR UT WOS:000362693100007 ER PT J AU Venne, VL Scheuner, MT AF Venne, Vickie L. Scheuner, Maren T. TI Securing and Documenting Cancer Family History in the Age of the Electronic Medical Record SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Family health history; Pedigree; Genetic risk assessment; Electronic medical records ID GENETIC RISK-ASSESSMENT; PRIMARY-CARE; BREAST-CANCER; DECISION-SUPPORT; HEREDITARY BREAST; OVARIAN-CANCER; TOOL; TELEPHONE; IMPACT; WOMEN AB Family health history is one of the least expensive, most useful, and most underused methods available to conduct assessments of the genetic aspect of a condition or to target the need for a genetic evaluation. This article introduces to the surgical oncologist the reason and process of collecting family history information. As medical records shift from paper to electronic formats, pedigree drawings are not readily available within the electronic health records. International efforts are underway to develop searchable, updatable, and interoperable formats that can collect family history information to inform clinical decision support for genetic risk assessment. C1 [Venne, Vickie L.] SLC VA Med Ctr, Genom Med Serv, Salt Lake City, UT 84148 USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Med Genet, Los Angeles, CA 90073 USA. RP Venne, VL (reprint author), SLC VA Med Ctr, Genom Med Serv, 500 Foothill Dr, Salt Lake City, UT 84148 USA. EM vickie.venne@va.gov NR 44 TC 2 Z9 2 U1 3 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1055-3207 EI 1558-5042 J9 SURG ONCOL CLIN N AM JI Surg. Oncol. Clin. N. Am. PD OCT PY 2015 VL 24 IS 4 BP 639 EP + DI 10.1016/j.soc.2015.06.001 PG 15 WC Oncology; Surgery SC Oncology; Surgery GA CT3GA UT WOS:000362694000004 PM 26363534 ER PT J AU Al-Alusi, MA Du, L Li, N Yeh, MW He, XM Braverman, LE Leung, AM AF Al-Alusi, Mostafa A. Du, Lin Li, Ning Yeh, Michael W. He, Xuemei Braverman, Lewis E. Leung, Angela M. TI Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption SO THYROID LA English DT Article ID DIABETIC-PATIENTS; RESPIRATORY-CHAIN; HYPOTHYROIDISM; WOMEN; TSH; EXPRESSION; THERAPY; KINASE; OBESE; CREB AB Background: Levothyroxine (LT4) absorption is affected by concomitant ingestion of certain minerals, medications, and foods. It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis. This study examined the effect of metformin ingestion on LT4 absorption, as assessed by serum total thyroxine (TT4) concentrations. Methods: A modified Food and Drug Administration LT4 bioequivalence protocol was applied to healthy, metformin-naive, euthyroid adult volunteers. Following an overnight fast, 600g LT4 was administered orally. Serum TT4 concentrations were measured at baseline and at 0.5, 1, 1.5, 2, 4, and 6h following LT4 administration. Measurements were performed before and after one week of metformin ingestion (850mg three times daily). Peak serum TT4 concentrations, time to peak TT4 concentrations, and area under the concentration-time curve (AUC) were calculated. Results: Twenty-six subjects (54% men, 27% white, age 3310 years) were studied. There were no significant differences in peak serum TT4 concentrations (p=0.13) and time to peak TT4 concentrations (p=0.19) before and after one week of metformin use. A trend toward reduced TT4 AUC was observed after metformin ingestion (pre-metformin 3893 +/- 568g/dL-min, post-metformin 3765 +/- 588g/dL-min, p=0.09). Conclusions: LT4 absorption is unchanged by concomitant metformin ingestion. Mechanisms other than increased LT4 absorption may be responsible for the suppressed TSH concentrations observed in patients ingesting both drugs. C1 [Al-Alusi, Mostafa A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Du, Lin] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90073 USA. [Li, Ning] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90073 USA. [Yeh, Michael W.] Univ Calif Los Angeles, David Geffen Sch Med, Sect Endocrine Surg, Los Angeles, CA 90073 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90073 USA. [He, Xuemei; Braverman, Lewis E.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. [Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. RP Leung, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu FU NIH [K23HD068552]; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI [UL1TR000124] FX This work was funded by NIH K23HD068552 (A.M.L.) and NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI UL1TR000124. This work was presented as an abstract at the 2015 Annual Meeting of the Endocrine Society under the title "The Effect of Metformin on Levothyroxine Absorption." NR 30 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD OCT 1 PY 2015 VL 25 IS 10 BP 1080 EP 1084 DI 10.1089/thy.2015.0211 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CS7LY UT WOS:000362266300002 PM 26191653 ER PT J AU Lee, RA Ray, M Kasuga, DT Kumar, V Witherspoon, CD Baddley, JW AF Lee, R. A. Ray, M. Kasuga, D. T. Kumar, V. Witherspoon, C. D. Baddley, J. W. TI Ocular bartonellosis in transplant recipients: two case reports and review of the literature SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Bartonella henselae; cat scratch disease; transplant; bartonellosis; chorioretinitis ID CAT-SCRATCH DISEASE; SOLID-ORGAN; COMPLICATIONS AB Cat scratch disease is caused by Bartonella henselae and usually manifests as localized lymphadenopathy and fever in immunocompetent patients. Immunocompromised patients are at risk for developing disseminated disease affecting the liver, spleen, eyes, central nervous system, and other organs. Bartonellosis is infrequently reported in solid organ transplant recipients, and published case reports usually discuss disseminated infection. Localized ocular disease with B.henselae, while well documented in immunocompetent hosts, is uncommon in immunocompromised patients. Herein, we present 2 cases of ocular bartonellosis in renal transplant patients, 1 with disseminated infection, and 1 without. C1 [Lee, R. A.; Ray, M.; Baddley, J. W.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. [Kasuga, D. T.; Witherspoon, C. D.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA. [Kumar, V.] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [Baddley, J. W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Lee, RA (reprint author), Univ Alabama Birmingham, Infect Dis, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA. EM ralee@uabmc.edu OI Witherspoon, Clark/0000-0003-4456-9437 NR 15 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD OCT PY 2015 VL 17 IS 5 BP 723 EP 727 DI 10.1111/tid.12418 PG 5 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CT1YB UT WOS:000362597900014 PM 26146758 ER PT J AU Grazioli, S Matute-Bello, G AF Grazioli, Serge Matute-Bello, Gustavo TI Ccn1, a molecular switch that imposes a self-limiting control on inflammation and wound healing in a multitude of organs? Reply SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Letter ID MYOFIBROBLASTS C1 [Grazioli, Serge] Univ Hosp Geneva, Pediat Crit Care Unit, Geneva, Switzerland. [Grazioli, Serge; Matute-Bello, Gustavo] Univ Washington, Div Pulm & Crit Med, Dept Med, Ctr Lung Biol, Seattle, WA 98109 USA. [Matute-Bello, Gustavo] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Matute-Bello, G (reprint author), Univ Washington, 850 Republican St, Seattle, WA 98109 USA. EM matuteb@u.washington.edu RI Grazioli, Serge/A-1457-2016 NR 5 TC 0 Z9 0 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD OCT 1 PY 2015 VL 309 IS 7 BP L749 EP L749 DI 10.1152/ajplung.00265.2015 PG 1 WC Physiology; Respiratory System SC Physiology; Respiratory System GA CS7BN UT WOS:000362238600012 PM 26429904 ER PT J AU Shriki, JE Seyal, AR Dighe, MK Yeh, MM Jalikis, FG Andeen, NK Lall, C Bhargava, P AF Shriki, Jabi E. Seyal, Adeel R. Dighe, Manjiri K. Yeh, Matthew M. Jalikis, Florencia G. Andeen, Nicole K. Lall, Chandana Bhargava, Puneet TI CT of Atypical and Uncommon Presentations of Hepatocellular Carcinoma SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE CT; hepatocellular carcinoma; imaging ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; MR-IMAGING DIAGNOSIS; OF-THE-LITERATURE; HEPATITIS-C; LIVER-TRANSPLANTATION; UNITED-STATES; US POPULATION; RISK-FACTORS; CIRRHOSIS; DISEASE AB OBJECTIVE. The purpose of this article is to familiarize radiologists with uncommon presentations of hepatocellular carcinoma (HCC) with an emphasis on the CT spectrum of atypical appearances. CONCLUSION. HCC is the fifth most common neoplasm worldwide and the second most common cause of cancer-related death. In many cases, HCC can be confidently diagnosed with noninvasive imaging. However, there are numerous unusual appearances of HCC with which the radiologist must be familiar. C1 [Shriki, Jabi E.; Dighe, Manjiri K.; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Shriki, Jabi E.; Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Seyal, Adeel R.] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Yeh, Matthew M.; Jalikis, Florencia G.; Andeen, Nicole K.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Lall, Chandana] Univ Calif Irvine, Dept Radiol, Orange, CA 92668 USA. RP Bhargava, P (reprint author), Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. EM bhargp@uw.edu NR 82 TC 0 Z9 0 U1 0 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD OCT PY 2015 VL 205 IS 4 BP W411 EP W423 DI 10.2214/AJR.14.14000 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CS1SF UT WOS:000361847300004 PM 26397348 ER PT J AU Rivera, CM Copeland, LA McNeal, CJ Mortensen, EM Pugh, MJ MacCarthy, DJ AF Rivera, Cathleen M. Copeland, Laurel A. McNeal, Catherine J. Mortensen, Eric M. Pugh, Mary J. MacCarthy, Daniel J. TI Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Aspirin; Epidemiology; Preventive Medicine; Primary Care; Veterans ID SECONDARY PREVENTION; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; STATIN THERAPY; NUTRITION EXAMINATION; ATHEROSCLEROSIS RISK; MEDICATION ADHERENCE; NATIONAL-HEALTH; METAANALYSIS; CORONARY AB Evidence-based guidelines for the use of aspirin in secondary prevention of cardiovascular disease events are well established. Despite this, the prevalence of aspirin use for secondary prevention is suboptimal. The study aimed to determine the prevalence of aspirin use for secondary prevention of cardiovascular disease events when it is dispensed as a prescription, as is performed in the Veterans Affairs (VA) managed care system. VA patients who had undergone major surgery and experienced a postoperative myocardial infarction (MI) or unstable angina between the years 2005 and 2009 were identified from administrative databases. VA pharmacy records were used to determine whether a prescription for aspirin was filled after the postoperative MI or unstable angina. Multivariable logistic regression models estimated odd ratios of filling aspirin prescriptions for the predictors of interest. Of the 321,131 men and women veterans who underwent major surgery, 7,700 experienced a postoperative MI or unstable angina. Among those 7,700, 47% filled an aspirin prescription. Only 59% of veterans with no co-pay filled an aspirin prescription. Aspirin fills were more common in younger veterans, Blacks, Hispanics, males, hypertensive veterans, mentally ill patients, those with no co-pay and those prescribed antiplatelets/anticoagulants in addition to aspirin postoperatively. These findings suggest that the impact of dispensing aspirin as a prescription may not be significant in increasing the appropriate use of aspirin for secondary prevention. C1 [Rivera, Cathleen M.; Copeland, Laurel A.; McNeal, Catherine J.] Baylor Scott & White Hlth, Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Dept Med, Temple, TX 76502 USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr, Dept Clin Sci, Dallas, TX 75390 USA. [Pugh, Mary J.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [MacCarthy, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX USA. RP Copeland, LA (reprint author), Baylor Scott & White Hlth, Cent Texas Vet Hlth Care Syst, Temple, TX 76502 USA. EM laurelacopeland@gmail.com OI Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 NR 34 TC 0 Z9 0 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD OCT PY 2015 VL 350 IS 4 BP 263 EP 267 DI 10.1097/MAJ.0000000000000560 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CS6UM UT WOS:000362218400005 PM 26351774 ER PT J AU Makris, UE Pugh, MJ Alvarez, CA Berlowitz, DR Turner, BJ Aung, K Mortensen, EM AF Makris, Una E. Pugh, Mary Jo Alvarez, Carlos A. Berlowitz, Dan R. Turner, Barbara J. Aung, KoKo Mortensen, Eric M. TI Exposure to High-Risk Medications is Associated With Worse Outcomes in Older Veterans With Chronic Pain SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Pharmacoepidemiology; Adverse drug outcomes; Chronic pain; Aging ID LOW-BACK-PAIN; RECEIVING PRIMARY-CARE; ADVERSE DRUG EVENTS; PERSISTENT PAIN; PREVALENCE; HEALTH; ADULTS; MANAGEMENT; TRENDS; METAANALYSIS AB Background:Chronic pain is common, costly and leads to significant morbidity in older adults, yet there are limited data on medication safety. The authors sought to evaluate the association of incident high-risk medication in the elderly (HRME) with mortality, emergency department (ED) or hospital care among older adults with chronic pain.Methods:A retrospective Veterans Health Administration cohort study was conducted examining older veterans with chronic pain diagnoses and use of incident HRME (opioids, skeletal muscle relaxants, antihistamines and psychotropics). Outcomes evaluated included all-cause mortality, ED visits or inpatient hospital care. Descriptive statistics summarized variables for the overall cohort, the chronic pain cohort and those with and without HRME. Separate generalized linear mixed-effect regression models were used to examine the association of incident HRME on each outcome, controlling for potential confounders.Results:Among 1,807,404 veterans who received Department of Veterans Affairs care in 2005 to 2006, 584,066 (32.3%) had chronic pain; 45,945 veterans with chronic pain (7.9%) had incident HRME exposure. The strongest significant associations of incident HRME were for high-risk opioids with all-cause hospitalizations (odds ratio [OR] 2.08, 95% confidence interval [CI] 1.95-2.23), skeletal muscle relaxants with all-cause ED visits (OR 2.62, 95% CI 2.52-2.73) and mortality (OR 0.80, 95% CI 0.74-0.86), antihistamines with all-cause ED visits (OR 2.82 95% CI 2.72-2.95) and psychotropics with all-cause hospitalizations (OR 2.15, 95% CI 1.96-2.35).Conclusions:Our data indicate that incident HRME is associated with clinically important adverse outcomes in older veterans with chronic pain and highlight the importance of being judicious with prescribing certain classes of drugs in this vulnerable population. C1 [Makris, Una E.; Alvarez, Carlos A.; Mortensen, Eric M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Makris, Una E.; Alvarez, Carlos A.; Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Alvarez, Carlos A.] Texas Tech Univ, Hlth Sci Ctr, Dallas, TX USA. [Pugh, Mary Jo; Turner, Barbara J.; Aung, KoKo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Berlowitz, Dan R.] Ctr Healthcare Org & Implementat Res, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. RP Mortensen, EM (reprint author), Dallas VA Med Ctr, Gen Internal Med 111E,4500 South Lancaster, Dallas, TX 75216 USA. EM Eric.Mortensen@UTSouthwestern.edu OI Mortensen, Eric/0000-0002-3880-5563 FU Rheumatology Research Foundation/ASP Junior Career Development Award in Geriatric Medicine; NIA GEMSSTAR [R03AG040653]; Center for Translational Medicine, NIH/NCATS [KL2TR001103, UL1TR001105] FX U.E.M. was supported by the Rheumatology Research Foundation/ASP Junior Career Development Award in Geriatric Medicine, an NIA GEMSSTAR (R03AG040653) and the Center for Translational Medicine, NIH/NCATS Grants (KL2TR001103 and UL1TR001105). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Center for Translational Medicine, UT Southwestern Medical Center and its affiliated academic and health care centers, the National Center for Advancing Translational Sciences, or the National Institutes of Health. NR 37 TC 2 Z9 2 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD OCT PY 2015 VL 350 IS 4 BP 279 EP 285 DI 10.1097/MAJ.0000000000000552 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CS6UM UT WOS:000362218400008 PM 26418380 ER PT J AU Kamen, DL Oates, JC AF Kamen, Diane L. Oates, Jim C. TI A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Systemic lupus erythematosus; Endothelial function; Nitric oxide; Vitamin D; Flow-mediated dilation ID NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; C-REACTIVE PROTEIN; 25-HYDROXYVITAMIN D; D DEFICIENCY; ARTERIAL STIFFNESS; DISEASE-ACTIVITY; CONTROLLED-TRIAL; S-NITROSYLATION; BRACHIAL-ARTERY AB Background:The endothelium is important not only in regulating vascular tone but also in modulating inflammation. Patients with systemic lupus erythematosus (SLE) have deficits in these endothelial functions. Vitamin D is a nuclear hormone that regulates vascular endothelial nitric oxide synthase activity and expression. Many SLE patients have insufficient levels of vitamin D. The effect of this hormone on vascular endothelial function in SLE patients is not known. This study was designed to determine the effect size of repleting vitamin D levels on endothelial function in patients with SLE and vitamin D deficiency.Methods:SLE patients with 25(OH) vitamin D (25(OH)D) levels <20 ng/mL were randomized to oral vitamin D3 (D3) doses that did or did not raise 25(OH)D levels to 32 ng/mL. Endothelial function was measured with flow-mediated dilation (FMD) before and after 16 weeks of vitamin D3 supplementation.Results:Half of those who achieved 25(OH)D levels of 32 ng/mL experienced increases in FMD, whereas none of those with continued low 25(OH)D levels did. Those with increases in FMD had significantly higher final 25(OH)D levels. Using the effect size from this study, future studies designed to test the effect of repleting 25(OH)D on FMD in vitamin D-deficient SLE patients will require 35 patients in each group.Conclusions:These results suggest a potential role for vitamin D in SLE-related endothelial dysfunction and that an adaptive, multi-arm, treat-to-target, serum-level trial design may increase the efficiency and likelihood of success of such a study. C1 [Kamen, Diane L.; Oates, Jim C.] Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA. [Oates, Jim C.] Ralph H Johnson VA Med Ctr, Med Serv, Rheumatol Sect, Charleston, SC USA. RP Oates, JC (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU Arthritis Foundation; NIH/NCRR MUSC-SCTR [UL1 RR029882]; NIH/NIAMS [K23 AR052364]; MUSC General and Clinical Research Center [M01RR001070] FX Supported by a grant from the Arthritis Foundation. This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center, NIH/NCRR MUSC-SCTR Grant number UL1 RR029882, NIH/NIAMS Grant number K23 AR052364 and the MUSC General and Clinical Research Center (M01RR001070). NR 49 TC 5 Z9 5 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD OCT PY 2015 VL 350 IS 4 BP 302 EP 307 DI 10.1097/MAJ.0000000000000556 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CS6UM UT WOS:000362218400012 PM 26351776 ER PT J AU Kobrin, DM McCarthy, FH Herrmann, HC Anwaruddin, S Kobrin, S Szeto, WY Bavaria, JE Groeneveld, PW Desai, ND AF Kobrin, Dale M. McCarthy, Fenton H. Herrmann, Howard C. Anwaruddin, Saif Kobrin, Sidney Szeto, Wilson Y. Bavaria, Joseph E. Groeneveld, Peter W. Desai, Nimesh D. TI Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity-Matched Comparison SO ANNALS OF THORACIC SURGERY LA English DT Article ID CHRONIC KIDNEY-DISEASE; LONG-TERM SURVIVAL; HIGH-RISK PATIENTS; CLINICAL-OUTCOMES; CARDIAC-SURGERY; STENOSIS; IMPLANTATION; MORTALITY; HEMODIALYSIS; IMPACT AB Background. Transcatheter aortic valve replacement (TAVR) clinical trials in North America excluded patients on dialysis and, consequently, the outcomes of TAVR in dialysis-dependent patients remain unknown. Methods. All Medicare fee-for-service patients undergoing TAVR (n=5,005) or surgical aortic valve replacement (SAVR) (n=32,634) between January 1, 2011, and November 30, 2012, were identified using procedural codes collected by the Centers for Medicare & Medicaid Services. Dialysis status and comorbidities were identified using diagnosis codes present on arrival for TAVR hospitalization. Patients supported on dialysis who underwent TAVR (n=224) were compared with non-dialysis patients who underwent TAVR as well as a propensity-matched group of contemporaneous dialysis patients who underwent SAVR (n=194 pairs). Results. The TAVR patients on dialysis were younger than non-dialysis TAVR patients (79.2 years vs 84.1 years; p < 0.01) but had higher prevalence of comorbidities. Dialysis TAVR patients had increased mortality at 30 days (13% vs 6%, p < 0.01) and significantly worse survival by Kaplan-Meier analysis. Multivariable regression found dialysis to be independently associated with worse survival (hazard ratio, 1.73; 95% confidence interval, 1.33% to 2.25%, p < 0.01) in TAVR patients. Propensity-matched dialysis SAVR and dialysis TAVR patients had no significant differences in demographic or risk factors. Matched dialysis TAVR patients had shorter length of stay (6 interquartile range, 4 to 10] vs 10 [IQR 7 to 18] days; p < 0.01) and comparable survival. Conclusions. TAVR in dialysis patients is associated with decreased survival compared with non-dialysis patients; however, it is comparable with SAVR in high risk dialysis patients based on a propensity-matched comparison. (C) 2015 by The Society of Thoracic Surgeons C1 [Desai, Nimesh D.] Univ Penn, Perelman Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med, Renal Elect & Hypertens Div, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. Philadephia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Desai, ND (reprint author), Univ Penn, Perelman Sch Med, Div Cardiovasc Surg, 3400 Spruce St,6 Silverstein, Philadelphia, PA 19104 USA. EM nimesh.desai@uphd.upenn.edu NR 26 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2015 VL 100 IS 4 BP 1230 EP 1237 DI 10.1016/j.athoracsur.2015.05.039 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CS7TE UT WOS:000362288000027 PM 26271581 ER PT J AU Fowler, CG Chiasson, KB Colman, RJ Kemnitz, JW Beasley, TM Weindruch, RH AF Fowler, Cynthia G. Chiasson, Kirstin Beach Colman, Ricki J. Kemnitz, Joseph W. Beasley, T. Mark Weindruch, Richard H. TI Hyperinsulinemia/diabetes, hearing, and aging in the University of Wisconsin calorie restriction monkeys SO HEARING RESEARCH LA English DT Article DE Age-related hearing loss; Auditory evoked potentials; Caloric restriction; Distortion product otoacoustic emissions; Hearing; Rhesus macaque; Hyperinsulinemia; Type 2 diabetes ID PRODUCT OTOACOUSTIC EMISSIONS; DEPENDENT DIABETES-MELLITUS; RHESUS-MONKEYS; AUDITORY FUNCTION; DIETARY RESTRICTION; MACACA-MULATTA; AGE; HUMANS; ASSOCIATION; POPULATION AB The purpose of this study was to determine the effects of hyperinsulinemia/Type 2 diabetes mellitus (HI-T2DM) on hearing impairment using rhesus monkeys to obtain control over diet and lifestyle factors that confound human studies. The study is a retrospective evaluation of rhesus monkeys from the Wisconsin National Primate Research Center (WNPRC) study on caloric restriction and aging. The research questions were the following: 1. Is HI-T2DM related to hearing impairment? 2. If so, what is the site of lesion in the auditory system? and 3. What physiological factors affect the risk of hearing loss in HI-T2DM? Three groups of eight monkeys each were matched by sex and age; the caloric restricted (CR) monkeys had a reduced risk of diabetes, the normal control (NL) group had a normal risk, and the hyperinsulinemia/diabetes (HI-D) group had already developed HI-T2DM. Auditory testing included distortion product otoacoustic emissions (DPOAEs) with 12 frequencies from 2211 to 8837 Hz and auditory brainstem responses (ABRs) obtained with clicks and tone bursts (8, 16, and 32 kHz). DPOAEs had signal-to-noise ratios 8-17 dB larger in the NL group than in the HI-D and CR groups, signifying that cochlear function was best in the NL group. ABR thresholds were 5-8 dB better in the NL group than in the HI-D group, although no significant differences across the groups were evident for the thresholds, latencies, inter-wave intervals, or amplitudes. Correlations were significant for quadratic relations between body mass index (BMI) and DPOAE, with largest DPOAEs for animals in the middle of the BMI range. ABR thresholds elicited with 16 and 32 kHz signals were significantly correlated, positively with BMI and HbA1c, and negatively with K-G (glucose tolerance), S-I (insulin sensitivity index) and DI (disposition index). These findings suggest that the hearing loss associated with HI-T2DM is predominantly cochlear, and auditory structures underlying the higher frequencies are at risk with HI-T2DM. Loss of auditory function begins in the hyperinsulinemia, pre-diabetic state. (C) 2015 Elsevier B.V. All rights reserved. C1 [Fowler, Cynthia G.] Univ Wisconsin, Dept Commun Sci & Disorders, Madison, WI 53706 USA. [Chiasson, Kirstin Beach] Cascade Ear Nose Throat & Facial Plast Surg, Klamath Falls, OR USA. [Colman, Ricki J.; Kemnitz, Joseph W.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Kemnitz, Joseph W.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53715 USA. [Beasley, T. Mark] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Weindruch, Richard H.] Univ Wisconsin, Dept Med, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Fowler, CG (reprint author), Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr Madison, Madison, WI 53706 USA. EM cgfowler@wisc.edu; rcolman@primate.wisc.edu; kemnitz@primate.wisc.edu; mbeasley@ms.soph.uab.edu; rhweindr@wisc.edu OI Kemnitz, Joseph/0000-0001-6511-404X FU National Institutes of Health (NIH) [P01 AG 11915, P51 RR000167, RO1AG040178]; Research Facilities Improvement Program [RR15459-01, RR020141-01] FX This publication was made possible by grants P01 AG 11915, P51 RR000167, and RO1AG040178 from the National Institutes of Health (NIH). This research was conducted at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. NR 37 TC 1 Z9 1 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD OCT PY 2015 VL 328 BP 78 EP 86 DI 10.1016/j.heares.2015.07.001 PG 9 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA CS5XQ UT WOS:000362152000008 PM 26163094 ER PT J AU Wagner, C Abramson, LY Alloy, LB AF Wagner, Clara Abramson, Lyn Y. Alloy, Lauren B. TI Brief report: Executive functions in adolescent offspring of mothers with a history of depression SO JOURNAL OF ADOLESCENCE LA English DT Article DE Executive functions; Depression; Adolescents; Maternal depression ID EVERYDAY-ATTENTION; CHILDREN; RISK; PSYCHOPATHOLOGY; PERFORMANCE; DISORDERS AB Deficits in executive functions (EFs) have been documented among individuals with unipolar depression, but controversy exists as to whether such deficits are state-dependent or are trait markers that precede disorder onset. The present study examined whether maternal history of unipolar depression was associated with deficits in EFs in early adolescent offspring, a finding that would support a trait marker conceptualization of EF deficits. Participants were a diverse sample (N = 493) of adolescents and their mothers recruited through local schools. Measures included semi-structured diagnostic interviews of mother and adolescent, mother-report forms assessing demographic information, and tests of executive function. Hierarchical linear regression analyses were conducted to examine the association between maternal depression diagnosis and adolescent offspring performance on tests of EF. Maternal lifetime history of depression was not associated with offspring EF task performance. Findings are not consistent with the conceptualization of impaired executive functions as trait markers of unipolar depression. Published by Elsevier Ltd on behalf of The Foundation for Professionals in Services for Adolescents. C1 [Wagner, Clara] Philadelphia VA Med Ctr, VA Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. [Abramson, Lyn Y.] Univ Wisconsin, Dept Psychol, Philadelphia, PA 19104 USA. [Alloy, Lauren B.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RP Wagner, C (reprint author), Philadelphia VA Med Ctr, VA Ctr Hlth Equity Res & Promot, 3900 Woodland Ave,Bldg 4100 Annex, Philadelphia, PA 19104 USA. EM Clara.Wagner@va.gov FU National Institute of Mental Health [MH79369, MH101168] FX This research was supported by National Institute of Mental Health grants MH79369 and MH101168 to Lauren B. Alloy. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 19 TC 1 Z9 1 U1 4 U2 12 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0140-1971 EI 1095-9254 J9 J ADOLESCENCE JI J. Adolesc. PD OCT PY 2015 VL 44 BP 32 EP 36 DI 10.1016/j.adolescence.2015.06.005 PG 5 WC Psychology, Developmental SC Psychology GA CS5PP UT WOS:000362130600004 PM 26208078 ER PT J AU Ahluwalia, SC Tisnado, DM Walling, AM Dy, SM Asch, SM Ettner, SL Kim, B Pantoja, P Schreibeis-Baum, HC Lorenz, KA AF Ahluwalia, Sangeeta C. Tisnado, Diana M. Walling, Anne M. Dy, Sydney M. Asch, Steven M. Ettner, Susan L. Kim, Benjamin Pantoja, Philip Schreibeis-Baum, Hannah C. Lorenz, Karl A. TI Association of Early Patient-Physician Care Planning Discussions and End-of-Life Care Intensity in Advanced Cancer SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID EARLY PALLIATIVE CARE; RANDOMIZED CONTROLLED-TRIAL; VETERANS-AFFAIRS; PRIVATE-SECTOR; OLDER PATIENTS; NEAR-DEATH; QUALITY; HEALTH; AGGRESSIVENESS; INDICATORS AB Background: Early patient-physician care planning discussions may influence the intensity of end-of-life (EOL) care received by veterans with advanced cancer. Objective: The study objective was to evaluate the association between medical record documentation of patient-physician care planning discussions and intensity of EOL care among veterans with advanced cancer. Methods: This was a retrospective cohort study. Subjects were 665 veteran decedents diagnosed with stage IV colorectal, lung, or pancreatic cancer in 2008, and followed till death or the end of the study period in 2011. We estimated the effect of patient-physician care planning discussions documented within one month of metastatic diagnosis on the intensity of EOL care measured by receipt of acute care, intensive interventions, chemotherapy, and hospice care, using multivariate logistic regression models. Results: Veterans in our study were predominantly male (97.1%), white (74.7%), with an average age at diagnosis of 66.4 years. Approximately 31% received some acute care, 9.3% received some intensive intervention, and 6.5% had a new chemotherapy regimen initiated in the last month of life. Approximately 41% of decedents received no hospice or were admitted within three days of death. Almost half (46.8%) had documentation of a care planning discussion within the first month after diagnosis and those who did were significantly less likely to receive acute care at EOL (OR: 0.67; p=0.025). Documented discussions were not significantly associated with intensive interventions, chemotherapy, or hospice care. Conclusion: Early care planning discussions are associated with lower rates of acute care use at the EOL in a system with already low rates of intensive EOL care. C1 [Ahluwalia, Sangeeta C.] RAND Corp, Santa Monica, CA 90401 USA. [Walling, Anne M.; Pantoja, Philip; Schreibeis-Baum, Hannah C.; Lorenz, Karl A.] VA Greater Los Angeles Med Ctr, Los Angeles, CA USA. [Walling, Anne M.; Lorenz, Karl A.] UCLA Sch Med, Los Angeles, CA USA. [Dy, Sydney M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Asch, Steven M.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ Sch Med, Palo Alto, CA USA. [Ettner, Susan L.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA. [Kim, Benjamin] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tisnado, Diana M.] Calif State Univ Fullerton, Dept Hlth Sci, Fullerton, CA 92634 USA. RP Ahluwalia, SC (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM sahluwal@rand.org FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research & Development Service [IIR 09-097]; National Palliative Care Research Center Career Development Award; VA/NIMH Implementation Research Fellowship [R25 MH080916-01A2]; UCLA CTSI [UL1TR000124]; NIH Loan Repayment Program FX This work was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research & Development Service (IIR 09-097). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. Dr. Ahluwalia was supported by a National Palliative Care Research Center Career Development Award and a VA/NIMH Implementation Research Fellowship (R25 MH080916-01A2). Dr. Walling was supported by UCLA CTSI grant number UL1TR000124 and the NIH Loan Repayment Program. NR 25 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT 1 PY 2015 VL 18 IS 10 BP 834 EP 841 DI 10.1089/jpm.2014.0431 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CS7MY UT WOS:000362268900009 PM 26186553 ER PT J AU Smith, D Kuzla, N Thorpe, J Scott, L Ersek, M AF Smith, Dawn Kuzla, Natalie Thorpe, Joshua Scott, Laura Ersek, Mary TI Exploring Nonresponse Bias in the Department of Veterans Affairs' Bereaved Family Survey SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PATIENT SATISFACTION SURVEYS; LIFE CARE; QUALITY MEASURE; HOSPITAL SURVEY; RESPONSE BIAS; END; HEALTH; NATIONWIDE; IMPACT; MODEL AB Background: Patients' and families' evaluations of health care, including palliative care, are widely used as performance measures. Survey scores may be affected by nonresponse bias, resulting in inaccurate performance evaluation. Objectives: Our aim was to examine nonresponse bias for the mailed version of the Department of Veterans Affairs (VA) Bereaved Family Survey Performance Measure (BFS-PM) and evaluate the effect of nonresponse bias on facilities' BFS-PM scores. Methods: A cross-sectional analysis of a national sample was conducted. The sample consisted of 20,540 veterans who died in one of 146 VA Medical Centers (VAMCs) between October 2012 and September 2013. Next of kin (NOK) were asked to complete and return the survey. The BFS-PM is defined as the proportion of NOK who rated overall care for the veteran during the last month of life as excellent. After creating a model to predict the likelihood of response based on patient and clinical characteristics, we applied inverse probability weights to examine their effect on facilities' scores. We also evaluated facility performance before and after weighting for nonresponse vis-a-vis varying benchmarks. Results: We received 8912 surveys (45% response rate). The mean change in facility BFS-PM scores after weighting was -2%, (range: -10% to+11%). The scores of 31% of facilities changed more than2%. The number of facilities meeting hypothetical benchmarks of 60%, 70%, and 80% also changed as a result of weighting for nonresponse. Conclusion: Our results underscore the importance of appropriately addressing nonresponse in the use of quality-of-care metrics based on Bereaved Family Survey (BFS) data. C1 [Smith, Dawn; Kuzla, Natalie; Thorpe, Joshua; Scott, Laura; Ersek, Mary] Philadelphia Vet Affairs Med Ctr, PROMISE Ctr, Philadelphia, PA 19104 USA. [Thorpe, Joshua] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Thorpe, Joshua] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Smith, Dawn; Kuzla, Natalie; Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Ersek, M (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave,Annex Suite 203, Philadelphia, PA 19104 USA. EM Mary.ersek@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, which had no role in the design, methods, participant recruitment, data collection, analysis, or preparation of manuscript or in the decision to submit the manuscript for publication. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. Government. NR 35 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT 1 PY 2015 VL 18 IS 10 BP 858 EP 864 DI 10.1089/jpm.2015.0050 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CS7MY UT WOS:000362268900012 PM 26172910 ER PT J AU Grubbs, V Vittinghoff, E Beck, JD Kshirsagar, AV Wang, W Griswold, ME Powe, NR Correa, A Young, B AF Grubbs, Vanessa Vittinghoff, Eric Beck, James D. Kshirsagar, Abhijit V. Wang, Wei Griswold, Michael E. Powe, Neil R. Correa, Adolfo Young, Bessie TI Association Between Periodontal Disease and Kidney Function Decline in African Americans: The Jackson Heart Study SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE African Americans; disease progression; health status disparities; periodontal disease; renal insufficiency; chronic; risk factors ID STAGE RENAL-DISEASE; ATHEROSCLEROSIS RISK; SERUM CREATININE; COMMUNITIES; POPULATION; PREVALENCE; ADULTS; CKD AB Background: Chronic kidney disease (CKD) remains a prevalent public health problem that disproportionately affects African Americans, despite intense efforts targeting traditional risk factors. Periodontal disease, a chronic bacterial infection of the oral cavity, is both common and modifiable and has been implicated as a novel potential CKD risk factor. The authors seek to examine to what extent periodontal disease is associated with kidney function decline. Methods: This retrospective cohort study examines 699 African American participants with preserved kidney function (defined by estimated glomerular filtration rate (eGFR) >60 mL/minute/1.73m(2) at baseline) who underwent complete dental examinations as part of the Dental-Atherosclerosis Risk in Communities study (1996 to 1998) and subsequently enrolled in the Jackson Heart Study (2000 to 2004). Using multivariable Poisson regression, the authors examined the association of periodontal disease (severe versus non-severe) with incident CKD, defined as incident eGFR <60 mL/minute/1.73m(2) and rapid (5% annualized) eGFR decline at follow-up among those with preserved eGFR at baseline. Results: Mean (+/- SD) age at baseline was 65.4 (+/- 5.2) years, and 16.3% (n = 114) had severe periodontal disease. There were 21 cases (3.0%) of incident CKD after a mean follow-up of 4.8 (+/- 0.6) years. Compared with participants with non-severe periodontal disease, those with severe periodontal disease had a four-fold greater rate of incident CKD (adjusted incidence rate ratio 4.18 [95% confidence interval 1.68 to 10.39], P = 0.002). Conclusions: Severe periodontal disease is prevalent among a population at high risk for CKD and is associated with clinically significant kidney function decline. Further research is needed to determine if periodontal disease treatment alters the trajectory of renal deterioration. C1 [Grubbs, Vanessa] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grubbs, Vanessa] San Francisco Gen Hosp, Div Nephrol, San Francisco, CA 94110 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Beck, James D.] Univ N Carolina, Sch Dent, Chapel Hill, NC USA. [Kshirsagar, Abhijit V.] Univ N Carolina, Div Nephrol & Hypertens, Chapel Hill, NC USA. [Wang, Wei; Griswold, Michael E.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA. [Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Young, Bessie] Univ Washington, Kidney Res Inst, Div Nephrol, Vet Affairs Puget Sound, Seattle, WA 98195 USA. RP Grubbs, V (reprint author), 1001 Potrero Ave,Bldg 100,Room 342, San Francisco, CA 94110 USA. EM vanessa.grubbs@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Bethesda, Maryland [1K23DK093710-01A1, 1R01DK102134-01]; Harold Amos Medical Faculty Development Program of Robert Wood Johnson Foundation, Princeton, New Jersey; National Heart, Lung, and Blood Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities, Bethesda, Maryland; Valeant Pharmaceuticals, Bridgewater, New Jersey; Amgen (Thousand Oaks, California) FX The authors thank the participants and staff of the Dental-Atherosclerosis Risk in Communities and Jackson Heart Studies. VG was supported by grant 1K23DK093710-01A1 from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Bethesda, Maryland, and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, Princeton, New Jersey. BY was supported by grant 1R01DK102134-01 from the NIDDK. The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, and HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities, Bethesda, Maryland. VG received investigator-initiated research funding from Valeant Pharmaceuticals, Bridgewater, New Jersey. AVK received investigator-initiated research funding from Amgen (Thousand Oaks, California) and has served on an advisory board for Fresenius (Waltham, Massachusetts). No other co-authors have any potential conflicts of interests to disclose. NR 23 TC 1 Z9 1 U1 0 U2 1 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD OCT PY 2015 VL 86 IS 10 BP 1126 EP 1132 DI 10.1902/jop.2015.150195 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CS4KR UT WOS:000362045200004 PM 26110451 ER PT J AU Rubinsky, AD Chen, C Batki, SL Williams, EC Harris, AHS AF Rubinsky, Anna D. Chen, Cheng Batki, Steven L. Williams, Emily C. Harris, Alex H. S. TI Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among US Veterans Health Administration patients with dual diagnoses SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Alcohol use disorder; Pharmacotherapy; Medication; Dual diagnosis; Psychiatric disorders ID NATIONAL EPIDEMIOLOGIC SURVEY; DSM-IV ALCOHOL; SUBSTANCE USE; MENTAL-DISORDERS; UNITED-STATES; SMOKING-CESSATION; TOBACCO USE; DEPENDENCE; CARE; METAANALYSIS AB Patients with alcohol use disorder (AUD) and another co-occurring psychiatric disorder are a vulnerable population with high symptom severity. Such patients may benefit from a full arsenal of treatment options including pharmacotherapy. Receipt of AUD pharmacotherapy is generally very low despite recommendations that it be made available to every patient with AUD, including those with co-occurring disorders. Little is known about pharmacotherapy rates for AUD compared to other psychiatric disorders among patients with dual diagnoses. This study compared rates of pharmacotherapy for AUD to those for non-substance use psychiatric disorders and tobacco use disorder among patients with dual diagnoses in the U.S. Veterans Affairs (VA) healthcare system. VA data were used to identify patients with AUD and another psychiatric disorder in fiscal year 2012, and to estimate the proportion receiving pharmacotherapy for AUD and for each comorbid condition. Among subsets of patients with AUD and co-occurring schizophrenic, bipolar, posttraumatic stress or major depressive disorder, receipt of medications for AUD ranged from 7% to 11%, whereas receipt of medications for the comorbid disorder ranged from 69% to 82%. Among patients with AUD and co-occurring tobacco use disorder, 6% received medication for their AUD and 34% for their tobacco use disorder. Among patients with dual diagnoses, rates of pharmacotherapy for AUD were far lower than those for the comorbid disorders and contrary to evidence that medications for AUD are effective. Additional system-wide implementation efforts to identify and address patient- and provider-level barriers are needed to increase AUD pharmacotherapy in this highneed population. Published by Elsevier Ltd. C1 [Rubinsky, Anna D.; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Vet Affairs VA Substance Use Disorder Qual Enhanc, Menlo Pk, CA 94025 USA. [Rubinsky, Anna D.; Chen, Cheng; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat Ci2i, Hlth Serv Res & Dev, Menlo Pk, CA 94025 USA. [Batki, Steven L.] San Francisco VA Med Ctr, Addict Psychiat Res Program, San Francisco, CA 94121 USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Williams, Emily C.] VA Puget Sound Hlth Care Syst, Seattle Ctr Innovat Veteran Ctr & Value Driven Ca, Hlth Serv Res & Dev S152, Seattle, WA 98108 USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Rubinsky, AD (reprint author), VA Palo Alto Hlth Care Syst, Vet Affairs VA Substance Use Disorder Qual Enhanc, 795 Willow Rd MPD 152, Menlo Pk, CA 94025 USA. EM Anna.Rubinsky@va.gov FU United States Department of Veterans Affairs (VA) Health Services Research & Development (HSRD) Program; VA HSR&D Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI); VA HSRD [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; VA HSRD QUERI FX This work was supported by the United States Department of Veterans Affairs (VA) Health Services Research & Development (HSR&D) Program and VA HSR&D Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI). Dr. Williams is supported by a Career Development Award from VA HSR&D (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the VA HSR&D QUERI. NR 73 TC 6 Z9 6 U1 3 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD OCT PY 2015 VL 69 BP 150 EP 157 DI 10.1016/j.jpsychires.2015.07.016 PG 8 WC Psychiatry SC Psychiatry GA CS2UP UT WOS:000361927800022 PM 26343607 ER PT J AU Isakova, T Ix, JH Sprague, SM Raphael, KL Fried, L Gassman, JJ Raj, D Cheung, AK Kusek, JW Flessner, MF Wolf, M Block, GA AF Isakova, Tamara Ix, Joachim H. Sprague, Stuart M. Raphael, Kalani L. Fried, Linda Gassman, Jennifer J. Raj, Dominic Cheung, Alfred K. Kusek, John W. Flessner, Michael F. Wolf, Myles Block, Geoffrey A. TI Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; DIETARY PHOSPHORUS RESTRICTION; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; LEFT-VENTRICULAR MASS; VITAMIN-D METABOLISM; HEMODIALYSIS-PATIENTS; PARATHYROID-HORMONE; CARDIOVASCULAR EVENTS AB Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. Phosphate excess induces arterial calcification, and although elevated FGF23 helps maintain serum phosphate levels in the normal range in CKD, it may contribute mechanistically to left ventricular hypertrophy (LVH). Consistent epidemiologic and experimental findings suggest the need to test therapeutic approaches that lower phosphate and FGF23 in CKD. Dietary phosphate absorption is one modifiable determinant of serum phosphate and FGF23 levels. Limited data from pilot studies in patients with CKD stages 3-4 suggest that phosphate binders, low phosphate diets, or vitamin B3 derivatives, such as niacin or nicotinamide, may reduce dietary phosphate absorption and serum phosphate and FGF23 levels. This review summarizes current knowledge regarding the deleterious systemic effects of phosphate and FGF23 excess, identifies questions that must be addressed before advancing to a full-scale clinical outcomes trial, and presents a novel therapeutic approach to lower serum phosphate and FGF23 levels that will be tested in the COMBINE Study: The CKD Optimal Management With Binders and NicotinannidE study. C1 [Isakova, Tamara; Wolf, Myles] Northwestern Univ, Feinberg Sch Med, Div Nephrol & Hypertens, Dept Med, Chicago, IL 60611 USA. [Isakova, Tamara; Wolf, Myles] Northwestern Univ, Feinberg Sch Med, Ctr Translat Metab & Hlth, Inst Publ Hlth & Med, Chicago, IL 60611 USA. [Ix, Joachim H.] Univ Calif San Diego, Nephrol Sect, Vet Affairs San Diego Healthcare Syst, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Prevent Med, San Diego, CA 92103 USA. [Sprague, Stuart M.] Univ Chicago, Pritzker Sch Med, NprthShore Univ Hlth Syst, Evanston, IL USA. [Raphael, Kalani L.; Cheung, Alfred K.] Univ Utah, Salt Lake City Vet Affairs Healthcare Syst, Salt Lake City, UT USA. [Raphael, Kalani L.; Cheung, Alfred K.] Univ Utah, Div Nephrol & Hypertens, Salt Lake City, UT USA. [Fried, Linda] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Gassman, Jennifer J.] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA. [Raj, Dominic] George Washington Univ, Div Renal Dis & Hypertens, Washington, DC USA. [Kusek, John W.; Flessner, Michael F.] NIDDK, Bethesda, MD USA. [Block, Geoffrey A.] Denver Nephrol, Denver, CO USA. RP Isakova, T (reprint author), 633 N St Clair St,Suite 18-083, Chicago, IL 60611 USA. EM tamara.isakova@northwestern.edu OI Raphael, Kalani/0000-0002-1378-2609 FU National Institute of Diabetes and Digestive and Kidney Diseases [K23-DK081673, R01-DK102438, U01-DK099877, U01-DK097093, U01-DK099930, U01-DK099933, U01-DK099924]; Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology Foundation for Kidney Research; VA Career Development Award [IK2CX000537]; Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation FX T.I. is supported by grants K23-DK081673 and R01-DK102438 from the National Institute of Diabetes and Digestive and Kidney Diseases and by the Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology Foundation for Kidney Research.; K.L.R. is supported by the VA Career Development Award (IK2CX000537) and the Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation.; The COMBINE study is supported by grants U01-DK099877, U01-DK097093, U01-DK099930, U01-DK099933, U01-DK099924, and R01-DK102438 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 102 TC 25 Z9 26 U1 0 U2 11 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD OCT PY 2015 VL 26 IS 10 BP 2328 EP 2339 DI 10.1681/ASN.2015020117 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA CS5ZL UT WOS:000362156700007 PM 25967123 ER PT J AU Ix, JH Biggs, ML Mukamal, K Djousse, L Siscovick, D Tracy, R Katz, R Delaney, JA Chaves, P Rifkin, DE Hughes-Austin, JM Garimella, PS Sarnak, MJ Shlipak, MG Kizer, JR AF Ix, Joachim H. Biggs, Mary L. Mukamal, Kenneth Djousse, Luc Siscovick, David Tracy, Russell Katz, Ronit Delaney, Joseph A. Chaves, Paulo Rifkin, Dena E. Hughes-Austin, Jan M. Garimella, Pranav S. Sarnak, Mark J. Shlipak, Michael G. Kizer, Jorge R. TI Urine Collagen Fragments and CKD Progression-The Cardiovascular Health Study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID AMINO-TERMINAL PROPEPTIDE; CREATININE EXCRETION RATE; INJURY MOLECULE-1 KIM-1; KIDNEY-FUNCTION DECLINE; CASE-COHORT DESIGNS; CYSTATIN-C; SERUM BICARBONATE; III PROCOLLAGEN; ATHEROSCLEROSIS MESA; LIPOCALIN NGAL AB Tubulointerstitial fibrosis is common with ageing and strongly prognostic for ESRD but is poorly captured by eGFR or urine albumin to creatinine ratio (ACR). Higher urine levels of procollagen type III N-terminal propeptide (PIIINP) mark the severity of tubulointerstitial fibrosis in biopsy studies, but the association of urine PIIINP with CKD progression is unknown. Among community-living persons aged >= 65 years, we measured PIIINP in spot urine specimens from the 1996 to 1997 Cardiovascular Health Study visit among individuals with CKD progression (30% decline in eGFR over 9 years, n=192) or incident ESRD (n=54) during follow-up, and in 958 randomly selected participants. We evaluated associations of urine PIIINP with CKD progression and incident ESRD. Associations of urine PIIINP with cardiovascular disease, heart failure, and death were evaluated as secondary end points. At baseline, mean age (+/- SD) was 78 +/- 5 years, mean eGFR was 63 +/- 18 ml/min per 1.73 m(2), and median urine PIIINP was 2.6 (interquartile range, 1.4-4.2) mu g/L. In a case-control study (192 participants, 231 controls), each doubling of urine PIIINP associated with 22% higher odds of CKD progression (adjusted odds ratio, 1.22; 95% confidence interval, 1.00 to 1.49). Higher urine PIIINP level was also associated with incident ESRD, but results were not significant in fully adjusted models. In a prospective study among the 958 randomly selected participants, higher urine PIIINP was significantly associated with death, but not with incident cardiovascular disease or heart failure. These data suggest higher urine PIIINP levels associate with CKD progression independently of eGFR and ACR in older individuals. C1 [Ix, Joachim H.; Rifkin, Dena E.] Univ Calif San Diego & Vet Affairs San Diego Heal, Div Nephrol Hypertens, San Diego, CA USA. [Biggs, Mary L.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. [Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Djousse, Luc] Brigham & Womens Hosp & Boston Vet Affairs Hlth S, Div Aging, Boston, MA USA. [Siscovick, David] New York Acad Med, New York, NY USA. [Tracy, Russell] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [Katz, Ronit] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Delaney, Joseph A.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. [Chaves, Paulo] Florida Int Univ, Dept Med, Miami, FL 33199 USA. [Hughes-Austin, Jan M.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Garimella, Pranav S.; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Div Nephrol Hypertens, 3350 La Jolla Village Dr,Mail Code 9111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU National Institute of Diabetes Digestive and Kidney Diseases [R01-DK098234]; National Heart, Lung, and Blood Institute [R01-HL094555, U01-HL080295]; American Heart Association Established Investigator Award [14EIA18560026]; National Institute on Aging [R01-AG027002, R01-AG023629]; [HHSN268201200036C]; [HHSN268200800007C]; [N01-HC55222]; [N01-HC85079]; [N01-HC85080]; [N01-HC85081]; [N01-HC85082]; [N01-HC85083]; [N01-HC85086] FX Supported by grants from the National Institute of Diabetes Digestive and Kidney Diseases (grant no. R01-DK098234) (to Drs. Ix and Shlipak); National Heart, Lung, and Blood Institute (grant no. R01-HL094555) (to Drs. Ix, Mukamal, Djousse, and Kizer); American Heart Association Established Investigator Award (award no. 14EIA18560026) (to Dr. Ix); and National Institute on Aging (grant nos. R01-AG027002) (Dr Sarnak). The CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC55222, N01-HC85079, N01-HC85080, N01-HC85081, N01-HC85082, N01-HC85083, N01-HC85086, and grant U01-HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke and from grant R01-AG023629 from the National Institute on Aging. This material is the result of work supported with resources of the VA San Diego Healthcare System. NR 38 TC 8 Z9 8 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD OCT PY 2015 VL 26 IS 10 BP 2494 EP 2503 DI 10.1681/ASN.2014070696 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CS5ZL UT WOS:000362156700021 PM 25655067 ER PT J AU Saxon, AJ AF Saxon, Andrew J. TI Comparative safety of methadone and buprenorphine SO LANCET PSYCHIATRY LA English DT Editorial Material ID PHARMACOKINETICS; DEPENDENCE; INDUCTION; HUMANS C1 Univ Washington, Dept Psychiat & Behav Sci, CESATE, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Saxon, AJ (reprint author), Univ Washington, Dept Psychiat & Behav Sci, CESATE, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM asaxon@uw.edu FU Alkermes FX I have received an honoraria for lectures from ReckittBenckiser, scientific advisory board fees from Alkermes, and royalties from UpToDate. NR 11 TC 0 Z9 0 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2215-0374 J9 LANCET PSYCHIAT JI Lancet Psychiatry PD OCT PY 2015 VL 2 IS 10 BP 855 EP 856 DI 10.1016/S2215-0366(15)00413-7 PG 2 WC Psychiatry SC Psychiatry GA CS5GU UT WOS:000362106500005 PM 26384620 ER PT J AU Bril, F Cusi, K AF Bril, Fernando Cusi, Kenneth TI Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? SO LIVER INTERNATIONAL LA English DT Letter ID FATTY LIVER C1 [Bril, Fernando; Cusi, Kenneth] Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA. [Bril, Fernando; Cusi, Kenneth] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA. [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. [Cusi, Kenneth] Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA. RP Bril, F (reprint author), Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA. NR 5 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD OCT PY 2015 VL 35 IS 10 BP 2341 EP 2342 DI 10.1111/liv.12869 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS6PC UT WOS:000362201800021 PM 25964992 ER PT J AU Molina, Y Silva, A Rauscher, GH AF Molina, Yamile Silva, Abigail Rauscher, Garth H. TI Racial/Ethnic Disparities in Time to a Breast Cancer Diagnosis The Mediating Effects of Health Care Facility Factors SO MEDICAL CARE LA English DT Article DE breast cancer; disparities; between-facility effects; accreditation; multisite care ID FOLLOW-UP; WOMEN; MAMMOGRAPHY; PREDICTORS; SURVIVAL; DELAY; STAGE; RACE/ETHNICITY; INSURANCE; HOSPITALS AB Background:Racial/ethnic disparities exist along the breast cancer continuum, including time to a diagnosis. Previous research has largely focused on patient-level factors, and less is known about the role that health care facilities may play in delayed breast cancer care.Objectives:We examined racial/ethnic disparities in delayed diagnosis for breast cancer in the Breast Cancer Care in Chicago Study and estimated the potential mediating effects of facility factors.Research Design and Subjects:Breast cancer patients (N=606) contributed interview and medical record data as part of a population-based study.Measures:Race/ethnicity was self-reported at interview. Diagnostic delay was defined as an excess of 60 days between medical presentation and a definitive diagnosis. Facility factors included the facility of medical presentation with respect to: (1) accreditation through the National Consortium of Breast Centers; (2) certification as a Breast Imaging Center of Excellence through the American College of Radiology; and (3) status as a disproportionate share hospital through the state of Illinois as well as the number of facilities used between presentation and diagnosis.Results:Relative to non-Hispanic whites, minorities were more likely to experience a diagnostic delay, present at a nonaccredited facility and at a disproportionate share hospital, and involve multiple facilities in their diagnosis. Together, facility factors accounted for 43% of the disparity in diagnostic delay (P<0.0001).Conclusions:Initial presentation of breast cancer at higher resourced facilities can reduce diagnostic delays. Disparities in delay are partly due to a disproportionate presentation at lower resourced facilities by minorities. C1 [Molina, Yamile; Rauscher, Garth H.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Molina, Yamile] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Silva, Abigail] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA. RP Molina, Y (reprint author), 1603 West Taylor,6th Floor, Chicago, IL 60612 USA. EM ymolin2@uic.edu OI Silva, Abigail/0000-0002-1112-1209; Rauscher, Garth/0000-0003-0374-944X FU National Institutes of Health [P50CA106743, P50CA148143, R25CA92408]; University of Illinois-Chicago Center for Research on Women and Gender; University of Illinois Cancer Center; Office of Academic Affiliations, Department of Veterans Affairs [TPP 42-013] FX Supported by multiple National Institutes of Health grants (P50CA106743, P50CA148143, R25CA92408). Dr Molina was supported by the University of Illinois-Chicago Center for Research on Women and Gender and the University of Illinois Cancer Center. Dr Silva's work was supported by the Office of Academic Affiliations (TPP 42-013), Department of Veterans Affairs. The conclusions, opinions, and recommendations expressed in this article are not necessarily that of the Department of Veterans Affairs nor National Institutes of Health. NR 46 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2015 VL 53 IS 10 BP 872 EP 878 DI 10.1097/MLR.0000000000000417 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS5IL UT WOS:000362111500006 PM 26366519 ER PT J AU Urech, TH Woodard, LD Virani, SS Dudley, RA Lutschg, MZ Petersen, LA AF Urech, Tracy H. Woodard, LeChauncy D. Virani, Salim S. Dudley, R. Adams Lutschg, Meghan Z. Petersen, Laura A. TI Calculations of Financial Incentives for Providers in a Pay-for-Performance Program Manual Review Versus Data From Structured Fields in Electronic Health Records SO MEDICAL CARE LA English DT Article DE payment system design; performance measurement; incentives ID QUALITY MEASURES; MEASURING-AGREEMENT; HYPERTENSION CARE; KAPPA; TRIAL AB Background:Hospital report cards and financial incentives linked to performance require clinical data that are reliable, appropriate, timely, and cost-effective to process. Pay-for-performance plans are transitioning to automated electronic health record (EHR) data as an efficient method to generate data needed for these programs.Objective:To determine how well data from automated processing of structured fields in the electronic health record (AP-EHR) reflect data from manual chart review and the impact of these data on performance rewards.Research Design:Cross-sectional analysis of performance measures used in a cluster randomized trial assessing the impact of financial incentives on guideline-recommended care for hypertension.Subjects:A total of 2840 patients with hypertension assigned to participating physicians at 12 Veterans Affairs hospital-based outpatient clinics. Fifty-two physicians and 33 primary care personnel received incentive payments.Measures:Overall, positive and negative agreement indices and Cohen's kappa were calculated for assessments of guideline-recommended antihypertensive medication use, blood pressure (BP) control, and appropriate response to uncontrolled BP. Pearson's correlation coefficient was used to assess how similar participants' calculated earnings were between the data sources.Results:By manual chart review data, 72.3% of patients were considered to have received guideline-recommended antihypertensive medications compared with 65.0% by AP-EHR review (=0.51). Manual review indicated 69.5% of patients had controlled BP compared with 66.8% by AP-EHR review (=0.87). Compared with 52.2% of patients per the manual review, 39.8% received an appropriate response by AP-EHR review (=0.28). Participants' incentive payments calculated using the 2 methods were highly correlated (r0.98). Using the AP-EHR data to calculate earnings, participants' payment changes ranged from a decrease of $91.00 (-30.3%) to an increase of $18.20 (+7.4%) for medication use (interquartile range, -14.4% to 0%) and a decrease of $100.10 (-31.4%) to an increase of $36.40 (+15.4%) for BP control or appropriate response to uncontrolled BP (interquartile range, -11.9% to -6.1%).Conclusions:Pay-for-performance plans that use only EHR data should carefully consider the measures and the structure of the EHR before data collection and financial incentive disbursement. For this study, we feel that a 10% difference in the total amount of incentive earnings disbursed based on AP-EHR data compared with manual review is acceptable given the time and resources required to abstract data from medical records. C1 [Urech, Tracy H.; Woodard, LeChauncy D.; Virani, Salim S.; Lutschg, Meghan Z.; Petersen, Laura A.] Baylor Coll Med, Hlth Policy Qual & Informat Program, Michael E DeBakey VA HSR&D Ctr Innovat Qual Effec, Houston, TX 77030 USA. [Urech, Tracy H.; Woodard, LeChauncy D.; Virani, Salim S.; Lutschg, Meghan Z.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Dudley, R. Adams] Univ Calif San Francisco, Dept Med, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA. [Dudley, R. Adams] Univ Calif San Francisco, Hlth Serv Informat, San Francisco, CA USA. RP Petersen, LA (reprint author), Michael E De Bakey Vet Affairs Med Ctr, HSR&D 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM laura.petersen@va.gov OI Virani, Salim/0000-0001-9541-6954 FU US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development (HSR&D) Investigator-Initiated Research (IIR) [04-349]; National Institutes of Health (NIH) [RO1 HL079173-01]; American Heart Association Established Investigator Award [0540043N] FX Supported in part by the US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development (HSR&D) Investigator-Initiated Research (IIR) 04-349 (L.A.P.) and the National Institutes of Health (NIH) RO1 HL079173-01 (L.A.P.).; L.A.P. is the Director at the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), Michael E. DeBakey VA Medical Center, Houston, TX. L.A.P. was a recipient of the American Heart Association Established Investigator Award (Grant number 0540043N). R.A.D. is a Robert Wood Johnson Investigator Awardee in Health Policy. The remaining authors declare no conflict of interest. NR 26 TC 0 Z9 0 U1 5 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2015 VL 53 IS 10 BP 901 EP 907 DI 10.1097/MLR.0000000000000418 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS5IL UT WOS:000362111500010 PM 26340661 ER PT J AU Rahimy, E Kuehlewein, L Sadda, SR Sarraf, D AF Rahimy, Ehsan Kuehlewein, Laura Sadda, Srinivas R. Sarraf, David TI Paracentral Acute Middle Maculopathy What We Knew Then and What We Know Now SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Editorial Material ID ACUTE MACULAR NEURORETINOPATHY; DEEP CAPILLARY ISCHEMIA; COHERENCE TOMOGRAPHY ANGIOGRAPHY; RETINAL ARTERY-OCCLUSION; FLUORESCEIN ANGIOGRAPHY; OXYGEN DISTRIBUTION; VASCULATURE; SPECTRUM; OCT C1 [Rahimy, Ehsan] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA USA. [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. NR 31 TC 7 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD OCT PY 2015 VL 35 IS 10 BP 1921 EP 1930 DI 10.1097/IAE.0000000000000785 PG 10 WC Ophthalmology SC Ophthalmology GA CS6US UT WOS:000362219000001 PM 26360227 ER PT J AU Kranz, TM Goetz, RR Walsh-Messinger, J Goetz, D Antonius, D Dolgalev, I Heguy, A Seandel, M Malaspina, D Chao, MV AF Kranz, Thorsten M. Goetz, Ray R. Walsh-Messinger, Julie Goetz, Deborah Antonius, Daniel Dolgalev, Igor Heguy, Adriana Seandel, Marco Malaspina, Dolores Chao, Moses V. TI Rare variants in the neurotrophin signaling pathway implicated in schizophrenia risk SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Sporadic; De novo; ARMS; Kidins220; Rare variant; Neurotrophin; Exome sequencing ID DENDRITIC SPINE PATHOLOGY; MEMBRANE-SPANNING PROTEIN; NEGATIVE SYNDROME SCALE; NERVE GROWTH-FACTOR; DE-NOVO MUTATIONS; ALZHEIMERS-DISEASE; DEVELOPMENTAL DELAY; BIPOLAR DISORDER; MOOD DISORDERS; MESSENGER-RNA AB Multiple lines of evidence corroborate impaired signaling pathways as relevant to the underpinnings of schizophrenia. There has been an interest in neurotrophins, since they are crucial mediators of neurodevelopment and in synaptic connectivity in the adult brain. Neurotrophins and their receptors demonstrate aberrant expression patterns in cortical areas for schizophrenia cases in comparison to control subjects. There is little known about the contribution of neurotrophin genes in psychiatric disorders. To begin to address this issue, we conducted high-coverage targeted exome capture in a subset of neurotrophin genes in 48 comprehensively characterized cases with schizophrenia-related psychosis. We herein report rare missense polymorphisms and novel missense mutations in neurotrophin receptor signaling pathway genes. Furthermore, we observed that several genes have a higher propensity to harbor missense coding variants than others. Based on this initial analysis we suggest that rare variants and missense mutations in neurotrophin genes might represent genetic contributions involved across psychiatric disorders. (C) 2015 Elsevier B.V. All rights reserved. C1 [Kranz, Thorsten M.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA. [Kranz, Thorsten M.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Dept Physiol & Neurosci, New York, NY 10016 USA. [Kranz, Thorsten M.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Dept Psychiat, New York, NY 10016 USA. [Goetz, Ray R.] New York State Psychiat Inst & Hosp, Div Clin Phenomenol, New York, NY 10032 USA. [Goetz, Ray R.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA. [Walsh-Messinger, Julie] James J Peters VA Med Ctr, MIRECC, Bronx, NY 10468 USA. [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Goetz, Deborah; Antonius, Daniel; Malaspina, Dolores] NYU, Dept Psychiat Social & Psychiat Initiat, New York, NY 10016 USA. [Antonius, Daniel] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14215 USA. [Dolgalev, Igor; Heguy, Adriana] NYU, Genome Technol Ctr, Langone Med Ctr, New York, NY 10016 USA. [Seandel, Marco] Weill Cornell Med Coll, Dept Surg, New York, NY 10065 USA. RP Kranz, TM (reprint author), NYU, Sch Med, Skirball Inst Biomol Med, 540 First Ave,Rm 5-15, New York, NY 10016 USA. EM Thorsten.Kranz@nyumc.org OI Dolgalev, Igor/0000-0003-4451-126X; Chao, Moses/0000-0002-6969-3744 FU National Institutes of Health [NS21072, MH086651, RC1-MH088843, 5K24MH001699]; NYU CTSI [UL1TR000038] FX This work was supported in part by the National Institutes of Health Grants NS21072 (MVC), MH086651 (MVC), RC1-MH088843 (DM), 5K24MH001699 (DM) and NYU CTSI UL1TR000038 (DM). NR 67 TC 6 Z9 6 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2015 VL 168 IS 1-2 BP 421 EP 428 DI 10.1016/j.schres.2015.07.002 PG 8 WC Psychiatry SC Psychiatry GA CS1LK UT WOS:000361826400060 PM 26215504 ER PT J AU Tabak, NT Horan, WP Green, MF AF Tabak, Naomi T. Horan, William P. Green, Michael F. TI Mindfulness in schizophrenia: Associations with self-reported motivation, emotion regulation, dysfunctional attitudes, and negative symptoms SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Mindfulness; Motivation; Emotion regulation; Cognitive reappraisal; Dysfunctional attitudes; Defeatist beliefs ID RANDOMIZED CONTROLLED-TRIAL; COMMITMENT THERAPY; BEHAVIORAL ACTIVATION; INHIBITION SYSTEMS; COGNITIVE THERAPY; MEDITATION; ACCEPTANCE; PSYCHOSIS; ASYMMETRY; DYSREGULATION AB Mindfulness-based interventions are gaining empirical support as alternative or adjunctive treatments for a variety of mental health conditions, including anxiety, depression, and substance use disorders. Emerging evidence now suggests that mindfulness-based treatments may also improve clinical features of schizophrenia, including negative symptoms. However, no research has examined the construct of mindfulness and its correlates in schizophrenia. In this study, we examined self-reported mindfulness in patients (n = 35) and controls (n = 25) using the Five-Facet Mindfulness Questionnaire. We examined correlations among mindfulness, negative symptoms, and psychological constructs associated with negative symptoms and adaptive functioning, including motivation, emotion regulation, and dysfunctional attitudes. As hypothesized, patients endorsed lower levels of mindfulness than controls. In patients, mindfulness was unrelated to negative symptoms, but it was associated with more adaptive emotion regulation (greater reappraisal) and beliefs (lower dysfunctional attitudes). Some facets of mindfulness were also associated with self-reported motivation (behavioral activation and inhibition). These patterns of correlations were similar in patients and controls. Findings from this initial study suggest that schizophrenia patients may benefit from mindfulness-based interventions because they (a) have lower self-reported mindfulness than controls and (b) demonstrate strong relationships between mindfulness and psychological constructs related to adaptive functioning. (C) 2015 Elsevier B.V. All rights reserved. C1 [Tabak, Naomi T.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Tabak, Naomi T.; Horan, William P.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. RP Tabak, NT (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ntabak@ucla.edu FU Veterans Affairs Merit grant; NIMH [MH095878]; NIMH training grant in Cognitive and Affective Dysfunctions in the Psychoses at the University of California, Los Angeles [T32MH09668] FX Funding for the current study was provided by a Veterans Affairs Merit grant (Dr. Horan) and NIMH grant MH095878 (Dr. Green). A postdoctoral fellowship for Dr. Tabak was supported by an NIMH training grant in Cognitive and Affective Dysfunctions in the Psychoses at the University of California, Los Angeles (T32MH09668). NR 48 TC 4 Z9 4 U1 8 U2 41 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2015 VL 168 IS 1-2 BP 537 EP 542 DI 10.1016/j.schres.2015.07.030 PG 6 WC Psychiatry SC Psychiatry GA CS1LK UT WOS:000361826400076 PM 26232242 ER PT J AU Hoerster, KD Millstein, RA Hall, KS Gray, KE Reiber, GE Nelson, KM Saelens, BE AF Hoerster, Katherine D. Millstein, Rachel A. Hall, Katherine S. Gray, Kristen E. Reiber, Gayle E. Nelson, Karin M. Saelens, Brian E. TI Individual and contextual correlates of physical activity among a clinical sample of United States Veterans SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Veterans; Physical activity; Neighborhood; Social support ID OLDER-ADULTS; MULTIPLE IMPUTATION; NATIONAL SAMPLE; HEALTH-CARE; ODDS RATIO; EXERCISE; OBESITY; ASSOCIATIONS; DISABILITY; LIFE AB Rationale: Veterans, especially those using U.S. Department of Veterans Affairs (VA) healthcare, have poorer health than the general population. In addition, Veterans using VA services are more likely than non-VA users to be physically inactive. Little is known about physical activity correlates among Veterans. To identify targets for health promotion interventions, understanding barriers to and facilitators of physical activity in this population is critical. Methods: This study examined individual-, social-, and perceived neighborhood-level associations of meeting weekly physical activity recommendations (150 min/week of combined leisure and transportation activity) based on the International Physical Activity Questionnaire (IPAQ) among N = 717 patients from VA Puget Sound, Seattle Division using a mailed survey sent 2012-2013 (response rate = 40%). Independent associations were identified with direct estimation of relative risks using generalized linear models (dichotomous outcome), and linear regression (continuous outcome), including variables associated in bivariate tests (p < .05). Results: Most participants were male, Caucasian, and unemployed, and had an annual income <=$40,000. Over two-thirds (69.9%) reported meeting physical activity recommendations. Fewer days of limitations due to physical or mental health (Relative Risk (RR) = 0.99 per day; 95% Confidence Interval (CI) = 0.98, 0.99; p = .01), others doing physical activity with the Veteran (RR = 1.18; 95% Cl = 1.04, 133; p = .01), receiving ideas from others regarding physical activity (RR = 1.14; 95% Cl = 1.01, 1.29; p = .03) and better perceived neighborhood aesthetics (RR = 1.14; 95% Cl = 1.06, 1.24; p = .001) were associated with meeting physical activity recommendations. Findings were comparable for total weekly physical activity, but lower depression symptom severity was also associated with increased physical activity. Conclusion: This study identified individual and contextual correlates of physical activity among VA-using Veterans. Targeting these factors will be important in promoting physical activity in order to address the disproportionate disease burden facing U.S. Veterans. Existing VA interventions targeting physical activity may need to be adapted to account for the influence of contextual factors. Published by Elsevier Ltd. C1 [Hoerster, Katherine D.; Millstein, Rachel A.] VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, Seattle, WA 98108 USA. [Hoerster, Katherine D.; Saelens, Brian E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Millstein, Rachel A.] San Diego State Univ, Univ Calif San Diego, Joint Doctoral Program Clin Psychol, San Diego, CA 92182 USA. [Hall, Katherine S.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Hall, Katherine S.] Duke Univ, Dept Med, Durham, NC 27706 USA. [Gray, Kristen E.; Reiber, Gayle E.; Nelson, Karin M.] VA Puget Sound Healthcare Syst, Seattle Div, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Gray, Kristen E.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Gen Internal Med Serv, Seattle, WA 98108 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Saelens, Brian E.] Seattle Childrens Res Inst, Seattle, WA USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, 1660 S Columbian Way S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov FU VA Puget Sound, Seattle Division Mental Illness Research Education and Clinical Center; VA Puget Sound, Seattle Division Health Services Research and Development Center of Excellence; VA Career Development Awards [RRD 1IK2RX001316, HSRD CDA 12-263]; VA HSR&D Senior Research Career Scientist Award [RCS 98-353] FX We would like to thank Linda Guerrero, David Tice, and Marie Lutton for their work on managing the survey mailing, Carol Malte for extracting VA administrative data, and Jeff Rodenbaugh for his assistance with running analyses. This material is the result of work supported by resources from VA Puget Sound Healthcare System. Funding for the study was provided by the VA Puget Sound, Seattle Division Mental Illness Research Education and Clinical Center and the VA Puget Sound, Seattle Division Health Services Research and Development Center of Excellence. Drs. Hall and Hoerster are supported by VA Career Development Awards (RRD 1IK2RX001316 and HSR&D CDA 12-263, respectively). Dr. Reiber is funded through a VA HSR&D Senior Research Career Scientist Award (RCS 98-353). The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the article; and in the decision to submit it for publication. The abstract for this paper was presented at the 2015 Society of Behavioral Medicine Annual Meeting. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 66 TC 3 Z9 3 U1 3 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD OCT PY 2015 VL 142 BP 100 EP 108 DI 10.1016/j.socscimed.2015.07.034 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CS4QL UT WOS:000362060900011 PM 26298646 ER PT J AU Zhang, WT Liu, J Hu, XM Li, PY Leak, RK Gao, YQ Chen, J AF Zhang, Wenting Liu, Jia Hu, Xiaoming Li, Peiying Leak, Rehana K. Gao, Yanqin Chen, Jun TI n-3 Polyunsaturated Fatty Acids Reduce Neonatal Hypoxic/Ischemic Brain Injury by Promoting Phosphatidylserine Formation and Akt Signaling SO STROKE LA English DT Article DE docosahexaenoic acids; eicosapentaenoic acid; neurons; omega-3 fatty acids; phosphatidylserine synthase ID FOCAL CEREBRAL-ISCHEMIA; DOCOSAHEXAENOIC ACID; NEURONAL APOPTOSIS; CELL-SURVIVAL; ACTIVATION; OMEGA-3-FATTY-ACIDS; NEUROPROTECTION; STROKE; DEATH; PHOSPHORYLATION AB Background and Purpose Omega-3 polyunsaturated fatty acids (n-3 PUFAs) attenuate neonatal hypoxic/ischemic (H/I) brain damage, but the underlying mechanisms are not fully understood. This study tested the hypothesis that n-3 PUFAs enhance Akt-dependent prosurvival signaling by promoting the biosynthesis of phosphatidylserine in neuronal cell membranes. Methods Dietary n-3 PUFA supplementation was initiated on the second day of pregnancy in dams. H/I was induced in 7-day-old rat pups by ipsilateral common carotid artery occlusion followed by hypoxia (8% oxygen for 2.5 hours). Neurological outcomes, brain tissue loss, cell death, and the activation of signaling events were assessed after H/I. The effects of n-3 PUFAs (docosahexaenoic acid and eicosapentaenoic acid) on oxygen-glucose deprivation-induced cell death and the underlying mechanism of protection were also examined in primary cortical neuron cultures. Resultsn-3 PUFAs reduced brain tissue loss at 7 days after H/I and improved neurological outcomes, whereas inhibition of PI3K/Akt signaling by LY294002 partially abrogated this neuroprotective effect. Docosahexaenoic acid/eicosapentaenoic acid also prevented ischemic neuronal death through the Akt prosurvival pathway in vitro. Furthermore, docosahexaenoic acid/eicosapentaenoic acid increased the production of phosphatidylserine, the major membrane-bound phospholipids, after ischemia both in vitro and in vivo. A reduction in membrane phosphatidylserine by shRNA-mediated knockdown of phosphatidylserine synthetase-1 attenuated Akt activation and neuronal survival after docosahexaenoic acid/eicosapentaenoic acid treatment in the oxygen-glucose deprivation model. Conclusionsn-3 PUFAs robustly protect against H/I-induced brain damage in neonates by activating Akt prosurvival pathway in compromised neurons. In addition, n-3 PUFAs promote the formation of membrane phosphatidylserine, thereby promoting Akt activity and improving cellular survival. C1 [Zhang, Wenting; Liu, Jia; Hu, Xiaoming; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Zhang, Wenting; Liu, Jia; Hu, Xiaoming; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200433, Peoples R China. [Hu, Xiaoming; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM wtzhang@fudan.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU US National Institutes of Health [NS095671, NS36736, NS089534, NS45048, NS092618]; US Department of Veterans Affairs [I01RX000420]; Chinese Natural Science Foundation [81020108021, 81171149, 81371306, 81571285, 81228008, 81529002]; Shanghai Committee of Science and Technology Support Program [14431907002]; American Heart Association [13SDG14570025]; China Postdoctoral Science Foundation [20110490665]; Shanghai Postdoctoral Sustentation Fund [11R21410500]; Fudan University [20520131150]; National Natural Science Foundation [81100978, 81471332, 81400956]; Science and Technology Commission of Shanghai Municipality [13ZR1452200] FX This project was supported by the US National Institutes of Health grants NS095671, NS36736, NS089534, and NS45048 (to Dr Chen) and NS092618 (to Dr Hu); the US Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review I01RX000420 (to Dr Chen); the Chinese Natural Science Foundation grants 81020108021, 81171149, 81371306, 81571285 (to Dr Gao), and 81228008, 81529002 (to Dr Chen); the Shanghai Committee of Science and Technology Support Program 14431907002 (to Dr Gao); and the American Heart Association Scientist Development grant 13SDG14570025 (to Dr Hu). Dr Zhang was supported by the China Postdoctoral Science Foundation grants (No. 20110490665), the Shanghai Postdoctoral Sustentation Fund (No. 11R21410500), the Young Teacher Program of Fudan University (No. 20520131150), and National Natural Science Foundation grants (No. 81100978 and No. 81471332). Dr Li is supported by the Science and Technology Commission of Shanghai Municipality (13ZR1452200) and National Natural Science Foundation grant (No. 81400956). NR 42 TC 3 Z9 4 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD OCT PY 2015 VL 46 IS 10 BP 2943 EP 2950 DI 10.1161/STROKEAHA.115.010815 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CS3TT UT WOS:000361998600034 PM 26374481 ER PT J AU Landow, SM Oh, DH Weinstock, MA AF Landow, Shoshana M. Oh, Dennis H. Weinstock, Martin A. TI Teledermatology Within the Veterans Health Administration, 2002-2014 SO TELEMEDICINE AND E-HEALTH LA English DT Article DE telehealth; telemedicine; teledermatology; teleconsultation AB Background:In order to increase veterans' access to dermatologic care, the Veterans Health Administration (VHA) has developed one of the largest teledermatology programs in the United States. This article describes the recent expansion of the VHA's teledermatology program after local and national initiatives and resource allocation.Materials and Methods:This report describes routinely collected VHA data.Results:For the first half of fiscal year 2014, the VHA recorded 31,926 teledermatology encounters, which represents 14% of all recorded teledermatology visits. Although every region in the VHA used teledermatology in the past year, four regions created 51% of the encounters. The use of store-and-forward telehealth (SFT), in which physicians view patient images after the patients were photographed, is increasing, whereas live video use is decreasing. Starting in 2012, encounters for patients in urban areas exceeded those in rural areas. The majority of patients were male veterans 60-79 years of age. Seventy-one percent of SFT consultations for the first half of 2014 were completed within 1 week.Conclusions:Although errors in and the evolution of coding encounters may distort results, the data show rapid growth of a telemedicine system that increases access to dermatology services for veterans. Most likely this growth reflects institutional commitment to telehealth via policy and resources. C1 [Landow, Shoshana M.; Weinstock, Martin A.] Providence VA Med Ctr, Providence, RI 02908 USA. [Landow, Shoshana M.; Weinstock, Martin A.] Brown Univ, Providence, RI 02912 USA. [Oh, Dennis H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Oh, Dennis H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Landow, SM (reprint author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA. EM Shoshana.Landow@va.gov NR 6 TC 6 Z9 6 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD OCT 1 PY 2015 VL 21 IS 10 BP 769 EP 773 DI 10.1089/tmj.2014.0225 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CS6LZ UT WOS:000362191800002 PM 26083585 ER PT J AU Wang, TY Henry, TD Mccoy, LA Berger, PB Cohen, DJ Effron, MB Zettler, M Baker, BA Messenger, JC Peterson, ED AF Wang, Tracy Y. Henry, Timothy D. Mccoy, Lisa A. Berger, Peter B. Cohen, David J. Effron, Mark B. Zettler, Marjorie Baker, Brian A. Messenger, John C. Peterson, Eric D. TI Contemporary use of platelet function and pharmacogenomic testingamongpatients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States SO AMERICAN HEART JOURNAL LA English DT Article ID ASSOCIATION TASK-FORCE; RANDOMIZED-TRIAL; CARDIOVASCULAR-ANGIOGRAPHY; PRACTICE GUIDELINES; CLOPIDOGREL; REACTIVITY; MANAGEMENT; PRASUGREL; THERAPY; SOCIETY AB Background Although platelet function and pharmacogenomic testing have been studied in clinical trials, their adoption into contemporary practice is unknown. Methods We studied patterns of platelet function and pharmacogenomic testing among 10,048 patients with acute myocardial infarction treated with percutaneous coronary intervention at 226 US hospitals in the TRANSLATE-ACS observational study between April 2010 and October 2012, excluding those receiving research protocol-mandated testing. Inverse probability-weighted propensity adjustment was used to compare 1-year bleeding and major adverse cardiac event risks between patients with and without testing. Results Overall, 337 (3.4%) patients underwent predischarge platelet function testing, whereas 85 (0.9%) underwent pharmacogenomic testing; 82% and 93% of hospitals never performed any platelet function or pharmacogenomic testing, respectively. Patients undergoing testing were more likely to be on an adenosine diphosphate receptor inhibitor preadmission or to have percutaneous coronary intervention of a previously treated lesion. Tested patients were more likely than nontested patients to be switched from clopidogrel to prasugrel/ticagrelor (25.7% vs 9.7%, P < .001) and were more likely to be on prasugrel/ticagrelor 6 months postdischarge (33.8% vs 25.1%, P < .001). No significant differences in 1-year bleeding and major adverse cardiac event risks were observed between tested and nontested patients (adjusted hazard ratios 1.06 [95% CI 0.68-1.65] and 1.21 [95% CI 0.94-1.54], respectively). Conclusions Platelet function and pharmacogenomic testing are rarely performed in contemporary myocardial infarction patients in the United States. When tested, patients were more likely to be treated with higher-potency adenosine diphosphate receptor inhibitors, yet no significant differences in longitudinal outcomes were observed. C1 [Wang, Tracy Y.; Mccoy, Lisa A.; Berger, Peter B.; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Henry, Timothy D.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA. [Cohen, David J.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Effron, Mark B.; Zettler, Marjorie] Lilly USA LLC, Indianapolis, IN USA. [Baker, Brian A.] Daiichi Sankyo Inc, Parsippany, NJ USA. [Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Wang, TY (reprint author), Duke Clin Res Inst, Durham, NC 27705 USA. EM tracy.wang@duke.edu RI Effron, Mark/P-9300-2015 FU Daiichi Sankyo, Inc; Lilly USA FX The TRANSLATE-ACS study (NCT01088503) is sponsored by Daiichi Sankyo, Inc, and Lilly USA. The Duke Clinical Research Institute is the coordinating center for this study, which represents a collaborative effort with the American College of Cardiology. NR 18 TC 2 Z9 2 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD OCT PY 2015 VL 170 IS 4 BP 706 EP 714 DI 10.1016/j.ahj.2015.06.021 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR8BD UT WOS:000361575200012 PM 26386794 ER PT J AU Kini, V McCarthy, FH Rajaei, S Epstein, AJ Heidenreich, PA Groeneveld, PW AF Kini, Vinay McCarthy, Fenton H. Rajaei, Sheeva Epstein, Andrew J. Heidenreich, Paul A. Groeneveld, Peter W. TI Variation in use of echocardiography among veterans who use the Veterans Health Administration vs Medicare SO AMERICAN HEART JOURNAL LA English DT Article ID LIFE TREATMENT INTENSITY; APPROPRIATE USE CRITERIA; QUALITY-OF-CARE; GEOGRAPHIC-VARIATION; UNITED-STATES; MYOCARDIAL-INFARCTION; REGIONAL-VARIATIONS; HEART-FAILURE; RISK; BENEFICIARIES AB Background Rapid growth in the provision of cardiac imaging tests has led to concerns about overuse. Little is known about the degree to which health care delivery system characteristics influence use and variation in echocardiography. Methods We analyzed administrative claims of veterans with heart failure older than 65 years from 2007 to 2010 across 34 metropolitan service areas (MSAs). We compared overall rates and geographic variation in use of transthoracic echocardiography (TTE) between veterans who used the Veterans Health Administration (VA) and propensity-matched veterans who used Medicare. "Dual users" were excluded. Results There were no significant differences in clinical characteristics ormortality between the propensity-matched cohorts (overall n = 30,404 veterans, mean age 76 years, mortality rate 52%). The Medicare cohort had a significantly higher overall rate of TTE use compared with the VA cohort (1.25 vs 0.38 TTEs per person-year, incidence rate ratio 2.89 [95% CI 2.80-3.00], both P < .001), but a similar coefficient of variation across MSAs (0.36 [95% CI 0.27-0.45] vs 0.48 [95% CI 0.37-0.59]). There was a moderate to strong correlation in variation at the MSA level between cohorts (Spearman r = 0.58, P < .001). Conclusion Overall rates of TTE use were significantly higher in a Medicare cohort compared with a propensity scorematched VA cohort of veterans with heart failure living in urban areas, with similar relative degrees of geographic variation and moderate to strong regional correlation. Rates of TTE use may be strongly influenced by health care system characteristics, but local practice styles influence echocardiography rates irrespective of health system. C1 [Kini, Vinay] Hosp Univ Penn, Div Cardiovasc Med, Philadelphia, PA 19104 USA. [Kini, Vinay; McCarthy, Fenton H.; Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [McCarthy, Fenton H.] Hosp Univ Penn, Div Cardiovasc Surg, Philadelphia, PA 19104 USA. [Rajaei, Sheeva; Heidenreich, Paul A.] Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA. [Epstein, Andrew J.; Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ & Res Promot, Dept Vet Affairs, Philadelphia, PA USA. [Epstein, Andrew J.; Groeneveld, Peter W.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Kini, V (reprint author), Hosp Univ Penn, Cardiovasc Med, 3400 Spruce St,9021 Gates, Philadelphia, PA 19104 USA. EM vinay.kini@uphs.upenn.edu FU NHLBI NIH HHS [T32 HL007843] NR 40 TC 1 Z9 1 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD OCT PY 2015 VL 170 IS 4 BP 805 EP 811 DI 10.1016/j.ahj.2015.07.016 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR8BD UT WOS:000361575200023 PM 26386805 ER PT J AU Melton, BL Zillich, AJ Russell, SA Weiner, M McManus, MS Spina, JR Russ, AL AF Melton, Brittany L. Zillich, Alan J. Russell, Scott A. Weiner, Michael McManus, M. Sue Spina, Jeffrey R. Russ, Alissa L. TI Reducing Prescribing Errors Through Creatinine Clearance Alert Redesign SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Electronic health records; Evaluation; Health information technology; Patient safety; Renal disease ID CLINICAL DECISION-SUPPORT; HUMAN-FACTORS PRINCIPLES; DRUG INTERACTION ALERTS; PHYSICIAN ORDER ENTRY; RENAL-INSUFFICIENCY; SAFETY ALERTS; SYSTEMS; DESIGN; EFFICIENCY; USABILITY AB BACKGROUND: Literature has shown that computerized creatinine clearance alerts reduce errors during prescribing, and applying human factors principles may further reduce errors. Our objective was to apply human factors principles to creatinine clearance alert design and assess whether the redesigned alerts increase usability and reduce prescribing errors compared with the original alerts. METHODS: Twenty Veterans Affairs (VA) outpatient providers (14 physicians, 2 nurse practitioners, and 4 clinical pharmacists) completed 2 usability sessions in a counterbalanced study to evaluate original and redesigned alerts. Each session consisted of fictional patient scenarios with 3 medications that warranted prescribing changes because of renal impairment, each associated with creatinine clearance alerts. Quantitative and qualitative data were collected to assess alert usability and the occurrence of prescribing errors. RESULTS: There were 43% fewer prescribing errors with the redesigned alerts compared with the original alerts (P = .001). Compared with the original alerts, redesigned alerts significantly reduced prescribing errors for allopurinol and ibuprofen (85% vs 40% and 65% vs 25%, P = .012 and P = .008, respectively), but not for spironolactone (85% vs 65%). Nine providers (45%) voiced confusion about why the alert was appearing when they encountered the original alert design. When laboratory links were presented on the redesigned alert, laboratory information was accessed 3.5 times more frequently. CONCLUSIONS: Although prescribing errors were high with both alert designs, the redesigned alerts significantly improved prescribing outcomes. This investigation provides some of the first evidence on how alerts may be designed to support safer prescribing for patients with renal impairment. (C) 2015 Elsevier Inc. All rights reserved. C1 [Melton, Brittany L.] Univ Kansas, Sch Pharm, Lawrence, KS 66045 USA. [Zillich, Alan J.; Russell, Scott A.; Weiner, Michael; Russ, Alissa L.] Hlth Serv Res & Dev Serv CIN 13 416, Ctr Hlth Informat & Commun, Dept Vet Affairs, Vet Hlth Adm, Indianapolis, IN USA. [Zillich, Alan J.; Weiner, Michael; Russ, Alissa L.] Regenstrief Inst Inc, Indianapolis, IN USA. [Zillich, Alan J.; Weiner, Michael; Russ, Alissa L.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Zillich, Alan J.; Russ, Alissa L.] Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA. [McManus, M. Sue] Nephrol Serv Cent Texas, Dept Vet Affairs, Temple, TX USA. [Spina, Jeffrey R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spina, Jeffrey R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Melton, BL (reprint author), 3901 Rainbow Blvd,Wescoe 6012,Mailstop 4047, Kansas City, KS 66160 USA. EM bmelton2@kumc.edu FU VA Health Services Research & Development Grant [PPO 09-298]; VA Health Services Research & Development Research Career Development Awards [CDA 11-214, RCD 06-304-1] FX This work was supported by VA Health Services Research & Development Grant PPO 09-298 (Principal Investigator, ALR). AJZ and ALR were supported by VA Health Services Research & Development Research Career Development Awards (CDA 11-214, and RCD 06-304-1, respectively). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US government. NR 42 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD OCT PY 2015 VL 128 IS 10 BP 1117 EP 1125 DI 10.1016/j.amjmed.2015.05.033 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CR9DE UT WOS:000361652600048 PM 26087048 ER PT J AU Brondfield, S Reid, M Patel, K Ten, R Dhaliwal, G AF Brondfield, Sam Reid, Michael Patel, Kiran Ten, Rosa Dhaliwal, Gurpreet TI Disseminated Mycobacterial Infection and Scabies Infestation SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Brondfield, Sam] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Reid, Michael] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Patel, Kiran] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Ten, Rosa] Univ Calif San Francisco, Dept Med, Div Pulm Allergy & Immunol, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Brondfield, S (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA. EM sam.brondfield@ucsf.edu NR 5 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD OCT PY 2015 VL 128 IS 10 BP E41 EP E42 DI 10.1016/j.amjmed.2015.06.008 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CR9DE UT WOS:000361652600015 PM 26149672 ER PT J AU Cavusoglu, E Marmur, JD Yanamadala, S Chopra, V Hegde, S Nazli, A Singh, KP Zhang, M Eng, C AF Cavusoglu, Erdal Marmur, Jonathan D. Yanamadala, Sunitha Chopra, Vineet Hegde, Sudhanva Nazli, Anila Singh, Kamal Preet Zhang, Ming Eng, Calvin TI Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome SO ATHEROSCLEROSIS LA English DT Article DE IL-8; Biomarkers; Acute coronary syndrome; Prognosis; Mortality ID HUMAN-ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; NATRIURETIC PEPTIDE; INTERLEUKIN-8; MACROPHAGES; EXPRESSION; PROTEIN; TISSUE; CHEMOATTRACTANT; POPULATION AB Objectives: To investigate the long-term prognostic significance of baseline plasma IL-8 levels in a group of well-characterized male patients presenting with acute coronary syndrome. Background: IL-8 is a cytokine that has been implicated in the pathogenesis of atherosclerosis and acute coronary syndrome. Elevated plasma levels have been reported in patients with acute coronary syndrome. Methods: Baseline plasma IL-8 levels were measured in 180 male patients with acute coronary syndrome who were referred for coronary angiography and followed prospectively for the development of all-cause mortality for 5 years. Results: In a multivariate model that included a wide variety of baseline clinical, laboratory and angiographic parameters in the selection process, baseline plasma IL-8 levels (analyzed as a continuous variable) emerged as a significant predictor of all-cause mortality at 5 years (HR, 1.43; 95% CI, 1.08-1.88; p = 0.0123). Furthermore, in 3 additional multivariate models that also included in the selection process a number of contemporary biomarkers with established prognostic efficacy in ACS (i.e., NT-proBNP, hs-CRP, hemoglobin and RDW), IL-8 remained an independent predictor of all-cause mortality at 5 years. Conclusion: Elevated baseline plasma levels of IL-8 are associated with an increased risk of long-term all-cause mortality in patients with acute coronary syndrome. Furthermore, this association is independent of a variety of clinical, laboratory and angiographic variables, including contemporary biomarkers with established prognostic efficacy in acute coronary syndrome. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Div Cardiol, Dept Med, Bronx, NY USA. [Cavusoglu, Erdal; Marmur, Jonathan D.; Yanamadala, Sunitha; Hegde, Sudhanva; Nazli, Anila; Singh, Kamal Preet] Suny Downstate Med Ctr, Div Cardiol, Dept Med, Brooklyn, NY 11203 USA. [Zhang, Ming] Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA. [Zhang, Ming] Suny Downstate Med Ctr, Dept Anesthesiol, Brooklyn, NY 11203 USA. RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 1199, Brooklyn, NY 11203 USA. EM ECavusoglu@aol.com NR 27 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD OCT PY 2015 VL 242 IS 2 BP 589 EP 594 DI 10.1016/j.atherosclerosis.2015.08.022 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CR7DV UT WOS:000361509000030 PM 26318109 ER PT J AU Nicolaidis, C Raymaker, DM Ashkenazy, E McDonald, KE Dern, S Baggs, AEV Kapp, SK Weiner, M Boisclair, WC AF Nicolaidis, Christina Raymaker, Dora M. Ashkenazy, Elesia McDonald, Katherine E. Dern, Sebastian Baggs, Amelia E. V. Kapp, Steven K. Weiner, Michael Boisclair, W. Cody TI "Respect the way I need to communicate with you": Healthcare experiences of adults on the autism spectrum SO AUTISM LA English DT Article DE adults; autism spectrum disorders; community-based participatory research; health services; qualitative research ID DISORDER; PARTNERSHIP; DISPARITIES; SERVICES; AQ AB Our objective was to obtain an in-depth understanding of autistic adults' experiences with healthcare and their recommendations for improving care. Our academic-community partnership used a community-based participatory research approach to conduct semi-structured, open-ended interviews with 39 autistic adults and 16 people who had experience supporting autistic adults in healthcare settings. Participants identified patient-level, autism-related factors that impact healthcare interactions, including verbal communication skills, sensory sensitivities, challenges with body awareness, slow processing speed, atypical non-verbal communication, and challenges with organization. However, the success of healthcare interactions largely depended on the interplay between patient- and provider-level factors, as well as the larger context in which patients were receiving care. Provider-level factors included providers' knowledge about autism in adults, incorrect assumptions about individual patients, willingness to allow written communication, use of accessible language, openness to providing other accommodations, and skill in appropriately incorporating supporters. System-level factors included the availability of supporters, complexity of the healthcare system, accessibility of healthcare facilities, and stigma about autism. Further efforts are needed to empower patients, adequately train providers, increase the accessibility of the healthcare system, and decrease discrimination. C1 [Nicolaidis, Christina; Raymaker, Dora M.] Portland State Univ, Portland, OR 97201 USA. [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Nicolaidis, Christina; Raymaker, Dora M.; Ashkenazy, Elesia; McDonald, Katherine E.; Dern, Sebastian; Baggs, Amelia E. V.; Kapp, Steven K.; Weiner, Michael; Boisclair, W. Cody] Acad Autist Spectrum Partnership Res & Educ, Washington, DC USA. [McDonald, Katherine E.] Syracuse Univ, Syracuse, NY 13244 USA. [Weiner, Michael] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Bloomington, IN 47405 USA. [Weiner, Michael] Regenstrief Inst Inc, Indianapolis, IN USA. [Weiner, Michael] US Dept Vet Affairs, Washington, DC USA. RP Nicolaidis, C (reprint author), Portland State Univ, Reg Res Inst, Sch Social Work, 1600 SW 4th Ave,Suite 900, Portland, OR 97201 USA. EM Nicol22@pdx.edu FU National Institute of Mental Health [R34MH092503]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research FX This study was funded by the National Institute of Mental Health [R34MH092503] and the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 20 TC 7 Z9 7 U1 2 U2 22 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1362-3613 EI 1461-7005 J9 AUTISM JI Autism PD OCT PY 2015 VL 19 IS 7 SI SI BP 824 EP 831 DI 10.1177/1362361315576221 PG 8 WC Psychology, Developmental SC Psychology GA CS0RK UT WOS:000361769700007 PM 25882392 ER PT J AU Williams, DL Minshew, NJ Goldstein, G AF Williams, Diane L. Minshew, Nancy J. Goldstein, Gerald TI Further understanding of complex information processing in verbal adolescents and adults with autism spectrum disorders SO AUTISM LA English DT Article DE adults; autism spectrum disorders; conceptual reasoning; information processing; language ID HIGH-FUNCTIONING AUTISM; DIAGNOSTIC OBSERVATION SCHEDULE; UNDERCONNECTIVITY; INDIVIDUALS; CHILDREN; SYNCHRONIZATION; COMPREHENSION; ACTIVATION; INTERVIEW; LANGUAGE AB More than 20years ago, Minshew and colleagues proposed the Complex Information Processing model of autism in which the impairment is characterized as a generalized deficit involving multiple modalities and cognitive domains that depend on distributed cortical systems responsible for higher order abilities. Subsequent behavioral work revealed a related dissociation between concept formation and concept identification in autism suggesting the lack of an underlying organizational structure to manage increases in processing loads. The results of a recent study supported the impact of this relative weakness in conceptual reasoning on adaptive functioning in children and adults with autism. In this study, we provide further evidence of the difficulty relatively able older adolescents and adults with autism have with conceptual reasoning and provide evidence that this characterizes their difference from age- and ability-matched controls with typical development better than their differences in language. For verbal adults with autism, language may serve as a bootstrap or compensatory mechanism for learning but cannot overcome an inherent weakness in concept formation that makes information processing challenging as task demands increase. C1 [Williams, Diane L.] Duquesne Univ, Pittsburgh, PA USA. [Minshew, Nancy J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr 151R, Pittsburgh, PA 15240 USA. EM ggold@nb.net RI Williams, Diane/B-4128-2017 FU National Institute of Neurological Disorders and Stroke (NINDS) [NS3335]; National Institute of Child Health and Human Development (NICHD) Collaborative Program of Excellence in Autism (CPEA) [HD35469]; Medical Research Service, Department of Veterans Affairs FX This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS) [grant NS3335]; by the National Institute of Child Health and Human Development (NICHD) Collaborative Program of Excellence in Autism (CPEA) [grant HD35469]; and the Medical Research Service, Department of Veterans Affairs. NR 49 TC 4 Z9 4 U1 5 U2 18 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1362-3613 EI 1461-7005 J9 AUTISM JI Autism PD OCT PY 2015 VL 19 IS 7 SI SI BP 859 EP 867 DI 10.1177/1362361315586171 PG 9 WC Psychology, Developmental SC Psychology GA CS0RK UT WOS:000361769700011 PM 26019307 ER PT J AU Urbano-Ispizua, A Pavletic, SZ Flowers, ME Klein, JP Zhang, MJ Carreras, J Montoto, S Perales, MA Aljurf, MD Akpek, G Bredeson, CN Costa, LJ Dandoy, C Freytes, CO Fung, HC Gale, RP Gibson, J Hamadani, M Hayashi, RJ Inamoto, Y Inwards, DJ Lazarus, HM Maloney, DG Martino, R Munker, R Nishihori, T Olsson, RF Rizzieri, DA Reshef, R Saad, A Savani, BN Schouten, HC Smith, SM Socie, G Wirk, B Yu, LC Saber, W AF Urbano-Ispizua, Alvaro Pavletic, Steven Z. Flowers, Mary E. Klein, John P. Zhang, Mei-Jie Carreras, Jeanette Montoto, Silvia Perales, Miguel-Angel Aljurf, Mahmoud D. Akpek, Goerguen Bredeson, Christopher N. Costa, Luciano J. Dandoy, Christopher Freytes, Cesar O. Fung, Henry C. Gale, Robert Peter Gibson, John Hamadani, Mehdi Hayashi, Robert J. Inamoto, Yoshihiro Inwards, David J. Lazarus, Hillard M. Maloney, David G. Martino, Rodrigo Munker, Reinhold Nishihori, Taiga Olsson, Richard F. Rizzieri, David A. Reshef, Ran Saad, Ayman Savani, Bipin N. Schouten, Harry C. Smith, Sonali M. Socie, Gerard Wirk, Baldeep Yu, Lolie C. Saber, Wael TI The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Graft-versus-host disease; Lymphoma ID STEM-CELL TRANSPLANTATION; BONE-MARROW TRANSPLANT; NON-HODGKIN-LYMPHOMA; ALLOGENEIC TRANSPLANTATION; FOLLICULAR LYMPHOMA; AUTOLOGOUS TRANSPLANTATION; EUROPEAN GROUP; BLOOD; INFUSIONS; REMISSIONS AB The purpose of this study was to analyze the impact of graft-versus-host disease (GVHD) on the relapse rate of different lymphoma subtypes after allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients with a diagnosis of Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma (FL), peripheral T cell lymphoma, or mantle cell lymphoma (MCL) undergoing HLA-identical sibling or unrelated donor hematopoietic cell transplantation between 1997 and 2009 were included. Two thousand six hundred eleven cases were included. A reduced-intensity conditioning (RIC) regimen was used in 62.8% of the transplantations. In a multivariate analysis of myeloablative cases (n = 970), neither acute (aGVHD) nor chronic GVHD (cGVHD) were significantly associated with a lower incidence of relapse/progression in any lymphoma subtype. In contrast, the analysis of RIC cases (n = 1641) showed that cGVHD was associated with a lower incidence of relapse/progression in FL (risk ratio [RR],.51; P = 3.049) and in MCL (RR,.41; P = .019). Patients with FL or MCL developing both aGVHD and cGVHD had the lowest risk of relapse (RR,.14; P = .007; and RR,.15; P = .0019, respectively). Of interest, the effect of GVHD on decreasing relapse was similar in patients with sensitive disease and chemoresistant disease. Unfortunately, both aGVHD and cGVHD had a deleterious effect on treatment-related mortality and overall survival (OS) in FL cases but did not affect treatment-related mortality, OS or PFS in MCL. This study reinforces the use of RIC allo-HCT as a platform for immunotherapy in FL and MCL patients. (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Urbano-Ispizua, Alvaro] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Hematol, Barcelona, Spain. [Urbano-Ispizua, Alvaro] Inst Res Josep Carreras, Barcelona, Spain. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Flowers, Mary E.; Inamoto, Yoshihiro; Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Klein, John P.; Zhang, Mei-Jie; Carreras, Jeanette; Hamadani, Mehdi; Saber, Wael] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Klein, John P.; Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Montoto, Silvia] Barts Hlth NHS Trust, St Bartholomews Hosp, Dept Haematooncol, London, England. [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, Bone Marrow Transplant Serv, New York, NY 10021 USA. [Aljurf, Mahmoud D.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. [Akpek, Goerguen] Banner MD Anderson Canc Ctr, Hematol Oncol Sect, Gilbert, AZ USA. [Bredeson, Christopher N.] Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada. [Bredeson, Christopher N.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Costa, Luciano J.; Saad, Ayman] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Dandoy, Christopher] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fung, Henry C.] Temple Hlth, Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA USA. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. [Gibson, John] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia. [Hayashi, Robert J.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA. [Inwards, David J.] Mayo Clin, Div Hematol, Rochester, MN USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Div Hematol, Barcelona, Spain. [Munker, Reinhold] Louisiana State Univ Hlth, Dept Internal Med, Div Hematol Oncol, Shreveport, LA USA. [Nishihori, Taiga] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Med Oncol, Tampa, FL 33612 USA. [Olsson, Richard F.] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden. [Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Rizzieri, David A.] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Reshef, Ran] Univ Penn, Dept Med, Abramson Canc Ctr, Med Ctr, Philadelphia, PA 19104 USA. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Schouten, Harry C.] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands. [Smith, Sonali M.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA. [Socie, Gerard] Hop St Louis, Dept Hematol, Paris, France. [Wirk, Baldeep] SUNY Stony Brook, Med Ctr, Dept Internal Med, Stony Brook, NY 11794 USA. [Yu, Lolie C.] Louisiana State Univ, Med Ctr, Childrens Hosp, Div Hematol Oncol,Ctr Canc & Blood Disorders, New Orleans, LA USA. RP Urbano-Ispizua, A (reprint author), Hosp Clin Barcelona, Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain. EM aurbano@clinic.ub.es OI Saad, Ayman /0000-0003-0003-0130 FU National Cancer Institute [U24-CA076518]; National Heart, Lung, and Blood Institute [5U10HL069294]; National Institute of Allergy and Infectious Diseases; Health Resources and Services Administration [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen FX The CIBMTR is supported by Public Health Service grant/cooperative agreement U24-CA076518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases; grant/cooperative agreement 5U10HL069294 from the National Heart, Lung, and Blood Institute and National Cancer Institute; contract HHSH250201200016C with Health Resources and Services Administration; 2 grants from the Office of Naval Research (N00014-12-1-0142 and N00014-13-1-0039); and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen; an anonymous donation to the Medical College of Wisconsin; Ariad; Be The Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; Roswell Park Cancer Institute; Histo-Genetics; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co., Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; 'Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *Terumo BCT; *Teva Neuroscience, Inc.; *Therakos; University of Minnesota; University of Utah; and *WellPoint. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. NR 27 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2015 VL 21 IS 10 BP 1746 EP 1753 DI 10.1016/j.bbmt.2015.05.010 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CS0VU UT WOS:000361781100009 PM 25981509 ER PT J AU Khera, N Majhail, NS Brazauskas, R Wang, ZW He, NY Aljurf, MD Akpek, G Atsuta, Y Beattie, S Bredeson, CN Burns, LJ Dalal, JD Freytes, CO Gupta, V Inamoto, Y Lazarus, HM LeMaistre, CF Steinberg, A Szwajcer, D Wingard, JR Wirk, B Wood, WA Joffe, S Hahn, TE Loberiza, FR Anasetti, C Horowitz, MM Lee, SJ AF Khera, Nandita Majhail, Navneet S. Brazauskas, Ruta Wang, Zhiwei He, Naya Aljurf, Mahmoud D. Akpek, Goerguen Atsuta, Yoshiko Beattie, Sara Bredeson, Christopher N. Burns, Linda J. Dalal, Jignesh D. Freytes, Cesar O. Gupta, Vikas Inamoto, Yoshihiro Lazarus, Hillard M. LeMaistre, Charles F. Steinberg, Amir Szwajcer, David Wingard, John R. Wirk, Baldeep Wood, William A. Joffe, Steven Hahn, Theresa E. Loberiza, Fausto R. Anasetti, Claudio Horowitz, Mary M. Lee, Stephanie J. TI Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Trial participation; Hematopoietic cell transplantation ID VERSUS-HOST-DISEASE; UNRELATED DONORS; MYOCARDIAL-INFARCTION; EXTERNAL VALIDITY; IMPROVED SURVIVAL; CANCER; POPULATION; GENERALIZABILITY; LEUKEMIA; REGISTRY AB Controversy surrounds the question of whether clinical trial participants have better outcomes than comparable patients who are not treated on a trial. We explored this question using a recent large, randomized, multicenter study comparing peripheral blood (PB) with bone marrow transplantation from unrelated donors, conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). We compared characteristics and outcomes of study participants (n = 494) and nonparticipants (n = 1384) who appeared eligible and received similar treatment without enrolling on the BMT CTN trial at participating centers during the study time period. Data were obtained from the Center for International Blood and Marrow Transplant Research. Outcomes were compared between the 2 groups using Cox proportional hazards regression models. No significant differences in age, sex, disease distribution, race/ethnicity, HLA matching, comorbidities, and interval from diagnosis to hematopoietic cell transplantation were seen between the participants and non-participants. Nonparticipants were more likely to have lower performance status, lower risk disease, and older donors, and to receive myeloablative conditioning and antithymocyte globulin. Nonparticipants were also more likely to receive PB grafts, the intervention tested in the trial (66% versus 50%, P < .001). Overall survival, transplantation-related mortality, and incidences of acute or chronic graft-versus-host disease were comparable between the 2 groups though relapse was higher (hazard ratio, 1.22; 95% confidence interval, 1.02 to 1.46; P = .028) in nonparticipants. Despite differences in certain baseline characteristics, survival was comparable between study participants and nonparticipants. The results of the BMT CTN trial appear generalizable to the population of trial-eligible patients. (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Khera, Nandita] Mayo Clin, Dept Hematol Oncol, Phoenix, AZ 85054 USA. [Majhail, Navneet S.] Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. [Brazauskas, Ruta; Wang, Zhiwei; He, Naya; Horowitz, Mary M.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Brazauskas, Ruta] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Aljurf, Mahmoud D.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. [Akpek, Goerguen] Banner MD Anderson Canc Ctr, Hematol Oncol Sect, Gilbert, AZ USA. [Atsuta, Yoshiko] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Aichi, Japan. [Atsuta, Yoshiko] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan. [Beattie, Sara] Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada. [Bredeson, Christopher N.] Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada. [Bredeson, Christopher N.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Burns, Linda J.] Be Match, Natl Marrow Donor Program, Hlth Serv Res, Minneapolis, MN USA. [Dalal, Jignesh D.] Childrens Mercy Hosp & Clin, Bone Marrow Transplantat, Pediat Hematol Oncol, Kansas City, MO USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gupta, Vikas] Univ Hlth Network, Blood & Marrow Transplant Program, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Inamoto, Yoshihiro] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan. [Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA. [LeMaistre, Charles F.] Sarah Cannon, Hematol & Bone Marrow Transplant, Nashville, TN USA. [Steinberg, Amir] Mt Sinai Hosp, Dept Hematol Oncol, New York, NY 10029 USA. [Szwajcer, David] Univ Manitoba, Dept Hematol, CancerCare Manitoba, Winnipeg, MB, Canada. [Wingard, John R.] Univ Florida, Div Hematol & Oncol, Dept Med, Gainesville, FL USA. [Wirk, Baldeep] SUNY Stony Brook, Dept Internal Med, Stony Brook, NY 11794 USA. [Wood, William A.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. [Joffe, Steven] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Hahn, Theresa E.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Loberiza, Fausto R.] Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. [Anasetti, Claudio] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Bone Marrow Transplant Program, Tampa, FL 33612 USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Clin Transplant Res, Seattle, WA 98104 USA. RP Khera, N (reprint author), Mayo Clin, Coll Med, Med, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA. EM khera.nandita@mayo.edu OI Joffe, Steven/0000-0002-0667-7384 FU NCI [U24-CA076518]; NHLBI; National Institute of Allergy and Infectious Diseases; NHLBI [5U10HL069294]; NCI; Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen FX The CIBMTR is supported by Public Health Service grant/cooperative agreement U24-CA076518 from the NCI, the NHLBI, and the National Institute of Allergy and Infectious Diseases; a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen; anonymous donation to the Medical College of Wisconsin; Ariad; Be The Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co., Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *Terumo BCT; *Teva Neuroscience, Inc.; *Therakos; University of Minnesota; University of Utah; and *WellPoint. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government. NR 24 TC 2 Z9 2 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2015 VL 21 IS 10 BP 1815 EP 1822 DI 10.1016/j.bbmt.2015.06.004 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CS0VU UT WOS:000361781100019 PM 26071866 ER PT J AU Ozieh, MN Bishu, KG Dismuke, CE Egede, LE AF Ozieh, Mukoso N. Bishu, Kinfe G. Dismuke, Clara E. Egede, Leonard E. TI Trends in Health Care Expenditure in US Adults With Diabetes: 2002-2011 SO DIABETES CARE LA English DT Article ID MEDICARE PART D; UNITED-STATES; DRUG COVERAGE; COSTS; HYPERTENSION; PROJECTIONS; DIAGNOSIS; MELLITUS; RECEIPT; BURDEN AB OBJECTIVEDirect medical cost of diabetes in the U.S. has been estimated to be 2.3 times higher relative to individuals without diabetes. This study examines trends in health care expenditures by expenditure category in U.S. adults with diabetes between 2002 and 2011.RESEARCH DESIGN AND METHODSWe analyzed 10 years of data representing a weighted population of 189,013,514 U.S. adults aged 18 years from the Medical Expenditure Panel Survey. We used a novel two-part model to estimate adjusted mean and incremental medical expenditures by diabetes status, while adjusting for demographics, comorbidities, and time.RESULTSRelative to individuals without diabetes ($5,058 [95% CI 4,949-5,166]), individuals with diabetes ($12,180 [11,775-12,586]) had more than double the unadjusted mean direct expenditures over the 10-year period. After adjustment for confounders, individuals with diabetes had $2,558 (2,266-2,849) significantly higher direct incremental expenditures compared with those without diabetes. For individuals with diabetes, inpatient expenditures rose initially from $4,014 in 2002/2003 to $4,183 in 2004/2005 and then decreased continuously to $3,443 in 2010/2011, while rising steadily for individuals without diabetes. The estimated unadjusted total direct expenditures for individuals with diabetes were $218.6 billion/year and adjusted total incremental expenditures were approximately $46 billion/year.CONCLUSIONSOur findings show that compared with individuals without diabetes, individuals with diabetes had significantly higher health expenditures from 2002 to 2011 and the bulk of the expenditures came from hospital inpatient and prescription expenditures. C1 [Ozieh, Mukoso N.; Bishu, Kinfe G.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Ozieh, Mukoso N.; Bishu, Kinfe G.; Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Dismuke, Clara E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K24DK093699] FX This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant K24DK093699, principal investigator L.E.E.). NR 36 TC 9 Z9 9 U1 2 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2015 VL 38 IS 10 BP 1844 EP 1851 DI 10.2337/dc15-0369 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CS1PW UT WOS:000361840500019 PM 26203060 ER PT J AU Markland, AD Burgio, KL Whitehead, WE Richter, HE Wilcox, CM Redden, DT Beasley, TM Goode, PS AF Markland, Alayne D. Burgio, Kathryn L. Whitehead, William E. Richter, Holly E. Wilcox, C. Mel Redden, David T. Beasley, Timothy M. Goode, Patricia S. TI Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence: The Fecal Incontinence Prescription (Rx) Management (FIRM) Randomized Clinical Trial SO DISEASES OF THE COLON & RECTUM LA English DT Article DE Accidental bowel leakage; Comparative effectiveness; Crossover design; Fecal incontinence; Functional bowel disorders; Quality of life; Randomized controlled trial ID QUALITY-OF-LIFE; RISK-FACTORS; CROSSOVER TRIALS; ANORECTAL DISORDERS; NICE GUIDANCE; ADULTS; PREVALENCE; HEALTH; OLDER; SUPPLEMENTATION AB BACKGROUND: Fecal incontinence is a devastating condition with few US Food and Drug Administration-approved pharmacologic treatment options. Loperamide and psyllium, both first-line treatments, have different mechanisms of action without any comparative data. OBJECTIVE: The purpose of this study was to examine the effectiveness and tolerability of loperamide compared with psyllium for reducing fecal incontinence. We hypothesized that psyllium fiber supplementation would be more effective than loperamide for reducing fecal incontinence episodes and have fewer adverse effects. DESIGN: We conducted a randomized, double-blind, placebo-controlled crossover trial comparing loperamide (followed by psyllium) with psyllium (followed by loperamide). SETTINGS: Our sites included outpatient clinics within a Veterans Affairs medical center and university affiliate. PATIENTS: Participants included community-dwelling adults (n = 80) with at least 1 fecal incontinent episode on a 7-day bowel diary. INTERVENTION: Participants received either daily loperamide (plus placebo psyllium powder) or psyllium powder (plus loperamide placebo) for 4 weeks. After a 2-week washout, participants crossed over to 4 weeks of alternate treatment. MAIN OUTCOME MEASURES: The primary outcome was the number of fecal incontinence episodes from 7-day bowel diaries. Secondary outcomes included symptom severity, quality of life, and tolerability. RESULTS: Mean age was 60.7 10.1 years; 68% were men. After determining nonsignificant carryover effects, combined analyses showed no differences between the loperamide and psyllium groups for reducing fecal incontinent episodes, symptom severity, or quality of life. Within each group, both loperamide and psyllium reduced fecal incontinent episodes and improved symptom severity and quality of life. Constipation occurred in 29% of participants for loperamide vs 10% for psyllium. LIMITATIONS: Limitations include the washout period length and dropout rate after crossing over to the second intervention. CONCLUSIONS: Both loperamide and psyllium improve fecal incontinence. Loperamide was associated with more adverse effects, especially constipation. C1 [Markland, Alayne D.; Burgio, Kathryn L.; Goode, Patricia S.] Birmingham Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Markland, Alayne D.; Burgio, Kathryn L.; Goode, Patricia S.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35233 USA. [Whitehead, William E.] Univ N Carolina, Dept Med, Div Gastroenterol, Chapel Hill, NC USA. [Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Urogynecol & Pelv Reconstruct Surg, Birmingham, AL 35233 USA. [Wilcox, C. Mel] Univ Alabama Birmingham, Dept Med, Div Gastroenterol, Birmingham, AL 35233 USA. [Redden, David T.; Beasley, Timothy M.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35233 USA. RP Markland, AD (reprint author), Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham Vet Affairs Med Ctr, GRECC 11-G,900 South 18th St, Birmingham, AL 35233 USA. EM markland@uab.edu OI Markland, Alayne/0000-0002-6567-6744 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Career Development Awards [CDA-2, B6126W]; John A. Hartford Foundation through the Southeast Center of Excellence in Geriatric Medicine FX This study was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Career Development Awards (CDA-2) to Dr Markland (B6126W) and a grant from the John A. Hartford Foundation through the Southeast Center of Excellence in Geriatric Medicine. NR 36 TC 7 Z9 7 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0012-3706 EI 1530-0358 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD OCT PY 2015 VL 58 IS 10 BP 983 EP 993 DI 10.1097/DCR.0000000000000442 PG 11 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CR6JJ UT WOS:000361452300010 PM 26347971 ER PT J AU Rodriguez, HP Meredith, LS Hamilton, AB Yano, EM Rubenstein, LV AF Rodriguez, Hector P. Meredith, Lisa S. Hamilton, Alison B. Yano, Elizabeth M. Rubenstein, Lisa V. TI Huddle up!: The adoption and use of structured team communication for VA medical home implementation SO HEALTH CARE MANAGEMENT REVIEW LA English DT Article DE huddles; organizational change; practice redesign; team communication; teamwork ID TRANSACTIVE MEMORY-SYSTEMS; PRIMARY-CARE; LEARNING ORGANIZATION; SITUATION AWARENESS; READINESS; FRAMEWORK; BURNOUT AB Background: Daily clinical team meetings (i.e., huddles) may be helpful in implementing new roles and responsibilities for patient care because they provide a regular opportunity for member learning and feedback. Purposes: We examined how huddles were implemented in the context of the VA patient-centered medical home (PCMH) transformation, including assessing barriers and facilitators to regular huddling among small teams (teamlets). We assessed the extent to which teamlet members that huddled had higher self-efficacy for PCMH changes, reported better teamwork experiences, and perceived more supportive practice environments. Methodology/Approach: We used a convergent mixed-methods approach to analyze 79 teamlet member interviews from six VA primary care practices and 418 clinician and staff PCMH survey responses from the six interviewed practices and 13 additional practices in the same region. Findings: Most members reported participating in teamlet huddles when asked in surveys (85%). A minority of interview participants, however, described routine huddling focused on previsit planning that included all members. When members reported routine teamlet huddling, activities included (a) previsit planning, (b) strategizing treatment plans for patients with special or complex needs, (c) addressing daily workflow and communication issues through collective problem solving, and (d) ensuring awareness of what team members do and what actions are happening on the teamlet and in the practice. Primary care providers (PCPs) were least likely to report routine huddling. PCP huddlers reported greater self-efficacy for implementing PCMH changes. All huddlers, irrespective of role, reported better teamwork and more supportive practice climates. The most common barriers to teamlet huddling were limited time and operational constraints. Practice Implications: In order to improve the impact of huddles on patient care, practice leaders should clearly communicate the goals, requirements, and benefits of huddling and provide adequate time and resources to ensure that frontline teams use huddle time to improve patient care. C1 [Rodriguez, Hector P.] Univ Calif Berkeley, Sch Publ Hlth, Ctr Healthcare Org & Innovat Res, Hlth Policy & Management, Berkeley, CA 94720 USA. [Rodriguez, Hector P.] Univ Calif Berkeley, Sch Publ Hlth, Ctr Healthcare Org & Innovat Res, Berkeley, CA 94720 USA. [Meredith, Lisa S.] RAND Corp, Behav & Policy Sci Res Dept, Santa Monica, CA USA. [Hamilton, Alison B.; Yano, Elizabeth M.] VA Greater Los Angeles Hlth Care Syst, HSR&D Ctr Study Healthcare Innovat Implementat &, North Hills, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ, Hlth Policy & Management, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] Ctr Implementat Practice & Res Support, North Hills, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Med, Los Angeles, CA 90024 USA. RP Rodriguez, HP (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Healthcare Org & Innovat Res, Hlth Policy & Management, Berkeley, CA 94720 USA. EM hrod@berkeley.edu FU Veterans Health Administration's PACT Demonstration Laboratory initiative; VA Office of Patient Care Services; VA HSR&D Service Senior Research Career Scientist award [05-195] FX This work was undertaken as part of the Veterans Health Administration's PACT Demonstration Laboratory initiative, supporting and evaluating VA's transition to a patient-centered medical home. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. Dr. Yano's effort was funded by a VA HSR&D Service Senior Research Career Scientist award (Project #05-195). The views expressed within are solely those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 32 TC 5 Z9 5 U1 3 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0361-6274 EI 1550-5030 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD OCT-DEC PY 2015 VL 40 IS 4 BP 286 EP 299 DI 10.1097/HMR.0000000000000036 PG 14 WC Health Policy & Services SC Health Care Sciences & Services GA CR8LU UT WOS:000361604800003 PM 25029511 ER PT J AU Lambiase, MJ Kubzansky, LD Thurston, RC AF Lambiase, Maya J. Kubzansky, Laura D. Thurston, Rebecca C. TI Positive Psychological Health and Stroke Risk: The Benefits of Emotional Vitality SO HEALTH PSYCHOLOGY LA English DT Article DE psychological health; emotions; stroke; cardiovascular disease; prospective ID CARDIOVASCULAR HEALTH; ASSOCIATION AB Objective: Stroke is a leading cause of death and disability. Various forms of positive psychological health (e.g., emotional vitality) are associated with lower risk for heart disease. However, it is unclear whether positive psychological health may also be beneficial for stroke risk. The purpose of the present study was to examine prospectively the association between emotional vitality and incident stroke in a nationally representative sample of 6,019 participants in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Methods: Emotional vitality was assessed via self-report at study baseline in 1971-1975. Stroke cases were identified from hospital/nursing home discharge reports and death certificates. Multivariate Cox proportional hazards regression models were used to estimate hazard ratios and 95% confidence intervals of incident stroke associated with a 1 SD increase in emotional vitality scores. Models were adjusted for traditional cardiovascular disease risk factors and subsequently for psychological distress. Results: Higher emotional vitality was associated with lower risk of incident stroke over a mean of 16.29 (SD = 4.75) years of follow -up (hazard ratio = 0.89; 95% confidence interval: 0.81, 0.99). Findings persisted when controlling for traditional cardiovascular disease risk factors and psychological distress. Conclusions: Higher levels of emotional vitality were prospectively associated with lower stroke risk in a representative sample of the U.S. population. Associations were independent of psychological distress. Results point to the potential importance of positive psychological functioning for cardiovascular health and for stroke prevention. C1 [Lambiase, Maya J.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Pittsburgh, PA 15240 USA. [Lambiase, Maya J.; Thurston, Rebecca C.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Kubzansky, Laura D.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Cambridge, MA 02138 USA. RP Lambiase, MJ (reprint author), VA Pittsburgh Healthcare Syst, Res Off Bldg 151R,Univ Dr C, Pittsburgh, PA 15240 USA. EM Maya.Lambiase@va.gov FU Department of Veterans Affairs Advanced Fellowship in Women's Health, VA Pittsburgh Healthcare System; National Institute of Mental Health [MH092707-01]; Robert Wood Johnson Foundation Health and Society Scholars Implementation [045821]; Robert Wood Johnson Foundation FX This work is supported by resources and funding from the Department of Veterans Affairs Advanced Fellowship in Women's Health, VA Pittsburgh Healthcare System. This work was also supported by the National Institute of Mental Health (MH092707-01), the Robert Wood Johnson Foundation Health and Society Scholars Implementation Grant 045821, and the Robert Wood Johnson Foundation grant, "Exploring the Concept of Positive Health." The contents do not represent the views of the Department of Veterans Affairs, Department of Defense, or the United States Government. NR 13 TC 3 Z9 3 U1 4 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD OCT PY 2015 VL 34 IS 10 BP 1043 EP 1046 DI 10.1037/hea0000228 PG 4 WC Psychology, Clinical; Psychology SC Psychology GA CR8XC UT WOS:000361636600009 PM 25867031 ER PT J AU Korsten, MA Spungen, AM Radulovic, M Rosman, AS Hunt, K Galea, MD Kornfeld, SD Lyons, BL Yen, C Bauman, WA AF Korsten, Mark A. Spungen, Ann M. Radulovic, Miroslav Rosman, Alan S. Hunt, Kristel Galea, Marinella D. Kornfeld, Stephen D. Lyons, Brian L. Yen, Christina Bauman, William A. TI Neostigmine Administered With MoviPrep Improves Bowel Preparation for Elective Colonoscopy in Patients With Spinal Cord Injury A Randomized Study SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE neostigmine; MoviPrep; paraplegia; tetraplegia; colonoscopy ID ORAL SODIUM-PHOSPHATE; POLYETHYLENE-GLYCOL SOLUTION; MAGNESIUM CITRATE; CONTROLLED-TRIAL; LAVAGE SOLUTION; GLYCOPYRROLATE; EVACUATION; REGIMENS; EFFICACY; SAFETY AB Background:Poor preparation for elective colonoscopy is exceedingly common in persons with spinal cord injury (SCI). This unsatisfactory outcome is likely due to long-standing difficulty with evacuation and decreased colonic motility, which may result in inadequate responses to conventional bowel preparation regimens. We determined whether the addition of neostigmine to MoviPrep before elective colonoscopy produced a higher percentage of acceptable bowel preparations in patients with SCI.Methods:Twenty-seven SCI subjects were prospectively randomized to 1 of 2 arms: low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep) or MoviPrep plus neostigmine methylsulfate and glycopyrrolate (MoviPrep+NG); 28 able-bodied subjects received MoviPrep alone. The quality of the cleansing preparation for colonoscopy was determined by gastroenterologists calibrated to use the Ottawa Scoring System, with an acceptable Ottawa Score (OS) considered to be 3.Results:The administration of MoviPrep alone resulted in suboptimal bowel cleansing in the SCI group compared with the able-bodied group (50% vs. 89% of subjects had an acceptable OS; (2)=7.94, P=0.05). However, when NG was added to MoviPrep in the SCI group, it markedly improved the quality of the bowel preparation, with 85% of patients then having an acceptable OS. The use of NG resulted in minimal bloating and distention before bowel evacuation (P=0.0005), and eye and muscle twitching; these were resolved within 1 hour after NG administration. No significant differences were noted among the preparation groups for adenoma detection rate (P=0.41).Conclusions:The combination of MoviPrep+NG was safe, well tolerated, and an effective approach to prepare the bowel for elective colonoscopy in patients with SCI. The side effects of this preparation were significant compared with the other treatment groups but were considered mild and anticipated. C1 [Korsten, Mark A.; Spungen, Ann M.; Radulovic, Miroslav; Galea, Marinella D.; Kornfeld, Stephen D.; Lyons, Brian L.; Yen, Christina; Bauman, William A.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Korsten, Mark A.; Radulovic, Miroslav; Rosman, Alan S.; Hunt, Kristel; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Korsten, Mark A.; Galea, Marinella D.; Kornfeld, Stephen D.; Bauman, William A.] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Korsten, Mark A.; Spungen, Ann M.; Radulovic, Miroslav; Rosman, Alan S.; Hunt, Kristel; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.; Galea, Marinella D.; Kornfeld, Stephen D.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP Korsten, MA (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Rm 7 A-13 K,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM mark.korsten@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service [A6428R, B2468-C, B4162-C]; James J. Peters VA Medical Center FX Supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (#A6428R, #B2468-C, #B4162-C) and the James J. Peters VA Medical Center. None of the authors have financial interests with Salix, the manufacturer of MoviPrep. NR 20 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD OCT PY 2015 VL 49 IS 9 BP 751 EP 756 DI 10.1097/MCG.0000000000000284 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CR6SR UT WOS:000361478200006 PM 25599220 ER PT J AU Ibrahim, SA AF Ibrahim, S. A. TI Equity in Lung Cancer Care and Outcomes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID SURVIVAL; COMORBIDITY; SMOKING; RACE C1 [Ibrahim, S. A.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Ibrahim, S. A.] Philadelphia VA Med Ctr ANNEX, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Ibrahim, SA (reprint author), Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. EM Said.Ibrahim2@va.gov FU NIAMS NIH HHS [K24AR055259, K24 AR055259] NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2015 VL 30 IS 10 BP 1385 EP 1386 DI 10.1007/s11606-015-3346-y PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CS0MR UT WOS:000361755000002 PM 25903994 ER PT J AU Aysola, J Werner, RM Keddem, S SoRelle, R Shea, JA AF Aysola, Jaya Werner, Rachel M. Keddem, Shimrit SoRelle, Richard Shea, Judy A. TI Asking the Patient About Patient-Centered Medical Homes: A Qualitative Analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Patient-centered care; Primary care redesign; Health care delivery; Health services research; Health policy ID PRIMARY-CARE; ETHNIC-DIFFERENCES AB What patients perceive and experience within a patient-centered medical home (PCMH) is an understudied area, and to date, the patient perspective has not been an integral component of existing PCMH measurement standards. However, upcoming guidelines necessitate the use of patient-reported experiences and satisfaction in evaluations of practice and provider performance. To characterize patients' experiences with care after PCMH adoption and their understanding and perceptions of the PCMH model and its key components, and to compare responses by degree of practice-level PCMH adoption and patient race/ethnicity. Qualitative study. Adult patients with diabetes and/or hypertension (n = 48). We surveyed and ranked all PCMH adult primary care practices affiliated with one academic medical center with at least three providers (n = 23), using an instrument quantifying the degree of PCMH adoption. We purposively sampled minority and non-minority patients from the four highest-ranked and four lowest-ranked PCMH-adopting practices to determine whether responses varied by degree of PCMH adoption or patient race/ethnicity. We conducted semi-structured telephone interviews with patients about their experiences with care and their perceptions and understanding of key PCMH domains. Interviews were recorded, transcribed, and imported into NVivo 10 for coding and analysis, using a modified grounded theory approach. We found that patients uniformly lacked awareness of the PCMH concept, and the vast majority perceived no PCMH-related structural changes, regardless of the degree of practice-reported PCMH adoption or the patient's race/ethnicity. Despite this lack of awareness, patients overwhelmingly reported positive relationships with their provider and positive overall experiences. As we continue to redesign primary care delivery with an emphasis on patient experience measures as performance metrics, we need to better understand what, if any, aspects of practice structure relate to patient experience and satisfaction with care. C1 [Aysola, Jaya; Werner, Rachel M.; Shea, Judy A.] Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Aysola, Jaya; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Keddem, Shimrit; SoRelle, Richard] Univ Penn, Dept Family Med & Community Hlth, Mixed Methods Res Lab, Philadelphia, PA 19104 USA. RP Aysola, J (reprint author), Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. EM jaysola@upenn.edu FU AHRQ PCOR [K12 HS021706-01] FX Jaya Aysola was funded by an AHRQ PCOR Institutional Award (K12 HS021706-01) for the duration of this study. NR 30 TC 4 Z9 4 U1 3 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2015 VL 30 IS 10 BP 1461 EP 1467 DI 10.1007/s11606-015-3312-8 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CS0MR UT WOS:000361755000021 PM 25876739 ER PT J AU Silverman, J Krieger, J Kiefer, M Hebert, P Robinson, J Nelson, K AF Silverman, Julie Krieger, James Kiefer, Meghan Hebert, Paul Robinson, June Nelson, Karin TI The Relationship Between Food Insecurity and Depression, Diabetes Distress and Medication Adherence Among Low-Income Patients with Poorly-Controlled Diabetes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE food insecurity; diabetes; glycemic control ID GLYCEMIC CONTROL; SELF-MANAGEMENT; SHORT-FORM; HEALTH; SCALE; INTERVENTION; HYPOGLYCEMIA; VALIDITY; COSTS AB Food insecurity- lack of dependable access to adequate food-may play a role in poor diabetes control. We aimed to determine the relationship between food security status and depression, diabetes distress, medication adherence and glycemic control. Secondary analysis of baseline data from Peer Support for Achieving Independence in Diabetes, a randomized controlled trial that enrolled patients from November 2011 to October 2013. Participants had poorly controlled type 2 diabetes (A1c a parts per thousand yen 8.0 % on eligibility screen), household income < 250 % of the federal poverty level, were 30-70 years old, and were recruited from a large public hospital, a VA medical center and a community-health center in King County, Washington. We measured food insecurity determined by the Department of Agriculture's 6-Item Food Security Module. Depression, diabetes distress and medication adherence measured by PHQ-8, Diabetes Distress Scale and Morisky Medication Adherence Scale, respectively. Diet was assessed through Summary of Diabetes Self-Care Activities and Starting the Conversation tool. Incidence of hypoglycemic episodes was by patient report. Glycemic control was assessed with glycosylated hemoglobin (A1c) values from fingerstick blood sample. The prevalence of food insecurity was 47.4 %. Chi-square tests revealed participants with food insecurity were more likely to be depressed (40.7 % vs. 15.4 %, p < 0.001), report diabetes distress (55.2 % vs. 33.8 %, p < 0.001) and have low medication adherence (52.9 % vs. 37.2 %, p = 0.02). Based on linear regression modeling, those with food insecurity had significantly higher mean A1c levels (beta = 0.51; p = 0.02) after adjusting for sex, age, race/ethnicity, language, education, marital status, BMI, insulin use, depression, diabetes distress and low medication adherence. Almost half of participants had food insecurity. Food insecurity was associated with depression, diabetes distress, low medication adherence and worse glycemic control. Even with adjustment, people with food insecurity had higher mean A1c levels than their food-secure counterparts, suggesting there may be other mediating factors, such as diet, that explain the relationship between food security status and diabetes control. C1 [Silverman, Julie; Hebert, Paul; Nelson, Karin] Northwest HSR&D Ctr Excellence, VA Puget Sound Healthcare Syst, Seattle, WA USA. [Silverman, Julie; Nelson, Karin] Gen Internal Med Serv, VA Puget Sound Healthcare Syst, Seattle, WA USA. [Silverman, Julie; Krieger, James; Kiefer, Meghan; Nelson, Karin] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Krieger, James; Hebert, Paul; Nelson, Karin] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Krieger, James; Robinson, June] Publ Hlth Seattle & King Cty, Seattle, WA USA. RP Silverman, J (reprint author), Northwest HSR&D Ctr Excellence, VA Puget Sound Healthcare Syst, Seattle, WA USA. EM Julie.Silverman@va.gov FU NIH/NIDDK [5R18DK088072]; Veterans Health Administration (VHA) Diabetes Quality Enhancement Research Initiative (QUERI) FX This study was supported by the NIH/NIDDK grant 5R18DK088072 to Drs. Nelson and Krieger (co-PIs). The sponsor had no role in designing the study; collecting, analyzing, or interpreting data; writing this manuscript; or in the decision to submit this manuscript for publication. Additional funding was provided by the Veterans Health Administration (VHA) Diabetes Quality Enhancement Research Initiative (QUERI) to support Veteran recruitment efforts. The views expressed in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 32 TC 6 Z9 6 U1 5 U2 41 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2015 VL 30 IS 10 BP 1476 EP 1480 DI 10.1007/s11606-015-3351-1 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CS0MR UT WOS:000361755000023 PM 25917659 ER PT J AU Perissinotto, CM Walter, LC AF Perissinotto, Carla Maria Walter, Louise C. TI Capsule Commentary on Wolff, et al., A Look at Person- and Family-Centered Care Among Older Adults: Results from a National Survey SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Perissinotto, Carla Maria; Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Perissinotto, CM (reprint author), Univ Calif San Francisco, 3333 Calif St Suite 380, San Francisco, CA 94143 USA. EM Carla.Perissinotto@ucsf.edu NR 3 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2015 VL 30 IS 10 BP 1536 EP 1536 DI 10.1007/s11606-015-3408-1 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CS0MR UT WOS:000361755000036 PM 26001544 ER PT J AU Shin, SS Dixon, CE AF Shin, Samuel S. Dixon, C. Edward TI Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Review DE acetylcholine; cholinergic; nicotinic; traumatic brain injury ID NICOTINIC ACETYLCHOLINE-RECEPTOR; POSITIVE ALLOSTERIC MODULATOR; FLUID-PERCUSSION INJURY; CLOSED-HEAD INJURY; SHORT-TERM-MEMORY; IMPROVES COGNITIVE PERFORMANCE; PROMOTE FUNCTIONAL RECOVERY; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CORTICAL IMPACT; REDUCED EVOKED RELEASE AB Traumatic brain injury (TBI) results in varying degrees of disability in a significant number of persons annually. The mechanisms of cognitive dysfunction after TBI have been explored in both animal models and human clinical studies for decades. Dopaminergic, serotonergic, and noradrenergic dysfunction has been described in many previous reports. In addition, cholinergic dysfunction has also been a familiar topic among TBI researchers for many years. Although pharmacological agents that modulate cholinergic neurotransmission have been used with varying degrees of success in previous studies, improving their function and maximizing cognitive recovery is an ongoing process. In this article, we review the previous findings on the biological mechanism of cholinergic dysfunction after TBI. In addition, we describe studies that use both older agents and newly developed agents as candidates for targeting cholinergic neurotransmission in future studies. C1 [Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA. [Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Dixon, CE (reprint author), Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu FU Pittsburgh Foundation Walter Copeland Fund FX The authors thank The Pittsburgh Foundation Walter Copeland Fund for their support of our TBI research. No competing financial interests exist. NR 147 TC 6 Z9 6 U1 2 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD OCT 1 PY 2015 VL 32 IS 19 BP 1429 EP 1440 DI 10.1089/neu.2014.3445 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CR8NC UT WOS:000361609500001 PM 25646580 ER PT J AU Hage, FG AF Hage, Fadi G. TI Training in nuclear cardiology: What's new? SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2015 VL 22 IS 5 BP 861 EP 862 DI 10.1007/s12350-015-0259-4 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CR8RU UT WOS:000361622400001 PM 26268827 ER PT J AU Hage, F AlJaroudi, W AF Hage, Fadi G. AlJaroudi, Wael TI Review of cardiovascular literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review C1 [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [AlJaroudi, Wael] Clemenceau Med Ctr, Beirut, Lebanon. RP AlJaroudi, W (reprint author), Clemenceau Med Ctr, Beirut, Lebanon. EM Wael.jaroudi@cmc.com.lb OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD OCT PY 2015 VL 22 IS 5 BP 874 EP 876 DI 10.1007/s12350-015-0220-6 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CR8RU UT WOS:000361622400004 PM 26134887 ER PT J AU Brothers, TE Ricotta, JJ Gillespie, DL Geraghty, PJ Kenwood, CT Siami, FS Ricotta, JJ White, RA AF Brothers, Thomas E. Ricotta, Joseph J., II Gillespie, David L. Geraghty, Patrick J. Kenwood, Christopher T. Siami, Flora S. Ricotta, John J. White, Rodney A. TI Contemporary results of carotid endarterectomy in "normal-risk" patients from the Society for Vascular Surgery Vascular Registry SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 41st Annual Symposium of the Society-for-Clinical-Vascular-Surgery CY MAR 12-16, 2013 CL Miami Beach, FL SP Soc Clin Vasc Surg ID ARTERY STENOSIS; OCCLUSION; MEDICARE; TRIAL; AGE AB Objective: Acceptable complication rates after carotid endarterectomy (CEA) are drawn from decades-old data. The recent Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) demonstrated improved stroke and mortality outcomes after CEA compared with carotid artery stenting, with 30-day periprocedural CEA stroke rates of 3.2% and 1.4% for symptomatic (SX) and asymptomatic (ASX) patients, respectively. It is unclear whether these target rates can be attained in "normal-risk" (NR) patients experienced outside of the trial. This study was done to determine the contemporary results of CEA from a broader selection of NR patients. Methods: The Society for Vascular Surgery (SVS) Vascular Registry was examined to determine in-hospital and 30-day event rates for NR, SX, and ASX patients undergoing CEA. NR was defined as patients without anatomic or physiologic risk factors as defined by SVS Carotid Practice Guidelines. Raw data and risk-adjusted rates of death, stroke, and myocardial infarction (MI) were compared between the ASX and SX cohorts. Results: There were 3977 patients (1456 SX, 2521 ASX) available for comparison. The SX group consisted of more men (61.7% vs 57.0%; P = .0045) but reflected a lower proportion of white patients (91.3% vs 94.4%; P = .0002), with lower prevalence of coronary artery disease (P < .0001), prior MI (P < .0001), peripheral vascular disease (P = .0017), and hypertension (P = .029), although New York Heart Association grade >3 congestive heart failure was equally present in both groups (P = .30). Baseline stenosis >80% on duplex imaging was less prevalent among SX patients (54.2% vs 67.8%; P < .0001). Perioperative stroke rates were higher for SX patients in the hospital (2.8% vs 0.8%; P < .0001) and at 30 days (3.4% vs 1.0%; P < .0001), which contributed to the higher composite death, stroke, andMI rates in the hospital (3.6% vs 1.8; P = .0003) and at 30 days (4.5% vs 2.2%; P < .0001) observed in SX patients. After risk adjustment, the rate of stroke/death was greater among SX patients in the hospital (odds ratio, 2.05; 95% confidence interval, 1.18-3.58) although not at 30 days (odds ratio, 1.36; 95% confidence interval, 0.85-2.17). No in-hospital or 30-day differences were observed for death or MI by symptom status. Conclusions: The SVS Vascular Registry results for CEA in NR patients are similar by symptom status to those reported for CREST and may serve as a benchmark for comparing results of alternative therapies for treatment of carotid stenosis in NR patients outside of monitored clinical trials. The contemporary perioperative risk of stroke after CEA in NR patients continues to be higher for SX than for ASX patients. C1 [Brothers, Thomas E.] Med Univ S Carolina, Surg Sect, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Brothers, Thomas E.] Med Univ S Carolina, Div Vasc Surg, Charleston, SC 29425 USA. [Ricotta, Joseph J., II] Northside Vasc Surg, Dept Vasc Surg & Endovasc Therapy, Atlanta, GA USA. [Gillespie, David L.] Southcoast Hlth Syst, Dept Vasc & Endovasc Surg, Fall River, MA USA. [Geraghty, Patrick J.] Washington Univ, Div Gen Surg, Vasc Surg Sect, St Louis, MO USA. [Kenwood, Christopher T.; Siami, Flora S.] New England Res Inst Inc, Inst Clin Trials & Registries, Watertown, MA 02472 USA. [Ricotta, John J.] Washington Hosp Ctr, Dept Vasc Surg, Washington, DC 20010 USA. [White, Rodney A.] Harbor UCLA, Div Vasc Surg, Los Angeles, CA USA. RP Siami, FS (reprint author), New England Res Inst Inc, 480 Pleasant St,Ste A100, Watertown, MA 02472 USA. EM ssiami@neriscience.com NR 20 TC 2 Z9 2 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2015 VL 62 IS 4 BP 923 EP 928 DI 10.1016/j.jvs.2015.05.003 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2GC UT WOS:000361885800014 PM 26194815 ER PT J AU Green, MF Horan, WP Lee, J AF Green, Michael F. Horan, William P. Lee, Junghee TI Social cognition in schizophrenia SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID EVENT-RELATED POTENTIALS; EMOTION REGULATION; BIPOLAR DISORDER; EMPATHIC ACCURACY; NEURAL RESPONSE; HUMAN BRAIN; NEUROCOGNITIVE DEFICITS; NEUROIMAGING LITERATURE; 1ST-EPISODE PSYCHOSIS; SENSORY CONTRIBUTIONS AB Individuals with schizophrenia exhibit impaired social cognition, which manifests as difficulties in identifying emotions, feeing connected to others, inferring people's thoughts and reacting emotionally to others. These social cognitive impairments interfere with social connections and are strong determinants of the degree of impaired daily functioning in such individuals. Here, we review recent findings from the fields of social cognition and social neuroscience and identify the social processes that are impaired in schizophrenia. We also consider empathy as an example of a complex social cognitive function that integrates several social processes and is impaired in schizophrenia. This information may guide interventions to improve social cognition in patients with this disorder. C1 [Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. US Dept Vet Affairs, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room 27-462, Los Angeles, CA 90024 USA. EM mgreen@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 NR 200 TC 56 Z9 57 U1 22 U2 67 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-003X EI 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD OCT PY 2015 VL 16 IS 10 BP 620 EP 631 DI 10.1038/nrn4005 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CR9QP UT WOS:000361691900009 PM 26373471 ER PT J AU Cohen, RG Gurfinkel, VS Kwak, E Warden, AC Horak, FB AF Cohen, Rajal G. Gurfinkel, Victor S. Kwak, Elizabeth Warden, Amelia C. Horak, Fay B. TI Lighten Up: Specific Postural Instructions Affect Axial Rigidity and Step Initiation in Patients With Parkinson's Disease SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE Parkinson's disease; postural sway; postural alignment; rigidity; gait initiation; Alexander Technique; mindfulness ID RANDOMIZED CONTROLLED-TRIAL; ALEXANDER TECHNIQUE LESSONS; LOW-BACK-PAIN; GAIT INITIATION; OLDER-ADULTS; TAI-CHI; INSTABILITY; MOVEMENT; ADJUSTMENTS; IMPROVEMENT AB Background. Parkinson's disease (PD) is associated with stooped postural alignment, increased postural sway, and reduced mobility. The Alexander Technique (AT) is a mindfulness-based approach to improving posture and mobility by reducing muscular interference while maintaining upward intentions. Evidence suggests that AT can reduce disability associated with PD, but a mechanism for this effect has not yet been established. Objective. We investigated whether AT-based instructions reduce axial rigidity and increase upright postural alignment, and whether these instructions have different effects on postural alignment, axial rigidity, postural sway, and mobility than effort-based instructions regarding posture. Method. Twenty subjects with PD practiced 2 sets of instructions and then attempted to implement both approaches (as well as a relaxed control condition) during quiet standing and step initiation. The Lighten Up instructions relied on AT principles of reducing excess tension while encouraging length. The Pull Up instructions relied on popular concepts of effortful posture correction. We measured kinematics, resistance to axial rotation, and ground reaction forces. Results. Both sets of experimental instructions led to increases in upright postural alignment relative to the control condition. Only the Lighten Up instructions led to reduced postural sway, reduced axial postural tone, greater modifiability of tone, and a smoother center of pressure trajectory during step initiation, possibly indicating greater movement efficiency. Conclusion. Mindful movement approaches such as AT may benefit balance and mobility in subjects with PD by acutely facilitating increased upright postural alignment while decreasing rigidity. C1 [Cohen, Rajal G.; Warden, Amelia C.] Univ Idaho, Moscow, ID 83844 USA. [Gurfinkel, Victor S.; Horak, Fay B.] Oregon Hlth & Sci Univ, Beaverton, OR USA. [Kwak, Elizabeth] Macalester Coll, St Paul, MN 55105 USA. [Horak, Fay B.] Portland VA Med Ctr, Portland, OR USA. RP Cohen, RG (reprint author), Univ Idaho, Dept Psychol & Commun Studies, 875 Perimeter Dr MS 3043, Moscow, ID 83844 USA. EM rcohen@uidaho.edu FU National Institutes of Health [AG-006457, T32-NS045553, T32-AT002688]; Medical Research Foundation of Oregon; University of Idaho College of Letters, Arts, and Social Sciences FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health (grants AG-006457, T32-NS045553, and T32-AT002688); Medical Research Foundation of Oregon; and University of Idaho College of Letters, Arts, and Social Sciences. NR 51 TC 5 Z9 5 U1 0 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD OCT PY 2015 VL 29 IS 9 BP 878 EP 888 DI 10.1177/1545968315570323 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CS2JW UT WOS:000361897800008 PM 25665828 ER PT J AU Ruben, MA van Osch, M Blanch-Hartigan, D AF Ruben, Mollie A. van Osch, Mara Blanch-Hartigan, Danielle TI Healthcare providers' accuracy in assessing patients' pain: A systematic review SO PATIENT EDUCATION AND COUNSELING LA English DT Article; Proceedings Paper CT Conference of the European-Association-for-Communication-in-Healthcare (EACH) CY SEP 28-OCT 01, 2014 CL Amsterdam, NETHERLANDS DE Pain assessment; Provider accuracy; Clinical experience; Chronic pain; Acute pain ID QUALITY-OF-LIFE; ADVANCED CANCER-PATIENTS; LOW-BACK-PAIN; FAMILY CAREGIVERS; SELF-REPORT; HOSPITALIZED-PATIENTS; EMERGENCY-DEPARTMENT; PERCEPTION ACCURACY; FACIAL EXPRESSION; REPORTED SYMPTOMS AB Objective: Healthcare providers satisfy an important role in providing appropriate care in the prevention and management of acute and chronic pain, highlighting the importance of providers' abilities to accurately assess patients' pain. We systematically reviewed the literature on healthcare providers' pain assessment accuracy. Methods: A systematic literature search was conducted in PubMed and PsycINFO to identify studies addressing providers' pain assessment accuracy, or studies that compared patients' self-report of pain with providers' assessment of pain. Results: 60 studies met the inclusion criteria. Healthcare providers had moderate to good pain assessment accuracy. Physicians and nurses showed similar pain assessment accuracy. Differences in pain assessment accuracy were found according to providers' clinical experience, the timing of the pain assessment, vulnerable patient populations and patients' pain intensity. Conclusion: Education and training aimed at improving providers with poor pain assessment accuracy is discussed especially in relation to those with limited clinical experience (<4 years) or a great deal of clinical experience (>10 years) and those providing care for vulnerable patient populations. Practice implications: More research on characteristics that influence providers' pain assessment accuracy and trainings to improve pain assessment accuracy in medical and continuing education may improve pain treatment for patients. Published by Elsevier Ireland Ltd. C1 [Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Boston, MA 02130 USA. [van Osch, Mara] NIVEL Netherlands Inst Hlth Serv Res, Utrecht, Netherlands. [Blanch-Hartigan, Danielle] Bentley Univ, Dept Nat & Appl Sci, Waltham, MA USA. RP Ruben, MA (reprint author), US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, 150 S Huntington Ave,Bldg 9, Boston, MA 02130 USA. EM Mollie.Ruben@va.gov OI Ruben, Mollie/0000-0001-8918-8932 NR 122 TC 3 Z9 3 U1 0 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD OCT PY 2015 VL 98 IS 10 SI SI BP 1197 EP 1206 DI 10.1016/j.pec.2015.07.009 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA CS1XR UT WOS:000361862700005 PM 26223850 ER PT J AU Williams, ED Stebbins, MJ Cavanagh, PR Haynor, DR Chu, BC Fassbind, MJ Isvilanonda, V Ledoux, WR AF Williams, Evan D. Stebbins, Michael J. Cavanagh, Peter R. Haynor, David R. Chu, Baocheng Fassbind, Michael J. Isvilanonda, Vara Ledoux, William R. TI The design and validation of a magnetic resonance imaging-compatible device for obtaining mechanical properties of plantar soft tissue via gated acquisition SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H-JOURNAL OF ENGINEERING IN MEDICINE LA English DT Article DE Heel pad; diabetes; magnetic resonance imaging-compatible; mechanical properties ID HEEL-PAD COMPRESSIBILITY; DIABETIC FOOT; THICKNESS; GAIT; MRI AB Changes in the mechanical properties of the plantar soft tissue in people with diabetes may contribute to the formation of plantar ulcers. Such ulcers have been shown to be in the causal pathway for lower extremity amputation. The hydraulic plantar soft tissue reducer (HyPSTER) was designed to measure in vivo, rate-dependent plantar soft tissue compressive force and three-dimensional deformations to help understand, predict, and prevent ulcer formation. These patient-specific values can then be used in an inverse finite element analysis to determine tissue moduli, and subsequently used in a foot model to show regions of high stress under a wide variety of loading conditions. The HyPSTER uses an actuator to drive a magnetic resonance imaging-compatible hydraulic loading platform. Pressure and actuator position were synchronized with gated magnetic resonance imaging acquisition. Achievable loading rates were slower than those found in normal walking because of a water-hammer effect (pressure wave ringing) in the hydraulic system when the actuator direction was changed rapidly. The subsequent verification tests were, therefore, performed at 0.2Hz. The unloaded displacement accuracy of the system was within 0.31%. Compliance, presumably in the system's plastic components, caused a displacement loss of 5.7mm during a 20-mm actuator test at 1354N. This was accounted for with a target to actual calibration curve. The positional accuracy of the HyPSTER during loaded displacement verification tests from 3 to 9mm against a silicone backstop was 95.9% with a precision of 98.7%. The HyPSTER generated minimal artifact in the magnetic resonance imaging scanner. Careful analysis of the synchronization of the HyPSTER and the magnetic resonance imaging scanner was performed. With some limitations, the HyPSTER provided key functionality in measuring dynamic, patient-specific plantar soft tissue mechanical properties. C1 [Williams, Evan D.; Stebbins, Michael J.; Fassbind, Michael J.; Isvilanonda, Vara; Ledoux, William R.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. [Williams, Evan D.; Stebbins, Michael J.; Cavanagh, Peter R.; Isvilanonda, Vara; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Cavanagh, Peter R.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Haynor, David R.; Chu, Baocheng] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, Ms 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@uw.edu FU United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service [A6973R] FX This work was supported by Merit Review Award A6973R from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service. NR 24 TC 1 Z9 1 U1 2 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0954-4119 EI 2041-3033 J9 P I MECH ENG H JI Proc. Inst. Mech. Eng. Part H-J. Eng. Med. PD OCT PY 2015 VL 229 IS 10 BP 732 EP 742 DI 10.1177/0954411915606150 PG 11 WC Engineering, Biomedical SC Engineering GA CS2KH UT WOS:000361899000005 PM 26405098 ER PT J AU Wiederhold, NP Patterson, TF AF Wiederhold, Nathan P. Patterson, Thomas F. TI Emergence of Azole Resistance in Aspergillus SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Aspergillus fumigatus; azole resistance; aspergillosis; voriconazole; itraconazole; posaconazole; CYP51A ID INVASIVE PULMONARY ASPERGILLOSIS; ANTIFUNGAL DRUG-RESISTANCE; AMPHOTERICIN-B; CYP51A GENE; NEOSARTORYA-PSEUDOFISCHERI; ITRACONAZOLE RESISTANCE; ISAVUCONAZOLE BAL4815; FUMIGATUS; VORICONAZOLE; POSACONAZOLE AB Resistance to the azole antifungals itraconazole, voriconazole, and posaconazole in Aspergillus species is a growing concern. This is especially alarming for A. fumigatus, where acquired resistance has been documented in patients with invasive disease caused by this species that were exposed to these agents, as well as in azole-naive individuals. The primary mechanisms of resistance that have been described in clinical strains include different point mutations in the CYP51A gene, which encodes the enzyme responsible for converting lanosterol to ergosterol via demethylation. Some resistant isolates also contain a tandem repeat in the promoter region of this gene that causes increased expression. These mutations, including TR34/L98H and TR46/Y121F/T289A have also been found in the environment in several areas of the world and have been demonstrated to cause resistance to azole fungicides used in agriculture, thus raising the concern of environmental spread of resistance. Treatment options are limited in patients with infections caused by azole-resistant isolates and include amphotericin B formulations or combination therapy involving an echinocandin. However, there are few clinical data available to help guide therapy, and infections caused by resistant A. fumigatus isolates have been reported to have high mortality rates. C1 [Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.; Patterson, Thomas F.] UTHSCSA, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Patterson, TF (reprint author), UTHSCSA, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MC 7750, San Antonio, TX 78229 USA. EM patterson@uthscsa.edu OI Patterson, Thomas /0000-0002-9513-7127; Wiederhold, Nathan/0000-0002-2225-5122 NR 75 TC 3 Z9 3 U1 3 U2 9 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD OCT PY 2015 VL 36 IS 5 BP 673 EP 680 DI 10.1055/s-0035-1562894 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CR8ZL UT WOS:000361642900005 PM 26398534 ER PT J AU Kuehlewein, L Bansal, M Lenis, TL Iafe, NA Sadda, SR Bonin, MA De Carlo, TE Waheed, NK Duker, JS Sarraf, D AF Kuehlewein, Laura Bansal, Mayank Lenis, Tamara L. Iafe, Nicholas A. Sadda, Srinivas R. Bonin Filho, Marco A. De Carlo, Talisa E. Waheed, Nadia K. Duker, Jay S. Sarraf, David TI Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; MOTION CORRECTION; EYES; AMD; CLASSIFICATION AB PURPOSE: To analyze type 1 neovascular membranes in age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography, to correlate morphologic characteristics with imaging and clinical criteria, and to analyze structural features of type 1 neovascularization sequentially after anti-vascular endothelial growth factor (VEGF) therapy. DESIGN: Prospective interventional Case series. METHODS: Macular OCT angiography images were acquired using the RTVue XR Avanti with AngioVue. Distinct morphologic patterns and quantifiable features of the neovascular membranes were studied on en face projection images at baseline and follow-up. RESULTS: Thirty-three eyes of 25 patients were included. In 75% of the eyes, a highly organized vascular complex could be identified. A large main central vessel trunk/feeder vessel could be seen in 72% of these eyes, with vessels radiating in a branching pattern either in all directions from the center of the lesion ("medusa" pattern), or from one side of the lesion ("seafan" pattern). Of the 18 eyes with follow-up OCT angiography, the lesion area and vessel density remained unchanged, even after anti-vascular endothelial growth factor (VEGF) therapy, indicating a more mature longstanding neovascular complex resistant to anti-VEGF therapy. CONCLUSIONS: OCT angiography provides a unique opportunity to study the morphology of occult type 1 neovascular membranes in AMP and allows precise structural and vascular assessment noninvasively. We identified a large mature neovascular complex in approximately 75% of eyes, typically consisting of a feeder vessel and large branching vessels resistant to anti-VEGF therapy. OCT angiography may better guide evaluation and treatment of neovascular AMD, and may contribute to the development of improved therapies. (C) 2015 by Elsevier Inc. All rights reserved. C1 [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA. [Kuehlewein, Laura; Bansal, Mayank; Lenis, Tamara L.; Iafe, Nicholas A.; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Bansal, Mayank; Lenis, Tamara L.; Iafe, Nicholas A.; Sarraf, David] Jules Stein Eye Inst, Los Angeles, CA 90024 USA. [Bonin Filho, Marco A.; De Carlo, Talisa E.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA. [Bonin Filho, Marco A.; De Carlo, Talisa E.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA. [Bonin Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil. [De Carlo, Talisa E.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [De Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Allergan, Irvine, California, USA; Carl Zeiss Meditec, Dublin, California, USA; Genentech, South San Francisco, California, USA; Optos, Marlborough, Massachusetts, USA; Carl Zeiss Meditec; Massachusetts Lions Club, South Attleboro, Massachusetts, USA; OptoVue, Fremont, California, USA; Research to Prevent Blindness, Columbia, Maryland, USA; Genentech; OptoVue; Regeneron, Tarrytown, New York, USA FX SriniVas R. Sadda: Research support, Allergan, Irvine, California, USA; Carl Zeiss Meditec, Dublin, California, USA; Genentech, South San Francisco, California, USA; and Optos, Marlborough, Massachusetts, USA; Nadia K. Waheed: Research support, Carl Zeiss Meditec; Jay S. Duker: Research support, Carl Zeiss Meditec; Grant, Massachusetts Lions Club, South Attleboro, Massachusetts, USA; Research support, OptoVue, Fremont, California, USA; Grant, Research to Prevent Blindness, Columbia, Maryland, USA; David Sarraf: Research grant, Genentech; OptoVue; and Regeneron, Tarrytown, New York, USA. All authors attest that they meet the current ICIvIJE requirements to qualify as authors. NR 27 TC 61 Z9 64 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD OCT PY 2015 VL 160 IS 4 BP 739 EP 748 DI 10.1016/j.ajo.2015.06.030 PG 10 WC Ophthalmology SC Ophthalmology GA CR7BR UT WOS:000361503400016 PM 26164826 ER PT J AU Gopalan, A Lorincz, IS Wirtalla, C Marcus, SC Long, JA AF Gopalan, Anjali Lorincz, Ilona S. Wirtalla, Christopher Marcus, Steven C. Long, Judith A. TI Awareness of Prediabetes and Engagement in Diabetes Risk-Reducing Behaviors SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID LIFE-STYLE INTERVENTION; INCIDENT CARDIOVASCULAR EVENTS; IMPAIRED GLUCOSE-TOLERANCE; PREVENTION PROGRAM; WEIGHT-LOSS; REDUCTION; COMMUNITY; EXERCISE; MELLITUS; DIET AB Introduction: Studies have demonstrated the benefit of weight loss and physical activity for diabetes prevention among those with prediabetes. Despite this evidence, only about half of people with prediabetes report engaging in these behaviors. One presumed barrier is low patient awareness of prediabetes. The purpose of this study is to examine the impact of prediabetes awareness on the odds of engagement in diabetes risk-reduction behaviors. Methods: A pooled cross-sectional analysis of adults from two cycles (2007-2008, 2009-2010) of the National Health and Nutrition Examination Survey was conducted. Those with prediabetes were identified by excluding people with self-reported diabetes and then screening for hemoglobin A1c values between 5.7% and 6.4%. This group was then divided based on self-reported prediabetes. Multivariate logistic regression was used to estimate the effect of prediabetes awareness on the odds of engagement in physical activity, weight management, and the combination of physical activity and weight management. Results: Of those meeting the defined criteria for prediabetes (n=2,694), only 11.8% (n=288) were aware of their status. Prediabetes-aware individuals had higher odds of engagement in the combination of moderate physical activity plus BMI-appropriate weight management (AOR=1.5, 95% CI=1.1, 2.0), and the combination of at least 150 minutes/week of moderate activity and 7% weight loss in the past year (AOR=2.4, 95% CI=1.1, 5.6). Conclusions: Prediabetes-aware adults have increased odds of engagement in physical activity and weight management. Increasing patients' awareness of prediabetes could result in increased performance of exercise and weight management behaviors and, most importantly, decreased risk of future diabetes. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Gopalan, Anjali; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Gopalan, Anjali] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Lorincz, Ilona S.] Univ Penn, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Wirtalla, Christopher] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.; Long, Judith A.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. RP Gopalan, A (reprint author), Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM agopalan@upenn.edu NR 23 TC 7 Z9 7 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2015 VL 49 IS 4 BP 512 EP 519 DI 10.1016/j.amepre.2015.03.007 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CR5YV UT WOS:000361421200003 PM 26091928 ER PT J AU Katon, JG Lehavot, K Simpson, TL Williams, EC Barnett, SB Grossbard, JR Schure, MB Gray, KE Reiber, GE AF Katon, Jodie G. Lehavot, Keren Simpson, Tracy L. Williams, Emily C. Barnett, Sarah Beth Grossbard, Joel R. Schure, Mark B. Gray, Kristen E. Reiber, Gayle E. TI Adverse Childhood Experiences, Military Service, and Adult Health SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMA EXPOSURE; MENTAL-HEALTH; NATIONAL SAMPLE; PHYSICAL HEALTH; WOMEN VETERANS; SEXUAL-ABUSE; LIFE; CARE; MALTREATMENT AB Introduction: Prevalence of adverse childhood experiences (ACE) and associations with adult health may vary by gender and military service. This study compares the gender-specific prevalence of ACE by military service and determines the associations of ACE with adult health risk factors and health-related quality of life (HRQOL). Methods: This 2014 analysis used data from the 2011 and 2012 CDC Behavioral Risk Factor Surveillance System. Total ACE was operationalized as the number of reported ACE. Associations of total ACE with adult health risk factors were estimated using general linear models; associations with HRQOL were estimated using negative binomial regression. All analyses adjusted for age and race/ethnicity. Results: Those with military service had more total ACE than civilians. Higher ACE was associated with poorer HRQOL among women (physical health, military service, relative risk [RR]=1.20, 95% CI=1.09, 1.33; civilians, RR=1.18, 95% CI=1.17, 1.20; mental health, military service, RR=1.21, 95% CI=1.12, 1.32; civilians, RR=1.25, 95% CI=1.23, 1.26). Among men, these associations were somewhat attenuated in those with military service relative to civilians (physical health, military service, RR=1.13, 95% CI=1.09, 1.18; civilians, RR=1.20, 95% CI=1.17, 1.24; mental health, military service, RR=1.21, 95% CI=1.16, 1.27; civilians, RR=1.30, 95% CI=1.27, 1.34). Conclusions: Relative to civilians, men and women with military service report more ACE, but associations of ACE with adult HRQOL are weaker among men with military service relative to civilians. There is a need to implement and disseminate evidence-based programs to prevent ACE and for research on the long-term health consequences of ACE in military populations. Published by Elsevier Inc. C1 [Katon, Jodie G.; Williams, Emily C.; Grossbard, Joel R.; Schure, Mark B.; Gray, Kristen E.; Reiber, Gayle E.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Lehavot, Keren; Simpson, Tracy L.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Simpson, Tracy L.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Katon, Jodie G.; Williams, Emily C.; Barnett, Sarah Beth; Schure, Mark B.; Gray, Kristen E.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Katon, Jodie G.] Dept Vet Affairs, Off Womens Hlth Serv, Vet Affairs Off Patient Care Serv, Washington, DC USA. RP Katon, JG (reprint author), 1660 South Columbian Way S-152, Seattle, WA 98108 USA. EM jodie.katon@va.gov FU Denver-Seattle Veterans Affairs (VA) Health Services Research and Development (HSR&D) Center of Innovation; VA Office Women's Health Services; VA Career Development Award from CSRD [CX000867]; VA Career Development Award from HSRD [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; VA HSR&D, Quality Enhancement Research Initiative; Office of Academic Affiliations' Associated Health Postdoctoral Fellowships [TPP 61-026, TPP 61-028]; VA HSR&D Senior Career Scientist Award [RCS 98-353] FX This work was supported by the Denver-Seattle Veterans Affairs (VA) Health Services Research and Development (HSR&D) Center of Innovation and the VA Office Women's Health Services. The authors declare no conflicts of interest. Drs. Lehavot and Williams are supported by VA Career Development Awards from CSR&D (CX000867) and HSR&D (CDA 12-276), respectively. Dr. Williams is also an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the VA HSR&D, Quality Enhancement Research Initiative. Drs. Gray and Schure are supported by the Office of Academic Affiliations' Associated Health Postdoctoral Fellowships (TPP 61-026 and TPP 61-028, respectively), and Dr. Reiber is supported by a VA HSR&D Senior Career Scientist Award (RCS 98-353). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA. NR 48 TC 5 Z9 5 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2015 VL 49 IS 4 BP 573 EP 582 DI 10.1016/j.amepre.2015.03.020 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CR5YV UT WOS:000361421200010 PM 26091925 ER PT J AU Kherada, N Heimowitz, T Rosendorff, C AF Kherada, Nisharahmed Heimowitz, Todd Rosendorff, Clive TI Antihypertensive Therapies and Cognitive Function: a Review SO CURRENT HYPERTENSION REPORTS LA English DT Review DE Dementia; Cognition; Alzheimer's disease; Stroke; Antihypertensive therapies ID RENIN-ANGIOTENSIN SYSTEM; ELDERLY HYPERTENSIVE PATIENTS; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; SYSTOLIC BLOOD-PRESSURE; ALZHEIMERS-DISEASE; OLDER-ADULTS; DOUBLE-BLIND; INTERVENTION TRIAL; GINKGO EVALUATION AB Increasing life expectancy has made old age-related health problems like dementia and cognitive decline more prevalent, and these are rapidly becoming important causes of disability and poor quality of life, causing significant add-ons to health-care costs worldwide. Hypertension is the most important modifiable vascular risk factor for the development and progression of both cognitive decline and dementia. In many observational and randomized studies, antihypertensive therapies have been shown to be beneficial in slowing cognitive decline. However, due to observed discrepancies by these studies, there is a lack of consensus on the best antihypertensive strategy for the prevention or slowing of cognitive decline. It is also not clear whether the beneficial effect of antihypertensive therapy is due to the use of a specific class of agents or combination therapy. Thus, we present a comprehensive review of overall antihypertensive therapies and cognition and of the individual antihypertensive therapy classes with their specific protective mechanisms and available clinical evidence behind their effect on cognitive function. C1 [Kherada, Nisharahmed; Heimowitz, Todd] Columbia Univ, Mt Sinai Med Ctr, Dept Cardiol, Miami Beach, FL 33140 USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Dept Cardiol, Bronx, NY 10468 USA. RP Kherada, N (reprint author), Columbia Univ, Mt Sinai Med Ctr, Dept Cardiol, 4300 Alton Rd,Suite 2070, Miami Beach, FL 33140 USA. EM kherada.1@gmail.com; Todd.Heimowitz@msmc.com; Clive.Rosendorff@va.gov NR 70 TC 5 Z9 5 U1 2 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1522-6417 EI 1534-3111 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD OCT PY 2015 VL 17 IS 10 AR 79 DI 10.1007/s11906-015-0592-7 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CR6IR UT WOS:000361450100003 PM 26298567 ER PT J AU Elder, GA AF Elder, Gregory A. TI Update on TBI and Cognitive Impairment in Military Veterans SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Alzheimer's disease; Blast; Chronic traumatic encephalopathy; Dementia; Traumatic brain injury; Military veterans ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DEPLOYED US MILITARY; ALZHEIMERS-DISEASE; HEAD-INJURY; SERVICE MEMBERS; ACUTE CONCUSSION; OLDER VETERANS; DEMENTIA RISK; ENCEPHALOPATHY AB Traumatic brain injury (TBI) is a common cause of morbidity and mortality in military life. Interest in military TBI has increased recently due to the conflicts in Iraq and Afghanistan. Certain types of TBI are relatively unique to the military, the most prominent being blast-related TBI. Blast-related mild TBI has been of particular concern in veterans from the most recent conflicts although controversy remains concerning its separation from post-traumatic stress disorder. TBI is also a risk factor for the later development of neurodegenerative diseases in which cognitive impairment is prominent putting veterans at risk for disorders including Alzheimer's disease and chronic traumatic encephalopathy. Recent evidence associating TBI with chronic cognitive impairment is reviewed in the context of its relevance to military veterans. C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. RP Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards [1I01RX000179-01, 1I01RX000996-01] FX The author has received research support from the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000179-01 and 1I01RX000996-01. NR 82 TC 1 Z9 1 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD OCT PY 2015 VL 15 IS 10 AR 68 DI 10.1007/s11910-015-0591-8 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CR6HO UT WOS:000361446400004 PM 26299275 ER PT J AU Chacko, L Macaron, C Burke, CA AF Chacko, Lyssa Macaron, Carole Burke, Carol A. TI Clinical Practice Patterns Suggest Female Patients Prefer Female Endoscopists Reply SO DIGESTIVE DISEASES AND SCIENCES LA English DT Letter C1 [Chacko, Lyssa] Denver Vet Affairs Med Ctr, Dept Gastroenterol & Hepatol, Denver, CO USA. [Macaron, Carole] Cleveland Vet Affairs Med Ctr, Gastroenterol Sect, Cleveland, OH USA. [Burke, Carol A.] Cleveland Clin, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA. RP Burke, CA (reprint author), Cleveland Clin, Dept Gastroenterol & Hepatol, Desk 30,9500 Euclid Ave, Cleveland, OH 44195 USA. EM Burkec1@ccf.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2015 VL 60 IS 10 BP 3150 EP 3150 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CR6ZU UT WOS:000361497900043 ER PT J AU Miller, PE Martin, SS Toth, PP Santos, RD Blaha, MJ Nasir, K Virani, SS Post, WS Blumenthal, RS Jones, SR AF Miller, P. Elliott Martin, Seth S. Toth, Peter P. Santos, Raul D. Blaha, Michael J. Nasir, Khurram Virani, Salim S. Post, Wendy S. Blumenthal, Roger S. Jones, Steven R. TI Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17) SO JOURNAL OF CLINICAL LIPIDOLOGY LA English DT Article DE Familial hypercholesterolethia; Screening; Lipid phenotyping; Friedewald equation; Low-density lipoprotein cholesterol; Lipoprotein(a); Remnant lipoprotein cholesterol ID DENSITY-LIPOPROTEIN CHOLESTEROL; ASSOCIATION EXPERT PANEL; ISCHEMIC-HEART-DISEASE; REMNANT CHOLESTEROL; GENERAL-POPULATION; UNITED-STATES; DIAGNOSIS; MANAGEMENT; GUIDANCE; RISK AB BACKGROUND: Familial hypercholesterolernia (FH) is an autosomal dominant dyslipidemia characterized by defective low-density lipoprotein (LDL) clearance. The aim of this study was to compare Friedewald-estimated LDL cholesterol (LDL-C) to biologic LDL-C in individuals screening positive for FH and then further characterize FH phenotypes. METHODS: We studied 1,320,581 individuals from the Very Large Database of Lipids, referred from 2009 to 2011 for Vertical Auto Profile ultracentrifugation testing. Friedewald LDL-C was defined as the cholesterol content of LDL-C, intermediate-density lipoprotein cholesterol, and lipoprotein(a) cholesterol (Lp(a)-C), with LDL-C representing biologic LDL-C. Using Friedewald LDL-C, we phenotypically categorized patients by the National Lipid Association guideline age-based screening thresholds for FH. In those meeting criteria, we categorized patients using population percentile-equivalent biologic LDL-C cutpoints and explored Lp(a)-C and remnant lipoprotein cholesterol (RLP-C) levels. RESULTS: Overall, 3829 patients met phenotypic criteria for FH by Friedewald LDL-C screening (FH+). Of those screening FH+, 78.8% were above and 21.2% were below the population percentile-equivalent biologic LDL-C. The mean difference in Friedewald biologic LDL-C percentiles was -0.01 (standard deviation, 0.17) for those above, and 1.92 (standard deviation, 9.16) for those below, respectively. Over 1 of 3 were found to have an elevated Lp(a)-C and over 50% had RLP-C greater than 95th percentile of the entire VLDL population CONCLUSIONS: Of those who screened FH+, Friedewald and biologic LDL-C levels were closely correlated. Large proportions of the FH+ group had excess levels of Lp(a)-C and RLP-C. Future C1 [Miller, P. Elliott; Martin, Seth S.; Toth, Peter P.; Blaha, Michael J.; Post, Wendy S.; Blumenthal, Roger S.; Jones, Steven R.] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. [Toth, Peter P.] CGH Med Ctr, Dept Prevent Cardiol, Sterling, IL USA. [Toth, Peter P.] Univ Illinois, Coll Med, Peoria, IL 61656 USA. [Santos, Raul D.] InCor Univ Sao Paulo, Lipid Clin Heart Inst, Prevent Med Ctr, Hosp Israelita Albert Einstein,Med Sch Hosp, Sao Paulo, Brazil. [Nasir, Khurram] Ctr Prevent & Wellness Res, Baptist Hlth Med Grp, Miami, FL USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Cardiovasc Res, Houston, TX 77030 USA. RP Miller, PE (reprint author), Johns Hopkins Univ Hosp, Dept Med, 600 N Wolfe St, Baltimore, MD 21287 USA. EM elliottmiller@jhmi.edu RI Santos, Raul/A-1170-2010 OI Santos, Raul/0000-0002-9860-6582; Virani, Salim/0000-0001-9541-6954 FU Pollin Cardiovascular Prevention Fellowship; Marie-Josee and Henry R. Kravis endowed fellowship; National Institutes of Health [T32HL07024]; US Food and Drug Administration; Department of Veterans Affairs; American Heart Association; American Diabetes Association FX S.S.M. is supported by the Pollin Cardiovascular Prevention Fellowship, Marie-Josee and Henry R. Kravis endowed fellowship, and a National Institutes of Health training grant (T32HL07024). The article has no funding.; Dr Martin and Dr Jones are listed as coinventors on a pending patent filed by Johns Hopkins University for a method of low-density lipoprotein cholesterol estimation. Dr Blaha reports pending grant funding from the National Institutes of Health and the US Food and Drug Administration and participating in a roundtable discussion with Regeneron. Dr Virani reports having received research funding from the Department of Veterans Affairs, American Heart Association, and the American Diabetes Association. Dr Toth serves on the medical advisory board for Atherotech Diagnostic Lab and has received compensation for consultancy and lecturers from Abbvie, Aegerion, Amgen, AstraZeneca, Glaxo-SmithKline, Kowa, and Merck & Co, Novartis, and Regeneron. Dr Jones serves on the medical advisory board for Atherotech Diagnostic Lab and as an advisor to Sanofi and Regeneron. Dr Santos has received honoraria for consulting and speaker activities from AstraZeneca, Amgen, Biolab, Boehringher-Ingelheim, Bristol Myers Squibb, Eli-Lilly, Jansen, Merck, Novartis, Pfizer, Praxis, Sanofi/Regeneron, Unilever. NR 36 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-2874 EI 1876-4789 J9 J CLIN LIPIDOL JI J. Clin. Lipidol. PD OCT PY 2015 VL 9 IS 5 BP 676 EP 683 DI 10.1016/j.jacl.2015.06.015 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CR5WQ UT WOS:000361415500009 PM 26350814 ER PT J AU Wood, KH Wheelock, MD Shumen, JR Bowen, KH Hoef, LWV Knight, DC AF Wood, Kimberly H. Wheelock, Muriah D. Shumen, Joshua R. Bowen, Kenton H. Hoef, Lawrence W. Ver Knight, David C. TI Controllability modulates the neural response to predictable but not unpredictable threat in humans SO NEUROIMAGE LA English DT Article DE Prefrontal cortex; Hippocampus; Controllability; Predictability; Stress resilience ID POSTTRAUMATIC-STRESS-DISORDER; FEAR-POTENTIATED STARTLE; MEDIAL PREFRONTAL CORTEX; DORSAL RAPHE NUCLEUS; SKIN-CONDUCTANCE RESPONSE; INDIVIDUAL-DIFFERENCES; BRAIN ACTIVITY; PERCEIVED CONTROLLABILITY; PHYSIOLOGICAL CONDITION; CONDITIONED DIMINUTION AB Stress resilience is mediated, in part, by our ability to predict and control threats within our environment. Therefore, determining the neural mechanisms that regulate the emotional response to predictable and controllable threats may provide important new insight into the processes that mediate resilience to emotional dysfunction and guide the future development of interventions for anxiety disorders. To better understand the effect of predictability and controllability on threat-related brain activity in humans, two groups of healthy volunteers participated in a yoked Pavlovian fear conditioning study during functional magnetic resonance imaging (fMRI). Threat predictability was manipulated by presenting an aversive unconditioned stimulus (UCS) that was either preceded by a conditioned stimulus (i.e., predictable) or by presenting the UCS alone (i.e., unpredictable). Similar to animal model research that has employed yoked fear conditioning procedures, one group (controllable condition; CC), but not the other group (uncontrollable condition; UC) was able to terminate the UCS. The fMRI signal response within the dorsolateral prefrontal cortex (PFC), dorsomedial PFC, ventromedial PFC, and posterior cingulate was diminished during predictable compared to unpredictable threat (i.e., UCS). In addition, threat-related activity within the ventromedial PFC and bilateral hippocampus was diminished only to threats that were both predictable and controllable. These findings provide insight into how threat predictability and controllability affects the activity of brain regions (i.e., ventromedial PFC and hippocampus) involved in emotion regulation, and may have important implications for better understanding neural processes that mediate emotional resilience to stress. (C) 2015 Elsevier Inc. All rights reserved. C1 [Wood, Kimberly H.; Wheelock, Muriah D.; Shumen, Joshua R.; Bowen, Kenton H.; Knight, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Hoef, Lawrence W. Ver] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Knight, DC (reprint author), CIRC 235H,1720 2nd Ave S, Birmingham, AL 35294 USA. EM knightdc@uab.edu FU National Institutes of Health [MH098348] FX This research was supported by National Institutes of Health grant MH098348 (DCK). NR 108 TC 3 Z9 4 U1 9 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD OCT 1 PY 2015 VL 119 BP 371 EP 381 DI 10.1016/j.neuroimage.2015.06.086 PG 11 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CR2TB UT WOS:000361182400036 PM 26149610 ER PT J AU Cardenas, DP Muir, ER Huang, SL Boley, A Lodge, D Duong, TQ AF Cardenas, Damon P. Muir, Eric R. Huang, Shiliang Boley, Angela Lodge, Daniel Duong, Timothy Q. TI Functional MRI during hyperbaric oxygen: Effects of oxygen on neurovascular coupling and BOLD fMRI signals SO NEUROIMAGE LA English DT Article DE Forepaw stimulation; CBF; Oxygen therapy; BOLD ID CEREBRAL-BLOOD-FLOW; BRAIN; HYPEROXIA; HYPOXIA; HYPERCAPNIA; PERFUSION; TENSION; DISEASE AB Hyperbaric oxygen (HBO) therapy is used to treat a number of ailments. Improved understanding of how HBO affects neuronal activity, cerebral blood flow (CBF) and blood-oxygenation-level dependent (BOLD) changes could shed light on the role of oxygen in neurovascular coupling and help guide HBO treatments. The goal of this study was to test two hypotheses: i) activation-induced CBF fMRI response is not dependent on hemoglobin deoxygenation, and ii) activation-induced BOLD fMRI is markedly attenuated under HBO. CBF and BOLD fMRI of forepaw stimulation in anesthetized rats under HBO at 3 atmospheres absolute (ATA) were compared with normobaric air. Robust BOLD and CBF fMRI were detected under HBO. Inflow effects and spin-density changes did not contribute significantly to the BOLD fMRI signal under HBO. Analysis of the T2*-weighted signal at normobaric air and 1, 2 and 3ATA oxygen in the tissue and the superior sagittal sinus showed a strong dependence on increasing inhaled [O-2]. Spontaneous electrophysiological activity and evoked local-field potentials were reduced under HBO. The differences between normobaric air and HBO in basal and evoked electrical activity could not fully account for the strong BOLD responses under HBO. We concluded that activation-induced CBF regulation in the brain does not operate through an oxygen-sensing mechanism and that stimulus-evoked BOLD responses and the venous T2*-weighted signals still have room to increase under 3ATA HBO. To our knowledge, this is the first fMRI study under HBO, providing insights into the effects of HBO on neural activity, neurovascular coupling, tissue oxygenation, and the BOLD signal. (C) 2015 Elsevier Inc. All rights reserved. C1 [Cardenas, Damon P.; Duong, Timothy Q.] Univ Texas San Antonio, Grad Sch Biomed Engn, San Antonio, TX USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Muir, Eric R.; Huang, Shiliang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Boley, Angela; Lodge, Daniel] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu FU NIH/NINDS [R01 NS45879]; NIH/NIMH [R01 MH090067]; NIH [T32HL007446] FX This work was supported in part by the NIH/NINDS (R01 NS45879), NIH/NIMH (R01 MH090067) and by NIH T32HL007446. NR 17 TC 6 Z9 6 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD OCT 1 PY 2015 VL 119 BP 382 EP 389 DI 10.1016/j.neuroimage.2015.06.082 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CR2TB UT WOS:000361182400037 PM 26143203 ER PT J AU Lin, Y Mallen-St Clair, J Luo, J Sharma, S Dubinett, S St John, M AF Lin, Yuan Mallen-St Clair, Jon Luo, Jie Sharma, Sherven Dubinett, Steven St John, Maie TI p53 modulates NF-kappa B mediated epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma SO ORAL ONCOLOGY LA English DT Article DE Head and neck cancer; Epithelial-to-mesenchymal transition; p53; NF-kappa B; p65 ID ALPHA-INDUCED APOPTOSIS; TNF-ALPHA; CANCER-CELLS; CROSS-TALK; ACTIVATION; EXPRESSION; BCL-2; PHOSPHORYLATION; TRANSCRIPTION; PROGRESSION AB Objectives: To investigate the role of p53 in NF-kappa B mediated epithelial-to-mesenchymal (EMT) in head and neck squamous cell carcinoma (HNSCC). Materials and methods: We utilized HNSCC and normal oral epithelial cell lines as our model system. We used a lentiviral shRNA system to silence the expression of p65 and p53 in these cell lines. Mutant and wild-type (WT) p53 background genotypes were analyzed. The expression of epithelial and mesenchymal markers was determined using western blotting and quantitative PCR assays. Cell morphology, growth, and invasion were determined using a 3-dimensional spheroid culture and anchorage independent growth (AIG) assays. Results: In HNSCC cells with mutant p53 we found that silencing p65 expression promoted EMT. In contrast, in the context of WT p53, ectopic p65 over-expression promoted EMT. Ablation of WT p53 in normal oral epithelial cells blocked EMT induced by p65 over-expression. We demonstrate that AIG and apoptosis induced by NF-kappa B activation is regulated by p53. Conclusion: Our data demonstrates that p53 mutational status is critical in determining the outcome of NF-kappa B activation in HNSCC. In the presence of WT p53, excess p65 signal can promote EMT. Conversely, ablation of p65 in the context of mutant p53 drives EMT. These results demonstrate that p53 mutational status alters the outcome of NF-kappa B signaling. These results, though preliminary, demonstrate the critical role of p53 mutational status in determining the outcome of NF-kappa B signaling and suggest that monitoring p53 status may inform the utility of NF-kappa B inhibitor treatment in HNSCC. (c) 2015 Elsevier Ltd. All rights reserved. C1 [Lin, Yuan; Mallen-St Clair, Jon; St John, Maie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Lin, Yuan; Luo, Jie; Sharma, Sherven; Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lin, Yuan; Sharma, Sherven; Dubinett, Steven; St John, Maie] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Sharma, Sherven; Dubinett, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP St John, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mstjohn@mednet.ucla.edu NR 41 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 EI 1879-0593 J9 ORAL ONCOL JI Oral Oncol. PD OCT PY 2015 VL 51 IS 10 BP 921 EP 928 DI 10.1016/j.oraloncology.2015.07.006 PG 8 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA CR3NP UT WOS:000361240200008 PM 26306422 ER PT J AU Tiourin, E Velasco, VS Rosales, MA Sullivan, PS Janzen, DM Memarzadeh, S AF Tiourin, Ekaterina Velasco, Victor S. Rosales, Miguel A. Sullivan, Peggy S. Janzen, Deanna M. Memarzadeh, Sanaz TI Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria SO REPRODUCTIVE SCIENCES LA English DT Article DE fallopian epithelial progenitors; tubal ligation; fallopian tube epithelial proliferation ID SEROUS OVARIAN-CANCER; DIVERTING COLOSTOMY; IMAGE-ANALYSIS; STERILIZATION; ANASTOMOSIS; CARCINOMA; CELLS; RISK; EXPRESSION; SYSTEM AB Tubal ligation keeps the fimbriated end of the fallopian tube intact while interrupting the conduit for sperm and egg between the uterus and ovary. Tubal ligation is associated with an approximately 20% decreased risk of high-grade serous ovarian cancers, which mounting evidence suggests arise from the distal fallopian tube epithelium. We postulated that biological changes at the epithelial cellular level of the distal fallopian tube may account for the surgical procedure's observed risk reduction. We compared the histology, presence of epithelial progenitors (basally located CD44-positive cells), and degree of epithelial proliferation (Ki67-positive cells) of distal fallopian tube from 10 patients with previous tubal ligation and 10 age-matched patients with uncut fallopian tubes. A significantly reduced population of proliferating epithelial progenitors (basally located CD44/Ki67 dual-positive cells) was detected in the tubal ligated specimens (P = .0002). To functionally assess the effect of tubal ligation, a murine model was utilized to compare the growth capacity of distal fallopian tube epithelial cells isolated from either ligated or sham-operated tubal epithelia. Murine fallopian tube epithelial cells isolated after tubal ligation showed a significantly reduced capacity to grow organoids in culture compared to sham-operated controls (P = .002). The findings of this study show that tubal ligation is associated with a reduced presence and decreased proliferation of progenitor cells in the distal fallopian tube epithelium. These compositional and functional changes suggest that tubal ligation induces quiescence of distal fallopian tube epithelial cells. C1 [Tiourin, Ekaterina; Velasco, Victor S.; Rosales, Miguel A.; Janzen, Deanna M.; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Sullivan, Peggy S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, 555 Westwood Plaza,Level B,Box 957243, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu FU VA CDA-2 Award; CDU/UCLA NIH/NCI [U54-CA-143931]; Sidney Kimmel Foundation; Concern foundation; Jonsson Comprehensive Cancer Center Seed grant; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI [UL1TR000124]; Leath L. and Marcia L. Millen Family Fund; Ovarian Cancer Circle; Gynecologic Oncology (GO) Discovery Lab Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SM is supported by a VA CDA-2 Award, the CDU/UCLA NIH/NCI Grant #U54-CA-143931 award, a Sidney Kimmel Foundation award, the Concern foundation, The Jonsson Comprehensive Cancer Center Seed grant, the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124, the Leath L. and Marcia L. Millen Family Fund, the Ovarian Cancer Circle Inspired by Robin Babbini, and the Gynecologic Oncology (GO) Discovery Lab Foundation. NR 43 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD OCT PY 2015 VL 22 IS 10 BP 1262 EP 1271 DI 10.1177/1933719115574345 PG 10 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CR7LD UT WOS:000361530300010 PM 25736327 ER PT J AU Ruggiero, KJ Bunnell, BE Andrews, AR Davidson, TM Hanson, RF Danielson, CK Saunders, BE Soltis, K Yarian, C Chu, B Adams, ZW AF Ruggiero, Kenneth J. Bunnell, Brian E. Andrews, Arthur R., III Davidson, Tatiana M. Hanson, Rochelle F. Danielson, Carla Kmett Saunders, Benjamin E. Soltis, Kathryn Yarian, Caleb Chu, Brian Adams, Zachary W. TI Development and Pilot Evaluation of a Tablet-Based Application to Improve Quality of Care in Child Mental Health Treatment SO JMIR RESEARCH PROTOCOLS LA English DT Article DE technology; mobile health; child mental health treatment; feasibility test; fidelity; patient engagement; traumatic stress ID REPLICATION-ADOLESCENT SUPPLEMENT; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED-CONTROLLED-TRIAL; PROVIDERS PERSPECTIVES; COMMUNITY TREATMENT; PHONE APPLICATION; TRAUMATIC EVENTS; PTSD SYMPTOMS; DEPRESSION; FIDELITY AB Background: Children need access to high quality mental health care. Effective treatments now exist for a wide range of mental health conditions. However, these interventions are delivered with variable effectiveness in traditional mental health service settings. Innovative solutions are needed to improve treatment delivery quality and effectiveness. Objective: The aim of this study was to develop a scalable, sustainable technology-based approach to improve the quality of care in child mental health treatment. Methods: A tablet-based resource was developed with input from mental health training experts, mental health providers, and patients. A series of qualitative data collection phases (ie, expert interviews, patient and provider focus groups, usability testing) guided the initial concept and design of the resource, and then its refinement. The result was an iPad-based "e-workbook" designed to improve child engagement and provider fidelity in implementation of a best-practice treatment. We are currently conducting a small scale randomized controlled trial to evaluate the feasibility of e-workbook facilitated child mental health treatment with 10 providers and 20 families recruited from 4 local community-based mental health clinics. Results: Usability and focus group testing yielded a number of strong, favorable reactions from providers and families. Recommendations for refining the e-workbook also were provided, and these guided several improvements to the resource prior to initiating the feasibility trial, which is currently underway. Conclusions: This study aimed to develop and preliminarily evaluate a tablet-based application to improve provider fidelity and child engagement in child mental health treatment. If successful, this approach may serve as a key step toward making best-practice treatment more accessible to children and families. As various technologies continue to increase in popularity worldwide and within the health care field more specifically, it is essential to rigorously test the usability, feasibility, acceptability, and effectiveness of novel health technology solutions. It is also essential to ensure that patients and providers drive decision making that supports the development of these resources to ensure that they can be seamlessly integrated into practice. C1 [Ruggiero, Kenneth J.; Bunnell, Brian E.; Davidson, Tatiana M.; Soltis, Kathryn] Med Univ South Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 99 Jonathan Lucas St, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Andrews, Arthur R., III; Davidson, Tatiana M.; Hanson, Rochelle F.; Danielson, Carla Kmett; Saunders, Benjamin E.; Soltis, Kathryn; Adams, Zachary W.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 171 Ashley Ave, Charleston, SC 29425 USA. [Yarian, Caleb] Fuzzco, Charleston, SC USA. [Chu, Brian] Rutgers State Univ, Piscataway, NJ USA. RP Ruggiero, KJ (reprint author), Med Univ South Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 99 Jonathan Lucas St, Charleston, SC 29425 USA. EM ruggierk@musc.edu OI Andrews III, Arthur/0000-0001-9071-0089; Chu, Brian/0000-0003-0275-1599 FU National Institute of Mental Health [R34-MH096907, R01-MH81056, R34-MH104470, T32-MH18869]; National Institute on Drug Abuse [K12-DA031794, K23-DA038257, R01-DA031285]; Substance Abuse and Mental Health Services Administration [U79-SM061269] FX We thank Judy Cohen, MD, Esther Deblinger, PhD, and Anthony Mannarino, PhD, who developed TF-CBT and have provided valuable input and feedback throughout every phase of this project. We thank Ben Jacobs of Fuzzco for his significant role in the design and development process of the TF-CBT e-workbook. We thank Josh Nissenboim of Fuzzco for his leadership and partnership in support of this project and related research. We thank Joel Sherrill of NIMH for his thoughtful feedback on early conceptualizations of this project. We also thank the families and providers who participated in this study for their time and insights. This research and the authors' time and effort were supported by National Institute of Mental Health grants R34-MH096907, R01-MH81056, R34-MH104470, and T32-MH18869; National Institute on Drug Abuse grants K12-DA031794, K23-DA038257, and R01-DA031285; and Substance Abuse and Mental Health Services Administration grant U79-SM061269. None of these funding agencies were involved in the design of the study; the collection, analysis, or interpretation of data; the writing of the manuscript, or the decision to submit the manuscript for publication. NR 62 TC 0 Z9 0 U1 0 U2 0 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1929-0748 J9 JMIR RES PROTOC JI JMIR RES. Protoc. PD OCT-DEC PY 2015 VL 4 IS 4 AR e143 DI 10.2196/resprot.4416 PG 18 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EI2LT UT WOS:000392319500010 PM 26717906 ER PT J AU Hall, DE Stone, RA Feske, U Ling, B Shasha, G Zickmund, S Zhang, SJ Arnold, R AF Hall, Daniel E. Stone, Roslyn A. Feske, Ulrike Ling, Bruce Shasha, Gao Zickmund, Susan Zhang, Sijian Arnold, Robert TI Systematic bias against expedited review procedures across institutional review boards (IRBs) in the Veterans Health Administration (VHA) SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 101st Annual Clinical Congress of the American-College-of-Surgeons (ACS) CY OCT 04-10, 2015 CL Chicago, IL SP Amer Coll Surg C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2015 VL 221 IS 4 SU 2 BP E14 EP E14 PG 1 WC Surgery SC Surgery GA EA8PP UT WOS:000386899000031 ER PT J AU Hall, DE AF Hall, Daniel E. TI Practical wisdom provides ethical justification for the negotiation and enforcement of surgical buy-in SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 101st Annual Clinical Congress of the American-College-of-Surgeons (ACS) CY OCT 04-10, 2015 CL Chicago, IL SP Amer Coll Surg C1 [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2015 VL 221 IS 4 SU 2 BP E13 EP E14 PG 2 WC Surgery SC Surgery GA EA8PP UT WOS:000386899000030 ER PT J AU Holland, CM Ritchie, ND Du Bois, SN AF Holland, Christine M. Ritchie, Natalie D. Du Bois, Steve N. TI iTunes Song-Gifting is a Low-Cost, Efficient Recruitment Tool to Engage High-Risk MSM in Internet Research SO AIDS AND BEHAVIOR LA English DT Article DE Internet research methodology; Recruitment; Incentives; Men who have sex with men; HIV/STI prevention ID MEN; SEX; PREVENTION; GAY AB This brief report describes methodology and results of a novel, efficient, and low-cost recruitment tool to engage high-risk MSM in online research. We developed an incentivization protocol using iTunes song-gifting to encourage participation of high-risk MSM in an Internet-based survey of HIV status, childhood sexual abuse, and adult behavior and functioning. Our recruitment methodology yielded 489 participants in 4.5 months at a total incentive cost of $1.43USD per participant. The sample comprised a critically high-risk group of MSM, including 71.0 % who reported recent condomless anal intercourse. We offer a "how-to" guide to aid future investigators in using iTunes song-gifting incentives. C1 [Holland, Christine M.] VA Greater Los Angeles Healthcare Syst, Dept Mental Hlth, Los Angeles, CA USA. [Ritchie, Natalie D.] Denver Hlth & Hosp Author, Denver Hlth Managed Care, Denver, CO 80204 USA. [Du Bois, Steve N.] Northwestern Univ, Family Inst, Evanston, IL USA. [Du Bois, Steve N.] Univ Illinois, Dept Psychol, Chicago, IL 60680 USA. RP Ritchie, ND (reprint author), Denver Hlth & Hosp Author, Denver Hlth Managed Care, 777 Bannock St,MC 6000, Denver, CO 80204 USA. EM natalie.ritchie@dhha.org FU University of Illinois at Chicago Chancellor's Committee on the Status of Lesbian, Gay, Bisexual, and Transgender Issues FX This work was supported by the University of Illinois at Chicago Chancellor's Committee on the Status of Lesbian, Gay, Bisexual, and Transgender Issues. NR 11 TC 1 Z9 1 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2015 VL 19 IS 10 BP 1914 EP 1918 DI 10.1007/s10461-015-1130-y PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CR0HK UT WOS:000360999000019 PM 26174208 ER PT J AU Neogi, T Jansen, TLTA Dalbeth, N Fransen, J Schumacher, HR Berendsen, D Brown, M Choi, H Edwards, NL Janssens, HJEM Liote, F Naden, RP Nuki, G Ogdie, A Perez-Ruiz, F Saag, K Singh, JA Sundy, JS Tausche, AK Vaquez-Mellado, J Yarows, SA Taylor, WJ AF Neogi, Tuhina Jansen, Tim L. Th A. Dalbeth, Nicola Fransen, Jaap Schumacher, H. Ralph Berendsen, Dianne Brown, Melanie Choi, Hyon Edwards, N. Lawrence Janssens, Hein J. E. M. Liote, Frederic Naden, Raymond P. Nuki, George Ogdie, Alexis Perez-Ruiz, Fernando Saag, Kenneth Singh, Jasvinder A. Sundy, John S. Tausche, Anne-Kathrin Vaquez-Mellado, Janitzia Yarows, Steven A. Taylor, William J. TI 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID SYSTEMIC-SCLEROSIS; PRIMARY-CARE; ARTHRITIS; IDENTIFICATION; UK; QUESTIONNAIRE; POPULATION; PREVALENCE; MANAGEMENT AB Objective Existing criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for gout. Methods An international group of investigators, supported by the American College of Rheumatology and the European League Against Rheumatism, conducted a systematic review of the literature on advanced imaging of gout, a diagnostic study in which the presence of monosodium urate monohydrate (MSU) crystals in synovial fluid or tophus was the gold standard, a ranking exercise of paper patient cases, and a multi-criterion decision analysis exercise. These data formed the basis for developing the classification criteria, which were tested in an independent data set. Results The entry criterion for the new classification criteria requires the occurrence of at least one episode of peripheral joint or bursal swelling, pain, or tenderness. The presence of MSU crystals in a symptomatic joint/bursa (ie, synovial fluid) or in a tophus is a sufficient criterion for classification of the subject as having gout, and does not require further scoring. The domains of the new classification criteria include clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate, MSU-negative synovial fluid aspirate), and imaging (double-contour sign on ultrasound or urate on dual-energy CT, radiographic gout-related erosion). The sensitivity and specificity of the criteria are high (92% and 89%, respectively). Conclusions The new classification criteria, developed using a data-driven and decision-analytic approach, have excellent performance characteristics and incorporate current state-of-the-art evidence regarding gout. C1 [Neogi, Tuhina; Choi, Hyon] Boston Univ, Sch Med, Boston, MA 02118 USA. [Jansen, Tim L. Th A.] Viecuri Med Ctr, Venlo, Netherlands. [Jansen, Tim L. Th A.; Fransen, Jaap; Berendsen, Dianne; Janssens, Hein J. E. M.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Dalbeth, Nicola] Univ Auckland, Auckland 1, New Zealand. [Schumacher, H. Ralph; Ogdie, Alexis] Univ Penn, Philadelphia, PA 19104 USA. [Brown, Melanie; Taylor, William J.] Univ Otago, Wellington, New Zealand. [Edwards, N. Lawrence] Univ Florida, Gainesville, FL USA. [Liote, Frederic] Hop Lariboisiere, AP HP, INSERM, UMR 1132, F-75475 Paris, France. [Liote, Frederic] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France. [Naden, Raymond P.] McMaster Univ, Med Ctr, Hamilton, ON, Canada. [Nuki, George] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Perez-Ruiz, Fernando] Hosp Univ Cruces, Vizcaya, Spain. [Perez-Ruiz, Fernando] BioCruces Hlth Res Inst, Vizcaya, Spain. [Saag, Kenneth] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Rochester, MN USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Rochester, MN USA. [Sundy, John S.] Duke Univ, Durham, NC USA. [Sundy, John S.] Duke Univ, Med Ctr, Durham, NC USA. [Sundy, John S.] Gilead Sci Inc, Foster City, CA 94404 USA. [Tausche, Anne-Kathrin] Univ Hosp Carl Gustav Carus, Dresden, Germany. [Vaquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Yarows, Steven A.] Univ Michigan Hlth Syst, Chelsea, MI USA. RP Neogi, T (reprint author), Boston Univ, Sch Med, X Bldg,Suite 200,650 Albany St, Boston, MA 02118 USA. EM tneogi@bu.edu RI Fransen, J./L-4310-2015 OI Ogdie, Alexis/0000-0002-4639-0775; Neogi, Tuhina/0000-0002-9515-1711; Perez-Ruiz, Fernando/0000-0002-5268-1894 FU American College of Rheumatology; European League Against Rheumatism; NIH [P60-AR-47785, K23-AR-055127]; Agency for Healthcare Research and Quality (Center for Education and Research on Therapeutics programme); NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases); NIH (National Institute on Aging); NIH (National Cancer Institute); Arthritis New Zealand FX Supported jointly by the American College of Rheumatology and the European League Against Rheumatism. TN's work was supported by the NIH (grants P60-AR-47785 and K23-AR-055127). JAS' work was supported by the NIH (grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, and the National Cancer Institute) and the Agency for Healthcare Research and Quality (Center for Education and Research on Therapeutics programme). WJT's work was supported by Arthritis New Zealand. NR 35 TC 39 Z9 50 U1 4 U2 17 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD OCT PY 2015 VL 74 IS 10 BP 1789 EP 1798 DI 10.1136/annrheumdis-2015-208237 PG 10 WC Rheumatology SC Rheumatology GA CR0WC UT WOS:000361043200005 PM 26359487 ER PT J AU Neogi, T Jansen, TLTA Dalbeth, N Fransen, J Schumacher, HR Berendsen, D Brown, M Choi, H Edwards, NL Janssens, HJEM Liote, F Naden, RP Nuki, G Ogdie, A Perez-Ruiz, F Saag, K Singh, JA Sundy, JS Tausche, AK Vaquez-Mellado, J Yarows, SA Taylor, WJ AF Neogi, Tuhina Jansen, Tim L. Th. A. Dalbeth, Nicola Fransen, Jaap Schumacher, H. Ralph Berendsen, Dianne Brown, Melanie Choi, Hyon Edwards, N. Lawrence Janssens, Hein J. E. M. Liote, Frederic Naden, Raymond P. Nuki, George Ogdie, Alexis Perez-Ruiz, Fernando Saag, Kenneth Singh, Jasvinder A. Sundy, John S. Tausche, Anne-Kathrin Vaquez-Mellado, Janitzia Yarows, Steven A. Taylor, William J. TI 2015 Gout Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID PRIMARY-CARE; ARTHRITIS; IDENTIFICATION; POPULATION; PREVALENCE; UK; MANAGEMENT AB ObjectiveExisting criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for gout. MethodsAn international group of investigators, supported by the American College of Rheumatology and the European League Against Rheumatism, conducted a systematic review of the literature on advanced imaging of gout, a diagnostic study in which the presence of monosodium urate monohydrate (MSU) crystals in synovial fluid or tophus was the gold standard, a ranking exercise of paper patient cases, and a multicriterion decision analysis exercise. These data formed the basis for developing the classification criteria, which were tested in an independent data set. ResultsThe entry criterion for the new classification criteria requires the occurrence of at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness. The presence of MSU crystals in a symptomatic joint/bursa (i.e., synovial fluid) or in a tophus is a sufficient criterion for classification of the subject as having gout, and does not require further scoring. The domains of the new classification criteria include clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate, MSU-negative synovial fluid aspirate), and imaging (double-contour sign on ultrasound or urate on dual-energy computed tomography, radiographic gout-related erosion). The sensitivity and specificity of the criteria are high (92% and 89%, respectively). ConclusionThe new classification criteria, developed using a data-driven and decision analytic approach, have excellent performance characteristics and incorporate current state-of-the-art evidence regarding gout. C1 [Neogi, Tuhina; Choi, Hyon] Boston Univ, Sch Med, Boston, MA 02118 USA. [Jansen, Tim L. Th. A.] Viecuri Med Ctr, Venlo, Netherlands. [Jansen, Tim L. Th. A.; Fransen, Jaap; Berendsen, Dianne; Janssens, Hein J. E. M.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands. [Dalbeth, Nicola] Univ Auckland, Auckland 1, New Zealand. [Schumacher, H. Ralph; Ogdie, Alexis] Univ Penn, Philadelphia, PA 19104 USA. [Brown, Melanie; Taylor, William J.] Univ Otago, Wellington, New Zealand. [Edwards, N. Lawrence] Univ Florida, Gainesville, FL USA. [Liote, Frederic] Hop Lariboisiere, AP HP, INSERM, UMR 1132, F-75475 Paris, France. [Liote, Frederic] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France. [Naden, Raymond P.] McMaster Univ, Med Ctr, Hamilton, ON, Canada. [Nuki, George] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Perez-Ruiz, Fernando] Hosp Univ Cruces, Vizcaya, Spain. [Perez-Ruiz, Fernando] BioCruces Hlth Res Inst, Vizcaya, Spain. [Saag, Kenneth; Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Rochester, MN USA. [Sundy, John S.] Duke Univ, Durham, NC USA. [Sundy, John S.] Duke Univ, Med Ctr, Durham, NC USA. [Tausche, Anne-Kathrin] Univ Hosp Carl Gustav Carus, Dresden, Germany. [Vaquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Yarows, Steven A.] Univ Michigan Hlth Syst, Chelsea, MI USA. RP Neogi, T (reprint author), Boston Univ, Sch Med, X Bldg,Suite 200,650 Albany St, Boston, MA 02118 USA. EM tneogi@bu.edu RI Fransen, J./L-4310-2015; Jansen, T.L.Th.A./L-4407-2015 OI Ogdie, Alexis/0000-0002-4639-0775; Perez-Ruiz, Fernando/0000-0002-5268-1894 FU American College of Rheumatology; European League Against Rheumatism; NIH [P60-AR-47785, K23-AR-055127]; Agency for Healthcare Research and Quality (Center for Education and Research on Therapeutics program); Arthritis New Zealand; NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases); NIH (National Institute on Aging); NIH (National Cancer Institute); AbbVie; Bristol-Myers Squibb; Roche; Janssen; Novartis; Menarini; Takeda; Teijin; Pfizer; Fonterra; AstraZeneca/Ardea; Regeneron; AstraZeneca; Metabolex; Crealta; CymaBay; Ardea; Ipsen; Savient; Mayoly-Spindler; Amgen; Allergan; Merck; Lilly; Navigant; Berlin-Chemie Menarini FX Supported jointly by the American College of Rheumatology and the European League Against Rheumatism. Dr. Neogi's work was supported by the NIH (grants P60-AR-47785 and K23-AR-055127). Dr. Singh's work was supported by the NIH (grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, and the National Cancer Institute) and the Agency for Healthcare Research and Quality (Center for Education and Research on Therapeutics program). Dr. Taylor's work was supported by Arthritis New Zealand.; Dr. Jansen has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, Roche, Janssen, Novartis, and Menarini (less than $10,000 each). Dr. Dalbeth has received consulting fees, speaking fees, and/or honoraria from Takeda, Teijin, Menarini, Pfizer, and Fonterra (less than $10,000 each) and AstraZeneca/Ardea (more than $10,000); she holds a patent for Fonterra milk products for gout. Dr. Schumacher has received consulting fees from Novartis, Regeneron, AstraZeneca, and Metabolex (less than $10,000 each). Dr. Choi has received consulting fees, speaking fees, and/or honoraria from AstraZeneca (less than $10,000) and Takeda (more than $10,000). Dr. Edwards has received consulting fees, speaking fees, and/or honoraria from AstraZeneca, Crealta, CymaBay, and Takeda (less than $10,000 each). Dr. Liote has received consulting fees, speaking fees, and/or honoraria from Novartis, Ardea, AstraZeneca, Ipsen, Menarini, and Savient (less than $10,000 each) and unrestricted academic grants from Novartis, AstraZeneca, Ipsen, Menarini, Savient, and Mayoly-Spindler. Dr. Perez-Ruiz has received consulting fees, speaking fees, and/or honoraria from AstraZeneca, Menarini, Pfizer, and CymaBay (less than $10,000 each). Dr. Saag has received consulting fees, speaking fees, and/or honoraria from Amgen, AstraZeneca/Ardea, Crealta, and Takeda (less than $10,000 each). Dr. Singh has received consulting fees, speaking fees, and/or honoraria from Regeneron, Allergan, and Savient (less than $10,000 each) and Takeda (more than $10,000) and research grants from Savient and Takeda. Dr. Sundy has received consulting fees from Merck, Lilly, AstraZeneca, Metabolex, Novartis, and Navigant (less than $10,000 each). Dr. Tausche has received consulting fees, speaking fees, and/or honoraria from Berlin-Chemie Menarini (less than $10,000) and has served as an expert witness on behalf of Ardea Biosciences/AstraZeneca and Novartis. Dr. Taylor has received consulting fees, speaking fees, and/or honoraria from Pfizer, AstraZeneca, AbbVie, and Roche (less than $10,000 each). NR 35 TC 30 Z9 30 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 IS 10 BP 2557 EP 2568 DI 10.1002/art.39254 PG 12 WC Rheumatology SC Rheumatology GA CR3QS UT WOS:000361248600001 PM 26352873 ER PT J AU Kaji, I Akiba, Y Said, H Narimatsu, K Kaunitz, JD AF Kaji, I. Akiba, Y. Said, H. Narimatsu, K. Kaunitz, J. D. TI Luminal 5-HT stimulates colonic bicarbonate secretion in rats SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article ID NITRIC-OXIDE; ION-TRANSPORT; CONCISE GUIDE; ELECTROLYTE TRANSPORT; ARRIVE GUIDELINES; SEROTONIN RELEASE; ANION SECRETION; G-PROTEIN; 5-HYDROXYTRYPTAMINE; RECEPTORS AB Background and PurposeThe bioactive monoamine 5-HT, implicated in the pathogenesis of functional gastrointestinal disorders, is abundantly synthesized and stored in rat proximal colonic mucosa and released to the gut lumen and subepithelial space. Despite much data regarding its expression and function, the effects of luminal 5-HT on colonic anion secretion have not been fully investigated. Experimental ApproachWe measured short-circuit current (I-sc) as an indicator of ion transport in mucosa-submucosa or mucosa-only preparations of rat proximal colon. Total CO2 output was measured in vitro and in vivo. Immunohistochemistry was performed to investigate the localization of 5-HT4, NOS1 and NOS2. Key ResultsLuminal 5-HT gradually increased the amplitude and sustained the elevation of I-sc. Luminal 5-HT-evoked I-sc was acetazolamide sensitive and HCO3- dependent, consistent with cytosolic carbonic anhydrase-dependent electrogenic HCO3- secretion, while not affected by tetrodotoxin (TTX), atropine or indomethacin. Pretreatment with the selective 5-HT4 antagonist GR113808, but not antagonists for 5-HT3, 5-HT6 or 5-HT7, inhibited luminal 5-HT-evoked I-sc. Furthermore, luminal cisapride and tegaserod increased I-sc to the same extent as did 5-HT in the presence of indomethacin and TTX. Removal of the submucosa or pretreatment with NOS inhibitors enhanced luminal 5-HT-evoked I-sc, suggesting that NO synthesized in the submucosa suppresses mucosal anion secretion. NOS1 and NOS2 were immunostained in the submucosal neurons and glial cells respectively. Luminal 5-HT-evoked HCO3- secretion was confirmed in vivo, inhibited by co-perfusion of GR113808, but not by ondansetron. Conclusions and ImplicationsA novel apical 5-HT4-mediated HCO3- secretory pathway and an NO-dependent inhibitory mechanism are present in the proximal colon. Luminal 5-HT-evoked HCO3- secretion may be important for the maintenance of mucosal integrity by regulating luminal pH. C1 [Kaji, I.; Akiba, Y.; Narimatsu, K.; Kaunitz, J. D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, J. D.] Univ Calif Los Angeles, Dept Surg, Sch Med, Los Angeles, CA 90024 USA. [Said, H.] Univ Calif Los Angeles, Coll Letters & Sci, Los Angeles, CA USA. [Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Akiba, Y.; Kaunitz, J. D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Department of Veterans Affairs Merit Review Award; NIH-NIDDK [R01 DK54221, P30 DK0413] FX The authors thank B. Palileo for preparing the manuscript. The helpful discussion of Dr E. Engel and Dr P. H. Guth is gratefully acknowledged. This study was supported by a Department of Veterans Affairs Merit Review Award, NIH-NIDDK R01 DK54221 (J. D. K.), and the animal core of NIH-NIDDK P30 DK0413 (J. E. Rozengurt). NR 57 TC 6 Z9 6 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1188 EI 1476-5381 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD OCT PY 2015 VL 172 IS 19 BP 4655 EP 4670 DI 10.1111/bph.13216 PG 16 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CQ9FM UT WOS:000360918200005 PM 26061462 ER PT J AU Somanna, NK Yariswamy, M Garagliano, JM Siebenlist, U Mummidi, S Valente, AJ Chandrasekar, B AF Somanna, Naveen K. Yariswamy, Manjunath Garagliano, Joseph M. Siebenlist, Ulrich Mummidi, Srinivas Valente, Anthony J. Chandrasekar, Bysani TI Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2 SO CELLULAR SIGNALLING LA English DT Article DE RAAS; Aldosterone; TRAF3IP2; Hypertrophy; Mitogenesis; Migration ID KAPPA-B KINASE; HEART-FAILURE; ANGIOTENSIN-II; MYOCARDIAL FIBROSIS; CARDIAC-HYPERTROPHY; MATRIX METALLOPROTEINASES; HYPERTENSIVE PATIENTS; SYSTOLIC DYSFUNCTION; PRESSURE-OVERLOAD; OXIDATIVE STRESS AB Sustained activation of the Renin-Angiotensin-Aldosterone System (RAAS) contributes to the pathogenesis of heart failure. Aldosterone (Aldo) is known to induce both myocardial hypertrophy and fibrosis through oxidative stress and proinflammatory pathways. Here we have investigated whether Aldo-mediated cardiomycocyte hypertrophy is dependent on TRAF3IP2, an upstream regulator of IKK and JNIC We also investigated whether the pro-mitogenic and pro-migratory effects of Aldo on cardiac fibroblasts are also mediated by TRAF3IP2. Aldo induced both superoxide and hydrogen peroxide in isolated adult mouse cardiomyocytes (CM), and upregulated TRAF3IP2 expression in part via the mineralocorticoid receptor and oxidative stress. Silencing TRAF3IP2 blunted Aldo-induced IKK beta, p65, JNK, and c-Jun activation, IL-18, IL-6 and CT-1 upregulation, and cardiomyocyte hypertrophy. In isolated adult mouse cardiac fibroblasts (CF), Aldo stimulated TRAF3IP2-dependent IL-18 and IL-6 production, CTGF, collagen land III expression, MMP2 activation, and proliferation and migration. These in vitro results suggest that TRAF3IP2 may play a causal role in Aldo-induced adverse cardiac remodeling in vivo, and identify TRAF3IP2 as a potential therapeutic target in hypertensive heart disease. (C) 2015 Elsevier Inc. All rights reserved. C1 [Somanna, Naveen K.] Tulane Univ, Sch Med, Dept Microbiol, New Orleans, LA 70112 USA. [Yariswamy, Manjunath; Garagliano, Joseph M.; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. [Yariswamy, Manjunath; Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, New Orleans, LA 70161 USA. [Siebenlist, Ulrich; Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Siebenlist, Ulrich; Chandrasekar, Bysani] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Mummidi, Srinivas; Valente, Anthony J.] NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA. RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA. FU Department of Veterans Affairs Research Career Scientist award; U.S. Department of Veterans Affairs, Office of Research and Development-Biomedical Laboratory Research and Development (ORD-BLRD) Service Award [VA-I01 BX002255]; Usha Ramadhyani Bourgeois Medical Student Research Endowed Fund; NIH/NIAID FX BC is a recipient of the Department of Veterans Affairs Research Career Scientist award, and is supported by the U.S. Department of Veterans Affairs, Office of Research and Development-Biomedical Laboratory Research and Development (ORD-BLRD) Service Award VA-I01 BX002255. JMG is a recipient of The Warren R Bourgeois III and Usha Ramadhyani Bourgeois Medical Student Research Endowed Fund. US is supported by the Intramural Research Program of the NIH/NIAID. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States government NR 44 TC 7 Z9 8 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD OCT PY 2015 VL 27 IS 10 BP 1928 EP 1938 DI 10.1016/j.cellsig.2015.07.001 PG 11 WC Cell Biology SC Cell Biology GA CQ7ID UT WOS:000360775300002 PM 26148936 ER PT J AU Siegler, JE Samai, A Albright, KC Boehme, AK Martin-Schild, S AF Siegler, James E. Samai, Alyana Albright, Karen C. Boehme, Amelia K. Martin-Schild, Sheryl TI Factoring in Factor VIII With Acute Ischemic Stroke SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS LA English DT Review DE stroke; von Willebrand factor; thrombosis; hypercoagulability; factor viii ID VON-WILLEBRAND-FACTOR; ELEVATED FACTOR-VIII; CLOTTING FACTOR-VIII; HIGH PLASMA-LEVELS; FACTOR-V-LEIDEN; RISK-FACTORS; MYOCARDIAL-INFARCTION; VENOUS THROMBOEMBOLISM; COAGULATION-FACTORS; HIGH PREVALENCE AB There is growing research interest into the etiologies of cryptogenic stroke, in particular as it relates to hypercoagulable states. An elevation in serum levels of the procoagulant factor VIII is recognized as one such culprit of occult cerebral infarctions. It is the objective of the present review to summarize the molecular role of factor VIII in thrombogenesis and its clinical use in the diagnosis and prognosis of acute ischemic stroke. We also discuss the utility of screening for serum factor VIII levels among patients at risk for, or those who have experienced, ischemic stroke. C1 [Siegler, James E.; Samai, Alyana; Martin-Schild, Sheryl] Tulane Univ Med Ctr Hosp & Clin, Tulane Stroke Res Program, Dept Neurol, New Orleans, LA USA. [Samai, Alyana] Tulane Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. [Albright, Karen C.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [Albright, Karen C.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Boehme, Amelia K.] Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, New York, NY USA. RP Martin-Schild, S (reprint author), Tulane Univ, Stroke Program, Tulane Stroke Res Program, Dept Neurol, 1440 Canal St,TB-52,Suite 1000, New Orleans, LA 70112 USA. EM smartin2@tulane.edu OI Siegler, James/0000-0003-0287-3967 FU NINDS NIH [T32 NS007153-31] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Boehme is supported by NINDS NIH T32 NS007153-31. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIH. NR 48 TC 0 Z9 0 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1076-0296 EI 1938-2723 J9 CLIN APPL THROMB-HEM JI Clin. Appl. Thromb.-Hemost. PD OCT PY 2015 VL 21 IS 7 BP 597 EP 602 DI 10.1177/1076029615571630 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CQ8AB UT WOS:000360827200001 PM 25669199 ER PT J AU Acher, AW LeCaire, TJ Hundt, AS Greenberg, CC Carayon, P Kind, AJ Weber, SM AF Acher, Alexandra W. LeCaire, Tamara J. Hundt, Ann Schoofs Greenberg, Caprice C. Carayon, Pascale Kind, Amy J. Weber, Sharon M. TI Using Human Factors and Systems Engineering to Evaluate Readmission after Complex Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID POSTOPERATIVE COGNITIVE DYSFUNCTION; 30-DAY HOSPITAL READMISSIONS; QUALITATIVE CONTENT-ANALYSIS; HEALTH-CARE PROFESSIONALS; ABDOMINAL-SURGERY; INFORMED-CONSENT; RISK-FACTORS; DELIRIUM; PATIENT; PANCREATICODUODENECTOMY AB BACKGROUND: Our objective was to use a human factors and systems engineering approach to understand contributors to surgical readmissions from a patient and provider perspective. Previous studies on readmission have neglected the patient perspective. To address this gap and to better inform intervention design, we evaluated how transitions of care relate to and influence readmission from the patient and clinician perspective using the Systems Engineering Initiative for Patient Safety (SEIPS) model. STUDY DESIGN: Patients readmitted within 30 days of discharge after complex abdominal surgery were interviewed. A focus group of inpatient clinician providers was conducted. Questions were guided by the SEIPS framework and content was analyzed. Data were collected concurrently from the medical record for a mixed-methods approach. RESULTS: Readmission occurred a median of 8 days (range 1 to 25 days) after discharge. All patients had follow-up scheduled with their surgeon, but readmission occurred before this in 72% of patients. Primary readmission diagnoses included infection, gastrointestinal complications, and dehydration. Patients (n = 18) and clinician providers (n = 6) identified a number of factors during the transition of care that may have contributed to readmission, including poor patient and caregiver understanding; inadequate discharge preparation for home care; insufficient educational process and materials, negatively affected by electronic health record design; and inadequate care team communication. CONCLUSIONS: This is the first study to use a human factors and systems engineering approach to evaluate the impact of the quality of the transition of care and its influence on readmission from the patient and clinician perspective. Important targets for future interventions include enhancing the discharge process, improving education materials, and increasing care team coordination, with the overarching theme that improved patient and caregiver understanding and engagement are essential to decrease readmission and postdischarge health care use. (C) 2015 by the American College of Surgeons C1 [Acher, Alexandra W.; LeCaire, Tamara J.; Greenberg, Caprice C.; Weber, Sharon M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Surg Outcomes Res Program, Madison, WI 53792 USA. [Kind, Amy J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [LeCaire, Tamara J.; Greenberg, Caprice C.; Weber, Sharon M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Hundt, Ann Schoofs; Greenberg, Caprice C.; Carayon, Pascale] Univ Wisconsin, Ctr Qual & Prod Improvement, Madison, WI 53792 USA. [Greenberg, Caprice C.; Carayon, Pascale] Univ Wisconsin, Dept Ind & Syst Engn, Coll Engn, Madison, WI 53792 USA. [Acher, Alexandra W.; Kind, Amy J.; Weber, Sharon M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Weber, SM (reprint author), Univ Wisconsin, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA. EM webers@surgery.wisc.edu FU Clinical and Translational Science Award (CTSA) program through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; University of Wisconsin School of Medicine and Public Health's Wisconsin Partnership Program (WPP); Agency for Healthcare Research and Quality (AHRQ) [K18 HS022446] FX This study was supported by the Clinical and Translational Science Award (CTSA) program, through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427; the University of Wisconsin School of Medicine and Public Health's Wisconsin Partnership Program (WPP); and by the Agency for Healthcare Research and Quality (AHRQ), grant K18 HS022446. NR 42 TC 5 Z9 5 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2015 VL 221 IS 4 BP 810 EP 820 DI 10.1016/j.jamcollsurg.2015.06.014 PG 11 WC Surgery SC Surgery GA CR1EQ UT WOS:000361067200006 PM 26228011 ER PT J AU Aggarwal, A Madigan, MC Cody, E Tzeng, E AF Aggarwal, Ankur Madigan, Michael C. Cody, Ellen Tzeng, Edith TI A Role for Topical Nitrite in Diabetic Wound Healing SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 70th Annual Sessions of the Scientific Forum and Annual Clinical Congress of the American-College-of-Surgeons CY OCT 04-08, 2015 CL Chicago, IL SP Amer Coll Surg C1 Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2015 VL 221 IS 4 SU 1 BP S176 EP S176 PG 1 WC Surgery SC Surgery GA CR1XX UT WOS:000361119700369 ER PT J AU Nalls, MA McLean, CY Rick, J Eberly, S Hutten, SJ Gwinn, K Sutherland, M Martinez, M Heutink, P Williams, NM Hardy, J Gasser, T Brice, A Price, TR Nicolas, A Keller, MF Molony, C Gibbs, JR Chen-Plotkin, A Suh, E Letson, C Fiandaca, MS Mapstone, M Federoff, HJ Noyce, AJ Morris, H Van Deerlin, VM Weintraub, D Zabetian, C Hernandez, DG Lesage, S Mullins, M Conley, ED Northover, CAM Frasier, M Marek, K Day-Williams, AG Stone, DJ Ioannidis, JPA Singleton, AB AF Nalls, Mike A. McLean, Cory Y. Rick, Jacqueline Eberly, Shirley Hutten, Samantha J. Gwinn, Katrina Sutherland, Margaret Martinez, Maria Heutink, Peter Williams, Nigel M. Hardy, John Gasser, Thomas Brice, Alexis Price, T. Ryan Nicolas, Aude Keller, Margaux F. Molony, Cliona Gibbs, J. Raphael Chen-Plotkin, Alice Suh, Eunran Letson, Christopher Fiandaca, Massimo S. Mapstone, Mark Federoff, Howard J. Noyce, Alastair J. Morris, Huw Van Deerlin, Vivianna M. Weintraub, Daniel Zabetian, Cyrus Hernandez, Dena G. Lesage, Suzanne Mullins, Meghan Conley, Emily Drabant Northover, Carrie A. M. Frasier, Mark Marek, Ken Day-Williams, Aaron G. Stone, David J. Ioannidis, John P. A. Singleton, Andrew B. CA Parkinson's Dis Biomarkers Program TI Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study SO LANCET NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; MUTATIONS; IDENTIFICATION; METAANALYSIS AB Background Accurate diagnosis and early detection of complex diseases, such as Parkinson's disease, has the potential to be of great benefit for researchers and clinical practice. We aimed to create a non-invasive, accurate classification model for the diagnosis of Parkinson's disease, which could serve as a basis for future disease prediction studies in longitudinal cohorts. Methods We developed a model for disease classification using data from the Parkinson's Progression Marker Initiative (PPMI) study for 367 patients with Parkinson's disease and phenotypically typical imaging data and 165 controls without neurological disease. Olfactory function, genetic risk, family history of Parkinson's disease, age, and gender were algorithmically selected by stepwise logistic regression as significant contributors to our classifying model. We then tested the model with data from 825 patients with Parkinson's disease and 261 controls from five independent cohorts with varying recruitment strategies and designs: the Parkinson's Disease Biomarkers Program (PDBP), the Parkinson's Associated Risk Study (PARS), 23andMe, the Longitudinal and Biomarker Study in PD (LABS-PD), and the Morris K Udall Parkinson's Disease Research Center of Excellence cohort (Penn-Udall). Additionally, we used our model to investigate patients who had imaging scans without evidence of dopaminergic deficit (SWEDD). Findings In the population from PPMI, our initial model correctly distinguished patients with Parkinson's disease from controls at an area under the curve (AUC) of 0.923 (95% CI 0.900-0.946) with high sensitivity (0.834, 95% CI 0.711-0.883) and specificity (0.903, 95% CI 0.824-0.946) at its optimum AUC threshold (0.655). All Hosmer-Lemeshow simulations suggested that when parsed into random subgroups, the subgroup data matched that of the overall cohort. External validation showed good classification of Parkinson's disease, with AUCs of 0.894 (95% CI 0.867-0.921) in the PDBP cohort, 0.998 (0.992-1.000) in PARS, 0.955 (no 95% CI available) in 23andMe, 0.929 (0.896-0.962) in LABS-PD, and 0.939 (0.891-0.986) in the Penn-Udall cohort. Four of 17 SWEDD participants who our model classified as having Parkinson's disease converted to Parkinson's disease within 1 year, whereas only one of 38 SWEDD participants who were not classified as having Parkinson's disease underwent conversion (test of proportions, p=0.003). Interpretation Our model provides a potential new approach to distinguish participants with Parkinson's disease from controls. If the model can also identify individuals with prodromal or preclinical Parkinson's disease in prospective cohorts, it could facilitate identification of biomarkers and interventions. C1 [Nalls, Mike A.; Price, T. Ryan; Nicolas, Aude; Gibbs, J. Raphael; Letson, Christopher; Hernandez, Dena G.; Singleton, Andrew B.] NIA, NIH, Neurogenet Lab, Bethesda, MD 20892 USA. [McLean, Cory Y.; Mullins, Meghan; Conley, Emily Drabant; Northover, Carrie A. M.] 23andMe, Mountain View, CA USA. [Rick, Jacqueline; Chen-Plotkin, Alice; Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Eberly, Shirley] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY 14627 USA. [Hutten, Samantha J.; Frasier, Mark] Michael J Fox Fdn, Parkinsons Res, New York, NY USA. [Gwinn, Katrina; Sutherland, Margaret] NINDS, NIH, Bethesda, MD 20892 USA. [Martinez, Maria] INSERM, UMR 1043, Ctr Physiopathol Toulouse Purpan, Toulouse, France. [Martinez, Maria] Univ Toulouse 3, F-31062 Toulouse, France. [Heutink, Peter] German Ctr Neurodegenerat Dis, Genome Biol Neurodegenerat Dis, Tubingen, Germany. [Williams, Nigel M.] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Gen, Inst Psychol Med & Clin Neurosci, Cardiff CF10 3AX, S Glam, Wales. [Hardy, John; Noyce, Alastair J.; Morris, Huw] UCL, Inst Neurol, Reta Lila Weston Inst, London, England. [Gasser, Thomas] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Tubingen, Germany. [Brice, Alexis; Lesage, Suzanne] Sorbonne Univ, UPMC Univ Paris 06, 1127, Paris, France. [Brice, Alexis; Lesage, Suzanne] CNRS, INSERM, UMR 7225,U 1127, Inst Cerveau & Moelle Epiniere, Paris, France. [Brice, Alexis; Lesage, Suzanne] Hop La Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, Paris, France. [Keller, Margaux F.; Molony, Cliona; Stone, David J.] Merck Res Labs, Genet & Pharmacogen, West Point, PA USA. [Keller, Margaux F.; Molony, Cliona; Stone, David J.] Merck Res Labs, Boston, MA USA. [Suh, Eunran; Van Deerlin, Vivianna M.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Fiandaca, Massimo S.; Federoff, Howard J.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA. [Mapstone, Mark] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Zabetian, Cyrus] VA Puget Sound Hlth Care Syst, Div Neurogenet, Dept Neurol, Seattle, WA USA. [Marek, Ken] Inst Neurodegenerat Disorders, New Haven, CT USA. [Day-Williams, Aaron G.] Biogen, Precis Med, Cambridge, MA USA. [Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA. RP Nalls, MA (reprint author), NIA, NIH, Neurogenet Lab, Bethesda, MD 20892 USA. RI Singleton, Andrew/C-3010-2009; Hardy, John/C-2451-2009; Martinez, Maria/B-3111-2013; Morris, Huw/B-8527-2008; corvol, jean-christophe/I-6387-2012 OI Martinez, Maria/0000-0003-2180-4537; Morris, Huw/0000-0002-5473-3774; corvol, jean-christophe/0000-0001-7325-0199; Gwinn, Katrina/0000-0002-8277-651X FU National Institute on Aging, National Institute of Neurological Disorders and Stroke; Michael J Fox Foundation FX National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the Michael J Fox Foundation. NR 20 TC 25 Z9 25 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD OCT PY 2015 VL 14 IS 10 BP 1002 EP 1009 DI 10.1016/S1474-4422(15)00178-7 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CR2VI UT WOS:000361188400011 PM 26271532 ER PT J AU Gray, NE Quinn, JF AF Gray, Nora E. Quinn, Joseph F. TI Alterations in mitochondrial number and function in Alzheimer's disease fibroblasts SO METABOLIC BRAIN DISEASE LA English DT Article DE beta-amyloid; Mitochondrial dysfunction; Alzheimer's disease ID MAGNETIC-RESONANCE-SPECTROSCOPY; MILD COGNITIVE IMPAIRMENT; CULTURED SKIN FIBROBLASTS; AMYLOID-BETA; MOUSE MODEL; BRAIN; PATHOLOGY; DEMENTIA; MICE AB Mitochondrial dysfunction is observed in brains of Alzheimer's Disease patients as well as many rodent model systems including those modeling mutations in preseinilin 1 (PSEN1). The aim of our study was to characterize mitochondrial function and number in fibroblasts from AD patients with PSEN1 mutations. We used biochemical assays, metabolic profiling and fluorescent labeling to assess mitochondrial number and function in fibroblasts from three AD patients compared to fibroblasts from three controls. The mutant AD fibroblasts had increased A beta 42 relative to controls along with reduction in ATP, basal and maximal mitochondrial respiration as well as impaired spare mitochondrial respiratory capacity. Fluorescent staining and expression of genes encoding electron transport chain enzymes showed diminished mitochondrial content in the AD fibroblasts. This study demonstrates that mitochondrial dysfunction is observable in AD fibroblasts and provides evidence that this model system could be useful as a tool to screen disease-modifying compounds. C1 [Gray, Nora E.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR 97239 USA. RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM grayn@ohsu.edu FU Department of Veterans Affairs Merit Review grant FX This work was funded by a Department of Veterans Affairs Merit Review grant awarded to J. Quinn. NR 28 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD OCT PY 2015 VL 30 IS 5 BP 1275 EP 1278 DI 10.1007/s11011-015-9667-z PG 4 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA CQ8TG UT WOS:000360881400019 PM 25862550 ER PT J AU Booi, AN Menendez, J Norton, HJ Anderson, WE Ellis, AC AF Booi, Amy N. Menendez, Jerome Norton, H. James Anderson, William E. Ellis, Amy C. TI Validation of a Screening Tool to Identify Undernutrition in Ambulatory Patients With Liver Cirrhosis SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE liver diseases; end-stage liver disease; nutrition assessment; malnutrition; liver cirrhosis ID MALNUTRITION; NUTRITION; DISEASE; PREVALENCE; MANAGEMENT AB Background: The prevalence of chronic liver disease is increasing in the United States. Malnutrition is common as liver disease progresses. However, an accepted method to screen these patients for malnutrition is lacking. The 6-question undernutrition screening tool was developed for professionals without nutrition training to identify a decline in the nutrition status of patients with liver cirrhosis. A 3-phase validation study was completed to assess face, content, and clinical validity of the screening tool in ambulatory patients with liver cirrhosis. Methods: In phase I, face validity was determined by surveying 13 liver disease professionals. In phase II, content validity was assessed by surveying 12 registered dietitians who specialize in liver disease. In phase III, a cross-sectional investigation was completed to compare the agreement between the undernutrition screening tool and nutrition assessment by a registered dietitian (RD). Results: Twenty-two patients with a diagnosis of liver cirrhosis participated in phase III of the investigation. The RD assessment identified undernutrition in 82% of patients (95% CI, 60%-95%). The statistic indicated a fair agreement between the screening tool and RD assessment. Sensitivity and specificity of the tool were 72% and 75%, respectively, and positive predictive value was 93%. Conclusions: Feedback from phase I, II, and III indicate that the undernutrition screening tool is simple, is easy to use, and measures the constructs that have the strongest link with undernutrition in liver disease. Additional minor adjustments to the screening tool and a multicenter investigation are indicated to confirm clinical effectiveness and cross-validity of the tool. C1 [Booi, Amy N.; Menendez, Jerome; Norton, H. James; Anderson, William E.] Carolinas Healthcare Syst, Charlotte, NC USA. [Ellis, Amy C.] Univ Alabama, Dept Human Nutr, Tuscaloosa, AL USA. RP Booi, AN (reprint author), Nutr & Food Serv, US Dept Vet Affairs, Southern Nevada Healthcare Syst, North Las Vegas Med Ctr, 6900 North Pecos Rd, North Las Vegas, NV 89096 USA. EM amybooi@gmail.com NR 15 TC 1 Z9 1 U1 3 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD OCT PY 2015 VL 30 IS 5 BP 683 EP 689 DI 10.1177/0884533615587537 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CQ7DQ UT WOS:000360763500009 PM 26024676 ER PT J AU Cunningham, SED Verkaik, D Gross, G Khazim, K Hirachan, P Agarwal, G Lorenzo, C Matteucci, E Bansal, S Fanti, P AF Cunningham, Sue E. D. Verkaik, Darlene Gross, Georgiana Khazim, Khalid Hirachan, Padam Agarwal, Gurav Lorenzo, Carlos Matteucci, Elena Bansal, Shweta Fanti, Paolo TI Comparison of Nutrition Profile and Diet Record Between Veteran and Nonveteran End-Stage Renal Disease Patients Receiving Hemodialysis in Veterans Affairs and Community Clinics in Metropolitan South-Central Texas SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE wasting syndrome; inflammation; diabetes mellitus; ethnic groups; healthcare disparities; socioeconomic factors ID ENERGY-INTAKE; KIDNEY-DISEASE; PROTEIN-INTAKE; MUSCLE MASS; DIALYSIS; ASSOCIATION; MORTALITY; MEMBRANES; SURVIVAL; FAILURE AB Background: U.S. military veterans have high rates of chronic disease and social disadvantage, which are risk factors for protein-energy wasting (PEW). It is not known whether this translates into high prevalence of PEW in veterans with end-stage renal disease. Methods: We compared the clinical, socioeconomic, and nutrition status and the diet of 33 veteran and 38 nonveteran clinically stable patients receiving maintenance hemodialysis (MHD) in south-central Texas. Results: The whole cohort included 82% Mexican Americans (MAs), 72% type 2 diabetics, and 73% males. The body mass index was 28.9 +/- 6.2, while energy intake was 21.5 +/- 8.2 kcal/kg/d and protein intake was 1.0 +/- 0.4 g/kg/d. Serum albumin (bromocresol purple) was 3.5 +/- 0.4 g/dL, transferrin was 171.9 +/- 27.8 mg/d, C-reactive protein was 2.9 (1.4-6.5) mg/L, interleukin-6 (IL-6) was 8.3 (4.2-17.9) pg/mL, neutrophil gelatinase-associated lipocalin was 729 (552-1256) ng/mL, and the malnutrition-inflammation score was 8.8 +/- 3.0. In group comparison that adjusted for sex and ethnicity, the veterans had better household income, less MAs (60% vs 100%), more males (94% vs 55%), more use of a renin-angiotensin-aldosterone system blockade (66% vs 33%), and lower IL-6 levels (4.4 [3.1-5.8] vs 15.4 [8.3-20.5] pg/mL; P = .01) than nonveterans. In regression analysis, the lower serum IL-6 level in veterans was independently explained by dialysis clinic, sex, and, possibly, household income (intermediate significance). Conclusion: In a relatively small cohort of clinically stable MHD patients, the veterans showed equivalent nutrition status and dietary intake and less inflammation than the nonveterans, thus not supporting the possibility that veteran MHD patients may have worse nutrition than the nonveteran counterpart. C1 [Cunningham, Sue E. D.; Khazim, Khalid; Hirachan, Padam; Agarwal, Gurav; Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, San Antonio, TX 78229 USA. [Cunningham, Sue E. D.; Gross, Georgiana] Univ Texas Hlth Sci Ctr San Antonio, Sch Hlth Profess, San Antonio, TX 78229 USA. [Verkaik, Darlene; Bansal, Shweta; Fanti, Paolo] Audie L Murphy Vet Mem Hosp, STVHCS, San Antonio, TX USA. [Khazim, Khalid] Western Galilee Hosp, Div Nephrol, Nahariyya, Israel. [Lorenzo, Carlos] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Clin Epidemiol, San Antonio, TX 78229 USA. [Matteucci, Elena] Univ Pisa, Div Endocrinol, I-56100 Pisa, Italy. RP Fanti, P (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA. EM fanti@uthscsa.edu FU NIH-NCCAM [AT004490]; Veterans Administration [1I01CX000264]; CTSA program [NIH-NCATS 1UL TR001120] FX This work was supported by grants to PF from NIH-NCCAM (AT004490) and from the Veterans Administration (Merit Review 1I01CX000264) and by the CTSA program award to UTHSCSA (NIH-NCATS 1UL TR001120). NR 51 TC 0 Z9 0 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD OCT PY 2015 VL 30 IS 5 BP 698 EP 708 DI 10.1177/0884533615575046 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CQ7DQ UT WOS:000360763500011 PM 25899538 ER PT J AU Genewsky, A Jost, I Busch, C Huber, C Stindl, J Skerka, C Zipfel, PF Rohrer, B Strauss, O AF Genewsky, Andreas Jost, Ingmar Busch, Catharina Huber, Christian Stindl, Julia Skerka, Christine Zipfel, Peter F. Rohrer, Baerbel Strauss, Olaf TI Activation of endogenously expressed ion channels by active complement in the retinal pigment epithelium SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY LA English DT Article DE (4-6): complement system; Retinal pigment epithelium; RPE; L-type channels; BK channels ID MEMBRANE-ATTACK-COMPLEX; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULAR FREE CALCIUM; MACULAR DEGENERATION; VEGF SECRETION; CA2+ CHANNELS; FACTOR-H; CELLS; FIBROBLASTS; INCREASE AB Defective regulation of the alternative pathway of the complement system is believed to contribute to damage of retinal pigment epithelial (RPE) cells in age-related macular degeneration. Thus we investigated the effect of complement activation on the RPE cell membrane by analyzing changes in membrane conductance via patch-clamp techniques and Ca2+ imaging. Exposure of human ARPE-19 cells to complement-sufficient normal human serum (NHS) (25 %) resulted in a biphasic increase in intracellular free Ca2+ ([Ca2+](i)); an initial peak followed by sustained Ca2+ increase. C5- or C7-depleted sera did not fully reproduce the signal generated by NHS. The initial peak of the Ca2+ response was reduced by sarcoplasmic Ca2+-ATPase inhibitor thapsigargin, L-type channel blockers (R)-(+)-BayK8644 and isradipine, transient-receptor-potential (TRP) channel blocker ruthenium-red and ryanodine receptor blocker dantrolene. The sustained phase was carried by Ca(V)1.3 L-type channels via tyrosine-phosphorylation. Changes in [Ca2+](I) were accompanied by an abrupt hyperpolarization, resulting from a transient increase in membrane conductance, which was absent under extracellular Ca2+- or K+-free conditions and blocked by (R)-(+)-BayK8644 or paxilline, a maxiK channel inhibitor. Single-channel recordings confirmed the contribution of maxiK channels. Primary porcine RPE cells responded to NHS in a comparable manner. Pre-incubation with NHS reduced H2O2-induced cell death. In summary, in a concerted manner, C3a, C5a and sC5b-9 increased [Ca2+](i) by ryanodine-receptor-dependent activation of L-type channels in addition to maxi-K channels and TRP channels absent from any insertion of a lytic pore. C1 [Genewsky, Andreas] Max Planck Inst Psychiat, D-80804 Munich, Germany. [Genewsky, Andreas; Jost, Ingmar; Stindl, Julia; Strauss, Olaf] Univ Med Ctr Regensburg, Eye Clin, Expt Ophthalmol, Regensburg, Germany. [Skerka, Christine; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany. [Zipfel, Peter F.] Univ Jena, Jena, Germany. [Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Busch, Catharina; Huber, Christian; Strauss, Olaf] Charite, Dept Ophthalmol, Expt Ophthalmol, Campus Virchow Klinikum, D-13353 Berlin, Germany. RP Strauss, O (reprint author), Charite, Dept Ophthalmol, Expt Ophthalmol, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany. EM olaf.strauss@charite.de FU National Institutes of Health (NIH) [R01EY019320]; Department for Veterans Affairs [RX000444]; Research to Prevent Blindness (RPB), New York, NY; Deutsche Forschungsgemeinschaft (DFG) [SK46/2-1, SK46/2-2] FX The authors thank Andrea Dannullis, Elfriede Eckert and Renate Fockler for expert technical assistance. Financial support: OS: Novartis Professorship; BR: in part by the National Institutes of Health (NIH) (R01EY019320), a Department for Veterans Affairs merit award RX000444 and an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New York, NY; CS: Deutsche Forschungsgemeinschaft (DFG) SK46/2-1, SK46/2-2. NR 44 TC 3 Z9 3 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-6768 EI 1432-2013 J9 PFLUG ARCH EUR J PHY JI Pflugers Arch. PD OCT PY 2015 VL 467 IS 10 BP 2179 EP 2191 DI 10.1007/s00424-014-1656-2 PG 13 WC Physiology SC Physiology GA CR0IB UT WOS:000361000800011 PM 25427445 ER PT J AU True, G Rigg, KK Butler, A AF True, Gala Rigg, Khary K. Butler, Anneliese TI Understanding Barriers to Mental Health Care for Recent War Veterans Through Photovoice SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE health care; access to; health care; users' experiences; lived experience; mental health and illness; participatory action research; photography; photovoice; post-traumatic stress disorder; stigma; visual methods; vulnerable populations ID RETURNING COMBAT VETERANS; TREATMENT-SEEKING; AFGHANISTAN VETERANS; IRAQ; SERVICES; INTERVENTIONS; DEPLOYMENT; SOLDIERS; PTSD; PERCEPTIONS AB Despite an urgent need for mental health care among U.S. service members returning from deployments to Iraq and Afghanistan, many veterans do not receive timely or adequate treatment. We used photovoice methods to engage veterans in identifying barriers to utilizing mental health services. Veterans described how key aspects of military culture and identity, highly adaptive during deployment, can deter help-seeking behavior and hinder recovery. Veterans' photographs highlighted how mental health symptoms and self-coping strategies operated as barriers to care. Many veterans' photos and stories revealed how negative health care encounters contributed to avoidance and abandonment of treatment; some veterans described these experiences as re-traumatizing. Visual methods can be a powerful tool for engaging recent war veterans in research. In particular, community-based participatory research approaches, which have rarely been used with veterans, hold great promise for informing effective interventions to improve access and enhance provision of patient-centered care for veterans. C1 [True, Gala] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Butler, Anneliese] Philadelphia Vet Affairs Med Ctr, VISN Ctr Evaluat Patient Aligned Care Teams 4, Philadelphia, PA 19104 USA. [Rigg, Khary K.] Univ S Florida, Dept Mental Hlth Law & Policy, Louis de la Parte Florida Mental Hlth Inst, Tampa, FL USA. RP True, G (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave,Bldg 4100, Philadelphia, PA 19104 USA. EM Jennifer.True2@va.gov FU VA Health Services Research Development [PPO 10-255]; VISN 4 Center for Evaluation of Patient Aligned Care Teams (CEPACT); Center for Health Equity Research and Promotion (CHERP) FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by a VA Health Services Research & Development grant to Gala True (PPO 10-255), with additional support from the VISN 4 Center for Evaluation of Patient Aligned Care Teams (CEPACT) and the Center for Health Equity Research and Promotion (CHERP). NR 45 TC 4 Z9 4 U1 2 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 EI 1552-7557 J9 QUAL HEALTH RES JI Qual. Health Res. PD OCT PY 2015 VL 25 IS 10 SI SI BP 1443 EP 1455 DI 10.1177/1049732314562894 PG 13 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA CR2AP UT WOS:000361127100012 PM 25488935 ER PT J AU Wood, PL Barnette, BL Kaye, JA Quinn, JF Woltjer, RL AF Wood, Paul L. Barnette, Brooke L. Kaye, Jeffrey A. Quinn, Joseph F. Woltjer, Randall L. TI Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects SO ACTA NEUROPSYCHIATRICA LA English DT Article DE Alzheimer's disease; lipidomics; diacylglycerols; mild cognitive impairment; frontal cortex ID PLASMALOGEN DEFICIENCY; MASS-SPECTROMETRY; HUMAN BRAIN; PATHOGENESIS; INDIVIDUALS; DEMENTIA; CERAMIDE; ENZYMES; MOUSE; AGE AB Objective: We undertook a non-targeted lipidomics analysis of postmortem cerebrospinal fluid (CSF), frontal cortex grey matter, and subjacent white matter to define potential biomarkers that distinguish cognitively intact subjects from those with incipient or established dementia. Our objective was to increase our understanding of the role of brain lipids in pathophysiology of aging and age-related cognitive impairment. Methods: Levels of 650 individual lipids, across 26 lipid subclasses, were measured utilising a high-resolution mass spectrometric analysis platform. Results: Monoacylglycerols (MAG), diacylglycerols (DAG), and the very-long-chain fatty acid 26: 0 were elevated in the grey matter of the mild cognitive impairment (MCI) and old dementia (OD) cohorts. Ethanolamine plasmalogens (PlsEtn) were decreased in the grey matter of the young dementia (YD) and OD cohorts while and phosphatidylethanolamines (PtdEth) were lower in the MCI, YD and OD cohorts. In the white matter, decrements in sulphatide levels were detected in the YD group, DAG levels were elevated in the MCI group, and MAG levels were increased in the YD and OD groups. Conclusion: The parallel changes in grey matter MAGs and DAGs in the MCI and OD groups suggest that these two cohorts may have a similar underlying pathophysiology; consistent with this, MCI subjects were more similar in age to OD than to YD subjects. While PlsEtn and phosphatidylethanolamine were decreased in the YD and OD groups they were unaltered in the MCI group indicating that alterations in plasmalogen synthesis are unlikely to represent an initiating event in the transition from MCI to dementia. C1 [Wood, Paul L.; Barnette, Brooke L.] Lincoln Mem Univ, DeBusk Coll Osteopath Med, Dept Physiol & Pharmacol, Metabol Unit, Harrogate, TN 37752 USA. [Kaye, Jeffrey A.; Quinn, Joseph F.; Woltjer, Randall L.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR USA. RP Wood, PL (reprint author), Lincoln Mem Univ, DeBusk Coll Osteopath Med, Dept Physiol & Pharmacol, Metabol Unit, 6965 Cumberland Gap Pkwy, Harrogate, TN 37752 USA. EM paul.wood@lmunet.edu FU Lincoln Memorial University, DeBusk College of Osteopathic medicine; [NIA-AG08017] FX This research was funded by Lincoln Memorial University, DeBusk College of Osteopathic medicine, and by NIA-AG08017. NR 36 TC 9 Z9 9 U1 1 U2 18 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1601-5215 J9 ACTA NEUROPSYCHIATR JI Acta Neuropsychiatr. PD OCT PY 2015 VL 27 IS 5 BP 270 EP 278 DI 10.1017/neu.2015.18 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CQ6CM UT WOS:000360692000002 PM 25858158 ER PT J AU Hazlehurst, BL Kurtz, SE Masica, A Stevens, VJ McBurnie, MA Puro, JE Vijayadeva, V Au, DH Brannon, ED Sittig, DF AF Hazlehurst, Brian L. Kurtz, Stephen E. Masica, Andrew Stevens, Victor J. McBurnie, Mary Ann Puro, Jon E. Vijayadeva, Vinutha Au, David H. Brannon, Elissa D. Sittig, Dean F. TI CER Hub: An informatics platform for conducting comparative effectiveness research using multi-institutional, heterogeneous, electronic clinical data SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Comparative effectiveness research; Natural language processing; Electronic health records ID MEDICAL-RECORD; RESEARCH NETWORK; SYSTEM; CARE; INFRASTRUCTURE; QUALITY; EVENTS AB Objectives: Comparative effectiveness research (CER) requires the capture and analysis of data from disparate sources, often from a variety of institutions with diverse electronic health record (EHR) implementations. In this paper we describe the CER Hub, a web-based informatics platform for developing and conducting research studies that combine comprehensive electronic clinical data from multiple health care organizations. Methods: The CER Hub platform implements a data processing pipeline that employs informatics standards for data representation and web-based tools for developing study-specific data processing applications, providing standardized access to the patient-centric electronic health record (EHR) across organizations. Results: The CER Hub is being used to conduct two CER studies utilizing data from six geographically distributed and demographically diverse health systems. These foundational studies address the effectiveness of medications for controlling asthma and the effectiveness of smoking cessation services delivered in primary care. Discussion: The CER Hub includes four key capabilities: the ability to process and analyze both free-text and coded clinical data in the EHR; a data processing environment supported by distributed data and study governance processes; a clinical data-interchange format for facilitating standardized extraction of clinical data from EHRs; and a library of shareable clinical data processing applications. Conclusion: CER requires coordinated and scalable methods for extracting, aggregating, and analyzing complex, multi-institutional clinical data. By offering a range of informatics tools integrated into a framework for conducting studies using EHR data, the CER Hub provides a solution to the challenges of multi-institutional research using electronic medical record data. (C) 2015 Published by Elsevier Ireland Ltd. C1 [Hazlehurst, Brian L.; Kurtz, Stephen E.; Stevens, Victor J.; McBurnie, Mary Ann] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Masica, Andrew] Baylor Scott & White Hlth, Ctr Clin Effectiveness, Dallas, TX USA. [Puro, Jon E.] OCHIN Inc, Portland, OR USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Brannon, Elissa D.] Kaiser Permanente Southeast, Atlanta, GA USA. [Sittig, Dean F.] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA. RP Hazlehurst, BL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res 3800 N, Interstate Ave Portland, Hillsboro, OR 97227 USA. EM Brian.hazlehurst@kpchr.org FU Agency for Health Care Research and Quality (AHRQ), Department of Health and Human Services [R01HS019828] FX The CER Hub project (www.cerhub.org) is funded by grant R01HS019828 (Hazlehurst, PI) from the Agency for Health Care Research and Quality (AHRQ), Department of Health and Human Services. The funders had no role in protocol development, data collection, analysis, interpretation, or manuscript production. The authors of this report are solely responsible for its content. NR 42 TC 1 Z9 1 U1 1 U2 19 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 EI 1872-8243 J9 INT J MED INFORM JI Int. J. Med. Inform. PD OCT PY 2015 VL 84 IS 10 BP 763 EP 773 DI 10.1016/j.ijmedinf.2015.06.002 PG 11 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA CQ4GI UT WOS:000360562100005 PM 26138036 ER PT J AU Schulte, M Hser, Y Saxon, A Evans, E Li, L Huang, D Hillhouse, M Thomas, C Ling, W AF Schulte, M. Hser, Y. Saxon, A. Evans, E. Li, L. Huang, D. Hillhouse, M. Thomas, C. Ling, W. TI Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Hepatitis C; Injection drug use; Buprenorphine; Methadone maintenance; Injection risk behavior ID HEPATITIS-C VIRUS; INJECTION-DRUG USERS; CORE ANTIGEN; GLOBAL EPIDEMIOLOGY; UNITED-STATES; HEROIN USERS; INFECTION; PREVALENCE; COCAINE; HEALTH AB We examined risk factors associated with hepatitis C virus (HCV) infection among opioid-dependent patients enrolled into medication-assisted therapy (buprenorphine or methadone) to determine factors affecting chronic infection. Patients (N = 1039) were randomized as part of a larger, multisite clinical trial sponsored by the National Drug Abuse Treatment Clinical Trials Network assessing liver function. HCV status was first assessed with an antibody screen; if positive, then current infection was determined with an antigen screen testing for detectable virus. Patients were classified as HCV negative, HCV positive but have cleared the virus, or as having chronic HCV. Logistic regression analysis was used to examine demographic and behavioral correlates of the three groups. Thirty-four percent of patients were classified with chronic infection and 14 % had evidence of prior infection with apparent clearing of the virus. Chronic infection was associated with recent injection drug use and cocaine use. Chronic HCV infection was also associated with being older and Hispanic. Age, ethnicity, and current drug use increase the likelihood of being chronically infected with HCV. Strategies targeting high risk subgroups can aid in preventing further disease escalation. C1 [Schulte, M.; Hser, Y.; Evans, E.; Li, L.; Huang, D.; Hillhouse, M.; Thomas, C.; Ling, W.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Integrated Subst Abuse Programs, Los Angeles, CA 90025 USA. [Saxon, A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Saxon, A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Schulte, M (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA 90025 USA. EM mtschulte@ucla.edu RI Evans, Elizabeth/C-5294-2013 OI Evans, Elizabeth/0000-0002-3478-9957 FU National Institute on Drug Abuse [U10DA013045, P30 DA016383] FX Funding has been provided by the National Institute on Drug Abuse through Grants U10DA013045 and P30 DA016383. Thanks to the participating Nodes of the Clinical Trials Network: Pacific Region Node (Matrix Institute, Los Angeles and BAART, Turk St. Clinic, San Francisco); Western States Node (Bi-Valley Medical Clinic Inc., Sacramento and CODA Research, Portland); Delaware Valley Node (NET Steps, Philadelphia); Pacific Northwest Node (Evergreen Treatment Services, Seattle); and New England Consortium (Connecticut Counseling Centers, Waterbury and Hartford Dispensary, Hartford). NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 40 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD OCT PY 2015 VL 40 IS 5 BP 940 EP 947 DI 10.1007/s10900-015-0016-2 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ5VC UT WOS:000360672800013 PM 25814381 ER PT J AU Caya, T Musuuza, J Yanke, E Schmitz, M Anderson, B Carayon, P Safdar, N AF Caya, Teresa Musuuza, Jackson Yanke, Eric Schmitz, Michelle Anderson, Brooke Carayon, Pascale Safdar, Nasia TI Using a Systems Engineering Initiative for Patient Safety to Evaluate a Hospital-wide Daily Chlorhexidine Bathing Intervention SO JOURNAL OF NURSING CARE QUALITY LA English DT Article DE chlorhexidine bathing; infection control; quality improvement; SEIPS; systems engineering ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; ACQUIRED INFECTIONS; REDUCE; IMPACT AB We undertook a systems engineering approach to evaluate housewide implementation of daily chlorhexidine bathing. We performed direct observations of the bathing process and conducted provider and patient surveys. The main outcome was compliance with bathing using a checklist. Fifty-seven percent of baths had full compliance with the chlorhexidine bathing protocol. Additional time was the main barrier. Institutions undertaking daily chlorhexidine bathing should perform a rigorous assessment of implementation to optimize the benefits of this intervention. C1 [Safdar, Nasia] Univ Wisconsin Madison, Dept Med, Madison, WI 53705 USA. [Caya, Teresa] Univ Wisconsin Madison, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Musuuza, Jackson] Univ Wisconsin Madison, Inst Clin & Translat Res, Madison, WI 53705 USA. [Carayon, Pascale] Univ Wisconsin Madison, Dept Ind & Syst Engn, Madison, WI 53705 USA. [Carayon, Pascale] Univ Wisconsin Madison, Ctr Qual & Prod Improvement, Madison, WI 53705 USA. [Yanke, Eric] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Div Infect Dis, Madison, WI USA. [Schmitz, Michelle; Anderson, Brooke] Univ Wisconsin Hosp & Clin, Dept Infect Control, Madison, WI 53792 USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Infect Dis, Madison, WI 53792 USA. RP Safdar, N (reprint author), Univ Wisconsin Madison, Dept Med, UWMF Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; United States Department of Veterans Affairs MERIT award FX The project described was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427, and the United States Department of Veterans Affairs MERIT award. NR 17 TC 2 Z9 2 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1057-3631 EI 1550-5065 J9 J NURS CARE QUAL JI J. Nurs. Care Qual. PD OCT-DEC PY 2015 VL 30 IS 4 BP 337 EP 344 DI 10.1097/NCQ.0000000000000129 PG 8 WC Nursing SC Nursing GA CQ5RN UT WOS:000360663300008 PM 26035708 ER PT J AU Post, RM Leverich, GS Kupka, R Keck, PE McElroy, SL Altshuler, LL Frye, MA Rowe, M Grunze, H Suppes, T Nolen, WA AF Post, Robert M. Leverich, Gabriele S. Kupka, Ralph, Jr. Keck, Paul E. McElroy, Susan L. Altshuler, Lori L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Nolen, Willem A. TI Increases in multiple psychiatric disorders in parents and grandparents of patients with bipolar disorder from the USA compared with The Netherlands and Germany SO PSYCHIATRIC GENETICS LA English DT Article DE alcohol abuse; depression; family history; genetics; substance abuse ID ASTERISK-D-CHILD; MENTAL-DISORDERS; UNITED-STATES; FOLLOW-UP; MATERNAL DEPRESSION; II DISORDER; EARLY-ONSET; HIGH-RISK; STEP-BD; PSYCHOPATHOLOGY AB ObjectiveWe previously found that compared with Europe more parents of the USA patients were positive for a mood disorder, and that this was associated with early onset bipolar disorder. Here we examine family history of psychiatric illness in more detail across several generations.MethodsA total of 968 outpatients (average age 41) with bipolar disorder from four sites in the USA and three in the Netherlands and Germany (abbreviated as Europe) gave informed consent and provided detailed demographic and family history information on a patient questionnaire. Family history of psychiatric illness (bipolar disorder, unipolar depression, suicide attempt, alcohol abuse, substance abuse, and other illness) was collected for each parent, four grandparents, siblings, and children.ResultsParents of the probands with bipolar disorder from the USA compared with Europe had a significantly higher incidence of both unipolar and bipolar mood disorders, as well as each of the other psychiatric conditions listed above. With a few exceptions, this burden of psychiatric disorders was also significantly greater in the grandparents, siblings, and children of the USA versus European patients.ConclusionThe increased complexity of psychiatric illness and its occurrence over several generations in the families of patients with bipolar disorder from the USA versus Europe could be contributing to the higher incidence of childhood onsets and greater virulence of illness in the USA compared with Europe. These data are convergent with others suggesting increased both genetic and environmental risk in the USA, but require replication in epidemiologically-derived populations with data based on interviews of the family members. C1 [Post, Robert M.; Leverich, Gabriele S.; Rowe, Michael] Bipolar Collaborat Network, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Biol Psychiat Program, Cincinnati, OH USA. [Keck, Paul E.; McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Suppes, Trisha] VA Palo Alto HealthCare Syst, Palo Alto, CA USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Kupka, Ralph, Jr.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Grunze, Heinz] Paracelsus Med Univ Salzburg, Dept Psychiat & Psychotherapy, Christian Doppler Klink, Salzburg, Austria. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Lane,Suite 201-B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU Stanley Foundation Bipolar Network FX The research funding for this article was provided by the Stanley Foundation Bipolar Network from 1995-2002. NR 57 TC 5 Z9 5 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0955-8829 EI 1473-5873 J9 PSYCHIAT GENET JI Psychiatr. Genet. PD OCT PY 2015 VL 25 IS 5 BP 194 EP 200 DI 10.1097/YPG.0000000000000093 PG 7 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA CQ5PQ UT WOS:000360658100002 PM 26146875 ER PT J AU Bowen, ME Ruch, A AF Bowen, Mary Elizabeth Ruch, Alexandra TI Depressive Symptoms and Disability Risk Among Older White and Latino Adults by Nativity Status SO JOURNAL OF AGING AND HEALTH LA English DT Article DE minority health; depression; activities of daily living (ADL); instrumental activities of daily living (IADL); health paradox ID MEXICAN-AMERICANS; RACIAL/ETHNIC DIFFERENCES; FUNCTIONAL LIMITATIONS; PHYSICAL-DISABILITY; HISPANIC IMMIGRANTS; HEALTH; US; COMMUNITY; ACCULTURATION; PREVALENCE AB Objective: To examine how the relationship between depressive symptoms and disability may vary by nativity status in later life. Method: This nationally representative prospective study of community-dwelling adults age 51 years and older in the Health and Retirement Study (1998-2010) used hierarchical linear modeling to examine how depressive symptoms (Center for Epidemiological Symptoms of Depression) and disability (instrumental activities of daily living [IADL]; activities of daily living [ADL]) vary by nativity status (U.S.- vs. foreign-born), accounting for changes in social support, health behaviors, and health conditions. Results: Depressive symptoms were associated with increased IADL and ADL disability among Latinos compared with Whites; foreign-born Latinos had lower than expected depressive symptom-related IADL and ADL (0.82; p .001) disability. Discussion: Given that U.S.-born Latinos had similar or poorer depressive symptom-related disability outcomes than Whites, interventions focused on early detection and treatment of depressive symptoms for this group are warranted and may improve disablement outcomes. C1 [Bowen, Mary Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Bowen, Mary Elizabeth; Ruch, Alexandra] West Chester Univ Penn, W Chester, PA USA. RP Bowen, ME (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Mary.Bowen3@va.gov FU Department of Veterans Affairs, Rehabilitation Research and Development [RRD CDA E7503W] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Bowen is supported by the Department of Veterans Affairs, Rehabilitation Research and Development (RR&D CDA E7503W). NR 41 TC 1 Z9 1 U1 3 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 EI 1552-6887 J9 J AGING HEALTH JI J. Aging Health PD OCT PY 2015 VL 27 IS 7 BP 1286 EP 1305 DI 10.1177/0898264315580121 PG 20 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA CQ2CI UT WOS:000360406600008 PM 25953809 ER PT J AU Suchomelova, L Lopez-Meraz, ML Niquet, J Kubova, H Wasterlain, CG AF Suchomelova, L. Lopez-Meraz, M. L. Niquet, J. Kubova, H. Wasterlain, C. G. TI HYPERTHERMIA AGGRAVATES STATUS EPILEPTICUS-INDUCED EPILEPTOGENESIS AND NEURONAL LOSS IN IMMATURE RATS SO NEUROSCIENCE LA English DT Article DE neuronal injury; temperature; immature brain; lithium/pilocarpine model; EEG monitoring ID TEMPORAL-LOBE EPILEPSY; PROLONGED FEBRILE SEIZURES; UNBIASED STEREOLOGICAL ESTIMATION; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; LITHIUM-PILOCARPINE MODEL; ACID-INDUCED SEIZURES; NEONATAL ENCEPHALOPATHY; BRAIN-DAMAGE; LONG-TERM; HIPPOCAMPAL EXCITABILITY AB This study tightly controlled seizure duration and severity during status epilepticus (SE) in postnatal day 10 (P10) rats, in order to isolate hyperthermia as the main variable and to study its consequences. Body temperature was maintained at 39 +/- 1 degrees C in hyperthermic SE rats (HT + SE) or at 35 +/- 1 degrees C in normothermic SE animals (NT + SE) during 30 min of SE, which was induced by lithium-pilocarpine (3 mEq/kg, 60 mg/kg) and terminated by diazepam and cooling to NT. All video/EEG measures of SE severity were similar between HT + SE and NT + SE pups. At 24 h, neuronal injury was present in the amygdala in the HT + SE group only, and was far more severe in the hippocampus in HT + SE than NT + SE pups. Separate groups of animals were monitored four months later for spontaneous recurrent seizures (SRS). Only HT + SE animals developed convulsive SRS. Both HT + SE and NT + SE animals developed electrographic SRS (83% vs. 55%), but SRS frequency and severity were higher in hyperthermic animals (12.5 +/- 3.5 vs. 4.2 +/- 2.0 SRS/day). The density of hilar neurons was lower, thickness of the amygdala and perirhinal cortex was reduced, and lateral ventricles were enlarged in HT + SE over NT + SE littermates and HT/NT controls. In this model, hyperthermia greatly increased the epileptogenicity of SE and its neuropathological sequelae. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Suchomelova, L.; Niquet, J.] Vet Adm Greater Los Angeles Healthcare Syst, Epilepsy Res 151, Los Angeles, CA 90073 USA. [Lopez-Meraz, M. L.] Univ Veracruzana, Ctr Invest Cerebrales, Xalapa 91190, Veracruz, Mexico. [Kubova, H.] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CR-14220 Prague, Czech Republic. [Wasterlain, C. G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, VA Med Ctr 127, Los Angeles, CA 90073 USA. RP Suchomelova, L (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, 11 301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM lsuchomelova@yahoo.com RI Kubova, Hana/C-4210-2012 OI Kubova, Hana/0000-0002-2016-7428 FU VHA Research Service; National Institute of Health [NS13515, NS059704, NS074926]; Grant Agency of the Czech Republic [P302/10/0971]; Ministry of Education of the Czech Republic [ME08045, LC554]; [AV0Z50110509]; [RVO 67985823] FX This work was supported by VHA Research Service, National Institute of Health [NS13515, NS059704, NS074926 to C.W.]; Grant Agency of the Czech Republic [P302/10/0971 to H.K.]; Ministry of Education of the Czech Republic [ME08045, LC554 to H.K.], and Research Project [AV0Z50110509 and RVO 67985823 to H.K.]. NR 88 TC 2 Z9 2 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD OCT 1 PY 2015 VL 305 BP 209 EP 224 DI 10.1016/j.neuroscience.2015.08.006 PG 16 WC Neurosciences SC Neurosciences & Neurology GA CQ4AT UT WOS:000360547100019 PM 26259902 ER PT J AU Van Horn, DHA Drapkin, M Lynch, KG Rennert, L Goodman, JD Thomas, T Ivey, M McKay, JR AF Van Horn, Deborah H. A. Drapkin, Michelle Lynch, Kevin G. Rennert, Lior Goodman, Jessica D. Thomas, Tyrone Ivey, Megan McKay, James R. TI Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment SO ADDICTION RESEARCH & THEORY LA English DT Article DE Adaptive treatment; intensive outpatient programmes; treatment choice; treatment disengagement ID CONTINUING CARE; ALCOHOL DEPENDENCE; COCAINE DEPENDENCE; RANDOMIZED-TRIAL; USE DISORDERS; ENGAGEMENT; RETENTION; RELAPSE; COMMITMENT; ABSTINENCE AB In an effort to increase engagement in effective treatment, we offered a choice of alternate evidence-based treatments to 137 alcohol- or cocaine-dependent adults (110 males, 27 females), who entered an intensive outpatient programme (IOP) but disengaged within the first 8 weeks. We hypothesised that disengaged patients would choose and subsequently attend alternatives to IOP when given the chance, that their choices would be consistent with their previously-stated preferences, and that demographic and clinical characteristics would be predictive of alternatives chosen. Of 96 participants reached by phone, 19% chose no treatment; 49% chose to return to IOP; 24% chose individual psychotherapy; 6% chose telephone counselling; 2% chose naltrexone with medication management. There were few relationships between participant characteristics and choices made upon disengagement. Participants who chose alternative treatments were equally likely to attend their chosen treatment as those who chose IOP. Limited interest in alternative treatments may reflect allegiance to IOP, which was initially chosen by all participants. Implications for implementation of patient-centred adaptive treatment are discussed. C1 [Van Horn, Deborah H. A.; Drapkin, Michelle; Lynch, Kevin G.; Rennert, Lior; Goodman, Jessica D.; Thomas, Tyrone; Ivey, Megan; McKay, James R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Drapkin, Michelle; Goodman, Jessica D.] Vet Affairs Med Ctr, Philadelphia, PA USA. [McKay, James R.] Philadelphia VA Med Ctr, CESATE, Philadelphia, PA USA. RP Van Horn, DHA (reprint author), Univ Penn, Dept Psychiat, 3440 Market St, Philadelphia, PA 19104 USA. EM dvh@mail.med.upenn.edu FU NIDA [P60-DA-05186, K24 DA029062]; NIAAA [P01-AA016821]; Department of Veterans Affairs FX The authors report no conflicts of interest. This research was supported by NIDA grants P60-DA-05186 and K24 DA029062, NIAAA grant P01-AA016821, and by the Department of Veterans Affairs. There was no involvement of a pharmaceutical company in funding this research. The sponsors played no role in preparation of this article. NR 42 TC 1 Z9 1 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1606-6359 EI 1476-7392 J9 ADDICT RES THEORY JI Addict. Res. Theory PD OCT PY 2015 VL 23 IS 5 BP 391 EP 403 DI 10.3109/16066359.2015.1017570 PG 13 WC Substance Abuse; Social Issues SC Substance Abuse; Social Issues GA CO0EZ UT WOS:000358824200006 PM 27667970 ER PT J AU Wang, LX Mogami, S Yakabi, S Karasawa, H Yamada, C Yakabi, K Hattori, T Tache, Y AF Wang, Lixin Mogami, Sachiko Yakabi, Seiichi Karasawa, Hiroshi Yamada, Chihiro Yakabi, Koji Hattori, Tomohisa Tache, Yvette TI Patterns of Brain Activation and Meal Reduction Induced by Abdominal Surgery in Mice and Modulation by Rikkunshito SO PLOS ONE LA English DT Article ID CORTICOTROPIN-RELEASING-FACTOR; HYPOTHALAMIC ARCUATE NUCLEUS; STRESS-RELATED ALTERATIONS; POSTOPERATIVE GASTRIC ILEUS; CISPLATIN-INDUCED ANOREXIA; GHRELIN RECEPTOR AGONIST; COLONIC MOTOR FUNCTION; CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; PARABRACHIAL NUCLEUS AB Abdominal surgery inhibits food intake and induces c-Fos expression in the hypothalamic and medullary nuclei in rats. Rikkunshito (RKT), a Kampo medicine improves anorexia. We assessed the alterations in meal microstructure and c-Fos expression in brain nuclei induced by abdominal surgery and the modulation by RKT in mice. RKT or vehicle was gavaged daily for 1 week. On day 8 mice had no access to food for 6-7 h and were treated twice with RKT or vehicle. Abdominal surgery (laparotomy-cecum palpation) was performed 1-2 h before the dark phase. The food intake and meal structures were monitored using an automated monitoring system for mice. Brain sections were processed for c-Fos immunoreactivity (ir) 2-h after abdominal surgery. Abdominal surgery significantly reduced bouts, meal frequency, size and duration, and time spent on meals, and increased inter-meal interval and satiety ratio resulting in 92-86% suppression of food intake at 2-24 h post-surgery compared with control group (no surgery). RKT significantly increased bouts, meal duration and the cumulative 12-h food intake by 11%. Abdominal surgery increased c-Fos in the prelimbic, cingulate and insular cortexes, and autonomic nuclei, such as the bed nucleus of the stria terminalis, central amygdala, hypothalamic supraoptic (SON), paraventricular and arcuate nuclei, Edinger-Westphal nucleus (E-W), lateral periaqueduct gray (PAG), lateral parabrachial nucleus, locus coeruleus, ventrolateral medulla and nucleus tractus solitarius (NTS). RKT induced a small increase in c-Fos-ir neurons in the SON and E-W of control mice, and in mice with surgery there was an increase in the lateral PAG and a decrease in the NTS. These findings indicate that abdominal surgery inhibits food intake by increasing both satiation (meal duration) and satiety (meal interval) and activates brain circuits involved in pain, feeding behavior and stress that may underlie the alterations of meal pattern and food intake inhibition. RKT improves food consumption post-surgically that may involve modulation of pain pathway. C1 [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Ctr, Los Angeles, CA 90089 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90024 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Mogami, Sachiko; Yamada, Chihiro; Hattori, Tomohisa] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Tsukuba, Ibaraki, Japan. [Yakabi, Koji] Saitama Med Univ, Saitama Med Ctr, Dept Gastroenterol & Hepatol, Saitama, Japan. RP Wang, LX (reprint author), Univ Calif Los Angeles, CURE Digest Dis Ctr, Los Angeles, CA 90089 USA. EM lixinw@ucla.edu RI Xu, Meiqu/C-5311-2016 FU Veterans Administration Research Career Scientist Award; VA Merit Award; Tsumura Co.; [NIHDDK-41303] FX The work was supported by NIHDDK-41303 (Animal core, YT, LW), Veterans Administration Research Career Scientist Award (YT), VA Merit Award (YT) and Tsumura & Co. Drs. SM, CY and TH are employees of Tsumura & Co. The funders of Tsumura & Co. had no role in study design, data collection and analysis, decision topublish, or preparation of the manuscript. NR 85 TC 1 Z9 1 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 30 PY 2015 VL 10 IS 9 AR e0139325 DI 10.1371/journal.pone.0139325 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS6GF UT WOS:000362175700094 PM 26421719 ER PT J AU Flanagan, JC Baker, NL McRae-Clark, AL Brady, KT Maria, MMMS AF Flanagan, Julianne C. Baker, Nathaniel L. McRae-Clark, Aimee L. Brady, Kathleen T. Maria, Margaret M. Moran-Santa TI Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence SO PSYCHIATRY RESEARCH LA English DT Article DE Oxytocin; Drug dependence; Social stress reactivity; HPA ID SUBSTANCE USE; PSYCHOLOGICAL DISTRESS; HOUSEHOLD DYSFUNCTION; MENTAL-HEALTH; AXIS ACTIVITY; DRUG-USE; RISK; ALCOHOL; ABUSE; ADDICTION AB Background: Drug dependence and adverse childhood experiences (ACE) are commonly reflected by dysregulation of the hypothalamic-pituitary-adrenal axis (HPA). Accumulating research indicates that the neuropeptide oxytocin may regulate HPA function, resulting in reductions in neuroendocrine reactivity to social stress among individuals with drug dependence. However, emerging literature suggests that individual differences may differentially impact intranasal oxytbcin's effects on human social behaviors. Methods: This study employed a double-blind, placebo-controlled design to examine the extent to which ACE influenced the effects of intranasal oxytocin (40 IU) on neuroendocrine reactivity to a laboratory social stress paradigm in a sample of 31 cocaine-dependent individuals. Results: ACE scores modified the relationship between intranasal oxytocin and cortisol reactivity. While ACE modified the relationship between intranasal oxytocin and DHEA response in a similar direction to what was seen in cortisol, it did not reach statistical significance. Conclusions: Findings are congruent with the emerging hypothesis that intranasal oxytocin may differentially attenuate social stress reactivity among individuals with specific vulnerabilities. Future research examining the nuances of intranasal oxytocin's therapeutic potential is necessary. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Flanagan, Julianne C.; McRae-Clark, Aimee L.; Brady, Kathleen T.; Maria, Margaret M. Moran-Santa] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29401 USA. [Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. RP Flanagan, JC (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29401 USA. EM hellmuth@musc.edu FU National Institute on Child Health and Human Development and the Office of Research on Women's Health [K12HD055885]; National Institute on Drug Abuse [P50DA016511]; National Center for Advancing Translational Sciences [UL1TR000062] FX This manuscript is the result of work supported, in part, by resources from the National Institute on Child Health and Human Development and the Office of Research on Women's Health (K12HD055885), the National Institute on Drug Abuse (P50DA016511), and the National Center for Advancing Translational Sciences (UL1TR000062). NR 60 TC 3 Z9 3 U1 4 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD SEP 30 PY 2015 VL 229 IS 1-2 BP 94 EP 100 DI 10.1016/j.psychres.2015.07.064 PG 7 WC Psychiatry SC Psychiatry GA CQ7HC UT WOS:000360772600013 PM 26231584 ER PT J AU Anderson, TS Good, CB Gellad, WF AF Anderson, Timothy S. Good, Chester B. Gellad, Walid F. TI Prevalence and compensation of academic leaders, professors, and trustees on publicly traded US healthcare company boards of directors: cross sectional study SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID CONFLICTS-OF-INTEREST; MEDICAL-CENTERS AB OBJECTIVE To identify the prevalence, characteristics, and compensation of members of the boards of directors of healthcare industry companies who hold academic appointments as leaders, professors, or trustees. DESIGN Cross sectional study. SETTING US healthcare companies publicly traded on the NASDAQ or New York Stock Exchange in 2013. PARTICIPANTS 3434 directors of pharmaceutical, biotechnology, medical equipment and supply, and healthcare provider companies. MAIN OUTCOME MEASURES Prevalence, annual compensation, and beneficial stock ownership of directors with affiliations as leaders, professors, or trustees of academic medical and research institutions. RESULTS 446 healthcare companies met the study search criteria, of which 442 (99%) had publicly accessible disclosures on boards of directors. 180 companies (41%) had one or more academically affiliated directors. Directors were affiliated with 85 geographically diverse non-profit academic institutions, including 19 of the top 20 National Institute of Health funded medical schools and all of the 17 US News honor roll hospitals. Overall, these 279 academically affiliated directors included 73 leaders, 121 professors, and 85 trustees. Leaders included 17 chief executive officers and 11 vice presidents or executive officers of health systems and hospitals; 15 university presidents, provosts, and chancellors; and eight medical school deans or presidents. The total annual compensation to academically affiliated directors for their services to companies was $54 995 786 (35 pound 836 000; (sic)49 185 900) (median individual compensation $193 000) and directors beneficially owned 59 831 477 shares of company stock (median 50 699 shares). CONCLUSIONS A substantial number and diversity of academic leaders, professors, and trustees hold directorships at US healthcare companies, with compensation often approaching or surpassing common academic clinical salaries. Dual obligations to for profit company shareholders and non-profit clinical and educational institutions pose considerable personal, financial, and institutional conflicts of interest beyond that of simple consulting relationships. These conflicts have not been fully addressed by professional societies or academic institutions and deserve additional review, regulation, and, in some cases, prohibition when conflicts cannot be reconciled. C1 [Anderson, Timothy S.] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA USA. [Good, Chester B.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Good, Chester B.] Univ Pittsburgh, VA Ctr Medicat Safety, Dept Vet Affairs, Sch Med, Pittsburgh, PA 15260 USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15240 USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15240 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM wfg3@pitt.edu FU VA Health Services Research and Development award [CDA 09-207] FX WFG was supported by a VA Health Services Research and Development award CDA 09-207. The funder had no role in the design and conduct of the study, collection, management, analysis, and interpretation of data, or preparation of the manuscript. NR 25 TC 3 Z9 3 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD SEP 29 PY 2015 VL 351 AR h4826 DI 10.1136/bmj.h4826 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CS9YU UT WOS:000362450900005 PM 26420786 ER PT J AU Namjou, B Marsolo, K Lingren, T Ritchie, MD Verma, SS Cobb, BL Perry, C Kitchner, TE Brilliant, MH Peissig, PL Borthwick, KM Williams, MS Grafton, J Jarvik, GP Holm, IA Harley, JB AF Namjou, Bahram Marsolo, Keith Lingren, Todd Ritchie, Marylyn D. Verma, Shefali S. Cobb, Beth L. Perry, Cassandra Kitchner, Terrie E. Brilliant, Murray H. Peissig, Peggy L. Borthwick, Kenneth M. Williams, Marc S. Grafton, Jane Jarvik, Gail P. Holm, Ingrid A. Harley, John B. TI A GWAS Study on Liver Function Test Using eMERGE Network Participants SO PLOS ONE LA English DT Article ID GENOME-WIDE ASSOCIATION; SERUM BILIRUBIN LEVELS; CORONARY-HEART-DISEASE; SYNDROME TYPE-II; 7-ETHYL-10-HYDROXYCAMPTOTHECIN SN-38; ALKALINE-PHOSPHATASE; ACTIVE METABOLITE; GILBERTS-SYNDROME; UGT1A1 GENE; POPULATION AB Introduction Liver enzyme levels and total serum bilirubin are under genetic control and in recent years genome-wide population-based association studies have identified different susceptibility loci for these traits. We conducted a genome-wide association study in European ancestry participants from the Electronic Medical Records and Genomics (eMERGE) Network dataset of patient medical records with available genotyping data in order to identify genetic contributors to variability in serum bilirubin levels and other liver function tests and to compare the effects between adult and pediatric populations. Methods The process of whole genome imputation of eMERGE samples with standard quality control measures have been described previously. After removing missing data and outliers based on principal components (PC) analyses, 3294 samples from European ancestry were used for the GWAS study. The association between each single nucleotide polymorphism (SNP) and total serum bilirubin and other liver function tests was tested using linear regression, adjusting for age, gender, site, platform and ancestry principal components (PC). Results Consistent with previous results, a strong association signal has been detected for UGT1A gene cluster (best SNP rs887829, beta = 0.15, p = 1.30x10(-118)) for total serum bilirubin level. Indeed, in this region more than 176 SNPs (or indels) had p<10(-8) spanning 150Kb on the long arm of chromosome 2q37.1. In addition, we found a similar level of magnitude in a pediatric group (p = 8.26x10(-47), beta = 0.17). Further imputation using sequencing data as a reference panel revealed association of other markers including known TA7 repeat indels (rs8175347) (p = 9.78x10(-117)) and rs111741722 (p = 5.41x10(-119)) which were in proxy (r2 = 0.99) with rs887829. Among rare variants, two Asian subjects homozygous for coding SNP rs4148323 (G71R) were identified. Additional known effects for total serum bilirubin were also confirmed including organic anion transporters SLCO1B1-SLCO1B3, TDRP and ZMYND8 at FDR<0.05 with no gene-gene interaction effects. Phenome-wide association studies (PheWAS) suggest a protective effect of TA7 repeat against cerebrovascular disease in an adult cohort (OR = 0.75, p = 0.0008). Among other liver function tests, we also confirmed the previous effect of the ABO blood group locus for variation in serum alkaline phosphatase (rs579459, p = 9.44x10(-15)). Conclusions Taken together, our data present interesting findings with strong confirmation of previous effects by simply using the eMERGE electronic health record phenotyping. In addition, our findings indicate that similar to the adult population, the UGT1A1 is the main locus responsible for normal variation of serum bilirubin in pediatric populations. C1 [Namjou, Bahram; Cobb, Beth L.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr CCHMC, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Namjou, Bahram; Marsolo, Keith; Lingren, Todd; Harley, John B.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Marsolo, Keith; Lingren, Todd] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA. [Ritchie, Marylyn D.; Verma, Shefali S.] Penn State Univ, Ctr Syst Genom, University Pk, PA 16802 USA. [Perry, Cassandra] Boston Childrens Hosp BCH, Div Genet & Genom, Boston, MA USA. [Kitchner, Terrie E.; Brilliant, Murray H.; Peissig, Peggy L.] Marshfield Clin Fdn Med Res & Educ, Ctr Human Genet, Marshfield, WI USA. [Borthwick, Kenneth M.; Williams, Marc S.] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA. [Grafton, Jane] Grp Hlth Res Inst, Seattle, WA USA. [Jarvik, Gail P.] Univ Washington, Dept Med, Seattle, WA USA. [Jarvik, Gail P.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Holm, Ingrid A.] Boston Childrens Hosp, Div Genet & Genom, Boston, MA USA. [Holm, Ingrid A.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA. [Holm, Ingrid A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Namjou, B (reprint author), Cincinnati Childrens Hosp Med Ctr CCHMC, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. EM Bahram.namjou@cchmc.org FU National Institutes of Health [U01HG006828, U01HG006389, U01HG006382, U01HG006375, U01HG006385, U01HG004438] FX This study was supported by the National Institutes of Health (http://www.nih.gov/) grants: U01HG006828-NHGRI-Cincinnati Children's Hospital Medical Center/Boston Children's Hospital (to JBH, IAH, BN, BLC, KM, TL, CP); U01HG006389-NHGRI-Essentia Institute of Rural Health, Marshfield Clinic Research Foundation and Pennsylvania State University (to PLP, MHB, TEK, MDR, SSV); U01HG006382-NHGRI-Geisinger Clinic (to MSW, KMB); U01HG006375-NHGRI-Group Health Cooperative/University of Washington (to GPJ, JG); U01HG006385-NHGRI-Vanderbilt University Medical Center serving as the Coordinating Center and the PGRNSeq dataset (eMERGE PGx); U01HG004438-NHGRI- The Center for Inherited Disease Research (CIDR) serving as a Sequencing Center for eMERGE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 6 Z9 6 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 28 PY 2015 VL 10 IS 9 AR e0138677 DI 10.1371/journal.pone.0138677 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS6EO UT WOS:000362170700020 PM 26413716 ER PT J AU Mata, IF Jang, Y Kim, CH Hanna, DS Dorschner, MO Samii, A Agarwal, P Roberts, JW Klepitskaya, O Shprecher, DR Chung, KA Factor, SA Espay, AJ Revilla, FJ Higgins, DS Litvan, I Leverenz, JB Yearout, D Inca-Martinez, M Martinez, E Thompson, TR Cholerton, BA Hu, SC Edwards, KL Kim, KS Zabetian, CP AF Mata, Ignacio F. Jang, Yongwoo Kim, Chun-Hyung Hanna, David S. Dorschner, Michael O. Samii, Ali Agarwal, Pinky Roberts, John W. Klepitskaya, Olga Shprecher, David R. Chung, Kathryn A. Factor, Stewart A. Espay, Alberto J. Revilla, Fredy J. Higgins, Donald S. Litvan, Irene Leverenz, James B. Yearout, Dora Inca-Martinez, Miguel Martinez, Erica Thompson, Tiffany R. Cholerton, Brenna A. Hu, Shu-Ching Edwards, Karen L. Kim, Kwang-Soo Zabetian, Cyrus P. TI The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease SO MOLECULAR NEURODEGENERATION LA English DT Article ID LEWY BODY; PATHOLOGY; VARIANTS; GTPASES; RISK AB Objective: To identify the causal gene in a multi-incident U.S. kindred with Parkinson's disease (PD). Methods: We characterized a family with a classical PD phenotype in which 7 individuals (5 males and 2 females) were affected with a mean age at onset of 46.1 years (range, 29-57 years). We performed whole exome sequencing on 4 affected and 1 unaffected family members. Sanger-sequencing was then used to verify and genotype all candidate variants in the remainder of the pedigree. Cultured cells transfected with wild-type or mutant constructs were used to characterize proteins of interest. Results: We identified a missense mutation (c.574G > A; p.G192R) in the RAB39B gene that closely segregated with disease and exhibited X-linked dominant inheritance with reduced penetrance in females. The mutation occurred in a highly conserved amino acid residue and was not observed among 87,725 X chromosomes in the Exome Aggregation Consortium dataset. Sequencing of the RAB39B coding region in 587 familial PD cases yielded two additional mutations (c.428C > G [p.A143G] and c.624_626delGAG [p.R209del]) that were predicted to be deleterious in silico but occurred in families that were not sufficiently informative to assess segregation with disease. Experiments in PC12 and SK-N-BE(2) C cells demonstrated that p.G192R resulted in mislocalization of the mutant protein, possibly by altering the structure of the hypervariable C-terminal domain which mediates intracellular targeting. Conclusions: Our findings implicate RAB39B, an essential regulator of vesicular-trafficking, in clinically typical PD. Further characterization of normal and aberrant RAB39B function might elucidate important mechanisms underlying neurodegeneration in PD and related disorders. C1 [Mata, Ignacio F.; Samii, Ali; Yearout, Dora; Martinez, Erica; Thompson, Tiffany R.; Cholerton, Brenna A.; Hu, Shu-Ching; Edwards, Karen L.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Mata, Ignacio F.; Samii, Ali; Yearout, Dora; Martinez, Erica; Hu, Shu-Ching; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Jang, Yongwoo; Kim, Chun-Hyung; Kim, Kwang-Soo] McLean Hosp, Dept Psychiat, Mol Neurobiol Lab, Belmont, MA 02178 USA. [Jang, Yongwoo; Kim, Chun-Hyung; Kim, Kwang-Soo] McLean Hosp, Program Neurosci, Belmont, MA 02178 USA. [Jang, Yongwoo; Kim, Chun-Hyung; Kim, Kwang-Soo] Harvard Univ, Sch Med, Belmont, MA 02178 USA. [Hanna, David S.; Dorschner, Michael O.; Cholerton, Brenna A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Hanna, David S.; Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Agarwal, Pinky] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Klepitskaya, Olga] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Shprecher, David R.] Univ Utah, Dept Neurol, Salt Lake City, UT USA. [Chung, Kathryn A.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Espay, Alberto J.] Univ Cincinnati, Dept Neurol Rehabil Med, Cincinnati, OH USA. [Revilla, Fredy J.] Div Neurol Greenville Hlth Syst, Greenville, SC USA. [Higgins, Donald S.] Univ S Carolina, Med Sch Greenville, Greenville, SC USA. [Higgins, Donald S.] Samuel Stratton Vet Affairs Med Ctr, Albany, NY USA. [Litvan, Irene] Univ Calif San Diego, Dept Neurosci, Movement Disorder Ctr, San Diego, CA 92103 USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Inca-Martinez, Miguel] Inst Nacl Ciencias Neurolog, Neurogenet Res Ctr, Lima, Peru. [Edwards, Karen L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. RP Zabetian, CP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM zabetian@u.washington.edu OI Litvan, Irene/0000-0002-3485-3445 FU National Institutes of Health [P50 NS062684, R01 NS065070, R01 NS084869]; Department of Veterans Affairs [1I01BX000531] FX This work was supported by grants from the National Institutes of Health (P50 NS062684, R01 NS065070, R01 NS084869) and the Department of Veterans Affairs (1I01BX000531), and by a gift from the Dolsen Foundation. We thanks all of the individuals who participated in the study and Drs. Jennifer Witt and Rosalind Chuang for assistance with patient recruitment. NR 23 TC 17 Z9 17 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD SEP 24 PY 2015 VL 10 AR 50 DI 10.1186/s13024-015-0045-4 PG 8 WC Neurosciences SC Neurosciences & Neurology GA CR8FE UT WOS:000361585700001 PM 26399558 ER PT J AU Baca, CB Barkley, GL AF Baca, Christine B. Barkley, Gregory L. TI Can big data help us close an epilepsy care gap? SO NEUROLOGY LA English DT Editorial Material ID DISPARITIES; OUTCOMES; PEOPLE AB Epilepsy has been termed an ambulatory care sensitive condition, meaning that high-quality outpatient epilepsy care can reduce unnecessary emergency department (ED) visits and hospitalizations. Using this framework, high ED use is a marker of poor disease control or limited access to care.(1) Do all people with epilepsy (PWE) with poorly controlled disease or limited access frequent the ED? Are other factors at play? In this changing health care landscape, with accountable care organizations and a need to reduce costs, can we predict PWE who are at high risk of frequent ED use? C1 [Baca, Christine B.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.] Vet Adm Greater Los Angeles, Dept Neurol, Los Angeles, CA USA. [Barkley, Gregory L.] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA. [Barkley, Gregory L.] Wayne State Univ, Sch Med, Detroit, MI USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. EM cbower@mednet.ucla.edu NR 8 TC 1 Z9 1 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD SEP 22 PY 2015 VL 85 IS 12 BP 1014 EP 1015 DI 10.1212/WNL.0000000000001961 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CX3CG UT WOS:000365572500002 PM 26311744 ER PT J AU Yuan, KY Yong, S Xu, F Zhou, T McDonald, JM Chen, YB AF Yuan, Kaiyu Yong, Sun Xu, Fei Zhou, Tong McDonald, Jay M. Chen, Yabing TI Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer SO ONCOTARGET LA English DT Article DE death receptor 5; apoptosis; resistance; calmodulin antagonists; pancreatic cancer ID APOPTOSIS-INDUCING LIGAND; TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; DEATH RECEPTOR EXPRESSION; MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; HEPATOMA-CELLS; IN-VITRO; ACTIVATION AB Pancreatic cancer is highly malignant with limited therapy and a poor prognosis. TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers. We investigated the effects of calmodulin(CaM) antagonists, trifluoperazine(TFP) and tamoxifen(TMX), on TRA-8-induced apoptosis and tumorigenesis of TRA-8-resistant pancreatic cancer cells, and underlying mechanisms. TFP or TMX alone did not induce apoptosis of resistant PANC-1 cells, while they dose-dependently enhanced TRA-8-induced apoptosis. TMX treatment enhanced efficacy of TRA-8 therapy on tumorigenesis in vivo. Analysis of TRA-8-induced death-inducing-signaling-complex (DISC) identified recruitment of survival signals, CaM/Src, into DR5-associated DISC, which was inhibited by TMX/TFP. In contrast, TMX/TFP increased TRA-8-induced DISC recruitment/activation of caspase-8. Consistently, caspase-8 inhibition blocked the effects of TFP/TMX on TRA-8-induced apoptosis. Moreover, TFP/TMX induced DR5 expression. With a series of deletion/point mutants, we identified CaM antagonist-responsive region in the putative Sp1-binding domain between -295 to -300 base pairs of DR5 gene. Altogether, we have demonstrated that CaM antagonists enhance TRA-8-induced apoptosis of TRA-8-resistant pancreatic cancer cells by increasing DR5 expression and enhancing recruitment of apoptotic signal while decreasing survival signals in DR5-associated DISC. Our studies support the use of these readily available CaM antagonists combined with TRAIL-activating agents for pancreatic cancer therapy. C1 [Yuan, Kaiyu; Yong, Sun; Xu, Fei; McDonald, Jay M.; Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhou, Tong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [McDonald, Jay M.; Chen, Yabing] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Chen, YB (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM ybchen@uab.edu FU VA Merit Review Awards [BX000311, BX002296] FX This work was supported by VA Merit Review Awards BX000311 (JMM) and BX002296 (YC). NR 50 TC 0 Z9 0 U1 2 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD SEP 22 PY 2015 VL 6 IS 28 BP 25308 EP 25319 DI 10.18632/oncotarget.4490 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CT9TS UT WOS:000363160100062 PM 26320171 ER PT J AU Balasubramanian, K Maeda, A Lee, JS Mohammadyani, D Dar, HH Jiang, JF Croix, CMS Watkins, S Tyurin, VA Tyurina, YY Kloditz, K Polimova, A Kapralova, VI Xiong, ZY Ray, P Klein-Seetharaman, J Mallampalli, RK Bayir, H Fadeel, B Kagan, VE AF Balasubramanian, Krishnakumar Maeda, Akihiro Lee, Janet S. Mohammadyani, Dariush Dar, Haider Hussain Jiang, Jian Fei Croix, Claudette M. St. Watkins, Simon Tyurin, Vladimir A. Tyurina, Yulia Y. Kloeditz, Katharina Polimova, Anastassia Kapralova, Valentyna I. Xiong, Zeyu Ray, Prabir Klein-Seetharaman, Judith Mallampalli, Rama K. Bayir, Huelya Fadeel, Bengt Kagan, Valerian E. TI Dichotomous roles for externalized cardiolipin in extracellular signaling: Promotion of phagocytosis and attenuation of innate immunity SO SCIENCE SIGNALING LA English DT Article ID APOPTOTIC CELLS; BACTERIAL LIPOPOLYSACCHARIDE; MACROPHAGE ACTIVATION; SCAVENGER RECEPTORS; MEDIATED APOPTOSIS; CELLULAR MEMBRANES; MOLECULAR-PATTERNS; ESCHERICHIA-COLI; MANNOSE RECEPTOR; STRUCTURAL BASIS AB Among the distinct molecular signatures present in the mitochondrion is the tetra-acylated anionic phospholipid cardiolipin, a lipid also present in primordial, single-cell bacterial ancestors of mitochondria and multiple bacterial species today. Cardiolipin is normally localized to the inner mitochondrial membrane; however, when cardiolipin becomes externalized to the surface of dysregulated mitochondria, it promotes inflammasome activation and stimulates the elimination of damaged or nonfunctional mitochondria by mitophagy. Given the immunogenicity of mitochondrial and bacterial membranes that are released during sterile and pathogen-induced trauma, we hypothesized that cardiolipins might function as "eat me" signals for professional phagocytes. In experiments with macrophage cell lines and primary macrophages, we found that membranes with mitochondrial or bacterial cardiolipins on their surface were engulfed through phagocytosis, which depended on the scavenger receptor CD36. Distinct from this process, the copresentation of cardiolipin with the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide dampened TLR4-stimulated production of cytokines. These data suggest that externalized, extracellular cardiolipins play a dual role in host-host and host-pathogen interactions by promoting phagocytosis and attenuating inflammatory immune responses. C1 [Balasubramanian, Krishnakumar; Mohammadyani, Dariush; Dar, Haider Hussain; Jiang, Jian Fei; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Polimova, Anastassia; Kapralova, Valentyna I.; Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15219 USA. [Maeda, Akihiro; Kloeditz, Katharina; Fadeel, Bengt] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden. [Lee, Janet S.; Xiong, Zeyu; Ray, Prabir] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Croix, Claudette M. St.; Watkins, Simon] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15261 USA. [Klein-Seetharaman, Judith] Univ Warwick, Div Metab & Vasc Hlth, Coventry CV4 7AL, W Midlands, England. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Internal Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15215 USA. [Bayir, Huelya] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA. RP Balasubramanian, K (reprint author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15219 USA. EM kris.balasub@gmail.com; bengt.fadeel@ki.se; kagan@pitt.edu OI Tyurin, Vladimir/0000-0002-3474-1697 FU NIH [PO1 HL114453, HL086884, U19AIO68021, ES020693, NS076511, NS061817, CA165065]; Human Frontier Science Program [HFSP-RGP0013/2014]; Swedish Research Council; NIH (NIOSH) [OH008282]; [P30CA047904] FX This study was supported by grants from the NIH (PO1 HL114453, HL086884, U19AIO68021, ES020693; NS076511, NS061817, CA165065; NIOSH OH008282), the Human Frontier Science Program (HFSP-RGP0013/2014), the Swedish Research Council, and a Core grant to the UPCI Cancer Biomarkers Facility/Luminex Core Laboratory (P30CA047904). NR 81 TC 11 Z9 11 U1 0 U2 16 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1945-0877 EI 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD SEP 22 PY 2015 VL 8 IS 395 AR ra95 DI 10.1126/scisignal.aaa6179 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CU1YJ UT WOS:000363318000002 PM 26396268 ER PT J AU Cummings, JL Lyketsos, CG Peskind, ER Porsteinsson, AP Mintzer, JE Scharre, D De La Gandara, JE Agronin, M Davis, CS Nguyen, U Shin, P Tariot, PN Siffert, J AF Cummings, Jeffrey L. Lyketsos, Constantine G. Peskind, Elaine R. Porsteinsson, Anton P. Mintzer, Jacobo E. Scharre, DouglasW. De La Gandara, Jose E. Agronin, Marc Davis, Charles S. Uyen Nguyen Shin, Paul Tariot, Pierre N. Siffert, Joao TI Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID PSEUDOBULBAR AFFECT; NEUROPSYCHIATRIC SYMPTOMS; BEHAVIORAL SYMPTOMS; PLACEBO-RESPONSE; IN-VITRO; AGGRESSION; DESIGN; RECOMMENDATIONS; PROGRESSION; MANAGEMENT AB IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score >= 4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3: 4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1: 1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60). MAIN OUTCOMES AND MEASURES The primary end point was change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]). RESULTS A total of 194 patients (88.2%) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders) showed significantly reduced NPI Agitation/Aggression scores for dextromethorphan-quinidine vs placebo( ordinaryleastsquareszstatistic,-3.95; P < .001). In stage 1, mean NPI Agitation/Aggression scores were reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0 to 5.3 with placebo. Between-groupt reatment differences were significantin stage 1(leasts quaresmean, -1.5; 95% CI, -2.3 to -0.7; P <. 001). In stage 2, NPI Agitation/Aggression scores were reduced from 5.8 to 3.8 with dextromethorphan-quinidine and from 6.7 to 5.8 with placebo. Between-group treatment differences were also significant in stage 2(least squares mean,-1.6; 95% CI,-2.9 to -0.3; P=.02). Adverseevents included falls (8.6% for dextromethorphan-quinidine vs3.9% for placebo), diarrhea (5.9% vs 3.1% respectively), and urinary tract infection (5.3% vs 3.9% respectively). Serious adverse events occurred in 7.9% with dextromethorphan-quinidine vs 4.7% with placebo. Dextromethorphan-quinidinewas not associated with cognitive impairment, sedation, or clinically significant QTc prolongation. CONCLUSIONS AND RELEVANCE In this preliminary 10-week phase 2 randomized clinical trial of patients with probable Alzheimer disease, combination dextromethorphan-quinidine demonstrated clinically relevant efficacy for agitation and was generally well tolerated. C1 [Cummings, Jeffrey L.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA. [Lyketsos, Constantine G.] Johns Hopkins Bayview, Johns Hopkins Memory & Alzheimers Treatment Ctr, Baltimore, MD USA. [Peskind, Elaine R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Mintzer, Jacobo E.] Roper St Francis Hosp, Clin Biotechnol Res Inst, Charleston, SC USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Scharre, DouglasW.] Ohio State Univ, Columbus, OH 43210 USA. [De La Gandara, Jose E.] Quantum Labs Inc, W Palm Beach, FL USA. [Agronin, Marc] Miami Jewish Hlth Syst, Miami, FL USA. [Davis, Charles S.] CSD Biostat Inc, Tucson, AZ USA. [Uyen Nguyen; Shin, Paul; Siffert, Joao] Avanir Pharmaceut Inc, Aliso Viejo, CA USA. [Tariot, Pierre N.] Banner Alzheimers Inst, Phoenix, AZ USA. RP Cummings, JL (reprint author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA. EM cumminj@ccf.org FU Avanir Pharmaceuticals Inc. FX This study was funded by Avanir Pharmaceuticals Inc. NR 34 TC 17 Z9 17 U1 1 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 22 PY 2015 VL 314 IS 12 BP 1242 EP 1254 DI 10.1001/jama.2015.10214 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CS5IE UT WOS:000362110700013 PM 26393847 ER PT J AU Foldes, ST Weber, DJ Collinger, JL AF Foldes, Stephen T. Weber, Douglas J. Collinger, Jennifer L. TI MEG-based neurofeedback for hand rehabilitation SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Article DE Brain-Computer Interface; Neurofeedback; Spinal Cord Injury; Magnetoencephalography; Neuroplasticity; Rehabilitation ID BRAIN-COMPUTER INTERFACE; MIRROR NEURON SYSTEM; MOTOR IMAGERY; STROKE REHABILITATION; PLASTICITY; FEEDBACK; SUPPRESSION; MODULATION; ARTIFACTS; RECOVERY AB Background: Providing neurofeedback (NF) of motor-related brain activity in a biologically-relevant and intuitive way could maximize the utility of a brain-computer interface (BCI) for promoting therapeutic plasticity. We present a BCI capable of providing intuitive and direct control of a video-based grasp. Methods: Utilizing magnetoencephalography's (MEG) high temporal and spatial resolution, we recorded sensorimotor rhythms (SMR) that were modulated by grasp or rest intentions. SMR modulation controlled the grasp aperture of a stop motion video of a human hand. The displayed hand grasp position was driven incrementally towards a closed or opened state and subjects were required to hold the targeted position for a time that was adjusted to change the task difficulty. Results: We demonstrated that three individuals with complete hand paralysis due to spinal cord injury (SCI) were able to maintain brain-control of closing and opening a virtual hand with an average of 63 % success which was significantly above the average chance rate of 19 %. This level of performance was achieved without pre-training and less than 4 min of calibration. In addition, successful grasp targets were reached in 1.96 +/- 0.15 s. Subjects performed 200 brain-controlled trials in approximately 30 min excluding breaks. Two of the three participants showed a significant improvement in SMR indicating that they had learned to change their brain activity within a single session of NF. Conclusions: This study demonstrated the utility of a MEG-based BCI system to provide realistic, efficient, and focused NF to individuals with paralysis with the goal of using NF to induce neuroplasticity. C1 [Foldes, Stephen T.; Weber, Douglas J.; Collinger, Jennifer L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Foldes, Stephen T.; Weber, Douglas J.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Foldes, Stephen T.; Weber, Douglas J.; Collinger, Jennifer L.] Univ Pittsburgh, Ctr Neural Basis Cognit, Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Weber, Douglas J.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA. RP Collinger, JL (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM collingr@pitt.edu FU Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research & Development Service [B7143R]; VISN 4 Competitive Pilot Project Fund FX The authors would like to express gratitude to Betsy Harchick, Debbie Harrington, and Michael Randazzo for assistance with the experiments and Emily Grattan and Juleen Rodakowski for assistance with the functional assessments. This work was supported by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research & Development Service (Grants #B7143R) and the VISN 4 Competitive Pilot Project Fund. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Department of Veterans Affairs or the United States Government. NR 47 TC 3 Z9 4 U1 2 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD SEP 22 PY 2015 VL 12 AR 85 DI 10.1186/s12984-015-0076-7 PG 9 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA CR6AS UT WOS:000361426100001 PM 26392353 ER PT J AU Zhu, L Zhong, MH Elder, GA Sano, M Holtzman, DM Gandy, S Cardozo, C Haroutunian, V Robakis, NK Cai, DM AF Zhu, Li Zhong, Minghao Elder, Gregory A. Sano, Mary Holtzman, David M. Gandy, Sam Cardozo, Christopher Haroutunian, Vahram Robakis, Nikolaos K. Cai, Dongming TI Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Alzheimer's disease; apolipoprotein E4; phospholipid; dysregulation; cognitive deficits ID AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; MOUSE MODEL; EPSILON-4 HOMOZYGOTES; ENDOCYTIC TRAFFICKING; BRAIN; METABOLISM; MEMORY; PHOSPHORYLATION; PERFORMANCE AB The apolipoprotein E4 (ApoE4) allele is the strongest genetic risk factor for developing sporadic Alzheimer's disease (AD). However, the mechanisms underlying the pathogenic nature of ApoE4 are not well understood. In this study, we have found that ApoE proteins are critical determinants of brain phospholipid homeostasis and that the ApoE4 isoform is dysfunctional in this process. We have found that the levels of phosphoinositol biphosphate (PIP2) are reduced in postmortem human brain tissues of ApoE4 carriers, in the brains of ApoE4 knock-in (KI) mice, and in primary neurons expressing ApoE4 alleles compared with those levels in ApoE3 counterparts. These changes are secondary to increased expression of a PIP2-degrading enzyme, the phosphoinositol phosphatase synaptojanin 1 (synj1), in ApoE4 carriers. Genetic reduction of synj1 in ApoE4 KI mouse models restores PIP2 levels and, more important, rescues AD-related cognitive deficits in these mice. Further studies indicate that ApoE4 behaves similar to ApoE null conditions, which fails to degrade synj1 mRNA efficiently, unlike ApoE3 does. These data suggest a loss of function of ApoE4 genotype. Together, our data uncover a previously unidentified mechanism that links ApoE4-induced phospholipid changes to the pathogenic nature of ApoE4 in AD. C1 [Zhu, Li; Elder, Gregory A.; Sano, Mary; Gandy, Sam; Cai, Dongming] James J Peters VA Med Ctr, Res & Dev, Bronx, NY 10468 USA. [Zhu, Li; Sano, Mary; Gandy, Sam; Haroutunian, Vahram; Cai, Dongming] Icahn Sch Med Mt Sinai, Alzheimer Dis Res Ctr, Dept Neurol, New York, NY 10029 USA. [Zhong, Minghao] New York Med Coll, Dept Pathol, Westchester Med Ctr, Valhalla, NY 10595 USA. [Holtzman, David M.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63100 USA. [Cardozo, Christopher] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Cardozo, Christopher] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Haroutunian, Vahram; Robakis, Nikolaos K.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. RP Cai, DM (reprint author), James J Peters VA Med Ctr, Res & Dev, Bronx, NY 10468 USA. EM dongming.cai@mssm.edu OI Cai, Dongming/0000-0002-0601-6826 FU Department of Veteran Affairs Basic Life Science Research & Development CDA; Alzheimer Association [NIRP14-304720]; Department of Veteran Affairs Rehabilitation Research & Development Small Projects in Rehabilitation Research [1I21RX001558-01A1]; NIH R01 [1R01AG048923-01, 2R01AG008200]; NIH R37 [AG017926]; NIH UO1 [AG046170]; NIH P50 [AG005138]; NIH R34 [AG049649]; NIH RO1 [NS075685]; Department of Veterans Affairs RR&D National Center for Excellence for the Medical Consequences of Spinal Cord Injury; James J. Peters VA Medical Center Research Core Facility FX We thank Dr. Pietro De Camilli (Yale School of Medicine) for providing synj1 haploinsufficiency mice. Antibody p369 was generously provided by Dr. Paul Greengard. We also thank Dr. William Netzer (The Rockefeller University) and Dr. Michaela Kiernan (Stanford University) for critical reading of the manuscript. This work was supported in whole or in part by funding from the Department of Veteran Affairs Basic Life Science Research & Development CDA (Award CAI-spring 2010); Alzheimer Association (Award NIRP14-304720); Department of Veteran Affairs Rehabilitation Research & Development Small Projects in Rehabilitation Research (Grant 1I21RX001558-01A1); and NIH R01 (Grant 1R01AG048923-01) (to D.C.), NIH R37 (Grant AG017926) and R01 (Grant 2R01AG008200) (to N.K.R.), NIH UO1 (Grant AG046170), P50 (Grant AG005138), R34 (Grant AG049649), and RO1 (Grant NS075685) (to S.G.); as well as Department of Veterans Affairs RR&D National Center for Excellence for the Medical Consequences of Spinal Cord Injury (Grant B9212C) (to C.C.). Confocal microscopy studies were supported by the James J. Peters VA Medical Center Research Core Facility. NR 47 TC 11 Z9 11 U1 2 U2 13 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD SEP 22 PY 2015 VL 112 IS 38 BP 11965 EP 11970 DI 10.1073/pnas.1510011112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR7JH UT WOS:000361525100066 PM 26372964 ER PT J AU Teshome, BF Lee, GC Reveles, KR Attridge, RT Koeller, J Wang, CP Mortensen, EM Frei, CR AF Teshome, Besu F. Lee, Grace C. Reveles, Kelly R. Attridge, Russell T. Koeller, Jim Wang, Chen-pin Mortensen, Eric M. Frei, Christopher R. TI Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment SO BMC INFECTIOUS DISEASES LA English DT Article ID CARE-ASSOCIATED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; ACQUIRED PNEUMONIA; NOSOCOMIAL PNEUMONIA; ANTIBIOTIC-THERAPY; INFLUENZA SEASON; PATHOGENS; ADULTS; COHORT; EPIDEMIOLOGY AB Background: Community-onset (CO) methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is an evolving problem, and there is a great need for a reliable method to assess MRSA risk at hospital admission. A new MRSA prediction score classifies CO-pneumonia patients into low, medium, and high-risk groups based on objective criteria available at baseline. Our objective was to assess the effect of initial MRSA therapy on mortality in these three risk groups. Methods: We conducted a retrospective cohort study using data from the Veterans Health Administration (VHA). Patients were included if they were hospitalized with pneumonia and received antibiotics within the first 48 h of admission. They were stratified into MRSA therapy and no MRSA therapy treatment arms based on antibiotics received in the first 48 h. Multivariable logistic regression was used to adjust for potential confounders. Results: A total of 80,330 patients met inclusion criteria, of which 36 % received MRSA therapy and 64 % did not receive MRSA therapy. The majority of patients were classified as either low (51 %) or medium (47 %) risk, with only 2 % classified as high-risk. Multivariable logistic regression analysis demonstrated that initial MRSA therapy was associated with a lower 30-day mortality in the high-risk group (adjusted odds ratio 0.57; 95 % confidence interval 0.42-0.77). Initial MRSA therapy was not beneficial in the low or medium-risk groups. Conclusions: This study demonstrated improved survival with initial MRSA therapy in high-risk CO-pneumonia patients. The MRSA risk score might help spare MRSA therapy for only those patients who are likely to benefit. C1 [Teshome, Besu F.] St Louis Coll Pharm, St Louis, MO USA. [Teshome, Besu F.; Lee, Grace C.; Reveles, Kelly R.; Koeller, Jim; Frei, Christopher R.] Univ Texas Austin, Coll Pharm, Pharmacotherapy Div, Austin, TX 78712 USA. [Teshome, Besu F.; Lee, Grace C.; Reveles, Kelly R.; Koeller, Jim; Frei, Christopher R.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Attridge, Russell T.] Univ Incarnate Word, Feik Sch Pharm, San Antonio, TX USA. [Attridge, Russell T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wang, Chen-pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Frei, CR (reprint author), Univ Texas Austin, Coll Pharm, Pharmacotherapy Div, Austin, TX 78712 USA. EM freic@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institutes of Health (NIH)/National Institute of Nursing Research [R01NR010828]; NIH Clinical Research Scholar (KL2) career development award (National Center for Research Resources) [5KL2 RR025766]; NIH Clinical Research Scholar (KL2) career development award (National Center for Advancing Translational Sciences) [8KL2 TR000118]; Agency for Healthcare Research and Quality [R24 HS022418]; University of Texas Southwestern Center for Patient-Centered Outcomes Research FX This study was supported by a grant from the National Institutes of Health (NIH)/National Institute of Nursing Research (R01NR010828). Dr. Frei was supported in part by a NIH Clinical Research Scholar (KL2) career development award (National Center for Research Resources 5KL2 RR025766 [2010-2012] and National Center for Advancing Translational Sciences 8KL2 TR000118 [2013]). Dr. Mortensen was supported in part by a grant from the Agency for Healthcare Research and Quality (R24 HS022418) and the University of Texas Southwestern Center for Patient-Centered Outcomes Research. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health. Finally, the co-authors would like to acknowledge the assistance of Stefan Allen and Ashley Pechal (pharmacy students at The University of Texas at Austin College of Pharmacy, who assisted the co-authors with literature searches during part of the peer review process). NR 40 TC 3 Z9 3 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD SEP 18 PY 2015 VL 15 AR 380 DI 10.1186/s12879-015-1119-1 PG 11 WC Infectious Diseases SC Infectious Diseases GA CR5BV UT WOS:000361355200001 PM 26385225 ER PT J AU Si, Y Kim, S Cui, XQ Zheng, L Oh, SJ Anderson, T AlSharabati, M Kazamel, M Volpicelli-Daley, L Bamman, MM Yu, SH King, PH AF Si, Ying Kim, Soojin Cui, Xiangqin Zheng, Lei Oh, Shin J. Anderson, Tina AlSharabati, Mohammad Kazamel, Mohamed Volpicelli-Daley, Laura Bamman, Marcas M. Yu, Shaohua King, Peter H. TI Transforming Growth Factor Beta (TGF-beta) Is a Muscle Biomarker of Disease Progression in ALS and Correlates with Smad Expression SO PLOS ONE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; MOTONEURONS; REGENERATION; ACTIVATION; CELLS; BONE; MASS AB We recently identified Smads1, 5 and 8 as muscle biomarkers in human ALS. In the ALS mouse, these markers are elevated and track disease progression. Smads are signal transducers and become activated upon receptor engagement of ligands from the TGF-beta superfamily. Here, we sought to characterize ligands linked to activation of Smads in ALS muscle and their role as biomarkers of disease progression. RNA sequencing data of ALS muscle samples were mined for TGF-beta superfamily ligands. Candidate targets were validated by qRT-PCR in a large cohort of human ALS muscle biopsy samples and in the G93A SOD1 mouse. Protein expression was evaluated by Western blot, ELISA and immunohistochemistry. C2C12 muscle cells were used to assess Smad activation and induction. TGF-beta 1, 2 and 3 mRNAs were increased in ALS muscle samples compared to controls and correlated with muscle strength and Smads1, 2, 5 and 8. In the G93A SOD1 mouse, the temporal pattern of TGF-beta expression paralleled the Smads and increased with disease progression. TGF-beta 1 immunoreactivity was detected in mononuclear cells surrounding muscle fibers in ALS samples. In muscle cells, TGF-beta ligands were capable of activating Smads. In conclusion, TGF-beta 1, 2 and 3 are novel biomarkers of ALS in skeletal muscle. Their correlation with weakness in human ALS and their progressive increase with advancing disease in the ALS mouse suggest that they, as with the Smads, can track disease progression. These ligands are capable of upregulating and activating Smads and thus may contribute to the Smad signaling pathway in ALS muscle. C1 [Si, Ying; Kim, Soojin; Zheng, Lei; Oh, Shin J.; Anderson, Tina; AlSharabati, Mohammad; Kazamel, Mohamed; Volpicelli-Daley, Laura; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Si, Ying; Zheng, Lei; King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA. [Cui, Xiangqin; Yu, Shaohua] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Bamman, Marcas M.; King, Peter H.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. RP King, PH (reprint author), Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. EM phking@uabmc.edu OI Cui, Xiangqin/0000-0003-0621-9313 FU United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program Merit Review [BX001148]; National Institute of Neurological Disorders [NS064133, R21NS081743, R21NS085497]; National Center for Medical Rehabilitation Research [R01HD084124] FX Funded by the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program Merit Review BX001148 (http://www.research.va.gov/services/blrd/), National Institute of Neurological Disorders NS064133, R21NS081743, R21NS085497 (http://www.ninds.nih.gov/), and National Center for Medical Rehabilitation Research R01HD084124 (https://www.nichd.nih.gov/about/org/ncmrr/Pages/overview.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 1 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 16 PY 2015 VL 10 IS 9 AR e0138425 DI 10.1371/journal.pone.0138425 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR8NH UT WOS:000361610200106 PM 26375954 ER PT J AU Lee, S Allendorfer, JB Gaston, TE Griffis, JC Hernando, KA Knowlton, RC Szaflarski, JP Hoef, LWV AF Lee, Seongtaek Allendorfer, Jane B. Gaston, Tyler E. Griffis, Joseph C. Hernando, Kathleen A. Knowlton, Robert C. Szaflarski, Jerzy P. Hoef, Lawrence W. Ver TI White matter diffusion abnormalities in patients with psychogenic non-epileptic seizures SO BRAIN RESEARCH LA English DT Article DE Psychogenic non-epileptic seizures (PNES); Diffusion tensor imaging (DTI); Tract-based spatial statistics (TBSS); Uncinate fasciculus (UF); Superior temporal gyrus (STG) ID UNCINATE FASCICULUS; FRACTIONAL ANISOTROPY; ICTAL SPECT; VIDEO-EEG; EPILEPSY; DISCONNECTION; CONNECTIVITY; DISSOCIATION; INTEGRITY; DIAGNOSIS AB The purpose of this study was to conduct a preliminary investigation of the white matter characteristics in patients with psychogenic non-epileptic seizures (PNES). Diffusion Tensor Imaging (DTI) data were collected at 3 T in 16 patients with PNES and 16 age- and sex-matched healthy controls (HC). All patients with PNES had their diagnosis confirmed via video/EEG monitoring; HCs had no comorbid neurological or psychiatric conditions. DTI indices including fractional anisotropy (FA), and mean diffusivity (MD) were calculated and compared between patients with PNES and HCs using Tract-Based Spatial Statistics (TBSS). Significantly higher FA values were observed in patients with PNES in the left corona radiata, left internal and external capsules, left superior temporal gyms, as well as left uncinate fasciculus (UP) (P < 0.05; corrected for multiple comparisons). There was no significant change in other indices between patients with PNES and HCs. These findings suggest that patients with PNES have significantly altered white matter structural connectivity when compared to age- and sex-matched HCs. These abnormalities are present in left hemispheric regions associated with emotion regulation and motor pathways. While the relationship between the pathophysiology of PNES and these abnormalities is not entirely clear, this work provides an initial basis to guide future prospective studies. (C) 2015 Elsevier B.V. All rights reserved. C1 [Lee, Seongtaek; Hoef, Lawrence W. Ver] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. [Allendorfer, Jane B.; Gaston, Tyler E.; Szaflarski, Jerzy P.; Hoef, Lawrence W. Ver] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Griffis, Joseph C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Hernando, Kathleen A.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Knowlton, Robert C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL 35294 USA. RP Hoef, LWV (reprint author), Univ Alabama Birmingham, Dept Biomed Engn, Suite 312,1719 6th Ave South, Birmingham, AL 35294 USA. EM lverhoef@uab.edu OI Lee, Seongtaek/0000-0001-8954-6103 NR 49 TC 10 Z9 10 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD SEP 16 PY 2015 VL 1620 BP 169 EP 176 DI 10.1016/j.brainres.2015.04.050 PG 8 WC Neurosciences SC Neurosciences & Neurology GA CR2LZ UT WOS:000361162800014 PM 25979311 ER PT J AU Goldman, JG Weintraub, D AF Goldman, Jennifer G. Weintraub, Daniel TI Advances in the Treatment of Cognitive Impairment in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Review DE cholinesterase inhibitor; clinical trials; dementia; executive function; mild cognitive impairment ID TRANSCRANIAL MAGNETIC STIMULATION; RANDOMIZED CONTROLLED-TRIAL; DEEP BRAIN-STIMULATION; ALZHEIMERS ASSOCIATION WORKGROUPS; PLACEBO-CONTROLLED TRIAL; LONG-TERM SAFETY; PHASE-III TRIAL; LEWY BODIES; NEUROPSYCHIATRIC SYMPTOMS; DOUBLE-BLIND AB Cognitive impairment in Parkinson's disease (PD) is a frequent complication, with significant interindividual variability in clinical symptoms, severity, timing, and neural substrates. Recent studies have focused not only on understanding PD dementia, but also mild cognitive impairment in PD, which may represent a prodromal stage for dementia. In recent years, there have been important advances regarding clinical characterizations, definitions, associated biomarkers, and risk factors for both mild cognitive impairment in PD and PD dementia. However, there is a paucity of effective therapies for cognitive impairment in PD, whether for mild symptoms or for moderate to severe dementia. At present, only rivastigmine is U.S. Food and Drug Administration approved for PD dementia, an indication received nearly a decade ago. Given the frequency of PD cognitive impairment and its substantial impact on both patients and families, the lack of available and effective treatments represents a striking gap in the field, especially when compared to the large number of available therapies for PD motor symptoms and complications. Improved symptomatic therapies, as well as potential disease-modifying agents, for PD cognitive impairment are needed. Most therapeutic trials for PD dementia and mild cognitive impairment in PD have focused on drugs developed for and tested in Alzheimer's disease, such as cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist, memantine, though recent and ongoing trials examine the effects of pharmacological agents affecting other neurotransmitters, as well as nonpharmacological therapies, including mental and physical exercise and neurostimulation. This review summarizes the design and outcomes of trials for PD cognitive impairment published since 2013 and highlights future therapeutic research opportunities and challenges. (c) 2015 International Parkinson and Movement Disorder Society C1 [Goldman, Jennifer G.] Rush Univ, Med Ctr, Dept Neurol Sci, Sect Parkinson Dis & Movement Disorders, Chicago, IL 60612 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Goldman, JG (reprint author), Rush Univ, Med Ctr, Dept Neurol Sci, 1725 West Harrison St,Suite 755, Chicago, IL 60612 USA. EM Jennifer_Goldman@rush.edu NR 95 TC 12 Z9 14 U1 10 U2 28 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2015 VL 30 IS 11 SI SI BP 1471 EP 1489 DI 10.1002/mds.26352 PG 19 WC Clinical Neurology SC Neurosciences & Neurology GA CW0AX UT WOS:000364652400005 PM 26297863 ER PT J AU Ecker, BL Paulson, EC Datta, J Jeganathan, AN Aarons, C Kelz, RR Mahmoud, NN AF Ecker, Brett L. Paulson, Emily C. Datta, Jashodeep Jeganathan, Arjun N. Aarons, Cary Kelz, Rachel R. Mahmoud, Najjia N. TI Lymph Node Identification Following Neoadjuvant Therapy in Rectal Cancer: A Stage-Stratified Analysis using the Surveillance, Epidemiology, and End Results (SEER)-Medicare Database SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE rectal cancer; lymph node staging; neoadjuvant therapy; survival; SEER ID PREOPERATIVE CHEMORADIOTHERAPY; COLORECTAL-CANCER; GASTRIC-CANCER; IMPACT; RADIOTHERAPY; SURVIVAL; RADIOCHEMOTHERAPY; CHEMOTHERAPY; GUIDELINES; RADIATION AB Background and Objectives: Neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma reduces lymph node (LN) identification following surgical resection. We sought to evaluate the relationship between LN identification following nCRT and disease-specific survival (DSS), stratified by pathologic stage. Methods: The SEER-Medicare database (2000-2009) was queried for 1,216 pathologic stage I-III rectal cancer patients who underwent nCRT followed by curative-intent resection. Cox regressions evaluated the association between pathologic stage and DSS for LN cut-points from >= 2 up to >= 12 LNs. Results: Extent of LN identification did not influence DSS in ypStage I or ypStage III disease; in particular, the 12 LN cut-point was not associated with DSS for ypStage I (HR 1.29, P = 0.51) or ypStage III (HR 1.08, P = 0.42) patients. In ypStage II patients, actuarial survival improved continually with increasing lymph node identification up to >= 12 LNs. The 5 LN cut-point was associated with the greatest reduction of risk of cancer death (HR 0.56, P = 0.006), with decreasing magnitudes of survival benefit associated with nodal counts beyond 5 LN. The 12 LN cut-point was not associated with DSS in ypStage II patients (HR 0.67, P = 0.07). Conclusion: The association between DSS and LN identification is a dynamic outcome that varies by pathologic stage, with unique prognostic significance for ypStage II patients. (c) 2015 Wiley Periodicals, Inc. C1 [Ecker, Brett L.; Paulson, Emily C.; Datta, Jashodeep; Jeganathan, Arjun N.; Aarons, Cary; Kelz, Rachel R.; Mahmoud, Najjia N.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. [Paulson, Emily C.] Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA USA. RP Mahmoud, NN (reprint author), Hosp Univ Penn, 3400 Spruce St,4 Silverstein, Philadelphia, PA 19104 USA. EM Najjia.Mahmoud@uphs.upenn.edu NR 24 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD SEP 15 PY 2015 VL 112 IS 4 BP 415 EP 420 DI 10.1002/jso.23991 PG 6 WC Oncology; Surgery SC Oncology; Surgery GA CT2VN UT WOS:000362662900014 PM 26250884 ER PT J AU Ye, SQ Cheng, B Lip, GYH Buchsbaum, R Sacco, RL Levin, B Di Tullio, MR Qian, M Mann, DL Pullicino, PM Freudenberger, RS Teerlink, JR Mohr, JP Graham, S Labovitz, AJ Estol, CJ Lok, DJ Ponikowski, P Anker, SD Thompson, JLP Homma, S AF Ye, Siqin Cheng, Bin Lip, Gregory Y. H. Buchsbaum, Richard Sacco, Ralph L. Levin, Bruce Di Tullio, Marco R. Qian, Mm Mann, Douglas L. Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Mohr, J. P. Graham, Susan Labovitz, Arthur J. Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. Thompson, John L. P. Homma, Shunichi CA WARCEF Investigators TI Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ATRIAL-FIBRILLATION; ANTICOAGULATED PATIENTS; SUBGROUP ANALYSIS; SCORES; TRIAL; RECLASSIFICATION; CHA(2)DS(2)-VASC; PERFORMANCE; HEMORRHAGE; CHADS(2) AB We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. Proportional hazards models were used to test whether each score predicted major bleeding, and comparison of different risk scores was performed using Harell C-statistic and net reclassification improvement index. For the warfarin arm, both scores predicted bleeding risk, with OBRI having significantly greater C-statistic (0.72 vs 0.61; p = 0.03) compared to HAS-BLED, although the net reclassification improvement for comparing OBRI to HAS-BLED was not significant (0.32, 95% confidence interval [CI] -0.18 to 0.37). Performance of the OBRI and HAS-BLED risk scores was similar for (the aspirin arm. For participants with OBRI scores of 0 to 1, warfarin compared with aspirin reduced ischemic stroke (hazard ratio [HR] 0.51, 95% CI 0.26 to 0.98, p = 0.042) without significantly increasing major bleeding (HR 1.24, 95% CI 0.66 to 2.30, p = 0.51). For those with OBRI score of there was a trend for reduced ischemic stroke with warfarin compared to aspirin (HR 0.56, 95% CI 0.27 to 1.15, p = 0.12),"but major bleeding was increased (HR 4.04, 95% CI 1.99 to 8.22, p <0.001). In conclusion, existing bleeding risk, scores can identify bleeding risk in patients with HFrEF in SR and could be tested for potentially identifying patients with a favorable risk/benefit profile for antithrombotic therapy with warfarin. (C) 2015 Elsevier Inc. All rights reserved. C1 [Ye, Siqin; Di Tullio, Marco R.; Homma, Shunichi] Columbia Univ, Dept Med, Med Ctr, Div Cardiol, New York, NY 10027 USA. [Mohr, J. P.] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA. [Cheng, Bin; Buchsbaum, Richard; Levin, Bruce; Qian, Mm; Thompson, John L. P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA. [Mann, Douglas L.] Washington Univ, Dept Med, St Louis, MO USA. [Pullicino, Patrick M.] Univ Kent, Kent Inst Med & Hlth Sci, Canterbury, Kent, England. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Dept Med, Div Cardiol, Allentown, PA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA. [Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. [Lok, Dirk J.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands. [Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] Univ Med Ctr Gottingen, Dept Innovat Clin Trials, Gottingen, Germany. RP Ye, SQ (reprint author), Columbia Univ, Dept Med, Med Ctr, Div Cardiol, New York, NY 10027 USA. EM sy2357@cumc.columbia.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Ye, Siqin/0000-0002-5229-9775 FU National Institute of Neurological Diseases and Stroke [U01-NS-043975, U01-NS-039143] FX The WARCEF trial was supported by Grant U01-NS-043975 (SH) and U01-NS-039143 (JLPT) from the National Institute of Neurological Diseases and Stroke. Warfarin and warfarin placebo were provided by Taro Pharmaceuticals USA, and aspirin and aspirin placebo by Bayer HealthCare. NR 23 TC 4 Z9 4 U1 1 U2 13 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 15 PY 2015 VL 116 IS 6 BP 904 EP 912 DI 10.1016/j.amjcard.2015.06.016 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR8ZU UT WOS:000361643800013 PM 26189039 ER PT J AU Pierre, JF Neuman, JC Brill, AL Brar, HK Thompson, MF Cadena, MT Connors, KM Busch, RA Heneghan, AF Cham, CM Jones, EK Kibbe, CR Davis, DB Groblewski, GE Kudsk, KA Kimple, ME AF Pierre, Joseph F. Neuman, Joshua C. Brill, Allison L. Brar, Harpreet K. Thompson, Mary F. Cadena, Mark T. Connors, Kelsey M. Busch, Rebecca A. Heneghan, Aaron F. Cham, Candace M. Jones, Elaina K. Kibbe, Carly R. Davis, Dawn B. Groblewski, Guy E. Kudsk, Kenneth A. Kimple, Michelle E. TI The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE bombesin; gut hormones; pancreas; parenteral nutrition; adjuvant therapy ID DIGESTIVE ENZYME EXPRESSION; PROTEIN-COUPLED RECEPTORS; GLUCAGON-LIKE PEPTIDE-1; GLUCOSE-INTOLERANCE; INSULIN-SECRETION; LYMPHOID-TISSUE; ACINAR-CELLS; RAT PANCREAS; AMINO-ACIDS; BETA-CELLS AB Stimulation of digestive organs by enteric peptides is lost during total parental nutrition (PN). Here we examine the role of the enteric peptide bombesin (BBS) in stimulation of the exocrine and endocrine pancreas during PN. BBS protects against exocrine pancreas atrophy and dysfunction caused by PN. BBS also augments circulating insulin levels, suggesting an endocrine pancreas phenotype. While no significant changes in gross endocrine pancreas morphology were observed, pancreatic islets isolated from BBS-treated PN mice showed a significantly enhanced insulin secretion response to the glucagon-like peptide-1 (GLP-1) agonist exendin-4, correlating with enhanced GLP-1 receptor expression. BBS itself had no effect on islet function, as reflected in low expression of BBS receptors in islet samples. Intestinal BBS receptor expression was enhanced in PN with BBS, and circulating active GLP-1 levels were significantly enhanced in BBS-treated PN mice. We hypothesized that BBS preserved islet function indirectly, through the enteroendocrine cell-pancreas axis. We confirmed the ability of BBS to directly stimulate intestinal enteroid cells to express the GLP-1 precursor preproglucagon. In conclusion, BBS preserves the exocrine and endocrine pancreas functions during PN; however, the endocrine stimulation is likely indirect, through the enteroendocrine cell-pancreas axis. C1 [Davis, Dawn B.; Kudsk, Kenneth A.; Kimple, Michelle E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Pierre, Joseph F.; Busch, Rebecca A.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Brill, Allison L.; Brar, Harpreet K.; Thompson, Mary F.; Cadena, Mark T.; Connors, Kelsey M.; Kibbe, Carly R.; Davis, Dawn B.; Kimple, Michelle E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Endocrinol, Madison, WI USA. [Neuman, Joshua C.; Jones, Elaina K.; Davis, Dawn B.; Groblewski, Guy E.; Kimple, Michelle E.] Univ Wisconsin, Coll Agr & Life Sci, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53706 USA. [Pierre, Joseph F.; Cham, Candace M.] Univ Chicago, Dept Med, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA. RP Kimple, ME (reprint author), 4148 UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM mkimple@medicine.wisc.edu OI Brill, Allison/0000-0002-5046-3578 FU Biomedical Laboratory Research and Development Service of the VA Office of Research and Development Award [I01BX001672]; American Diabetes Association [1-14-BS-115]; National Institutes of Health (NIH) [DK-102598, DK-070888]; Wisconsin Partnership Program Grant; US Department of Agriculture/HATCH [WIS01583]; University of Chicago Training Grant in Digestive Diseases and Nutrition (NIH) [T32 DK-007074]; University of Wisconsin Institute on Aging (NIH) [T32 AG-000213]; University of Wisconsin Surgical Oncology Research Training Program (NIH) [T32 CA-090217] FX This research is supported by Biomedical Laboratory Research and Development Service of the VA Office of Research and Development Award I01BX001672 (to K. A. Kudsk) and also by American Diabetes Association Grant 1-14-BS-115 (to M. E. Kimple), National Institutes of Health (NIH) Grant DK-102598 (to M. E. Kudsk), a Wisconsin Partnership Program Grant (to D. B. Davis), NIH Grant DK-070888 (to G. E. Groblewski), and US Department of Agriculture/HATCH Grant WIS01583 (to G. E. Groblewski). J. F. Pierre is supported in part by a University of Chicago Training Grant in Digestive Diseases and Nutrition (NIH Grant T32 DK-007074). J. C. Neuman and C. R. Kibbe are supported in part by a training grant from the University of Wisconsin Institute on Aging (NIH Grant T32 AG-000213). R. A. Busch is supported in part by a training grant from the University of Wisconsin Surgical Oncology Research Training Program (NIH Grant T32 CA-090217). NR 63 TC 1 Z9 1 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP 15 PY 2015 VL 309 IS 6 BP G431 EP G442 DI 10.1152/ajpgi.00072.2015 PG 12 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA CS1IO UT WOS:000361817700004 PM 26185331 ER PT J AU Hwang, VJ Kim, J Rand, A Yang, CZ Sturdivant, S Hammock, B Bell, PD Guay-Woodford, LM Weiss, RH AF Hwang, Vicki J. Kim, Jeffrey Rand, Amy Yang, Chaozhe Sturdivant, Steve Hammock, Bruce Bell, P. Darwin Guay-Woodford, Lisa M. Weiss, Robert H. TI The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ARPKD; glutamine; metabolomics; oncometabolite; reprogramming ID POLYCYSTIC KIDNEY-DISEASE; REDUCTIVE CARBOXYLATION; ALPHA-KETOGLUTARATE; IDH2 MUTATIONS; CANCER; CELLS; METABOLISM; D-2-HYDROXYGLUTARATE; HYPOXIA; GROWTH AB Since polycystic kidney disease (PKD) was first noted over 30 years ago to have neoplastic parallels, there has been a resurgent interest in elucidating neoplasia-relevant pathways in PKD. Taking a nontargeted metabolomics approach in the B6(Cg)-Cys1(cpk/)J (cpk) mouse model of recessive PKD, we have now characterized metabolic reprogramming in these tissues, leading to a glutamine-dependent TCA cycle shunt toward total 2-hydroxyglutarate (2-HG) production in cpk compared with B6 wild-type kidney tissue. After confirmation of increased 2-HG expression in immortalized collecting duct cpk cells as well as in human autosomal recessive PKD tissue using targeted analysis, we show that the increase in 2-HG is likely due to glutamine-sourced alpha-ketoglutarate. In addition, cpk cells require exogenous glutamine for growth such that inhibition of glutaminase-1 decreases cell viability as well as proliferation. This study is a demonstration of the striking parallels between recessive PKD and cancer metabolism. Our data, once confirmed in other PKD models, suggest that future therapeutic approaches targeting this pathway, such as using glutaminase inhibitors, have the potential to open novel treatment options for renal cystic disease. C1 [Hwang, Vicki J.; Weiss, Robert H.] Univ Calif Davis, Grad Grp Integrat Genet & Genom, Davis, CA 95616 USA. [Hwang, Vicki J.; Kim, Jeffrey; Weiss, Robert H.] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA. [Rand, Amy; Hammock, Bruce] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Hammock, Bruce; Weiss, Robert H.] Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA. [Yang, Chaozhe; Guay-Woodford, Lisa M.] Childrens Natl Hlth Syst, Ctr Translat Sci, Washington, DC USA. [Sturdivant, Steve] Metabolon, Durham, NC USA. [Bell, P. Darwin] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Bell, P. Darwin] Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Weiss, Robert H.] Sacramento Vet Affairs Med Ctr, Med Serv, Sacramento, CA USA. RP Weiss, RH (reprint author), Univ Calif Davis, Dept Internal Med, Div Nephrol, Genome & Biomed Sci Bldg,Rm 6312,451 Hlth Sci Dr, Davis, CA 95616 USA. EM rhweiss@ucdavis.edu FU National Institutes of Health (NIH) [1R01CA135401-01A1, 1R03CA181837-01, 1R01DK082690-01A1]; Medical Service of the US Department of Veterans Affairs, and Dialysis Clinics; NIEHS [R01 ES002710, P42 ES004699]; UAB Hepato-Renal Fibrocystic Diseases Core Center [P30 DK074038] FX This work was supported by National Institutes of Health (NIH) Grants 1R01CA135401-01A1, 1R03CA181837-01, and 1R01DK082690-01A1, the Medical Service of the US Department of Veterans Affairs, and Dialysis Clinics (all to R. H. Weiss). Partial support was provided by NIEHS R01 ES002710 and NIEHS Superfund Program P42 ES004699 (to. B. D. Hammock), and the UAB Hepato-Renal Fibrocystic Diseases Core Center, P30 DK074038 (to L. Guay-Woodford and P. D. Bell). A. Rand is a fellow of NIH/NIEHS T32 CA108459. NR 34 TC 3 Z9 3 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD SEP 15 PY 2015 VL 309 IS 6 BP F492 EP F498 DI 10.1152/ajprenal.00238.2015 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CS1KD UT WOS:000361822100003 PM 26155843 ER PT J AU Anzueto, A Wise, R Calverley, P Dusser, D Tang, WB Metzdorf, N Dahl, R AF Anzueto, Antonio Wise, Robert Calverley, Peter Dusser, Daniel Tang, Wenbo Metzdorf, Norbert Dahl, Ronald TI The Tiotropium Safety and Performance in Respimat (R) (TIOSPIR (R)) Trial: Spirometry Outcomes SO RESPIRATORY RESEARCH LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION; COPD AB Background: Tiotropium Safety and Performance in Respimat (R) (TIOSPIR (R)) compared the safety and efficacy of tiotropium Respimat (R) and tiotropium HandiHaler (R) in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR (R) was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24 weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat (R) 5 mu g (n = 461), 2.5 mu g (n = 464), or tiotropium HandiHaler (R) 18 mu g (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295 L in the Respimat (R) 5 mu g, 2.5 mu g, and HandiHaler (R) 18 mu g groups (difference versus HandiHaler (R) [95 % CI]: -10 [-38, 18] mL for Respimat (R) 5 mu g and, -37 [-65, -9] mL for Respimat (R) 2.5 mu g); achieving noninferiority to tiotropium HandiHaler (R) 18 mu g for tiotropium Respimat (R) 5 but not for 2.5 mu g (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593 L in the Respimat (R) 5 mu g, 2.5 mu g, and HandiHaler (R) 18 mu g groups. The rates of FEV1 decline over 24 to 120 weeks were similar for the three treatment arms (26, 40, and 34 mL/year for the tiotropium Respimat (R) 5-mu g, 2.5-mu g, and HandiHaler (R) 18-mu g groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23 mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR (R) spirometry substudy showed that tiotropium Respimat (R) 5 mu g was noninferior to tiotropium HandiHaler (R) 18 mu g for trough FEV1, but Respimat (R) 2.5 mu g was not. Tiotropium Respimat (R) 5 mu g provides similar bronchodilator efficacy to tiotropium HandiHaler (R) 18 mu g with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Pulm Crit Care, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Wise, Robert] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Calverley, Peter] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England. [Dusser, Daniel] Hop Cochin, Serv Pneumol, F-75674 Paris, France. [Tang, Wenbo] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Metzdorf, Norbert] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Dahl, Ronald] Odense Univ Hosp, DK-5000 Odense, Denmark. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Pulm Crit Care, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu FU Boehringer Ingelheim FX This study was funded by Boehringer Ingelheim. Writing assistance was provided by Sarah J. Petit of PAREXEL, funded by Boehringer Ingelheim. Data have been reported in part in the primary data publication [7] and at the CHEST/ACCP congress 2013 [21]. NR 19 TC 4 Z9 5 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD SEP 15 PY 2015 VL 16 AR 107 DI 10.1186/s12931-015-0269-4 PG 9 WC Respiratory System SC Respiratory System GA CR5EH UT WOS:000361362500001 PM 26369563 ER PT J AU Moin, T Duru, OK Mangione, CM AF Moin, Tannaz Duru, O. Kenrik Mangione, Carol M. TI Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012 RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID DIABETES PREVENTION PROGRAM C1 [Moin, Tannaz] Vet Affairs Greater Los Angeles Hlth Syst, Vet Affairs Hlth Serv Res & Dev Serv, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. [Moin, Tannaz; Duru, O. Kenrik; Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Moin, T (reprint author), Vet Affairs Greater Los Angeles Hlth Syst, Vet Affairs Hlth Serv Res & Dev Serv, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 15 PY 2015 VL 163 IS 6 BP 483 EP 483 DI 10.7326/L15-5136-2 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CR5FL UT WOS:000361365900031 PM 26370017 ER PT J AU Cox, A Varma, A Barry, J Vertegel, A Banik, N AF Cox, April Varma, Abhay Barry, John Vertegel, Alexey Banik, Naren TI Nanoparticle Estrogen in Rat Spinal Cord Injury Elicits Rapid Anti-Inflammatory Effects in Plasma, Cerebrospinal Fluid, and Tissue SO JOURNAL OF NEUROTRAUMA LA English DT Article DE spinal cord injury; MCP-1; IL-6; GRO-KC; S100 beta; nanoparticle; estrogen; CSF ID TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; APOPTOTIC CELL-DEATH; INFLAMMATORY CYTOKINES; CLINICAL-TRIALS; POSTMENOPAUSAL WOMEN; FUNCTIONAL RECOVERY; LOCOMOTOR FUNCTION; RECEPTOR-ALPHA; SEX STEROIDS AB Persons with spinal cord injury (SCI) are in need of effective therapeutics. Estrogen (E2), as a steroid hormone, is a highly pleiotropic agent; with anti-inflammatory, anti-apoptotic, and neurotrophic properties, it is ideal for use in treatment of patients with SCI. Safety concerns around the use of high doses of E2 have limited clinical application, however. To address these concerns, low doses of E2 (25 mu g and 2.5 mu g) were focally delivered to the injured spinal cord using nanoparticles. A per-acute model (6 h after injury) was used to assess nanoparticle release of E2 into damaged spinal cord tissue; in addition, E2 was evaluated as a rapid anti-inflammatory. To assess inflammation, 27-plex cytokine/chemokine arrays were conducted in plasma, cerebrospinal fluid (CSF), and spinal cord tissue. A particular focus was placed on IL-6, GRO-KC, and MCP-1 as these have been identified from CSF in human studies as potential biomarkers in SCI. S100 beta, an additional proposed biomarker, was also assessed in spinal cord tissue only. Tissue concentrations of E2 were double those found in the plasma, indicating focal release. E2 showed rapid anti-inflammatory effects, significantly reducing interleukin (IL)-6, GRO-KC, MCP-1, and S100 beta in one or all compartments. Numerous additional targets of rapid E2 modulation were identified including: leptin, MIP-1 alpha, IL-4, IL-2, IL-10, IFN gamma, tumor necrosis factor-alpha, etc. These data further elucidate the rapid anti-inflammatory effects E2 exerts in an acute rat SCI model, have identified additional targets of estrogen efficacy, and suggest nanoparticle delivered estrogen may provide a safe and efficacious treatment option in persons with acute SCI. C1 [Cox, April; Varma, Abhay; Banik, Naren] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA. [Barry, John; Vertegel, Alexey] Clemson Univ, Dept Bioengn, Clemson, SC USA. [Banik, Naren] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Cox, A (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,MSC 606, Charleston, SC 29412 USA. EM coxaa@musc.edu FU NIH [NINDS-RO1 NS-31622, NS-45967]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC [1IOBX001262]; South Carolina Spinal Cord Injury Research Fund; National Institutes of Health from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455] FX The funding for this project was provided in part by NIH, NINDS-RO1 NS-31622 and NS-45967; also by 1IOBX001262 from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC, and South Carolina Spinal Cord Injury Research Fund. This work was conducted in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We would like to acknowledge Dr. Supriti Samantaray and Nakul Thakore for help in organizing this article. NR 67 TC 5 Z9 5 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD SEP 15 PY 2015 VL 32 IS 18 BP 1413 EP 1421 DI 10.1089/neu.2014.3730 PG 9 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CQ8AR UT WOS:000360828900004 PM 25845398 ER PT J AU Bell, SP Orr, NM Dodson, JA Rich, MW Wenger, NK Blum, K Harold, JG Tinetti, ME Maurer, MS Forman, DE AF Bell, Susan P. Orr, Nicole M. Dodson, John A. Rich, Michael W. Wenger, Nanette K. Blum, Kay Harold, John Gordon Tinetti, Mary E. Maurer, Mathew S. Forman, Daniel E. TI What to Expect From the Evolving Field of Geriatric Cardiology SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE aging; cardiovascular disease; geriatrics; quality; training ID AMERICAN-HEART-ASSOCIATION; OLDER-ADULTS; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; COGNITIVE IMPAIRMENT; HEALTH-BENEFITS; GAIT SPEED; MINI-COG; CARE; FAILURE AB The population of older adults is expanding rapidly, and aging predisposes to cardiovascular disease. The principle of patient-centered care must respond to the preponderance of cardiac disease that now occurs in combination with the complexities of old age. Geriatric cardiology melds cardiovascular perspectives with multimorbidity, polypharmacy, frailty, cognitive decline, and other clinical, social, financial, and psychological dimensions of aging. Although some assume that a cardiologist may instinctively cultivate some of these skills over the course of a career, we assert that the volume and complexity of older cardiovascular patients in contemporary practice warrants a more direct approach to achieve suitable training and a more reliable process of care. We present a rationale and vision for geriatric cardiology as a melding of primary cardiovascular and geriatrics skills, thereby infusing cardiology practice with expanded proficiencies in diagnosis, risks, care coordination, communications, end-of-life, and other competences required to best manage older cardiovascular patients. (C) 2015 by the American College of Cardiology Foundation. C1 [Bell, Susan P.] Vanderbilt Univ, Sch Med, Dept Med, Div Cardiovasc Med, Nashville, TN 37212 USA. [Bell, Susan P.] Vanderbilt Univ, Sch Med, Div Geriatr Med, Ctr Qual Aging, Nashville, TN 37212 USA. [Orr, Nicole M.] Tufts Med Ctr, Div Cardiol, Boston, MA USA. [Orr, Nicole M.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA. [Dodson, John A.] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol, New York, NY USA. [Rich, Michael W.] Washington Univ, Sch Med, Div Cardiol, St Louis, MO USA. [Wenger, Nanette K.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. [Blum, Kay] Amer Coll Cardiol, Geriatr Cardiol Sect, Washington, DC USA. [Harold, John Gordon] Univ Calif Los Angeles, Cedars Sinai Heart Inst, Los Angeles, CA USA. [Harold, John Gordon] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Tinetti, Mary E.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Tinetti, Mary E.] Yale Univ, Sch Med, Dept Publ Hlth & Epidemiol, New Haven, CT USA. [Maurer, Mathew S.] Columbia Univ, Dept Med, Med Ctr, Div Cardiol, New York, NY USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Dept Med, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu FU National Institute of Child Health and Human Development [2K12HD043483-11]; Eisenstein's Women's Heart Fund; National Institute on Aging (NIA) grant [U13 AG047008]; John A. Hartford Foundation; NIA [AG045148, AG036778, P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R] FX Dr. Bell is supported by a grant from the National Institute of Child Health and Human Development (2K12HD043483-11) and the Eisenstein's Women's Heart Fund. Dr. Rich is supported by National Institute on Aging (NIA) grant U13 AG047008. Dr. Tinetti receives funding from the John A. Hartford Foundation for work related to developing a patient goals-directed approach to the care of older adults with multiple chronic conditions; and is supported by an NIA R21 grant (AG045148). Dr. Maurer receives funding from an NIA K24 award (AG036778). Dr. Forman is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 47 TC 14 Z9 15 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 15 PY 2015 VL 66 IS 11 BP 1286 EP 1299 DI 10.1016/j.jacc.2015.07.048 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CQ7XV UT WOS:000360820800012 PM 26361161 ER PT J AU Oleson, BJ McGraw, JA Broniowska, KA Annamalai, M Chen, J Bushkofsky, JR Davis, DB Corbett, JA Mathews, CE AF Oleson, Bryndon J. McGraw, Jennifer A. Broniowska, Katarzyna A. Annamalai, Mani Chen, Jing Bushkofsky, Justin R. Davis, Dawn B. Corbett, John A. Mathews, Clayton E. TI Distinct differences in the responses of the human pancreatic beta-cell line EndoC-beta H1 and human islets to proinflammatory cytokines SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE insulinoma; islet; diabetes; nitric oxide; cytokine ID NITRIC-OXIDE SYNTHASE; INSULIN-SECRETING CELLS; CONFERS RESISTANCE; INDUCED INHIBITION; S-NITROSATION; DNA-DAMAGE; RAT ISLETS; ER STRESS; APOPTOSIS; LANGERHANS AB While insulinoma cells have been developed and proven to be extremely useful in studies focused on mechanisms controlling beta-cell function and viability, translating findings to human beta-cells has proven difficult because of the limited access to human islets and the absence of suitable insulinoma cell lines of human origin. Recently, a human beta-cell line, EndoC-beta H1, has been derived from human fetal pancreatic buds. The purpose of this study was to determine whether human EndoC-beta H1 cells respond to cytokines in a fashion comparable to human islets. Unlike most rodent-derived insulinoma cell lines that respond to cytokines in a manner consistent with rodent islets, EndoC-beta H1 cells fail to respond to a combination of cytokines (IL-1, IFN-gamma, and TNF) in a manner consistent with human islets. Nitric oxide, produced following inducible nitric oxide synthase (iNOS) expression, is a major mediator of cytokine-induced human islet cell damage. We show that EndoC-beta H1 cells fail to express iNOS or produce nitric oxide in response to this combination of cytokines. Inhibitors of iNOS prevent cytokine-induced loss of human islet cell viability; however, they do not prevent cytokine-induced EndoC-beta H1 cell death. Stressed human islets or human islets expressing heat shock protein 70 (HSP70) are resistant to cytokines, and, much like stressed human islets, EndoC-beta H1 cells express HSP70 under basal conditions. Elevated basal expression of HSP70 in EndoC-beta H1 cells is consistent with the lack of iNOS expression in response to cytokine treatment. While expressing HSP70, EndoC-beta H1 cells fail to respond to endoplasmic reticulum stress activators, such as thapsigargin. These findings indicate that EndoC-beta H1 cells do not faithfully recapitulate the response of human islets to cytokines. Therefore, caution should be exercised when making conclusions regarding the actions of cytokines on human islets when using this human-derived insulinoma cell line. C1 [Oleson, Bryndon J.; McGraw, Jennifer A.; Broniowska, Katarzyna A.; Corbett, John A.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA. [Annamalai, Mani; Chen, Jing; Mathews, Clayton E.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Bushkofsky, Justin R.; Davis, Dawn B.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI USA. [Davis, Dawn B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Corbett, JA (reprint author), Med Coll Wisconsin, Dept Biochem, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA. EM jcorbett@mcw.edu OI Broniowska, Katarzyna/0000-0002-8000-9093 FU National Institutes of Health [DK-083442, DK-074656, UC4 DK-104194, UC4 DK-104167, P01 AI-042288, DK-052194, AI-44458]; United States Department of Veterans Affairs [1101BX001880]; American Diabetes Association (ADA) [1-11-BS-104]; American Health Association [13POST16940076, 14PRE20380585]; University of Wisconsin; Integrated Islet Distribution Program FX This work was supported by grants from the National Institutes of Health (DK-083442 to D. B. Davis; DK-074656, UC4 DK-104194, UC4 DK-104167, and P01 AI-042288 to C. E. Matthews; and DK-052194 and AI-44458 to J. A. Corbett), United States Department of Veterans Affairs (1101BX001880 to D. B. Davis), American Diabetes Association (ADA 1-11-BS-104 to C. E. Mathews), American Health Association 13POST16940076 (to K. A. Broniowska) and 14PRE20380585 (B. J. Oleson), and by support from the University of Wisconsin. Human pancreatic islets were provided by the National Institute of Diabetes and Digestive and Kidney Diseases funded Integrated Islet Distribution Program. This work was performed, in part, using facilities and resources from the William S. Middleton Memorial Veterans Hospital. NR 65 TC 6 Z9 6 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP 15 PY 2015 VL 309 IS 5 BP R525 EP R534 DI 10.1152/ajpregu.00544.2014 PG 10 WC Physiology SC Physiology GA CQ4BE UT WOS:000360548300010 PM 26084699 ER PT J AU Shelton, MA Newman, JT Gu, H Sampson, AR Fish, KN MacDonald, ML Moyer, CE DiBitetto, JV Dorph-Petersen, KA Penzes, P Lewis, DA Sweet, RA AF Shelton, Micah A. Newman, Jason T. Gu, Hong Sampson, Allan R. Fish, Kenneth N. MacDonald, Matthew L. Moyer, Caitlin E. DiBitetto, James V. Dorph-Petersen, Karl-Anton Penzes, Peter Lewis, David A. Sweet, Robert A. TI Loss of Microtubule-Associated Protein 2 Immunoreactivity Linked to Dendritic Spine Loss in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Schizophrenia; Microtubule-Associated Protein 2; Dendritic spines; Auditory cortex; Postmortem human tissue; Confocal microscopy ID PRIMARY AUDITORY-CORTEX; MISMATCH NEGATIVITY GENERATION; SUPERIOR TEMPORAL GYRUS; PREFRONTAL CORTEX; PYRAMIDAL NEURONS; HIPPOCAMPAL-FORMATION; PLANUM TEMPORALE; MOOD DISORDERS; HESCHL GYRUS; MAP2 AB BACKGROUND: Microtubule-associated protein 2 (MAP2) is a neuronal protein that plays a role in maintaining dendritic structure through its interaction with microtubules. In schizophrenia (Sz), numerous studies have revealed that the typically robust immunoreactivity (IR) of MAP2 is significantly reduced across several cortical regions. The relationship between MAP2-IR reduction and lower dendritic spine density, which is frequently reported in Sz, has not been explored in previous studies, and MAP2-IR loss has not been investigated in the primary auditory cortex (Brodmann area 41), a site of conserved pathology in Sz. METHODS: Using quantitative spinning disk confocal microscopy in two cohorts of subjects with Sz and matched control subjects (Sz subjects, n = 20; control subjects, n = 20), we measured MAP2-IR and dendritic spine density and spine number in deep layer 3 of BA41. RESULTS: Subjects with Sz exhibited a significant reduction in MAP2-IR. The reductions in MAP2-IR were not associated with neuron loss, loss of MAP2 protein, clinical confounders, or technical factors. Dendritic spine density and number also were reduced in Sz and correlated with MAP2-IR. In 12 (60%) subjects with Sz, MAP2-IR values were lower than the lowest values in control subjects; only in this group were spine density and number significantly reduced. CONCLUSIONS: These findings demonstrate that MAP2-IR loss is closely linked to dendritic spine pathology in Sz. Because MAP2 shares substantial sequence, regulatory, and functional homology with MAP tau, the wealth of knowledge regarding tau biology and the rapidly expanding field of tau therapeutics provide resources for identifying how MAP2 is altered in Sz and possible leads to novel therapeutics. Keywords: Schizophrenia, Microtubule-Associated Protein 2, Dendritic spines, Auditory cortex, Postmortem human tissue, Confocal microscopy C1 [Shelton, Micah A.; Newman, Jason T.; Fish, Kenneth N.; MacDonald, Matthew L.; Moyer, Caitlin E.; DiBitetto, James V.; Dorph-Petersen, Karl-Anton; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Translat Neurosci Program, Pittsburgh, PA USA. [Shelton, Micah A.; Newman, Jason T.; Fish, Kenneth N.; MacDonald, Matthew L.; Moyer, Caitlin E.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Gu, Hong; Sampson, Allan R.] Univ Pittsburgh, Sch Med, Dept Stat, Pittsburgh, PA USA. [Dorph-Petersen, Karl-Anton] Aarhus Univ, Dept Clin Med, Translat Neuropsychiat Unit, Aarhus, Denmark. [Dorph-Petersen, Karl-Anton] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Aarhus, Denmark. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Room W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Dorph-Petersen, Karl-Anton/A-9039-2015; Penzes, Peter/L-3987-2016 OI Dorph-Petersen, Karl-Anton/0000-0002-6676-034X; Penzes, Peter/0000-0001-5449-1640; Lewis, David/0000-0002-3225-6778 FU National Institutes of Health [DC011499-03, MH16804, MH096985, MH071316, MH097216, MH071533]; University of Pittsburgh Cancer Institute Cancer Biomarker Facility [P30CA047904]; Biomedical Mass Spectrometry Center; Bristol-Myers Squibb; Pfizer FX This work was supported by National Institutes of Health Grant Nos. DC011499-03 (MAS), MH16804 (MLM), MH096985 (KNF), MH071316 and MH097216 (PP), and MH071533 (RAS). The Biomedical Mass Spectrometry Center and University of Pittsburgh Cancer Institute Cancer Biomarker Facility are supported in part by award P30CA047904.; ARS is a statistical consultant to Janssen Pharmaceutical Research and Development LLC. DAL currently receives investigator-initiated research support from Bristol-Myers Squibb and Pfizer and in 2012-2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals, and Sunovion. MAS, JTN, HG, KNF, MLM, CEM, JVD, K-AD-P, PP, and RAS report no biomedical financial interests or potential conflicts of interest. NR 68 TC 13 Z9 14 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 15 PY 2015 VL 78 IS 6 BP 374 EP 385 DI 10.1016/j.biopsych.2014.12.029 PG 12 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CP5SR UT WOS:000359945000005 PM 25818630 ER PT J AU Hammerstad, SS Grock, SF Lee, HJ Hasham, A Sundaram, N Tomer, Y AF Hammerstad, Sara Salehi Grock, Shira Frankel Lee, Hanna J. Hasham, Alia Sundaram, Nina Tomer, Yaron TI Diabetes and hepatitis C: a two-way association SO FRONTIERS IN ENDOCRINOLOGY LA English DT Review DE type 1 diabetes; type 2 diabetes; hepatitis C virus; hepatitis C; insulin resistance; interferon alpha; hepatocellular carcinoma; outcomes; treatment ID NECROSIS-FACTOR-ALPHA; BETA-CELL FUNCTION; SUSTAINED VIROLOGICAL RESPONSE; INSULIN-RECEPTOR SUBSTRATE-1; CHRONIC LIVER-DISEASE; VIRUS CORE PROTEIN; ENDOPLASMIC-RETICULUM STRESS; GENOTYPE-SPECIFIC MECHANISMS; CHRONIC VIRAL-HEPATITIS; REGULATORY T-CELLS AB Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are associated with increased morbidity and mortality. Most studies, but not all, have shown that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) compared to healthy controls, as well as when compared to patients with other liver diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that patients with T2D may also be at higher risk for worse outcomes of their hepatitis C infection, including reduced rate of sustained virological response, progression to fibrosis and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, hepatitis C infection and mainly its treatment, interferon a, can trigger the development of type 1 diabetes. In this review, we discuss the existing data on this two-way association between diabetes and hepatitis C infection with emphasis on possible mechanisms. It remains to be determined whether the new curative therapies for chronic hepatitis C will improve outcomes in diabetic hepatitis C patients, and conversely whether treatment with Metformin will reduce complications from hepatitis C virus infection. We propose an algorithm for diabetes screening and follow-up in hepatitis C patients. C1 [Hammerstad, Sara Salehi; Grock, Shira Frankel; Lee, Hanna J.; Hasham, Alia; Sundaram, Nina; Tomer, Yaron] Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. [Hammerstad, Sara Salehi] Oslo Univ Hosp Ulleval, Dept Pediat, Oslo, Norway. [Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA. RP Tomer, Y (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM yaron.tomer@mssm.edu FU NIDDK [DK061659, DK067555, DK073681]; Helse Sor-Ost FX Supported by DK061659, DK067555, and DK073681 from NIDDK and Helse Sor-Ost. We wish to thank Dr. Emily Gallagher for helpful discussions. NR 217 TC 5 Z9 5 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PD SEP 14 PY 2015 VL 6 AR 134 DI 10.3389/fendo.2015.00134 PG 19 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP4SF UT WOS:000378485800001 PM 26441826 ER PT J AU Gomez, H Kautza, B Escobar, D Nassour, I Luciano, J Botero, AM Gordon, L Martinez, S Holder, A Ogundele, O Loughran, P Rosengart, MR Pinsky, M Shiva, S Zuckerbraun, BS AF Gomez, Hernando Kautza, Benjamin Escobar, Daniel Nassour, Ibrahim Luciano, Jason Botero, Ana Maria Gordon, Lisa Martinez, Silvia Holder, Andre Ogundele, Olufunmilayo Loughran, Patricia Rosengart, Matthew R. Pinsky, Michael Shiva, Sruti Zuckerbraun, Brian S. TI Inhaled Carbon Monoxide Protects against the Development of Shock and Mitochondrial Injury following Hemorrhage and Resuscitation SO PLOS ONE LA English DT Article ID HEME OXYGENASE-1; TRANSCRIPTIONAL CONTROL; CELLULAR RESPIRATION; LUNG INJURY; BIOGENESIS; LIVER; INHALATION; MODEL; INHIBITION; MECHANISM AB Aims Currently, there is no effective resuscitative adjunct to fluid and blood products to limit tissue injury for traumatic hemorrhagic shock. The objective of this study was to investigate the role of inhaled carbon monoxide (CO) to limit inflammation and tissue injury, and specifically mitochondrial damage, in experimental models of hemorrhage and resuscitation. Results Inhaled CO (250 ppm for 30 minutes) protected against mortality in severe murine hemorrhagic shock and resuscitation (HS/R) (20% vs. 80%; P < 0.01). Additionally, CO limited the development of shock as determined by arterial blood pH (7.25 +/- 0.06 vs. 7.05 +/- 0.05; P < 0.05), lactate levels (7.2 +/- 5.1 vs 13.3 +/- 6.0; P < 0.05), and base deficit (13 +/- 3.0 vs 24 +/- 3.1; P < 0.05). A dose response of CO (25-500 ppm) demonstrated protection against HS/R lung and liver injury as determined by MPO activity and serum ALT, respectively. CO limited HS/R-induced increases in serum tumor necrosis factor-alpha and interleukin-6 levels as determined by ELISA (P < 0.05 for doses of 100-500ppm). Furthermore, inhaled CO limited HS/R induced oxidative stress as determined by hepatic oxidized glutathione: reduced glutathione levels and lipid peroxidation. In porcine HS/R, CO did not influence hemodynamics. However, CO limited HS/R-induced skeletal muscle and platelet mitochondrial injury as determined by respiratory control ratio (muscle) and ATP-linked respiration and mitochondrial reserve capacity (platelets). Conclusion These preclinical studies suggest that inhaled CO can be a protective therapy in HS/R; however, further clinical studies are warranted. C1 [Gomez, Hernando; Gordon, Lisa; Holder, Andre; Ogundele, Olufunmilayo; Rosengart, Matthew R.; Pinsky, Michael] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Gomez, Hernando; Rosengart, Matthew R.; Zuckerbraun, Brian S.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA 15260 USA. [Kautza, Benjamin; Escobar, Daniel; Nassour, Ibrahim; Luciano, Jason; Botero, Ana Maria; Martinez, Silvia; Loughran, Patricia; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Shiva, Sruti] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA. [Shiva, Sruti; Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA 15260 USA. EM zuckerbraunbs@upmc.edu OI Nassour, Ibrahim/0000-0002-9845-1074 FU National Institutes of Health [R01GM082830, UM1 HL120877-01, 1K12HL109068-02]; Veterans Affairs Merit Award [1I01BX000566]; Department of Defense [DM102439]; Hemophilia Center of Western Pennsylvania; UPMC Military Medicine Center FX This work is supported by National Institutes of Health grants R01GM082830 (BSZ), UM1 HL120877-01 (BSZ), 1K12HL109068-02 (HG), Veterans Affairs Merit Award 1I01BX000566 (BSZ), Department of Defense DM102439 (BSZ), Hemophilia Center of Western Pennsylvania (SS) and UPMC Military Medicine Center (SS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 0 Z9 0 U1 5 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 14 PY 2015 VL 10 IS 9 AR e0135032 DI 10.1371/journal.pone.0135032 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR8KS UT WOS:000361601100008 PM 26366865 ER PT J AU Wang, XF Zhao, X Feng, C Weinstein, A Xia, R Wen, W Lv, QS Zuo, ST Tang, PJ Yang, X Chen, XJ Wang, HR Zang, SY Stollings, L Denning, TL Jiang, JJ Fan, J Zhang, GB Zhang, XG Zhu, YB Storkus, W Lu, BF AF Wang, Xuefeng Zhao, Xin Feng, Chao Weinstein, Aliyah Xia, Rui Wen, Wen Lv, Quansheng Zuo, Shuting Tang, Peijun Yang, Xi Chen, Xiaojuan Wang, Hongrui Zang, Shayang Stollings, Lindsay Denning, Timothy L. Jiang, Jingting Fan, Jie Zhang, Guangbo Zhang, Xueguang Zhu, Yibei Storkus, Walter Lu, Binfeng TI IL-36 gamma Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses SO CANCER CELL LA English DT Article ID NF-KAPPA-B; T-CELLS; CANCER; EXPRESSION; MELANOMA; ANTIBODY; SKIN; TH1; IMMUNOGENICITY; ACTIVATION AB Cytokines play a pivotal role in regulating tumor immunogenicity and antitumor immunity. IL-36 gamma is important for the IL-23/IL-17-dominated inflammation and anti-BCG Th1 immune responses. However, the impact of IL-36 gamma on tumor immunity is unknown. Here we found that IL-36 gamma stimulated CD8(+) T cells, NK cells, and gamma delta T cells synergistically with TCR signaling and/or IL-12. Importantly, IL-36 gamma exerted profound antitumor effects in vivo and transformed the tumor microenvironment in favor of tumor eradication. Furthermore, IL-36 gamma strongly increased the efficacy of tumor vaccination. Moreover, IL-36 gamma expression inversely correlated with the progression of human melanoma and lung cancer. Our study establishes a role of IL-36 gamma in promoting antitumor immune responses and suggests its potential clinical translation into cancer immunotherapy. C1 [Wang, Xuefeng; Zhao, Xin; Weinstein, Aliyah; Xia, Rui; Zuo, Shuting; Yang, Xi; Chen, Xiaojuan; Zang, Shayang; Storkus, Walter; Lu, Binfeng] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA. [Wang, Xuefeng] Soochow Univ, Sch Biol & Basic Med Sci, Dept Biochem & Mol Biol, Suzhou 215123, Peoples R China. [Wang, Xuefeng; Feng, Chao; Xia, Rui; Wen, Wen; Lv, Quansheng; Zang, Shayang; Zhang, Xueguang; Zhu, Yibei] Soochow Univ, Sch Biol & Basic Med Sci, Inst Med Biotechnol, Dept Immunol, Suzhou 215123, Peoples R China. [Lu, Binfeng] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA. [Jiang, Jingting] Soochow Univ, Affiliated Hosp 3, Dept Tumor Biotherapy, Changzhou 213003, Peoples R China. [Wang, Hongrui] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China. [Stollings, Lindsay] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Weinstein, Aliyah; Storkus, Walter] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15213 USA. [Zhao, Xin] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou 215006, Peoples R China. [Yang, Xi] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China. [Tang, Peijun] Soochow Univ, Affiliated Hosp Infect Dis, Dept Pulm TB, Suzhou 215007, Peoples R China. [Zhang, Guangbo] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou 215006, Peoples R China. [Denning, Timothy L.] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA. [Zuo, Shuting] Jilin Univ, Hosp 2, Dept Surg, Changchun 130041, Peoples R China. [Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Chen, Xiaojuan] Soochow Univ, Affiliated Hosp 1, Dept Gastroenterol, Suzhou 215006, Peoples R China. RP Lu, BF (reprint author), Univ Pittsburgh, Sch Med, Dept Immunol, 200 Lothrop St, Pittsburgh, PA 15261 USA. EM binfeng@pitt.edu FU NIH [R21CA167229, UL1 RR024153, UL1TR000005, 1P50 CA097190, T32 GM075770]; Roswell Park Cancer Institute/University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Programs of Research Excellence [P50CA159981]; National Natural Science Foundation of China (NSFC) [31428005, 31320103918, 81273208]; 973 grant [2013CB530501] FX The project was mainly supported by the NIH through grants R21CA167229, UL1 RR024153, UL1TR000005, and 1P50 CA097190 (to B.L.); Roswell Park Cancer Institute/University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Programs of Research Excellence grant P50CA159981 (to B.L.); National Natural Science Foundation of China (NSFC) grants 31428005 (to B.L. and J.J.), 31320103918 (to X.Z. and B.L.), and 81273208 (to Y.Z.); and 973 grant 2013CB530501 (to X.Z.). L.S. is supported by NIH grant T32 GM075770. R.X., S.Z., X.Y., and X.C. are supported by a scholarship from the NSFC. NR 38 TC 4 Z9 4 U1 3 U2 17 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 EI 1878-3686 J9 CANCER CELL JI Cancer Cell PD SEP 14 PY 2015 VL 28 IS 3 BP 296 EP 306 DI 10.1016/j.ccell.2015.07.014 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CR5YS UT WOS:000361420900008 PM 26321222 ER PT J AU Balbale, SN Hill, JN Guihan, M Hogan, TP Cameron, KA Goldstein, B Evans, CT AF Balbale, Salva N. Hill, Jennifer N. Guihan, Marylou Hogan, Timothy P. Cameron, Kenzie A. Goldstein, Barry Evans, Charlesnika T. TI Evaluating implementation of methicillin-resistant Staphylococcus aureus (MRSA) prevention guidelines in spinal cord injury centers using the PARIHS framework: a mixed methods study SO IMPLEMENTATION SCIENCE LA English DT Article ID CONCEPTUAL-FRAMEWORK; QUALITATIVE RESEARCH; UNITED-STATES; VETERANS; INFECTIONS; HOSPITALIZATIONS; EPIDEMIOLOGY; DISORDER; CONTEXT; BUNDLE AB Background: To prevent methicillin-resistant Staphylococcus aureus (MRSA) in Spinal Cord Injury and Disorder (SCI/D) Centers, the "Guidelines for Implementation of MRSA Prevention Initiative in the Spinal Cord Injury Centers" were released in July 2008 in the Veterans Affairs (VA) Health Care System. The purpose of this study was to use the Promoting Action on Research Implementation in Health Systems (PARiHS) framework to evaluate the experiences of implementation of SCI/D MRSA prevention guidelines in VA SCI/D Centers approximately 2-3 years after the guidelines were released. Methods: Mixed methods were used across two phases in this study. The first phase included an anonymous, web-based cross-sectional survey administered to providers at all 24 VA SCI/D Centers. The second phase included semi-structured telephone interviews with providers at 9 SCI/D Centers. The PARiHS framework was used as the foundation of both the survey questions and semi-structured interview guide. Results: The survey was completed by 295 SCI/D providers (43.8 % response rate) from 22 of the 24 SCI/D Centers (91.7 % participation rate). Respondents included nurses (57.3 %), therapists (24.4 %), physicians (11.1 %), physician assistants (3.4 %), and other health care professionals (3.8 %). Approximately 36 % of the SCI/D providers surveyed had not seen, did not remember seeing, or had never heard of the MRSA SCI/D guidelines, whereas 42.3 % of providers reported that the MRSA SCI/D guidelines were fully implemented in their SCI/D Center. Data revealed numerous barriers and facilitators to guideline implementation. Facilitators included enhanced leadership support and provider education, focused guideline dissemination to reach SCI/D providers, and strong perceived evidence supporting the guidelines. Barriers included lack of awareness of the guidelines among physical therapists and physician assistants and challenges in cohorting/isolating MRSA-positive patients and following contact precautions. Conclusions: Successful implementation of MRSA infection prevention guidelines in SCI/D settings requires (1) guideline dissemination that reaches the full range of SCI/D providers working in inpatient, outpatient, and other care settings, (2) provider education that is frequent and systematic, (3) strong leadership support, and (4) that barriers unique to the recommendations are addressed. These findings may be used to inform selection of implementation strategies and optimize infection prevention beyond MRSA as well as in other specialty care populations. C1 [Balbale, Salva N.; Hill, Jennifer N.; Guihan, Marylou; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Balbale, Salva N.; Hill, Jennifer N.; Guihan, Marylou; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA. [Balbale, Salva N.; Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Inst Publ Hlth & Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Guihan, Marylou] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA. [Hogan, Timothy P.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Hogan, Timothy P.] US Dept Vet Affairs, EHlth Qual Enhancement Res Initiat, Natl EHlth QUERI Coordinating Ctr, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Dept Quantitat Hlth Sci, Worcester, MA USA. [Cameron, Kenzie A.] Northwestern Univ, Dept Med, Div Gen Internal Med & Geriatr, Feinberg Sch Med, Chicago, IL 60611 USA. [Cameron, Kenzie A.; Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Goldstein, Barry] US Dept Vet Affairs, Patient Care Serv, Spinal Cord Injury Disorders Serv, Seattle, WA USA. [Goldstein, Barry] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Evans, CT (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM Charlesnika.Evans@va.gov FU Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Quality Enhancement Research Initiative [RRP-09-163] FX The views expressed in this article are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs. This study was supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Quality Enhancement Research Initiative (RRP-09-163). NR 42 TC 4 Z9 4 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD SEP 9 PY 2015 VL 10 AR 130 DI 10.1186/s13012-015-0318-x PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CQ9SX UT WOS:000360956500001 PM 26353798 ER PT J AU Chan, ES Chen, C Cole, GM Wong, BS AF Chan, Elizabeth S. Chen, Christopher Cole, Gregory M. Wong, Boon-Seng TI Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice SO SCIENTIFIC REPORTS LA English DT Article ID BETA A-BETA; ALZHEIMERS-DISEASE; TARGETED REPLACEMENT; INTRANASAL INSULIN; COGNITIVE DECLINE; APOE GENOTYPE; MOUSE MODELS; NEURONS; BINDING; CLEARANCE AB It is unclear how human apolipoprotein E4 (ApoE4) increases the risk for Alzheimer's disease (AD). Although A beta levels can lead to insulin signaling impairment, these experiments were done in the absence of human ApoE. To examine ApoE role, we crossed the human ApoE-targeted replacement mice with mutant human amyloid precursor protein (APP) mice. In 26 week old mice with lower A beta levels, the expression and phosphorylation of insulin signaling proteins remained comparable among APP, ApoE3xAPP and ApoE4xAPP mouse brains. When the mice aged to 78 weeks, these proteins were markedly reduced in APP and ApoE4xAPP mouse brains. While A beta can bind to insulin receptor, how ApoE isoforms modulate this interaction remains unknown. Here, we showed that ApoE3 had greater association with insulin receptor as compared to ApoE4, regardless of A beta 42 concentration. In contrast, ApoE4 bound more A beta 42 with increasing peptide levels. Using primary hippocampal neurons, we showed that ApoE3 and ApoE4 neurons are equally sensitive to physiological levels of insulin. However, in the presence of A beta 42, insulin failed to elicit a downstream response only in ApoE4 hippocampal neurons. Taken together, our data show that ApoE genotypes can modulate this A beta-mediated insulin signaling impairment. C1 [Chan, Elizabeth S.; Chen, Christopher; Wong, Boon-Seng] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore. [Chen, Christopher] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore. [Chen, Christopher] NUHS, MACC, Singapore, Singapore. [Cole, Gregory M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res & Clin Ctr, Los Angeles, CA USA. RP Wong, BS (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore. EM bswong@nus.edu.sg RI Chen, Christopher/E-7023-2013 FU National University Health System [NUHSRO/2011/005/STB/B2B-01]; Singapore Ministry of Education FX We thank Ms Mei Li Lim, Shiau Chen H'ng and Ket Yin Goh for help in maintaining and genotyping the transgenic mice. This work was supported by a seed grant to BSW from the National University Health System (NUHSRO/2011/005/STB/B2B-01). ESC was supported by a graduate scholarship from Singapore Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 4 Z9 4 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD SEP 8 PY 2015 VL 5 AR 13842 DI 10.1038/srep13842 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CQ7PD UT WOS:000360795200002 PM 26346625 ER PT J AU Hook, G Jacobsen, JS Grabstein, K Kindy, M Hook, V AF Hook, Gregory Jacobsen, J. Steven Grabstein, Kenneth Kindy, Mark Hook, Vivian TI Cathepsin B is a New Drug Target for Traumatic Brain injury Therapeutics: evidence for E64d as a Promising Lead Drug Candidate SO FRONTIERS IN NEUROLOGY LA English DT Review DE traumatic brain injury; cathepsin B; protease; E64d; drug; therapeutics ID CYSTEINE PROTEASE INHIBITOR; AMYOTROPHIC-LATERAL-SCLEROSIS; MIDDLE CEREBRAL-ARTERY; TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; LYSOSOMAL MEMBRANE PERMEABILIZATION; HIPPOCAMPAL NEURONAL DEATH; PYROGLUTAMATE AMYLOID-BETA; IMPROVES MEMORY DEFICITS; PH-INDUCED INACTIVATION AB There is currently no therapeutic drug treatment for traumatic brain injury (TBI) despite decades of experimental clinical trials. This may be because the mechanistic pathways for improving TBI outcomes have yet to be identified and exploited. As such, there remains a need to seek out new molecular targets and their drug candidates to find new treatments for TBI. This review presents supporting evidence for cathepsin B, a cysteine protease, as a potentially important drug target for TBI. Cathepsin B expression is greatly up-regulated in TBI animal models, as well as in trauma patients. Importantly, knockout of the cathepsin B gene in TBI mice results in substantial improvements of TBI-caused deficits in behavior, pathology, and biomarkers, as well as improvements in related injury models. During the process of TBI-induced injury, cathepsin B likely escapes the lysosome, its normal subcellular location, into the cytoplasm or extracellular matrix (ECM) where the unleashed proteolytic power causes destruction via necrotic, apoptotic, autophagic, and activated glia-induced cell death, together with ECM breakdown and inflammation. Significantly, chemical inhibitors of cathepsin B are effective for improving deficits in TBI and related injuries including ischemia, cerebral bleeding, cerebral aneurysm, edema, pain, infection, rheumatoid arthritis, epilepsy, Huntington's disease, multiple sclerosis, and Alzheimer's disease. The inhibitor E64d is unique among cathepsin B inhibitors in being the only compound to have demonstrated oral efficacy in a TBI model and prior safe use in man and as such it is an excellent tool compound for preclinical testing and clinical compound development. These data support the conclusion that drug development of cathepsin B inhibitors for TBI treatment should be accelerated. C1 [Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA USA. [Jacobsen, J. Steven] AstraZeneca Neurosci iMed, Cambridge, MA USA. [Grabstein, Kenneth] Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Pharmacol, Dept Neurosci, La Jolla, CA 92093 USA. RP Hook, V (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr MC 0719, San Diego, CA 92093 USA. EM vhook@ucsd.edu FU United States National Institutes of Health (NIH) [R44AG032784]; NIH [R21AG042828, ES016774-01, R21AG043718, 1P20GM109091, 2P20GM103444, 5P30GM103342]; United States Veterans Administration (VA) [1I01RX001450, 1I01RX000331]; NSF [IIP-0903795] FX The authors wish to thank Professor Tetsumori Yamashima at the Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, for his insightful discussions. This work was supported in part by the United States National Institutes of Health (NIH) grants R44AG032784 (to American Life Science Pharmaceuticals, ALSP), NIH R21AG042828 (to VH), and the United States Veterans Administration (VA) Merit Reviews 1I01RX001450 and 1I01RX000331, NIH grants ES016774-01, R21AG043718, 1P20GM109091, 2P20GM103444, and 5P30GM103342, and NSF grants IIP-0903795 (to MK). MK is a Senior Research Career Scientist in the VA. NR 309 TC 8 Z9 9 U1 1 U2 15 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PD SEP 2 PY 2015 VL 6 AR 178 DI 10.3389/fneur.2015.00178 PG 27 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CV0GG UT WOS:000363927400001 PM 26388830 ER PT J AU Singh, JA Akhras, KS Shiozawa, A AF Singh, Jasvinder A. Akhras, Kasem S. Shiozawa, Aki TI Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort (vol 17, 120, 2015) SO ARTHRITIS RESEARCH & THERAPY LA English DT Correction C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. [Akhras, Kasem S.; Shiozawa, Aki] Takeda Pharmaceut Int Inc, Deerfield, IL 60015 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA. EM jassingh@uab.edu FU NIAMS NIH HHS [P50 AR060772] NR 1 TC 0 Z9 0 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD SEP 2 PY 2015 VL 17 AR 236 DI 10.1186/s13075-015-0752-9 PG 2 WC Rheumatology SC Rheumatology GA CQ2KM UT WOS:000360428900002 PM 26330228 ER PT J AU Jennings, LA Reuben, DB Kim, SB Keeler, E Roth, CP Zingmond, DS Wenger, NS Ganz, DA AF Jennings, Lee A. Reuben, David B. Kim, Sung-Bou Keeler, Emmett Roth, Carol P. Zingmond, David S. Wenger, Neil S. Ganz, David A. TI Targeting a High-Risk Group for Fall Prevention: Strategies for Health Plans SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID OLDER AMERICANS; COMMUNITY; INJURIES; CARE; ADULTS AB Objectives: Although Medicare has implemented incentives for health plans to reduce fall risk, the best way to identify older people at high risk of falling and to use screening results to target fall prevention services remains unknown. We evaluated 4 different strategies using a combination of administrative data and patient-reported information that health plans could easily obtain. Study Design: Observational study. Methods: We used data from 1776 patients 75 years or older in 4 community-based primary care practices who screened positive for a fear of falling and/or a history of falls. For these patients, we predicted fall-related injuries in the 24 months after the date of screening using claims/encounter data. After controlling for age and gender, we predicted the number of fall-related injuries by adding Elixhauser comorbidity count, any claim for a fall-related injury during the 12 months prior to screening, and falls screening question responses in a sequential fashion using negative binomial regression models. Results: Basic patient characteristics, including age and Elixhauser comorbidity count, were strong predictors of fall-related injury. Among falls screening questions, a positive response to, "Have you fallen 2 or more times in the past year?" was the most predictive of a fall-related injury (incidence rate ratio [IRR], 1.56; 95% CI, 1.25-1.94). Prior claim for a fall-related injury also independently predicted this type of injury (IRR, 1.41; 95% CI, 1.051.89). The best model for predicting fall-related injuries combined all of these approaches. Conclusions: The combination of administrative data and a simple screening item can be used by health plans to target patients at high risk for future fall-related injuries. C1 [Jennings, Lee A.; Reuben, David B.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. [Zingmond, David S.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Kim, Sung-Bou] Pardee RAND Grad Sch, Santa Monica, CA USA. [Keeler, Emmett; Roth, Carol P.; Wenger, Neil S.; Ganz, David A.] RAND Hlth, Santa Monica, CA USA. [Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Jennings, LA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte Ave,Ste 2339, Los Angeles, CA 90095 USA. EM lajennings@mednet.ucla.edu FU National Institute on Aging [R01AG036776]; UCLA Claude Pepper Older Americans Independence Center - National Institute on Aging [(5P30AG028748)33]; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant [UL1TR000124] FX This project was supported by a grant from the National Institute on Aging (R01AG036776). Dr Jennings was supported by the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute on Aging (5P30AG028748)33 and the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124. NR 26 TC 0 Z9 0 U1 1 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2015 VL 21 IS 9 BP E519 EP + PG 14 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4YF UT WOS:000379908800003 PM 26618439 ER PT J AU Villa, NM Li, N Yeh, MW Hurvitz, SA Dawson, NA Leung, AM AF Villa, Natalie M. Li, Ning Yeh, Michael W. Hurvitz, Sara A. Dawson, Nicole A. Leung, Angela M. TI SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS SO ENDOCRINE PRACTICE LA English DT Article ID THYROID AUTOIMMUNITY; COLORECTAL-CANCER; DISEASES; HYPOTHYROIDISM; DISORDERS; PREVALENCE; IODINE; WOMEN; ASSOCIATION; CARCINOMA AB Objective: The potential influence of hypothyroidism on breast cancer remains incompletely understood. The objective of this study was to investigate the relationship between serum thyrotropin (thyroid-stimulating hormone, TSH) concentration and markers of aggressive breast cancer biology as defined by receptor expression profile, tumor grade, and American Joint Committee on Cancer (AJCC) stage characteristics. Methods: This was a retrospective cohort study of patients from 2002 to 2014. All breast cancer patients who had complete receptor (estrogen receptor, ER; progesterone receptor, PR; and human epidermal growth factor receptor 2, Her2/neu) and prediagnosis serum TSH data (n = 437) were included. All patients had 1 of 6 receptor profiles: ER+ PR+ Her2/neu-, ER+ PR- Her2/neu-, ER+ PR+ Her2/neu+, ER+ PR- Her2/neu+, ER- PR- Her2/neu+, or ER- PR- Her2/neu-. Log-transformed serum TSH concentrations were analyzed using multinomial and logistic regressions to identify potential relationships with markers of breast cancer aggressiveness. Results: Increasing serum TSH concentration was associated with a lower probability of having the receptor expression profile ER+ PR+ Her2/neu+ compared to patients with the ER+ PR+ Her2/neu- profile (odds ratio [OR] = 0.52, P = .0045). No significant associations between other receptor expression profiles and serum TSH concentration were found. All time-weighted and unweighted median serum TSH concentrations were within normal limits. No significant associations between serum TSH concentration and tumor grade, overall AJCC stage, tumor size (T), lymph node positivity (N), or presence of metastasis (M) were observed. Conclusions: Serum TSH was not associated with markers of breast cancer aggressiveness in our cohort. C1 [Villa, Natalie M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Li, Ning] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90073 USA. [Yeh, Michael W.] Univ Calif Los Angeles, David Geffen Sch Med, Sect Endocrine Surg, Los Angeles, CA 90073 USA. [Hurvitz, Sara A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90073 USA. [Dawson, Nicole A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. [Leung, Angela M.] VA Greater Los Angeles Hlth Syst, Div Endocrinol, Los Angeles, CA USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. RP Leung, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu FU NIH [K23HD068552]; NIH/National Center for Advancing Translational Science (NCATS) [UL1TR000124] FX This work was supported by NIH K23HD068552 (to A.M.L.) and NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124. NR 30 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD SEP PY 2015 VL 21 IS 9 BP 1040 EP 1045 DI 10.4158/EP15733.OR PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7LX UT WOS:000377965200009 PM 26121443 ER PT J AU Post, RM Altshuler, L Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E., Jr. Leverich, Gabriele S. Nolen, Willem A. TI Multigenerational Positive Family History of Psychiatric Disorders Is Associated With a Poor Prognosis in Bipolar Disorder SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID UNITED-STATES; CHILDHOOD ADVERSITY; MENTAL-DISORDERS; EARLY-ONSET; EARLY AGE; STEP-BD; RISK; DEPRESSION; ILLNESS; TRIAL AB The authors assessed how family history loading affected the course of illness in patients from the United States. A total of 676 outpatients with bipolar disorder from the United States rated their illness and provided a parental and grandparental history of mood disorder, substance abuse, and other clinical conditions. A positive family history for each illness was associated with almost all of the seven poor prognosis factors established in the study (abuse in childhood, early onset, anxiety and substance abuse comorbidity, rapid cycling, multiple episodes, and worsening of severity or frequency of episodes). Family history for psychiatric difficulties in parents and grandparents was associated with a more complex and difficult course of bipolar illness. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori] West Los Angeles Healthcare Ctr, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kupka, Ralph] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands. [McElroy, Susan L.; Keck, Paul E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MN USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, Bethesda, MD USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU Stanley Medical Research Institute FX The acquisition of the initial clinical data was funded by the Stanley Medical Research Institute. NR 40 TC 6 Z9 6 U1 0 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2015 VL 27 IS 4 BP 304 EP 310 DI 10.1176/appi.neuropsych.14080204 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DM0ON UT WOS:000376045400008 PM 26258489 ER PT J AU Byrd, D Mullen, L Renfro, D Harris, TA AF Byrd, Debra Mullen, Linda Renfro, David Harris, Theodore A. TI Implementing a Perioperative RN Training Program for Recent Graduates SO AORN JOURNAL LA English DT Article DE RN graduate nurse; OR; Periop 101; orientation; perioperative workforce AB In 2010, nurse educators at one health care facility implemented a new program that emphasized placing new graduates in specialty areas, including the hemodialysis unit, the gastroenterology unit, and the OR. Managers in the OR faced staffing challenges because of the difficulty in recruiting and retaining experienced perioperative nurses and the expected retirement of a significant number of staff members. Surgical services managers agreed to participate in the new graduate program and decided to use AORN's Periop 101 (TM) course and a series of monthly simulation training sessions to supplement the program and provide recently graduated nurses with a strong perioperative nursing foundation. In three years, a total of nine newly graduated RNs successfully completed the program. The three-year retention rate was 78%. (C) AORN, Inc, 2015. C1 [Byrd, Debra] VA Palo Alto Hlth Care Syst, OR Postanesthesia Care Unit, Palo Alto, CA USA. [Mullen, Linda] Ralph H Johnson VA Med Ctr, Outpatient Clin, Charleston, SC USA. [Mullen, Linda] Ralph H Johnson VA Med Ctr, Specialty Clin, Charleston, SC USA. [Renfro, David] VA Palo Alto Hlth Care Syst, Specialty Serv, Palo Alto, CA USA. [Renfro, David] VA Palo Alto Hlth Care Syst, Hosp Based Serv, Palo Alto, CA USA. [Harris, Theodore A.] VA Palo Alto Hlth Care Syst, OR, Palo Alto, CA USA. RP Byrd, D (reprint author), VA Palo Alto Hlth Care Syst, OR Postanesthesia Care Unit, Palo Alto, CA USA. OI Renfro, David/0000-0001-6405-3257; Mullen, Linda/0000-0001-9266-0134 NR 4 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0001-2092 J9 ASSOC OPER ROOM NURS JI AORN J. PD SEP PY 2015 VL 102 IS 3 BP 236 EP 240 DI 10.1016/j.aorn.2015.06.015 PG 5 WC Nursing SC Nursing GA DI4FM UT WOS:000373455800008 PM 26323221 ER PT J AU Burfeind, WR Hoo, GS Batra, R Schwarz, Y Peled, N Kaplan, T Fink, G AF Burfeind, William R., Jr. Hoo, Guy Soo Batra, Raj Schwarz, Yehuda Peled, Nir Kaplan, Tal Fink, Gershon TI Early Detection of Lung Cancer by a FISH-Based Sputum Test SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE lung cancer; Screening; Early Detection C1 [Burfeind, William R., Jr.] St Lukes Univ Hlth Network, Thorac Surg, Bethlehem, PA USA. [Hoo, Guy Soo] Los Angeles VA Med Ctr, Los Angeles, CA USA. [Batra, Raj] Los Angeles VA Med Ctr, Pulm & Crit Care, Los Angeles, CA USA. [Schwarz, Yehuda] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Pulm & Crit Care, IL-69978 Tel Aviv, Israel. [Peled, Nir] Rabin Med Ctr, Tel Aviv, Israel. [Kaplan, Tal] Bioview Ltd, Rehovot, Israel. [Fink, Gershon] Kaplan Med Ctr, Rehovot, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA ORAL39.02 BP S251 EP S251 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365100434 ER PT J AU Dwyer-Nield, LD Tennis, M Choo, KS Keith, RL Redente, EF AF Dwyer-Nield, Lori D. Tennis, Meredith Choo, Kevin S. Keith, Robert L. Redente, Elizabeth F. TI Temporal Programming of Murine Pulmonary Macrophages in N-Nitroso-Tris-(2-Chloroethyl) Urea (NTCU)-Induced Squamous Dysplasia SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE squamous dysplasia; mouse models; macrophage programming C1 [Dwyer-Nield, Lori D.] Univ Colorado Denver, Pharmaceut Sci, Aurora, CO USA. [Tennis, Meredith] Univ Colorado Denver Anschutz, Pulm, Aurora, CO USA. [Choo, Kevin S.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Pulm Med, Denver, CO USA. [Redente, Elizabeth F.] Natl Jewish Hlth, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA P2.04-062 BP S598 EP S598 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365102641 ER PT J AU Keith, RL Blatchford, PJ Jackson, MK Franklin, WA Bunn, PA Bagwell, B Merrick, DT Miller, YE AF Keith, Robert L. Blatchford, Patrick J. Jackson, Mary K. Franklin, Wilbur A. Bunn, Paul A., Jr. Bagwell, Brandi Merrick, Daniel T. Miller, York E. TI Pioglitazone for the Chemoprevention of Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE pioglitazone; chemoprevention; endobronchial dysplasia C1 [Keith, Robert L.; Miller, York E.] Denver Vet Affairs Med Ctr, Pulm Med, Denver, CO USA. [Blatchford, Patrick J.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Jackson, Mary K.; Bagwell, Brandi] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA. [Franklin, Wilbur A.; Merrick, Daniel T.] Univ Colorado, Pathol, Aurora, CO USA. [Bunn, Paul A., Jr.] Univ Colorado Denver, Dept Med Oncol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA ORAL23.02 BP S218 EP S218 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365100340 ER PT J AU Keith, RL AF Keith, Robert L. TI Preclinical Models: How Good Are They? SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE murine models; lung cancer; chemoprevention C1 [Keith, Robert L.] Denver VAMC, UC Denver, Med, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA MS14.01 BP S111 EP S111 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365100093 ER PT J AU Merrick, DT Donald, EJ Olson, D Okeefe, MC Edwards, MG Franklin, WA Dwyer-Nield, L Orlicky, D Keith, RL Miller, YE Tennis, M Baron, AE Lu, X Van Bokhoven, A Malinowski, H Bunn, PA Geraci, MW Nemenoff, R AF Merrick, Daniel T. Donald, Elizabeth J. Olson, Damon Okeefe, Mary C. Edwards, Michael G. Franklin, Wilbur A. Dwyer-Nield, Lori Orlicky, David Keith, Robert L. Miller, York E. Tennis, Meredith Baron, Anna E. Lu, Xian Van Bokhoven, Adrie Malinowski, Heather Bunn, Paul A., Jr. Geraci, Mark W. Nemenoff, Raphael TI Role of Inflammatory Infiltrates in Promoting Persistence or Regression of Bronchial Dysplasia SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE inflammation; prevention; bronchial dysplasia C1 [Merrick, Daniel T.; Donald, Elizabeth J.; Olson, Damon; Franklin, Wilbur A.; Van Bokhoven, Adrie; Malinowski, Heather] Univ Colorado, Pathol, Aurora, CO USA. [Okeefe, Mary C.] Stanford Univ, Pathol, Palo Alto, CA 94304 USA. [Edwards, Michael G.; Tennis, Meredith; Nemenoff, Raphael] Univ Colorado, Med, Aurora, CO USA. [Dwyer-Nield, Lori; Orlicky, David] Univ Colorado, Aurora, CO USA. [Keith, Robert L.; Miller, York E.] Denver Vet Affairs Med Ctr, Med, Denver, CO USA. [Baron, Anna E.; Lu, Xian] Univ Colorado, Colorado Sch Publ Hlth, Biostat & Informat, Aurora, CO USA. [Bunn, Paul A., Jr.] Univ Colorado Denver, Dept Med Oncol, Aurora, CO USA. [Geraci, Mark W.] Univ Colorado Denver, Dept Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA ORAL23.03 BP S218 EP S218 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365100341 ER PT J AU Nakachi, I Stearman, RS Edwards, M Franklin, WA Rice, JL Tan, AC Kim, J Yoo, M Fujisawa, A Betsuyaku, T Soejima, K Miller, YE Geraci, MW AF Nakachi, Ichiro Stearman, Robert S. Edwards, Michael Franklin, Wilbur A. Rice, Jessica L. Tan, Aik-Choon Kim, Jihye Yoo, Minjae Fujisawa, Akihiro Betsuyaku, Tomoko Soejima, Kenzo Miller, York E. Geraci, Mark W. TI Subtraction of Allelic Fractions (Delta-theta): A Sensitive Metric to Detect Chromosomal Alterations in Heterogeneous Premalignant Specimens SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE SNP array; bronchial dysplasia; chromosomal alteration; chemoprevention C1 [Nakachi, Ichiro] Saiseikai Utsunomiya Hosp, Dept Pulm Med, Utsunomiya, Tochigi, Japan. [Stearman, Robert S.; Edwards, Michael; Franklin, Wilbur A.; Rice, Jessica L.; Geraci, Mark W.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Tan, Aik-Choon; Kim, Jihye; Yoo, Minjae] Univ Colorado Denver AMC, Med, Aurora, CO USA. [Fujisawa, Akihiro] Kyoto Univ, Dermatol, Kyoto, Japan. [Betsuyaku, Tomoko; Soejima, Kenzo] Keio Univ, Sch Med, Pulm Med, Tokyo, Japan. [Miller, York E.] Univ Colorado, Pulm & Crit Care Med, Aurora, CO USA. [Miller, York E.] Denver Vet Affairs Med Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA MINI23.10 BP S347 EP S347 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365101258 ER PT J AU Ostroff, R Delisle, K Franklin, WA Gold, L Merrick, DT Williams, S Miller, YE AF Ostroff, Rachel Delisle, Kirk Franklin, Wilbur A. Gold, Larry Merrick, Daniel T. Williams, Stephen Miller, York E. TI A New Approach to Large Scale Proteomic Profiling to Uncover Tumor Phenotypes SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Tumor phenotype; Proteomic analysis; SOMAmer C1 [Ostroff, Rachel; Delisle, Kirk; Gold, Larry; Williams, Stephen] Somalogic Inc, Boulder, CO USA. [Franklin, Wilbur A.; Merrick, Daniel T.] Univ Colorado, Pathol, Aurora, CO USA. [Miller, York E.] Univ Colorado, Pulm & Crit Care Med, Aurora, CO USA. [Miller, York E.] Denver Vet Affairs Med Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA MINI22.10 BP S343 EP S344 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365101247 ER PT J AU Hoffmire, CA Kemp, JE Bossarte, RM AF Hoffmire, Claire A. Kemp, Janet E. Bossarte, Robert M. TI Changes in Suicide Mortality for Veterans and Nonveterans by Gender and History of VHA Service Use, 2000-2010 SO PSYCHIATRIC SERVICES LA English DT Article ID ADVERSE CHILDHOOD EXPERIENCES; DEATH REPORTING SYSTEM; TRAUMATIC BRAIN-INJURY; 16 STATES; RISK; AFGHANISTAN; IRAQ; INDIVIDUALS; INCREASE; RATES AB Objective: Veterans are believed to be at high risk of suicide. However, research comparing suicide rates between veterans and nonveterans is limited, and even less is known regarding differences by history of Veterans Health Administration (VHA) service use. This study directly compared veteran and nonveteran suicide risk while for the first time differentiating veterans by VHA service use. Methods: The cross-sectional study analyzed data from 173,969 adult suicide decedents from 23 states (2000-2010) included in the U.S. Department of Veterans Affairs suicide data archive. Annual standardized mortality ratios (SMRs) were computed for veterans compared with nonveterans and for veterans who used VHA services compared with veterans who did not, overall and separately for males and females. Results: After the analysis controlled for age and gender differences, the number of observed veteran suicides was approximately 20% higher than expected in 2000 (SMR=1.19, 95% confidence interval [CI]=1.10-1.28), and this increased to 60% higher by 2010 (SMR=1.63, CI=1.58-1.68). The elevated risk for female veterans (2010 SMR=5.89) was higher than that observed for male veterans (2010 SMR=1.54). Trends for non-VHA-utilizing veterans mirrored those of the veteran population as a whole, and the SMR for VHA-utilizing veterans declined. Since 2003, the number of suicides among VHA-utilizing veterans was less than expected when compared directly with the suicide rate among non-VHA-utilizing veterans. Conclusions: Veterans are members of the community and, as such, are an important part of observed increases in U.S. suicide rates. Not all veterans are at equal or increasing risk of suicide, however. VHA-utilizing veterans appear to have declining absolute and relative suicide rates. C1 [Hoffmire, Claire A.; Kemp, Janet E.] US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA. [Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA. [Hoffmire, Claire A.; Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Hoffmire, CA (reprint author), US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA. EM claire.hoffmire@va.gov NR 33 TC 14 Z9 14 U1 0 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2015 VL 66 IS 9 BP 959 EP 965 DI 10.1176/appi.ps.201400031 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE6EB UT WOS:000370725400016 PM 25930036 ER PT J AU Sripada, RK Richards, SKH Rauch, SAM Walters, HM Ganoczy, D Bohnert, KM Gorman, LA Kees, M Blow, AJ Valenstein, M AF Sripada, Rebecca K. Richards, Sarah K. H. Rauch, Sheila A. M. Walters, Heather M. Ganoczy, Dara Bohnert, Kipling M. Gorman, Lisa A. Kees, Michelle Blow, Adrian J. Valenstein, Marcia TI Socioeconomic Status and Mental Health Service Use Among National Guard Soldiers SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TREATMENT-SEEKING; UNITED-STATES; CARE; PSYCHOTHERAPY; VETERANS; BARRIERS; IRAQ AB Objective: Convergent evidence suggests that low socioeconomic status (SES) may be related to reduced mental health service use. However, this relationship has not been tested in the National Guard (NG) population, in which the prevalence of mental health symptoms is high. Methods: Surveys were completed by 1,262 NG soldiers. SES was measured by education and income. Adjusted multivariable regression models assessed associations between SES, overall service use, and use of specific types of services. Results: SES was not associated with overall use but was associated with use of certain types of services. Higher SES was associated with lower likelihood of psychotropic medication use (odds ratio=.83, 95% confidence interval=.72-.96), and higher SES strengthened the positive relationship between PTSD and use of individual therapy. Conclusions: Higher SES may increase the use of individual therapy among soldiers with PTSD. Barriers to care among individuals with low SES merit continued attention and outreach efforts. C1 [Sripada, Rebecca K.; Walters, Heather M.; Ganoczy, Dara; Bohnert, Kipling M.; Valenstein, Marcia] Ann Arbor Hlth Care Syst, US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ctr Clin Management Res, Ann Arbor, MI USA. [Richards, Sarah K. H.; Rauch, Sheila A. M.] Ann Arbor Hlth Care Syst, US Dept Vet Affairs, Mental Hlth Serv, Ann Arbor, MI USA. [Sripada, Rebecca K.; Walters, Heather M.; Bohnert, Kipling M.; Kees, Michelle; Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Gorman, Lisa A.] Michigan Publ Hlth Inst, Okemos, MI 48864 USA. [Blow, Adrian J.] Michigan State Univ, Dept Family & Child Ecol, E Lansing, MI 48824 USA. RP Sripada, RK (reprint author), Ann Arbor Hlth Care Syst, US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ctr Clin Management Res, Ann Arbor, MI USA. EM rekaufma@umich.edu OI Sripada, Rebecca/0000-0002-2844-3458 FU VA Health Services Research and Development (HSRD) [RRP 09-420, SDP 10-047]; Welcome Back Veterans Initiative; McCormick Foundation, Families and Communities Together Coalition of Michigan State University; VA Advanced Fellowship Program in Mental Illness Research and Treatment; VA Serious Mental Illness Treatment Resource and Evaluation Center; Mental Health Service of the VA Ann Arbor Healthcare System; VA HSRD [CDA 11-245] FX This work was supported by VA Health Services Research and Development (HSR&D) grants RRP 09-420 and SDP 10-047, the Welcome Back Veterans Initiative, the McCormick Foundation, Families and Communities Together Coalition of Michigan State University, the VA Advanced Fellowship Program in Mental Illness Research and Treatment, the VA Serious Mental Illness Treatment Resource and Evaluation Center, and the Mental Health Service of the VA Ann Arbor Healthcare System. Dr. Bohnert is supported by VA HSR&D grant CDA 11-245. NR 15 TC 0 Z9 0 U1 1 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2015 VL 66 IS 9 BP 992 EP 995 DI 10.1176/appi.ps.201400346 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE6EB UT WOS:000370725400022 PM 25930042 ER PT J AU Grande, D Asch, DA Wan, F Bradbury, AR Jagsi, R Mitra, N AF Grande, David Asch, David A. Wan, Fei Bradbury, Angela R. Jagsi, Reshma Mitra, Nandita TI Are Patients With Cancer Less Willing to Share Their Health Information? Privacy, Sensitivity, and Social Purpose SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Article ID CONJOINT-ANALYSIS; CARE-SYSTEM; ATTITUDES; DISCRIMINATION; PERCEPTIONS; CONSENT AB Purpose: Growing use of electronic health information increases opportunities to build population cancer databases for research and care delivery. Understanding patient views on reuse of health information is essential to shape privacy policies and build trust in these initiatives. Methods: We randomly assigned nationally representative participants (N = 3,336) with and without prior cancer to six of 18 scenarios describing different uses of electronic health information. The scenarios varied the user, use, and sensitivity of the information. Participants rated each scenario on a scale of 1 to 10 assessing their willingness to share their electronic health information. We used conjoint analysis to measure the relative importance of each attribute (ie, use, user, and sensitivity). Results: Participants with and without a prior diagnosis of cancer had a similar willingness to share health information (0.27; P = .42). Both cancer and noncancer participants rated the purpose of information use as the most important factor (importance weights, 67.1% and 45.6%, respectively). For cancer participants, the sensitivity of the information was more important (importance weights, 29.8% v 1.2%). However, cancer participants were more willing to share their health information when the information included more sensitive genetic information (0.48; P = .015). Cancer and noncancer respondents rated uses and users similarly. Conclusion: The information sharing preferences of participants with and without a prior diagnosis of cancer were driven mainly by the purpose of information reuse. Although conventional thinking suggests patients with cancer might be less willing to share their health information, we found participants with cancer were more willing to share their inherited genetic information. C1 Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Michigan, Sch Med, Ann Arbor, MI USA. RP Grande, D (reprint author), 3641 Locust Walk,Colonial Penn Ctr 407, Philadelphia, PA 19014 USA. EM dgrande@wharton.upenn.edu FU NCI NIH HHS [P30 CA016520]; NHGRI NIH HHS [5R21HG006047-02, R21 HG006047] NR 28 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD SEP PY 2015 VL 11 IS 5 BP 378 EP + DI 10.1200/JOP.2015.004820 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DE4ZG UT WOS:000370638800007 PM 26265174 ER PT J AU Lo-Ciganic, WH Gellad, WF Gordon, AJ Cochrane, G Donohue, JM AF Lo-Ciganic, Wei-Hsuan Gellad, Walid F. Gordon, Adam J. Cochrane, Gerald Donohue, Julie M. TI Trajectories of Buprenorphine Treatment and Associated Emergency Department and Inpatient Use in a Large Medicaid Program SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA. [Gellad, Walid F.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Cochrane, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 47 BP 27 EP 28 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200048 ER PT J AU Lo-Ciganic, WH Donohue, JM Thorpe, JM Perera, S Thorpe, CT Marcum, ZA Gellad, WF AF Lo-Ciganic, Wei-Hsuan Donohue, Julie M. Thorpe, Joshua M. Perera, Subashan Thorpe, Carolyn T. Marcum, Zachary A. Gellad, Walid F. TI Using Machine Learning to Examine Medication Adherence Thresholds and Risk of Hospitalization SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. [Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Perera, Subashan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Perera, Subashan; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Marcum, Zachary A.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 374 BP 210 EP 211 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200365 ER PT J AU Iyer, SP Jones, A Talamantes, E Barnert, ES Kanzaria, HK Detz, A Daskivich, TJ Jones, L Ryan, GW Mahajan, AP AF Iyer, Sharat P. Jones, Andrea Talamantes, Efrain Barnert, Elizabeth S. Kanzaria, Hemal K. Detz, Alissa Daskivich, Timothy J. Jones, Loretta Ryan, Gery W. Mahajan, Anish P. TI IMPROVING HEALTH CARE FOR THE FUTURE UNINSURED IN LOS ANGELES COUNTY: A COMMUNITY-PARTNERED DIALOGUE SO ETHNICITY & DISEASE LA English DT Article DE Medically Uninsured; Patient Protection and Affordable Care Act; Health Services Accessibility; Community Health Services ID PARTICIPATORY RESEARCH; ENGAGEMENT; SERVICES; ACT AB Objectives: To understand the health care access issues faced by Los Angeles (LA) County's uninsured and residually uninsured after implementation of the Affordable Care Act (ACA) and to identify potential solutions using a community-partnered dialogue. Design: Qualitative study using a community-partnered participatory research framework. Setting: Community forum breakout discussion. Discussants: Representatives from LA County health care agencies, community health care provider organizations, local community advocacy and service organizations including uninsured individuals, and the county school district. Main Outcome Measures: Key structural and overarching value themes identified through community-partnered pile sort, c-coefficients measuring overlap between themes. Results: Five overarching value themes were identified - knowledge, trust, quality, partnership, and solutions. Lack of knowledge and misinformation were identified as barriers to successful enrollment of the eligible uninsured and providing health care to undocumented individuals. Discussants noted dissatisfaction with the quality of traditional sources of health care and a broken cycle of trust and disengagement. They also described inherent trust by the uninsured in "outsider" community-based providers not related to quality. Conclusions: Improving health care for the residually uninsured after ACA implementation will require addressing dissatisfaction in safety-net providers, disseminating knowledge and providing health care through trusted nontraditional sources, and using effective and trusted partnerships between community and health care agencies with mutual respect. Community-academic partnerships can be a trusted conduit to discuss issues related to the health care of vulnerable populations. C1 [Iyer, Sharat P.; Talamantes, Efrain; Barnert, Elizabeth S.; Kanzaria, Hemal K.; Daskivich, Timothy J.] Univ Calif Los Angeles, Robert Wood Johnson Fdn Clin Scholars, Los Angeles, CA 90024 USA. [Iyer, Sharat P.] James J Peters VA Med Ctr, VISN3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Iyer, Sharat P.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Jones, Andrea; Jones, Loretta] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Jones, Andrea; Jones, Loretta] Hlth African Amer Families, Los Angeles, CA USA. [Talamantes, Efrain; Detz, Alissa] Univ Calif Los Angeles, Natl Res Serv Award GIM Fellowship Primary Care &, Los Angeles, CA 90024 USA. [Kanzaria, Hemal K.] Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Kanzaria, Hemal K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. [Ryan, Gery W.; Mahajan, Anish P.] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Mahajan, Anish P.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Mahajan, Anish P.] Univ Calif Los Angeles, Hlth Serv Res, Los Angeles, CA 90024 USA. RP Iyer, SP (reprint author), James J Peters VA Med Ctr MIRECC OOMH, 130 W Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM Sharat.Iyer@mssm.edu FU Robert Wood Johnson Foundation Clinical Scholars program; Ruth L. Kirschstein National Research Service Award Institutional Training Grant [T32HP19001]; US Department of Veterans Affairs FX The authors would like to acknowledge the contributions of the many community partners who participated in the community forum and in the production of this manuscript. We also thank the faculty and program staff of the Robert Wood Johnson Foundation Clinical Scholars and the National Research Service Award General Internal Medicine Fellowship at UCLA, especially Dr. Kenneth Wells. Funding for this study was provided by the Robert Wood Johnson Foundation Clinical Scholars program, the Ruth L. Kirschstein National Research Service Award Institutional Training Grant #T32HP19001, and the US Department of Veterans Affairs. This material is the result of work supported with resources and the use of facilities at the James J. Peters VA Medical Center, Bronx, NY, and the West Los Angeles VA Medical Center, Los Angeles, CA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 13 TC 0 Z9 0 U1 2 U2 6 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2015 VL 25 IS 4 BP 487 EP 494 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DC9CA UT WOS:000369517100016 PM 26675541 ER PT J AU Manuel, JK Satre, DD Tsoh, J Moreno-John, G Ramos, JS McCance-Katz, EF Satterfield, JM AF Manuel, Jennifer K. Satre, Derek D. Tsoh, Janice Moreno-John, Gina Ramos, Jacqueline S. McCance-Katz, Elinore F. Satterfield, Jason M. TI Adapting Screening, Brief Intervention, and Referral to Treatment for Alcohol and Drugs to Culturally Diverse Clinical Populations SO JOURNAL OF ADDICTION MEDICINE LA English DT Review DE Alcohol; cultural competence; motivational interviewing; SBIRT; substance use disorders ID SUBSTANCE-ABUSE TREATMENT; DISORDERS IDENTIFICATION TEST; CITY EMERGENCY-DEPARTMENT; OF-VETERANS-AFFAIRS; PRIMARY-CARE; MEXICAN-AMERICANS; MOTIVATIONAL INTERVENTIONS; SERVICE UTILIZATION; METHADONE TREATMENT; ETHNIC-DIFFERENCES AB Objectives: To review the literature on the screening, brief intervention, and referral to treatment (SBIRT) approach to alcohol and drug use with racial and ethnic subgroups in the United States and to develop recommendations for culturally competent SBIRT practice. Methods: Articles reporting on the use of SBIRT components (screening, brief intervention, referral to treatment) for alcohol and drug use were identified through a comprehensive literature search of PubMed from 1995 to 2015. Results: A synthesis of the published literature on racial and ethnic considerations regarding SBIRT components (including motivational interviewing techniques) was created using evidence-based findings. Recommendations on culturally competent use of SBIRT with specific ethnic groups are also described. Conclusions: On the basis of the literature reviewed, SBIRToffers a useful set of tools to help reduce risky or problematic substance use. Special attention to validated screeners, appropriate use of language/ literacy, trust building, and incorporation of patient and community health care preferences may enhance SBIRT acceptability and effectiveness. Practice Implications: Providers should consider the implications of previous research when adapting SBIRT for diverse populations, and use validated screening and brief intervention methods. The accompanying case illustration provides additional information relevant to clinical practice. C1 [Manuel, Jennifer K.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Satre, Derek D.; Tsoh, Janice; Ramos, Jacqueline S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Satre, Derek D.] Kaiser Permanente Northern Calif Reg, Div Res, Oakland, CA USA. [Moreno-John, Gina; Satterfield, Jason M.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [McCance-Katz, Elinore F.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA. RP Manuel, JK (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Jennifer.manuel@va.gov FU SAMHSA/CSAT [U79T1020295]; NIHNIDA [P50DA09253, U10DA015815] FX This study was supported by grant U79T1020295 from SAMHSA/CSAT awarded to Dr Satterfield, and was also supported by NIHNIDA Grants P50DA09253 (PI = Joseph Guydish; joseph.guydish@ucsf.edu), U10DA015815 (PI = James Sorensen; james.Sorensen@ucsf.edu). NR 64 TC 3 Z9 3 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD SEP-OCT PY 2015 VL 9 IS 5 BP 343 EP 351 DI 10.1097/ADM.0000000000000150 PG 9 WC Substance Abuse SC Substance Abuse GA DC9CK UT WOS:000369518300001 PM 26428359 ER EF